DDI-MedLine.d145.s0	IGF1R-targeted	0	13	O	IGF1R-targeted	ted	eted	JJ	False
DDI-MedLine.d145.s0	therapy	15	21	O	therapy	apy	rapy	NN	False
DDI-MedLine.d145.s0	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d145.s0	its	27	29	O	its	its	its	PRP$	False
DDI-MedLine.d145.s0	enhancement	31	41	O	enhancement	ent	ment	NN	False
DDI-MedLine.d145.s0	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d145.s0	doxorubicin	46	56	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d145.s0	chemosensitivity	58	73	O	chemosensitivity	ity	vity	NN	False
DDI-MedLine.d145.s0	in	75	76	O	in	in	in	IN	False
DDI-MedLine.d145.s0	human	78	82	O	human	man	uman	NN	False
DDI-MedLine.d145.s0	osteosarcoma	84	95	O	osteosarcoma	oma	coma	NN	False
DDI-MedLine.d145.s0	cell	97	100	O	cell	ell	cell	NN	False
DDI-MedLine.d145.s0	lines	102	106	O	lines	nes	ines	NNS	group
DDI-MedLine.d145.s0	.	107	107	O	.	.	.	.	False

DDI-MedLine.d145.s1	Type-I	0	5	O	Type-I	e-I	pe-I	NN	False
DDI-MedLine.d145.s1	insulin-like	7	18	O	insulin-like	ike	like	NN	False
DDI-MedLine.d145.s1	growth	20	25	O	growth	wth	owth	NN	False
DDI-MedLine.d145.s1	factor	27	32	O	factor	tor	ctor	NN	False
DDI-MedLine.d145.s1	receptor	34	41	O	receptor	tor	ptor	NN	False
DDI-MedLine.d145.s1	(	43	43	O	(	(	(	(	False
DDI-MedLine.d145.s1	IGF1R	44	48	O	IGF1R	F1R	GF1R	NN	brand
DDI-MedLine.d145.s1	)	49	49	O	)	)	)	)	False
DDI-MedLine.d145.s1	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d145.s1	its	55	57	O	its	its	its	PRP$	False
DDI-MedLine.d145.s1	signaling	59	67	O	signaling	ing	ling	VBG	False
DDI-MedLine.d145.s1	play	69	72	O	play	lay	play	NN	False
DDI-MedLine.d145.s1	an	74	75	O	an	an	an	DT	False
DDI-MedLine.d145.s1	important	77	85	O	important	ant	tant	JJ	False
DDI-MedLine.d145.s1	role	87	90	O	role	ole	role	NN	False
DDI-MedLine.d145.s1	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d145.s1	osteosarcomagenesis	95	113	O	osteosarcomagenesis	sis	esis	NN	False
DDI-MedLine.d145.s1	,	114	114	O	,	,	,	,	False
DDI-MedLine.d145.s1	tumor	116	120	O	tumor	mor	umor	NN	False
DDI-MedLine.d145.s1	progression	122	132	O	progression	ion	sion	NN	False
DDI-MedLine.d145.s1	,	133	133	O	,	,	,	,	False
DDI-MedLine.d145.s1	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d145.s1	chemoresistance	139	153	O	chemoresistance	nce	ance	NN	False
DDI-MedLine.d145.s1	.	154	154	O	.	.	.	.	False

DDI-MedLine.d145.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d145.s2	purpose	4	10	O	purpose	ose	pose	NN	False
DDI-MedLine.d145.s2	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d145.s2	this	15	18	O	this	his	this	DT	False
DDI-MedLine.d145.s2	study	20	24	O	study	udy	tudy	NN	False
DDI-MedLine.d145.s2	was	26	28	O	was	was	was	VBD	False
DDI-MedLine.d145.s2	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d145.s2	investigate	33	43	O	investigate	ate	gate	NN	False
DDI-MedLine.d145.s2	both	45	48	O	both	oth	both	DT	False
DDI-MedLine.d145.s2	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d145.s2	effect	54	59	O	effect	ect	fect	NN	False
DDI-MedLine.d145.s2	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d145.s2	mechanisms	65	74	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d145.s2	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d145.s2	IGF1R	79	83	O	IGF1R	F1R	GF1R	NN	brand
DDI-MedLine.d145.s2	inhibition	85	94	O	inhibition	ion	tion	NN	False
DDI-MedLine.d145.s2	by	96	97	O	by	by	by	IN	False
DDI-MedLine.d145.s2	tyrphostin	99	108	B-drug_n	tyrphostin	tin	stin	NN	False
DDI-MedLine.d145.s2	AG1024	110	115	I-drug_n	AG1024	024	1024	NN	brand
DDI-MedLine.d145.s2	in	117	118	O	in	in	in	IN	False
DDI-MedLine.d145.s2	the	120	122	O	the	the	the	DT	False
DDI-MedLine.d145.s2	presence	124	131	O	presence	nce	ence	NN	False
DDI-MedLine.d145.s2	or	133	134	O	or	or	or	CC	False
DDI-MedLine.d145.s2	absence	136	142	O	absence	nce	ence	NN	False
DDI-MedLine.d145.s2	of	144	145	O	of	of	of	IN	False
DDI-MedLine.d145.s2	doxorubicin	147	157	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d145.s2	in	159	160	O	in	in	in	IN	False
DDI-MedLine.d145.s2	a	162	162	O	a	a	a	DT	False
DDI-MedLine.d145.s2	panel	164	168	O	panel	nel	anel	NN	False
DDI-MedLine.d145.s2	of	170	171	O	of	of	of	IN	False
DDI-MedLine.d145.s2	six	173	175	O	six	six	six	CD	False
DDI-MedLine.d145.s2	osteosarcoma	177	188	O	osteosarcoma	oma	coma	NN	False
DDI-MedLine.d145.s2	cell	190	193	O	cell	ell	cell	NN	False
DDI-MedLine.d145.s2	lines	195	199	O	lines	nes	ines	NNS	group
DDI-MedLine.d145.s2	and	201	203	O	and	and	and	CC	False
DDI-MedLine.d145.s2	a	205	205	O	a	a	a	DT	False
DDI-MedLine.d145.s2	self-established	207	222	O	self-established	hed	shed	JJ	False
DDI-MedLine.d145.s2	doxorubicin-resistant	224	244	O	doxorubicin-resistant	ant	tant	JJ	False
DDI-MedLine.d145.s2	cell	246	249	O	cell	ell	cell	NN	False
DDI-MedLine.d145.s2	line	251	254	O	line	ine	line	NN	drug
DDI-MedLine.d145.s2	.	255	255	O	.	.	.	.	False

DDI-MedLine.d145.s3	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d145.s3	are	3	5	O	are	are	are	VBP	False
DDI-MedLine.d145.s3	the	7	9	O	the	the	the	DT	False
DDI-MedLine.d145.s3	first	11	15	O	first	rst	irst	RB	False
DDI-MedLine.d145.s3	to	17	18	O	to	to	to	TO	False
DDI-MedLine.d145.s3	indicate	20	27	O	indicate	ate	cate	NN	False
DDI-MedLine.d145.s3	that	29	32	O	that	hat	that	IN	False
DDI-MedLine.d145.s3	targeting	34	42	O	targeting	ing	ting	VBG	False
DDI-MedLine.d145.s3	IGF1R	44	48	O	IGF1R	F1R	GF1R	NN	brand
DDI-MedLine.d145.s3	together	50	57	O	together	her	ther	RB	False
DDI-MedLine.d145.s3	with	59	62	O	with	ith	with	IN	False
DDI-MedLine.d145.s3	doxorubicin	64	74	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d145.s3	achieved	76	83	O	achieved	ved	eved	VBN	False
DDI-MedLine.d145.s3	additive	85	92	O	additive	ive	tive	JJ	False
DDI-MedLine.d145.s3	anti-osteosarcoma	94	110	O	anti-osteosarcoma	oma	coma	NN	False
DDI-MedLine.d145.s3	growth	112	117	O	growth	wth	owth	NN	False
DDI-MedLine.d145.s3	effect	119	124	O	effect	ect	fect	NN	False
DDI-MedLine.d145.s3	,	125	125	O	,	,	,	,	False
DDI-MedLine.d145.s3	accompanied	127	137	O	accompanied	ied	nied	VBN	False
DDI-MedLine.d145.s3	with	139	142	O	with	ith	with	IN	False
DDI-MedLine.d145.s3	increased	144	152	O	increased	sed	ased	VBN	False
DDI-MedLine.d145.s3	apoptosis	154	162	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d145.s3	,	163	163	O	,	,	,	,	False
DDI-MedLine.d145.s3	cytotoxicity	165	176	O	cytotoxicity	ity	city	NN	False
DDI-MedLine.d145.s3	,	177	177	O	,	,	,	,	False
DDI-MedLine.d145.s3	and	179	181	O	and	and	and	CC	False
DDI-MedLine.d145.s3	dual	183	186	O	dual	ual	dual	JJ	False
DDI-MedLine.d145.s3	cell	188	191	O	cell	ell	cell	NN	False
DDI-MedLine.d145.s3	cycle	193	197	O	cycle	cle	ycle	NN	False
DDI-MedLine.d145.s3	arrests	199	205	O	arrests	sts	ests	NNS	False
DDI-MedLine.d145.s3	.	206	206	O	.	.	.	.	False

DDI-MedLine.d145.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d145.s4	conclusion	3	12	O	conclusion	ion	sion	NN	False
DDI-MedLine.d145.s4	,	13	13	O	,	,	,	,	False
DDI-MedLine.d145.s4	IGF1R	15	19	O	IGF1R	F1R	GF1R	NN	brand
DDI-MedLine.d145.s4	inhibition	21	30	O	inhibition	ion	tion	NN	False
DDI-MedLine.d145.s4	can	32	34	O	can	can	can	MD	False
DDI-MedLine.d145.s4	enhance	36	42	O	enhance	nce	ance	NN	False
DDI-MedLine.d145.s4	doxorubicin	44	54	B-drug	doxorubicin	cin	icin	NN	drug
DDI-MedLine.d145.s4	chemotherapy	56	67	O	chemotherapy	apy	rapy	NN	False
DDI-MedLine.d145.s4	in	69	70	O	in	in	in	IN	False
DDI-MedLine.d145.s4	some	72	75	O	some	ome	some	DT	False
DDI-MedLine.d145.s4	osteosarcoma	77	88	O	osteosarcoma	oma	coma	NN	False
DDI-MedLine.d145.s4	cell	90	93	O	cell	ell	cell	NN	False
DDI-MedLine.d145.s4	lines	95	99	O	lines	nes	ines	NNS	group
DDI-MedLine.d145.s4	.	100	100	O	.	.	.	.	False

DDI-MedLine.d212.s0	Improvement	0	10	O	Improvement	ent	ment	NN	False
DDI-MedLine.d212.s0	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d212.s0	colchicine	15	24	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s0	oral	26	29	O	oral	ral	oral	JJ	False
DDI-MedLine.d212.s0	bioavailability	31	45	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d212.s0	by	47	48	O	by	by	by	IN	False
DDI-MedLine.d212.s0	incorporating	50	62	O	incorporating	ing	ting	VBG	False
DDI-MedLine.d212.s0	eugenol	64	70	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s0	in	72	73	O	in	in	in	IN	False
DDI-MedLine.d212.s0	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d212.s0	nanoemulsion	79	90	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s0	as	92	93	O	as	as	as	IN	False
DDI-MedLine.d212.s0	an	95	96	O	an	an	an	DT	False
DDI-MedLine.d212.s0	oil	98	100	O	oil	oil	oil	NN	False
DDI-MedLine.d212.s0	excipient	102	110	O	excipient	ent	ient	NN	False
DDI-MedLine.d212.s0	and	112	114	O	and	and	and	CC	False
DDI-MedLine.d212.s0	enhancer	116	123	O	enhancer	cer	ncer	NN	False
DDI-MedLine.d212.s0	.	124	124	O	.	.	.	.	False

DDI-MedLine.d212.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d212.s1	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d212.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d212.s1	eugenol	14	20	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s1	on	22	23	O	on	on	on	IN	False
DDI-MedLine.d212.s1	colchicine	25	34	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s1	transport	36	44	O	transport	ort	port	NN	False
DDI-MedLine.d212.s1	across	46	51	O	across	oss	ross	IN	False
DDI-MedLine.d212.s1	an	53	54	O	an	an	an	DT	False
DDI-MedLine.d212.s1	isolated	56	63	O	isolated	ted	ated	JJ	False
DDI-MedLine.d212.s1	rat	65	67	O	rat	rat	rat	NN	False
DDI-MedLine.d212.s1	intestinal	69	78	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d212.s1	membrane	80	87	O	membrane	ane	rane	NN	False
DDI-MedLine.d212.s1	was	89	91	O	was	was	was	VBD	False
DDI-MedLine.d212.s1	studied	93	99	O	studied	ied	died	VBN	False
DDI-MedLine.d212.s1	using	101	105	O	using	ing	sing	VBG	False
DDI-MedLine.d212.s1	an	107	108	O	an	an	an	DT	False
DDI-MedLine.d212.s1	in	110	111	O	in	in	in	IN	False
DDI-MedLine.d212.s1	vitro	113	117	O	vitro	tro	itro	NN	False
DDI-MedLine.d212.s1	diffusion	119	127	O	diffusion	ion	sion	NN	False
DDI-MedLine.d212.s1	chamber	129	135	O	chamber	ber	mber	NN	False
DDI-MedLine.d212.s1	system	137	142	O	system	tem	stem	NN	False
DDI-MedLine.d212.s1	.	143	143	O	.	.	.	.	False

DDI-MedLine.d212.s2	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d212.s2	found	3	7	O	found	und	ound	NN	False
DDI-MedLine.d212.s2	that	9	12	O	that	hat	that	IN	False
DDI-MedLine.d212.s2	eugenol	14	20	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s2	increased	22	30	O	increased	sed	ased	VBN	False
DDI-MedLine.d212.s2	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d212.s2	absorptive	36	45	O	absorptive	ive	tive	JJ	False
DDI-MedLine.d212.s2	transport	47	55	O	transport	ort	port	NN	False
DDI-MedLine.d212.s2	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d212.s2	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d212.s2	drug	64	67	O	drug	rug	drug	NN	False
DDI-MedLine.d212.s2	efficiently	69	79	O	efficiently	tly	ntly	RB	False
DDI-MedLine.d212.s2	.	80	80	O	.	.	.	.	False

DDI-MedLine.d212.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d212.s3	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d212.s3	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d212.s3	eugenol	14	20	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s3	on	22	23	O	on	on	on	IN	False
DDI-MedLine.d212.s3	intestinal	25	34	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d212.s3	absorption	36	45	O	absorption	ion	tion	NN	False
DDI-MedLine.d212.s3	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d212.s3	colchicine	50	59	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s3	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d212.s3	an	64	65	O	an	an	an	DT	False
DDI-MedLine.d212.s3	oral	67	70	O	oral	ral	oral	JJ	False
DDI-MedLine.d212.s3	administrative	72	85	O	administrative	ive	tive	JJ	False
DDI-MedLine.d212.s3	nanoemulsion	87	98	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s3	formulation	100	110	O	formulation	ion	tion	NN	False
DDI-MedLine.d212.s3	was	112	114	O	was	was	was	VBD	False
DDI-MedLine.d212.s3	also	116	119	O	also	lso	also	RB	False
DDI-MedLine.d212.s3	demonstrated	121	132	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d212.s3	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d212.s3	vivo	137	140	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d212.s3	.	141	141	O	.	.	.	.	False

DDI-MedLine.d212.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d212.s4	colchicine	4	13	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s4	nanoemulsion	15	26	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s4	was	28	30	O	was	was	was	VBD	False
DDI-MedLine.d212.s4	prepared	32	39	O	prepared	red	ared	JJ	False
DDI-MedLine.d212.s4	with	41	44	O	with	ith	with	IN	False
DDI-MedLine.d212.s4	isopropyl	46	54	B-drug_n	isopropyl	pyl	opyl	NN	False
DDI-MedLine.d212.s4	myristate	56	64	I-drug_n	myristate	ate	tate	NN	False
DDI-MedLine.d212.s4	,	65	65	O	,	,	,	,	False
DDI-MedLine.d212.s4	eugenol	67	73	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s4	,	74	74	O	,	,	,	,	False
DDI-MedLine.d212.s4	Tween80	76	82	B-drug_n	Tween80	n80	en80	NN	False
DDI-MedLine.d212.s4	,	83	83	O	,	,	,	,	False
DDI-MedLine.d212.s4	ethanol	85	91	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d212.s4	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d212.s4	water	97	101	O	water	ter	ater	NN	False
DDI-MedLine.d212.s4	,	102	102	O	,	,	,	,	False
DDI-MedLine.d212.s4	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d212.s4	eugenol	108	114	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s4	was	116	118	O	was	was	was	VBD	False
DDI-MedLine.d212.s4	used	120	123	O	used	sed	used	VBN	False
DDI-MedLine.d212.s4	as	125	126	O	as	as	as	IN	False
DDI-MedLine.d212.s4	an	128	129	O	an	an	an	DT	False
DDI-MedLine.d212.s4	oil	131	133	O	oil	oil	oil	NN	False
DDI-MedLine.d212.s4	phase	135	139	O	phase	ase	hase	NN	False
DDI-MedLine.d212.s4	in	141	142	O	in	in	in	IN	False
DDI-MedLine.d212.s4	the	144	146	O	the	the	the	DT	False
DDI-MedLine.d212.s4	formulation	148	158	O	formulation	ion	tion	NN	False
DDI-MedLine.d212.s4	;	159	159	O	;	;	;	:	False

DDI-MedLine.d212.s5	an	0	1	O	an	an	an	DT	False
DDI-MedLine.d212.s5	average	3	9	O	average	age	rage	JJ	False
DDI-MedLine.d212.s5	particle	11	18	O	particle	cle	icle	NN	False
DDI-MedLine.d212.s5	size	20	23	O	size	ize	size	NN	False
DDI-MedLine.d212.s5	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d212.s5	this	28	31	O	this	his	this	DT	False
DDI-MedLine.d212.s5	nanoemulsion	33	44	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s5	was	46	48	O	was	was	was	VBD	False
DDI-MedLine.d212.s5	41.2	50	53	O	41.2	1.2	41.2	CD	False
DDI-MedLine.d212.s5	7.2	58	60	O	7.2	7.2	7.2	CD	False
DDI-MedLine.d212.s5	nm	62	63	O	nm	nm	nm	NN	False
DDI-MedLine.d212.s5	.	64	64	O	.	.	.	.	False

DDI-MedLine.d212.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d212.s6	permeation	4	13	O	permeation	ion	tion	NN	False
DDI-MedLine.d212.s6	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d212.s6	colchicine	18	27	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s6	in	29	30	O	in	in	in	IN	False
DDI-MedLine.d212.s6	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d212.s6	nanoemulsion	36	47	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s6	across	49	54	O	across	oss	ross	IN	False
DDI-MedLine.d212.s6	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d212.s6	intestinal	60	69	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d212.s6	membrane	71	78	O	membrane	ane	rane	NN	False
DDI-MedLine.d212.s6	was	80	82	O	was	was	was	VBD	False
DDI-MedLine.d212.s6	significantly	84	96	O	significantly	tly	ntly	RB	False
DDI-MedLine.d212.s6	different	98	106	O	different	ent	rent	JJ	False
DDI-MedLine.d212.s6	from	108	111	O	from	rom	from	IN	False
DDI-MedLine.d212.s6	that	113	116	O	that	hat	that	IN	False
DDI-MedLine.d212.s6	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d212.s6	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d212.s6	control	125	131	O	control	rol	trol	NN	False
DDI-MedLine.d212.s6	group	133	137	O	group	oup	roup	NN	False
DDI-MedLine.d212.s6	(	139	139	O	(	(	(	(	False
DDI-MedLine.d212.s6	0.2	140	142	O	0.2	0.2	0.2	CD	False
DDI-MedLine.d212.s6	mM	144	145	O	mM	mM	mM	NN	False
DDI-MedLine.d212.s6	colchicine	147	156	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s6	)	157	157	O	)	)	)	)	False
DDI-MedLine.d212.s6	.	158	158	O	.	.	.	.	False

DDI-MedLine.d212.s7	Finally	0	6	O	Finally	lly	ally	RB	False
DDI-MedLine.d212.s7	,	7	7	O	,	,	,	,	False
DDI-MedLine.d212.s7	co-administration	9	25	O	co-administration	ion	tion	NN	False
DDI-MedLine.d212.s7	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d212.s7	eugenol	30	36	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s7	in	38	39	O	in	in	in	IN	False
DDI-MedLine.d212.s7	colchicine	41	50	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s7	nanoemulsion	52	63	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s7	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d212.s7	enhance	68	74	O	enhance	nce	ance	NN	False
DDI-MedLine.d212.s7	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d212.s7	colchicine	80	89	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s7	bioavailability	91	105	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d212.s7	was	107	109	O	was	was	was	VBD	False
DDI-MedLine.d212.s7	investigated	111	122	O	investigated	ted	ated	VBN	False
DDI-MedLine.d212.s7	by	124	125	O	by	by	by	IN	False
DDI-MedLine.d212.s7	an	127	128	O	an	an	an	DT	False
DDI-MedLine.d212.s7	oral	130	133	O	oral	ral	oral	JJ	False
DDI-MedLine.d212.s7	administration	135	148	O	administration	ion	tion	NN	False
DDI-MedLine.d212.s7	method	150	155	O	method	hod	thod	NN	False
DDI-MedLine.d212.s7	.	156	156	O	.	.	.	.	False

DDI-MedLine.d212.s8	After	0	4	O	After	ter	fter	IN	False
DDI-MedLine.d212.s8	oral	6	9	O	oral	ral	oral	JJ	False
DDI-MedLine.d212.s8	administration	11	24	O	administration	ion	tion	NN	False
DDI-MedLine.d212.s8	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d212.s8	colchicine	29	38	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s8	(	40	40	O	(	(	(	(	False
DDI-MedLine.d212.s8	8	41	41	O	8	8	8	CD	False
DDI-MedLine.d212.s8	mg/kg	43	47	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d212.s8	)	48	48	O	)	)	)	)	False
DDI-MedLine.d212.s8	in	50	51	O	in	in	in	IN	False
DDI-MedLine.d212.s8	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d212.s8	form	57	60	O	form	orm	form	NN	False
DDI-MedLine.d212.s8	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d212.s8	either	65	70	O	either	her	ther	DT	False
DDI-MedLine.d212.s8	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d212.s8	nanoemulsion	76	87	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s8	or	89	90	O	or	or	or	CC	False
DDI-MedLine.d212.s8	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d212.s8	free	95	98	O	free	ree	free	JJ	False
DDI-MedLine.d212.s8	colchicine	100	109	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s8	solution	111	118	O	solution	ion	tion	NN	False
DDI-MedLine.d212.s8	,	119	119	O	,	,	,	,	False
DDI-MedLine.d212.s8	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d212.s8	relative	125	132	O	relative	ive	tive	NN	False
DDI-MedLine.d212.s8	bioavailability	134	148	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d212.s8	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d212.s8	nanoemulsion	153	164	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s8	and	166	168	O	and	and	and	CC	False
DDI-MedLine.d212.s8	eugenol-nanoemulsion	170	189	O	eugenol-nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s8	were	191	194	O	were	ere	were	VBD	False
DDI-MedLine.d212.s8	enhanced	196	203	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d212.s8	by	205	206	O	by	by	by	IN	False
DDI-MedLine.d212.s8	about	208	212	O	about	out	bout	IN	False
DDI-MedLine.d212.s8	1.6-	214	217	O	1.6-	.6-	1.6-	JJ	False
DDI-MedLine.d212.s8	and	219	221	O	and	and	and	CC	False
DDI-MedLine.d212.s8	2.1-fold	223	230	O	2.1-fold	old	fold	JJ	False
DDI-MedLine.d212.s8	,	231	231	O	,	,	,	,	False
DDI-MedLine.d212.s8	respectively	233	244	O	respectively	ely	vely	RB	False
DDI-MedLine.d212.s8	,	245	245	O	,	,	,	,	False
DDI-MedLine.d212.s8	compared	247	254	O	compared	red	ared	VBN	False
DDI-MedLine.d212.s8	with	256	259	O	with	ith	with	IN	False
DDI-MedLine.d212.s8	free	261	264	O	free	ree	free	JJ	False
DDI-MedLine.d212.s8	colchicine	266	275	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s8	solution	277	284	O	solution	ion	tion	NN	False
DDI-MedLine.d212.s8	.	285	285	O	.	.	.	.	False

DDI-MedLine.d212.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d212.s9	procedure	4	12	O	procedure	ure	dure	NN	False
DDI-MedLine.d212.s9	indicated	14	22	O	indicated	ted	ated	VBN	False
DDI-MedLine.d212.s9	that	24	27	O	that	hat	that	IN	False
DDI-MedLine.d212.s9	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d212.s9	intestinal	33	42	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d212.s9	absorption	44	53	O	absorption	ion	tion	NN	False
DDI-MedLine.d212.s9	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d212.s9	colchicine	58	67	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s9	was	69	71	O	was	was	was	VBD	False
DDI-MedLine.d212.s9	enhanced	73	80	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d212.s9	significantly	82	94	O	significantly	tly	ntly	RB	False
DDI-MedLine.d212.s9	by	96	97	O	by	by	by	IN	False
DDI-MedLine.d212.s9	eugenol	99	105	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s9	in	107	108	O	in	in	in	IN	False
DDI-MedLine.d212.s9	the	110	112	O	the	the	the	DT	False
DDI-MedLine.d212.s9	tested	114	119	O	tested	ted	sted	VBN	False
DDI-MedLine.d212.s9	nanoemulsion	121	132	O	nanoemulsion	ion	sion	NN	False
DDI-MedLine.d212.s9	.	133	133	O	.	.	.	.	False

DDI-MedLine.d212.s10	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d212.s10	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d212.s10	results	8	14	O	results	lts	ults	NNS	False
DDI-MedLine.d212.s10	suggested	16	24	O	suggested	ted	sted	VBN	False
DDI-MedLine.d212.s10	that	26	29	O	that	hat	that	IN	False
DDI-MedLine.d212.s10	eugenol	31	37	B-drug	eugenol	nol	enol	NN	False
DDI-MedLine.d212.s10	is	39	40	O	is	is	is	VBZ	False
DDI-MedLine.d212.s10	an	42	43	O	an	an	an	DT	False
DDI-MedLine.d212.s10	efficient	45	53	O	efficient	ent	ient	NN	False
DDI-MedLine.d212.s10	component	55	63	O	component	ent	nent	NN	False
DDI-MedLine.d212.s10	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d212.s10	an	68	69	O	an	an	an	DT	False
DDI-MedLine.d212.s10	oral	71	74	O	oral	ral	oral	JJ	False
DDI-MedLine.d212.s10	administrative	76	89	O	administrative	ive	tive	JJ	False
DDI-MedLine.d212.s10	formulation	91	101	O	formulation	ion	tion	NN	False
DDI-MedLine.d212.s10	for	103	105	O	for	for	for	IN	False
DDI-MedLine.d212.s10	improving	107	115	O	improving	ing	ving	VBG	False
DDI-MedLine.d212.s10	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d212.s10	intestinal	121	130	O	intestinal	nal	inal	JJ	False
DDI-MedLine.d212.s10	absorption	132	141	O	absorption	ion	tion	NN	False
DDI-MedLine.d212.s10	of	143	144	O	of	of	of	IN	False
DDI-MedLine.d212.s10	colchicine	146	155	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d212.s10	.	156	156	O	.	.	.	.	False

DDI-MedLine.d149.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d149.s0	Protective	1	10	O	Protective	ive	tive	JJ	False
DDI-MedLine.d149.s0	effects	12	18	O	effects	cts	ects	NNS	False
DDI-MedLine.d149.s0	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d149.s0	ginseng-ginko	23	35	O	ginseng-ginko	nko	inko	NN	False
DDI-MedLine.d149.s0	extracts	37	44	O	extracts	cts	acts	NNS	False
DDI-MedLine.d149.s0	combination	46	56	O	combination	ion	tion	NN	False
DDI-MedLine.d149.s0	on	58	59	O	on	on	on	IN	False
DDI-MedLine.d149.s0	rat	61	63	O	rat	rat	rat	NN	False
DDI-MedLine.d149.s0	primary	65	71	O	primary	ary	mary	NN	False
DDI-MedLine.d149.s0	cultured	73	80	O	cultured	red	ured	VBN	False
DDI-MedLine.d149.s0	neurons	82	88	O	neurons	ons	rons	NNS	False
DDI-MedLine.d149.s0	induced	90	96	O	induced	ced	uced	JJ	False
DDI-MedLine.d149.s0	by	98	99	O	by	by	by	IN	False
DDI-MedLine.d149.s0	Abeta	101	105	B-drug_n	Abeta	eta	beta	NN	False
DDI-MedLine.d149.s0	(	106	106	I-drug_n	(	(	(	(	False
DDI-MedLine.d149.s0	1-40	107	110	I-drug_n	1-40	-40	1-40	JJ	False
DDI-MedLine.d149.s0	)	111	111	I-drug_n	)	)	)	)	False
DDI-MedLine.d149.s0	]	112	112	O	]	]	]	NN	False
DDI-MedLine.d149.s0	.	113	113	O	.	.	.	.	False

DDI-MedLine.d149.s1	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d149.s1	observe	3	9	O	observe	rve	erve	NN	False
DDI-MedLine.d149.s1	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d149.s1	injury	15	20	O	injury	ury	jury	NN	False
DDI-MedLine.d149.s1	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d149.s1	rat	25	27	O	rat	rat	rat	NN	False
DDI-MedLine.d149.s1	primary	29	35	O	primary	ary	mary	NN	False
DDI-MedLine.d149.s1	cultured	37	44	O	cultured	red	ured	VBN	False
DDI-MedLine.d149.s1	neurons	46	52	O	neurons	ons	rons	NNS	False
DDI-MedLine.d149.s1	induced	54	60	O	induced	ced	uced	JJ	False
DDI-MedLine.d149.s1	by	62	63	O	by	by	by	IN	False
DDI-MedLine.d149.s1	Abeta	65	69	B-drug_n	Abeta	eta	beta	NN	False
DDI-MedLine.d149.s1	(	70	70	I-drug_n	(	(	(	(	False
DDI-MedLine.d149.s1	1-40	71	74	I-drug_n	1-40	-40	1-40	JJ	False
DDI-MedLine.d149.s1	)	75	75	I-drug_n	)	)	)	)	False
DDI-MedLine.d149.s1	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d149.s1	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d149.s1	protective	85	94	O	protective	ive	tive	NN	False
DDI-MedLine.d149.s1	effects	96	102	O	effects	cts	ects	NNS	False
DDI-MedLine.d149.s1	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d149.s1	combination	107	117	O	combination	ion	tion	NN	False
DDI-MedLine.d149.s1	of	119	120	O	of	of	of	IN	False
DDI-MedLine.d149.s1	ginseng	122	128	B-drug	ginseng	eng	seng	NN	False
DDI-MedLine.d149.s1	and	130	132	O	and	and	and	CC	False
DDI-MedLine.d149.s1	ginko	134	138	B-drug	ginko	nko	inko	NN	False
DDI-MedLine.d149.s1	extracts	140	147	O	extracts	cts	acts	NNS	False
DDI-MedLine.d149.s1	.	148	148	O	.	.	.	.	False

DDI-MedLine.d149.s2	Primary	0	6	O	Primary	ary	mary	JJ	False
DDI-MedLine.d149.s2	neurons	8	14	O	neurons	ons	rons	NNS	False
DDI-MedLine.d149.s2	were	16	19	O	were	ere	were	VBD	False
DDI-MedLine.d149.s2	induced	21	27	O	induced	ced	uced	JJ	False
DDI-MedLine.d149.s2	by	29	30	O	by	by	by	IN	False
DDI-MedLine.d149.s2	Abeta	32	36	B-drug_n	Abeta	eta	beta	NN	False
DDI-MedLine.d149.s2	(	37	37	I-drug_n	(	(	(	(	False
DDI-MedLine.d149.s2	1-40	38	41	I-drug_n	1-40	-40	1-40	JJ	False
DDI-MedLine.d149.s2	)	42	42	I-drug_n	)	)	)	)	False
DDI-MedLine.d149.s2	to	44	45	O	to	to	to	TO	False
DDI-MedLine.d149.s2	establish	47	55	O	establish	ish	lish	VB	False
DDI-MedLine.d149.s2	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d149.s2	cell	61	64	O	cell	ell	cell	NN	False
DDI-MedLine.d149.s2	model	66	70	O	model	del	odel	NN	False
DDI-MedLine.d149.s2	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d149.s2	toxic	75	79	O	toxic	xic	oxic	NN	False
DDI-MedLine.d149.s2	injury	81	86	O	injury	ury	jury	NN	False
DDI-MedLine.d149.s2	.	87	87	O	.	.	.	.	False

DDI-MedLine.d149.s3	Using	0	4	O	Using	ing	sing	VBG	False
DDI-MedLine.d149.s3	flow	6	9	O	flow	low	flow	NN	False
DDI-MedLine.d149.s3	cytometry	11	19	O	cytometry	try	etry	NN	False
DDI-MedLine.d149.s3	with	21	24	O	with	ith	with	IN	False
DDI-MedLine.d149.s3	Annexin	26	32	O	Annexin	xin	exin	NN	False
DDI-MedLine.d149.s3	V-FITC/PI	34	42	O	V-FITC/PI	/PI	C/PI	NN	brand
DDI-MedLine.d149.s3	double	44	49	O	double	ble	uble	RB	False
DDI-MedLine.d149.s3	staining	51	58	O	staining	ing	ning	VBG	False
DDI-MedLine.d149.s3	,	59	59	O	,	,	,	,	False
DDI-MedLine.d149.s3	MTP	61	63	O	MTP	MTP	MTP	NN	brand
DDI-MedLine.d149.s3	assay	65	69	O	assay	say	ssay	NN	False
DDI-MedLine.d149.s3	,	70	70	O	,	,	,	,	False
DDI-MedLine.d149.s3	transmission	72	83	O	transmission	ion	sion	NN	False
DDI-MedLine.d149.s3	electron	85	92	O	electron	ron	tron	NN	False
DDI-MedLine.d149.s3	microscopy	94	103	O	microscopy	opy	copy	NN	False
DDI-MedLine.d149.s3	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d149.s3	Western	109	115	O	Western	ern	tern	JJ	False
DDI-MedLine.d149.s3	blot	117	120	O	blot	lot	blot	NN	False
DDI-MedLine.d149.s3	,	121	121	O	,	,	,	,	False
DDI-MedLine.d149.s3	the	123	125	O	the	the	the	DT	False
DDI-MedLine.d149.s3	appropriate	127	137	O	appropriate	ate	iate	NN	False
DDI-MedLine.d149.s3	concentration	139	151	O	concentration	ion	tion	NN	False
DDI-MedLine.d149.s3	and	153	155	O	and	and	and	CC	False
DDI-MedLine.d149.s3	duration	157	164	O	duration	ion	tion	NN	False
DDI-MedLine.d149.s3	of	166	167	O	of	of	of	IN	False
DDI-MedLine.d149.s3	AP	169	170	O	AP	AP	AP	NN	brand
DDI-MedLine.d149.s3	for	172	174	O	for	for	for	IN	False
DDI-MedLine.d149.s3	cell	176	179	O	cell	ell	cell	NN	False
DDI-MedLine.d149.s3	model	181	185	O	model	del	odel	NN	False
DDI-MedLine.d149.s3	establishment	187	199	O	establishment	ent	ment	NN	False
DDI-MedLine.d149.s3	were	201	204	O	were	ere	were	VBD	False
DDI-MedLine.d149.s3	determined	206	215	O	determined	ned	ined	VBN	False
DDI-MedLine.d149.s3	.	216	216	O	.	.	.	.	False

DDI-MedLine.d149.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d149.s4	effects	4	10	O	effects	cts	ects	NNS	False
DDI-MedLine.d149.s4	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d149.s4	extracts	15	22	O	extracts	cts	acts	NNS	False
DDI-MedLine.d149.s4	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d149.s4	ginseng	27	33	B-drug	ginseng	eng	seng	NN	False
DDI-MedLine.d149.s4	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d149.s4	ginko	39	43	B-drug	ginko	nko	inko	NN	False
DDI-MedLine.d149.s4	(	45	45	O	(	(	(	(	False
DDI-MedLine.d149.s4	EGGB	46	49	B-drug	EGGB	GGB	EGGB	NN	brand
DDI-MedLine.d149.s4	)	50	50	O	)	)	)	)	False
DDI-MedLine.d149.s4	on	52	53	O	on	on	on	IN	False
DDI-MedLine.d149.s4	cellular	55	62	O	cellular	lar	ular	JJ	False
DDI-MedLine.d149.s4	proliferative	64	76	O	proliferative	ive	tive	NN	False
DDI-MedLine.d149.s4	activity	78	85	O	activity	ity	vity	NN	False
DDI-MedLine.d149.s4	,	86	86	O	,	,	,	,	False
DDI-MedLine.d149.s4	apoptotic	88	96	O	apoptotic	tic	otic	JJ	False
DDI-MedLine.d149.s4	rate	98	101	O	rate	ate	rate	NN	False
DDI-MedLine.d149.s4	,	102	102	O	,	,	,	,	False
DDI-MedLine.d149.s4	ultrastructure	104	117	O	ultrastructure	ure	ture	NN	False
DDI-MedLine.d149.s4	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d149.s4	caspase-3	123	131	O	caspase-3	e-3	se-3	NN	False
DDI-MedLine.d149.s4	expression	133	142	O	expression	ion	sion	NN	False
DDI-MedLine.d149.s4	were	144	147	O	were	ere	were	VBD	False
DDI-MedLine.d149.s4	detected	149	156	O	detected	ted	cted	VBN	False
DDI-MedLine.d149.s4	.	157	157	O	.	.	.	.	False

DDI-MedLine.d149.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d149.s5	apoptotic	4	12	O	apoptotic	tic	otic	JJ	False
DDI-MedLine.d149.s5	rate	14	17	O	rate	ate	rate	NN	False
DDI-MedLine.d149.s5	was	19	21	O	was	was	was	VBD	False
DDI-MedLine.d149.s5	increased	23	31	O	increased	sed	ased	VBN	False
DDI-MedLine.d149.s5	significantly	33	45	O	significantly	tly	ntly	RB	False
DDI-MedLine.d149.s5	after	47	51	O	after	ter	fter	IN	False
DDI-MedLine.d149.s5	neurons	53	59	O	neurons	ons	rons	NNS	False
DDI-MedLine.d149.s5	were	61	64	O	were	ere	were	VBD	False
DDI-MedLine.d149.s5	induced	66	72	O	induced	ced	uced	JJ	False
DDI-MedLine.d149.s5	by	74	75	O	by	by	by	IN	False
DDI-MedLine.d149.s5	1	77	77	O	1	1	1	CD	False
DDI-MedLine.d149.s5	micromol	79	86	O	micromol	mol	omol	NN	False
DDI-MedLine.d149.s5	x	88	88	O	x	x	x	NN	False
DDI-MedLine.d149.s5	L	90	90	O	L	L	L	NN	brand
DDI-MedLine.d149.s5	(	91	91	O	(	(	(	(	False
DDI-MedLine.d149.s5	-1	92	93	O	-1	-1	-1	NN	False
DDI-MedLine.d149.s5	)	94	94	O	)	)	)	)	False
DDI-MedLine.d149.s5	Abeta	96	100	B-drug_n	Abeta	eta	beta	NN	False
DDI-MedLine.d149.s5	(	101	101	I-drug_n	(	(	(	(	False
DDI-MedLine.d149.s5	-40	102	104	I-drug_n	-40	-40	-40	NN	False
DDI-MedLine.d149.s5	)	105	105	I-drug_n	)	)	)	)	False
DDI-MedLine.d149.s5	for	107	109	O	for	for	for	IN	False
DDI-MedLine.d149.s5	24	111	112	O	24	24	24	CD	False
DDI-MedLine.d149.s5	h	114	114	O	h	h	h	NN	False
DDI-MedLine.d149.s5	(	116	116	O	(	(	(	(	False
DDI-MedLine.d149.s5	P	117	117	O	P	P	P	NN	brand
DDI-MedLine.d149.s5	<	119	119	O	<	<	<	NN	False
DDI-MedLine.d149.s5	0.01	121	124	O	0.01	.01	0.01	CD	False
DDI-MedLine.d149.s5	)	125	125	O	)	)	)	)	False
DDI-MedLine.d149.s5	.	126	126	O	.	.	.	.	False

DDI-MedLine.d149.s6	EGGB	0	3	B-drug	EGGB	GGB	EGGB	NN	brand
DDI-MedLine.d149.s6	(	5	5	O	(	(	(	(	False
DDI-MedLine.d149.s6	5	6	6	O	5	5	5	CD	False
DDI-MedLine.d149.s6	,	7	7	O	,	,	,	,	False
DDI-MedLine.d149.s6	50	9	10	O	50	50	50	CD	False
DDI-MedLine.d149.s6	mg	12	13	O	mg	mg	mg	NN	False
DDI-MedLine.d149.s6	L	15	15	O	L	L	L	NN	brand
DDI-MedLine.d149.s6	(	16	16	O	(	(	(	(	False
DDI-MedLine.d149.s6	-1	17	18	O	-1	-1	-1	NN	False
DDI-MedLine.d149.s6	)	19	19	O	)	)	)	)	False
DDI-MedLine.d149.s6	)	20	20	O	)	)	)	)	False
DDI-MedLine.d149.s6	significantly	22	34	O	significantly	tly	ntly	RB	False
DDI-MedLine.d149.s6	enhanced	36	43	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d149.s6	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d149.s6	proliferative	49	61	O	proliferative	ive	tive	NN	False
DDI-MedLine.d149.s6	activity	63	70	O	activity	ity	vity	NN	False
DDI-MedLine.d149.s6	(	72	72	O	(	(	(	(	False
DDI-MedLine.d149.s6	P	73	73	O	P	P	P	NN	brand
DDI-MedLine.d149.s6	<	75	75	O	<	<	<	NN	False
DDI-MedLine.d149.s6	0.05	77	80	O	0.05	.05	0.05	CD	False
DDI-MedLine.d149.s6	)	81	81	O	)	)	)	)	False
DDI-MedLine.d149.s6	.	82	82	O	.	.	.	.	False

DDI-MedLine.d149.s7	Meanwhile	0	8	O	Meanwhile	ile	hile	RB	False
DDI-MedLine.d149.s7	,	9	9	O	,	,	,	,	False
DDI-MedLine.d149.s7	EGGB	11	14	B-drug	EGGB	GGB	EGGB	NN	brand
DDI-MedLine.d149.s7	(	16	16	O	(	(	(	(	False
DDI-MedLine.d149.s7	50	17	18	O	50	50	50	CD	False
DDI-MedLine.d149.s7	mg	20	21	O	mg	mg	mg	NN	False
DDI-MedLine.d149.s7	L	23	23	O	L	L	L	NN	brand
DDI-MedLine.d149.s7	(	24	24	O	(	(	(	(	False
DDI-MedLine.d149.s7	-1	25	26	O	-1	-1	-1	NN	False
DDI-MedLine.d149.s7	)	27	27	O	)	)	)	)	False
DDI-MedLine.d149.s7	)	28	28	O	)	)	)	)	False
DDI-MedLine.d149.s7	inhibited	30	38	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d149.s7	neuronal	40	47	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d149.s7	apoptosis	49	57	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d149.s7	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d149.s7	caspase-3	63	71	O	caspase-3	e-3	se-3	NN	False
DDI-MedLine.d149.s7	overexpression	73	86	O	overexpression	ion	sion	NN	False
DDI-MedLine.d149.s7	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d149.s7	improved	92	99	O	improved	ved	oved	VBN	False
DDI-MedLine.d149.s7	cellular	101	108	O	cellular	lar	ular	JJ	False
DDI-MedLine.d149.s7	ultrastructure	110	123	O	ultrastructure	ure	ture	NN	False
DDI-MedLine.d149.s7	remarkably	125	134	O	remarkably	bly	ably	RB	False
DDI-MedLine.d149.s7	(	136	136	O	(	(	(	(	False
DDI-MedLine.d149.s7	P	137	137	O	P	P	P	NN	brand
DDI-MedLine.d149.s7	<	139	139	O	<	<	<	NN	False
DDI-MedLine.d149.s7	0.05	141	144	O	0.05	.05	0.05	CD	False
DDI-MedLine.d149.s7	,	145	145	O	,	,	,	,	False
DDI-MedLine.d149.s7	P	147	147	O	P	P	P	NN	brand
DDI-MedLine.d149.s7	<	149	149	O	<	<	<	NN	False
DDI-MedLine.d149.s7	0.01	151	154	O	0.01	.01	0.01	CD	False
DDI-MedLine.d149.s7	)	155	155	O	)	)	)	)	False
DDI-MedLine.d149.s7	.	156	156	O	.	.	.	.	False

DDI-MedLine.d149.s8	Abeta	0	4	B-drug	Abeta	eta	beta	NN	False
DDI-MedLine.d149.s8	(	5	5	I-drug	(	(	(	(	False
DDI-MedLine.d149.s8	1-40	6	9	I-drug	1-40	-40	1-40	JJ	False
DDI-MedLine.d149.s8	)	10	10	I-drug	)	)	)	)	False
DDI-MedLine.d149.s8	could	12	16	O	could	uld	ould	MD	False
DDI-MedLine.d149.s8	significantly	18	30	O	significantly	tly	ntly	RB	False
DDI-MedLine.d149.s8	induce	32	37	O	induce	uce	duce	NN	False
DDI-MedLine.d149.s8	primary	39	45	O	primary	ary	mary	NN	False
DDI-MedLine.d149.s8	cultured	47	54	O	cultured	red	ured	VBN	False
DDI-MedLine.d149.s8	neurons	56	62	O	neurons	ons	rons	NNS	False
DDI-MedLine.d149.s8	to	64	65	O	to	to	to	TO	False
DDI-MedLine.d149.s8	apoptosis	67	75	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d149.s8	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d149.s8	vitro	80	84	O	vitro	tro	itro	NN	False
DDI-MedLine.d149.s8	.	85	85	O	.	.	.	.	False

DDI-MedLine.d149.s9	EGGB	0	3	B-drug	EGGB	GGB	EGGB	NN	brand
DDI-MedLine.d149.s9	showed	5	10	O	showed	wed	owed	VBD	False
DDI-MedLine.d149.s9	beneficial	12	21	O	beneficial	ial	cial	JJ	False
DDI-MedLine.d149.s9	neuroprotective	23	37	O	neuroprotective	ive	tive	JJ	False
DDI-MedLine.d149.s9	effects	39	45	O	effects	cts	ects	NNS	False
DDI-MedLine.d149.s9	against	47	53	O	against	nst	inst	IN	False
DDI-MedLine.d149.s9	neuronal	55	62	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d149.s9	apoptosis	64	72	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d149.s9	,	73	73	O	,	,	,	,	False
DDI-MedLine.d149.s9	which	75	79	O	which	ich	hich	WDT	False
DDI-MedLine.d149.s9	might	81	85	O	might	ght	ight	MD	False
DDI-MedLine.d149.s9	be	87	88	O	be	be	be	VB	False
DDI-MedLine.d149.s9	due	90	92	O	due	due	due	JJ	False
DDI-MedLine.d149.s9	to	94	95	O	to	to	to	TO	False
DDI-MedLine.d149.s9	improving	97	105	O	improving	ing	ving	VBG	False
DDI-MedLine.d149.s9	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d149.s9	structures	111	120	O	structures	res	ures	NNS	False
DDI-MedLine.d149.s9	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d149.s9	neuron	125	130	O	neuron	ron	uron	NN	False
DDI-MedLine.d149.s9	and	132	134	O	and	and	and	CC	False
DDI-MedLine.d149.s9	its	136	138	O	its	its	its	PRP$	False
DDI-MedLine.d149.s9	subcellular	140	150	O	subcellular	lar	ular	NN	False
DDI-MedLine.d149.s9	organelles	152	161	O	organelles	les	lles	NNS	False
DDI-MedLine.d149.s9	,	162	162	O	,	,	,	,	False
DDI-MedLine.d149.s9	enhancing	164	172	O	enhancing	ing	cing	VBG	False
DDI-MedLine.d149.s9	cellular	174	181	O	cellular	lar	ular	JJ	False
DDI-MedLine.d149.s9	proliferative	183	195	O	proliferative	ive	tive	NN	False
DDI-MedLine.d149.s9	activity	197	204	O	activity	ity	vity	NN	False
DDI-MedLine.d149.s9	and	206	208	O	and	and	and	CC	False
DDI-MedLine.d149.s9	inhibiting	210	219	O	inhibiting	ing	ting	VBG	False
DDI-MedLine.d149.s9	caspase-3	221	229	O	caspase-3	e-3	se-3	NN	False
DDI-MedLine.d149.s9	overexpression	231	244	O	overexpression	ion	sion	NN	False
DDI-MedLine.d149.s9	in	246	247	O	in	in	in	IN	False
DDI-MedLine.d149.s9	neurons	249	255	O	neurons	ons	rons	NNS	False
DDI-MedLine.d149.s9	.	256	256	O	.	.	.	.	False

DDI-MedLine.d220.s0	Evaluation	0	9	O	Evaluation	ion	tion	NN	False
DDI-MedLine.d220.s0	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d220.s0	hepatic	14	20	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d220.s0	clearance	22	30	O	clearance	nce	ance	NN	False
DDI-MedLine.d220.s0	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d220.s0	drug-drug	36	44	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d220.s0	interactions	46	57	O	interactions	ons	ions	NNS	False
DDI-MedLine.d220.s0	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d220.s0	luteolin	62	69	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s0	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d220.s0	apigenin	75	82	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s0	by	84	85	O	by	by	by	IN	False
DDI-MedLine.d220.s0	using	87	91	O	using	ing	sing	VBG	False
DDI-MedLine.d220.s0	primary	93	99	O	primary	ary	mary	NN	False
DDI-MedLine.d220.s0	cultured	101	108	O	cultured	red	ured	VBN	False
DDI-MedLine.d220.s0	rat	110	112	O	rat	rat	rat	NN	False
DDI-MedLine.d220.s0	hepatocytes	114	124	O	hepatocytes	tes	ytes	NNS	False
DDI-MedLine.d220.s0	.	125	125	O	.	.	.	.	False

DDI-MedLine.d220.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d220.s1	hepatic	4	10	O	hepatic	tic	atic	JJ	False
DDI-MedLine.d220.s1	clearance	12	20	O	clearance	nce	ance	NN	False
DDI-MedLine.d220.s1	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d220.s1	drug-drug	26	34	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d220.s1	interactions	36	47	O	interactions	ons	ions	NNS	False
DDI-MedLine.d220.s1	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d220.s1	luteolin	52	59	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s1	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d220.s1	apigenin	65	72	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s1	were	74	77	O	were	ere	were	VBD	False
DDI-MedLine.d220.s1	studied	79	85	O	studied	ied	died	VBN	False
DDI-MedLine.d220.s1	by	87	88	O	by	by	by	IN	False
DDI-MedLine.d220.s1	using	90	94	O	using	ing	sing	VBG	False
DDI-MedLine.d220.s1	primary	96	102	O	primary	ary	mary	NN	False
DDI-MedLine.d220.s1	cultured	104	111	O	cultured	red	ured	VBN	False
DDI-MedLine.d220.s1	rat	113	115	O	rat	rat	rat	NN	False
DDI-MedLine.d220.s1	hepatocytes	117	127	O	hepatocytes	tes	ytes	NNS	False
DDI-MedLine.d220.s1	.	128	128	O	.	.	.	.	False

DDI-MedLine.d220.s2	Luteolin	0	7	B-drug_n	Luteolin	lin	olin	NN	False
DDI-MedLine.d220.s2	and	9	11	O	and	and	and	CC	False
DDI-MedLine.d220.s2	apigenin	13	20	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s2	experienced	22	32	O	experienced	ced	nced	JJ	False
DDI-MedLine.d220.s2	extensive	34	42	O	extensive	ive	sive	JJ	False
DDI-MedLine.d220.s2	first-pass	44	53	O	first-pass	ass	pass	NN	False
DDI-MedLine.d220.s2	metabolism	55	64	O	metabolism	ism	lism	NN	False
DDI-MedLine.d220.s2	.	65	65	O	.	.	.	.	False

DDI-MedLine.d220.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d220.s3	elimination	4	14	O	elimination	ion	tion	NN	False
DDI-MedLine.d220.s3	percent	16	22	O	percent	ent	cent	NN	False
DDI-MedLine.d220.s3	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d220.s3	luteolin	27	34	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s3	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d220.s3	apigenin	40	47	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s3	was	49	51	O	was	was	was	VBD	False
DDI-MedLine.d220.s3	found	53	57	O	found	und	ound	NN	False
DDI-MedLine.d220.s3	to	59	60	O	to	to	to	TO	False
DDI-MedLine.d220.s3	be	62	63	O	be	be	be	VB	False
DDI-MedLine.d220.s3	91.9	65	68	O	91.9	1.9	91.9	CD	False
DDI-MedLine.d220.s3	%	69	69	O	%	%	%	NN	False
DDI-MedLine.d220.s3	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d220.s3	86.7	75	78	O	86.7	6.7	86.7	CD	False
DDI-MedLine.d220.s3	%	79	79	O	%	%	%	NN	False
DDI-MedLine.d220.s3	after	81	85	O	after	ter	fter	IN	False
DDI-MedLine.d220.s3	120	87	89	O	120	120	120	CD	False
DDI-MedLine.d220.s3	min	91	93	O	min	min	min	NN	False
DDI-MedLine.d220.s3	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d220.s3	incubation	98	107	O	incubation	ion	tion	NN	False
DDI-MedLine.d220.s3	.	108	108	O	.	.	.	.	False

DDI-MedLine.d220.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d220.s4	predicted	4	12	O	predicted	ted	cted	VBN	False
DDI-MedLine.d220.s4	%	14	14	O	%	%	%	NN	False
DDI-MedLine.d220.s4	liver	16	20	O	liver	ver	iver	NN	False
DDI-MedLine.d220.s4	blood	22	26	O	blood	ood	lood	NN	False
DDI-MedLine.d220.s4	flow	28	31	O	flow	low	flow	NN	False
DDI-MedLine.d220.s4	was	33	35	O	was	was	was	VBD	False
DDI-MedLine.d220.s4	82.3	37	40	O	82.3	2.3	82.3	CD	False
DDI-MedLine.d220.s4	%	41	41	O	%	%	%	NN	False
DDI-MedLine.d220.s4	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d220.s4	85.4	47	50	O	85.4	5.4	85.4	CD	False
DDI-MedLine.d220.s4	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d220.s4	for	53	55	O	for	for	for	IN	False
DDI-MedLine.d220.s4	luteolin	57	64	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s4	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d220.s4	apigenin	70	77	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s4	,	78	78	O	,	,	,	,	False
DDI-MedLine.d220.s4	respectively	80	91	O	respectively	ely	vely	RB	False
DDI-MedLine.d220.s4	.	92	92	O	.	.	.	.	False

DDI-MedLine.d220.s5	Total	0	4	O	Total	tal	otal	JJ	False
DDI-MedLine.d220.s5	glucuronidated/sulfated	6	28	O	glucuronidated/sulfated	ted	ated	VBN	False
DDI-MedLine.d220.s5	conjugates	30	39	O	conjugates	tes	ates	NNS	False
DDI-MedLine.d220.s5	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d220.s5	luteolin/apigenin	44	60	O	luteolin/apigenin	nin	enin	NN	False
DDI-MedLine.d220.s5	were	62	65	O	were	ere	were	VBD	False
DDI-MedLine.d220.s5	determined	67	76	O	determined	ned	ined	VBN	False
DDI-MedLine.d220.s5	by	78	79	O	by	by	by	IN	False
DDI-MedLine.d220.s5	an	81	82	O	an	an	an	DT	False
DDI-MedLine.d220.s5	enzyme	84	89	O	enzyme	yme	zyme	NN	False
DDI-MedLine.d220.s5	hydrolysis	91	100	O	hydrolysis	sis	ysis	NN	False
DDI-MedLine.d220.s5	method	102	107	O	method	hod	thod	NN	False
DDI-MedLine.d220.s5	.	108	108	O	.	.	.	.	False

DDI-MedLine.d220.s6	Compared	0	7	O	Compared	red	ared	VBN	False
DDI-MedLine.d220.s6	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d220.s6	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d220.s6	elimination	18	28	O	elimination	ion	tion	NN	False
DDI-MedLine.d220.s6	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d220.s6	pure	33	36	O	pure	ure	pure	NN	False
DDI-MedLine.d220.s6	luteolin	38	45	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s6	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d220.s6	apigenin	51	58	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s6	,	59	59	O	,	,	,	,	False
DDI-MedLine.d220.s6	the	61	63	O	the	the	the	DT	False
DDI-MedLine.d220.s6	elimination	65	75	O	elimination	ion	tion	NN	False
DDI-MedLine.d220.s6	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d220.s6	luteolin	80	87	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s6	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d220.s6	apigenin	93	100	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s6	was	102	104	O	was	was	was	VBD	False
DDI-MedLine.d220.s6	much	106	109	O	much	uch	much	JJ	False
DDI-MedLine.d220.s6	lower	111	115	O	lower	wer	ower	JJR	False
DDI-MedLine.d220.s6	in	117	118	O	in	in	in	IN	False
DDI-MedLine.d220.s6	hydrolyzed	120	129	O	hydrolyzed	zed	yzed	VBN	False
DDI-MedLine.d220.s6	Flos	131	134	O	Flos	los	Flos	NN	False
DDI-MedLine.d220.s6	Chrysanthemi	136	147	O	Chrysanthemi	emi	hemi	NN	False
DDI-MedLine.d220.s6	extract	149	155	O	extract	act	ract	NN	False
DDI-MedLine.d220.s6	(	157	157	O	(	(	(	(	False
DDI-MedLine.d220.s6	FCE	158	160	O	FCE	FCE	FCE	NN	brand
DDI-MedLine.d220.s6	)	161	161	O	)	)	)	)	False
DDI-MedLine.d220.s6	containing	163	172	O	containing	ing	ning	VBG	False
DDI-MedLine.d220.s6	comparable	174	183	O	comparable	ble	able	JJ	False
DDI-MedLine.d220.s6	amounts	185	191	O	amounts	nts	unts	NNS	False
DDI-MedLine.d220.s6	of	193	194	O	of	of	of	IN	False
DDI-MedLine.d220.s6	luteolin	196	203	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s6	and	205	207	O	and	and	and	CC	False
DDI-MedLine.d220.s6	apigenin	209	216	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s6	.	217	217	O	.	.	.	.	False

DDI-MedLine.d220.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d220.s7	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d220.s7	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d220.s7	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d220.s7	series	16	21	O	series	ies	ries	NN	False
DDI-MedLine.d220.s7	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d220.s7	flavonoids	26	35	B-drug_n	flavonoids	ids	oids	NNS	False
DDI-MedLine.d220.s7	,	36	36	O	,	,	,	,	False
DDI-MedLine.d220.s7	including	38	46	O	including	ing	ding	VBG	False
DDI-MedLine.d220.s7	flavonols	48	56	B-drug_n	flavonols	ols	nols	NNS	False
DDI-MedLine.d220.s7	,	57	57	O	,	,	,	,	False
DDI-MedLine.d220.s7	flavones	59	66	B-drug_n	flavones	nes	ones	NNS	False
DDI-MedLine.d220.s7	,	67	67	O	,	,	,	,	False
DDI-MedLine.d220.s7	isoflavone	69	78	B-drug_n	isoflavone	one	vone	NN	False
DDI-MedLine.d220.s7	,	79	79	O	,	,	,	,	False
DDI-MedLine.d220.s7	flavanone	81	89	B-drug_n	flavanone	one	none	NN	False
DDI-MedLine.d220.s7	,	90	90	O	,	,	,	,	False
DDI-MedLine.d220.s7	flavanonols	92	102	B-drug_n	flavanonols	ols	nols	NNS	False
DDI-MedLine.d220.s7	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d220.s7	catechins	108	116	B-drug_n	catechins	ins	hins	NNS	False
DDI-MedLine.d220.s7	,	117	117	O	,	,	,	,	False
DDI-MedLine.d220.s7	on	119	120	O	on	on	on	IN	False
DDI-MedLine.d220.s7	the	122	124	O	the	the	the	DT	False
DDI-MedLine.d220.s7	elimination	126	136	O	elimination	ion	tion	NN	False
DDI-MedLine.d220.s7	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d220.s7	luteolin	141	148	B-drug_n	luteolin	lin	olin	NN	False
DDI-MedLine.d220.s7	and	150	152	O	and	and	and	CC	False
DDI-MedLine.d220.s7	apigenin	154	161	B-drug_n	apigenin	nin	enin	NN	False
DDI-MedLine.d220.s7	was	163	165	O	was	was	was	VBD	False
DDI-MedLine.d220.s7	studied	167	173	O	studied	ied	died	VBN	False
DDI-MedLine.d220.s7	.	174	174	O	.	.	.	.	False

DDI-MedLine.d220.s8	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d220.s8	least	3	7	O	least	ast	east	JJS	False
DDI-MedLine.d220.s8	four	9	12	O	four	our	four	CD	False
DDI-MedLine.d220.s8	key	14	16	O	key	key	key	NN	False
DDI-MedLine.d220.s8	determinants	18	29	O	determinants	nts	ants	NNS	False
DDI-MedLine.d220.s8	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d220.s8	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d220.s8	chemical	38	45	O	chemical	cal	ical	NN	False
DDI-MedLine.d220.s8	structures	47	56	O	structures	res	ures	NNS	False
DDI-MedLine.d220.s8	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d220.s8	flavonoids	61	70	B-drug_n	flavonoids	ids	oids	NNS	False
DDI-MedLine.d220.s8	are	72	74	O	are	are	are	VBP	False
DDI-MedLine.d220.s8	necessary	76	84	O	necessary	ary	sary	JJ	False
DDI-MedLine.d220.s8	for	86	88	O	for	for	for	IN	False
DDI-MedLine.d220.s8	exerting	90	97	O	exerting	ing	ting	VBG	False
DDI-MedLine.d220.s8	the	99	101	O	the	the	the	DT	False
DDI-MedLine.d220.s8	inhibitory	103	112	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d220.s8	effects	114	120	O	effects	cts	ects	NNS	False
DDI-MedLine.d220.s8	on	122	123	O	on	on	on	IN	False
DDI-MedLine.d220.s8	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d220.s8	conjugation	129	139	O	conjugation	ion	tion	NN	False
DDI-MedLine.d220.s8	:	140	140	O	:	:	:	:	False
DDI-MedLine.d220.s8	1	142	142	O	1	1	1	CD	False
DDI-MedLine.d220.s8	)	143	143	O	)	)	)	)	False
DDI-MedLine.d220.s8	catechol	145	152	O	catechol	hol	chol	NN	False
DDI-MedLine.d220.s8	structure	154	162	O	structure	ure	ture	NN	False
DDI-MedLine.d220.s8	(	164	164	O	(	(	(	(	False
DDI-MedLine.d220.s8	3',4'-dihydroxylation	165	185	O	3',4'-dihydroxylation	ion	tion	NN	False
DDI-MedLine.d220.s8	)	186	186	O	)	)	)	)	False
DDI-MedLine.d220.s8	in	188	189	O	in	in	in	IN	False
DDI-MedLine.d220.s8	the	191	193	O	the	the	the	DT	False
DDI-MedLine.d220.s8	B-ring	195	200	O	B-ring	ing	ring	NN	False
DDI-MedLine.d220.s8	;	201	201	O	;	;	;	:	False

DDI-MedLine.d220.s9	2	0	0	O	2	2	2	CD	False
DDI-MedLine.d220.s9	)	1	1	O	)	)	)	)	False
DDI-MedLine.d220.s9	B-ring	3	8	O	B-ring	ing	ring	NN	False
DDI-MedLine.d220.s9	is	10	11	O	is	is	is	VBZ	False
DDI-MedLine.d220.s9	attached	13	20	O	attached	hed	ched	VBN	False
DDI-MedLine.d220.s9	to	22	23	O	to	to	to	TO	False
DDI-MedLine.d220.s9	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d220.s9	C-2	29	31	O	C-2	C-2	C-2	NN	brand
DDI-MedLine.d220.s9	position	33	40	O	position	ion	tion	NN	False
DDI-MedLine.d220.s9	on	42	43	O	on	on	on	IN	False
DDI-MedLine.d220.s9	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d220.s9	C-ring	49	54	O	C-ring	ing	ring	NN	False
DDI-MedLine.d220.s9	;	55	55	O	;	;	;	:	False

DDI-MedLine.d220.s10	3	0	0	O	3	3	3	CD	False
DDI-MedLine.d220.s10	)	1	1	O	)	)	)	)	False
DDI-MedLine.d220.s10	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d220.s10	C2-3	7	10	O	C2-3	2-3	C2-3	NN	brand
DDI-MedLine.d220.s10	double	12	17	O	double	ble	uble	RB	False
DDI-MedLine.d220.s10	bond	19	22	O	bond	ond	bond	NN	False
DDI-MedLine.d220.s10	in	24	25	O	in	in	in	IN	False
DDI-MedLine.d220.s10	conjunction	27	37	O	conjunction	ion	tion	NN	False
DDI-MedLine.d220.s10	with	39	42	O	with	ith	with	IN	False
DDI-MedLine.d220.s10	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d220.s10	C4	48	49	O	C4	C4	C4	NN	brand
DDI-MedLine.d220.s10	carbonyl	51	58	O	carbonyl	nyl	onyl	NN	False
DDI-MedLine.d220.s10	group	60	64	O	group	oup	roup	NN	False
DDI-MedLine.d220.s10	on	66	67	O	on	on	on	IN	False
DDI-MedLine.d220.s10	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d220.s10	C-ring	73	78	O	C-ring	ing	ring	NN	False
DDI-MedLine.d220.s10	;	79	79	O	;	;	;	:	False

DDI-MedLine.d220.s11	4	0	0	O	4	4	4	CD	False
DDI-MedLine.d220.s11	)	1	1	O	)	)	)	)	False
DDI-MedLine.d220.s11	no	3	4	O	no	no	no	DT	False
DDI-MedLine.d220.s11	glycoside	6	14	O	glycoside	ide	side	NN	False
DDI-MedLine.d220.s11	present	16	22	O	present	ent	sent	NN	False
DDI-MedLine.d220.s11	.	23	23	O	.	.	.	.	False

DDI-MedLine.d220.s12	Investigation	0	12	O	Investigation	ion	tion	NN	False
DDI-MedLine.d220.s12	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d220.s12	clearance	17	25	O	clearance	nce	ance	NN	False
DDI-MedLine.d220.s12	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d220.s12	interaction	31	41	O	interaction	ion	tion	NN	False
DDI-MedLine.d220.s12	among	43	47	O	among	ong	mong	IN	False
DDI-MedLine.d220.s12	flavonoids	49	58	B-drug_n	flavonoids	ids	oids	NNS	False
DDI-MedLine.d220.s12	could	60	64	O	could	uld	ould	MD	False
DDI-MedLine.d220.s12	help	66	69	O	help	elp	help	NN	False
DDI-MedLine.d220.s12	us	71	72	O	us	us	us	PRP	False
DDI-MedLine.d220.s12	better	74	79	O	better	ter	tter	RBR	False
DDI-MedLine.d220.s12	understand	81	90	O	understand	and	tand	NN	False
DDI-MedLine.d220.s12	their	92	96	O	their	eir	heir	PRP$	False
DDI-MedLine.d220.s12	bioavailability	98	112	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d220.s12	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d220.s12	offer	118	122	O	offer	fer	ffer	NN	False
DDI-MedLine.d220.s12	insight	124	130	O	insight	ght	ight	NN	False
DDI-MedLine.d220.s12	into	132	135	O	into	nto	into	IN	False
DDI-MedLine.d220.s12	the	137	139	O	the	the	the	DT	False
DDI-MedLine.d220.s12	approaches	141	150	O	approaches	hes	ches	NNS	False
DDI-MedLine.d220.s12	to	152	153	O	to	to	to	TO	False
DDI-MedLine.d220.s12	be	155	156	O	be	be	be	VB	False
DDI-MedLine.d220.s12	taken	158	162	O	taken	ken	aken	VBN	False
DDI-MedLine.d220.s12	to	164	165	O	to	to	to	TO	False
DDI-MedLine.d220.s12	minimize	167	174	O	minimize	ize	mize	VB	False
DDI-MedLine.d220.s12	competitive	176	186	O	competitive	ive	tive	JJ	False
DDI-MedLine.d220.s12	effects	188	194	O	effects	cts	ects	NNS	False
DDI-MedLine.d220.s12	,	195	195	O	,	,	,	,	False
DDI-MedLine.d220.s12	and	197	199	O	and	and	and	CC	False
DDI-MedLine.d220.s12	to	201	202	O	to	to	to	TO	False
DDI-MedLine.d220.s12	design	204	209	O	design	ign	sign	NN	False
DDI-MedLine.d220.s12	appropriate	211	221	O	appropriate	ate	iate	NN	False
DDI-MedLine.d220.s12	bioavailability	223	237	O	bioavailability	ity	lity	NN	False
DDI-MedLine.d220.s12	studies	239	245	O	studies	ies	dies	NNS	False
DDI-MedLine.d220.s12	in	247	248	O	in	in	in	IN	False
DDI-MedLine.d220.s12	humans	250	255	O	humans	ans	mans	NNS	False
DDI-MedLine.d220.s12	.	256	256	O	.	.	.	.	False

DDI-MedLine.d183.s0	Neuropharmacological	0	19	O	Neuropharmacological	cal	ical	JJ	False
DDI-MedLine.d183.s0	approach	21	28	O	approach	ach	oach	NN	False
DDI-MedLine.d183.s0	against	30	36	O	against	nst	inst	IN	False
DDI-MedLine.d183.s0	MPTP	38	41	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d183.s0	(	43	43	O	(	(	(	(	False
DDI-MedLine.d183.s0	1-methyl-4-phenyl-1,2,3,6-	44	69	B-drug_n	1-methyl-4-phenyl-1,2,3,6-	,6-	3,6-	JJ	False
DDI-MedLine.d183.s0	tetrahydropyridine	71	88	I-drug_n	tetrahydropyridine	ine	dine	NN	drug
DDI-MedLine.d183.s0	)	89	89	O	)	)	)	)	False
DDI-MedLine.d183.s0	-induced	90	97	O	-induced	ced	uced	VBN	False
DDI-MedLine.d183.s0	mouse	99	103	O	mouse	use	ouse	NN	False
DDI-MedLine.d183.s0	model	105	109	O	model	del	odel	NN	False
DDI-MedLine.d183.s0	of	111	112	O	of	of	of	IN	False
DDI-MedLine.d183.s0	Parkinson	114	122	O	Parkinson	son	nson	NN	False
DDI-MedLine.d183.s0	's	123	124	O	's	's	's	POS	False
DDI-MedLine.d183.s0	disease	126	132	O	disease	ase	ease	NN	False
DDI-MedLine.d183.s0	.	133	133	O	.	.	.	.	False

DDI-MedLine.d183.s1	Parkinson	0	8	O	Parkinson	son	nson	NN	False
DDI-MedLine.d183.s1	's	9	10	O	's	's	's	POS	False
DDI-MedLine.d183.s1	disease	12	18	O	disease	ase	ease	NN	False
DDI-MedLine.d183.s1	(	20	20	O	(	(	(	(	False
DDI-MedLine.d183.s1	PD	21	22	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s1	)	23	23	O	)	)	)	)	False
DDI-MedLine.d183.s1	is	25	26	O	is	is	is	VBZ	False
DDI-MedLine.d183.s1	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d183.s1	common	30	35	O	common	mon	mmon	JJ	False
DDI-MedLine.d183.s1	neurodegenerative	37	53	O	neurodegenerative	ive	tive	JJ	False
DDI-MedLine.d183.s1	disease	55	61	O	disease	ase	ease	NN	False
DDI-MedLine.d183.s1	that	63	66	O	that	hat	that	IN	False
DDI-MedLine.d183.s1	appears	68	74	O	appears	ars	ears	VBZ	False
DDI-MedLine.d183.s1	essentially	76	86	O	essentially	lly	ally	RB	False
DDI-MedLine.d183.s1	as	88	89	O	as	as	as	IN	False
DDI-MedLine.d183.s1	a	91	91	O	a	a	a	DT	False
DDI-MedLine.d183.s1	sporadic	93	100	O	sporadic	dic	adic	NN	False
DDI-MedLine.d183.s1	condition	102	110	O	condition	ion	tion	NN	False
DDI-MedLine.d183.s1	.	111	111	O	.	.	.	.	False

DDI-MedLine.d183.s2	PD	0	1	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d183.s2	well	6	9	O	well	ell	well	RB	False
DDI-MedLine.d183.s2	known	11	15	O	known	own	nown	VBN	False
DDI-MedLine.d183.s2	to	17	18	O	to	to	to	TO	False
DDI-MedLine.d183.s2	be	20	21	O	be	be	be	VB	False
DDI-MedLine.d183.s2	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d183.s2	chronic	25	31	O	chronic	nic	onic	NN	False
DDI-MedLine.d183.s2	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d183.s2	progressive	37	47	O	progressive	ive	sive	NN	False
DDI-MedLine.d183.s2	neurodegenerative	49	65	O	neurodegenerative	ive	tive	JJ	False
DDI-MedLine.d183.s2	disease	67	73	O	disease	ase	ease	NN	False
DDI-MedLine.d183.s2	produced	75	82	O	produced	ced	uced	VBN	False
DDI-MedLine.d183.s2	by	84	85	O	by	by	by	IN	False
DDI-MedLine.d183.s2	a	87	87	O	a	a	a	DT	False
DDI-MedLine.d183.s2	selective	89	97	O	selective	ive	tive	NN	False
DDI-MedLine.d183.s2	degeneration	99	110	O	degeneration	ion	tion	NN	False
DDI-MedLine.d183.s2	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d183.s2	dopaminergic	115	126	O	dopaminergic	gic	rgic	NN	False
DDI-MedLine.d183.s2	neurons	128	134	O	neurons	ons	rons	NNS	False
DDI-MedLine.d183.s2	in	136	137	O	in	in	in	IN	False
DDI-MedLine.d183.s2	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d183.s2	substantia	143	152	O	substantia	tia	ntia	NN	False
DDI-MedLine.d183.s2	nigra	154	158	O	nigra	gra	igra	NN	False
DDI-MedLine.d183.s2	pars	160	163	O	pars	ars	pars	NNS	False
DDI-MedLine.d183.s2	compacta	165	172	O	compacta	cta	acta	NN	False
DDI-MedLine.d183.s2	.	173	173	O	.	.	.	.	False

DDI-MedLine.d183.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d183.s3	main	4	7	O	main	ain	main	JJ	False
DDI-MedLine.d183.s3	clinical	9	16	O	clinical	cal	ical	JJ	False
DDI-MedLine.d183.s3	features	18	25	O	features	res	ures	NNS	False
DDI-MedLine.d183.s3	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d183.s3	PD	30	31	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s3	include	33	39	O	include	ude	lude	NN	False
DDI-MedLine.d183.s3	tremor	41	46	O	tremor	mor	emor	NN	False
DDI-MedLine.d183.s3	,	47	47	O	,	,	,	,	False
DDI-MedLine.d183.s3	bradykinesia	49	60	O	bradykinesia	sia	esia	NN	False
DDI-MedLine.d183.s3	,	61	61	O	,	,	,	,	False
DDI-MedLine.d183.s3	rigidity	63	70	O	rigidity	ity	dity	NN	False
DDI-MedLine.d183.s3	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d183.s3	postural	76	83	O	postural	ral	ural	JJ	False
DDI-MedLine.d183.s3	instability	85	95	O	instability	ity	lity	NN	False
DDI-MedLine.d183.s3	.	96	96	O	.	.	.	.	False

DDI-MedLine.d183.s4	Most	0	3	O	Most	ost	Most	JJS	False
DDI-MedLine.d183.s4	insights	5	12	O	insights	hts	ghts	NNS	False
DDI-MedLine.d183.s4	into	14	17	O	into	nto	into	IN	False
DDI-MedLine.d183.s4	pathogenesis	19	30	O	pathogenesis	sis	esis	NN	False
DDI-MedLine.d183.s4	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d183.s4	PD	35	36	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s4	come	38	41	O	come	ome	come	VB	False
DDI-MedLine.d183.s4	from	43	46	O	from	rom	from	IN	False
DDI-MedLine.d183.s4	investigations	48	61	O	investigations	ons	ions	NNS	False
DDI-MedLine.d183.s4	performed	63	71	O	performed	med	rmed	VBN	False
DDI-MedLine.d183.s4	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d183.s4	experimental	76	87	O	experimental	tal	ntal	NN	False
DDI-MedLine.d183.s4	models	89	94	O	models	els	dels	NNS	False
DDI-MedLine.d183.s4	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d183.s4	PD	99	100	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s4	,	101	101	O	,	,	,	,	False
DDI-MedLine.d183.s4	especially	103	112	O	especially	lly	ally	RB	False
DDI-MedLine.d183.s4	those	114	118	O	those	ose	hose	DT	False
DDI-MedLine.d183.s4	produced	120	127	O	produced	ced	uced	VBN	False
DDI-MedLine.d183.s4	by	129	130	O	by	by	by	IN	False
DDI-MedLine.d183.s4	neurotoxins	132	142	O	neurotoxins	ins	xins	NNS	False
DDI-MedLine.d183.s4	.	143	143	O	.	.	.	.	False

DDI-MedLine.d183.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d183.s5	biochemical	4	14	O	biochemical	cal	ical	JJ	False
DDI-MedLine.d183.s5	and	16	18	O	and	and	and	CC	False
DDI-MedLine.d183.s5	cellular	20	27	O	cellular	lar	ular	JJ	False
DDI-MedLine.d183.s5	alterations	29	39	O	alterations	ons	ions	NNS	False
DDI-MedLine.d183.s5	that	41	44	O	that	hat	that	IN	False
DDI-MedLine.d183.s5	occur	46	50	O	occur	cur	ccur	NN	False
DDI-MedLine.d183.s5	after	52	56	O	after	ter	fter	IN	False
DDI-MedLine.d183.s5	1-methyl-4-phenyl-1,2,3,6-	58	83	B-drug_n	1-methyl-4-phenyl-1,2,3,6-	,6-	3,6-	JJ	False
DDI-MedLine.d183.s5	tetrahydropyridine	85	102	I-drug_n	tetrahydropyridine	ine	dine	NN	drug
DDI-MedLine.d183.s5	(	104	104	O	(	(	(	(	False
DDI-MedLine.d183.s5	MPTP	105	108	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d183.s5	)	109	109	O	)	)	)	)	False
DDI-MedLine.d183.s5	treatment	111	119	O	treatment	ent	ment	NN	False
DDI-MedLine.d183.s5	are	121	123	O	are	are	are	VBP	False
DDI-MedLine.d183.s5	remarkably	125	134	O	remarkably	bly	ably	RB	False
DDI-MedLine.d183.s5	similar	136	142	O	similar	lar	ilar	JJ	False
DDI-MedLine.d183.s5	to	144	145	O	to	to	to	TO	False
DDI-MedLine.d183.s5	that	147	150	O	that	hat	that	IN	False
DDI-MedLine.d183.s5	observed	152	159	O	observed	ved	rved	VBN	False
DDI-MedLine.d183.s5	in	161	162	O	in	in	in	IN	False
DDI-MedLine.d183.s5	idiopathic	164	173	O	idiopathic	hic	thic	JJ	False
DDI-MedLine.d183.s5	PD	175	176	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s5	.	177	177	O	.	.	.	.	False

DDI-MedLine.d183.s6	Furthermore	0	10	O	Furthermore	ore	more	RB	False
DDI-MedLine.d183.s6	,	11	11	O	,	,	,	,	False
DDI-MedLine.d183.s6	it	13	14	O	it	it	it	PRP	False
DDI-MedLine.d183.s6	is	16	17	O	is	is	is	VBZ	False
DDI-MedLine.d183.s6	well	19	22	O	well	ell	well	RB	False
DDI-MedLine.d183.s6	known	24	28	O	known	own	nown	VBN	False
DDI-MedLine.d183.s6	that	30	33	O	that	hat	that	IN	False
DDI-MedLine.d183.s6	acute	35	39	O	acute	ute	cute	NN	False
DDI-MedLine.d183.s6	treatment	41	49	O	treatment	ent	ment	NN	False
DDI-MedLine.d183.s6	with	51	54	O	with	ith	with	IN	False
DDI-MedLine.d183.s6	MPTP	56	59	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d183.s6	can	61	63	O	can	can	can	MD	False
DDI-MedLine.d183.s6	cause	65	69	O	cause	use	ause	NN	False
DDI-MedLine.d183.s6	a	71	71	O	a	a	a	DT	False
DDI-MedLine.d183.s6	severe	73	78	O	severe	ere	vere	JJ	False
DDI-MedLine.d183.s6	loss	80	83	O	loss	oss	loss	NN	False
DDI-MedLine.d183.s6	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d183.s6	tyrosine	88	95	O	tyrosine	ine	sine	NN	drug
DDI-MedLine.d183.s6	hydroxylase	97	107	O	hydroxylase	ase	lase	NN	False
DDI-MedLine.d183.s6	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d183.s6	dopamine	113	120	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d183.s6	transporter	122	132	O	transporter	ter	rter	NN	False
DDI-MedLine.d183.s6	protein	134	140	O	protein	ein	tein	NN	False
DDI-MedLine.d183.s6	levels	142	147	O	levels	els	vels	NNS	False
DDI-MedLine.d183.s6	and	149	151	O	and	and	and	CC	False
DDI-MedLine.d183.s6	dopamine	153	160	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d183.s6	contents	162	169	O	contents	nts	ents	NNS	False
DDI-MedLine.d183.s6	in	171	172	O	in	in	in	IN	False
DDI-MedLine.d183.s6	the	174	176	O	the	the	the	DT	False
DDI-MedLine.d183.s6	striatum	178	185	O	striatum	tum	atum	NN	False
DDI-MedLine.d183.s6	of	187	188	O	of	of	of	IN	False
DDI-MedLine.d183.s6	mice	190	193	O	mice	ice	mice	NN	False
DDI-MedLine.d183.s6	,	194	194	O	,	,	,	,	False
DDI-MedLine.d183.s6	as	196	197	O	as	as	as	IN	False
DDI-MedLine.d183.s6	compared	199	206	O	compared	red	ared	VBN	False
DDI-MedLine.d183.s6	to	208	209	O	to	to	to	TO	False
DDI-MedLine.d183.s6	continuous	211	220	O	continuous	ous	uous	JJ	False
DDI-MedLine.d183.s6	MPTP	222	225	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d183.s6	treatment	227	235	O	treatment	ent	ment	NN	False
DDI-MedLine.d183.s6	.	236	236	O	.	.	.	.	False

DDI-MedLine.d183.s7	Thus	0	3	O	Thus	hus	Thus	RB	False
DDI-MedLine.d183.s7	these	5	9	O	these	ese	hese	DT	False
DDI-MedLine.d183.s7	findings	11	18	O	findings	ngs	ings	NNS	False
DDI-MedLine.d183.s7	may	20	22	O	may	may	may	MD	False
DDI-MedLine.d183.s7	support	24	30	O	support	ort	port	NN	False
DDI-MedLine.d183.s7	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d183.s7	validity	36	43	O	validity	ity	dity	NN	False
DDI-MedLine.d183.s7	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d183.s7	acute	48	52	O	acute	ute	cute	NN	False
DDI-MedLine.d183.s7	MPTP	54	57	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d183.s7	treatment	59	67	O	treatment	ent	ment	NN	False
DDI-MedLine.d183.s7	model	69	73	O	model	del	odel	NN	False
DDI-MedLine.d183.s7	for	75	77	O	for	for	for	IN	False
DDI-MedLine.d183.s7	unraveling	79	88	O	unraveling	ing	ling	VBG	False
DDI-MedLine.d183.s7	in	90	91	O	in	in	in	IN	False
DDI-MedLine.d183.s7	the	93	95	O	the	the	the	DT	False
DDI-MedLine.d183.s7	neurodegenerative	97	113	O	neurodegenerative	ive	tive	JJ	False
DDI-MedLine.d183.s7	processes	115	123	O	processes	ses	sses	NNS	False
DDI-MedLine.d183.s7	in	125	126	O	in	in	in	IN	False
DDI-MedLine.d183.s7	PD	128	129	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s7	.	130	130	O	.	.	.	.	False

DDI-MedLine.d183.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d183.s8	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d183.s8	review	8	13	O	review	iew	view	NN	False
DDI-MedLine.d183.s8	,	14	14	O	,	,	,	,	False
DDI-MedLine.d183.s8	we	16	17	O	we	we	we	PRP	False
DDI-MedLine.d183.s8	discuss	19	25	O	discuss	uss	cuss	NN	False
DDI-MedLine.d183.s8	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d183.s8	neuroprotective	31	45	O	neuroprotective	ive	tive	JJ	False
DDI-MedLine.d183.s8	effects	47	53	O	effects	cts	ects	NNS	False
DDI-MedLine.d183.s8	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d183.s8	various	58	64	O	various	ous	ious	JJ	False
DDI-MedLine.d183.s8	compounds	66	74	O	compounds	nds	unds	NNS	False
DDI-MedLine.d183.s8	against	76	82	O	against	nst	inst	IN	False
DDI-MedLine.d183.s8	neuronal	84	91	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d183.s8	cell	93	96	O	cell	ell	cell	NN	False
DDI-MedLine.d183.s8	loss	98	101	O	loss	oss	loss	NN	False
DDI-MedLine.d183.s8	in	103	104	O	in	in	in	IN	False
DDI-MedLine.d183.s8	an	106	107	O	an	an	an	DT	False
DDI-MedLine.d183.s8	MPTP	109	112	B-drug_n	MPTP	PTP	MPTP	NN	brand
DDI-MedLine.d183.s8	model	114	118	O	model	del	odel	NN	False
DDI-MedLine.d183.s8	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d183.s8	PD	123	124	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s8	.	125	125	O	.	.	.	.	False

DDI-MedLine.d183.s9	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d183.s9	review	5	10	O	review	iew	view	NN	False
DDI-MedLine.d183.s9	may	12	14	O	may	may	may	MD	False
DDI-MedLine.d183.s9	lead	16	19	O	lead	ead	lead	NN	False
DDI-MedLine.d183.s9	to	21	22	O	to	to	to	TO	False
DDI-MedLine.d183.s9	a	24	24	O	a	a	a	DT	False
DDI-MedLine.d183.s9	much	26	29	O	much	uch	much	JJ	False
DDI-MedLine.d183.s9	better	31	36	O	better	ter	tter	RBR	False
DDI-MedLine.d183.s9	understanding	38	50	O	understanding	ing	ding	VBG	False
DDI-MedLine.d183.s9	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d183.s9	PD	55	56	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s9	as	58	59	O	as	as	as	IN	False
DDI-MedLine.d183.s9	well	61	64	O	well	ell	well	RB	False
DDI-MedLine.d183.s9	as	66	67	O	as	as	as	IN	False
DDI-MedLine.d183.s9	provide	69	75	O	provide	ide	vide	NN	False
DDI-MedLine.d183.s9	novel	77	81	O	novel	vel	ovel	NN	False
DDI-MedLine.d183.s9	clues	83	87	O	clues	ues	lues	NNS	False
DDI-MedLine.d183.s9	to	89	90	O	to	to	to	TO	False
DDI-MedLine.d183.s9	new	92	94	O	new	new	new	JJ	False
DDI-MedLine.d183.s9	targets	96	102	O	targets	ets	gets	NNS	False
DDI-MedLine.d183.s9	for	104	106	O	for	for	for	IN	False
DDI-MedLine.d183.s9	therapeutic	108	118	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d183.s9	interventions	120	132	O	interventions	ons	ions	NNS	False
DDI-MedLine.d183.s9	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d183.s9	PD	137	138	O	PD	PD	PD	NN	brand
DDI-MedLine.d183.s9	patients	140	147	O	patients	nts	ents	NNS	False
DDI-MedLine.d183.s9	.	148	148	O	.	.	.	.	False

DDI-MedLine.d168.s0	Spontaneous	0	10	O	Spontaneous	ous	eous	JJ	False
DDI-MedLine.d168.s0	spiking	12	18	O	spiking	ing	king	VBG	False
DDI-MedLine.d168.s0	and	20	22	O	and	and	and	CC	False
DDI-MedLine.d168.s0	synaptic	24	31	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d168.s0	depression	33	42	O	depression	ion	sion	NN	False
DDI-MedLine.d168.s0	underlie	44	51	O	underlie	lie	rlie	NN	False
DDI-MedLine.d168.s0	noradrenergic	53	65	O	noradrenergic	gic	rgic	NN	False
DDI-MedLine.d168.s0	control	67	73	O	control	rol	trol	NN	False
DDI-MedLine.d168.s0	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d168.s0	feed-forward	78	89	O	feed-forward	ard	ward	NN	False
DDI-MedLine.d168.s0	inhibition	91	100	O	inhibition	ion	tion	NN	False
DDI-MedLine.d168.s0	.	101	101	O	.	.	.	.	False

DDI-MedLine.d168.s1	Inhibitory	0	9	O	Inhibitory	ory	tory	NN	False
DDI-MedLine.d168.s1	interneurons	11	22	O	interneurons	ons	rons	NNS	False
DDI-MedLine.d168.s1	across	24	29	O	across	oss	ross	IN	False
DDI-MedLine.d168.s1	diverse	31	37	O	diverse	rse	erse	NN	False
DDI-MedLine.d168.s1	brain	39	43	O	brain	ain	rain	NN	False
DDI-MedLine.d168.s1	regions	45	51	O	regions	ons	ions	NNS	False
DDI-MedLine.d168.s1	commonly	53	60	O	commonly	nly	only	RB	False
DDI-MedLine.d168.s1	exhibit	62	68	O	exhibit	bit	ibit	NN	False
DDI-MedLine.d168.s1	spontaneous	70	80	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d168.s1	spiking	82	88	O	spiking	ing	king	VBG	False
DDI-MedLine.d168.s1	activity	90	97	O	activity	ity	vity	NN	False
DDI-MedLine.d168.s1	,	98	98	O	,	,	,	,	False
DDI-MedLine.d168.s1	even	100	103	O	even	ven	even	RB	False
DDI-MedLine.d168.s1	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d168.s1	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d168.s1	absence	112	118	O	absence	nce	ence	NN	False
DDI-MedLine.d168.s1	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d168.s1	external	123	130	O	external	nal	rnal	JJ	False
DDI-MedLine.d168.s1	stimuli	132	138	O	stimuli	uli	muli	NNS	False
DDI-MedLine.d168.s1	.	139	139	O	.	.	.	.	False

DDI-MedLine.d168.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d168.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d168.s2	not	6	8	O	not	not	not	RB	False
DDI-MedLine.d168.s2	well	10	13	O	well	ell	well	RB	False
DDI-MedLine.d168.s2	understood	15	24	O	understood	ood	tood	NN	False
DDI-MedLine.d168.s2	how	26	28	O	how	how	how	WRB	False
DDI-MedLine.d168.s2	stimulus-evoked	30	44	O	stimulus-evoked	ked	oked	JJ	False
DDI-MedLine.d168.s2	inhibition	46	55	O	inhibition	ion	tion	NN	False
DDI-MedLine.d168.s2	can	57	59	O	can	can	can	MD	False
DDI-MedLine.d168.s2	be	61	62	O	be	be	be	VB	False
DDI-MedLine.d168.s2	distinguished	64	76	O	distinguished	hed	shed	VBN	False
DDI-MedLine.d168.s2	from	78	81	O	from	rom	from	IN	False
DDI-MedLine.d168.s2	background	83	92	O	background	und	ound	NN	False
DDI-MedLine.d168.s2	inhibition	94	103	O	inhibition	ion	tion	NN	False
DDI-MedLine.d168.s2	arising	105	111	O	arising	ing	sing	VBG	False
DDI-MedLine.d168.s2	from	113	116	O	from	rom	from	IN	False
DDI-MedLine.d168.s2	spontaneous	118	128	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d168.s2	firing	130	135	O	firing	ing	ring	VBG	False
DDI-MedLine.d168.s2	.	136	136	O	.	.	.	.	False

DDI-MedLine.d168.s3	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d168.s3	found	3	7	O	found	und	ound	NN	False
DDI-MedLine.d168.s3	that	9	12	O	that	hat	that	IN	False
DDI-MedLine.d168.s3	noradrenaline	14	26	O	noradrenaline	ine	line	NN	drug
DDI-MedLine.d168.s3	simultaneously	28	41	O	simultaneously	sly	usly	RB	False
DDI-MedLine.d168.s3	reduced	43	49	O	reduced	ced	uced	VBN	False
DDI-MedLine.d168.s3	spontaneous	51	61	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d168.s3	inhibitory	63	72	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d168.s3	inputs	74	79	O	inputs	uts	puts	NNS	False
DDI-MedLine.d168.s3	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d168.s3	enhanced	85	92	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d168.s3	evoked	94	99	O	evoked	ked	oked	VBN	False
DDI-MedLine.d168.s3	inhibitory	101	110	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d168.s3	currents	112	119	O	currents	nts	ents	NNS	False
DDI-MedLine.d168.s3	recorded	121	128	O	recorded	ded	rded	VBN	False
DDI-MedLine.d168.s3	from	130	133	O	from	rom	from	IN	False
DDI-MedLine.d168.s3	principal	135	143	O	principal	pal	ipal	NN	False
DDI-MedLine.d168.s3	neurons	145	151	O	neurons	ons	rons	NNS	False
DDI-MedLine.d168.s3	of	153	154	O	of	of	of	IN	False
DDI-MedLine.d168.s3	the	156	158	O	the	the	the	DT	False
DDI-MedLine.d168.s3	mouse	160	164	O	mouse	use	ouse	NN	False
DDI-MedLine.d168.s3	dorsal	166	171	O	dorsal	sal	rsal	NN	False
DDI-MedLine.d168.s3	cochlear	173	180	O	cochlear	ear	lear	NN	False
DDI-MedLine.d168.s3	nucleus	182	188	O	nucleus	eus	leus	NN	False
DDI-MedLine.d168.s3	(	190	190	O	(	(	(	(	False
DDI-MedLine.d168.s3	DCN	191	193	O	DCN	DCN	DCN	NN	brand
DDI-MedLine.d168.s3	)	194	194	O	)	)	)	)	False
DDI-MedLine.d168.s3	.	195	195	O	.	.	.	.	False

DDI-MedLine.d168.s4	Together	0	7	O	Together	her	ther	RB	False
DDI-MedLine.d168.s4	,	8	8	O	,	,	,	,	False
DDI-MedLine.d168.s4	these	10	14	O	these	ese	hese	DT	False
DDI-MedLine.d168.s4	effects	16	22	O	effects	cts	ects	NNS	False
DDI-MedLine.d168.s4	produced	24	31	O	produced	ced	uced	VBN	False
DDI-MedLine.d168.s4	a	33	33	O	a	a	a	DT	False
DDI-MedLine.d168.s4	large	35	39	O	large	rge	arge	JJ	False
DDI-MedLine.d168.s4	increase	41	48	O	increase	ase	ease	NN	False
DDI-MedLine.d168.s4	in	50	51	O	in	in	in	IN	False
DDI-MedLine.d168.s4	signal-to-noise	53	67	O	signal-to-noise	ise	oise	NN	False
DDI-MedLine.d168.s4	ratio	69	73	O	ratio	tio	atio	NN	False
DDI-MedLine.d168.s4	for	75	77	O	for	for	for	IN	False
DDI-MedLine.d168.s4	stimulus-evoked	79	93	O	stimulus-evoked	ked	oked	JJ	False
DDI-MedLine.d168.s4	inhibition	95	104	O	inhibition	ion	tion	NN	False
DDI-MedLine.d168.s4	.	105	105	O	.	.	.	.	False

DDI-MedLine.d168.s5	Surprisingly	0	11	O	Surprisingly	gly	ngly	RB	False
DDI-MedLine.d168.s5	,	12	12	O	,	,	,	,	False
DDI-MedLine.d168.s5	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d168.s5	opposing	18	25	O	opposing	ing	sing	VBG	False
DDI-MedLine.d168.s5	effects	27	33	O	effects	cts	ects	NNS	False
DDI-MedLine.d168.s5	on	35	36	O	on	on	on	IN	False
DDI-MedLine.d168.s5	background	38	47	O	background	und	ound	NN	False
DDI-MedLine.d168.s5	and	49	51	O	and	and	and	CC	False
DDI-MedLine.d168.s5	evoked	53	58	O	evoked	ked	oked	VBN	False
DDI-MedLine.d168.s5	currents	60	67	O	currents	nts	ents	NNS	False
DDI-MedLine.d168.s5	could	69	73	O	could	uld	ould	MD	False
DDI-MedLine.d168.s5	both	75	78	O	both	oth	both	DT	False
DDI-MedLine.d168.s5	be	80	81	O	be	be	be	VB	False
DDI-MedLine.d168.s5	attributed	83	92	O	attributed	ted	uted	VBN	False
DDI-MedLine.d168.s5	to	94	95	O	to	to	to	TO	False
DDI-MedLine.d168.s5	noradrenergic	97	109	O	noradrenergic	gic	rgic	NN	False
DDI-MedLine.d168.s5	silencing	111	119	O	silencing	ing	cing	VBG	False
DDI-MedLine.d168.s5	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d168.s5	spontaneous	124	134	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d168.s5	spiking	136	142	O	spiking	ing	king	VBG	False
DDI-MedLine.d168.s5	in	144	145	O	in	in	in	IN	False
DDI-MedLine.d168.s5	glycinergic	147	157	O	glycinergic	gic	rgic	NN	False
DDI-MedLine.d168.s5	interneurons	159	170	O	interneurons	ons	rons	NNS	False
DDI-MedLine.d168.s5	.	171	171	O	.	.	.	.	False

DDI-MedLine.d168.s6	During	0	5	O	During	ing	ring	IN	False
DDI-MedLine.d168.s6	spontaneous	7	17	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d168.s6	firing	19	24	O	firing	ing	ring	VBG	False
DDI-MedLine.d168.s6	,	25	25	O	,	,	,	,	False
DDI-MedLine.d168.s6	glycine	27	33	O	glycine	ine	cine	NN	drug
DDI-MedLine.d168.s6	release	35	41	O	release	ase	ease	NN	False
DDI-MedLine.d168.s6	was	43	45	O	was	was	was	VBD	False
DDI-MedLine.d168.s6	decreased	47	55	O	decreased	sed	ased	VBN	False
DDI-MedLine.d168.s6	due	57	59	O	due	due	due	JJ	False
DDI-MedLine.d168.s6	to	61	62	O	to	to	to	TO	False
DDI-MedLine.d168.s6	strong	64	69	O	strong	ong	rong	JJ	False
DDI-MedLine.d168.s6	short-term	71	80	O	short-term	erm	term	JJ	False
DDI-MedLine.d168.s6	depression	82	91	O	depression	ion	sion	NN	False
DDI-MedLine.d168.s6	.	92	92	O	.	.	.	.	False

DDI-MedLine.d168.s7	Elimination	0	10	O	Elimination	ion	tion	NN	False
DDI-MedLine.d168.s7	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d168.s7	background	15	24	O	background	und	ound	NN	False
DDI-MedLine.d168.s7	spiking	26	32	O	spiking	ing	king	VBG	False
DDI-MedLine.d168.s7	relieved	34	41	O	relieved	ved	eved	VBN	False
DDI-MedLine.d168.s7	inhibitory	43	52	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d168.s7	synapses	54	61	O	synapses	ses	pses	NNS	False
DDI-MedLine.d168.s7	from	63	66	O	from	rom	from	IN	False
DDI-MedLine.d168.s7	depression	68	77	O	depression	ion	sion	NN	False
DDI-MedLine.d168.s7	and	79	81	O	and	and	and	CC	False
DDI-MedLine.d168.s7	thereby	83	89	O	thereby	eby	reby	RB	False
DDI-MedLine.d168.s7	enhanced	91	98	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d168.s7	stimulus-evoked	100	114	O	stimulus-evoked	ked	oked	JJ	False
DDI-MedLine.d168.s7	inhibition	116	125	O	inhibition	ion	tion	NN	False
DDI-MedLine.d168.s7	.	126	126	O	.	.	.	.	False

DDI-MedLine.d168.s8	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d168.s8	findings	4	11	O	findings	ngs	ings	NNS	False
DDI-MedLine.d168.s8	illustrate	13	22	O	illustrate	ate	rate	NN	False
DDI-MedLine.d168.s8	a	24	24	O	a	a	a	DT	False
DDI-MedLine.d168.s8	simple	26	31	O	simple	ple	mple	NN	False
DDI-MedLine.d168.s8	yet	33	35	O	yet	yet	yet	RB	False
DDI-MedLine.d168.s8	powerful	37	44	O	powerful	ful	rful	JJ	False
DDI-MedLine.d168.s8	neuromodulatory	46	60	O	neuromodulatory	ory	tory	NN	False
DDI-MedLine.d168.s8	mechanism	62	70	O	mechanism	ism	nism	NN	False
DDI-MedLine.d168.s8	to	72	73	O	to	to	to	TO	False
DDI-MedLine.d168.s8	shift	75	79	O	shift	ift	hift	NN	False
DDI-MedLine.d168.s8	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d168.s8	balance	85	91	O	balance	nce	ance	NN	False
DDI-MedLine.d168.s8	between	93	99	O	between	een	ween	IN	False
DDI-MedLine.d168.s8	background	101	110	O	background	und	ound	NN	False
DDI-MedLine.d168.s8	and	112	114	O	and	and	and	CC	False
DDI-MedLine.d168.s8	stimulus-evoked	116	130	O	stimulus-evoked	ked	oked	JJ	False
DDI-MedLine.d168.s8	signals	132	138	O	signals	als	nals	NNS	False
DDI-MedLine.d168.s8	.	139	139	O	.	.	.	.	False

DDI-MedLine.d207.s0	Approach	0	7	O	Approach	ach	oach	NN	False
DDI-MedLine.d207.s0	to	9	10	O	to	to	to	TO	False
DDI-MedLine.d207.s0	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d207.s0	evaluation	16	25	O	evaluation	ion	tion	NN	False
DDI-MedLine.d207.s0	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d207.s0	a	30	30	O	a	a	a	DT	False
DDI-MedLine.d207.s0	patient	32	38	O	patient	ent	ient	NN	False
DDI-MedLine.d207.s0	with	40	43	O	with	ith	with	IN	False
DDI-MedLine.d207.s0	an	45	46	O	an	an	an	DT	False
DDI-MedLine.d207.s0	increased	48	56	O	increased	sed	ased	VBN	False
DDI-MedLine.d207.s0	serum	58	62	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s0	osmolal	64	70	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s0	gap	72	74	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s0	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d207.s0	high-anion-gap	80	93	O	high-anion-gap	gap	-gap	NN	False
DDI-MedLine.d207.s0	metabolic	95	103	O	metabolic	lic	olic	NN	False
DDI-MedLine.d207.s0	acidosis	105	112	O	acidosis	sis	osis	NN	False
DDI-MedLine.d207.s0	.	113	113	O	.	.	.	.	False

DDI-MedLine.d207.s1	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d207.s1	increase	3	10	O	increase	ase	ease	NN	False
DDI-MedLine.d207.s1	in	12	13	O	in	in	in	IN	False
DDI-MedLine.d207.s1	serum	15	19	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s1	osmolality	21	30	O	osmolality	ity	lity	NN	False
DDI-MedLine.d207.s1	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d207.s1	serum	36	40	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s1	osmolal	42	48	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s1	gap	50	52	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s1	with	54	57	O	with	ith	with	IN	False
DDI-MedLine.d207.s1	or	59	60	O	or	or	or	CC	False
DDI-MedLine.d207.s1	without	62	68	O	without	out	hout	IN	False
DDI-MedLine.d207.s1	high-anion-gap	70	83	O	high-anion-gap	gap	-gap	NN	False
DDI-MedLine.d207.s1	metabolic	85	93	O	metabolic	lic	olic	NN	False
DDI-MedLine.d207.s1	acidosis	95	102	O	acidosis	sis	osis	NN	False
DDI-MedLine.d207.s1	is	104	105	O	is	is	is	VBZ	False
DDI-MedLine.d207.s1	an	107	108	O	an	an	an	DT	False
DDI-MedLine.d207.s1	important	110	118	O	important	ant	tant	JJ	False
DDI-MedLine.d207.s1	clue	120	123	O	clue	lue	clue	NN	False
DDI-MedLine.d207.s1	to	125	126	O	to	to	to	TO	False
DDI-MedLine.d207.s1	exposure	128	135	O	exposure	ure	sure	NN	False
DDI-MedLine.d207.s1	to	137	138	O	to	to	to	TO	False
DDI-MedLine.d207.s1	one	140	142	O	one	one	one	CD	False
DDI-MedLine.d207.s1	of	144	145	O	of	of	of	IN	False
DDI-MedLine.d207.s1	the	147	149	O	the	the	the	DT	False
DDI-MedLine.d207.s1	toxic	151	155	O	toxic	xic	oxic	NN	False
DDI-MedLine.d207.s1	alcohols	157	164	O	alcohols	ols	hols	NNS	False
DDI-MedLine.d207.s1	,	165	165	O	,	,	,	,	False
DDI-MedLine.d207.s1	which	167	171	O	which	ich	hich	WDT	False
DDI-MedLine.d207.s1	include	173	179	O	include	ude	lude	NN	False
DDI-MedLine.d207.s1	methanol	181	188	B-drug_n	methanol	nol	anol	NN	False
DDI-MedLine.d207.s1	,	189	189	O	,	,	,	,	False
DDI-MedLine.d207.s1	ethylene	191	198	B-drug_n	ethylene	ene	lene	NN	False
DDI-MedLine.d207.s1	glycol	200	205	I-drug_n	glycol	col	ycol	NN	False
DDI-MedLine.d207.s1	,	206	206	O	,	,	,	,	False
DDI-MedLine.d207.s1	diethylene	208	217	B-drug_n	diethylene	ene	lene	NN	False
DDI-MedLine.d207.s1	glycol	219	224	I-drug_n	glycol	col	ycol	NN	False
DDI-MedLine.d207.s1	,	225	225	O	,	,	,	,	False
DDI-MedLine.d207.s1	propylene	227	235	B-drug_n	propylene	ene	lene	NN	False
DDI-MedLine.d207.s1	glycol	237	242	I-drug_n	glycol	col	ycol	NN	False
DDI-MedLine.d207.s1	,	243	243	O	,	,	,	,	False
DDI-MedLine.d207.s1	or	245	246	O	or	or	or	CC	False
DDI-MedLine.d207.s1	isopropanol	248	258	B-drug	isopropanol	nol	anol	NN	False
DDI-MedLine.d207.s1	.	259	259	O	.	.	.	.	False

DDI-MedLine.d207.s2	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d207.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d207.s2	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d207.s2	increase	13	20	O	increase	ase	ease	NN	False
DDI-MedLine.d207.s2	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d207.s2	serum	25	29	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s2	osmolal	31	37	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s2	gap	39	41	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s2	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d207.s2	metabolic	47	55	O	metabolic	lic	olic	NN	False
DDI-MedLine.d207.s2	acidosis	57	64	O	acidosis	sis	osis	NN	False
DDI-MedLine.d207.s2	can	66	68	O	can	can	can	MD	False
DDI-MedLine.d207.s2	occur	70	74	O	occur	cur	ccur	NN	False
DDI-MedLine.d207.s2	either	76	81	O	either	her	ther	DT	False
DDI-MedLine.d207.s2	together	83	90	O	together	her	ther	RB	False
DDI-MedLine.d207.s2	or	92	93	O	or	or	or	CC	False
DDI-MedLine.d207.s2	alone	95	99	O	alone	one	lone	RB	False
DDI-MedLine.d207.s2	depending	101	109	O	depending	ing	ding	VBG	False
DDI-MedLine.d207.s2	on	111	112	O	on	on	on	IN	False
DDI-MedLine.d207.s2	several	114	120	O	several	ral	eral	JJ	False
DDI-MedLine.d207.s2	factors	122	128	O	factors	ors	tors	NNS	False
DDI-MedLine.d207.s2	,	129	129	O	,	,	,	,	False
DDI-MedLine.d207.s2	including	131	139	O	including	ing	ding	VBG	False
DDI-MedLine.d207.s2	baseline	141	148	O	baseline	ine	line	NN	drug
DDI-MedLine.d207.s2	serum	150	154	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s2	osmolal	156	162	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s2	gap	164	166	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s2	,	167	167	O	,	,	,	,	False
DDI-MedLine.d207.s2	molecular	169	177	O	molecular	lar	ular	NN	False
DDI-MedLine.d207.s2	weight	179	184	O	weight	ght	ight	NN	False
DDI-MedLine.d207.s2	of	186	187	O	of	of	of	IN	False
DDI-MedLine.d207.s2	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d207.s2	alcohol	193	199	O	alcohol	hol	ohol	NN	False
DDI-MedLine.d207.s2	,	200	200	O	,	,	,	,	False
DDI-MedLine.d207.s2	and	202	204	O	and	and	and	CC	False
DDI-MedLine.d207.s2	stage	206	210	O	stage	age	tage	NN	False
DDI-MedLine.d207.s2	of	212	213	O	of	of	of	IN	False
DDI-MedLine.d207.s2	metabolism	215	224	O	metabolism	ism	lism	NN	False
DDI-MedLine.d207.s2	of	226	227	O	of	of	of	IN	False
DDI-MedLine.d207.s2	the	229	231	O	the	the	the	DT	False
DDI-MedLine.d207.s2	alcohol	233	239	O	alcohol	hol	ohol	NN	False
DDI-MedLine.d207.s2	.	240	240	O	.	.	.	.	False

DDI-MedLine.d207.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d207.s3	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d207.s3	,	11	11	O	,	,	,	,	False
DDI-MedLine.d207.s3	other	13	17	O	other	her	ther	JJ	False
DDI-MedLine.d207.s3	disorders	19	27	O	disorders	ers	ders	NNS	False
DDI-MedLine.d207.s3	,	28	28	O	,	,	,	,	False
DDI-MedLine.d207.s3	including	30	38	O	including	ing	ding	VBG	False
DDI-MedLine.d207.s3	diabetic	40	47	O	diabetic	tic	etic	JJ	False
DDI-MedLine.d207.s3	or	49	50	O	or	or	or	CC	False
DDI-MedLine.d207.s3	alcoholic	52	60	O	alcoholic	lic	olic	JJ	False
DDI-MedLine.d207.s3	ketoacidosis	62	73	O	ketoacidosis	sis	osis	NN	False
DDI-MedLine.d207.s3	,	74	74	O	,	,	,	,	False
DDI-MedLine.d207.s3	acute	76	80	O	acute	ute	cute	NN	False
DDI-MedLine.d207.s3	kidney	82	87	O	kidney	ney	dney	NN	False
DDI-MedLine.d207.s3	injury	89	94	O	injury	ury	jury	NN	False
DDI-MedLine.d207.s3	,	95	95	O	,	,	,	,	False
DDI-MedLine.d207.s3	chronic	97	103	O	chronic	nic	onic	NN	False
DDI-MedLine.d207.s3	kidney	105	110	O	kidney	ney	dney	NN	False
DDI-MedLine.d207.s3	disease	112	118	O	disease	ase	ease	NN	False
DDI-MedLine.d207.s3	,	119	119	O	,	,	,	,	False
DDI-MedLine.d207.s3	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d207.s3	lactic	125	130	O	lactic	tic	ctic	JJ	False
DDI-MedLine.d207.s3	acidosis	132	139	O	acidosis	sis	osis	NN	False
DDI-MedLine.d207.s3	,	140	140	O	,	,	,	,	False
DDI-MedLine.d207.s3	can	142	144	O	can	can	can	MD	False
DDI-MedLine.d207.s3	cause	146	150	O	cause	use	ause	NN	False
DDI-MedLine.d207.s3	high-anion-gap	152	165	O	high-anion-gap	gap	-gap	NN	False
DDI-MedLine.d207.s3	metabolic	167	175	O	metabolic	lic	olic	NN	False
DDI-MedLine.d207.s3	acidosis	177	184	O	acidosis	sis	osis	NN	False
DDI-MedLine.d207.s3	associated	186	195	O	associated	ted	ated	VBN	False
DDI-MedLine.d207.s3	with	197	200	O	with	ith	with	IN	False
DDI-MedLine.d207.s3	an	202	203	O	an	an	an	DT	False
DDI-MedLine.d207.s3	increased	205	213	O	increased	sed	ased	VBN	False
DDI-MedLine.d207.s3	serum	215	219	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s3	osmolal	221	227	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s3	gap	229	231	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s3	and	233	235	O	and	and	and	CC	False
DDI-MedLine.d207.s3	therefore	237	245	O	therefore	ore	fore	RB	False
DDI-MedLine.d207.s3	should	247	252	O	should	uld	ould	MD	False
DDI-MedLine.d207.s3	be	254	255	O	be	be	be	VB	False
DDI-MedLine.d207.s3	explored	257	264	O	explored	red	ored	VBN	False
DDI-MedLine.d207.s3	in	266	267	O	in	in	in	IN	False
DDI-MedLine.d207.s3	the	269	271	O	the	the	the	DT	False
DDI-MedLine.d207.s3	differential	273	284	O	differential	ial	tial	NN	False
DDI-MedLine.d207.s3	diagnosis	286	294	O	diagnosis	sis	osis	NN	False
DDI-MedLine.d207.s3	.	295	295	O	.	.	.	.	False

DDI-MedLine.d207.s4	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d207.s4	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d207.s4	essential	6	14	O	essential	ial	tial	JJ	False
DDI-MedLine.d207.s4	for	16	18	O	for	for	for	IN	False
DDI-MedLine.d207.s4	clinicians	20	29	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d207.s4	to	31	32	O	to	to	to	TO	False
DDI-MedLine.d207.s4	understand	34	43	O	understand	and	tand	NN	False
DDI-MedLine.d207.s4	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d207.s4	value	49	53	O	value	lue	alue	NN	False
DDI-MedLine.d207.s4	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d207.s4	limitations	59	69	O	limitations	ons	ions	NNS	False
DDI-MedLine.d207.s4	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d207.s4	osmolal	74	80	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s4	gap	82	84	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s4	to	86	87	O	to	to	to	TO	False
DDI-MedLine.d207.s4	assist	89	94	O	assist	ist	sist	NN	False
DDI-MedLine.d207.s4	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d207.s4	reaching	99	106	O	reaching	ing	hing	VBG	False
DDI-MedLine.d207.s4	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d207.s4	correct	112	118	O	correct	ect	rect	NN	False
DDI-MedLine.d207.s4	diagnosis	120	128	O	diagnosis	sis	osis	NN	False
DDI-MedLine.d207.s4	and	130	132	O	and	and	and	CC	False
DDI-MedLine.d207.s4	initiating	134	143	O	initiating	ing	ting	VBG	False
DDI-MedLine.d207.s4	appropriate	145	155	O	appropriate	ate	iate	NN	False
DDI-MedLine.d207.s4	treatment	157	165	O	treatment	ent	ment	NN	False
DDI-MedLine.d207.s4	.	166	166	O	.	.	.	.	False

DDI-MedLine.d207.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d207.s5	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d207.s5	teaching	8	15	O	teaching	ing	hing	VBG	False
DDI-MedLine.d207.s5	case	17	20	O	case	ase	case	NN	False
DDI-MedLine.d207.s5	,	21	21	O	,	,	,	,	False
DDI-MedLine.d207.s5	we	23	24	O	we	we	we	PRP	False
DDI-MedLine.d207.s5	present	26	32	O	present	ent	sent	NN	False
DDI-MedLine.d207.s5	a	34	34	O	a	a	a	DT	False
DDI-MedLine.d207.s5	systematic	36	45	O	systematic	tic	atic	JJ	False
DDI-MedLine.d207.s5	approach	47	54	O	approach	ach	oach	NN	False
DDI-MedLine.d207.s5	to	56	57	O	to	to	to	TO	False
DDI-MedLine.d207.s5	diagnosing	59	68	O	diagnosing	ing	sing	VBG	False
DDI-MedLine.d207.s5	high	70	73	O	high	igh	high	JJ	False
DDI-MedLine.d207.s5	serum	75	79	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s5	osmolality	81	90	O	osmolality	ity	lity	NN	False
DDI-MedLine.d207.s5	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d207.s5	increased	96	104	O	increased	sed	ased	VBN	False
DDI-MedLine.d207.s5	serum	106	110	O	serum	rum	erum	NN	False
DDI-MedLine.d207.s5	osmolal	112	118	O	osmolal	lal	olal	NN	False
DDI-MedLine.d207.s5	gap	120	122	O	gap	gap	gap	NN	False
DDI-MedLine.d207.s5	with	124	127	O	with	ith	with	IN	False
DDI-MedLine.d207.s5	or	129	130	O	or	or	or	CC	False
DDI-MedLine.d207.s5	without	132	138	O	without	out	hout	IN	False
DDI-MedLine.d207.s5	high-anion-gap	140	153	O	high-anion-gap	gap	-gap	NN	False
DDI-MedLine.d207.s5	metabolic	155	163	O	metabolic	lic	olic	NN	False
DDI-MedLine.d207.s5	acidosis	165	172	O	acidosis	sis	osis	NN	False
DDI-MedLine.d207.s5	.	173	173	O	.	.	.	.	False

DDI-MedLine.d210.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d210.s0	Drug	1	4	O	Drug	rug	Drug	NN	False
DDI-MedLine.d210.s0	interactions	6	17	O	interactions	ons	ions	NNS	False
DDI-MedLine.d210.s0	on	19	20	O	on	on	on	IN	False
DDI-MedLine.d210.s0	P-glycoprotein	22	35	O	P-glycoprotein	ein	tein	NN	False
DDI-MedLine.d210.s0	transport	37	45	O	transport	ort	port	NN	False
DDI-MedLine.d210.s0	level	47	51	O	level	vel	evel	NN	False
DDI-MedLine.d210.s0	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d210.s0	its	57	59	O	its	its	its	PRP$	False
DDI-MedLine.d210.s0	application	61	71	O	application	ion	tion	NN	False
DDI-MedLine.d210.s0	]	72	72	O	]	]	]	NN	False
DDI-MedLine.d210.s0	.	73	73	O	.	.	.	.	False

DDI-MedLine.d210.s1	Potential	0	8	O	Potential	ial	tial	JJ	False
DDI-MedLine.d210.s1	drug	10	13	O	drug	rug	drug	NN	False
DDI-MedLine.d210.s1	interactions	15	26	O	interactions	ons	ions	NNS	False
DDI-MedLine.d210.s1	on	28	29	O	on	on	on	IN	False
DDI-MedLine.d210.s1	P-glycoprotein	31	44	O	P-glycoprotein	ein	tein	NN	False
DDI-MedLine.d210.s1	transport	46	54	O	transport	ort	port	NN	False
DDI-MedLine.d210.s1	level	56	60	O	level	vel	evel	NN	False
DDI-MedLine.d210.s1	were	62	65	O	were	ere	were	VBD	False
DDI-MedLine.d210.s1	discussed	67	75	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d210.s1	in	77	78	O	in	in	in	IN	False
DDI-MedLine.d210.s1	this	80	83	O	this	his	this	DT	False
DDI-MedLine.d210.s1	article	85	91	O	article	cle	icle	NN	False
DDI-MedLine.d210.s1	.	92	92	O	.	.	.	.	False

DDI-MedLine.d210.s2	As	0	1	O	As	As	As	IN	False
DDI-MedLine.d210.s2	an	3	4	O	an	an	an	DT	False
DDI-MedLine.d210.s2	efflux	6	11	O	efflux	lux	flux	NN	False
DDI-MedLine.d210.s2	transporter	13	23	O	transporter	ter	rter	NN	False
DDI-MedLine.d210.s2	protein	25	31	O	protein	ein	tein	NN	False
DDI-MedLine.d210.s2	widely	33	38	O	widely	ely	dely	RB	False
DDI-MedLine.d210.s2	distributed	40	50	O	distributed	ted	uted	VBN	False
DDI-MedLine.d210.s2	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d210.s2	various	55	61	O	various	ous	ious	JJ	False
DDI-MedLine.d210.s2	tissues	63	69	O	tissues	ues	sues	NNS	False
DDI-MedLine.d210.s2	,	70	70	O	,	,	,	,	False
DDI-MedLine.d210.s2	P-glycoprotein	72	85	O	P-glycoprotein	ein	tein	NN	False
DDI-MedLine.d210.s2	plays	87	91	O	plays	ays	lays	NNS	False
DDI-MedLine.d210.s2	an	93	94	O	an	an	an	DT	False
DDI-MedLine.d210.s2	important	96	104	O	important	ant	tant	JJ	False
DDI-MedLine.d210.s2	role	106	109	O	role	ole	role	NN	False
DDI-MedLine.d210.s2	in	111	112	O	in	in	in	IN	False
DDI-MedLine.d210.s2	many	114	117	O	many	any	many	JJ	False
DDI-MedLine.d210.s2	drugs	119	123	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d210.s2	interactions	125	136	O	interactions	ons	ions	NNS	False
DDI-MedLine.d210.s2	,	137	137	O	,	,	,	,	False
DDI-MedLine.d210.s2	via	139	141	O	via	via	via	IN	False
DDI-MedLine.d210.s2	affecting	143	151	O	affecting	ing	ting	VBG	False
DDI-MedLine.d210.s2	the	153	155	O	the	the	the	DT	False
DDI-MedLine.d210.s2	metabolic	157	165	O	metabolic	lic	olic	NN	False
DDI-MedLine.d210.s2	process	167	173	O	process	ess	cess	NN	False
DDI-MedLine.d210.s2	to	175	176	O	to	to	to	TO	False
DDI-MedLine.d210.s2	alter	178	182	O	alter	ter	lter	NN	False
DDI-MedLine.d210.s2	the	184	186	O	the	the	the	DT	False
DDI-MedLine.d210.s2	concentration	188	200	O	concentration	ion	tion	NN	False
DDI-MedLine.d210.s2	of	202	203	O	of	of	of	IN	False
DDI-MedLine.d210.s2	drug	205	208	O	drug	rug	drug	NN	False
DDI-MedLine.d210.s2	in	210	211	O	in	in	in	IN	False
DDI-MedLine.d210.s2	plasma	213	218	O	plasma	sma	asma	NN	False
DDI-MedLine.d210.s2	and	220	222	O	and	and	and	CC	False
DDI-MedLine.d210.s2	tissue	224	229	O	tissue	sue	ssue	NN	False
DDI-MedLine.d210.s2	.	230	230	O	.	.	.	.	False

DDI-MedLine.d210.s3	Interactions	0	11	O	Interactions	ons	ions	NNS	False
DDI-MedLine.d210.s3	between	13	19	O	between	een	ween	IN	False
DDI-MedLine.d210.s3	herb	21	24	O	herb	erb	herb	NN	False
DDI-MedLine.d210.s3	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d210.s3	western	30	36	O	western	ern	tern	JJ	False
DDI-MedLine.d210.s3	drug	38	41	O	drug	rug	drug	NN	False
DDI-MedLine.d210.s3	may	43	45	O	may	may	may	MD	False
DDI-MedLine.d210.s3	occur	47	51	O	occur	cur	ccur	NN	False
DDI-MedLine.d210.s3	by	53	54	O	by	by	by	IN	False
DDI-MedLine.d210.s3	inducing	56	63	O	inducing	ing	cing	VBG	False
DDI-MedLine.d210.s3	or	65	66	O	or	or	or	CC	False
DDI-MedLine.d210.s3	inhibiting	68	77	O	inhibiting	ing	ting	VBG	False
DDI-MedLine.d210.s3	P-glycoprotein	79	92	O	P-glycoprotein	ein	tein	NN	False
DDI-MedLine.d210.s3	,	93	93	O	,	,	,	,	False
DDI-MedLine.d210.s3	resulting	95	103	O	resulting	ing	ting	VBG	False
DDI-MedLine.d210.s3	in	105	106	O	in	in	in	IN	False
DDI-MedLine.d210.s3	either	108	113	O	either	her	ther	DT	False
DDI-MedLine.d210.s3	efficacy	115	122	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d210.s3	enhancement	124	134	O	enhancement	ent	ment	NN	False
DDI-MedLine.d210.s3	or	136	137	O	or	or	or	CC	False
DDI-MedLine.d210.s3	adverse	139	145	O	adverse	rse	erse	NN	False
DDI-MedLine.d210.s3	effects	147	153	O	effects	cts	ects	NNS	False
DDI-MedLine.d210.s3	.	154	154	O	.	.	.	.	False

DDI-MedLine.d210.s4	So	0	1	O	So	So	So	RB	False
DDI-MedLine.d210.s4	it	3	4	O	it	it	it	PRP	False
DDI-MedLine.d210.s4	is	6	7	O	is	is	is	VBZ	False
DDI-MedLine.d210.s4	important	9	17	O	important	ant	tant	JJ	False
DDI-MedLine.d210.s4	for	19	21	O	for	for	for	IN	False
DDI-MedLine.d210.s4	clinical	23	30	O	clinical	cal	ical	JJ	False
DDI-MedLine.d210.s4	drug	32	35	O	drug	rug	drug	NN	False
DDI-MedLine.d210.s4	use	37	39	O	use	use	use	NN	False
DDI-MedLine.d210.s4	by	41	42	O	by	by	by	IN	False
DDI-MedLine.d210.s4	rational	44	51	O	rational	nal	onal	JJ	False
DDI-MedLine.d210.s4	utilization	53	63	O	utilization	ion	tion	NN	False
DDI-MedLine.d210.s4	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d210.s4	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d210.s4	interaction	72	82	O	interaction	ion	tion	NN	False
DDI-MedLine.d210.s4	between	84	90	O	between	een	ween	IN	False
DDI-MedLine.d210.s4	herb	92	95	O	herb	erb	herb	NN	False
DDI-MedLine.d210.s4	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d210.s4	western	101	107	O	western	ern	tern	JJ	False
DDI-MedLine.d210.s4	drug	109	112	O	drug	rug	drug	NN	False
DDI-MedLine.d210.s4	which	114	118	O	which	ich	hich	WDT	False
DDI-MedLine.d210.s4	medicated	120	128	O	medicated	ted	ated	VBN	False
DDI-MedLine.d210.s4	by	130	131	O	by	by	by	IN	False
DDI-MedLine.d210.s4	P-glycoprotein	133	146	O	P-glycoprotein	ein	tein	NN	False
DDI-MedLine.d210.s4	.	147	147	O	.	.	.	.	False

DDI-MedLine.d202.s0	Flow	0	3	O	Flow	low	Flow	NN	False
DDI-MedLine.d202.s0	cytometry-based	5	19	O	cytometry-based	sed	ased	JJ	False
DDI-MedLine.d202.s0	pharmacodynamic	21	35	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d202.s0	monitoring	37	46	O	monitoring	ing	ring	NN	False
DDI-MedLine.d202.s0	after	48	52	O	after	ter	fter	IN	False
DDI-MedLine.d202.s0	organ	54	58	O	organ	gan	rgan	NN	False
DDI-MedLine.d202.s0	transplantation	60	74	O	transplantation	ion	tion	NN	False
DDI-MedLine.d202.s0	.	75	75	O	.	.	.	.	False

DDI-MedLine.d202.s1	Conventional	0	11	O	Conventional	nal	onal	JJ	False
DDI-MedLine.d202.s1	therapeutic	13	23	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d202.s1	drug	25	28	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s1	monitoring	30	39	O	monitoring	ing	ring	NN	False
DDI-MedLine.d202.s1	based	41	45	O	based	sed	ased	VBN	False
DDI-MedLine.d202.s1	on	47	48	O	on	on	on	IN	False
DDI-MedLine.d202.s1	measuring	50	58	O	measuring	ing	ring	VBG	False
DDI-MedLine.d202.s1	immunosupressive	60	75	B-group	immunosupressive	ive	sive	JJ	False
DDI-MedLine.d202.s1	drug	77	80	I-group	drug	rug	drug	NN	False
DDI-MedLine.d202.s1	concentrations	82	95	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d202.s1	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d202.s1	blood	100	104	O	blood	ood	lood	NN	False
DDI-MedLine.d202.s1	is	106	107	O	is	is	is	VBZ	False
DDI-MedLine.d202.s1	important	109	117	O	important	ant	tant	JJ	False
DDI-MedLine.d202.s1	in	119	120	O	in	in	in	IN	False
DDI-MedLine.d202.s1	the	122	124	O	the	the	the	DT	False
DDI-MedLine.d202.s1	clinical	126	133	O	clinical	cal	ical	JJ	False
DDI-MedLine.d202.s1	management	135	144	O	management	ent	ment	NN	False
DDI-MedLine.d202.s1	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d202.s1	immunosuppressive	149	165	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d202.s1	therapy	167	173	O	therapy	apy	rapy	NN	False
DDI-MedLine.d202.s1	in	175	176	O	in	in	in	IN	False
DDI-MedLine.d202.s1	transplantation	178	192	O	transplantation	ion	tion	NN	False
DDI-MedLine.d202.s1	medicine	194	201	O	medicine	ine	cine	NN	drug
DDI-MedLine.d202.s1	.	202	202	O	.	.	.	.	False

DDI-MedLine.d202.s2	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d202.s2	rejection	6	14	O	rejection	ion	tion	NN	False
DDI-MedLine.d202.s2	or	16	17	O	or	or	or	CC	False
DDI-MedLine.d202.s2	infection	19	27	O	infection	ion	tion	NN	False
DDI-MedLine.d202.s2	occurs	29	34	O	occurs	urs	curs	NNS	False
DDI-MedLine.d202.s2	at	36	37	O	at	at	at	IN	False
DDI-MedLine.d202.s2	irregular	39	47	O	irregular	lar	ular	NN	False
DDI-MedLine.d202.s2	drug	49	52	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s2	concentrations	54	67	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d202.s2	immunosuppressive	69	85	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d202.s2	drug	87	90	I-group	drug	rug	drug	NN	False
DDI-MedLine.d202.s2	therapy	92	98	O	therapy	apy	rapy	NN	False
DDI-MedLine.d202.s2	is	100	101	O	is	is	is	VBZ	False
DDI-MedLine.d202.s2	often	103	107	O	often	ten	ften	RB	False
DDI-MedLine.d202.s2	empiric	109	115	O	empiric	ric	iric	NN	False
DDI-MedLine.d202.s2	and	117	119	O	and	and	and	CC	False
DDI-MedLine.d202.s2	prophylactic	121	132	O	prophylactic	tic	ctic	JJ	False
DDI-MedLine.d202.s2	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d202.s2	nature	137	142	O	nature	ure	ture	NN	False
DDI-MedLine.d202.s2	.	143	143	O	.	.	.	.	False

DDI-MedLine.d202.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d202.s3	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d202.s3	,	11	11	O	,	,	,	,	False
DDI-MedLine.d202.s3	blood	13	17	O	blood	ood	lood	NN	False
DDI-MedLine.d202.s3	immunosuppressant	19	35	B-group	immunosuppressant	ant	sant	NN	False
DDI-MedLine.d202.s3	levels	37	42	O	levels	els	vels	NNS	False
DDI-MedLine.d202.s3	are	44	46	O	are	are	are	VBP	False
DDI-MedLine.d202.s3	only	48	51	O	only	nly	only	RB	False
DDI-MedLine.d202.s3	indirect	53	60	O	indirect	ect	rect	NN	False
DDI-MedLine.d202.s3	predictors	62	71	O	predictors	ors	tors	NNS	False
DDI-MedLine.d202.s3	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d202.s3	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d202.s3	pharmacologic	80	92	O	pharmacologic	gic	ogic	NN	False
DDI-MedLine.d202.s3	effects	94	100	O	effects	cts	ects	NNS	False
DDI-MedLine.d202.s3	on	102	103	O	on	on	on	IN	False
DDI-MedLine.d202.s3	immune	105	110	O	immune	une	mune	NN	False
DDI-MedLine.d202.s3	cells	112	116	O	cells	lls	ells	NNS	False
DDI-MedLine.d202.s3	,	117	117	O	,	,	,	,	False
DDI-MedLine.d202.s3	because	119	125	O	because	use	ause	IN	False
DDI-MedLine.d202.s3	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d202.s3	genetic	131	137	O	genetic	tic	etic	JJ	False
DDI-MedLine.d202.s3	heterogeneity	139	151	O	heterogeneity	ity	eity	NN	False
DDI-MedLine.d202.s3	the	153	155	O	the	the	the	DT	False
DDI-MedLine.d202.s3	immune	157	162	O	immune	une	mune	NN	False
DDI-MedLine.d202.s3	systems	164	170	O	systems	ems	tems	NNS	False
DDI-MedLine.d202.s3	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d202.s3	transplant	175	184	O	transplant	ant	lant	NN	False
DDI-MedLine.d202.s3	recipients	186	195	O	recipients	nts	ents	NNS	False
DDI-MedLine.d202.s3	are	197	199	O	are	are	are	VBP	False
DDI-MedLine.d202.s3	not	201	203	O	not	not	not	RB	False
DDI-MedLine.d202.s3	equally	205	211	O	equally	lly	ally	RB	False
DDI-MedLine.d202.s3	sensitive	213	221	O	sensitive	ive	tive	JJ	False
DDI-MedLine.d202.s3	to	223	224	O	to	to	to	TO	False
DDI-MedLine.d202.s3	drug	226	229	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s3	effects	231	237	O	effects	cts	ects	NNS	False
DDI-MedLine.d202.s3	.	238	238	O	.	.	.	.	False

DDI-MedLine.d202.s4	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d202.s4	,	9	9	O	,	,	,	,	False
DDI-MedLine.d202.s4	therapeutic	11	21	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d202.s4	drug	23	26	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s4	monitoring	28	37	O	monitoring	ing	ring	NN	False
DDI-MedLine.d202.s4	requires	39	46	O	requires	res	ires	VBZ	False
DDI-MedLine.d202.s4	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d202.s4	application	52	62	O	application	ion	tion	NN	False
DDI-MedLine.d202.s4	of	64	65	O	of	of	of	IN	False
DDI-MedLine.d202.s4	reliable	67	74	O	reliable	ble	able	JJ	False
DDI-MedLine.d202.s4	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d202.s4	effective	80	88	O	effective	ive	tive	JJ	False
DDI-MedLine.d202.s4	methods	90	96	O	methods	ods	hods	NNS	False
DDI-MedLine.d202.s4	to	98	99	O	to	to	to	TO	False
DDI-MedLine.d202.s4	study	101	105	O	study	udy	tudy	NN	False
DDI-MedLine.d202.s4	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d202.s4	pharmacodynamic	111	125	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d202.s4	variability	127	137	O	variability	ity	lity	NN	False
DDI-MedLine.d202.s4	by	139	140	O	by	by	by	IN	False
DDI-MedLine.d202.s4	direct	142	147	O	direct	ect	rect	JJ	False
DDI-MedLine.d202.s4	measurements	149	160	O	measurements	nts	ents	NNS	False
DDI-MedLine.d202.s4	of	162	163	O	of	of	of	IN	False
DDI-MedLine.d202.s4	drug	165	168	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s4	effects	170	176	O	effects	cts	ects	NNS	False
DDI-MedLine.d202.s4	on	178	179	O	on	on	on	IN	False
DDI-MedLine.d202.s4	immune	181	186	O	immune	une	mune	NN	False
DDI-MedLine.d202.s4	cell	188	191	O	cell	ell	cell	NN	False
DDI-MedLine.d202.s4	functions	193	201	O	functions	ons	ions	NNS	False
DDI-MedLine.d202.s4	.	202	202	O	.	.	.	.	False

DDI-MedLine.d202.s5	Flow	0	3	O	Flow	low	Flow	NN	False
DDI-MedLine.d202.s5	cytometry	5	13	O	cytometry	try	etry	NN	False
DDI-MedLine.d202.s5	offers	15	20	O	offers	ers	fers	NNS	False
DDI-MedLine.d202.s5	a	22	22	O	a	a	a	DT	False
DDI-MedLine.d202.s5	multiplicity	24	35	O	multiplicity	ity	city	NN	False
DDI-MedLine.d202.s5	of	37	38	O	of	of	of	IN	False
DDI-MedLine.d202.s5	quantitative	40	51	O	quantitative	ive	tive	NN	False
DDI-MedLine.d202.s5	analysis	53	60	O	analysis	sis	ysis	NN	False
DDI-MedLine.d202.s5	possibilities	62	74	O	possibilities	ies	ties	NNS	False
DDI-MedLine.d202.s5	,	75	75	O	,	,	,	,	False
DDI-MedLine.d202.s5	from	77	80	O	from	rom	from	IN	False
DDI-MedLine.d202.s5	detection	82	90	O	detection	ion	tion	NN	False
DDI-MedLine.d202.s5	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d202.s5	phosphorylated	95	108	O	phosphorylated	ted	ated	VBN	False
DDI-MedLine.d202.s5	molecules	110	118	O	molecules	les	ules	NNS	False
DDI-MedLine.d202.s5	up	120	121	O	up	up	up	RB	False
DDI-MedLine.d202.s5	to	123	124	O	to	to	to	TO	False
DDI-MedLine.d202.s5	complex	126	132	O	complex	lex	plex	JJ	False
DDI-MedLine.d202.s5	multicolor	134	143	O	multicolor	lor	olor	NN	False
DDI-MedLine.d202.s5	analysis	145	152	O	analysis	sis	ysis	NN	False
DDI-MedLine.d202.s5	of	154	155	O	of	of	of	IN	False
DDI-MedLine.d202.s5	whole	157	161	O	whole	ole	hole	JJ	False
DDI-MedLine.d202.s5	blood	163	167	O	blood	ood	lood	NN	False
DDI-MedLine.d202.s5	samples	169	175	O	samples	les	ples	NNS	False
DDI-MedLine.d202.s5	.	176	176	O	.	.	.	.	False

DDI-MedLine.d202.s6	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d202.s6	large	2	6	O	large	rge	arge	JJ	False
DDI-MedLine.d202.s6	spectrum	8	15	O	spectrum	rum	trum	NN	False
DDI-MedLine.d202.s6	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d202.s6	flow	20	23	O	flow	low	flow	NN	False
DDI-MedLine.d202.s6	cytometry-based	25	39	O	cytometry-based	sed	ased	JJ	False
DDI-MedLine.d202.s6	applications	41	52	O	applications	ons	ions	NNS	False
DDI-MedLine.d202.s6	for	54	56	O	for	for	for	IN	False
DDI-MedLine.d202.s6	pharmacodynamic	58	72	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d202.s6	monitoring	74	83	O	monitoring	ing	ring	NN	False
DDI-MedLine.d202.s6	is	85	86	O	is	is	is	VBZ	False
DDI-MedLine.d202.s6	available	88	96	O	available	ble	able	JJ	False
DDI-MedLine.d202.s6	and	98	100	O	and	and	and	CC	False
DDI-MedLine.d202.s6	allows	102	107	O	allows	ows	lows	NNS	False
DDI-MedLine.d202.s6	detection	109	117	O	detection	ion	tion	NN	False
DDI-MedLine.d202.s6	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d202.s6	analysis	123	130	O	analysis	sis	ysis	NN	False
DDI-MedLine.d202.s6	of	132	133	O	of	of	of	IN	False
DDI-MedLine.d202.s6	diverse	135	141	O	diverse	rse	erse	NN	False
DDI-MedLine.d202.s6	function	143	150	O	function	ion	tion	NN	False
DDI-MedLine.d202.s6	of	152	153	O	of	of	of	IN	False
DDI-MedLine.d202.s6	T	155	155	O	T	T	T	NN	brand
DDI-MedLine.d202.s6	cells	157	161	O	cells	lls	ells	NNS	False
DDI-MedLine.d202.s6	and	163	165	O	and	and	and	CC	False
DDI-MedLine.d202.s6	dendritic	167	175	O	dendritic	tic	itic	JJ	False
DDI-MedLine.d202.s6	cell	177	180	O	cell	ell	cell	NN	False
DDI-MedLine.d202.s6	subsets	182	188	O	subsets	ets	sets	NNS	False
DDI-MedLine.d202.s6	.	189	189	O	.	.	.	.	False

DDI-MedLine.d202.s7	By	0	1	O	By	By	By	IN	False
DDI-MedLine.d202.s7	combining	3	11	O	combining	ing	ning	VBG	False
DDI-MedLine.d202.s7	several	13	19	O	several	ral	eral	JJ	False
DDI-MedLine.d202.s7	assays	21	26	O	assays	ays	says	NNS	False
DDI-MedLine.d202.s7	,	27	27	O	,	,	,	,	False
DDI-MedLine.d202.s7	it	29	30	O	it	it	it	PRP	False
DDI-MedLine.d202.s7	is	32	33	O	is	is	is	VBZ	False
DDI-MedLine.d202.s7	possible	35	42	O	possible	ble	ible	JJ	False
DDI-MedLine.d202.s7	to	44	45	O	to	to	to	TO	False
DDI-MedLine.d202.s7	generate	47	54	O	generate	ate	rate	NN	False
DDI-MedLine.d202.s7	a	56	56	O	a	a	a	DT	False
DDI-MedLine.d202.s7	broad	58	62	O	broad	oad	road	JJ	False
DDI-MedLine.d202.s7	picture	64	70	O	picture	ure	ture	NN	False
DDI-MedLine.d202.s7	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d202.s7	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d202.s7	immune	79	84	O	immune	une	mune	NN	False
DDI-MedLine.d202.s7	status	86	91	O	status	tus	atus	NN	False
DDI-MedLine.d202.s7	of	93	94	O	of	of	of	IN	False
DDI-MedLine.d202.s7	every	96	100	O	every	ery	very	DT	False
DDI-MedLine.d202.s7	single	102	107	O	single	gle	ngle	JJ	False
DDI-MedLine.d202.s7	transplanted	109	120	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d202.s7	recipient	122	130	O	recipient	ent	ient	NN	False
DDI-MedLine.d202.s7	.	131	131	O	.	.	.	.	False

DDI-MedLine.d202.s8	Furthermore	0	10	O	Furthermore	ore	more	RB	False
DDI-MedLine.d202.s8	,	11	11	O	,	,	,	,	False
DDI-MedLine.d202.s8	it	13	14	O	it	it	it	PRP	False
DDI-MedLine.d202.s8	is	16	17	O	is	is	is	VBZ	False
DDI-MedLine.d202.s8	even	19	22	O	even	ven	even	RB	False
DDI-MedLine.d202.s8	possible	24	31	O	possible	ble	ible	JJ	False
DDI-MedLine.d202.s8	to	33	34	O	to	to	to	TO	False
DDI-MedLine.d202.s8	differentiate	36	48	O	differentiate	ate	iate	NN	False
DDI-MedLine.d202.s8	between	50	56	O	between	een	ween	IN	False
DDI-MedLine.d202.s8	synergistic	58	68	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d202.s8	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d202.s8	antagonistic	74	85	O	antagonistic	tic	stic	JJ	False
DDI-MedLine.d202.s8	pharmacodynamic	87	101	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d202.s8	effects	103	109	O	effects	cts	ects	NNS	False
DDI-MedLine.d202.s8	of	111	112	O	of	of	of	IN	False
DDI-MedLine.d202.s8	immunosuppressive	114	130	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d202.s8	drug	132	135	I-group	drug	rug	drug	NN	False
DDI-MedLine.d202.s8	combination	137	147	O	combination	ion	tion	NN	False
DDI-MedLine.d202.s8	therapy	149	155	O	therapy	apy	rapy	NN	False
DDI-MedLine.d202.s8	in	157	158	O	in	in	in	IN	False
DDI-MedLine.d202.s8	vitro	160	164	O	vitro	tro	itro	NN	False
DDI-MedLine.d202.s8	and	166	168	O	and	and	and	CC	False
DDI-MedLine.d202.s8	to	170	171	O	to	to	to	TO	False
DDI-MedLine.d202.s8	predict	173	179	O	predict	ict	dict	NN	False
DDI-MedLine.d202.s8	the	181	183	O	the	the	the	DT	False
DDI-MedLine.d202.s8	pharmacodynamic	185	199	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d202.s8	drug	201	204	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s8	effects	206	212	O	effects	cts	ects	NNS	False
DDI-MedLine.d202.s8	in	214	215	O	in	in	in	IN	False
DDI-MedLine.d202.s8	transplanted	217	228	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d202.s8	recipients	230	239	O	recipients	nts	ents	NNS	False
DDI-MedLine.d202.s8	.	240	240	O	.	.	.	.	False

DDI-MedLine.d202.s9	Such	0	3	O	Such	uch	Such	JJ	False
DDI-MedLine.d202.s9	a	5	5	O	a	a	a	DT	False
DDI-MedLine.d202.s9	pharmacodynamic	7	21	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d202.s9	drug	23	26	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s9	monitoring	28	37	O	monitoring	ing	ring	NN	False
DDI-MedLine.d202.s9	may	39	41	O	may	may	may	MD	False
DDI-MedLine.d202.s9	offer	43	47	O	offer	fer	ffer	NN	False
DDI-MedLine.d202.s9	the	49	51	O	the	the	the	DT	False
DDI-MedLine.d202.s9	opportunity	53	63	O	opportunity	ity	nity	NN	False
DDI-MedLine.d202.s9	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d202.s9	complete	68	75	O	complete	ete	lete	JJ	False
DDI-MedLine.d202.s9	conventional	77	88	O	conventional	nal	onal	JJ	False
DDI-MedLine.d202.s9	therapeutic	90	100	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d202.s9	drug	102	105	O	drug	rug	drug	NN	False
DDI-MedLine.d202.s9	monitoring	107	116	O	monitoring	ing	ring	NN	False
DDI-MedLine.d202.s9	and	118	120	O	and	and	and	CC	False
DDI-MedLine.d202.s9	,	121	121	O	,	,	,	,	False
DDI-MedLine.d202.s9	therefore	123	131	O	therefore	ore	fore	RB	False
DDI-MedLine.d202.s9	,	132	132	O	,	,	,	,	False
DDI-MedLine.d202.s9	to	134	135	O	to	to	to	TO	False
DDI-MedLine.d202.s9	tailor	137	142	O	tailor	lor	ilor	NN	False
DDI-MedLine.d202.s9	immunosuppressive	144	160	B-group	immunosuppressive	ive	sive	JJ	False
DDI-MedLine.d202.s9	therapy	162	168	O	therapy	apy	rapy	NN	False
DDI-MedLine.d202.s9	more	170	173	O	more	ore	more	RBR	False
DDI-MedLine.d202.s9	individually	175	186	O	individually	lly	ally	RB	False
DDI-MedLine.d202.s9	.	187	187	O	.	.	.	.	False

DDI-MedLine.d232.s0	Stroke	0	5	O	Stroke	oke	roke	NN	False
DDI-MedLine.d232.s0	prevention	7	16	O	prevention	ion	tion	NN	False
DDI-MedLine.d232.s0	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d232.s0	atrial	21	26	O	atrial	ial	rial	JJ	False
DDI-MedLine.d232.s0	fibrillation	28	39	O	fibrillation	ion	tion	NN	False
DDI-MedLine.d232.s0	:	40	40	O	:	:	:	:	False
DDI-MedLine.d232.s0	current	42	48	O	current	ent	rent	JJ	False
DDI-MedLine.d232.s0	status	50	55	O	status	tus	atus	NN	False
DDI-MedLine.d232.s0	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d232.s0	near-future	61	71	O	near-future	ure	ture	NN	False
DDI-MedLine.d232.s0	directions	73	82	O	directions	ons	ions	NNS	False
DDI-MedLine.d232.s0	.	83	83	O	.	.	.	.	False

DDI-MedLine.d232.s1	Prevention	0	9	O	Prevention	ion	tion	NN	False
DDI-MedLine.d232.s1	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d232.s1	atrial	14	19	O	atrial	ial	rial	JJ	False
DDI-MedLine.d232.s1	fibrillation-related	21	40	O	fibrillation-related	ted	ated	JJ	False
DDI-MedLine.d232.s1	stroke	42	47	O	stroke	oke	roke	NN	False
DDI-MedLine.d232.s1	is	49	50	O	is	is	is	VBZ	False
DDI-MedLine.d232.s1	an	52	53	O	an	an	an	DT	False
DDI-MedLine.d232.s1	important	55	63	O	important	ant	tant	JJ	False
DDI-MedLine.d232.s1	part	65	68	O	part	art	part	NN	False
DDI-MedLine.d232.s1	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d232.s1	atrial	73	78	O	atrial	ial	rial	JJ	False
DDI-MedLine.d232.s1	fibrillation	80	91	O	fibrillation	ion	tion	NN	False
DDI-MedLine.d232.s1	management	93	102	O	management	ent	ment	NN	False
DDI-MedLine.d232.s1	.	103	103	O	.	.	.	.	False

DDI-MedLine.d232.s2	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d232.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d232.s2	stroke	9	14	O	stroke	oke	roke	NN	False
DDI-MedLine.d232.s2	risk	16	19	O	risk	isk	risk	NN	False
DDI-MedLine.d232.s2	is	21	22	O	is	is	is	VBZ	False
DDI-MedLine.d232.s2	not	24	26	O	not	not	not	RB	False
DDI-MedLine.d232.s2	homogeneous	28	38	O	homogeneous	ous	eous	JJ	False
DDI-MedLine.d232.s2	and	40	42	O	and	and	and	CC	False
DDI-MedLine.d232.s2	varies	44	49	O	varies	ies	ries	NNS	False
DDI-MedLine.d232.s2	with	51	54	O	with	ith	with	IN	False
DDI-MedLine.d232.s2	associated	56	65	O	associated	ted	ated	VBN	False
DDI-MedLine.d232.s2	morbidities	67	77	O	morbidities	ies	ties	NNS	False
DDI-MedLine.d232.s2	and	79	81	O	and	and	and	CC	False
DDI-MedLine.d232.s2	risk	83	86	O	risk	isk	risk	NN	False
DDI-MedLine.d232.s2	factors	88	94	O	factors	ors	tors	NNS	False
DDI-MedLine.d232.s2	.	95	95	O	.	.	.	.	False

DDI-MedLine.d232.s3	Risk	0	3	O	Risk	isk	Risk	NN	False
DDI-MedLine.d232.s3	stratification	5	18	O	stratification	ion	tion	NN	False
DDI-MedLine.d232.s3	schemes	20	26	O	schemes	mes	emes	NNS	False
DDI-MedLine.d232.s3	have	28	31	O	have	ave	have	VB	False
DDI-MedLine.d232.s3	been	33	36	O	been	een	been	VBN	False
DDI-MedLine.d232.s3	developed	38	46	O	developed	ped	oped	NN	False
DDI-MedLine.d232.s3	that	48	51	O	that	hat	that	IN	False
DDI-MedLine.d232.s3	categorize	53	62	O	categorize	ize	rize	NN	False
DDI-MedLine.d232.s3	patients	64	71	O	patients	nts	ents	NNS	False
DDI-MedLine.d232.s3	'	72	72	O	'	'	'	''	False
DDI-MedLine.d232.s3	stroke	74	79	O	stroke	oke	roke	NN	False
DDI-MedLine.d232.s3	risk	81	84	O	risk	isk	risk	NN	False
DDI-MedLine.d232.s3	into	86	89	O	into	nto	into	IN	False
DDI-MedLine.d232.s3	classes	91	97	O	classes	ses	sses	NNS	False
DDI-MedLine.d232.s3	based	99	103	O	based	sed	ased	VBN	False
DDI-MedLine.d232.s3	on	105	106	O	on	on	on	IN	False
DDI-MedLine.d232.s3	a	108	108	O	a	a	a	DT	False
DDI-MedLine.d232.s3	combination	110	120	O	combination	ion	tion	NN	False
DDI-MedLine.d232.s3	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d232.s3	risk	125	128	O	risk	isk	risk	NN	False
DDI-MedLine.d232.s3	factors	130	136	O	factors	ors	tors	NNS	False
DDI-MedLine.d232.s3	.	137	137	O	.	.	.	.	False

DDI-MedLine.d232.s4	According	0	8	O	According	ing	ding	VBG	False
DDI-MedLine.d232.s4	to	10	11	O	to	to	to	TO	False
DDI-MedLine.d232.s4	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d232.s4	calculated	17	26	O	calculated	ted	ated	VBN	False
DDI-MedLine.d232.s4	level	28	32	O	level	vel	evel	NN	False
DDI-MedLine.d232.s4	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d232.s4	risk	37	40	O	risk	isk	risk	NN	False
DDI-MedLine.d232.s4	,	41	41	O	,	,	,	,	False
DDI-MedLine.d232.s4	guidelines	43	52	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d232.s4	recommend	54	62	O	recommend	end	mend	NN	False
DDI-MedLine.d232.s4	patients	64	71	O	patients	nts	ents	NNS	False
DDI-MedLine.d232.s4	with	73	76	O	with	ith	with	IN	False
DDI-MedLine.d232.s4	atrial	78	83	O	atrial	ial	rial	JJ	False
DDI-MedLine.d232.s4	fibrillation	85	96	O	fibrillation	ion	tion	NN	False
DDI-MedLine.d232.s4	receive	98	104	O	receive	ive	eive	NN	False
DDI-MedLine.d232.s4	antithrombotic	106	119	B-group	antithrombotic	tic	otic	JJ	False
DDI-MedLine.d232.s4	therapy	121	127	O	therapy	apy	rapy	NN	False
DDI-MedLine.d232.s4	either	129	134	O	either	her	ther	DT	False
DDI-MedLine.d232.s4	as	136	137	O	as	as	as	IN	False
DDI-MedLine.d232.s4	a	139	139	O	a	a	a	DT	False
DDI-MedLine.d232.s4	vitamin	141	147	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d232.s4	K	149	149	I-group	K	K	K	NNP	brand
DDI-MedLine.d232.s4	antagonist	151	160	I-group	antagonist	ist	nist	NN	False
DDI-MedLine.d232.s4	or	162	163	O	or	or	or	CC	False
DDI-MedLine.d232.s4	aspirin	165	171	B-brand	aspirin	rin	irin	NN	False
DDI-MedLine.d232.s4	.	172	172	O	.	.	.	.	False

DDI-MedLine.d232.s5	Despite	0	6	O	Despite	ite	pite	IN	False
DDI-MedLine.d232.s5	recommendations	8	22	O	recommendations	ons	ions	NNS	False
DDI-MedLine.d232.s5	,	23	23	O	,	,	,	,	False
DDI-MedLine.d232.s5	however	25	31	O	however	ver	ever	RB	False
DDI-MedLine.d232.s5	,	32	32	O	,	,	,	,	False
DDI-MedLine.d232.s5	many	34	37	O	many	any	many	JJ	False
DDI-MedLine.d232.s5	patients	39	46	O	patients	nts	ents	NNS	False
DDI-MedLine.d232.s5	with	48	51	O	with	ith	with	IN	False
DDI-MedLine.d232.s5	atrial	53	58	O	atrial	ial	rial	JJ	False
DDI-MedLine.d232.s5	fibrillation	60	71	O	fibrillation	ion	tion	NN	False
DDI-MedLine.d232.s5	do	73	74	O	do	do	do	VB	False
DDI-MedLine.d232.s5	not	76	78	O	not	not	not	RB	False
DDI-MedLine.d232.s5	receive	80	86	O	receive	ive	eive	NN	False
DDI-MedLine.d232.s5	adequate	88	95	O	adequate	ate	uate	NN	False
DDI-MedLine.d232.s5	thromboprophylaxis	97	114	O	thromboprophylaxis	xis	axis	NN	False
DDI-MedLine.d232.s5	.	115	115	O	.	.	.	.	False

DDI-MedLine.d232.s6	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d232.s6	will	3	6	O	will	ill	will	MD	False
DDI-MedLine.d232.s6	discuss	8	14	O	discuss	uss	cuss	NN	False
DDI-MedLine.d232.s6	some	16	19	O	some	ome	some	DT	False
DDI-MedLine.d232.s6	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d232.s6	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d232.s6	underlying	28	37	O	underlying	ing	ying	VBG	False
DDI-MedLine.d232.s6	reasons	39	45	O	reasons	ons	sons	NNS	False
DDI-MedLine.d232.s6	,	46	46	O	,	,	,	,	False
DDI-MedLine.d232.s6	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d232.s6	part	51	54	O	part	art	part	NN	False
DDI-MedLine.d232.s6	related	56	62	O	related	ted	ated	JJ	False
DDI-MedLine.d232.s6	to	64	65	O	to	to	to	TO	False
DDI-MedLine.d232.s6	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d232.s6	drawbacks	71	79	O	drawbacks	cks	acks	NNS	False
DDI-MedLine.d232.s6	associated	81	90	O	associated	ted	ated	VBN	False
DDI-MedLine.d232.s6	with	92	95	O	with	ith	with	IN	False
DDI-MedLine.d232.s6	vitamin	97	103	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d232.s6	K	105	105	I-group	K	K	K	NNP	brand
DDI-MedLine.d232.s6	antagonists	107	117	I-group	antagonists	sts	ists	NNS	False
DDI-MedLine.d232.s6	.	118	118	O	.	.	.	.	False

DDI-MedLine.d232.s7	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d232.s7	highlight	6	14	O	highlight	ght	ight	NN	False
DDI-MedLine.d232.s7	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d232.s7	need	20	23	O	need	eed	need	NN	False
DDI-MedLine.d232.s7	for	25	27	O	for	for	for	IN	False
DDI-MedLine.d232.s7	new	29	31	O	new	new	new	JJ	False
DDI-MedLine.d232.s7	anticoagulants	33	46	B-group	anticoagulants	nts	ants	NNS	False
DDI-MedLine.d232.s7	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d232.s7	atrial	51	56	O	atrial	ial	rial	JJ	False
DDI-MedLine.d232.s7	fibrillation	58	69	O	fibrillation	ion	tion	NN	False
DDI-MedLine.d232.s7	.	70	70	O	.	.	.	.	False

DDI-MedLine.d232.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d232.s8	novel	4	8	O	novel	vel	ovel	NN	False
DDI-MedLine.d232.s8	oral	10	13	O	oral	ral	oral	JJ	False
DDI-MedLine.d232.s8	anticoagulants	15	28	B-group	anticoagulants	nts	ants	NNS	False
DDI-MedLine.d232.s8	in	30	31	O	in	in	in	IN	False
DDI-MedLine.d232.s8	development	33	43	O	development	ent	ment	NN	False
DDI-MedLine.d232.s8	may	45	47	O	may	may	may	MD	False
DDI-MedLine.d232.s8	overcome	49	56	O	overcome	ome	come	NN	False
DDI-MedLine.d232.s8	some	58	61	O	some	ome	some	DT	False
DDI-MedLine.d232.s8	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d232.s8	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d232.s8	limitations	70	80	O	limitations	ons	ions	NNS	False
DDI-MedLine.d232.s8	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d232.s8	vitamin	85	91	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d232.s8	K	93	93	I-group	K	K	K	NNP	brand
DDI-MedLine.d232.s8	antagonists	95	105	I-group	antagonists	sts	ists	NNS	False
DDI-MedLine.d232.s8	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d232.s8	address	111	117	O	address	ess	ress	NN	False
DDI-MedLine.d232.s8	their	119	123	O	their	eir	heir	PRP$	False
DDI-MedLine.d232.s8	underuse	125	132	O	underuse	use	ruse	NN	False
DDI-MedLine.d232.s8	and	134	136	O	and	and	and	CC	False
DDI-MedLine.d232.s8	safety	138	143	O	safety	ety	fety	NN	False
DDI-MedLine.d232.s8	concerns	145	152	O	concerns	rns	erns	NNS	False
DDI-MedLine.d232.s8	.	153	153	O	.	.	.	.	False

DDI-MedLine.d182.s0	Antimicrobial	0	12	O	Antimicrobial	ial	bial	JJ	False
DDI-MedLine.d182.s0	effects	14	20	O	effects	cts	ects	NNS	False
DDI-MedLine.d182.s0	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d182.s0	o-cymen-5-ol	25	36	B-drug_n	o-cymen-5-ol	-ol	5-ol	NN	False
DDI-MedLine.d182.s0	and	38	40	O	and	and	and	CC	False
DDI-MedLine.d182.s0	zinc	42	45	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d182.s0	,	46	46	O	,	,	,	,	False
DDI-MedLine.d182.s0	alone	48	52	O	alone	one	lone	RB	False
DDI-MedLine.d182.s0	&	54	54	O	&	&	&	CC	False

DDI-MedLine.d182.s1	in	0	1	O	in	in	in	IN	False
DDI-MedLine.d182.s1	combination	3	13	O	combination	ion	tion	NN	False
DDI-MedLine.d182.s1	in	15	16	O	in	in	in	IN	False
DDI-MedLine.d182.s1	simple	18	23	O	simple	ple	mple	NN	False
DDI-MedLine.d182.s1	solutions	25	33	O	solutions	ons	ions	NNS	False
DDI-MedLine.d182.s1	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d182.s1	toothpaste	39	48	O	toothpaste	ste	aste	NN	False
DDI-MedLine.d182.s1	formulations	50	61	O	formulations	ons	ions	NNS	False
DDI-MedLine.d182.s1	.	62	62	O	.	.	.	.	False

DDI-MedLine.d182.s2	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d182.s2	study	5	9	O	study	udy	tudy	NN	False
DDI-MedLine.d182.s2	aimed	11	15	O	aimed	med	imed	VBN	False
DDI-MedLine.d182.s2	to	17	18	O	to	to	to	TO	False
DDI-MedLine.d182.s2	evaluate	20	27	O	evaluate	ate	uate	NN	False
DDI-MedLine.d182.s2	antimicrobial	29	41	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d182.s2	effects	43	49	O	effects	cts	ects	NNS	False
DDI-MedLine.d182.s2	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d182.s2	an	54	55	O	an	an	an	DT	False
DDI-MedLine.d182.s2	o-cymen-5-ol/zinc	57	73	O	o-cymen-5-ol/zinc	inc	zinc	NN	False
DDI-MedLine.d182.s2	system	75	80	O	system	tem	stem	NN	False
DDI-MedLine.d182.s2	.	81	81	O	.	.	.	.	False

DDI-MedLine.d182.s3	o-Cymen-5-ol	0	11	B-drug_n	o-Cymen-5-ol	-ol	5-ol	NN	False
DDI-MedLine.d182.s3	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d182.s3	zinc	17	20	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d182.s3	gluconate	22	30	I-drug	gluconate	ate	nate	NN	False
DDI-MedLine.d182.s3	minimum	32	38	O	minimum	mum	imum	NN	False
DDI-MedLine.d182.s3	inhibitory	40	49	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d182.s3	concentration	51	63	O	concentration	ion	tion	NN	False
DDI-MedLine.d182.s3	(	65	65	O	(	(	(	(	False
DDI-MedLine.d182.s3	MIC	66	68	O	MIC	MIC	MIC	NN	brand
DDI-MedLine.d182.s3	)	69	69	O	)	)	)	)	False
DDI-MedLine.d182.s3	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d182.s3	minimum	75	81	O	minimum	mum	imum	NN	False
DDI-MedLine.d182.s3	bactericidal	83	94	O	bactericidal	dal	idal	NN	False
DDI-MedLine.d182.s3	concentration	96	108	O	concentration	ion	tion	NN	False
DDI-MedLine.d182.s3	(	110	110	O	(	(	(	(	False
DDI-MedLine.d182.s3	MBC	111	113	O	MBC	MBC	MBC	NN	brand
DDI-MedLine.d182.s3	)	114	114	O	)	)	)	)	False
DDI-MedLine.d182.s3	were	116	119	O	were	ere	were	VBD	False
DDI-MedLine.d182.s3	determined	121	130	O	determined	ned	ined	VBN	False
DDI-MedLine.d182.s3	against	132	138	O	against	nst	inst	IN	False
DDI-MedLine.d182.s3	Streptococcus	140	152	O	Streptococcus	cus	ccus	NN	False
DDI-MedLine.d182.s3	mutans	154	159	O	mutans	ans	tans	NNS	False
DDI-MedLine.d182.s3	,	160	160	O	,	,	,	,	False
DDI-MedLine.d182.s3	Actinomyces	162	172	O	Actinomyces	ces	yces	NNS	False
DDI-MedLine.d182.s3	viscosus	174	181	O	viscosus	sus	osus	NN	False
DDI-MedLine.d182.s3	,	182	182	O	,	,	,	,	False
DDI-MedLine.d182.s3	Porphyromonas	184	196	O	Porphyromonas	nas	onas	NNS	False
DDI-MedLine.d182.s3	gingivalis	198	207	O	gingivalis	lis	alis	NN	False
DDI-MedLine.d182.s3	,	208	208	O	,	,	,	,	False
DDI-MedLine.d182.s3	Fusobacterium	210	222	O	Fusobacterium	ium	rium	NN	drug
DDI-MedLine.d182.s3	nucleatum	224	232	O	nucleatum	tum	atum	NN	False
DDI-MedLine.d182.s3	and	234	236	O	and	and	and	CC	False
DDI-MedLine.d182.s3	Candida	238	244	O	Candida	ida	dida	NN	False
DDI-MedLine.d182.s3	albicans	246	253	O	albicans	ans	cans	NNS	False
DDI-MedLine.d182.s3	.	254	254	O	.	.	.	.	False

DDI-MedLine.d182.s4	Synergy	0	6	O	Synergy	rgy	ergy	NN	False
DDI-MedLine.d182.s4	was	8	10	O	was	was	was	VBD	False
DDI-MedLine.d182.s4	investigated	12	23	O	investigated	ted	ated	VBN	False
DDI-MedLine.d182.s4	by	25	26	O	by	by	by	IN	False
DDI-MedLine.d182.s4	checkerboard	28	39	O	checkerboard	ard	oard	NN	False
DDI-MedLine.d182.s4	MIC/MBC	41	47	O	MIC/MBC	MBC	/MBC	NN	brand
DDI-MedLine.d182.s4	;	48	48	O	;	;	;	:	False

DDI-MedLine.d182.s5	inhibition	0	9	O	inhibition	ion	tion	NN	False
DDI-MedLine.d182.s5	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d182.s5	P	14	14	O	P	P	P	NN	brand
DDI-MedLine.d182.s5	.	15	15	O	.	.	.	.	False

DDI-MedLine.d182.s6	gingivalis	0	9	O	gingivalis	lis	alis	NN	False
DDI-MedLine.d182.s6	protease	11	18	O	protease	ase	ease	NN	False
DDI-MedLine.d182.s6	activity	20	27	O	activity	ity	vity	NN	False
DDI-MedLine.d182.s6	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d182.s6	S	33	33	O	S	S	S	NN	brand
DDI-MedLine.d182.s6	.	34	34	O	.	.	.	.	False

DDI-MedLine.d182.s7	mutans	0	5	O	mutans	ans	tans	NNS	False
DDI-MedLine.d182.s7	glycolysis	7	16	O	glycolysis	sis	ysis	NN	False
DDI-MedLine.d182.s7	were	18	21	O	were	ere	were	VBD	False
DDI-MedLine.d182.s7	investigated	23	34	O	investigated	ted	ated	VBN	False
DDI-MedLine.d182.s7	.	35	35	O	.	.	.	.	False

DDI-MedLine.d182.s8	Slurried	0	7	O	Slurried	ied	ried	VBN	False
DDI-MedLine.d182.s8	toothpastes	9	19	O	toothpastes	tes	stes	NNS	False
DDI-MedLine.d182.s8	containing	21	30	O	containing	ing	ning	VBG	False
DDI-MedLine.d182.s8	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d182.s8	system	36	41	O	system	tem	stem	NN	False
DDI-MedLine.d182.s8	were	43	46	O	were	ere	were	VBD	False
DDI-MedLine.d182.s8	assessed	48	55	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d182.s8	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d182.s8	kill	60	63	O	kill	ill	kill	NN	False
DDI-MedLine.d182.s8	time	65	68	O	time	ime	time	NN	False
DDI-MedLine.d182.s8	assays	70	75	O	assays	ays	says	NNS	False
DDI-MedLine.d182.s8	against	77	83	O	against	nst	inst	IN	False
DDI-MedLine.d182.s8	S	85	85	O	S	S	S	NN	brand
DDI-MedLine.d182.s8	.	86	86	O	.	.	.	.	False

DDI-MedLine.d182.s9	mutans	0	5	O	mutans	ans	tans	NNS	False
DDI-MedLine.d182.s9	and	7	9	O	and	and	and	CC	False
DDI-MedLine.d182.s9	E	11	11	O	E	E	E	NN	brand
DDI-MedLine.d182.s9	.	12	12	O	.	.	.	.	False

DDI-MedLine.d182.s10	coli	0	3	O	coli	oli	coli	NNS	False
DDI-MedLine.d182.s10	.	4	4	O	.	.	.	.	False

DDI-MedLine.d182.s11	o-Cymen-5-ol	0	11	B-drug_n	o-Cymen-5-ol	-ol	5-ol	NN	False
DDI-MedLine.d182.s11	MIC	13	15	O	MIC	MIC	MIC	NN	brand
DDI-MedLine.d182.s11	was	17	19	O	was	was	was	VBD	False
DDI-MedLine.d182.s11	between	21	27	O	between	een	ween	IN	False
DDI-MedLine.d182.s11	1.7	29	31	O	1.7	1.7	1.7	CD	False
DDI-MedLine.d182.s11	mM	33	34	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s11	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d182.s11	3.4	39	41	O	3.4	3.4	3.4	CD	False
DDI-MedLine.d182.s11	mM	43	44	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s11	;	45	45	O	;	;	;	:	False

DDI-MedLine.d182.s12	MBC	0	2	O	MBC	MBC	MBC	NN	brand
DDI-MedLine.d182.s12	was	4	6	O	was	was	was	VBD	False
DDI-MedLine.d182.s12	3.4	8	10	O	3.4	3.4	3.4	CD	False
DDI-MedLine.d182.s12	mM	12	13	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s12	to	15	16	O	to	to	to	TO	False
DDI-MedLine.d182.s12	6.7	18	20	O	6.7	6.7	6.7	CD	False
DDI-MedLine.d182.s12	mM	22	23	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s12	.	24	24	O	.	.	.	.	False

DDI-MedLine.d182.s13	Zinc	0	3	B-drug	Zinc	inc	Zinc	NN	False
DDI-MedLine.d182.s13	gluconate	5	13	I-drug	gluconate	ate	nate	NN	False
DDI-MedLine.d182.s13	MIC	15	17	O	MIC	MIC	MIC	NN	brand
DDI-MedLine.d182.s13	was	19	21	O	was	was	was	VBD	False
DDI-MedLine.d182.s13	2.8	23	25	O	2.8	2.8	2.8	CD	False
DDI-MedLine.d182.s13	mM	27	28	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s13	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d182.s13	11	33	34	O	11	11	11	CD	False
DDI-MedLine.d182.s13	mM	36	37	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s13	;	38	38	O	;	;	;	:	False

DDI-MedLine.d182.s14	MBC	0	2	O	MBC	MBC	MBC	NN	brand
DDI-MedLine.d182.s14	was	4	6	O	was	was	was	VBD	False
DDI-MedLine.d182.s14	between	8	14	O	between	een	ween	IN	False
DDI-MedLine.d182.s14	11	16	17	O	11	11	11	CD	False
DDI-MedLine.d182.s14	mM	19	20	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s14	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d182.s14	>	26	26	O	>	>	>	NN	False
DDI-MedLine.d182.s14	44	27	28	O	44	44	44	CD	False
DDI-MedLine.d182.s14	mM	30	31	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s14	.	32	32	O	.	.	.	.	False

DDI-MedLine.d182.s15	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d182.s15	two	4	6	O	two	two	two	CD	False
DDI-MedLine.d182.s15	agents	8	13	O	agents	nts	ents	NNS	False
DDI-MedLine.d182.s15	in	15	16	O	in	in	in	IN	False
DDI-MedLine.d182.s15	solution	18	25	O	solution	ion	tion	NN	False
DDI-MedLine.d182.s15	showed	27	32	O	showed	wed	owed	VBD	False
DDI-MedLine.d182.s15	synergy	34	40	O	synergy	rgy	ergy	NN	False
DDI-MedLine.d182.s15	(	42	42	O	(	(	(	(	False
DDI-MedLine.d182.s15	FICI	43	46	O	FICI	ICI	FICI	NN	brand
DDI-MedLine.d182.s15	0.50	50	53	O	0.50	.50	0.50	CD	False
DDI-MedLine.d182.s15	)	54	54	O	)	)	)	)	False
DDI-MedLine.d182.s15	against	56	62	O	against	nst	inst	IN	False
DDI-MedLine.d182.s15	P	64	64	O	P	P	P	NN	brand
DDI-MedLine.d182.s15	.	65	65	O	.	.	.	.	False

DDI-MedLine.d182.s16	gingivalis	0	9	O	gingivalis	lis	alis	NN	False
DDI-MedLine.d182.s16	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d182.s16	F	15	15	O	F	F	F	NN	brand
DDI-MedLine.d182.s16	.	16	16	O	.	.	.	.	False

DDI-MedLine.d182.s17	nucleatum	0	8	O	nucleatum	tum	atum	NN	False
DDI-MedLine.d182.s17	,	9	9	O	,	,	,	,	False
DDI-MedLine.d182.s17	with	11	14	O	with	ith	with	IN	False
DDI-MedLine.d182.s17	MIC	16	18	O	MIC	MIC	MIC	NN	brand
DDI-MedLine.d182.s17	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d182.s17	0.42	23	26	O	0.42	.42	0.42	CD	False
DDI-MedLine.d182.s17	mM/0.69	28	34	O	mM/0.69	.69	0.69	NN	False
DDI-MedLine.d182.s17	mM	36	37	O	mM	mM	mM	NN	False
DDI-MedLine.d182.s17	for	39	41	O	for	for	for	IN	False
DDI-MedLine.d182.s17	o-cymen-5-ol/zinc	43	59	O	o-cymen-5-ol/zinc	inc	zinc	NN	False
DDI-MedLine.d182.s17	gluconate	61	69	I-drug	gluconate	ate	nate	NN	False
DDI-MedLine.d182.s17	,	70	70	O	,	,	,	,	False
DDI-MedLine.d182.s17	respectively	72	83	O	respectively	ely	vely	RB	False
DDI-MedLine.d182.s17	.	84	84	O	.	.	.	.	False

DDI-MedLine.d182.s18	Zinc	0	3	B-drug	Zinc	inc	Zinc	NN	False
DDI-MedLine.d182.s18	inhibited	5	13	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d182.s18	glycolysis	15	24	O	glycolysis	sis	ysis	NN	False
DDI-MedLine.d182.s18	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d182.s18	protease	30	37	O	protease	ase	ease	NN	False
DDI-MedLine.d182.s18	to	39	40	O	to	to	to	TO	False
DDI-MedLine.d182.s18	a	42	42	O	a	a	a	DT	False
DDI-MedLine.d182.s18	greater	44	50	O	greater	ter	ater	JJR	False
DDI-MedLine.d182.s18	degree	52	57	O	degree	ree	gree	NN	False
DDI-MedLine.d182.s18	than	59	62	O	than	han	than	IN	False
DDI-MedLine.d182.s18	o-cymen-5-ol	64	75	B-drug_n	o-cymen-5-ol	-ol	5-ol	NN	False
DDI-MedLine.d182.s18	;	76	76	O	;	;	;	:	False

DDI-MedLine.d182.s19	glycolysis	0	9	O	glycolysis	sis	ysis	NN	False
DDI-MedLine.d182.s19	inhibition	11	20	O	inhibition	ion	tion	NN	False
DDI-MedLine.d182.s19	by	22	23	O	by	by	by	IN	False
DDI-MedLine.d182.s19	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d182.s19	two	29	31	O	two	two	two	CD	False
DDI-MedLine.d182.s19	agents	33	38	O	agents	nts	ents	NNS	False
DDI-MedLine.d182.s19	was	40	42	O	was	was	was	VBD	False
DDI-MedLine.d182.s19	additive	44	51	O	additive	ive	tive	JJ	False
DDI-MedLine.d182.s19	.	52	52	O	.	.	.	.	False

DDI-MedLine.d182.s20	o-Cymen-5-ol/zinc	0	16	O	o-Cymen-5-ol/zinc	inc	zinc	NN	False
DDI-MedLine.d182.s20	chloride	18	25	I-drug	chloride	ide	ride	NN	False
DDI-MedLine.d182.s20	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d182.s20	toothpaste	30	39	O	toothpaste	ste	aste	NN	False
DDI-MedLine.d182.s20	showed	41	46	O	showed	wed	owed	VBD	False
DDI-MedLine.d182.s20	greater	48	54	O	greater	ter	ater	JJR	False
DDI-MedLine.d182.s20	effects	56	62	O	effects	cts	ects	NNS	False
DDI-MedLine.d182.s20	than	64	67	O	than	han	than	IN	False
DDI-MedLine.d182.s20	placebo	69	75	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d182.s20	(	77	77	O	(	(	(	(	False
DDI-MedLine.d182.s20	120s	78	81	O	120s	20s	120s	CD	False
DDI-MedLine.d182.s20	log10	83	87	O	log10	g10	og10	NN	False
DDI-MedLine.d182.s20	kill=7.35	89	97	O	kill=7.35	.35	7.35	NN	False
DDI-MedLine.d182.s20	0.40	100	103	O	0.40	.40	0.40	CD	False
DDI-MedLine.d182.s20	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d182.s20	4.02	109	112	O	4.02	.02	4.02	CD	False
DDI-MedLine.d182.s20	0.40	115	118	O	0.40	.40	0.40	CD	False
DDI-MedLine.d182.s20	,	119	119	O	,	,	,	,	False
DDI-MedLine.d182.s20	respectively	121	132	O	respectively	ely	vely	RB	False
DDI-MedLine.d182.s20	)	133	133	O	)	)	)	)	False
DDI-MedLine.d182.s20	.	134	134	O	.	.	.	.	False

DDI-MedLine.d182.s21	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d182.s21	zinc/o-cymen-5-ol	4	20	O	zinc/o-cymen-5-ol	-ol	5-ol	NN	False
DDI-MedLine.d182.s21	system	22	27	O	system	tem	stem	NN	False
DDI-MedLine.d182.s21	has	29	31	O	has	has	has	VBZ	False
DDI-MedLine.d182.s21	direct	33	38	O	direct	ect	rect	JJ	False
DDI-MedLine.d182.s21	antimicrobial	40	52	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d182.s21	effects	54	60	O	effects	cts	ects	NNS	False
DDI-MedLine.d182.s21	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d182.s21	inhibits	66	73	O	inhibits	its	bits	NNS	False
DDI-MedLine.d182.s21	oral	75	78	O	oral	ral	oral	JJ	False
DDI-MedLine.d182.s21	disease-related	80	94	O	disease-related	ted	ated	JJ	False
DDI-MedLine.d182.s21	processes	96	104	O	processes	ses	sses	NNS	False
DDI-MedLine.d182.s21	.	105	105	O	.	.	.	.	False

DDI-MedLine.d182.s22	Synergistic	0	10	O	Synergistic	tic	stic	JJ	False
DDI-MedLine.d182.s22	effects	12	18	O	effects	cts	ects	NNS	False
DDI-MedLine.d182.s22	were	20	23	O	were	ere	were	VBD	False
DDI-MedLine.d182.s22	seen	25	28	O	seen	een	seen	VBN	False
DDI-MedLine.d182.s22	against	30	36	O	against	nst	inst	IN	False
DDI-MedLine.d182.s22	anaerobes	38	46	O	anaerobes	bes	obes	NNS	False
DDI-MedLine.d182.s22	.	47	47	O	.	.	.	.	False

DDI-MedLine.d182.s23	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d182.s23	system	2	7	O	system	tem	stem	NN	False
DDI-MedLine.d182.s23	combining	9	17	O	combining	ing	ning	VBG	False
DDI-MedLine.d182.s23	o-cymen-5-ol	19	30	B-drug_n	o-cymen-5-ol	-ol	5-ol	NN	False
DDI-MedLine.d182.s23	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d182.s23	zinc	36	39	B-drug	zinc	inc	zinc	NN	False
DDI-MedLine.d182.s23	shows	41	45	O	shows	ows	hows	NNS	False
DDI-MedLine.d182.s23	properties	47	56	O	properties	ies	ties	NNS	False
DDI-MedLine.d182.s23	desirable	58	66	O	desirable	ble	able	JJ	False
DDI-MedLine.d182.s23	for	68	70	O	for	for	for	IN	False
DDI-MedLine.d182.s23	incorporation	72	84	O	incorporation	ion	tion	NN	False
DDI-MedLine.d182.s23	in	86	87	O	in	in	in	IN	False
DDI-MedLine.d182.s23	toothpastes	89	99	O	toothpastes	tes	stes	NNS	False
DDI-MedLine.d182.s23	.	100	100	O	.	.	.	.	False

DDI-MedLine.d155.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d155.s0	role	4	7	O	role	ole	role	NN	False
DDI-MedLine.d155.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d155.s0	interneurons	12	23	O	interneurons	ons	rons	NNS	False
DDI-MedLine.d155.s0	in	25	26	O	in	in	in	IN	False
DDI-MedLine.d155.s0	shaping	28	34	O	shaping	ing	ping	VBG	False
DDI-MedLine.d155.s0	Purkinje	36	43	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s0	cell	45	48	O	cell	ell	cell	NN	False
DDI-MedLine.d155.s0	responses	50	58	O	responses	ses	nses	NNS	False
DDI-MedLine.d155.s0	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d155.s0	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d155.s0	cerebellar	67	76	O	cerebellar	lar	llar	NN	False
DDI-MedLine.d155.s0	cortex	78	83	O	cortex	tex	rtex	NN	False
DDI-MedLine.d155.s0	.	84	84	O	.	.	.	.	False

DDI-MedLine.d155.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d155.s1	well	4	7	O	well	ell	well	RB	False
DDI-MedLine.d155.s1	established	9	19	O	established	hed	shed	VBN	False
DDI-MedLine.d155.s1	anatomy	21	27	O	anatomy	omy	tomy	NN	False
DDI-MedLine.d155.s1	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d155.s1	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d155.s1	cerebellar	36	45	O	cerebellar	lar	llar	NN	False
DDI-MedLine.d155.s1	cortex	47	52	O	cortex	tex	rtex	NN	False
DDI-MedLine.d155.s1	has	54	56	O	has	has	has	VBZ	False
DDI-MedLine.d155.s1	led	58	60	O	led	led	led	VBN	False
DDI-MedLine.d155.s1	to	62	63	O	to	to	to	TO	False
DDI-MedLine.d155.s1	suggestions	65	75	O	suggestions	ons	ions	NNS	False
DDI-MedLine.d155.s1	that	77	80	O	that	hat	that	IN	False
DDI-MedLine.d155.s1	cerebellar	82	91	O	cerebellar	lar	llar	NN	False
DDI-MedLine.d155.s1	molecular	93	101	O	molecular	lar	ular	NN	False
DDI-MedLine.d155.s1	layer	103	107	O	layer	yer	ayer	NN	False
DDI-MedLine.d155.s1	interneurons	109	120	O	interneurons	ons	rons	NNS	False
DDI-MedLine.d155.s1	laterally	122	130	O	laterally	lly	ally	RB	False
DDI-MedLine.d155.s1	inhibit	132	138	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d155.s1	Purkinje	140	147	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s1	cells	149	153	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s1	.	154	154	O	.	.	.	.	False

DDI-MedLine.d155.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d155.s2	support	3	9	O	support	ort	port	NN	False
DDI-MedLine.d155.s2	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d155.s2	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d155.s2	anatomical	18	27	O	anatomical	cal	ical	JJ	False
DDI-MedLine.d155.s2	predictions	29	39	O	predictions	ons	ions	NNS	False
DDI-MedLine.d155.s2	,	40	40	O	,	,	,	,	False
DDI-MedLine.d155.s2	on-beam	42	48	O	on-beam	eam	beam	NN	False
DDI-MedLine.d155.s2	excitation	50	59	O	excitation	ion	tion	NN	False
DDI-MedLine.d155.s2	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d155.s2	off-beam	65	72	O	off-beam	eam	beam	NN	False
DDI-MedLine.d155.s2	inhibition	74	83	O	inhibition	ion	tion	NN	False
DDI-MedLine.d155.s2	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d155.s2	Purkinje	88	95	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s2	cells	97	101	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s2	have	103	106	O	have	ave	have	VB	False
DDI-MedLine.d155.s2	been	108	111	O	been	een	been	VBN	False
DDI-MedLine.d155.s2	shown	113	117	O	shown	own	hown	VBN	False
DDI-MedLine.d155.s2	to	119	120	O	to	to	to	TO	False
DDI-MedLine.d155.s2	occur	122	126	O	occur	cur	ccur	NN	False
DDI-MedLine.d155.s2	when	128	131	O	when	hen	when	WRB	False
DDI-MedLine.d155.s2	the	133	135	O	the	the	the	DT	False
DDI-MedLine.d155.s2	surface	137	143	O	surface	ace	face	NN	False
DDI-MedLine.d155.s2	of	145	146	O	of	of	of	IN	False
DDI-MedLine.d155.s2	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d155.s2	cerebellum	152	161	O	cerebellum	lum	llum	NN	False
DDI-MedLine.d155.s2	is	163	164	O	is	is	is	VBZ	False
DDI-MedLine.d155.s2	electrically	166	177	O	electrically	lly	ally	RB	False
DDI-MedLine.d155.s2	excited	179	185	O	excited	ted	ited	VBN	False
DDI-MedLine.d155.s2	.	186	186	O	.	.	.	.	False

DDI-MedLine.d155.s3	Patchy	0	5	O	Patchy	chy	tchy	NN	False
DDI-MedLine.d155.s3	excitation	7	16	O	excitation	ion	tion	NN	False
DDI-MedLine.d155.s3	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d155.s3	Purkinje	21	28	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s3	cells	30	34	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s3	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d155.s3	flanking	41	48	O	flanking	ing	king	VBG	False
DDI-MedLine.d155.s3	inhibition	50	59	O	inhibition	ion	tion	NN	False
DDI-MedLine.d155.s3	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d155.s3	sagittally	64	73	O	sagittally	lly	ally	RB	False
DDI-MedLine.d155.s3	oriented	75	82	O	oriented	ted	nted	VBN	False
DDI-MedLine.d155.s3	Purkinje	84	91	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s3	cells	93	97	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s3	have	99	102	O	have	ave	have	VB	False
DDI-MedLine.d155.s3	also	104	107	O	also	lso	also	RB	False
DDI-MedLine.d155.s3	been	109	112	O	been	een	been	VBN	False
DDI-MedLine.d155.s3	demonstrated	114	125	O	demonstrated	ted	ated	VBN	False
DDI-MedLine.d155.s3	following	127	135	O	following	ing	wing	VBG	False
DDI-MedLine.d155.s3	peripheral	137	146	O	peripheral	ral	eral	JJ	False
DDI-MedLine.d155.s3	stimulation	148	158	O	stimulation	ion	tion	NN	False
DDI-MedLine.d155.s3	in	160	161	O	in	in	in	IN	False
DDI-MedLine.d155.s3	vivo	163	166	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d155.s3	.	167	167	O	.	.	.	.	False

DDI-MedLine.d155.s4	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d155.s4	extend	3	8	O	extend	end	tend	NN	False
DDI-MedLine.d155.s4	these	10	14	O	these	ese	hese	DT	False
DDI-MedLine.d155.s4	observations	16	27	O	observations	ons	ions	NNS	False
DDI-MedLine.d155.s4	,	28	28	O	,	,	,	,	False
DDI-MedLine.d155.s4	we	30	31	O	we	we	we	PRP	False
DDI-MedLine.d155.s4	mapped	33	38	O	mapped	ped	pped	NNS	False
DDI-MedLine.d155.s4	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d155.s4	functional	44	53	O	functional	nal	onal	JJ	False
DDI-MedLine.d155.s4	connectivity	55	66	O	connectivity	ity	vity	NN	False
DDI-MedLine.d155.s4	between	68	74	O	between	een	ween	IN	False
DDI-MedLine.d155.s4	granule	76	82	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s4	cells	84	88	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s4	,	89	89	O	,	,	,	,	False
DDI-MedLine.d155.s4	molecular	91	99	O	molecular	lar	ular	NN	False
DDI-MedLine.d155.s4	layer	101	105	O	layer	yer	ayer	NN	False
DDI-MedLine.d155.s4	interneurons	107	118	O	interneurons	ons	rons	NNS	False
DDI-MedLine.d155.s4	,	119	119	O	,	,	,	,	False
DDI-MedLine.d155.s4	and	121	123	O	and	and	and	CC	False
DDI-MedLine.d155.s4	Purkinje	125	132	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s4	cells	134	138	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s4	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d155.s4	rats	143	146	O	rats	ats	rats	NNS	False
DDI-MedLine.d155.s4	.	147	147	O	.	.	.	.	False

DDI-MedLine.d155.s5	Patches	0	6	O	Patches	hes	ches	NNS	False
DDI-MedLine.d155.s5	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d155.s5	granule	11	17	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s5	cells	19	23	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s5	were	25	28	O	were	ere	were	VBD	False
DDI-MedLine.d155.s5	asynchronously	30	43	O	asynchronously	sly	usly	RB	False
DDI-MedLine.d155.s5	activated	45	53	O	activated	ted	ated	VBN	False
DDI-MedLine.d155.s5	by	55	56	O	by	by	by	IN	False
DDI-MedLine.d155.s5	photostimulation	58	73	O	photostimulation	ion	tion	NN	False
DDI-MedLine.d155.s5	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d155.s5	mimic	78	82	O	mimic	mic	imic	NN	False
DDI-MedLine.d155.s5	their	84	88	O	their	eir	heir	PRP$	False
DDI-MedLine.d155.s5	excitation	90	99	O	excitation	ion	tion	NN	False
DDI-MedLine.d155.s5	by	101	102	O	by	by	by	IN	False
DDI-MedLine.d155.s5	a	104	104	O	a	a	a	DT	False
DDI-MedLine.d155.s5	mossy	106	110	O	mossy	ssy	ossy	NN	False
DDI-MedLine.d155.s5	fiber	112	116	O	fiber	ber	iber	NN	False
DDI-MedLine.d155.s5	as	118	119	O	as	as	as	IN	False
DDI-MedLine.d155.s5	it	121	122	O	it	it	it	PRP	False
DDI-MedLine.d155.s5	occurs	124	129	O	occurs	urs	curs	NNS	False
DDI-MedLine.d155.s5	in	131	132	O	in	in	in	IN	False
DDI-MedLine.d155.s5	vivo	134	137	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d155.s5	.	138	138	O	.	.	.	.	False

DDI-MedLine.d155.s6	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d155.s6	found	3	7	O	found	und	ound	NN	False
DDI-MedLine.d155.s6	with	9	12	O	with	ith	with	IN	False
DDI-MedLine.d155.s6	remarkable	14	23	O	remarkable	ble	able	JJ	False
DDI-MedLine.d155.s6	consistency	25	35	O	consistency	ncy	ency	NN	False
DDI-MedLine.d155.s6	that	37	40	O	that	hat	that	IN	False
DDI-MedLine.d155.s6	,	41	41	O	,	,	,	,	False
DDI-MedLine.d155.s6	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d155.s6	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d155.s6	sagittal	50	57	O	sagittal	tal	ttal	NN	False
DDI-MedLine.d155.s6	orientation	59	69	O	orientation	ion	tion	NN	False
DDI-MedLine.d155.s6	,	70	70	O	,	,	,	,	False
DDI-MedLine.d155.s6	granule	72	78	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s6	cells	80	84	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s6	elicit	86	91	O	elicit	cit	icit	NN	False
DDI-MedLine.d155.s6	a	93	93	O	a	a	a	DT	False
DDI-MedLine.d155.s6	stereotypic	95	105	O	stereotypic	pic	ypic	NN	False
DDI-MedLine.d155.s6	set	107	109	O	set	set	set	NN	False
DDI-MedLine.d155.s6	of	111	112	O	of	of	of	IN	False
DDI-MedLine.d155.s6	responses	114	122	O	responses	ses	nses	NNS	False
DDI-MedLine.d155.s6	.	123	123	O	.	.	.	.	False

DDI-MedLine.d155.s7	Granule	0	6	O	Granule	ule	nule	NN	False
DDI-MedLine.d155.s7	cells	8	12	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s7	immediately	14	24	O	immediately	ely	tely	RB	False
DDI-MedLine.d155.s7	underneath	26	35	O	underneath	ath	eath	NN	False
DDI-MedLine.d155.s7	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d155.s7	Purkinje	39	46	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s7	cell	48	51	O	cell	ell	cell	NN	False
DDI-MedLine.d155.s7	provide	53	59	O	provide	ide	vide	NN	False
DDI-MedLine.d155.s7	pure	61	64	O	pure	ure	pure	NN	False
DDI-MedLine.d155.s7	excitation	66	75	O	excitation	ion	tion	NN	False
DDI-MedLine.d155.s7	.	76	76	O	.	.	.	.	False

DDI-MedLine.d155.s8	Granule	0	6	O	Granule	ule	nule	NN	False
DDI-MedLine.d155.s8	cells	8	12	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s8	positioned	14	23	O	positioned	ned	oned	VBN	False
DDI-MedLine.d155.s8	340-400	25	31	O	340-400	400	-400	JJ	False
DDI-MedLine.d155.s8	m	35	35	O	m	m	m	NN	False
DDI-MedLine.d155.s8	laterally	37	45	O	laterally	lly	ally	RB	False
DDI-MedLine.d155.s8	provided	47	54	O	provided	ded	ided	VBN	False
DDI-MedLine.d155.s8	pure	56	59	O	pure	ure	pure	NN	False
DDI-MedLine.d155.s8	inhibition	61	70	O	inhibition	ion	tion	NN	False
DDI-MedLine.d155.s8	,	71	71	O	,	,	,	,	False
DDI-MedLine.d155.s8	consistent	73	82	O	consistent	ent	tent	NN	False
DDI-MedLine.d155.s8	with	84	87	O	with	ith	with	IN	False
DDI-MedLine.d155.s8	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d155.s8	lateral	93	99	O	lateral	ral	eral	JJ	False
DDI-MedLine.d155.s8	inhibition	101	110	O	inhibition	ion	tion	NN	False
DDI-MedLine.d155.s8	proposed	112	119	O	proposed	sed	osed	VBN	False
DDI-MedLine.d155.s8	earlier	121	127	O	earlier	ier	lier	RBR	False
DDI-MedLine.d155.s8	.	128	128	O	.	.	.	.	False

DDI-MedLine.d155.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d155.s9	net	4	6	O	net	net	net	NN	False
DDI-MedLine.d155.s9	effect	8	13	O	effect	ect	fect	NN	False
DDI-MedLine.d155.s9	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d155.s9	exciting	18	25	O	exciting	ing	ting	VBG	False
DDI-MedLine.d155.s9	granule	27	33	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s9	cells	35	39	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s9	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d155.s9	between	44	50	O	between	een	ween	IN	False
DDI-MedLine.d155.s9	these	52	56	O	these	ese	hese	DT	False
DDI-MedLine.d155.s9	two	58	60	O	two	two	two	CD	False
DDI-MedLine.d155.s9	extremes	62	69	O	extremes	mes	emes	NNS	False
DDI-MedLine.d155.s9	was	71	73	O	was	was	was	VBD	False
DDI-MedLine.d155.s9	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d155.s9	provide	78	84	O	provide	ide	vide	NN	False
DDI-MedLine.d155.s9	a	86	86	O	a	a	a	DT	False
DDI-MedLine.d155.s9	systematic	88	97	O	systematic	tic	atic	JJ	False
DDI-MedLine.d155.s9	change	99	104	O	change	nge	ange	NN	False
DDI-MedLine.d155.s9	in	106	107	O	in	in	in	IN	False
DDI-MedLine.d155.s9	the	109	111	O	the	the	the	DT	False
DDI-MedLine.d155.s9	response	113	120	O	response	nse	onse	NN	False
DDI-MedLine.d155.s9	of	122	123	O	of	of	of	IN	False
DDI-MedLine.d155.s9	Purkinje	125	132	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s9	cells	134	138	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s9	,	139	139	O	,	,	,	,	False
DDI-MedLine.d155.s9	from	141	144	O	from	rom	from	IN	False
DDI-MedLine.d155.s9	net	146	148	O	net	net	net	NN	False
DDI-MedLine.d155.s9	excitation	150	159	O	excitation	ion	tion	NN	False
DDI-MedLine.d155.s9	to	161	162	O	to	to	to	TO	False
DDI-MedLine.d155.s9	net	164	166	O	net	net	net	NN	False
DDI-MedLine.d155.s9	inhibition	168	177	O	inhibition	ion	tion	NN	False
DDI-MedLine.d155.s9	moving	179	184	O	moving	ing	ving	VBG	False
DDI-MedLine.d155.s9	laterally	186	194	O	laterally	lly	ally	RB	False
DDI-MedLine.d155.s9	from	196	199	O	from	rom	from	IN	False
DDI-MedLine.d155.s9	the	201	203	O	the	the	the	DT	False
DDI-MedLine.d155.s9	Purkinje	205	212	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s9	cell	214	217	O	cell	ell	cell	NN	False
DDI-MedLine.d155.s9	.	218	218	O	.	.	.	.	False

DDI-MedLine.d155.s10	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d155.s10	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d155.s10	to	12	13	O	to	to	to	TO	False
DDI-MedLine.d155.s10	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d155.s10	sagittal	19	26	O	sagittal	tal	ttal	NN	False
DDI-MedLine.d155.s10	orientation	28	38	O	orientation	ion	tion	NN	False
DDI-MedLine.d155.s10	,	39	39	O	,	,	,	,	False
DDI-MedLine.d155.s10	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d155.s10	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d155.s10	coronal	48	54	O	coronal	nal	onal	NN	False
DDI-MedLine.d155.s10	orientation	56	66	O	orientation	ion	tion	NN	False
DDI-MedLine.d155.s10	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d155.s10	organization	72	83	O	organization	ion	tion	NN	False
DDI-MedLine.d155.s10	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d155.s10	Purkinje	88	95	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s10	cell	97	100	O	cell	ell	cell	NN	False
DDI-MedLine.d155.s10	responses	102	110	O	responses	ses	nses	NNS	False
DDI-MedLine.d155.s10	with	112	115	O	with	ith	with	IN	False
DDI-MedLine.d155.s10	granule	117	123	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s10	cell	125	128	O	cell	ell	cell	NN	False
DDI-MedLine.d155.s10	activation	130	139	O	activation	ion	tion	NN	False
DDI-MedLine.d155.s10	was	141	143	O	was	was	was	VBD	False
DDI-MedLine.d155.s10	remarkably	145	154	O	remarkably	bly	ably	RB	False
DDI-MedLine.d155.s10	different	156	164	O	different	ent	rent	JJ	False
DDI-MedLine.d155.s10	.	165	165	O	.	.	.	.	False

DDI-MedLine.d155.s11	Independent	0	10	O	Independent	ent	dent	NN	False
DDI-MedLine.d155.s11	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d155.s11	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d155.s11	location	19	26	O	location	ion	tion	NN	False
DDI-MedLine.d155.s11	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d155.s11	granule	31	37	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s11	cells	39	43	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s11	,	44	44	O	,	,	,	,	False
DDI-MedLine.d155.s11	within	46	51	O	within	hin	thin	IN	False
DDI-MedLine.d155.s11	the	53	55	O	the	the	the	DT	False
DDI-MedLine.d155.s11	480	57	59	O	480	480	480	CD	False
DDI-MedLine.d155.s11	m	63	63	O	m	m	m	NN	False
DDI-MedLine.d155.s11	lateral	65	71	O	lateral	ral	eral	JJ	False
DDI-MedLine.d155.s11	distance	73	80	O	distance	nce	ance	NN	False
DDI-MedLine.d155.s11	examined	82	89	O	examined	ned	ined	VBN	False
DDI-MedLine.d155.s11	,	90	90	O	,	,	,	,	False
DDI-MedLine.d155.s11	molecular	92	100	O	molecular	lar	ular	NN	False
DDI-MedLine.d155.s11	layer	102	106	O	layer	yer	ayer	NN	False
DDI-MedLine.d155.s11	interneurons	108	119	O	interneurons	ons	rons	NNS	False
DDI-MedLine.d155.s11	reduced	121	127	O	reduced	ced	uced	VBN	False
DDI-MedLine.d155.s11	the	129	131	O	the	the	the	DT	False
DDI-MedLine.d155.s11	strength	133	140	O	strength	gth	ngth	NN	False
DDI-MedLine.d155.s11	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d155.s11	granule	145	151	O	granule	ule	nule	NN	False
DDI-MedLine.d155.s11	cell	153	156	O	cell	ell	cell	NN	False
DDI-MedLine.d155.s11	inputs	158	163	O	inputs	uts	puts	NNS	False
DDI-MedLine.d155.s11	to	165	166	O	to	to	to	TO	False
DDI-MedLine.d155.s11	Purkinje	168	175	O	Purkinje	nje	inje	NN	False
DDI-MedLine.d155.s11	cells	177	181	O	cells	lls	ells	NNS	False
DDI-MedLine.d155.s11	to	183	184	O	to	to	to	TO	False
DDI-MedLine.d155.s11	a	186	186	O	a	a	a	DT	False
DDI-MedLine.d155.s11	comparable	188	197	O	comparable	ble	able	JJ	False
DDI-MedLine.d155.s11	extent	199	204	O	extent	ent	tent	NN	False
DDI-MedLine.d155.s11	.	205	205	O	.	.	.	.	False

DDI-MedLine.d219.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d219.s0	Tuberculosis	1	12	O	Tuberculosis	sis	osis	NN	False
DDI-MedLine.d219.s0	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d219.s0	HIV	18	20	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d219.s0	-	22	22	O	-	-	-	:	False
DDI-MedLine.d219.s0	features	24	31	O	features	res	ures	NNS	False
DDI-MedLine.d219.s0	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d219.s0	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d219.s0	co-infection	40	51	O	co-infection	ion	tion	NN	False
DDI-MedLine.d219.s0	]	52	52	O	]	]	]	NN	False
DDI-MedLine.d219.s0	.	53	53	O	.	.	.	.	False

DDI-MedLine.d219.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d219.s1	human	4	8	O	human	man	uman	NN	False
DDI-MedLine.d219.s1	immunodeficiency	10	25	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d219.s1	virus	27	31	O	virus	rus	irus	NN	False
DDI-MedLine.d219.s1	(	33	33	O	(	(	(	(	False
DDI-MedLine.d219.s1	HIV	34	36	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d219.s1	)	37	37	O	)	)	)	)	False
DDI-MedLine.d219.s1	epidemic	39	46	O	epidemic	mic	emic	JJ	False
DDI-MedLine.d219.s1	has	48	50	O	has	has	has	VBZ	False
DDI-MedLine.d219.s1	allowed	52	58	O	allowed	wed	owed	VBN	False
DDI-MedLine.d219.s1	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d219.s1	incidence	64	72	O	incidence	nce	ence	NN	False
DDI-MedLine.d219.s1	of	74	75	O	of	of	of	IN	False
DDI-MedLine.d219.s1	tuberculosis	77	88	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d219.s1	to	90	91	O	to	to	to	TO	False
DDI-MedLine.d219.s1	rise	93	96	O	rise	ise	rise	NN	False
DDI-MedLine.d219.s1	globally	98	105	O	globally	lly	ally	RB	False
DDI-MedLine.d219.s1	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d219.s1	particularly	111	122	O	particularly	rly	arly	RB	False
DDI-MedLine.d219.s1	in	124	125	O	in	in	in	IN	False
DDI-MedLine.d219.s1	sub-Saharan	127	137	O	sub-Saharan	ran	aran	NN	False
DDI-MedLine.d219.s1	Africa	139	144	O	Africa	ica	rica	NNP	False
DDI-MedLine.d219.s1	.	145	145	O	.	.	.	.	False

DDI-MedLine.d219.s2	Diagnosis	0	8	O	Diagnosis	sis	osis	NN	False
DDI-MedLine.d219.s2	and	10	12	O	and	and	and	CC	False
DDI-MedLine.d219.s2	treatment	14	22	O	treatment	ent	ment	NN	False
DDI-MedLine.d219.s2	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d219.s2	tuberculosis	27	38	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d219.s2	is	40	41	O	is	is	is	VBZ	False
DDI-MedLine.d219.s2	more	43	46	O	more	ore	more	RBR	False
DDI-MedLine.d219.s2	complex	48	54	O	complex	lex	plex	JJ	False
DDI-MedLine.d219.s2	in	56	57	O	in	in	in	IN	False
DDI-MedLine.d219.s2	patients	59	66	O	patients	nts	ents	NNS	False
DDI-MedLine.d219.s2	with	68	71	O	with	ith	with	IN	False
DDI-MedLine.d219.s2	HIV/AIDS	73	80	O	HIV/AIDS	IDS	AIDS	NN	brand
DDI-MedLine.d219.s2	.	81	81	O	.	.	.	.	False

DDI-MedLine.d219.s3	Sputum	0	5	O	Sputum	tum	utum	NN	False
DDI-MedLine.d219.s3	smear	7	11	O	smear	ear	mear	NN	False
DDI-MedLine.d219.s3	microscopy	13	22	O	microscopy	opy	copy	NN	False
DDI-MedLine.d219.s3	is	24	25	O	is	is	is	VBZ	False
DDI-MedLine.d219.s3	performing	27	36	O	performing	ing	ming	VBG	False
DDI-MedLine.d219.s3	poorly	38	43	O	poorly	rly	orly	RB	False
DDI-MedLine.d219.s3	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d219.s3	HIV-infected	48	59	O	HIV-infected	ted	cted	JJ	False
DDI-MedLine.d219.s3	individuals	61	71	O	individuals	als	uals	NNS	False
DDI-MedLine.d219.s3	,	72	72	O	,	,	,	,	False
DDI-MedLine.d219.s3	who	74	76	O	who	who	who	WP	False
DDI-MedLine.d219.s3	are	78	80	O	are	are	are	VBP	False
DDI-MedLine.d219.s3	often	82	86	O	often	ten	ften	RB	False
DDI-MedLine.d219.s3	started	88	94	O	started	ted	rted	VBN	False
DDI-MedLine.d219.s3	on	96	97	O	on	on	on	IN	False
DDI-MedLine.d219.s3	antituberculosis	99	114	O	antituberculosis	sis	osis	NN	False
DDI-MedLine.d219.s3	treatment	116	124	O	treatment	ent	ment	NN	False
DDI-MedLine.d219.s3	on	126	127	O	on	on	on	IN	False
DDI-MedLine.d219.s3	clinical	129	136	O	clinical	cal	ical	JJ	False
DDI-MedLine.d219.s3	grounds	138	144	O	grounds	nds	unds	NNS	False
DDI-MedLine.d219.s3	.	145	145	O	.	.	.	.	False

DDI-MedLine.d219.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d219.s4	treatment	4	12	O	treatment	ent	ment	NN	False
DDI-MedLine.d219.s4	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d219.s4	coinfected	17	26	O	coinfected	ted	cted	VBN	False
DDI-MedLine.d219.s4	patients	28	35	O	patients	nts	ents	NNS	False
DDI-MedLine.d219.s4	requires	37	44	O	requires	res	ires	VBZ	False
DDI-MedLine.d219.s4	antituberculosis	46	61	B-group	antituberculosis	sis	osis	NN	False
DDI-MedLine.d219.s4	and	63	65	O	and	and	and	CC	False
DDI-MedLine.d219.s4	antiretroviral	67	80	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d219.s4	drugs	82	86	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d219.s4	to	88	89	O	to	to	to	TO	False
DDI-MedLine.d219.s4	be	91	92	O	be	be	be	VB	False
DDI-MedLine.d219.s4	administered	94	105	O	administered	red	ered	VBN	False
DDI-MedLine.d219.s4	concomittantly	107	120	O	concomittantly	tly	ntly	RB	False
DDI-MedLine.d219.s4	;	121	121	O	;	;	;	:	False

DDI-MedLine.d219.s5	challenges	0	9	O	challenges	ges	nges	NNS	False
DDI-MedLine.d219.s5	include	11	17	O	include	ude	lude	NN	False
DDI-MedLine.d219.s5	pill	19	22	O	pill	ill	pill	NN	False
DDI-MedLine.d219.s5	burden	24	29	O	burden	den	rden	NN	False
DDI-MedLine.d219.s5	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d219.s5	patient	35	41	O	patient	ent	ient	NN	False
DDI-MedLine.d219.s5	compliance	43	52	O	compliance	nce	ance	NN	False
DDI-MedLine.d219.s5	,	53	53	O	,	,	,	,	False
DDI-MedLine.d219.s5	drug	55	58	O	drug	rug	drug	NN	False
DDI-MedLine.d219.s5	interactions	60	71	O	interactions	ons	ions	NNS	False
DDI-MedLine.d219.s5	,	72	72	O	,	,	,	,	False
DDI-MedLine.d219.s5	overlapping	74	84	O	overlapping	ing	ping	VBG	False
DDI-MedLine.d219.s5	toxic	86	90	O	toxic	xic	oxic	NN	False
DDI-MedLine.d219.s5	effects	92	98	O	effects	cts	ects	NNS	False
DDI-MedLine.d219.s5	,	99	99	O	,	,	,	,	False
DDI-MedLine.d219.s5	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d219.s5	immune	105	110	O	immune	une	mune	NN	False
DDI-MedLine.d219.s5	reconstitution	112	125	O	reconstitution	ion	tion	NN	False
DDI-MedLine.d219.s5	inflammatory	127	138	O	inflammatory	ory	tory	NN	False
DDI-MedLine.d219.s5	syndrome	140	147	O	syndrome	ome	rome	NN	False
DDI-MedLine.d219.s5	.	148	148	O	.	.	.	.	False

DDI-MedLine.d219.s6	Current	0	6	O	Current	ent	rent	NN	False
DDI-MedLine.d219.s6	guidelines	8	17	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d219.s6	recommend	19	27	O	recommend	end	mend	NN	False
DDI-MedLine.d219.s6	starting	29	36	O	starting	ing	ting	VBG	False
DDI-MedLine.d219.s6	antiretroviral	38	51	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d219.s6	treatment	53	61	O	treatment	ent	ment	NN	False
DDI-MedLine.d219.s6	within	63	68	O	within	hin	thin	IN	False
DDI-MedLine.d219.s6	a	70	70	O	a	a	a	DT	False
DDI-MedLine.d219.s6	few	72	74	O	few	few	few	JJ	False
DDI-MedLine.d219.s6	weeks	76	80	O	weeks	eks	eeks	NNS	False
DDI-MedLine.d219.s6	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d219.s6	antituberculosis	85	100	B-group	antituberculosis	sis	osis	NN	False
DDI-MedLine.d219.s6	therapy	102	108	O	therapy	apy	rapy	NN	False
DDI-MedLine.d219.s6	for	110	112	O	for	for	for	IN	False
DDI-MedLine.d219.s6	patients	114	121	O	patients	nts	ents	NNS	False
DDI-MedLine.d219.s6	with	123	126	O	with	ith	with	IN	False
DDI-MedLine.d219.s6	CD4	128	130	O	CD4	CD4	CD4	NN	brand
DDI-MedLine.d219.s6	cell	132	135	O	cell	ell	cell	NN	False
DDI-MedLine.d219.s6	counts	137	142	O	counts	nts	unts	NNS	False

DDI-MedLine.d219.s7	350	0	2	O	350	350	350	CD	False
DDI-MedLine.d219.s7	cells/ul	4	11	O	cells/ul	/ul	s/ul	NN	False
DDI-MedLine.d219.s7	.	12	12	O	.	.	.	.	False

DDI-MedLine.d192.s0	Identification	0	13	O	Identification	ion	tion	NN	False
DDI-MedLine.d192.s0	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d192.s0	a	18	18	O	a	a	a	DT	False
DDI-MedLine.d192.s0	dopamine	20	27	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d192.s0	receptor-mediated	29	45	O	receptor-mediated	ted	ated	JJ	False
DDI-MedLine.d192.s0	opiate	47	52	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s0	reward	54	59	O	reward	ard	ward	NN	False
DDI-MedLine.d192.s0	memory	61	66	O	memory	ory	mory	NN	False
DDI-MedLine.d192.s0	switch	68	73	O	switch	tch	itch	NN	False
DDI-MedLine.d192.s0	in	75	76	O	in	in	in	IN	False
DDI-MedLine.d192.s0	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d192.s0	basolateral	82	92	O	basolateral	ral	eral	JJ	False
DDI-MedLine.d192.s0	amygdala-nucleus	94	109	O	amygdala-nucleus	eus	leus	NN	False
DDI-MedLine.d192.s0	accumbens	111	119	O	accumbens	ens	bens	NNS	False
DDI-MedLine.d192.s0	circuit	121	127	O	circuit	uit	cuit	NN	False
DDI-MedLine.d192.s0	.	128	128	O	.	.	.	.	False

DDI-MedLine.d192.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d192.s1	basolateral	4	14	O	basolateral	ral	eral	JJ	False
DDI-MedLine.d192.s1	amygdala	16	23	O	amygdala	ala	dala	NN	False
DDI-MedLine.d192.s1	(	25	25	O	(	(	(	(	False
DDI-MedLine.d192.s1	BLA	26	28	O	BLA	BLA	BLA	NN	brand
DDI-MedLine.d192.s1	)	29	29	O	)	)	)	)	False
DDI-MedLine.d192.s1	,	30	30	O	,	,	,	,	False
DDI-MedLine.d192.s1	ventral	32	38	O	ventral	ral	tral	JJ	False
DDI-MedLine.d192.s1	tegmental	40	48	O	tegmental	tal	ntal	NN	False
DDI-MedLine.d192.s1	area	50	53	O	area	rea	area	NN	False
DDI-MedLine.d192.s1	(	55	55	O	(	(	(	(	False
DDI-MedLine.d192.s1	VTA	56	58	O	VTA	VTA	VTA	NN	brand
DDI-MedLine.d192.s1	)	59	59	O	)	)	)	)	False
DDI-MedLine.d192.s1	,	60	60	O	,	,	,	,	False
DDI-MedLine.d192.s1	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d192.s1	nucleus	66	72	O	nucleus	eus	leus	NN	False
DDI-MedLine.d192.s1	accumbens	74	82	O	accumbens	ens	bens	NNS	False
DDI-MedLine.d192.s1	(	84	84	O	(	(	(	(	False
DDI-MedLine.d192.s1	NAc	85	87	O	NAc	NAc	NAc	NN	False
DDI-MedLine.d192.s1	)	88	88	O	)	)	)	)	False
DDI-MedLine.d192.s1	play	90	93	O	play	lay	play	NN	False
DDI-MedLine.d192.s1	central	95	101	O	central	ral	tral	JJ	False
DDI-MedLine.d192.s1	roles	103	107	O	roles	les	oles	NNS	group
DDI-MedLine.d192.s1	in	109	110	O	in	in	in	IN	False
DDI-MedLine.d192.s1	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d192.s1	processing	116	125	O	processing	ing	sing	NN	False
DDI-MedLine.d192.s1	of	127	128	O	of	of	of	IN	False
DDI-MedLine.d192.s1	opiate-related	130	143	O	opiate-related	ted	ated	JJ	False
DDI-MedLine.d192.s1	associative	145	155	O	associative	ive	tive	JJ	False
DDI-MedLine.d192.s1	reward	157	162	O	reward	ard	ward	NN	False
DDI-MedLine.d192.s1	learning	164	171	O	learning	ing	ning	VBG	False
DDI-MedLine.d192.s1	and	173	175	O	and	and	and	CC	False
DDI-MedLine.d192.s1	memory	177	182	O	memory	ory	mory	NN	False
DDI-MedLine.d192.s1	.	183	183	O	.	.	.	.	False

DDI-MedLine.d192.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d192.s2	BLA	4	6	O	BLA	BLA	BLA	NN	brand
DDI-MedLine.d192.s2	receives	8	15	O	receives	ves	ives	NNS	False
DDI-MedLine.d192.s2	innervation	17	27	O	innervation	ion	tion	NN	False
DDI-MedLine.d192.s2	from	29	32	O	from	rom	from	IN	False
DDI-MedLine.d192.s2	dopaminergic	34	45	O	dopaminergic	gic	rgic	NN	False
DDI-MedLine.d192.s2	fibers	47	52	O	fibers	ers	bers	NNS	False
DDI-MedLine.d192.s2	originating	54	64	O	originating	ing	ting	VBG	False
DDI-MedLine.d192.s2	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d192.s2	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d192.s2	VTA	73	75	O	VTA	VTA	VTA	NN	brand
DDI-MedLine.d192.s2	,	76	76	O	,	,	,	,	False
DDI-MedLine.d192.s2	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d192.s2	both	82	85	O	both	oth	both	DT	False
DDI-MedLine.d192.s2	dopamine	87	94	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d192.s2	(	96	96	O	(	(	(	(	False
DDI-MedLine.d192.s2	DA	97	98	O	DA	DA	DA	NN	brand
DDI-MedLine.d192.s2	)	99	99	O	)	)	)	)	False
DDI-MedLine.d192.s2	D1	101	102	O	D1	D1	D1	NN	brand
DDI-MedLine.d192.s2	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d192.s2	D2	108	109	O	D2	D2	D2	NN	brand
DDI-MedLine.d192.s2	receptors	111	119	O	receptors	ors	tors	NNS	False
DDI-MedLine.d192.s2	are	121	123	O	are	are	are	VBP	False
DDI-MedLine.d192.s2	expressed	125	133	O	expressed	sed	ssed	VBN	False
DDI-MedLine.d192.s2	in	135	136	O	in	in	in	IN	False
DDI-MedLine.d192.s2	this	138	141	O	this	his	this	DT	False
DDI-MedLine.d192.s2	region	143	148	O	region	ion	gion	NN	False
DDI-MedLine.d192.s2	.	149	149	O	.	.	.	.	False

DDI-MedLine.d192.s3	Using	0	4	O	Using	ing	sing	VBG	False
DDI-MedLine.d192.s3	a	6	6	O	a	a	a	DT	False
DDI-MedLine.d192.s3	combination	8	18	O	combination	ion	tion	NN	False
DDI-MedLine.d192.s3	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d192.s3	in	23	24	O	in	in	in	IN	False
DDI-MedLine.d192.s3	vivo	26	29	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d192.s3	single-unit	31	41	O	single-unit	nit	unit	NN	False
DDI-MedLine.d192.s3	extracellular	43	55	O	extracellular	lar	ular	NN	False
DDI-MedLine.d192.s3	recording	57	65	O	recording	ing	ding	VBG	False
DDI-MedLine.d192.s3	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d192.s3	the	70	72	O	the	the	the	DT	False
DDI-MedLine.d192.s3	NAc	74	76	O	NAc	NAc	NAc	NN	False
DDI-MedLine.d192.s3	combined	78	85	O	combined	ned	ined	VBN	False
DDI-MedLine.d192.s3	with	87	90	O	with	ith	with	IN	False
DDI-MedLine.d192.s3	behavioral	92	101	O	behavioral	ral	oral	JJ	False
DDI-MedLine.d192.s3	pharmacology	103	114	O	pharmacology	ogy	logy	NN	False
DDI-MedLine.d192.s3	studies	116	122	O	studies	ies	dies	NNS	False
DDI-MedLine.d192.s3	,	123	123	O	,	,	,	,	False
DDI-MedLine.d192.s3	we	125	126	O	we	we	we	PRP	False
DDI-MedLine.d192.s3	have	128	131	O	have	ave	have	VB	False
DDI-MedLine.d192.s3	identified	133	142	O	identified	ied	fied	VBN	False
DDI-MedLine.d192.s3	a	144	144	O	a	a	a	DT	False
DDI-MedLine.d192.s3	double	146	151	O	double	ble	uble	RB	False
DDI-MedLine.d192.s3	dissociation	153	164	O	dissociation	ion	tion	NN	False
DDI-MedLine.d192.s3	in	166	167	O	in	in	in	IN	False
DDI-MedLine.d192.s3	the	169	171	O	the	the	the	DT	False
DDI-MedLine.d192.s3	functional	173	182	O	functional	nal	onal	JJ	False
DDI-MedLine.d192.s3	roles	184	188	O	roles	les	oles	NNS	group
DDI-MedLine.d192.s3	of	190	191	O	of	of	of	IN	False
DDI-MedLine.d192.s3	DA	193	194	O	DA	DA	DA	NN	brand
DDI-MedLine.d192.s3	D1	196	197	O	D1	D1	D1	NN	brand
DDI-MedLine.d192.s3	versus	199	204	O	versus	sus	rsus	NN	False
DDI-MedLine.d192.s3	D2	206	207	O	D2	D2	D2	NN	brand
DDI-MedLine.d192.s3	receptor	209	216	O	receptor	tor	ptor	NN	False
DDI-MedLine.d192.s3	transmission	218	229	O	transmission	ion	sion	NN	False
DDI-MedLine.d192.s3	in	231	232	O	in	in	in	IN	False
DDI-MedLine.d192.s3	the	234	236	O	the	the	the	DT	False
DDI-MedLine.d192.s3	BLA	238	240	O	BLA	BLA	BLA	NN	brand
DDI-MedLine.d192.s3	,	241	241	O	,	,	,	,	False
DDI-MedLine.d192.s3	which	243	247	O	which	ich	hich	WDT	False
DDI-MedLine.d192.s3	depends	249	255	O	depends	nds	ends	NNS	False
DDI-MedLine.d192.s3	on	257	258	O	on	on	on	IN	False
DDI-MedLine.d192.s3	opiate	260	265	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s3	exposure	267	274	O	exposure	ure	sure	NN	False
DDI-MedLine.d192.s3	state	276	280	O	state	ate	tate	NN	False
DDI-MedLine.d192.s3	;	281	281	O	;	;	;	:	False

DDI-MedLine.d192.s4	thus	0	3	O	thus	hus	thus	RB	False
DDI-MedLine.d192.s4	,	4	4	O	,	,	,	,	False
DDI-MedLine.d192.s4	in	6	7	O	in	in	in	IN	False
DDI-MedLine.d192.s4	previously	9	18	O	previously	sly	usly	RB	False
DDI-MedLine.d192.s4	opiate-naive	20	31	O	opiate-naive	ive	aive	JJ	False
DDI-MedLine.d192.s4	rats	33	36	O	rats	ats	rats	NNS	False
DDI-MedLine.d192.s4	,	37	37	O	,	,	,	,	False
DDI-MedLine.d192.s4	blockade	39	46	O	blockade	ade	kade	NN	False
DDI-MedLine.d192.s4	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d192.s4	intra-BLA	51	59	O	intra-BLA	BLA	-BLA	NN	False
DDI-MedLine.d192.s4	D1	61	62	O	D1	D1	D1	NN	brand
DDI-MedLine.d192.s4	,	63	63	O	,	,	,	,	False
DDI-MedLine.d192.s4	but	65	67	O	but	but	but	CC	False
DDI-MedLine.d192.s4	not	69	71	O	not	not	not	RB	False
DDI-MedLine.d192.s4	D2	73	74	O	D2	D2	D2	NN	brand
DDI-MedLine.d192.s4	,	75	75	O	,	,	,	,	False
DDI-MedLine.d192.s4	receptor	77	84	O	receptor	tor	ptor	NN	False
DDI-MedLine.d192.s4	transmission	86	97	O	transmission	ion	sion	NN	False
DDI-MedLine.d192.s4	blocked	99	105	O	blocked	ked	cked	VBN	False
DDI-MedLine.d192.s4	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d192.s4	acquisition	111	121	O	acquisition	ion	tion	NN	False
DDI-MedLine.d192.s4	of	123	124	O	of	of	of	IN	False
DDI-MedLine.d192.s4	associative	126	136	O	associative	ive	tive	JJ	False
DDI-MedLine.d192.s4	opiate	138	143	O	opiate	ate	iate	NN	False
DDI-MedLine.d192.s4	reward	145	150	O	reward	ard	ward	NN	False
DDI-MedLine.d192.s4	memory	152	157	O	memory	ory	mory	NN	False
DDI-MedLine.d192.s4	,	158	158	O	,	,	,	,	False
DDI-MedLine.d192.s4	measured	160	167	O	measured	red	ured	VBN	False
DDI-MedLine.d192.s4	in	169	170	O	in	in	in	IN	False
DDI-MedLine.d192.s4	an	172	173	O	an	an	an	DT	False
DDI-MedLine.d192.s4	unbiased	175	182	O	unbiased	sed	ased	JJ	False
DDI-MedLine.d192.s4	conditioned	184	194	O	conditioned	ned	oned	VBN	False
DDI-MedLine.d192.s4	place	196	200	O	place	ace	lace	NN	False
DDI-MedLine.d192.s4	preference	202	211	O	preference	nce	ence	NN	False
DDI-MedLine.d192.s4	procedure	213	221	O	procedure	ure	dure	NN	False
DDI-MedLine.d192.s4	.	222	222	O	.	.	.	.	False

DDI-MedLine.d192.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d192.s5	direct	3	8	O	direct	ect	rect	JJ	False
DDI-MedLine.d192.s5	contrast	10	17	O	contrast	ast	rast	NN	False
DDI-MedLine.d192.s5	,	18	18	O	,	,	,	,	False
DDI-MedLine.d192.s5	in	20	21	O	in	in	in	IN	False
DDI-MedLine.d192.s5	rats	23	26	O	rats	ats	rats	NNS	False
DDI-MedLine.d192.s5	made	28	31	O	made	ade	made	VBN	False
DDI-MedLine.d192.s5	opiate	33	38	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s5	dependent	40	48	O	dependent	ent	dent	NN	False
DDI-MedLine.d192.s5	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d192.s5	conditioned	54	64	O	conditioned	ned	oned	VBN	False
DDI-MedLine.d192.s5	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d192.s5	a	69	69	O	a	a	a	DT	False
DDI-MedLine.d192.s5	state	71	75	O	state	ate	tate	NN	False
DDI-MedLine.d192.s5	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d192.s5	withdrawal	80	89	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d192.s5	,	90	90	O	,	,	,	,	False
DDI-MedLine.d192.s5	intra-BLA	92	100	O	intra-BLA	BLA	-BLA	NN	False
DDI-MedLine.d192.s5	D2	102	103	O	D2	D2	D2	NN	brand
DDI-MedLine.d192.s5	,	104	104	O	,	,	,	,	False
DDI-MedLine.d192.s5	but	106	108	O	but	but	but	CC	False
DDI-MedLine.d192.s5	not	110	112	O	not	not	not	RB	False
DDI-MedLine.d192.s5	D1	114	115	O	D1	D1	D1	NN	brand
DDI-MedLine.d192.s5	,	116	116	O	,	,	,	,	False
DDI-MedLine.d192.s5	receptor	118	125	O	receptor	tor	ptor	NN	False
DDI-MedLine.d192.s5	blockade	127	134	O	blockade	ade	kade	NN	False
DDI-MedLine.d192.s5	blocked	136	142	O	blocked	ked	cked	VBN	False
DDI-MedLine.d192.s5	opiate	144	149	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s5	reward	151	156	O	reward	ard	ward	NN	False
DDI-MedLine.d192.s5	encoding	158	165	O	encoding	ing	ding	VBG	False
DDI-MedLine.d192.s5	.	166	166	O	.	.	.	.	False

DDI-MedLine.d192.s6	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d192.s6	functional	5	14	O	functional	nal	onal	JJ	False
DDI-MedLine.d192.s6	switch	16	21	O	switch	tch	itch	NN	False
DDI-MedLine.d192.s6	was	23	25	O	was	was	was	VBD	False
DDI-MedLine.d192.s6	dependent	27	35	O	dependent	ent	dent	NN	False
DDI-MedLine.d192.s6	on	37	38	O	on	on	on	IN	False
DDI-MedLine.d192.s6	cAMP	40	43	O	cAMP	AMP	cAMP	NN	False
DDI-MedLine.d192.s6	signaling	45	53	O	signaling	ing	ling	VBG	False
DDI-MedLine.d192.s6	as	55	56	O	as	as	as	IN	False
DDI-MedLine.d192.s6	comodulation	58	69	O	comodulation	ion	tion	NN	False
DDI-MedLine.d192.s6	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d192.s6	intra-BLA	74	82	O	intra-BLA	BLA	-BLA	NN	False
DDI-MedLine.d192.s6	cAMP	84	87	O	cAMP	AMP	cAMP	NN	False
DDI-MedLine.d192.s6	levels	89	94	O	levels	els	vels	NNS	False
DDI-MedLine.d192.s6	reversed	96	103	O	reversed	sed	rsed	VBN	False
DDI-MedLine.d192.s6	or	105	106	O	or	or	or	CC	False
DDI-MedLine.d192.s6	replicated	108	117	O	replicated	ted	ated	VBN	False
DDI-MedLine.d192.s6	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d192.s6	functional	123	132	O	functional	nal	onal	JJ	False
DDI-MedLine.d192.s6	effects	134	140	O	effects	cts	ects	NNS	False
DDI-MedLine.d192.s6	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d192.s6	intra-BLA	145	153	O	intra-BLA	BLA	-BLA	NN	False
DDI-MedLine.d192.s6	D1	155	156	O	D1	D1	D1	NN	brand
DDI-MedLine.d192.s6	or	158	159	O	or	or	or	CC	False
DDI-MedLine.d192.s6	D2	161	162	O	D2	D2	D2	NN	brand
DDI-MedLine.d192.s6	transmission	164	175	O	transmission	ion	sion	NN	False
DDI-MedLine.d192.s6	during	177	182	O	during	ing	ring	IN	False
DDI-MedLine.d192.s6	opiate	184	189	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s6	reward	191	196	O	reward	ard	ward	NN	False
DDI-MedLine.d192.s6	processing	198	207	O	processing	ing	sing	NN	False
DDI-MedLine.d192.s6	.	208	208	O	.	.	.	.	False

DDI-MedLine.d192.s7	Single-unit	0	10	O	Single-unit	nit	unit	NN	False
DDI-MedLine.d192.s7	in	12	13	O	in	in	in	IN	False
DDI-MedLine.d192.s7	vivo	15	18	O	vivo	ivo	vivo	NN	False
DDI-MedLine.d192.s7	extracellular	20	32	O	extracellular	lar	ular	NN	False
DDI-MedLine.d192.s7	recordings	34	43	O	recordings	ngs	ings	NNS	False
DDI-MedLine.d192.s7	performed	45	53	O	performed	med	rmed	VBN	False
DDI-MedLine.d192.s7	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d192.s7	neurons	58	64	O	neurons	ons	rons	NNS	False
DDI-MedLine.d192.s7	of	66	67	O	of	of	of	IN	False
DDI-MedLine.d192.s7	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d192.s7	NAc	73	75	O	NAc	NAc	NAc	NN	False
DDI-MedLine.d192.s7	confirmed	77	85	O	confirmed	med	rmed	VBN	False
DDI-MedLine.d192.s7	an	87	88	O	an	an	an	DT	False
DDI-MedLine.d192.s7	opiate-state-dependent	90	111	O	opiate-state-dependent	ent	dent	NN	False
DDI-MedLine.d192.s7	role	113	116	O	role	ole	role	NN	False
DDI-MedLine.d192.s7	for	118	120	O	for	for	for	IN	False
DDI-MedLine.d192.s7	BLA	122	124	O	BLA	BLA	BLA	NN	brand
DDI-MedLine.d192.s7	D1/D2	126	130	O	D1/D2	/D2	1/D2	NN	brand
DDI-MedLine.d192.s7	transmission	132	143	O	transmission	ion	sion	NN	False
DDI-MedLine.d192.s7	in	145	146	O	in	in	in	IN	False
DDI-MedLine.d192.s7	NAc	148	150	O	NAc	NAc	NAc	NN	False
DDI-MedLine.d192.s7	neuronal	152	159	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d192.s7	response	161	168	O	response	nse	onse	NN	False
DDI-MedLine.d192.s7	patterns	170	177	O	patterns	rns	erns	NNS	False
DDI-MedLine.d192.s7	to	179	180	O	to	to	to	TO	False
DDI-MedLine.d192.s7	morphine	182	189	B-drug	morphine	ine	hine	NN	drug
DDI-MedLine.d192.s7	.	190	190	O	.	.	.	.	False

DDI-MedLine.d192.s8	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d192.s8	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d192.s8	characterize	12	23	O	characterize	ize	rize	NN	False
DDI-MedLine.d192.s8	and	25	27	O	and	and	and	CC	False
DDI-MedLine.d192.s8	identify	29	36	O	identify	ify	tify	VB	False
DDI-MedLine.d192.s8	a	38	38	O	a	a	a	DT	False
DDI-MedLine.d192.s8	novel	40	44	O	novel	vel	ovel	NN	False
DDI-MedLine.d192.s8	opiate	46	51	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s8	addiction	53	61	O	addiction	ion	tion	NN	False
DDI-MedLine.d192.s8	switching	63	71	O	switching	ing	hing	VBG	False
DDI-MedLine.d192.s8	mechanism	73	81	O	mechanism	ism	nism	NN	False
DDI-MedLine.d192.s8	directly	83	90	O	directly	tly	ctly	RB	False
DDI-MedLine.d192.s8	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d192.s8	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d192.s8	BLA	99	101	O	BLA	BLA	BLA	NN	brand
DDI-MedLine.d192.s8	that	103	106	O	that	hat	that	IN	False
DDI-MedLine.d192.s8	can	108	110	O	can	can	can	MD	False
DDI-MedLine.d192.s8	control	112	118	O	control	rol	trol	NN	False
DDI-MedLine.d192.s8	the	120	122	O	the	the	the	DT	False
DDI-MedLine.d192.s8	processing	124	133	O	processing	ing	sing	NN	False
DDI-MedLine.d192.s8	of	135	136	O	of	of	of	IN	False
DDI-MedLine.d192.s8	opiate	138	143	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s8	reward	145	150	O	reward	ard	ward	NN	False
DDI-MedLine.d192.s8	information	152	162	O	information	ion	tion	NN	False
DDI-MedLine.d192.s8	as	164	165	O	as	as	as	IN	False
DDI-MedLine.d192.s8	a	167	167	O	a	a	a	DT	False
DDI-MedLine.d192.s8	direct	169	174	O	direct	ect	rect	JJ	False
DDI-MedLine.d192.s8	function	176	183	O	function	ion	tion	NN	False
DDI-MedLine.d192.s8	of	185	186	O	of	of	of	IN	False
DDI-MedLine.d192.s8	opiate	188	193	B-group	opiate	ate	iate	NN	False
DDI-MedLine.d192.s8	exposure	195	202	O	exposure	ure	sure	NN	False
DDI-MedLine.d192.s8	state	204	208	O	state	ate	tate	NN	False
DDI-MedLine.d192.s8	via	210	212	O	via	via	via	IN	False
DDI-MedLine.d192.s8	D1	214	215	O	D1	D1	D1	NN	brand
DDI-MedLine.d192.s8	or	217	218	O	or	or	or	CC	False
DDI-MedLine.d192.s8	D2	220	221	O	D2	D2	D2	NN	brand
DDI-MedLine.d192.s8	receptor	223	230	O	receptor	tor	ptor	NN	False
DDI-MedLine.d192.s8	signaling	232	240	O	signaling	ing	ling	VBG	False
DDI-MedLine.d192.s8	substrates	242	251	O	substrates	tes	ates	NNS	False
DDI-MedLine.d192.s8	.	252	252	O	.	.	.	.	False

DDI-MedLine.d187.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d187.s0	Variability	1	11	O	Variability	ity	lity	NN	False
DDI-MedLine.d187.s0	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d187.s0	cannabinoid	16	26	B-drug_n	cannabinoid	oid	noid	NN	False
DDI-MedLine.d187.s0	findings	28	35	O	findings	ngs	ings	NNS	False
DDI-MedLine.d187.s0	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d187.s0	blood	40	44	O	blood	ood	lood	NN	False
DDI-MedLine.d187.s0	]	45	45	O	]	]	]	NN	False
DDI-MedLine.d187.s0	.	46	46	O	.	.	.	.	False

DDI-MedLine.d187.s1	Cannabis	0	7	O	Cannabis	bis	abis	NN	False
DDI-MedLine.d187.s1	products	9	16	O	products	cts	ucts	NNS	False
DDI-MedLine.d187.s1	have	18	21	O	have	ave	have	VB	False
DDI-MedLine.d187.s1	been	23	26	O	been	een	been	VBN	False
DDI-MedLine.d187.s1	administered	28	39	O	administered	red	ered	VBN	False
DDI-MedLine.d187.s1	for	41	43	O	for	for	for	IN	False
DDI-MedLine.d187.s1	many	45	48	O	many	any	many	JJ	False
DDI-MedLine.d187.s1	centuries	50	58	O	centuries	ies	ries	NNS	False
DDI-MedLine.d187.s1	;	59	59	O	;	;	;	:	False

DDI-MedLine.d187.s2	today	0	4	O	today	day	oday	NN	False
DDI-MedLine.d187.s2	,	5	5	O	,	,	,	,	False
DDI-MedLine.d187.s2	cannabis	7	14	O	cannabis	bis	abis	NN	False
DDI-MedLine.d187.s2	is	16	17	O	is	is	is	VBZ	False
DDI-MedLine.d187.s2	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d187.s2	most	23	26	O	most	ost	most	JJS	False
DDI-MedLine.d187.s2	widely	28	33	O	widely	ely	dely	RB	False
DDI-MedLine.d187.s2	used	35	38	O	used	sed	used	VBN	False
DDI-MedLine.d187.s2	illegal	40	46	O	illegal	gal	egal	JJ	False
DDI-MedLine.d187.s2	drug	48	51	O	drug	rug	drug	NN	False
DDI-MedLine.d187.s2	all	53	55	O	all	all	all	DT	False
DDI-MedLine.d187.s2	over	57	60	O	over	ver	over	IN	False
DDI-MedLine.d187.s2	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d187.s2	world	66	70	O	world	rld	orld	NN	False
DDI-MedLine.d187.s2	.	71	71	O	.	.	.	.	False

DDI-MedLine.d187.s3	Nevertheless	0	11	O	Nevertheless	ess	less	RB	False
DDI-MedLine.d187.s3	,	12	12	O	,	,	,	,	False
DDI-MedLine.d187.s3	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d187.s3	interpretation	18	31	O	interpretation	ion	tion	NN	False
DDI-MedLine.d187.s3	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d187.s3	cannabis	36	43	O	cannabis	bis	abis	NN	False
DDI-MedLine.d187.s3	findings	45	52	O	findings	ngs	ings	NNS	False
DDI-MedLine.d187.s3	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d187.s3	blood	57	61	O	blood	ood	lood	NN	False
DDI-MedLine.d187.s3	with	63	66	O	with	ith	with	IN	False
DDI-MedLine.d187.s3	regard	68	73	O	regard	ard	gard	NN	False
DDI-MedLine.d187.s3	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d187.s3	consumption	78	88	O	consumption	ion	tion	NN	False
DDI-MedLine.d187.s3	behaviour	90	98	O	behaviour	our	iour	NN	False
DDI-MedLine.d187.s3	and/or	100	105	O	and/or	/or	d/or	NN	False
DDI-MedLine.d187.s3	estimating	107	116	O	estimating	ing	ting	VBG	False
DDI-MedLine.d187.s3	the	118	120	O	the	the	the	DT	False
DDI-MedLine.d187.s3	elapsed	122	128	O	elapsed	sed	psed	VBN	False
DDI-MedLine.d187.s3	time	130	133	O	time	ime	time	NN	False
DDI-MedLine.d187.s3	since	135	139	O	since	nce	ince	IN	False
DDI-MedLine.d187.s3	the	141	143	O	the	the	the	DT	False
DDI-MedLine.d187.s3	last	145	148	O	last	ast	last	JJ	False
DDI-MedLine.d187.s3	cannabis	150	157	O	cannabis	bis	abis	NN	False
DDI-MedLine.d187.s3	use	159	161	O	use	use	use	NN	False
DDI-MedLine.d187.s3	is	163	164	O	is	is	is	VBZ	False
DDI-MedLine.d187.s3	still	166	170	O	still	ill	till	RB	False
DDI-MedLine.d187.s3	a	172	172	O	a	a	a	DT	False
DDI-MedLine.d187.s3	very	174	177	O	very	ery	very	RB	False
DDI-MedLine.d187.s3	challenging	179	189	O	challenging	ing	ging	VBG	False
DDI-MedLine.d187.s3	task	191	194	O	task	ask	task	NN	False
DDI-MedLine.d187.s3	.	195	195	O	.	.	.	.	False

DDI-MedLine.d187.s4	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d187.s4	wide	2	5	O	wide	ide	wide	JJ	False
DDI-MedLine.d187.s4	variation	7	15	O	variation	ion	tion	NN	False
DDI-MedLine.d187.s4	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d187.s4	pharmacokinetic	20	34	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d187.s4	parameters	36	45	O	parameters	ers	ters	NNS	False
DDI-MedLine.d187.s4	has	47	49	O	has	has	has	VBZ	False
DDI-MedLine.d187.s4	been	51	54	O	been	een	been	VBN	False
DDI-MedLine.d187.s4	observed	56	63	O	observed	ved	rved	VBN	False
DDI-MedLine.d187.s4	even	65	68	O	even	ven	even	RB	False
DDI-MedLine.d187.s4	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d187.s4	experimental	73	84	O	experimental	tal	ntal	NN	False
DDI-MedLine.d187.s4	studies	86	92	O	studies	ies	dies	NNS	False
DDI-MedLine.d187.s4	.	93	93	O	.	.	.	.	False

DDI-MedLine.d187.s5	Different	0	8	O	Different	ent	rent	NN	False
DDI-MedLine.d187.s5	chemical	10	17	O	chemical	cal	ical	NN	False
DDI-MedLine.d187.s5	structures	19	28	O	structures	res	ures	NNS	False
DDI-MedLine.d187.s5	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d187.s5	precursors	33	42	O	precursors	ors	sors	NNS	False
DDI-MedLine.d187.s5	,	43	43	O	,	,	,	,	False
DDI-MedLine.d187.s5	smoking	45	51	O	smoking	ing	king	NN	False
DDI-MedLine.d187.s5	dynamics	53	60	O	dynamics	ics	mics	NNS	False
DDI-MedLine.d187.s5	,	61	61	O	,	,	,	,	False
DDI-MedLine.d187.s5	pyrolysis	63	71	O	pyrolysis	sis	ysis	NN	False
DDI-MedLine.d187.s5	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d187.s5	phytocannabinoids	76	92	B-drug_n	phytocannabinoids	ids	oids	NNS	False
DDI-MedLine.d187.s5	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d187.s5	frequency	98	106	O	frequency	ncy	ency	NN	False
DDI-MedLine.d187.s5	of	108	109	O	of	of	of	IN	False
DDI-MedLine.d187.s5	drug	111	114	O	drug	rug	drug	NN	False
DDI-MedLine.d187.s5	use	116	118	O	use	use	use	NN	False
DDI-MedLine.d187.s5	affect	120	125	O	affect	ect	fect	NN	False
DDI-MedLine.d187.s5	the	127	129	O	the	the	the	DT	False
DDI-MedLine.d187.s5	amount	131	136	O	amount	unt	ount	NN	False
DDI-MedLine.d187.s5	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d187.s5	THC	141	143	B-drug_n	THC	THC	THC	NN	brand
DDI-MedLine.d187.s5	absorbed	145	152	O	absorbed	bed	rbed	NNS	False
DDI-MedLine.d187.s5	.	153	153	O	.	.	.	.	False

DDI-MedLine.d187.s6	Polymorphic	0	10	O	Polymorphic	hic	phic	JJ	False
DDI-MedLine.d187.s6	enzymes	12	18	O	enzymes	mes	ymes	NNS	False
DDI-MedLine.d187.s6	are	20	22	O	are	are	are	VBP	False
DDI-MedLine.d187.s6	involved	24	31	O	involved	ved	lved	VBN	False
DDI-MedLine.d187.s6	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d187.s6	phase-I-metabolism	36	53	O	phase-I-metabolism	ism	lism	NN	False
DDI-MedLine.d187.s6	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d187.s6	THC	58	60	B-drug_n	THC	THC	THC	NN	brand
DDI-MedLine.d187.s6	.	61	61	O	.	.	.	.	False

DDI-MedLine.d187.s7	Pharmacological	0	14	O	Pharmacological	cal	ical	JJ	False
DDI-MedLine.d187.s7	effects	16	22	O	effects	cts	ects	NNS	False
DDI-MedLine.d187.s7	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d187.s7	other	27	31	O	other	her	ther	JJ	False
DDI-MedLine.d187.s7	cannabinoids	33	44	B-drug_n	cannabinoids	ids	oids	NNS	False
DDI-MedLine.d187.s7	or	46	47	O	or	or	or	CC	False
DDI-MedLine.d187.s7	medication	49	58	O	medication	ion	tion	NN	False
DDI-MedLine.d187.s7	on	60	61	O	on	on	on	IN	False
DDI-MedLine.d187.s7	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d187.s7	pharmacokinetics	67	82	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d187.s7	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d187.s7	THC	87	89	B-drug_n	THC	THC	THC	NN	brand
DDI-MedLine.d187.s7	have	91	94	O	have	ave	have	VB	False
DDI-MedLine.d187.s7	not	96	98	O	not	not	not	RB	False
DDI-MedLine.d187.s7	yet	100	102	O	yet	yet	yet	RB	False
DDI-MedLine.d187.s7	been	104	107	O	been	een	been	VBN	False
DDI-MedLine.d187.s7	studied	109	115	O	studied	ied	died	VBN	False
DDI-MedLine.d187.s7	in	117	118	O	in	in	in	IN	False
DDI-MedLine.d187.s7	detail	120	125	O	detail	ail	tail	NN	False
DDI-MedLine.d187.s7	.	126	126	O	.	.	.	.	False

DDI-MedLine.d187.s8	Hydrolysis	0	9	O	Hydrolysis	sis	ysis	NN	False
DDI-MedLine.d187.s8	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d187.s8	cannabis	14	21	O	cannabis	bis	abis	NN	False
DDI-MedLine.d187.s8	conjugates	23	32	O	conjugates	tes	ates	NNS	False
DDI-MedLine.d187.s8	may	34	36	O	may	may	may	MD	False
DDI-MedLine.d187.s8	occur	38	42	O	occur	cur	ccur	NN	False
DDI-MedLine.d187.s8	during	44	49	O	during	ing	ring	IN	False
DDI-MedLine.d187.s8	storage	51	57	O	storage	age	rage	NN	False
DDI-MedLine.d187.s8	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d187.s8	blood	62	66	O	blood	ood	lood	NN	False
DDI-MedLine.d187.s8	samples	68	74	O	samples	les	ples	NNS	False
DDI-MedLine.d187.s8	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d187.s8	processing	80	89	O	processing	ing	sing	NN	False
DDI-MedLine.d187.s8	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d187.s8	specimens	94	102	O	specimens	ens	mens	NNS	False
DDI-MedLine.d187.s8	for	104	106	O	for	for	for	IN	False
DDI-MedLine.d187.s8	analysis	108	115	O	analysis	sis	ysis	NN	False
DDI-MedLine.d187.s8	;	116	116	O	;	;	;	:	False

DDI-MedLine.d187.s9	knowledge	0	8	O	knowledge	dge	edge	NN	False
DDI-MedLine.d187.s9	on	10	11	O	on	on	on	IN	False
DDI-MedLine.d187.s9	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d187.s9	stability	17	25	O	stability	ity	lity	NN	False
DDI-MedLine.d187.s9	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d187.s9	cannabinoids	30	41	B-drug_n	cannabinoids	ids	oids	NNS	False
DDI-MedLine.d187.s9	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d187.s9	forensic	46	53	O	forensic	sic	nsic	JJ	False
DDI-MedLine.d187.s9	specimens	55	63	O	specimens	ens	mens	NNS	False
DDI-MedLine.d187.s9	is	65	66	O	is	is	is	VBZ	False
DDI-MedLine.d187.s9	still	68	72	O	still	ill	till	RB	False
DDI-MedLine.d187.s9	poor	74	77	O	poor	oor	poor	JJ	False
DDI-MedLine.d187.s9	.	78	78	O	.	.	.	.	False

DDI-MedLine.d187.s10	Whether	0	6	O	Whether	her	ther	IN	False
DDI-MedLine.d187.s10	determination	8	20	O	determination	ion	tion	NN	False
DDI-MedLine.d187.s10	of	22	23	O	of	of	of	IN	False
DDI-MedLine.d187.s10	cannabinoid	25	35	B-drug_n	cannabinoid	oid	noid	NN	False
DDI-MedLine.d187.s10	conjugates	37	46	O	conjugates	tes	ates	NNS	False
DDI-MedLine.d187.s10	may	48	50	O	may	may	may	MD	False
DDI-MedLine.d187.s10	be	52	53	O	be	be	be	VB	False
DDI-MedLine.d187.s10	useful	55	60	O	useful	ful	eful	JJ	False
DDI-MedLine.d187.s10	is	62	63	O	is	is	is	VBZ	False
DDI-MedLine.d187.s10	a	65	65	O	a	a	a	DT	False
DDI-MedLine.d187.s10	matter	67	72	O	matter	ter	tter	NN	False
DDI-MedLine.d187.s10	of	74	75	O	of	of	of	IN	False
DDI-MedLine.d187.s10	further	77	83	O	further	her	ther	RB	False
DDI-MedLine.d187.s10	consideration	85	97	O	consideration	ion	tion	NN	False
DDI-MedLine.d187.s10	.	98	98	O	.	.	.	.	False

DDI-MedLine.d187.s11	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d187.s11	present	3	9	O	present	ent	sent	NN	False
DDI-MedLine.d187.s11	,	10	10	O	,	,	,	,	False
DDI-MedLine.d187.s11	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d187.s11	broad	16	20	O	broad	oad	road	JJ	False
DDI-MedLine.d187.s11	variation	22	30	O	variation	ion	tion	NN	False
DDI-MedLine.d187.s11	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d187.s11	pharmacokinetic	35	49	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d187.s11	parameters	51	60	O	parameters	ers	ters	NNS	False
DDI-MedLine.d187.s11	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d187.s11	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d187.s11	limiting	70	77	O	limiting	ing	ting	VBG	False
DDI-MedLine.d187.s11	factors	79	85	O	factors	ors	tors	NNS	False
DDI-MedLine.d187.s11	discussed	87	95	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d187.s11	in	97	98	O	in	in	in	IN	False
DDI-MedLine.d187.s11	the	100	102	O	the	the	the	DT	False
DDI-MedLine.d187.s11	present	104	110	O	present	ent	sent	NN	False
DDI-MedLine.d187.s11	paper	112	116	O	paper	per	aper	NN	False
DDI-MedLine.d187.s11	should	118	123	O	should	uld	ould	MD	False
DDI-MedLine.d187.s11	be	125	126	O	be	be	be	VB	False
DDI-MedLine.d187.s11	taken	128	132	O	taken	ken	aken	VBN	False
DDI-MedLine.d187.s11	into	134	137	O	into	nto	into	IN	False
DDI-MedLine.d187.s11	account	139	145	O	account	unt	ount	NN	False
DDI-MedLine.d187.s11	when	147	150	O	when	hen	when	WRB	False
DDI-MedLine.d187.s11	using	152	156	O	using	ing	sing	VBG	False
DDI-MedLine.d187.s11	data	158	161	O	data	ata	data	NNS	False
DDI-MedLine.d187.s11	from	163	166	O	from	rom	from	IN	False
DDI-MedLine.d187.s11	experimental	168	179	O	experimental	tal	ntal	NN	False
DDI-MedLine.d187.s11	studies	181	187	O	studies	ies	dies	NNS	False
DDI-MedLine.d187.s11	for	189	191	O	for	for	for	IN	False
DDI-MedLine.d187.s11	interpretation	193	206	O	interpretation	ion	tion	NN	False
DDI-MedLine.d187.s11	of	208	209	O	of	of	of	IN	False
DDI-MedLine.d187.s11	analytical	211	220	O	analytical	cal	ical	JJ	False
DDI-MedLine.d187.s11	results	222	228	O	results	lts	ults	NNS	False
DDI-MedLine.d187.s11	in	230	231	O	in	in	in	IN	False
DDI-MedLine.d187.s11	forensic	233	240	O	forensic	sic	nsic	JJ	False
DDI-MedLine.d187.s11	case	242	245	O	case	ase	case	NN	False
DDI-MedLine.d187.s11	work	247	250	O	work	ork	work	NN	False
DDI-MedLine.d187.s11	.	251	251	O	.	.	.	.	False

DDI-MedLine.d176.s0	Nitric	0	5	B-drug	Nitric	ric	tric	JJ	False
DDI-MedLine.d176.s0	oxide	7	11	I-drug	oxide	ide	xide	NN	False
DDI-MedLine.d176.s0	is	13	14	O	is	is	is	VBZ	False
DDI-MedLine.d176.s0	an	16	17	O	an	an	an	DT	False
DDI-MedLine.d176.s0	activity-dependent	19	36	O	activity-dependent	ent	dent	NN	False
DDI-MedLine.d176.s0	regulator	38	46	O	regulator	tor	ator	NN	False
DDI-MedLine.d176.s0	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d176.s0	target	51	56	O	target	get	rget	NN	False
DDI-MedLine.d176.s0	neuron	58	63	O	neuron	ron	uron	NN	False
DDI-MedLine.d176.s0	intrinsic	65	73	O	intrinsic	sic	nsic	JJ	False
DDI-MedLine.d176.s0	excitability	75	86	O	excitability	ity	lity	NN	False
DDI-MedLine.d176.s0	.	87	87	O	.	.	.	.	False

DDI-MedLine.d176.s1	Activity-dependent	0	17	O	Activity-dependent	ent	dent	JJ	False
DDI-MedLine.d176.s1	changes	19	25	O	changes	ges	nges	NNS	False
DDI-MedLine.d176.s1	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d176.s1	synaptic	30	37	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d176.s1	strength	39	46	O	strength	gth	ngth	NN	False
DDI-MedLine.d176.s1	are	48	50	O	are	are	are	VBP	False
DDI-MedLine.d176.s1	well	52	55	O	well	ell	well	RB	False
DDI-MedLine.d176.s1	established	57	67	O	established	hed	shed	VBN	False
DDI-MedLine.d176.s1	as	69	70	O	as	as	as	IN	False
DDI-MedLine.d176.s1	mediating	72	80	O	mediating	ing	ting	VBG	False
DDI-MedLine.d176.s1	long-term	82	90	O	long-term	erm	term	JJ	False
DDI-MedLine.d176.s1	plasticity	92	101	O	plasticity	ity	city	NN	False
DDI-MedLine.d176.s1	underlying	103	112	O	underlying	ing	ying	VBG	False
DDI-MedLine.d176.s1	learning	114	121	O	learning	ing	ning	VBG	False
DDI-MedLine.d176.s1	and	123	125	O	and	and	and	CC	False
DDI-MedLine.d176.s1	memory	127	132	O	memory	ory	mory	NN	False
DDI-MedLine.d176.s1	,	133	133	O	,	,	,	,	False
DDI-MedLine.d176.s1	but	135	137	O	but	but	but	CC	False
DDI-MedLine.d176.s1	modulation	139	148	O	modulation	ion	tion	NN	False
DDI-MedLine.d176.s1	of	150	151	O	of	of	of	IN	False
DDI-MedLine.d176.s1	target	154	159	O	target	get	rget	NN	False
DDI-MedLine.d176.s1	neuron	161	166	O	neuron	ron	uron	NN	False
DDI-MedLine.d176.s1	excitability	168	179	O	excitability	ity	lity	NN	False
DDI-MedLine.d176.s1	could	181	185	O	could	uld	ould	MD	False
DDI-MedLine.d176.s1	complement	187	196	O	complement	ent	ment	NN	False
DDI-MedLine.d176.s1	changes	198	204	O	changes	ges	nges	NNS	False
DDI-MedLine.d176.s1	in	206	207	O	in	in	in	IN	False
DDI-MedLine.d176.s1	synaptic	209	216	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d176.s1	strength	218	225	O	strength	gth	ngth	NN	False
DDI-MedLine.d176.s1	and	227	229	O	and	and	and	CC	False
DDI-MedLine.d176.s1	regulate	231	238	O	regulate	ate	late	NN	False
DDI-MedLine.d176.s1	network	240	246	O	network	ork	work	NN	False
DDI-MedLine.d176.s1	activity	248	255	O	activity	ity	vity	NN	False
DDI-MedLine.d176.s1	.	256	256	O	.	.	.	.	False

DDI-MedLine.d176.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d176.s2	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d176.s2	thought	6	12	O	thought	ght	ught	NN	False
DDI-MedLine.d176.s2	that	14	17	O	that	hat	that	IN	False
DDI-MedLine.d176.s2	homeostatic	19	29	O	homeostatic	tic	atic	JJ	False
DDI-MedLine.d176.s2	mechanisms	31	40	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d176.s2	match	42	46	O	match	tch	atch	NN	False
DDI-MedLine.d176.s2	intrinsic	48	56	O	intrinsic	sic	nsic	JJ	False
DDI-MedLine.d176.s2	excitability	58	69	O	excitability	ity	lity	NN	False
DDI-MedLine.d176.s2	to	71	72	O	to	to	to	TO	False
DDI-MedLine.d176.s2	the	74	76	O	the	the	the	DT	False
DDI-MedLine.d176.s2	incoming	78	85	O	incoming	ing	ming	VBG	False
DDI-MedLine.d176.s2	synaptic	87	94	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d176.s2	drive	96	100	O	drive	ive	rive	NN	False
DDI-MedLine.d176.s2	,	101	101	O	,	,	,	,	False
DDI-MedLine.d176.s2	but	103	105	O	but	but	but	CC	False
DDI-MedLine.d176.s2	evidence	107	114	O	evidence	nce	ence	NN	False
DDI-MedLine.d176.s2	for	116	118	O	for	for	for	IN	False
DDI-MedLine.d176.s2	involvement	120	130	O	involvement	ent	ment	NN	False
DDI-MedLine.d176.s2	of	132	133	O	of	of	of	IN	False
DDI-MedLine.d176.s2	voltage-gated	135	147	O	voltage-gated	ted	ated	JJ	False
DDI-MedLine.d176.s2	conductances	149	160	O	conductances	ces	nces	NNS	False
DDI-MedLine.d176.s2	is	162	163	O	is	is	is	VBZ	False
DDI-MedLine.d176.s2	sparse	165	170	O	sparse	rse	arse	NN	False
DDI-MedLine.d176.s2	.	171	171	O	.	.	.	.	False

DDI-MedLine.d176.s3	Here	0	3	O	Here	ere	Here	RB	False
DDI-MedLine.d176.s3	,	4	4	O	,	,	,	,	False
DDI-MedLine.d176.s3	we	6	7	O	we	we	we	PRP	False
DDI-MedLine.d176.s3	show	9	12	O	show	how	show	NN	False
DDI-MedLine.d176.s3	that	14	17	O	that	hat	that	IN	False
DDI-MedLine.d176.s3	glutamatergic	19	31	O	glutamatergic	gic	rgic	NN	False
DDI-MedLine.d176.s3	synaptic	33	40	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d176.s3	activity	42	49	O	activity	ity	vity	NN	False
DDI-MedLine.d176.s3	modulates	51	59	O	modulates	tes	ates	NNS	False
DDI-MedLine.d176.s3	target	61	66	O	target	get	rget	NN	False
DDI-MedLine.d176.s3	neuron	68	73	O	neuron	ron	uron	NN	False
DDI-MedLine.d176.s3	excitability	75	86	O	excitability	ity	lity	NN	False
DDI-MedLine.d176.s3	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d176.s3	switches	92	99	O	switches	hes	ches	NNS	False
DDI-MedLine.d176.s3	the	101	103	O	the	the	the	DT	False
DDI-MedLine.d176.s3	basis	105	109	O	basis	sis	asis	NN	False
DDI-MedLine.d176.s3	of	111	112	O	of	of	of	IN	False
DDI-MedLine.d176.s3	action	114	119	O	action	ion	tion	NN	False
DDI-MedLine.d176.s3	potential	121	129	O	potential	ial	tial	JJ	False
DDI-MedLine.d176.s3	repolarization	131	144	O	repolarization	ion	tion	NN	False
DDI-MedLine.d176.s3	from	146	149	O	from	rom	from	IN	False
DDI-MedLine.d176.s3	Kv3	151	153	O	Kv3	Kv3	Kv3	NNP	False
DDI-MedLine.d176.s3	to	155	156	O	to	to	to	TO	False
DDI-MedLine.d176.s3	Kv2	158	160	O	Kv2	Kv2	Kv2	NNP	False
DDI-MedLine.d176.s3	potassium	162	170	O	potassium	ium	sium	NN	drug
DDI-MedLine.d176.s3	channel	172	178	O	channel	nel	nnel	NNS	False
DDI-MedLine.d176.s3	dominance	180	188	O	dominance	nce	ance	NN	False
DDI-MedLine.d176.s3	,	189	189	O	,	,	,	,	False
DDI-MedLine.d176.s3	thereby	191	197	O	thereby	eby	reby	RB	False
DDI-MedLine.d176.s3	adjusting	199	207	O	adjusting	ing	ting	VBG	False
DDI-MedLine.d176.s3	neuronal	209	216	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d176.s3	signaling	218	226	O	signaling	ing	ling	VBG	False
DDI-MedLine.d176.s3	between	228	234	O	between	een	ween	IN	False
DDI-MedLine.d176.s3	low	236	238	O	low	low	low	JJ	False
DDI-MedLine.d176.s3	and	240	242	O	and	and	and	CC	False
DDI-MedLine.d176.s3	high	244	247	O	high	igh	high	JJ	False
DDI-MedLine.d176.s3	activity	249	256	O	activity	ity	vity	NN	False
DDI-MedLine.d176.s3	states	258	263	O	states	tes	ates	NNS	False
DDI-MedLine.d176.s3	,	264	264	O	,	,	,	,	False
DDI-MedLine.d176.s3	respectively	266	277	O	respectively	ely	vely	RB	False
DDI-MedLine.d176.s3	.	278	278	O	.	.	.	.	False

DDI-MedLine.d176.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d176.s4	nitric	5	10	O	nitric	ric	tric	JJ	False
DDI-MedLine.d176.s4	oxide-mediated	12	25	O	oxide-mediated	ted	ated	JJ	False
DDI-MedLine.d176.s4	signaling	27	35	O	signaling	ing	ling	VBG	False
DDI-MedLine.d176.s4	dramatically	37	48	O	dramatically	lly	ally	RB	False
DDI-MedLine.d176.s4	increases	50	58	O	increases	ses	ases	NNS	False
DDI-MedLine.d176.s4	Kv2	60	62	O	Kv2	Kv2	Kv2	NNP	False
DDI-MedLine.d176.s4	currents	64	71	O	currents	nts	ents	NNS	False
DDI-MedLine.d176.s4	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d176.s4	both	76	79	O	both	oth	both	DT	False
DDI-MedLine.d176.s4	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d176.s4	auditory	85	92	O	auditory	ory	tory	NN	False
DDI-MedLine.d176.s4	brain	94	98	O	brain	ain	rain	NN	False
DDI-MedLine.d176.s4	stem	100	103	O	stem	tem	stem	NN	False
DDI-MedLine.d176.s4	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d176.s4	hippocampus	109	119	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d176.s4	(	121	121	O	(	(	(	(	False
DDI-MedLine.d176.s4	&	122	122	O	&	&	&	CC	False
DDI-MedLine.d176.s4	gt	123	124	O	gt	gt	gt	NN	False
DDI-MedLine.d176.s4	;	125	125	O	;	;	;	:	False
DDI-MedLine.d176.s4	3-fold	126	131	O	3-fold	old	fold	JJ	False
DDI-MedLine.d176.s4	)	132	132	O	)	)	)	)	False
DDI-MedLine.d176.s4	transforming	134	145	O	transforming	ing	ming	VBG	False
DDI-MedLine.d176.s4	synaptic	147	154	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d176.s4	integration	156	166	O	integration	ion	tion	NN	False
DDI-MedLine.d176.s4	and	168	170	O	and	and	and	CC	False
DDI-MedLine.d176.s4	information	172	182	O	information	ion	tion	NN	False
DDI-MedLine.d176.s4	transmission	184	195	O	transmission	ion	sion	NN	False
DDI-MedLine.d176.s4	but	197	199	O	but	but	but	CC	False
DDI-MedLine.d176.s4	with	201	204	O	with	ith	with	IN	False
DDI-MedLine.d176.s4	only	206	209	O	only	nly	only	RB	False
DDI-MedLine.d176.s4	modest	211	216	O	modest	est	dest	JJ	False
DDI-MedLine.d176.s4	changes	218	224	O	changes	ges	nges	NNS	False
DDI-MedLine.d176.s4	in	226	227	O	in	in	in	IN	False
DDI-MedLine.d176.s4	action	229	234	O	action	ion	tion	NN	False
DDI-MedLine.d176.s4	potential	236	244	O	potential	ial	tial	JJ	False
DDI-MedLine.d176.s4	waveform	246	253	O	waveform	orm	form	NN	False
DDI-MedLine.d176.s4	.	254	254	O	.	.	.	.	False

DDI-MedLine.d176.s5	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d176.s5	conclude	3	10	O	conclude	ude	lude	NN	False
DDI-MedLine.d176.s5	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d176.s5	nitric	17	22	O	nitric	ric	tric	JJ	False
DDI-MedLine.d176.s5	oxide	24	28	O	oxide	ide	xide	NN	False
DDI-MedLine.d176.s5	is	30	31	O	is	is	is	VBZ	False
DDI-MedLine.d176.s5	a	33	33	O	a	a	a	DT	False
DDI-MedLine.d176.s5	homeostatic	35	45	O	homeostatic	tic	atic	JJ	False
DDI-MedLine.d176.s5	regulator	47	55	O	regulator	tor	ator	NN	False
DDI-MedLine.d176.s5	,	56	56	O	,	,	,	,	False
DDI-MedLine.d176.s5	tuning	58	63	O	tuning	ing	ning	VBG	False
DDI-MedLine.d176.s5	neuronal	65	72	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d176.s5	excitability	74	85	O	excitability	ity	lity	NN	False
DDI-MedLine.d176.s5	to	87	88	O	to	to	to	TO	False
DDI-MedLine.d176.s5	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d176.s5	recent	94	99	O	recent	ent	cent	JJ	False
DDI-MedLine.d176.s5	history	101	107	O	history	ory	tory	NN	False
DDI-MedLine.d176.s5	of	109	110	O	of	of	of	IN	False
DDI-MedLine.d176.s5	excitatory	112	121	O	excitatory	ory	tory	NN	False
DDI-MedLine.d176.s5	synaptic	123	130	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d176.s5	inputs	132	137	O	inputs	uts	puts	NNS	False
DDI-MedLine.d176.s5	over	139	142	O	over	ver	over	IN	False
DDI-MedLine.d176.s5	intervals	144	152	O	intervals	als	vals	NNS	False
DDI-MedLine.d176.s5	of	154	155	O	of	of	of	IN	False
DDI-MedLine.d176.s5	minutes	157	163	O	minutes	tes	utes	NNS	False
DDI-MedLine.d176.s5	to	165	166	O	to	to	to	TO	False
DDI-MedLine.d176.s5	hours	168	172	O	hours	urs	ours	NNS	False
DDI-MedLine.d176.s5	.	173	173	O	.	.	.	.	False

DDI-MedLine.d157.s0	Tradition	0	8	O	Tradition	ion	tion	NN	False
DDI-MedLine.d157.s0	and	10	12	O	and	and	and	CC	False
DDI-MedLine.d157.s0	toxicity	14	21	O	toxicity	ity	city	NN	False
DDI-MedLine.d157.s0	:	22	22	O	:	:	:	:	False
DDI-MedLine.d157.s0	evidential	24	33	O	evidential	ial	tial	JJ	False
DDI-MedLine.d157.s0	cultures	35	42	O	cultures	res	ures	NNS	False
DDI-MedLine.d157.s0	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d157.s0	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d157.s0	kava	51	54	O	kava	ava	kava	NN	False
DDI-MedLine.d157.s0	safety	56	61	O	safety	ety	fety	NN	False
DDI-MedLine.d157.s0	debate	63	68	O	debate	ate	bate	NN	False
DDI-MedLine.d157.s0	.	69	69	O	.	.	.	.	False

DDI-MedLine.d157.s1	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d157.s1	paper	5	9	O	paper	per	aper	NN	False
DDI-MedLine.d157.s1	examines	11	18	O	examines	nes	ines	NNS	group
DDI-MedLine.d157.s1	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d157.s1	debate	24	29	O	debate	ate	bate	NN	False
DDI-MedLine.d157.s1	about	31	35	O	about	out	bout	IN	False
DDI-MedLine.d157.s1	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d157.s1	safety	41	46	O	safety	ety	fety	NN	False
DDI-MedLine.d157.s1	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d157.s1	kava	51	54	O	kava	ava	kava	NN	False
DDI-MedLine.d157.s1	(	56	56	O	(	(	(	(	False
DDI-MedLine.d157.s1	Piper	57	61	O	Piper	per	iper	NN	False
DDI-MedLine.d157.s1	methysticum	63	73	O	methysticum	cum	icum	NN	False
DDI-MedLine.d157.s1	Forst	75	79	O	Forst	rst	orst	NNP	False
DDI-MedLine.d157.s1	.	80	80	O	.	.	.	.	False
DDI-MedLine.d157.s1	f	82	82	O	f	f	f	NN	False
DDI-MedLine.d157.s1	,	83	83	O	,	,	,	,	False
DDI-MedLine.d157.s1	Piperaceae	85	94	O	Piperaceae	eae	ceae	NN	False
DDI-MedLine.d157.s1	)	95	95	O	)	)	)	)	False
DDI-MedLine.d157.s1	,	96	96	O	,	,	,	,	False
DDI-MedLine.d157.s1	a	98	98	O	a	a	a	DT	False
DDI-MedLine.d157.s1	plant	100	104	O	plant	ant	lant	NN	False
DDI-MedLine.d157.s1	native	106	111	O	native	ive	tive	JJ	False
DDI-MedLine.d157.s1	to	113	114	O	to	to	to	TO	False
DDI-MedLine.d157.s1	Oceania	116	122	O	Oceania	nia	ania	NN	False
DDI-MedLine.d157.s1	,	123	123	O	,	,	,	,	False
DDI-MedLine.d157.s1	where	125	129	O	where	ere	here	WRB	False
DDI-MedLine.d157.s1	it	131	132	O	it	it	it	PRP	False
DDI-MedLine.d157.s1	has	134	136	O	has	has	has	VBZ	False
DDI-MedLine.d157.s1	a	138	138	O	a	a	a	DT	False
DDI-MedLine.d157.s1	long	140	143	O	long	ong	long	RB	False
DDI-MedLine.d157.s1	history	145	151	O	history	ory	tory	NN	False
DDI-MedLine.d157.s1	of	153	154	O	of	of	of	IN	False
DDI-MedLine.d157.s1	traditional	156	166	O	traditional	nal	onal	JJ	False
DDI-MedLine.d157.s1	use	168	170	O	use	use	use	NN	False
DDI-MedLine.d157.s1	.	171	171	O	.	.	.	.	False

DDI-MedLine.d157.s2	Kava	0	3	O	Kava	ava	Kava	NNP	False
DDI-MedLine.d157.s2	became	5	10	O	became	ame	came	VBD	False
DDI-MedLine.d157.s2	popular	12	18	O	popular	lar	ular	JJ	False
DDI-MedLine.d157.s2	as	20	21	O	as	as	as	IN	False
DDI-MedLine.d157.s2	an	23	24	O	an	an	an	DT	False
DDI-MedLine.d157.s2	anti-anxiety	26	37	O	anti-anxiety	ety	iety	NN	False
DDI-MedLine.d157.s2	treatment	39	47	O	treatment	ent	ment	NN	False
DDI-MedLine.d157.s2	in	49	50	O	in	in	in	IN	False
DDI-MedLine.d157.s2	Western	52	58	O	Western	ern	tern	JJ	False
DDI-MedLine.d157.s2	countries	60	68	O	countries	ies	ries	NNS	False
DDI-MedLine.d157.s2	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d157.s2	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d157.s2	late	77	80	O	late	ate	late	RB	False
DDI-MedLine.d157.s2	1990s	82	86	O	1990s	90s	990s	CD	False
DDI-MedLine.d157.s2	,	87	87	O	,	,	,	,	False
DDI-MedLine.d157.s2	but	89	91	O	but	but	but	CC	False
DDI-MedLine.d157.s2	it	93	94	O	it	it	it	PRP	False
DDI-MedLine.d157.s2	was	96	98	O	was	was	was	VBD	False
DDI-MedLine.d157.s2	subsequently	100	111	O	subsequently	tly	ntly	RB	False
DDI-MedLine.d157.s2	banned	113	118	O	banned	ned	nned	VBN	False
DDI-MedLine.d157.s2	in	120	121	O	in	in	in	IN	False
DDI-MedLine.d157.s2	many	123	126	O	many	any	many	JJ	False
DDI-MedLine.d157.s2	places	128	133	O	places	ces	aces	NNS	False
DDI-MedLine.d157.s2	due	135	137	O	due	due	due	JJ	False
DDI-MedLine.d157.s2	to	139	140	O	to	to	to	TO	False
DDI-MedLine.d157.s2	adverse	142	148	O	adverse	rse	erse	NN	False
DDI-MedLine.d157.s2	reports	150	156	O	reports	rts	orts	NNS	False
DDI-MedLine.d157.s2	of	158	159	O	of	of	of	IN	False
DDI-MedLine.d157.s2	liver	161	165	O	liver	ver	iver	NN	False
DDI-MedLine.d157.s2	toxicity	167	174	O	toxicity	ity	city	NN	False
DDI-MedLine.d157.s2	.	175	175	O	.	.	.	.	False

DDI-MedLine.d157.s3	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d157.s3	paper	5	9	O	paper	per	aper	NN	False
DDI-MedLine.d157.s3	focuses	11	17	O	focuses	ses	uses	NNS	False
DDI-MedLine.d157.s3	on	19	20	O	on	on	on	IN	False
DDI-MedLine.d157.s3	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d157.s3	responses	26	34	O	responses	ses	nses	NNS	False
DDI-MedLine.d157.s3	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d157.s3	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d157.s3	bans	43	46	O	bans	ans	bans	NNS	False
DDI-MedLine.d157.s3	by	48	49	O	by	by	by	IN	False
DDI-MedLine.d157.s3	scientists	51	60	O	scientists	sts	ists	NNS	False
DDI-MedLine.d157.s3	involved	62	69	O	involved	ved	lved	VBN	False
DDI-MedLine.d157.s3	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d157.s3	kava	74	77	O	kava	ava	kava	NN	False
DDI-MedLine.d157.s3	research	79	86	O	research	rch	arch	NN	False
DDI-MedLine.d157.s3	,	87	87	O	,	,	,	,	False
DDI-MedLine.d157.s3	contrasting	89	99	O	contrasting	ing	ting	VBG	False
DDI-MedLine.d157.s3	their	101	105	O	their	eir	heir	PRP$	False
DDI-MedLine.d157.s3	evidential	107	116	O	evidential	ial	tial	JJ	False
DDI-MedLine.d157.s3	culture	118	124	O	culture	ure	ture	NN	False
DDI-MedLine.d157.s3	with	126	129	O	with	ith	with	IN	False
DDI-MedLine.d157.s3	that	131	134	O	that	hat	that	IN	False
DDI-MedLine.d157.s3	employed	136	143	O	employed	yed	oyed	VBN	False
DDI-MedLine.d157.s3	by	145	146	O	by	by	by	IN	False
DDI-MedLine.d157.s3	clinicians	148	157	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d157.s3	and	159	161	O	and	and	and	CC	False
DDI-MedLine.d157.s3	regulatory	163	172	O	regulatory	ory	tory	JJ	False
DDI-MedLine.d157.s3	officials	174	182	O	officials	als	ials	NNS	False
DDI-MedLine.d157.s3	.	183	183	O	.	.	.	.	False

DDI-MedLine.d157.s4	Cultural	0	7	O	Cultural	ral	ural	JJ	False
DDI-MedLine.d157.s4	constructions	9	21	O	constructions	ons	ions	NNS	False
DDI-MedLine.d157.s4	and	23	25	O	and	and	and	CC	False
DDI-MedLine.d157.s4	social	27	32	O	social	ial	cial	JJ	False
DDI-MedLine.d157.s4	negotiations	34	45	O	negotiations	ons	ions	NNS	False
DDI-MedLine.d157.s4	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d157.s4	risk	50	53	O	risk	isk	risk	NN	False
DDI-MedLine.d157.s4	are	55	57	O	are	are	are	VBP	False
DDI-MedLine.d157.s4	shown	59	63	O	shown	own	hown	VBN	False
DDI-MedLine.d157.s4	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d157.s4	be	68	69	O	be	be	be	VB	False
DDI-MedLine.d157.s4	context-specific	71	86	O	context-specific	fic	ific	NN	False
DDI-MedLine.d157.s4	,	87	87	O	,	,	,	,	False
DDI-MedLine.d157.s4	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d157.s4	are	93	95	O	are	are	are	VBP	False
DDI-MedLine.d157.s4	shaped	97	102	O	shaped	ped	aped	VBD	False
DDI-MedLine.d157.s4	by	104	105	O	by	by	by	IN	False
DDI-MedLine.d157.s4	professional	107	118	O	professional	nal	onal	JJ	False
DDI-MedLine.d157.s4	,	119	119	O	,	,	,	,	False
DDI-MedLine.d157.s4	disciplinary	121	132	O	disciplinary	ary	nary	JJ	False
DDI-MedLine.d157.s4	,	133	133	O	,	,	,	,	False
DDI-MedLine.d157.s4	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d157.s4	organizational	139	152	O	organizational	nal	onal	JJ	False
DDI-MedLine.d157.s4	factors	154	160	O	factors	ors	tors	NNS	False
DDI-MedLine.d157.s4	,	161	161	O	,	,	,	,	False
DDI-MedLine.d157.s4	among	163	167	O	among	ong	mong	IN	False
DDI-MedLine.d157.s4	others	169	174	O	others	ers	hers	NNS	False
DDI-MedLine.d157.s4	.	175	175	O	.	.	.	.	False

DDI-MedLine.d157.s5	Though	0	5	O	Though	ugh	ough	IN	False
DDI-MedLine.d157.s5	the	7	9	O	the	the	the	DT	False
DDI-MedLine.d157.s5	science	11	17	O	science	nce	ence	NN	False
DDI-MedLine.d157.s5	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d157.s5	hepatotoxicity	22	35	O	hepatotoxicity	ity	city	NN	False
DDI-MedLine.d157.s5	is	37	38	O	is	is	is	VBZ	False
DDI-MedLine.d157.s5	uncertain	40	48	O	uncertain	ain	tain	JJ	False
DDI-MedLine.d157.s5	enough	50	55	O	enough	ugh	ough	RB	False
DDI-MedLine.d157.s5	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d157.s5	allow	60	64	O	allow	low	llow	VB	False
DDI-MedLine.d157.s5	for	66	68	O	for	for	for	IN	False
DDI-MedLine.d157.s5	multiple	70	77	O	multiple	ple	iple	NN	False
DDI-MedLine.d157.s5	interpretations	79	93	O	interpretations	ons	ions	NNS	False
DDI-MedLine.d157.s5	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d157.s5	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d157.s5	same	102	105	O	same	ame	same	JJ	False
DDI-MedLine.d157.s5	data	107	110	O	data	ata	data	NNS	False
DDI-MedLine.d157.s5	,	111	111	O	,	,	,	,	False
DDI-MedLine.d157.s5	the	113	115	O	the	the	the	DT	False
DDI-MedLine.d157.s5	biomedical/clinical	117	135	O	biomedical/clinical	cal	ical	JJ	False
DDI-MedLine.d157.s5	narrative	137	145	O	narrative	ive	tive	JJ	False
DDI-MedLine.d157.s5	about	147	151	O	about	out	bout	IN	False
DDI-MedLine.d157.s5	kava	153	156	O	kava	ava	kava	NN	False
DDI-MedLine.d157.s5	remains	158	164	O	remains	ins	ains	NNS	False
DDI-MedLine.d157.s5	dominant	166	173	O	dominant	ant	nant	NN	False
DDI-MedLine.d157.s5	.	174	174	O	.	.	.	.	False

DDI-MedLine.d157.s6	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d157.s6	case	5	8	O	case	ase	case	NN	False
DDI-MedLine.d157.s6	study	10	14	O	study	udy	tudy	NN	False
DDI-MedLine.d157.s6	explores	16	23	O	explores	res	ores	NNS	False
DDI-MedLine.d157.s6	the	25	27	O	the	the	the	DT	False
DDI-MedLine.d157.s6	influence	29	37	O	influence	nce	ence	NN	False
DDI-MedLine.d157.s6	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d157.s6	these	42	46	O	these	ese	hese	DT	False
DDI-MedLine.d157.s6	cultural	48	55	O	cultural	ral	ural	JJ	False
DDI-MedLine.d157.s6	,	56	56	O	,	,	,	,	False
DDI-MedLine.d157.s6	social	58	63	O	social	ial	cial	JJ	False
DDI-MedLine.d157.s6	,	64	64	O	,	,	,	,	False
DDI-MedLine.d157.s6	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d157.s6	political	70	78	O	political	cal	ical	JJ	False
DDI-MedLine.d157.s6	factors	80	86	O	factors	ors	tors	NNS	False
DDI-MedLine.d157.s6	on	88	89	O	on	on	on	IN	False
DDI-MedLine.d157.s6	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d157.s6	production	95	104	O	production	ion	tion	NN	False
DDI-MedLine.d157.s6	of	106	107	O	of	of	of	IN	False
DDI-MedLine.d157.s6	scientific	109	118	O	scientific	fic	ific	JJ	False
DDI-MedLine.d157.s6	knowledge	120	128	O	knowledge	dge	edge	NN	False
DDI-MedLine.d157.s6	and	130	132	O	and	and	and	CC	False
DDI-MedLine.d157.s6	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d157.s6	assessment	138	147	O	assessment	ent	ment	NN	False
DDI-MedLine.d157.s6	of	149	150	O	of	of	of	IN	False
DDI-MedLine.d157.s6	benefit/risk	152	163	O	benefit/risk	isk	risk	NN	False
DDI-MedLine.d157.s6	posed	165	169	O	posed	sed	osed	VBN	False
DDI-MedLine.d157.s6	by	171	172	O	by	by	by	IN	False
DDI-MedLine.d157.s6	comestibles	174	184	O	comestibles	les	bles	NNS	False
DDI-MedLine.d157.s6	.	185	185	O	.	.	.	.	False

DDI-MedLine.d221.s0	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d221.s0	autopsy	3	9	O	autopsy	psy	opsy	NN	False
DDI-MedLine.d221.s0	case	11	14	O	case	ase	case	NN	False
DDI-MedLine.d221.s0	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d221.s0	multiple	19	26	O	multiple	ple	iple	NN	False
DDI-MedLine.d221.s0	psychotropic	28	39	B-group	psychotropic	pic	opic	NN	False
DDI-MedLine.d221.s0	drug	41	44	I-group	drug	rug	drug	NN	False
DDI-MedLine.d221.s0	poisoning	46	54	O	poisoning	ing	ning	VBG	False
DDI-MedLine.d221.s0	.	55	55	O	.	.	.	.	False

DDI-MedLine.d221.s1	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d221.s1	fatal	2	6	O	fatal	tal	atal	NN	False
DDI-MedLine.d221.s1	poisoning	8	16	O	poisoning	ing	ning	VBG	False
DDI-MedLine.d221.s1	case	18	21	O	case	ase	case	NN	False
DDI-MedLine.d221.s1	involving	23	31	O	involving	ing	ving	VBG	False
DDI-MedLine.d221.s1	etizolam	33	40	B-drug	etizolam	lam	olam	NN	False
DDI-MedLine.d221.s1	,	41	41	O	,	,	,	,	False
DDI-MedLine.d221.s1	phenobarbital	43	55	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d221.s1	,	56	56	O	,	,	,	,	False
DDI-MedLine.d221.s1	promethazine	58	69	B-drug	promethazine	ine	zine	NN	drug
DDI-MedLine.d221.s1	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d221.s1	chlorpromazine	75	88	B-drug	chlorpromazine	ine	zine	NN	drug
DDI-MedLine.d221.s1	is	90	91	O	is	is	is	VBZ	False
DDI-MedLine.d221.s1	presented	93	101	O	presented	ted	nted	VBN	False
DDI-MedLine.d221.s1	.	102	102	O	.	.	.	.	False

DDI-MedLine.d221.s2	Quantitative	0	11	O	Quantitative	ive	tive	JJ	False
DDI-MedLine.d221.s2	toxicological	13	25	O	toxicological	cal	ical	JJ	False
DDI-MedLine.d221.s2	analysis	27	34	O	analysis	sis	ysis	NN	False
DDI-MedLine.d221.s2	showed	36	41	O	showed	wed	owed	VBD	False
DDI-MedLine.d221.s2	that	43	46	O	that	hat	that	IN	False
DDI-MedLine.d221.s2	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d221.s2	concentrations	52	65	O	concentrations	ons	ions	NNS	False
DDI-MedLine.d221.s2	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d221.s2	etizolam	70	77	B-drug	etizolam	lam	olam	NN	False
DDI-MedLine.d221.s2	,	78	78	O	,	,	,	,	False
DDI-MedLine.d221.s2	phenobarbital	80	92	B-drug	phenobarbital	tal	ital	NN	False
DDI-MedLine.d221.s2	,	93	93	O	,	,	,	,	False
DDI-MedLine.d221.s2	promethazine	95	106	B-drug	promethazine	ine	zine	NN	drug
DDI-MedLine.d221.s2	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d221.s2	chlorpromazine	112	125	B-drug	chlorpromazine	ine	zine	NN	drug
DDI-MedLine.d221.s2	in	127	128	O	in	in	in	IN	False
DDI-MedLine.d221.s2	the	130	132	O	the	the	the	DT	False
DDI-MedLine.d221.s2	femoral	134	140	O	femoral	ral	oral	JJ	False
DDI-MedLine.d221.s2	blood	142	146	O	blood	ood	lood	NN	False
DDI-MedLine.d221.s2	were	148	151	O	were	ere	were	VBD	False
DDI-MedLine.d221.s2	86	153	154	O	86	86	86	CD	False
DDI-MedLine.d221.s2	ng/ml	156	160	O	ng/ml	/ml	g/ml	NN	False
DDI-MedLine.d221.s2	,	161	161	O	,	,	,	,	False
DDI-MedLine.d221.s2	5082	163	166	O	5082	082	5082	CD	False
DDI-MedLine.d221.s2	microg/ml	168	176	O	microg/ml	/ml	g/ml	NN	False
DDI-MedLine.d221.s2	,	177	177	O	,	,	,	,	False
DDI-MedLine.d221.s2	0.107	179	183	O	0.107	107	.107	CD	False
DDI-MedLine.d221.s2	microg/ml	185	193	O	microg/ml	/ml	g/ml	NN	False
DDI-MedLine.d221.s2	and	195	197	O	and	and	and	CC	False
DDI-MedLine.d221.s2	0.144	199	203	O	0.144	144	.144	CD	False
DDI-MedLine.d221.s2	microg/ml	205	213	O	microg/ml	/ml	g/ml	NN	False
DDI-MedLine.d221.s2	,	214	214	O	,	,	,	,	False
DDI-MedLine.d221.s2	respectively	216	227	O	respectively	ely	vely	RB	False
DDI-MedLine.d221.s2	,	228	228	O	,	,	,	,	False
DDI-MedLine.d221.s2	and	230	232	O	and	and	and	CC	False
DDI-MedLine.d221.s2	large	234	238	O	large	rge	arge	JJ	False
DDI-MedLine.d221.s2	amounts	240	246	O	amounts	nts	unts	NNS	False
DDI-MedLine.d221.s2	of	248	249	O	of	of	of	IN	False
DDI-MedLine.d221.s2	drugs	251	255	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d221.s2	were	257	260	O	were	ere	were	VBD	False
DDI-MedLine.d221.s2	also	262	265	O	also	lso	also	RB	False
DDI-MedLine.d221.s2	detected	267	274	O	detected	ted	cted	VBN	False
DDI-MedLine.d221.s2	in	276	277	O	in	in	in	IN	False
DDI-MedLine.d221.s2	the	279	281	O	the	the	the	DT	False
DDI-MedLine.d221.s2	stomach	283	289	O	stomach	ach	mach	NN	False
DDI-MedLine.d221.s2	contents	291	298	O	contents	nts	ents	NNS	False
DDI-MedLine.d221.s2	.	299	299	O	.	.	.	.	False

DDI-MedLine.d221.s3	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d221.s3	conclude	3	10	O	conclude	ude	lude	NN	False
DDI-MedLine.d221.s3	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d221.s3	the	17	19	O	the	the	the	DT	False
DDI-MedLine.d221.s3	cause	21	25	O	cause	use	ause	NN	False
DDI-MedLine.d221.s3	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d221.s3	death	30	34	O	death	ath	eath	NN	False
DDI-MedLine.d221.s3	was	36	38	O	was	was	was	VBD	False
DDI-MedLine.d221.s3	due	40	42	O	due	due	due	JJ	False
DDI-MedLine.d221.s3	to	44	45	O	to	to	to	TO	False
DDI-MedLine.d221.s3	the	47	49	O	the	the	the	DT	False
DDI-MedLine.d221.s3	interaction	51	61	O	interaction	ion	tion	NN	False
DDI-MedLine.d221.s3	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d221.s3	multiple	66	73	O	multiple	ple	iple	NN	False
DDI-MedLine.d221.s3	psychotropic	75	86	B-group	psychotropic	pic	opic	NN	False
DDI-MedLine.d221.s3	drugs	88	92	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d221.s3	.	93	93	O	.	.	.	.	False

DDI-MedLine.d223.s0	Polypharmacy	0	11	O	Polypharmacy	acy	macy	NN	False
DDI-MedLine.d223.s0	in	13	14	O	in	in	in	IN	False
DDI-MedLine.d223.s0	older	16	20	O	older	der	lder	JJR	False
DDI-MedLine.d223.s0	adults	22	27	O	adults	lts	ults	NNS	False
DDI-MedLine.d223.s0	.	28	28	O	.	.	.	.	False

DDI-MedLine.d223.s1	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d223.s1	article	5	11	O	article	cle	icle	NN	False
DDI-MedLine.d223.s1	explores	13	20	O	explores	res	ores	NNS	False
DDI-MedLine.d223.s1	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d223.s1	issue	26	30	O	issue	sue	ssue	NN	False
DDI-MedLine.d223.s1	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d223.s1	polypharmacy	35	46	O	polypharmacy	acy	macy	NN	False
DDI-MedLine.d223.s1	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d223.s1	older	51	55	O	older	der	lder	JJR	False
DDI-MedLine.d223.s1	adults	57	62	O	adults	lts	ults	NNS	False
DDI-MedLine.d223.s1	.	63	63	O	.	.	.	.	False

DDI-MedLine.d223.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d223.s2	physiological	4	16	O	physiological	cal	ical	JJ	False
DDI-MedLine.d223.s2	changes	18	24	O	changes	ges	nges	NNS	False
DDI-MedLine.d223.s2	in	26	27	O	in	in	in	IN	False
DDI-MedLine.d223.s2	organ	29	33	O	organ	gan	rgan	NN	False
DDI-MedLine.d223.s2	function	35	42	O	function	ion	tion	NN	False
DDI-MedLine.d223.s2	in	44	45	O	in	in	in	IN	False
DDI-MedLine.d223.s2	older	47	51	O	older	der	lder	JJR	False
DDI-MedLine.d223.s2	people	53	58	O	people	ple	ople	NNS	False
DDI-MedLine.d223.s2	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d223.s2	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d223.s2	effect	68	73	O	effect	ect	fect	NN	False
DDI-MedLine.d223.s2	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d223.s2	this	78	81	O	this	his	this	DT	False
DDI-MedLine.d223.s2	on	83	84	O	on	on	on	IN	False
DDI-MedLine.d223.s2	pharmacokinetics	86	101	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d223.s2	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d223.s2	pharmacodynamics	107	122	O	pharmacodynamics	ics	mics	NNS	False
DDI-MedLine.d223.s2	are	124	126	O	are	are	are	VBP	False
DDI-MedLine.d223.s2	discussed	128	136	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d223.s2	.	137	137	O	.	.	.	.	False

DDI-MedLine.d223.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d223.s3	risks	4	8	O	risks	sks	isks	NNS	False
DDI-MedLine.d223.s3	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d223.s3	adverse	13	19	O	adverse	rse	erse	NN	False
DDI-MedLine.d223.s3	drug	21	24	O	drug	rug	drug	NN	False
DDI-MedLine.d223.s3	reactions	26	34	O	reactions	ons	ions	NNS	False
DDI-MedLine.d223.s3	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d223.s3	adverse	40	46	O	adverse	rse	erse	NN	False
DDI-MedLine.d223.s3	drug	48	51	O	drug	rug	drug	NN	False
DDI-MedLine.d223.s3	interactions	53	64	O	interactions	ons	ions	NNS	False
DDI-MedLine.d223.s3	linked	66	71	O	linked	ked	nked	VBN	False
DDI-MedLine.d223.s3	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d223.s3	polypharmacy	76	87	O	polypharmacy	acy	macy	NN	False
DDI-MedLine.d223.s3	are	89	91	O	are	are	are	VBP	False
DDI-MedLine.d223.s3	explored	93	100	O	explored	red	ored	VBN	False
DDI-MedLine.d223.s3	.	101	101	O	.	.	.	.	False

DDI-MedLine.d223.s4	Strategies	0	9	O	Strategies	ies	gies	NNS	False
DDI-MedLine.d223.s4	to	11	12	O	to	to	to	TO	False
DDI-MedLine.d223.s4	achieve	14	20	O	achieve	eve	ieve	NN	False
DDI-MedLine.d223.s4	optimal	22	28	O	optimal	mal	imal	JJ	False
DDI-MedLine.d223.s4	prescribing	30	40	O	prescribing	ing	bing	VBG	False
DDI-MedLine.d223.s4	in	42	43	O	in	in	in	IN	False
DDI-MedLine.d223.s4	older	45	49	O	older	der	lder	JJR	False
DDI-MedLine.d223.s4	people	51	56	O	people	ple	ople	NNS	False
DDI-MedLine.d223.s4	are	58	60	O	are	are	are	VBP	False
DDI-MedLine.d223.s4	considered	62	71	O	considered	red	ered	VBN	False
DDI-MedLine.d223.s4	.	72	72	O	.	.	.	.	False

DDI-MedLine.d215.s0	In-vitro	0	7	O	In-vitro	tro	itro	JJ	False
DDI-MedLine.d215.s0	antimicrobial	9	21	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d215.s0	activity	23	30	O	activity	ity	vity	NN	False
DDI-MedLine.d215.s0	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d215.s0	synergistic/antagonistic	36	59	O	synergistic/antagonistic	tic	stic	JJ	False
DDI-MedLine.d215.s0	effect	61	66	O	effect	ect	fect	NN	False
DDI-MedLine.d215.s0	of	68	69	O	of	of	of	IN	False
DDI-MedLine.d215.s0	interactions	71	82	O	interactions	ons	ions	NNS	False
DDI-MedLine.d215.s0	between	84	90	O	between	een	ween	IN	False
DDI-MedLine.d215.s0	antibiotics	92	102	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d215.s0	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d215.s0	some	108	111	O	some	ome	some	DT	False
DDI-MedLine.d215.s0	spice	113	117	O	spice	ice	pice	NN	False
DDI-MedLine.d215.s0	essential	119	127	O	essential	ial	tial	JJ	False
DDI-MedLine.d215.s0	oils	129	132	O	oils	ils	oils	NNS	False
DDI-MedLine.d215.s0	.	133	133	O	.	.	.	.	False

DDI-MedLine.d215.s1	Spices	0	5	O	Spices	ces	ices	NNS	False
DDI-MedLine.d215.s1	and	7	9	O	and	and	and	CC	False
DDI-MedLine.d215.s1	herbs	11	15	O	herbs	rbs	erbs	NN	False
DDI-MedLine.d215.s1	have	17	20	O	have	ave	have	VB	False
DDI-MedLine.d215.s1	been	22	25	O	been	een	been	VBN	False
DDI-MedLine.d215.s1	used	27	30	O	used	sed	used	VBN	False
DDI-MedLine.d215.s1	for	32	34	O	for	for	for	IN	False
DDI-MedLine.d215.s1	many	36	39	O	many	any	many	JJ	False
DDI-MedLine.d215.s1	years	41	45	O	years	ars	ears	NNS	False
DDI-MedLine.d215.s1	by	47	48	O	by	by	by	IN	False
DDI-MedLine.d215.s1	different	50	58	O	different	ent	rent	JJ	False
DDI-MedLine.d215.s1	cultures	60	67	O	cultures	res	ures	NNS	False
DDI-MedLine.d215.s1	.	68	68	O	.	.	.	.	False

DDI-MedLine.d215.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d215.s2	aim	4	6	O	aim	aim	aim	NN	False
DDI-MedLine.d215.s2	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d215.s2	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d215.s2	present	15	21	O	present	ent	sent	NN	False
DDI-MedLine.d215.s2	study	23	27	O	study	udy	tudy	NN	False
DDI-MedLine.d215.s2	is	29	30	O	is	is	is	VBZ	False
DDI-MedLine.d215.s2	(	32	32	O	(	(	(	(	False
DDI-MedLine.d215.s2	1	33	33	O	1	1	1	CD	False
DDI-MedLine.d215.s2	)	34	34	O	)	)	)	)	False
DDI-MedLine.d215.s2	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d215.s2	investigate	39	49	O	investigate	ate	gate	NN	False
DDI-MedLine.d215.s2	in-vitro	51	58	O	in-vitro	tro	itro	NN	False
DDI-MedLine.d215.s2	antimicrobial	60	72	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d215.s2	effects	74	80	O	effects	cts	ects	NNS	False
DDI-MedLine.d215.s2	of	82	83	O	of	of	of	IN	False
DDI-MedLine.d215.s2	different	85	93	O	different	ent	rent	JJ	False
DDI-MedLine.d215.s2	spices	95	100	O	spices	ces	ices	NNS	False
DDI-MedLine.d215.s2	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d215.s2	herbs	106	110	O	herbs	rbs	erbs	NN	False
DDI-MedLine.d215.s2	(	112	112	O	(	(	(	(	False
DDI-MedLine.d215.s2	5	113	113	O	5	5	5	CD	False
DDI-MedLine.d215.s2	species	115	121	O	species	ies	cies	NNS	False
DDI-MedLine.d215.s2	:	122	122	O	:	:	:	:	False
DDI-MedLine.d215.s2	Rosmarinus	124	133	O	Rosmarinus	nus	inus	NN	False
DDI-MedLine.d215.s2	officinalis	135	145	O	officinalis	lis	alis	NN	False
DDI-MedLine.d215.s2	(	147	147	O	(	(	(	(	False
DDI-MedLine.d215.s2	Rosemary	148	155	O	Rosemary	ary	mary	JJ	False
DDI-MedLine.d215.s2	)	156	156	O	)	)	)	)	False
DDI-MedLine.d215.s2	,	157	157	O	,	,	,	,	False
DDI-MedLine.d215.s2	Coriandrum	159	168	O	Coriandrum	rum	drum	NN	False
DDI-MedLine.d215.s2	sativum	170	176	O	sativum	vum	ivum	NN	False
DDI-MedLine.d215.s2	(	178	178	O	(	(	(	(	False
DDI-MedLine.d215.s2	coriander	179	187	O	coriander	der	nder	NN	False
DDI-MedLine.d215.s2	)	188	188	O	)	)	)	)	False
DDI-MedLine.d215.s2	,	189	189	O	,	,	,	,	False
DDI-MedLine.d215.s2	Micromeria	191	200	O	Micromeria	ria	eria	NNS	False
DDI-MedLine.d215.s2	fruticosa	202	210	O	fruticosa	osa	cosa	NN	False
DDI-MedLine.d215.s2	(	212	212	O	(	(	(	(	False
DDI-MedLine.d215.s2	L	213	213	O	L	L	L	NN	brand
DDI-MedLine.d215.s2	.	214	214	O	.	.	.	.	False
DDI-MedLine.d215.s2	)	215	215	O	)	)	)	)	False

DDI-MedLine.d215.s3	Druce	0	4	O	Druce	uce	ruce	NN	False
DDI-MedLine.d215.s3	subsp	6	10	O	subsp	bsp	ubsp	NN	False
DDI-MedLine.d215.s3	.	11	11	O	.	.	.	.	False

DDI-MedLine.d215.s4	Brachycalyx	0	10	O	Brachycalyx	lyx	alyx	NN	False
DDI-MedLine.d215.s4	P.H	12	14	O	P.H	P.H	P.H	NN	brand
DDI-MedLine.d215.s4	.	15	15	O	.	.	.	.	False

DDI-MedLine.d215.s5	Davis	0	4	O	Davis	vis	avis	NN	False
DDI-MedLine.d215.s5	(	6	6	O	(	(	(	(	False
DDI-MedLine.d215.s5	White	7	11	O	White	ite	hite	NNP	False
DDI-MedLine.d215.s5	micromeria	13	22	O	micromeria	ria	eria	NNS	False
DDI-MedLine.d215.s5	)	23	23	O	)	)	)	)	False
DDI-MedLine.d215.s5	,	24	24	O	,	,	,	,	False
DDI-MedLine.d215.s5	Cumium	26	31	O	Cumium	ium	mium	NN	drug
DDI-MedLine.d215.s5	cyminum	33	39	O	cyminum	num	inum	NN	False
DDI-MedLine.d215.s5	(	41	41	O	(	(	(	(	False
DDI-MedLine.d215.s5	cumin	42	46	O	cumin	min	umin	NN	False
DDI-MedLine.d215.s5	)	47	47	O	)	)	)	)	False
DDI-MedLine.d215.s5	,	48	48	O	,	,	,	,	False
DDI-MedLine.d215.s5	Mentha	50	55	O	Mentha	tha	ntha	NN	False
DDI-MedLine.d215.s5	piperita	57	64	O	piperita	ita	rita	NN	False
DDI-MedLine.d215.s5	(	66	66	O	(	(	(	(	False
DDI-MedLine.d215.s5	Peppermint	67	76	O	Peppermint	int	mint	NN	False
DDI-MedLine.d215.s5	)	77	77	O	)	)	)	)	False
DDI-MedLine.d215.s5	against	79	85	O	against	nst	inst	IN	False
DDI-MedLine.d215.s5	different	87	95	O	different	ent	rent	JJ	False
DDI-MedLine.d215.s5	bacteria	97	104	O	bacteria	ria	eria	NNS	False
DDI-MedLine.d215.s5	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d215.s5	fungi	110	114	O	fungi	ngi	ungi	NNS	False
DDI-MedLine.d215.s5	species	116	122	O	species	ies	cies	NNS	False
DDI-MedLine.d215.s5	,	123	123	O	,	,	,	,	False
DDI-MedLine.d215.s5	and	125	127	O	and	and	and	CC	False
DDI-MedLine.d215.s5	(	129	129	O	(	(	(	(	False
DDI-MedLine.d215.s5	2	130	130	O	2	2	2	CD	False
DDI-MedLine.d215.s5	)	131	131	O	)	)	)	)	False
DDI-MedLine.d215.s5	to	133	134	O	to	to	to	TO	False
DDI-MedLine.d215.s5	discuss	136	142	O	discuss	uss	cuss	NN	False
DDI-MedLine.d215.s5	the	144	146	O	the	the	the	DT	False
DDI-MedLine.d215.s5	in-vitro	148	155	O	in-vitro	tro	itro	NN	False
DDI-MedLine.d215.s5	possible	157	164	O	possible	ble	ible	JJ	False
DDI-MedLine.d215.s5	effects	166	172	O	effects	cts	ects	NNS	False
DDI-MedLine.d215.s5	between	174	180	O	between	een	ween	IN	False
DDI-MedLine.d215.s5	the	182	184	O	the	the	the	DT	False
DDI-MedLine.d215.s5	plants	186	191	O	plants	nts	ants	NNS	False
DDI-MedLine.d215.s5	and	193	195	O	and	and	and	CC	False
DDI-MedLine.d215.s5	antibiotics	197	207	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d215.s5	.	208	208	O	.	.	.	.	False

DDI-MedLine.d215.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d215.s6	microorganisms	4	17	O	microorganisms	sms	isms	NNS	False
DDI-MedLine.d215.s6	used	19	22	O	used	sed	used	VBN	False
DDI-MedLine.d215.s6	were	24	27	O	were	ere	were	VBD	False
DDI-MedLine.d215.s6	Micrococcus	29	39	O	Micrococcus	cus	ccus	NN	False
DDI-MedLine.d215.s6	luteus	41	46	O	luteus	eus	teus	NN	False
DDI-MedLine.d215.s6	LA	48	49	O	LA	LA	LA	NNP	brand
DDI-MedLine.d215.s6	2971	51	54	O	2971	971	2971	CD	False
DDI-MedLine.d215.s6	,	55	55	O	,	,	,	,	False
DDI-MedLine.d215.s6	Bacillus	57	64	O	Bacillus	lus	llus	NN	False
DDI-MedLine.d215.s6	megaterium	66	75	O	megaterium	ium	rium	NN	drug
DDI-MedLine.d215.s6	NRS	77	79	O	NRS	NRS	NRS	NN	brand
DDI-MedLine.d215.s6	,	80	80	O	,	,	,	,	False
DDI-MedLine.d215.s6	Bacillus	82	89	O	Bacillus	lus	llus	NN	False
DDI-MedLine.d215.s6	brevis	91	96	O	brevis	vis	evis	NN	False
DDI-MedLine.d215.s6	FMC	98	100	O	FMC	FMC	FMC	NN	brand
DDI-MedLine.d215.s6	3	102	102	O	3	3	3	CD	False
DDI-MedLine.d215.s6	,	103	103	O	,	,	,	,	False
DDI-MedLine.d215.s6	Enterococcus	105	116	O	Enterococcus	cus	ccus	NN	False
DDI-MedLine.d215.s6	faecalis	118	125	O	faecalis	lis	alis	NN	False
DDI-MedLine.d215.s6	ATCC	127	130	O	ATCC	TCC	ATCC	NN	brand
DDI-MedLine.d215.s6	15753	132	136	O	15753	753	5753	CD	False
DDI-MedLine.d215.s6	,	137	137	O	,	,	,	,	False
DDI-MedLine.d215.s6	Pseudomonas	139	149	O	Pseudomonas	nas	onas	NNS	False
DDI-MedLine.d215.s6	pyocyaneus	151	160	O	pyocyaneus	eus	neus	NN	False
DDI-MedLine.d215.s6	DC	162	163	O	DC	DC	DC	NN	brand
DDI-MedLine.d215.s6	127	165	167	O	127	127	127	CD	False
DDI-MedLine.d215.s6	,	168	168	O	,	,	,	,	False
DDI-MedLine.d215.s6	Mycobacterium	170	182	O	Mycobacterium	ium	rium	NN	drug
DDI-MedLine.d215.s6	smegmatis	184	192	O	smegmatis	tis	atis	NN	False
DDI-MedLine.d215.s6	CCM	194	196	O	CCM	CCM	CCM	NN	brand
DDI-MedLine.d215.s6	2067	198	201	O	2067	067	2067	CD	False
DDI-MedLine.d215.s6	,	202	202	O	,	,	,	,	False
DDI-MedLine.d215.s6	Escherichia	204	214	O	Escherichia	hia	chia	NN	False
DDI-MedLine.d215.s6	coil	216	219	O	coil	oil	coil	NN	False
DDI-MedLine.d215.s6	DM	221	222	O	DM	DM	DM	NN	brand
DDI-MedLine.d215.s6	,	223	223	O	,	,	,	,	False
DDI-MedLine.d215.s6	Aeromonas	225	233	O	Aeromonas	nas	onas	NNS	False
DDI-MedLine.d215.s6	hydrophila	235	244	O	hydrophila	ila	hila	NN	False
DDI-MedLine.d215.s6	ATCC	246	249	O	ATCC	TCC	ATCC	NN	brand
DDI-MedLine.d215.s6	7966	251	254	O	7966	966	7966	CD	False
DDI-MedLine.d215.s6	,	255	255	O	,	,	,	,	False
DDI-MedLine.d215.s6	Yersinia	257	264	O	Yersinia	nia	inia	NN	False
DDI-MedLine.d215.s6	enterocolitica	266	279	O	enterocolitica	ica	tica	NN	False
DDI-MedLine.d215.s6	AU	281	282	O	AU	AU	AU	NN	brand
DDI-MedLine.d215.s6	19	284	285	O	19	19	19	CD	False
DDI-MedLine.d215.s6	,	286	286	O	,	,	,	,	False
DDI-MedLine.d215.s6	Staphylococcus	288	301	O	Staphylococcus	cus	ccus	NN	False
DDI-MedLine.d215.s6	aureus	303	308	O	aureus	eus	reus	NN	False
DDI-MedLine.d215.s6	Cowan	310	314	O	Cowan	wan	owan	NNP	False
DDI-MedLine.d215.s6	1	316	316	O	1	1	1	CD	False
DDI-MedLine.d215.s6	,	317	317	O	,	,	,	,	False
DDI-MedLine.d215.s6	Streptococcus	319	331	O	Streptococcus	cus	ccus	NN	False
DDI-MedLine.d215.s6	faecalis	333	340	O	faecalis	lis	alis	NN	False
DDI-MedLine.d215.s6	DC	342	343	O	DC	DC	DC	NN	brand
DDI-MedLine.d215.s6	74	345	346	O	74	74	74	CD	False
DDI-MedLine.d215.s6	bacteria	348	355	O	bacteria	ria	eria	NNS	False
DDI-MedLine.d215.s6	,	356	356	O	,	,	,	,	False
DDI-MedLine.d215.s6	and	358	360	O	and	and	and	CC	False
DDI-MedLine.d215.s6	Saccharomyces	362	374	O	Saccharomyces	ces	yces	NNS	False
DDI-MedLine.d215.s6	cerevisiae	376	385	O	cerevisiae	iae	siae	NN	False
DDI-MedLine.d215.s6	WET	387	389	O	WET	WET	WET	NN	brand
DDI-MedLine.d215.s6	136	391	393	O	136	136	136	CD	False
DDI-MedLine.d215.s6	,	394	394	O	,	,	,	,	False
DDI-MedLine.d215.s6	Kluvyeromyces	396	408	O	Kluvyeromyces	ces	yces	NNS	False
DDI-MedLine.d215.s6	fragilis	410	417	O	fragilis	lis	ilis	NN	False
DDI-MedLine.d215.s6	DC	419	420	O	DC	DC	DC	NN	brand
DDI-MedLine.d215.s6	98	422	423	O	98	98	98	CD	False
DDI-MedLine.d215.s6	fungi	425	429	O	fungi	ngi	ungi	NNS	False
DDI-MedLine.d215.s6	in	431	432	O	in	in	in	IN	False
DDI-MedLine.d215.s6	this	434	437	O	this	his	this	DT	False
DDI-MedLine.d215.s6	study	439	443	O	study	udy	tudy	NN	False
DDI-MedLine.d215.s6	.	444	444	O	.	.	.	.	False

DDI-MedLine.d215.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d215.s7	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d215.s7	indicated	12	20	O	indicated	ted	ated	VBN	False
DDI-MedLine.d215.s7	that	22	25	O	that	hat	that	IN	False
DDI-MedLine.d215.s7	essential	27	35	O	essential	ial	tial	JJ	False
DDI-MedLine.d215.s7	oils	37	40	O	oils	ils	oils	NNS	False
DDI-MedLine.d215.s7	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d215.s7	Rosmarinus	45	54	O	Rosmarinus	nus	inus	NN	False
DDI-MedLine.d215.s7	officinalis	56	66	O	officinalis	lis	alis	NN	False
DDI-MedLine.d215.s7	,	67	67	O	,	,	,	,	False
DDI-MedLine.d215.s7	Coriandrum	69	78	O	Coriandrum	rum	drum	NN	False
DDI-MedLine.d215.s7	sativum	80	86	O	sativum	vum	ivum	NN	False
DDI-MedLine.d215.s7	L.	88	89	O	L.	L.	L.	NNP	brand
DDI-MedLine.d215.s7	,	90	90	O	,	,	,	,	False
DDI-MedLine.d215.s7	Micromeria	92	101	O	Micromeria	ria	eria	NNS	False
DDI-MedLine.d215.s7	fruticosa	103	111	O	fruticosa	osa	cosa	NN	False
DDI-MedLine.d215.s7	(	113	113	O	(	(	(	(	False
DDI-MedLine.d215.s7	L	114	114	O	L	L	L	NN	brand
DDI-MedLine.d215.s7	.	115	115	O	.	.	.	.	False
DDI-MedLine.d215.s7	)	116	116	O	)	)	)	)	False

DDI-MedLine.d215.s8	Druce	0	4	O	Druce	uce	ruce	NN	False
DDI-MedLine.d215.s8	subsp	6	10	O	subsp	bsp	ubsp	NN	False
DDI-MedLine.d215.s8	.	11	11	O	.	.	.	.	False

DDI-MedLine.d215.s9	brachycalyx	0	10	O	brachycalyx	lyx	alyx	NN	False
DDI-MedLine.d215.s9	P.H	12	14	O	P.H	P.H	P.H	NN	brand
DDI-MedLine.d215.s9	.	15	15	O	.	.	.	.	False

DDI-MedLine.d215.s10	Davis	0	4	O	Davis	vis	avis	NN	False
DDI-MedLine.d215.s10	,	5	5	O	,	,	,	,	False
DDI-MedLine.d215.s10	Cumium	7	12	O	Cumium	ium	mium	NN	drug
DDI-MedLine.d215.s10	cyminum	14	20	O	cyminum	num	inum	NN	False
DDI-MedLine.d215.s10	L.	22	23	O	L.	L.	L.	NNP	brand
DDI-MedLine.d215.s10	,	24	24	O	,	,	,	,	False
DDI-MedLine.d215.s10	Mentha	26	31	O	Mentha	tha	ntha	NN	False
DDI-MedLine.d215.s10	piperita	33	40	O	piperita	ita	rita	NN	False
DDI-MedLine.d215.s10	L	42	42	O	L	L	L	NN	brand
DDI-MedLine.d215.s10	.	43	43	O	.	.	.	.	False

DDI-MedLine.d215.s11	were	0	3	O	were	ere	were	VBD	False
DDI-MedLine.d215.s11	shown	5	9	O	shown	own	hown	VBN	False
DDI-MedLine.d215.s11	antimicrobial	11	23	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d215.s11	activity	25	32	O	activity	ity	vity	NN	False
DDI-MedLine.d215.s11	in	34	35	O	in	in	in	IN	False
DDI-MedLine.d215.s11	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d215.s11	range	41	45	O	range	nge	ange	NN	False
DDI-MedLine.d215.s11	of	47	48	O	of	of	of	IN	False
DDI-MedLine.d215.s11	7-60	50	53	O	7-60	-60	7-60	JJ	False
DDI-MedLine.d215.s11	mm	55	56	O	mm	mm	mm	NN	False
DDI-MedLine.d215.s11	2	58	58	O	2	2	2	CD	False
DDI-MedLine.d215.s11	microl	60	65	O	microl	rol	crol	NN	False
DDI-MedLine.d215.s11	(	66	66	O	(	(	(	(	False
DDI-MedLine.d215.s11	-1	67	68	O	-1	-1	-1	NN	False
DDI-MedLine.d215.s11	)	69	69	O	)	)	)	)	False
DDI-MedLine.d215.s11	inhibition	71	80	O	inhibition	ion	tion	NN	False
DDI-MedLine.d215.s11	zone	82	85	O	zone	one	zone	NN	False
DDI-MedLine.d215.s11	to	87	88	O	to	to	to	TO	False
DDI-MedLine.d215.s11	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d215.s11	microorganisms	94	107	O	microorganisms	sms	isms	NNS	False
DDI-MedLine.d215.s11	tested	109	114	O	tested	ted	sted	VBN	False
DDI-MedLine.d215.s11	,	115	115	O	,	,	,	,	False
DDI-MedLine.d215.s11	using	117	121	O	using	ing	sing	VBG	False
DDI-MedLine.d215.s11	disc	123	126	O	disc	isc	disc	NN	False
DDI-MedLine.d215.s11	diffusion	128	136	O	diffusion	ion	sion	NN	False
DDI-MedLine.d215.s11	method	138	143	O	method	hod	thod	NN	False
DDI-MedLine.d215.s11	.	144	144	O	.	.	.	.	False

DDI-MedLine.d215.s12	Standard	0	7	O	Standard	ard	dard	NN	False
DDI-MedLine.d215.s12	antibiotic	9	18	B-group	antibiotic	tic	otic	JJ	False
DDI-MedLine.d215.s12	such	20	23	O	such	uch	such	JJ	False
DDI-MedLine.d215.s12	as	25	26	O	as	as	as	IN	False
DDI-MedLine.d215.s12	Gentamicin	28	37	B-drug	Gentamicin	cin	icin	NN	drug
DDI-MedLine.d215.s12	(	39	39	O	(	(	(	(	False
DDI-MedLine.d215.s12	10	40	41	O	10	10	10	CD	False
DDI-MedLine.d215.s12	microg	43	48	O	microg	rog	crog	NN	False
DDI-MedLine.d215.s12	)	49	49	O	)	)	)	)	False
DDI-MedLine.d215.s12	,	50	50	O	,	,	,	,	False
DDI-MedLine.d215.s12	Cephalothin	52	62	B-drug	Cephalothin	hin	thin	NN	False
DDI-MedLine.d215.s12	(	64	64	O	(	(	(	(	False
DDI-MedLine.d215.s12	30	65	66	O	30	30	30	CD	False
DDI-MedLine.d215.s12	microg	68	73	O	microg	rog	crog	NN	False
DDI-MedLine.d215.s12	)	74	74	O	)	)	)	)	False
DDI-MedLine.d215.s12	,	75	75	O	,	,	,	,	False
DDI-MedLine.d215.s12	Ceftriaxone	77	87	B-drug	Ceftriaxone	one	xone	NN	False
DDI-MedLine.d215.s12	(	89	89	O	(	(	(	(	False
DDI-MedLine.d215.s12	10	90	91	O	10	10	10	CD	False
DDI-MedLine.d215.s12	microg	93	98	O	microg	rog	crog	NN	False
DDI-MedLine.d215.s12	)	99	99	O	)	)	)	)	False
DDI-MedLine.d215.s12	,	100	100	O	,	,	,	,	False
DDI-MedLine.d215.s12	Nystatin	102	109	B-drug	Nystatin	tin	atin	NN	False
DDI-MedLine.d215.s12	(	111	111	O	(	(	(	(	False
DDI-MedLine.d215.s12	10	112	113	O	10	10	10	CD	False
DDI-MedLine.d215.s12	U	115	115	O	U	U	U	NN	brand
DDI-MedLine.d215.s12	)	116	116	O	)	)	)	)	False
DDI-MedLine.d215.s12	discs	118	122	O	discs	scs	iscs	NN	False
DDI-MedLine.d215.s12	were	124	127	O	were	ere	were	VBD	False
DDI-MedLine.d215.s12	used	129	132	O	used	sed	used	VBN	False
DDI-MedLine.d215.s12	for	134	136	O	for	for	for	IN	False
DDI-MedLine.d215.s12	comparison	138	147	O	comparison	son	ison	NN	False
DDI-MedLine.d215.s12	with	149	152	O	with	ith	with	IN	False
DDI-MedLine.d215.s12	the	154	156	O	the	the	the	DT	False
DDI-MedLine.d215.s12	antimicrobial	158	170	O	antimicrobial	ial	bial	JJ	False
DDI-MedLine.d215.s12	activities	172	181	O	activities	ies	ties	NNS	False
DDI-MedLine.d215.s12	of	183	184	O	of	of	of	IN	False
DDI-MedLine.d215.s12	essential	186	194	O	essential	ial	tial	JJ	False
DDI-MedLine.d215.s12	oils	196	199	O	oils	ils	oils	NNS	False
DDI-MedLine.d215.s12	of	201	202	O	of	of	of	IN	False
DDI-MedLine.d215.s12	these	204	208	O	these	ese	hese	DT	False
DDI-MedLine.d215.s12	plants	210	215	O	plants	nts	ants	NNS	False
DDI-MedLine.d215.s12	.	216	216	O	.	.	.	.	False

DDI-MedLine.d215.s13	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d215.s13	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d215.s13	,	11	11	O	,	,	,	,	False
DDI-MedLine.d215.s13	antibacterial	13	25	O	antibacterial	ial	rial	JJ	False
DDI-MedLine.d215.s13	activity	27	34	O	activity	ity	vity	NN	False
DDI-MedLine.d215.s13	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d215.s13	essential	39	47	O	essential	ial	tial	JJ	False
DDI-MedLine.d215.s13	oils	49	52	O	oils	ils	oils	NNS	False
DDI-MedLine.d215.s13	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d215.s13	these	57	61	O	these	ese	hese	DT	False
DDI-MedLine.d215.s13	plants	63	68	O	plants	nts	ants	NNS	False
DDI-MedLine.d215.s13	was	70	72	O	was	was	was	VBD	False
DDI-MedLine.d215.s13	researched	74	83	O	researched	hed	ched	VBN	False
DDI-MedLine.d215.s13	by	85	86	O	by	by	by	IN	False
DDI-MedLine.d215.s13	effects	88	94	O	effects	cts	ects	NNS	False
DDI-MedLine.d215.s13	when	96	99	O	when	hen	when	WRB	False
DDI-MedLine.d215.s13	it	101	102	O	it	it	it	PRP	False
DDI-MedLine.d215.s13	was	104	106	O	was	was	was	VBD	False
DDI-MedLine.d215.s13	used	108	111	O	used	sed	used	VBN	False
DDI-MedLine.d215.s13	together	113	120	O	together	her	ther	RB	False
DDI-MedLine.d215.s13	with	122	125	O	with	ith	with	IN	False
DDI-MedLine.d215.s13	these	127	131	O	these	ese	hese	DT	False
DDI-MedLine.d215.s13	standard	133	140	O	standard	ard	dard	NN	False
DDI-MedLine.d215.s13	antibiotics	142	152	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d215.s13	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d215.s13	vitro	157	161	O	vitro	tro	itro	NN	False
DDI-MedLine.d215.s13	.	162	162	O	.	.	.	.	False

DDI-MedLine.d215.s14	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d215.s14	,	7	7	O	,	,	,	,	False
DDI-MedLine.d215.s14	antibacterial	9	21	O	antibacterial	ial	rial	JJ	False
DDI-MedLine.d215.s14	activity	23	30	O	activity	ity	vity	NN	False
DDI-MedLine.d215.s14	changed	32	38	O	changed	ged	nged	VBN	False
DDI-MedLine.d215.s14	also	40	43	O	also	lso	also	RB	False
DDI-MedLine.d215.s14	by	45	46	O	by	by	by	IN	False
DDI-MedLine.d215.s14	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d215.s14	vitro	51	55	O	vitro	tro	itro	NN	False
DDI-MedLine.d215.s14	interactions	57	68	O	interactions	ons	ions	NNS	False
DDI-MedLine.d215.s14	between	70	76	O	between	een	ween	IN	False
DDI-MedLine.d215.s14	these	78	82	O	these	ese	hese	DT	False
DDI-MedLine.d215.s14	standard	84	91	O	standard	ard	dard	NN	False
DDI-MedLine.d215.s14	antibiotics	93	103	B-group	antibiotics	ics	tics	NNS	False
DDI-MedLine.d215.s14	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d215.s14	essential	109	117	O	essential	ial	tial	JJ	False
DDI-MedLine.d215.s14	oils	119	122	O	oils	ils	oils	NNS	False
DDI-MedLine.d215.s14	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d215.s14	these	127	131	O	these	ese	hese	DT	False
DDI-MedLine.d215.s14	plants	133	138	O	plants	nts	ants	NNS	False
DDI-MedLine.d215.s14	.	139	139	O	.	.	.	.	False

DDI-MedLine.d215.s15	Synergic	0	7	O	Synergic	gic	rgic	NN	False
DDI-MedLine.d215.s15	,	8	8	O	,	,	,	,	False
DDI-MedLine.d215.s15	additive	10	17	O	additive	ive	tive	JJ	False
DDI-MedLine.d215.s15	or	19	20	O	or	or	or	CC	False
DDI-MedLine.d215.s15	antagonist	22	31	O	antagonist	ist	nist	NN	False
DDI-MedLine.d215.s15	effects	33	39	O	effects	cts	ects	NNS	False
DDI-MedLine.d215.s15	were	41	44	O	were	ere	were	VBD	False
DDI-MedLine.d215.s15	observed	46	53	O	observed	ved	rved	VBN	False
DDI-MedLine.d215.s15	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d215.s15	antibacterial	58	70	O	antibacterial	ial	rial	JJ	False
DDI-MedLine.d215.s15	activity	72	79	O	activity	ity	vity	NN	False
DDI-MedLine.d215.s15	.	80	80	O	.	.	.	.	False

DDI-MedLine.d224.s0	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d224.s0	influence	4	12	O	influence	nce	ence	NN	False
DDI-MedLine.d224.s0	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d224.s0	chemical	17	24	O	chemical	cal	ical	NN	False
DDI-MedLine.d224.s0	activation	26	35	O	activation	ion	tion	NN	False
DDI-MedLine.d224.s0	on	37	38	O	on	on	on	IN	False
DDI-MedLine.d224.s0	tooth	40	44	O	tooth	oth	ooth	NN	False
DDI-MedLine.d224.s0	bleaching	46	54	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s0	using	56	60	O	using	ing	sing	VBG	False
DDI-MedLine.d224.s0	10	62	63	O	10	10	10	CD	False
DDI-MedLine.d224.s0	%	64	64	O	%	%	%	NN	False
DDI-MedLine.d224.s0	carbamide	66	74	B-drug_n	carbamide	ide	mide	NN	False
DDI-MedLine.d224.s0	peroxide	76	83	I-drug_n	peroxide	ide	xide	NN	False
DDI-MedLine.d224.s0	.	84	84	O	.	.	.	.	False

DDI-MedLine.d224.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d224.s1	aim	4	6	O	aim	aim	aim	NN	False
DDI-MedLine.d224.s1	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d224.s1	this	11	14	O	this	his	this	DT	False
DDI-MedLine.d224.s1	study	16	20	O	study	udy	tudy	NN	False
DDI-MedLine.d224.s1	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d224.s1	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d224.s1	assess	29	34	O	assess	ess	sess	NN	False
DDI-MedLine.d224.s1	the	36	38	O	the	the	the	DT	False
DDI-MedLine.d224.s1	influence	40	48	O	influence	nce	ence	NN	False
DDI-MedLine.d224.s1	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d224.s1	manganese	53	61	B-drug_n	manganese	ese	nese	NNS	False
DDI-MedLine.d224.s1	gluconate	63	71	I-drug_n	gluconate	ate	nate	NN	False
DDI-MedLine.d224.s1	,	72	72	O	,	,	,	,	False
DDI-MedLine.d224.s1	a	74	74	O	a	a	a	DT	False
DDI-MedLine.d224.s1	chemical	76	83	O	chemical	cal	ical	NN	False
DDI-MedLine.d224.s1	activator	85	93	O	activator	tor	ator	NN	False
DDI-MedLine.d224.s1	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d224.s1	bleaching	98	106	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s1	agents	108	113	O	agents	nts	ents	NNS	False
DDI-MedLine.d224.s1	,	114	114	O	,	,	,	,	False
DDI-MedLine.d224.s1	at	116	117	O	at	at	at	IN	False
DDI-MedLine.d224.s1	a	119	119	O	a	a	a	DT	False
DDI-MedLine.d224.s1	concentration	121	133	O	concentration	ion	tion	NN	False
DDI-MedLine.d224.s1	of	135	136	O	of	of	of	IN	False
DDI-MedLine.d224.s1	0.01	138	141	O	0.01	.01	0.01	CD	False
DDI-MedLine.d224.s1	%	142	142	O	%	%	%	NN	False
DDI-MedLine.d224.s1	on	144	145	O	on	on	on	IN	False
DDI-MedLine.d224.s1	the	147	149	O	the	the	the	DT	False
DDI-MedLine.d224.s1	efficiency	151	160	O	efficiency	ncy	ency	NN	False
DDI-MedLine.d224.s1	of	162	163	O	of	of	of	IN	False
DDI-MedLine.d224.s1	a	165	165	O	a	a	a	DT	False
DDI-MedLine.d224.s1	10	167	168	O	10	10	10	CD	False
DDI-MedLine.d224.s1	%	169	169	O	%	%	%	NN	False
DDI-MedLine.d224.s1	carbamide	171	179	B-drug_n	carbamide	ide	mide	NN	False
DDI-MedLine.d224.s1	peroxide-based	181	194	O	peroxide-based	sed	ased	JJ	False
DDI-MedLine.d224.s1	bleaching	196	204	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s1	agent	206	210	O	agent	ent	gent	NN	False
DDI-MedLine.d224.s1	.	211	211	O	.	.	.	.	False

DDI-MedLine.d224.s2	Forty	0	4	O	Forty	rty	orty	NN	False
DDI-MedLine.d224.s2	bovine	6	11	O	bovine	ine	vine	NN	drug
DDI-MedLine.d224.s2	incisors	13	20	O	incisors	ors	sors	NNS	False
DDI-MedLine.d224.s2	were	22	25	O	were	ere	were	VBD	False
DDI-MedLine.d224.s2	immersed	27	34	O	immersed	sed	rsed	VBN	False
DDI-MedLine.d224.s2	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d224.s2	a	39	39	O	a	a	a	DT	False
DDI-MedLine.d224.s2	25	41	42	O	25	25	25	CD	False
DDI-MedLine.d224.s2	%	43	43	O	%	%	%	NN	False
DDI-MedLine.d224.s2	instant	45	51	O	instant	ant	tant	NN	False
DDI-MedLine.d224.s2	coffee	53	58	O	coffee	fee	ffee	NN	False
DDI-MedLine.d224.s2	solution	60	67	O	solution	ion	tion	NN	False
DDI-MedLine.d224.s2	for	69	71	O	for	for	for	IN	False
DDI-MedLine.d224.s2	seven	73	77	O	seven	ven	even	CD	False
DDI-MedLine.d224.s2	days	79	82	O	days	ays	days	NNS	False
DDI-MedLine.d224.s2	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d224.s2	randomly	88	95	O	randomly	mly	omly	RB	False
DDI-MedLine.d224.s2	divided	97	103	O	divided	ded	ided	VBN	False
DDI-MedLine.d224.s2	into	105	108	O	into	nto	into	IN	False
DDI-MedLine.d224.s2	two	110	112	O	two	two	two	CD	False
DDI-MedLine.d224.s2	groups	114	119	O	groups	ups	oups	NNS	False
DDI-MedLine.d224.s2	.	120	120	O	.	.	.	.	False

DDI-MedLine.d224.s3	Group	0	4	O	Group	oup	roup	NNP	False
DDI-MedLine.d224.s3	1	6	6	O	1	1	1	CD	False
DDI-MedLine.d224.s3	was	8	10	O	was	was	was	VBD	False
DDI-MedLine.d224.s3	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d224.s3	control	16	22	O	control	rol	trol	NN	False
DDI-MedLine.d224.s3	group	24	28	O	group	oup	roup	NN	False
DDI-MedLine.d224.s3	and	30	32	O	and	and	and	CC	False
DDI-MedLine.d224.s3	consisted	34	42	O	consisted	ted	sted	VBN	False
DDI-MedLine.d224.s3	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d224.s3	10	47	48	O	10	10	10	CD	False
DDI-MedLine.d224.s3	%	49	49	O	%	%	%	NN	False
DDI-MedLine.d224.s3	carbamide	51	59	B-drug_n	carbamide	ide	mide	NN	False
DDI-MedLine.d224.s3	peroxide-based	61	74	O	peroxide-based	sed	ased	JJ	False
DDI-MedLine.d224.s3	bleaching	76	84	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s3	gel	86	88	O	gel	gel	gel	NN	False
DDI-MedLine.d224.s3	only	90	93	O	only	nly	only	RB	False
DDI-MedLine.d224.s3	.	94	94	O	.	.	.	.	False

DDI-MedLine.d224.s4	Group	0	4	O	Group	oup	roup	NNP	False
DDI-MedLine.d224.s4	2	6	6	O	2	2	2	CD	False
DDI-MedLine.d224.s4	consisted	8	16	O	consisted	ted	sted	VBN	False
DDI-MedLine.d224.s4	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d224.s4	10	21	22	O	10	10	10	CD	False
DDI-MedLine.d224.s4	%	23	23	O	%	%	%	NN	False
DDI-MedLine.d224.s4	carbamide	25	33	B-drug_n	carbamide	ide	mide	NN	False
DDI-MedLine.d224.s4	peroxide-based	35	48	O	peroxide-based	sed	ased	JJ	False
DDI-MedLine.d224.s4	bleaching	50	58	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s4	gel	60	62	O	gel	gel	gel	NN	False
DDI-MedLine.d224.s4	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d224.s4	0.01	68	71	O	0.01	.01	0.01	CD	False
DDI-MedLine.d224.s4	%	72	72	O	%	%	%	NN	False
DDI-MedLine.d224.s4	manganese	74	82	B-drug_n	manganese	ese	nese	NNS	False
DDI-MedLine.d224.s4	gluconate	84	92	I-drug_n	gluconate	ate	nate	NN	False
DDI-MedLine.d224.s4	.	93	93	O	.	.	.	.	False

DDI-MedLine.d224.s5	Three	0	4	O	Three	ree	hree	CD	False
DDI-MedLine.d224.s5	readings	6	13	O	readings	ngs	ings	NNS	False
DDI-MedLine.d224.s5	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d224.s5	color	18	22	O	color	lor	olor	NN	False
DDI-MedLine.d224.s5	were	24	27	O	were	ere	were	VBD	False
DDI-MedLine.d224.s5	taken	29	33	O	taken	ken	aken	VBN	False
DDI-MedLine.d224.s5	using	35	39	O	using	ing	sing	VBG	False
DDI-MedLine.d224.s5	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d224.s5	Vita	45	48	O	Vita	ita	Vita	NNP	False
DDI-MedLine.d224.s5	Easyshade	50	58	O	Easyshade	ade	hade	NN	False
DDI-MedLine.d224.s5	spectrophotometer	60	76	O	spectrophotometer	ter	eter	NN	False
DDI-MedLine.d224.s5	:	77	77	O	:	:	:	:	False
DDI-MedLine.d224.s5	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d224.s5	initial	83	89	O	initial	ial	tial	JJ	False
DDI-MedLine.d224.s5	reading	91	97	O	reading	ing	ding	NN	False
DDI-MedLine.d224.s5	,	98	98	O	,	,	,	,	False
DDI-MedLine.d224.s5	a	100	100	O	a	a	a	DT	False
DDI-MedLine.d224.s5	reading	102	108	O	reading	ing	ding	NN	False
DDI-MedLine.d224.s5	at	110	111	O	at	at	at	IN	False
DDI-MedLine.d224.s5	seven	113	117	O	seven	ven	even	CD	False
DDI-MedLine.d224.s5	days	119	122	O	days	ays	days	NNS	False
DDI-MedLine.d224.s5	,	123	123	O	,	,	,	,	False
DDI-MedLine.d224.s5	and	125	127	O	and	and	and	CC	False
DDI-MedLine.d224.s5	a	129	129	O	a	a	a	DT	False
DDI-MedLine.d224.s5	reading	131	137	O	reading	ing	ding	NN	False
DDI-MedLine.d224.s5	at	139	140	O	at	at	at	IN	False
DDI-MedLine.d224.s5	14	142	143	O	14	14	14	CD	False
DDI-MedLine.d224.s5	days	145	148	O	days	ays	days	NNS	False
DDI-MedLine.d224.s5	.	149	149	O	.	.	.	.	False

DDI-MedLine.d224.s6	Total	0	4	O	Total	tal	otal	JJ	False
DDI-MedLine.d224.s6	color	6	10	O	color	lor	olor	NN	False
DDI-MedLine.d224.s6	variation	12	20	O	variation	ion	tion	NN	False
DDI-MedLine.d224.s6	was	22	24	O	was	was	was	VBD	False
DDI-MedLine.d224.s6	calculated	26	35	O	calculated	ted	ated	VBN	False
DDI-MedLine.d224.s6	by	37	38	O	by	by	by	IN	False
DDI-MedLine.d224.s6	E*Lab	42	46	O	E*Lab	Lab	*Lab	NN	False
DDI-MedLine.d224.s6	.	47	47	O	.	.	.	.	False

DDI-MedLine.d224.s7	Data	0	3	O	Data	ata	Data	NNS	False
DDI-MedLine.d224.s7	were	5	8	O	were	ere	were	VBD	False
DDI-MedLine.d224.s7	submitted	10	18	O	submitted	ted	tted	VBN	False
DDI-MedLine.d224.s7	to	20	21	O	to	to	to	TO	False
DDI-MedLine.d224.s7	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d224.s7	statistical	27	37	O	statistical	cal	ical	JJ	False
DDI-MedLine.d224.s7	t-test	39	44	O	t-test	est	test	NN	False
DDI-MedLine.d224.s7	(	46	46	O	(	(	(	(	False
DDI-MedLine.d224.s7	5	47	47	O	5	5	5	CD	False
DDI-MedLine.d224.s7	%	48	48	O	%	%	%	NN	False
DDI-MedLine.d224.s7	)	49	49	O	)	)	)	)	False
DDI-MedLine.d224.s7	,	50	50	O	,	,	,	,	False
DDI-MedLine.d224.s7	which	52	56	O	which	ich	hich	WDT	False
DDI-MedLine.d224.s7	showed	58	63	O	showed	wed	owed	VBD	False
DDI-MedLine.d224.s7	that	65	68	O	that	hat	that	IN	False
DDI-MedLine.d224.s7	after	70	74	O	after	ter	fter	IN	False
DDI-MedLine.d224.s7	seven	76	80	O	seven	ven	even	CD	False
DDI-MedLine.d224.s7	days	82	85	O	days	ays	days	NNS	False
DDI-MedLine.d224.s7	group	87	91	O	group	oup	roup	NN	False
DDI-MedLine.d224.s7	2	93	93	O	2	2	2	CD	False
DDI-MedLine.d224.s7	had	95	97	O	had	had	had	VBD	False
DDI-MedLine.d224.s7	a	99	99	O	a	a	a	DT	False
DDI-MedLine.d224.s7	significant	101	111	O	significant	ant	cant	JJ	False
DDI-MedLine.d224.s7	increase	113	120	O	increase	ase	ease	NN	False
DDI-MedLine.d224.s7	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d224.s7	the	125	127	O	the	the	the	DT	False
DDI-MedLine.d224.s7	degree	129	134	O	degree	ree	gree	NN	False
DDI-MedLine.d224.s7	of	136	137	O	of	of	of	IN	False
DDI-MedLine.d224.s7	tooth	139	143	O	tooth	oth	ooth	NN	False
DDI-MedLine.d224.s7	bleaching	145	153	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s7	compared	155	162	O	compared	red	ared	VBN	False
DDI-MedLine.d224.s7	with	164	167	O	with	ith	with	IN	False
DDI-MedLine.d224.s7	group	169	173	O	group	oup	roup	NN	False
DDI-MedLine.d224.s7	1	175	175	O	1	1	1	CD	False
DDI-MedLine.d224.s7	.	176	176	O	.	.	.	.	False

DDI-MedLine.d224.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d224.s8	mean	4	7	O	mean	ean	mean	NN	False
DDI-MedLine.d224.s8	values	9	14	O	values	ues	lues	NNS	False
DDI-MedLine.d224.s8	(	16	16	O	(	(	(	(	False
DDI-MedLine.d224.s8	SD	19	20	O	SD	SD	SD	NN	brand
DDI-MedLine.d224.s8	)	21	21	O	)	)	)	)	False
DDI-MedLine.d224.s8	were	23	26	O	were	ere	were	VBD	False
DDI-MedLine.d224.s8	16.33	28	32	O	16.33	.33	6.33	CD	False
DDI-MedLine.d224.s8	(	34	34	O	(	(	(	(	False
DDI-MedLine.d224.s8	3.95	37	40	O	3.95	.95	3.95	CD	False
DDI-MedLine.d224.s8	)	41	41	O	)	)	)	)	False
DDI-MedLine.d224.s8	for	43	45	O	for	for	for	IN	False
DDI-MedLine.d224.s8	group	47	51	O	group	oup	roup	NN	False
DDI-MedLine.d224.s8	1	53	53	O	1	1	1	CD	False
DDI-MedLine.d224.s8	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d224.s8	19.29	59	63	O	19.29	.29	9.29	CD	False
DDI-MedLine.d224.s8	(	65	65	O	(	(	(	(	False
DDI-MedLine.d224.s8	4.97	68	71	O	4.97	.97	4.97	CD	False
DDI-MedLine.d224.s8	)	72	72	O	)	)	)	)	False
DDI-MedLine.d224.s8	for	74	76	O	for	for	for	IN	False
DDI-MedLine.d224.s8	group	78	82	O	group	oup	roup	NN	False
DDI-MedLine.d224.s8	2	84	84	O	2	2	2	CD	False
DDI-MedLine.d224.s8	.	85	85	O	.	.	.	.	False

DDI-MedLine.d224.s9	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d224.s9	,	7	7	O	,	,	,	,	False
DDI-MedLine.d224.s9	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d224.s9	results	13	19	O	results	lts	ults	NNS	False
DDI-MedLine.d224.s9	for	21	23	O	for	for	for	IN	False
DDI-MedLine.d224.s9	group	25	29	O	group	oup	roup	NN	False
DDI-MedLine.d224.s9	1	31	31	O	1	1	1	CD	False
DDI-MedLine.d224.s9	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d224.s9	group	37	41	O	group	oup	roup	NN	False
DDI-MedLine.d224.s9	2	43	43	O	2	2	2	CD	False
DDI-MedLine.d224.s9	were	45	48	O	were	ere	were	VBD	False
DDI-MedLine.d224.s9	similar	50	56	O	similar	lar	ilar	JJ	False
DDI-MedLine.d224.s9	after	58	62	O	after	ter	fter	IN	False
DDI-MedLine.d224.s9	14	64	65	O	14	14	14	CD	False
DDI-MedLine.d224.s9	days	67	70	O	days	ays	days	NNS	False
DDI-MedLine.d224.s9	.	71	71	O	.	.	.	.	False

DDI-MedLine.d224.s10	Adding	0	5	O	Adding	ing	ding	VBG	False
DDI-MedLine.d224.s10	0.01	7	10	O	0.01	.01	0.01	CD	False
DDI-MedLine.d224.s10	%	11	11	O	%	%	%	NN	False
DDI-MedLine.d224.s10	manganese	13	21	B-drug_n	manganese	ese	nese	NNS	False
DDI-MedLine.d224.s10	gluconate	23	31	I-drug_n	gluconate	ate	nate	NN	False
DDI-MedLine.d224.s10	to	33	34	O	to	to	to	TO	False
DDI-MedLine.d224.s10	10	36	37	O	10	10	10	CD	False
DDI-MedLine.d224.s10	%	38	38	O	%	%	%	NN	False
DDI-MedLine.d224.s10	carbamide	40	48	B-drug_n	carbamide	ide	mide	NN	False
DDI-MedLine.d224.s10	peroxide	50	57	I-drug_n	peroxide	ide	xide	NN	False
DDI-MedLine.d224.s10	bleaching	59	67	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s10	gel	69	71	O	gel	gel	gel	NN	False
DDI-MedLine.d224.s10	increased	73	81	O	increased	sed	ased	VBN	False
DDI-MedLine.d224.s10	the	83	85	O	the	the	the	DT	False
DDI-MedLine.d224.s10	degree	87	92	O	degree	ree	gree	NN	False
DDI-MedLine.d224.s10	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d224.s10	tooth	97	101	O	tooth	oth	ooth	NN	False
DDI-MedLine.d224.s10	bleaching	103	111	O	bleaching	ing	hing	NN	False
DDI-MedLine.d224.s10	after	113	117	O	after	ter	fter	IN	False
DDI-MedLine.d224.s10	a	119	119	O	a	a	a	DT	False
DDI-MedLine.d224.s10	seven-day	121	129	O	seven-day	day	-day	JJ	False
DDI-MedLine.d224.s10	treatment	131	139	O	treatment	ent	ment	NN	False
DDI-MedLine.d224.s10	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d224.s10	did	145	147	O	did	did	did	VBD	False
DDI-MedLine.d224.s10	not	149	151	O	not	not	not	RB	False
DDI-MedLine.d224.s10	influence	153	161	O	influence	nce	ence	NN	False
DDI-MedLine.d224.s10	the	163	165	O	the	the	the	DT	False
DDI-MedLine.d224.s10	resulting	167	175	O	resulting	ing	ting	VBG	False
DDI-MedLine.d224.s10	shade	177	181	O	shade	ade	hade	NN	False
DDI-MedLine.d224.s10	after	183	187	O	after	ter	fter	IN	False
DDI-MedLine.d224.s10	14	189	190	O	14	14	14	CD	False
DDI-MedLine.d224.s10	days	192	195	O	days	ays	days	NNS	False
DDI-MedLine.d224.s10	.	196	196	O	.	.	.	.	False

DDI-MedLine.d173.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d173.s0	Medical	1	7	O	Medical	cal	ical	JJ	False
DDI-MedLine.d173.s0	treatment	9	17	O	treatment	ent	ment	NN	False
DDI-MedLine.d173.s0	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d173.s0	tuberculosis	22	33	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d173.s0	-	35	35	O	-	-	-	:	False
DDI-MedLine.d173.s0	update	37	42	O	update	ate	date	NN	False
DDI-MedLine.d173.s0	2011	44	47	O	2011	011	2011	CD	False
DDI-MedLine.d173.s0	]	48	48	O	]	]	]	NN	False
DDI-MedLine.d173.s0	.	49	49	O	.	.	.	.	False

DDI-MedLine.d173.s1	Tuberculosis	0	11	O	Tuberculosis	sis	osis	NN	False
DDI-MedLine.d173.s1	is	13	14	O	is	is	is	VBZ	False
DDI-MedLine.d173.s1	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d173.s1	second	20	25	O	second	ond	cond	JJ	False
DDI-MedLine.d173.s1	most	27	30	O	most	ost	most	JJS	False
DDI-MedLine.d173.s1	common	32	37	O	common	mon	mmon	JJ	False
DDI-MedLine.d173.s1	cause	39	43	O	cause	use	ause	NN	False
DDI-MedLine.d173.s1	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d173.s1	death	48	52	O	death	ath	eath	NN	False
DDI-MedLine.d173.s1	from	54	57	O	from	rom	from	IN	False
DDI-MedLine.d173.s1	an	59	60	O	an	an	an	DT	False
DDI-MedLine.d173.s1	infectious	62	71	O	infectious	ous	ious	JJ	False
DDI-MedLine.d173.s1	disease	73	79	O	disease	ase	ease	NN	False
DDI-MedLine.d173.s1	after	81	85	O	after	ter	fter	IN	False
DDI-MedLine.d173.s1	HIV/AIDS	87	94	O	HIV/AIDS	IDS	AIDS	NN	brand
DDI-MedLine.d173.s1	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d173.s1	the	100	102	O	the	the	the	DT	False
DDI-MedLine.d173.s1	leading	104	110	O	leading	ing	ding	VBG	False
DDI-MedLine.d173.s1	cause	112	116	O	cause	use	ause	NN	False
DDI-MedLine.d173.s1	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d173.s1	death	121	125	O	death	ath	eath	NN	False
DDI-MedLine.d173.s1	from	127	130	O	from	rom	from	IN	False
DDI-MedLine.d173.s1	an	132	133	O	an	an	an	DT	False
DDI-MedLine.d173.s1	infectious	135	144	O	infectious	ous	ious	JJ	False
DDI-MedLine.d173.s1	disease	146	152	O	disease	ase	ease	NN	False
DDI-MedLine.d173.s1	in	154	155	O	in	in	in	IN	False
DDI-MedLine.d173.s1	HIV-co-infected	157	171	O	HIV-co-infected	ted	cted	JJ	False
DDI-MedLine.d173.s1	patients	173	180	O	patients	nts	ents	NNS	False
DDI-MedLine.d173.s1	.	181	181	O	.	.	.	.	False

DDI-MedLine.d173.s2	Currently	0	8	O	Currently	tly	ntly	RB	False
DDI-MedLine.d173.s2	,	9	9	O	,	,	,	,	False
DDI-MedLine.d173.s2	drug	11	14	O	drug	rug	drug	NN	False
DDI-MedLine.d173.s2	susceptible	16	26	O	susceptible	ble	ible	JJ	False
DDI-MedLine.d173.s2	TB	28	29	O	TB	TB	TB	NN	brand
DDI-MedLine.d173.s2	is	31	32	O	is	is	is	VBZ	False
DDI-MedLine.d173.s2	treated	34	40	O	treated	ted	ated	VBN	False
DDI-MedLine.d173.s2	with	42	45	O	with	ith	with	IN	False
DDI-MedLine.d173.s2	a	47	47	O	a	a	a	DT	False
DDI-MedLine.d173.s2	four	49	52	O	four	our	four	CD	False
DDI-MedLine.d173.s2	drug	54	57	O	drug	rug	drug	NN	False
DDI-MedLine.d173.s2	regimen	59	65	O	regimen	men	imen	NNS	False
DDI-MedLine.d173.s2	given	67	71	O	given	ven	iven	VBN	False
DDI-MedLine.d173.s2	over	73	76	O	over	ver	over	IN	False
DDI-MedLine.d173.s2	a	78	78	O	a	a	a	DT	False
DDI-MedLine.d173.s2	period	80	85	O	period	iod	riod	NN	False
DDI-MedLine.d173.s2	of	87	88	O	of	of	of	IN	False
DDI-MedLine.d173.s2	two	90	92	O	two	two	two	CD	False
DDI-MedLine.d173.s2	months	94	99	O	months	ths	nths	NNS	False
DDI-MedLine.d173.s2	followed	101	108	O	followed	wed	owed	VBD	False
DDI-MedLine.d173.s2	by	110	111	O	by	by	by	IN	False
DDI-MedLine.d173.s2	two	113	115	O	two	two	two	CD	False
DDI-MedLine.d173.s2	drugs	117	121	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d173.s2	for	123	125	O	for	for	for	IN	False
DDI-MedLine.d173.s2	four	127	130	O	four	our	four	CD	False
DDI-MedLine.d173.s2	months	132	137	O	months	ths	nths	NNS	False
DDI-MedLine.d173.s2	.	138	138	O	.	.	.	.	False

DDI-MedLine.d173.s3	Drug	0	3	O	Drug	rug	Drug	NN	False
DDI-MedLine.d173.s3	resistant	5	13	O	resistant	ant	tant	NN	False
DDI-MedLine.d173.s3	tuberculosis	15	26	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d173.s3	requires	28	35	O	requires	res	ires	VBZ	False
DDI-MedLine.d173.s3	more	37	40	O	more	ore	more	RBR	False
DDI-MedLine.d173.s3	complex	42	48	O	complex	lex	plex	JJ	False
DDI-MedLine.d173.s3	and	50	52	O	and	and	and	CC	False
DDI-MedLine.d173.s3	longer	54	59	O	longer	ger	nger	NN	False
DDI-MedLine.d173.s3	treatment	61	69	O	treatment	ent	ment	NN	False
DDI-MedLine.d173.s3	with	71	74	O	with	ith	with	IN	False
DDI-MedLine.d173.s3	alternative	76	86	O	alternative	ive	tive	NN	False
DDI-MedLine.d173.s3	substances	88	97	O	substances	ces	nces	NNS	False
DDI-MedLine.d173.s3	.	98	98	O	.	.	.	.	False

DDI-MedLine.d173.s4	New	0	2	O	New	New	New	NNP	False
DDI-MedLine.d173.s4	antituberculosis	4	19	B-group	antituberculosis	sis	osis	NN	False
DDI-MedLine.d173.s4	drugs	21	25	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d173.s4	are	27	29	O	are	are	are	VBP	False
DDI-MedLine.d173.s4	currently	31	39	O	currently	tly	ntly	RB	False
DDI-MedLine.d173.s4	being	41	45	O	being	ing	eing	VBG	False
DDI-MedLine.d173.s4	developed	47	55	O	developed	ped	oped	NN	False
DDI-MedLine.d173.s4	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d173.s4	investigated	61	72	O	investigated	ted	ated	VBN	False
DDI-MedLine.d173.s4	and	74	76	O	and	and	and	CC	False
DDI-MedLine.d173.s4	are	78	80	O	are	are	are	VBP	False
DDI-MedLine.d173.s4	urgently	82	89	O	urgently	tly	ntly	RB	False
DDI-MedLine.d173.s4	needed	91	96	O	needed	ded	eded	VBN	False
DDI-MedLine.d173.s4	to	98	99	O	to	to	to	TO	False
DDI-MedLine.d173.s4	treat	101	105	O	treat	eat	reat	NN	False
DDI-MedLine.d173.s4	drug	107	110	O	drug	rug	drug	NN	False
DDI-MedLine.d173.s4	susceptible	112	122	O	susceptible	ble	ible	JJ	False
DDI-MedLine.d173.s4	and	124	126	O	and	and	and	CC	False
DDI-MedLine.d173.s4	drug	128	131	O	drug	rug	drug	NN	False
DDI-MedLine.d173.s4	resistant	133	141	O	resistant	ant	tant	NN	False
DDI-MedLine.d173.s4	TB	143	144	O	TB	TB	TB	NN	brand
DDI-MedLine.d173.s4	.	145	145	O	.	.	.	.	False

DDI-MedLine.d162.s0	Placebo	0	6	O	Placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s0	effect	8	13	O	effect	ect	fect	NN	False
DDI-MedLine.d162.s0	in	15	16	O	in	in	in	IN	False
DDI-MedLine.d162.s0	patients	18	25	O	patients	nts	ents	NNS	False
DDI-MedLine.d162.s0	with	27	30	O	with	ith	with	IN	False
DDI-MedLine.d162.s0	irritable	32	40	O	irritable	ble	able	JJ	False
DDI-MedLine.d162.s0	bowel	42	46	O	bowel	wel	owel	NN	False
DDI-MedLine.d162.s0	syndrome	48	55	O	syndrome	ome	rome	NN	False
DDI-MedLine.d162.s0	.	56	56	O	.	.	.	.	False

DDI-MedLine.d162.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d162.s1	placebo	4	10	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s1	effect	12	17	O	effect	ect	fect	NN	False
DDI-MedLine.d162.s1	has	19	21	O	has	has	has	VBZ	False
DDI-MedLine.d162.s1	evolved	23	29	O	evolved	ved	lved	VBN	False
DDI-MedLine.d162.s1	from	31	34	O	from	rom	from	IN	False
DDI-MedLine.d162.s1	being	36	40	O	being	ing	eing	VBG	False
DDI-MedLine.d162.s1	considered	42	51	O	considered	red	ered	VBN	False
DDI-MedLine.d162.s1	a	53	53	O	a	a	a	DT	False
DDI-MedLine.d162.s1	nuisance	55	62	O	nuisance	nce	ance	NN	False
DDI-MedLine.d162.s1	factor	64	69	O	factor	tor	ctor	NN	False
DDI-MedLine.d162.s1	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d162.s1	clinical	74	81	O	clinical	cal	ical	JJ	False
DDI-MedLine.d162.s1	research	83	90	O	research	rch	arch	NN	False
DDI-MedLine.d162.s1	to	92	93	O	to	to	to	TO	False
DDI-MedLine.d162.s1	a	95	95	O	a	a	a	DT	False
DDI-MedLine.d162.s1	hot	97	99	O	hot	hot	hot	JJ	False
DDI-MedLine.d162.s1	topic	101	105	O	topic	pic	opic	NN	False
DDI-MedLine.d162.s1	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d162.s1	scientific	110	119	O	scientific	fic	ific	JJ	False
DDI-MedLine.d162.s1	investigation	121	133	O	investigation	ion	tion	NN	False
DDI-MedLine.d162.s1	.	134	134	O	.	.	.	.	False

DDI-MedLine.d162.s2	New	0	2	O	New	New	New	NNP	False
DDI-MedLine.d162.s2	research	4	11	O	research	rch	arch	NN	False
DDI-MedLine.d162.s2	findings	13	20	O	findings	ngs	ings	NNS	False
DDI-MedLine.d162.s2	show	22	25	O	show	how	show	NN	False
DDI-MedLine.d162.s2	that	27	30	O	that	hat	that	IN	False
DDI-MedLine.d162.s2	a	32	32	O	a	a	a	DT	False
DDI-MedLine.d162.s2	placebo	34	40	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s2	has	42	44	O	has	has	has	VBZ	False
DDI-MedLine.d162.s2	real	46	49	O	real	eal	real	JJ	False
DDI-MedLine.d162.s2	psychobiological	51	66	O	psychobiological	cal	ical	JJ	False
DDI-MedLine.d162.s2	and	68	70	O	and	and	and	CC	False
DDI-MedLine.d162.s2	biological	72	81	O	biological	cal	ical	JJ	False
DDI-MedLine.d162.s2	effects	83	89	O	effects	cts	ects	NNS	False
DDI-MedLine.d162.s2	that	91	94	O	that	hat	that	IN	False
DDI-MedLine.d162.s2	are	96	98	O	are	are	are	VBP	False
DDI-MedLine.d162.s2	attributable	100	111	O	attributable	ble	able	JJ	False
DDI-MedLine.d162.s2	to	113	114	O	to	to	to	TO	False
DDI-MedLine.d162.s2	the	116	118	O	the	the	the	DT	False
DDI-MedLine.d162.s2	overall	120	126	O	overall	all	rall	JJ	False
DDI-MedLine.d162.s2	therapeutic	128	138	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d162.s2	context	140	146	O	context	ext	text	NN	False
DDI-MedLine.d162.s2	.	147	147	O	.	.	.	.	False

DDI-MedLine.d162.s3	Irritable	0	8	O	Irritable	ble	able	JJ	False
DDI-MedLine.d162.s3	bowel	10	14	O	bowel	wel	owel	NN	False
DDI-MedLine.d162.s3	syndrome	16	23	O	syndrome	ome	rome	NN	False
DDI-MedLine.d162.s3	(	25	25	O	(	(	(	(	False
DDI-MedLine.d162.s3	IBS	26	28	O	IBS	IBS	IBS	NN	brand
DDI-MedLine.d162.s3	)	29	29	O	)	)	)	)	False
DDI-MedLine.d162.s3	is	31	32	O	is	is	is	VBZ	False
DDI-MedLine.d162.s3	a	34	34	O	a	a	a	DT	False
DDI-MedLine.d162.s3	functional	36	45	O	functional	nal	onal	JJ	False
DDI-MedLine.d162.s3	disorder	47	54	O	disorder	der	rder	NN	False
DDI-MedLine.d162.s3	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d162.s3	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d162.s3	gastrointestinal	63	78	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d162.s3	tract	80	84	O	tract	act	ract	NN	False
DDI-MedLine.d162.s3	that	86	89	O	that	hat	that	IN	False
DDI-MedLine.d162.s3	shows	91	95	O	shows	ows	hows	NNS	False
DDI-MedLine.d162.s3	a	97	97	O	a	a	a	DT	False
DDI-MedLine.d162.s3	significant	99	109	O	significant	ant	cant	JJ	False
DDI-MedLine.d162.s3	placebo	111	117	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s3	response	119	126	O	response	nse	onse	NN	False
DDI-MedLine.d162.s3	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d162.s3	around	131	136	O	around	und	ound	IN	False
DDI-MedLine.d162.s3	40	138	139	O	40	40	40	CD	False
DDI-MedLine.d162.s3	50	143	144	O	50	50	50	CD	False
DDI-MedLine.d162.s3	%	145	145	O	%	%	%	NN	False
DDI-MedLine.d162.s3	among	147	151	O	among	ong	mong	IN	False
DDI-MedLine.d162.s3	different	153	161	O	different	ent	rent	JJ	False
DDI-MedLine.d162.s3	clinical	163	170	O	clinical	cal	ical	JJ	False
DDI-MedLine.d162.s3	trials.A	172	179	O	trials.A	s.A	ls.A	NN	False
DDI-MedLine.d162.s3	positive	181	188	O	positive	ive	tive	JJ	False
DDI-MedLine.d162.s3	patient-practitioner	190	209	O	patient-practitioner	ner	oner	NN	False
DDI-MedLine.d162.s3	relationship	211	222	O	relationship	hip	ship	NN	False
DDI-MedLine.d162.s3	can	224	226	O	can	can	can	MD	False
DDI-MedLine.d162.s3	enhance	228	234	O	enhance	nce	ance	NN	False
DDI-MedLine.d162.s3	the	236	238	O	the	the	the	DT	False
DDI-MedLine.d162.s3	placebo	240	246	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s3	effect	248	253	O	effect	ect	fect	NN	False
DDI-MedLine.d162.s3	in	255	256	O	in	in	in	IN	False
DDI-MedLine.d162.s3	IBS	258	260	O	IBS	IBS	IBS	NN	brand
DDI-MedLine.d162.s3	patients	262	269	O	patients	nts	ents	NNS	False
DDI-MedLine.d162.s3	.	270	270	O	.	.	.	.	False

DDI-MedLine.d162.s4	Emerging	0	7	O	Emerging	ing	ging	VBG	False
DDI-MedLine.d162.s4	literature	9	18	O	literature	ure	ture	NN	False
DDI-MedLine.d162.s4	using	20	24	O	using	ing	sing	VBG	False
DDI-MedLine.d162.s4	functional	26	35	O	functional	nal	onal	JJ	False
DDI-MedLine.d162.s4	brain	37	41	O	brain	ain	rain	NN	False
DDI-MedLine.d162.s4	imaging	43	49	O	imaging	ing	ging	VBG	False
DDI-MedLine.d162.s4	has	51	53	O	has	has	has	VBZ	False
DDI-MedLine.d162.s4	started	55	61	O	started	ted	rted	VBN	False
DDI-MedLine.d162.s4	to	63	64	O	to	to	to	TO	False
DDI-MedLine.d162.s4	document	66	73	O	document	ent	ment	NN	False
DDI-MedLine.d162.s4	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d162.s4	neuronal	79	86	O	neuronal	nal	onal	JJ	False
DDI-MedLine.d162.s4	changes	88	94	O	changes	ges	nges	NNS	False
DDI-MedLine.d162.s4	associated	96	105	O	associated	ted	ated	VBN	False
DDI-MedLine.d162.s4	with	107	110	O	with	ith	with	IN	False
DDI-MedLine.d162.s4	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d162.s4	placebo	116	122	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s4	phenomenon	124	133	O	phenomenon	non	enon	NN	False
DDI-MedLine.d162.s4	in	135	136	O	in	in	in	IN	False
DDI-MedLine.d162.s4	IBS	138	140	O	IBS	IBS	IBS	NN	brand
DDI-MedLine.d162.s4	patients	142	149	O	patients	nts	ents	NNS	False
DDI-MedLine.d162.s4	,	150	150	O	,	,	,	,	False
DDI-MedLine.d162.s4	showing	152	158	O	showing	ing	wing	VBG	False
DDI-MedLine.d162.s4	aberrant	160	167	O	aberrant	ant	rant	NN	False
DDI-MedLine.d162.s4	neural	169	174	O	neural	ral	ural	JJ	False
DDI-MedLine.d162.s4	network	176	182	O	network	ork	work	NN	False
DDI-MedLine.d162.s4	during	184	189	O	during	ing	ring	IN	False
DDI-MedLine.d162.s4	visceral	191	198	O	visceral	ral	eral	JJ	False
DDI-MedLine.d162.s4	placebo	200	206	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s4	analgesia	208	216	O	analgesia	sia	esia	NN	False
DDI-MedLine.d162.s4	when	218	221	O	when	hen	when	WRB	False
DDI-MedLine.d162.s4	compared	223	230	O	compared	red	ared	VBN	False
DDI-MedLine.d162.s4	to	232	233	O	to	to	to	TO	False
DDI-MedLine.d162.s4	controls	235	242	O	controls	ols	rols	NNS	False
DDI-MedLine.d162.s4	.	243	243	O	.	.	.	.	False

DDI-MedLine.d162.s5	Further	0	6	O	Further	her	ther	RB	False
DDI-MedLine.d162.s5	promotion	8	16	O	promotion	ion	tion	NN	False
DDI-MedLine.d162.s5	and	18	20	O	and	and	and	CC	False
DDI-MedLine.d162.s5	integration	22	32	O	integration	ion	tion	NN	False
DDI-MedLine.d162.s5	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d162.s5	laboratory	37	46	O	laboratory	ory	tory	NN	False
DDI-MedLine.d162.s5	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d162.s5	clinical	52	59	O	clinical	cal	ical	JJ	False
DDI-MedLine.d162.s5	research	61	68	O	research	rch	arch	NN	False
DDI-MedLine.d162.s5	are	70	72	O	are	are	are	VBP	False
DDI-MedLine.d162.s5	encouraged	74	83	O	encouraged	ged	aged	VBN	False
DDI-MedLine.d162.s5	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d162.s5	advance	88	94	O	advance	nce	ance	NN	False
DDI-MedLine.d162.s5	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d162.s5	understanding	100	112	O	understanding	ing	ding	VBG	False
DDI-MedLine.d162.s5	of	114	115	O	of	of	of	IN	False
DDI-MedLine.d162.s5	placebo	117	123	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d162.s5	mechanisms	125	134	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d162.s5	in	136	137	O	in	in	in	IN	False
DDI-MedLine.d162.s5	IBS	139	141	O	IBS	IBS	IBS	NN	brand
DDI-MedLine.d162.s5	patients	143	150	O	patients	nts	ents	NNS	False
DDI-MedLine.d162.s5	.	151	151	O	.	.	.	.	False

DDI-MedLine.d174.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d174.s0	Cyclooxygenase	1	14	B-group	Cyclooxygenase	ase	nase	NN	False
DDI-MedLine.d174.s0	inhibitors	16	25	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d174.s0	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d174.s0	antiplatelet	31	42	O	antiplatelet	let	elet	NN	False
DDI-MedLine.d174.s0	effect	44	49	O	effect	ect	fect	NN	False
DDI-MedLine.d174.s0	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d174.s0	acetylsalicylic	54	68	B-drug	acetylsalicylic	lic	ylic	NN	False
DDI-MedLine.d174.s0	acid	70	73	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d174.s0	.	74	74	O	.	.	.	.	False
DDI-MedLine.d174.s0	selective	76	84	O	selective	ive	tive	NN	False
DDI-MedLine.d174.s0	approach	86	93	O	approach	ach	oach	NN	False
DDI-MedLine.d174.s0	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d174.s0	nonsteroidal	98	109	B-group	nonsteroidal	dal	idal	NN	False
DDI-MedLine.d174.s0	anti-inflammatory	111	127	I-group	anti-inflammatory	ory	tory	NN	False
DDI-MedLine.d174.s0	drugs	129	133	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d174.s0	in	135	136	O	in	in	in	IN	False
DDI-MedLine.d174.s0	cardiological	138	150	O	cardiological	cal	ical	JJ	False
DDI-MedLine.d174.s0	practice	152	159	O	practice	ice	tice	NN	False
DDI-MedLine.d174.s0	]	160	160	O	]	]	]	NN	False
DDI-MedLine.d174.s0	.	161	161	O	.	.	.	.	False

DDI-MedLine.d174.s1	Nonsteroidal	0	11	B-group	Nonsteroidal	dal	idal	NN	False
DDI-MedLine.d174.s1	anti-inflammatory	13	29	I-group	anti-inflammatory	ory	tory	NN	False
DDI-MedLine.d174.s1	drugs	31	35	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d174.s1	(	37	37	O	(	(	(	(	False
DDI-MedLine.d174.s1	NSAIDs	38	43	B-group	NSAIDs	IDs	AIDs	NN	False
DDI-MedLine.d174.s1	)	44	44	O	)	)	)	)	False
DDI-MedLine.d174.s1	represent	46	54	O	represent	ent	sent	NN	False
DDI-MedLine.d174.s1	class	56	60	O	class	ass	lass	NN	False
DDI-MedLine.d174.s1	of	62	63	O	of	of	of	IN	False
DDI-MedLine.d174.s1	medicines	65	73	O	medicines	nes	ines	NNS	group
DDI-MedLine.d174.s1	which	75	79	O	which	ich	hich	WDT	False
DDI-MedLine.d174.s1	is	81	82	O	is	is	is	VBZ	False
DDI-MedLine.d174.s1	wide	84	87	O	wide	ide	wide	JJ	False
DDI-MedLine.d174.s1	concerning	89	98	O	concerning	ing	ning	VBG	False
DDI-MedLine.d174.s1	chemical	100	107	O	chemical	cal	ical	NN	False
DDI-MedLine.d174.s1	structure	109	117	O	structure	ure	ture	NN	False
DDI-MedLine.d174.s1	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d174.s1	mechanism	123	131	O	mechanism	ism	nism	NN	False
DDI-MedLine.d174.s1	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d174.s1	action	136	141	O	action	ion	tion	NN	False
DDI-MedLine.d174.s1	.	142	142	O	.	.	.	.	False

DDI-MedLine.d174.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d174.s2	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d174.s2	light	7	11	O	light	ght	ight	NN	False
DDI-MedLine.d174.s2	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d174.s2	contradictory	16	28	O	contradictory	ory	tory	NN	False
DDI-MedLine.d174.s2	data	30	33	O	data	ata	data	NNS	False
DDI-MedLine.d174.s2	on	35	36	O	on	on	on	IN	False
DDI-MedLine.d174.s2	efficacy	38	45	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d174.s2	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d174.s2	safety	51	56	O	safety	ety	fety	NN	False
DDI-MedLine.d174.s2	of	58	59	O	of	of	of	IN	False
DDI-MedLine.d174.s2	NSAID	61	65	B-group	NSAID	AID	SAID	NN	brand
DDI-MedLine.d174.s2	in	67	68	O	in	in	in	IN	False
DDI-MedLine.d174.s2	cardiovascular	70	83	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d174.s2	patients	85	92	O	patients	nts	ents	NNS	False
DDI-MedLine.d174.s2	selection	94	102	O	selection	ion	tion	NN	False
DDI-MedLine.d174.s2	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d174.s2	most	107	110	O	most	ost	most	JJS	False
DDI-MedLine.d174.s2	appropriate	112	122	O	appropriate	ate	iate	NN	False
DDI-MedLine.d174.s2	NSAID	124	128	B-group	NSAID	AID	SAID	NN	brand
DDI-MedLine.d174.s2	(	130	130	O	(	(	(	(	False
DDI-MedLine.d174.s2	basing	131	136	O	basing	ing	sing	VBG	False
DDI-MedLine.d174.s2	on	138	139	O	on	on	on	IN	False
DDI-MedLine.d174.s2	profile	141	147	O	profile	ile	file	NN	False
DDI-MedLine.d174.s2	of	149	150	O	of	of	of	IN	False
DDI-MedLine.d174.s2	efficacy	152	159	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d174.s2	and	161	163	O	and	and	and	CC	False
DDI-MedLine.d174.s2	safety	165	170	O	safety	ety	fety	NN	False
DDI-MedLine.d174.s2	)	171	171	O	)	)	)	)	False
DDI-MedLine.d174.s2	in	173	174	O	in	in	in	IN	False
DDI-MedLine.d174.s2	patients	176	183	O	patients	nts	ents	NNS	False
DDI-MedLine.d174.s2	receiving	185	193	O	receiving	ing	ving	VBG	False
DDI-MedLine.d174.s2	continuous	195	204	O	continuous	ous	uous	JJ	False
DDI-MedLine.d174.s2	therapy	206	212	O	therapy	apy	rapy	NN	False
DDI-MedLine.d174.s2	with	214	217	O	with	ith	with	IN	False
DDI-MedLine.d174.s2	low	219	221	O	low	low	low	JJ	False
DDI-MedLine.d174.s2	dose	223	226	O	dose	ose	dose	NN	False
DDI-MedLine.d174.s2	aspirin	228	234	B-brand	aspirin	rin	irin	NN	False
DDI-MedLine.d174.s2	appears	236	242	O	appears	ars	ears	VBZ	False
DDI-MedLine.d174.s2	to	244	245	O	to	to	to	TO	False
DDI-MedLine.d174.s2	be	247	248	O	be	be	be	VB	False
DDI-MedLine.d174.s2	a	250	250	O	a	a	a	DT	False
DDI-MedLine.d174.s2	problem	252	258	O	problem	lem	blem	NN	False
DDI-MedLine.d174.s2	.	259	259	O	.	.	.	.	False

DDI-MedLine.d174.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d174.s3	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d174.s3	paper	8	12	O	paper	per	aper	NN	False
DDI-MedLine.d174.s3	we	14	15	O	we	we	we	PRP	False
DDI-MedLine.d174.s3	discuss	17	23	O	discuss	uss	cuss	NN	False
DDI-MedLine.d174.s3	peculiarities	25	37	O	peculiarities	ies	ties	NNS	False
DDI-MedLine.d174.s3	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d174.s3	drug	42	45	O	drug	rug	drug	NN	False
DDI-MedLine.d174.s3	interaction	47	57	O	interaction	ion	tion	NN	False
DDI-MedLine.d174.s3	between	59	65	O	between	een	ween	IN	False
DDI-MedLine.d174.s3	cyclooxygenase	67	80	B-group	cyclooxygenase	ase	nase	NN	False
DDI-MedLine.d174.s3	inhibitors	82	91	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d174.s3	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d174.s3	acetylsalicylic	97	111	B-drug	acetylsalicylic	lic	ylic	NN	False
DDI-MedLine.d174.s3	acid	113	116	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d174.s3	,	117	117	O	,	,	,	,	False
DDI-MedLine.d174.s3	and	119	121	O	and	and	and	CC	False
DDI-MedLine.d174.s3	principles	123	132	O	principles	les	ples	NNS	False
DDI-MedLine.d174.s3	of	134	135	O	of	of	of	IN	False
DDI-MedLine.d174.s3	selection	137	145	O	selection	ion	tion	NN	False
DDI-MedLine.d174.s3	of	147	148	O	of	of	of	IN	False
DDI-MedLine.d174.s3	adequate	150	157	O	adequate	ate	uate	NN	False
DDI-MedLine.d174.s3	NSAI	159	162	B-group	NSAI	SAI	NSAI	NN	brand
DDI-MedLine.d174.s3	.	163	163	O	.	.	.	.	False

DDI-MedLine.d197.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d197.s0	Vitamin	1	7	B-group	Vitamin	min	amin	NN	False
DDI-MedLine.d197.s0	D	9	9	I-group	D	D	D	NN	brand
DDI-MedLine.d197.s0	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d197.s0	drugs	15	19	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s0	]	20	20	O	]	]	]	NN	False
DDI-MedLine.d197.s0	.	21	21	O	.	.	.	.	False
DDI-MedLine.d197.s0	;	22	22	O	;	;	;	:	False

DDI-MedLine.d197.s1	Interactions	0	11	O	Interactions	ons	ions	NNS	False
DDI-MedLine.d197.s1	between	13	19	O	between	een	ween	IN	False
DDI-MedLine.d197.s1	drugs	21	25	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s1	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d197.s1	vitamin	31	37	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d197.s1	D	39	39	I-group	D	D	D	NN	brand
DDI-MedLine.d197.s1	have	41	44	O	have	ave	have	VB	False
DDI-MedLine.d197.s1	received	46	53	O	received	ved	ived	VBN	False
DDI-MedLine.d197.s1	only	55	58	O	only	nly	only	RB	False
DDI-MedLine.d197.s1	little	60	65	O	little	tle	ttle	JJ	False
DDI-MedLine.d197.s1	or	67	68	O	or	or	or	CC	False
DDI-MedLine.d197.s1	no	70	71	O	no	no	no	DT	False
DDI-MedLine.d197.s1	attention	73	81	O	attention	ion	tion	NN	False
DDI-MedLine.d197.s1	in	83	84	O	in	in	in	IN	False
DDI-MedLine.d197.s1	the	86	88	O	the	the	the	DT	False
DDI-MedLine.d197.s1	medical	90	96	O	medical	cal	ical	JJ	False
DDI-MedLine.d197.s1	and	98	100	O	and	and	and	CC	False
DDI-MedLine.d197.s1	pharmaceutical	102	115	O	pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d197.s1	world	117	121	O	world	rld	orld	NN	False
DDI-MedLine.d197.s1	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d197.s1	the	126	128	O	the	the	the	DT	False
DDI-MedLine.d197.s1	past	130	133	O	past	ast	past	NN	False
DDI-MedLine.d197.s1	.	134	134	O	.	.	.	.	False

DDI-MedLine.d197.s2	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d197.s2	more	6	9	O	more	ore	more	RBR	False
DDI-MedLine.d197.s2	and	11	13	O	and	and	and	CC	False
DDI-MedLine.d197.s2	more	15	18	O	more	ore	more	RBR	False
DDI-MedLine.d197.s2	drugs	20	24	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s2	are	26	28	O	are	are	are	VBP	False
DDI-MedLine.d197.s2	used	30	33	O	used	sed	used	VBN	False
DDI-MedLine.d197.s2	for	35	37	O	for	for	for	IN	False
DDI-MedLine.d197.s2	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d197.s2	treatment	43	51	O	treatment	ent	ment	NN	False
DDI-MedLine.d197.s2	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d197.s2	patients	56	63	O	patients	nts	ents	NNS	False
DDI-MedLine.d197.s2	,	64	64	O	,	,	,	,	False
DDI-MedLine.d197.s2	this	66	69	O	this	his	this	DT	False
DDI-MedLine.d197.s2	topic	71	75	O	topic	pic	opic	NN	False
DDI-MedLine.d197.s2	is	77	78	O	is	is	is	VBZ	False
DDI-MedLine.d197.s2	increasingly	80	91	O	increasingly	gly	ngly	RB	False
DDI-MedLine.d197.s2	relevant	93	100	O	relevant	ant	vant	NN	False
DDI-MedLine.d197.s2	.	101	101	O	.	.	.	.	False

DDI-MedLine.d197.s3	As	0	1	O	As	As	As	IN	False
DDI-MedLine.d197.s3	such	3	6	O	such	uch	such	JJ	False
DDI-MedLine.d197.s3	interactions	8	19	O	interactions	ons	ions	NNS	False
DDI-MedLine.d197.s3	impact	21	26	O	impact	act	pact	NN	False
DDI-MedLine.d197.s3	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d197.s3	health	32	37	O	health	lth	alth	NN	False
DDI-MedLine.d197.s3	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d197.s3	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d197.s3	patient	46	52	O	patient	ent	ient	NN	False
DDI-MedLine.d197.s3	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d197.s3	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d197.s3	action	62	67	O	action	ion	tion	NN	False
DDI-MedLine.d197.s3	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d197.s3	side	73	76	O	side	ide	side	NN	False
DDI-MedLine.d197.s3	effects	78	84	O	effects	cts	ects	NNS	False
DDI-MedLine.d197.s3	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d197.s3	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d197.s3	drug	93	96	O	drug	rug	drug	NN	False
DDI-MedLine.d197.s3	,	97	97	O	,	,	,	,	False
DDI-MedLine.d197.s3	physicians	99	108	O	physicians	ans	ians	NNS	False
DDI-MedLine.d197.s3	and	110	112	O	and	and	and	CC	False
DDI-MedLine.d197.s3	pharmacists	114	124	O	pharmacists	sts	ists	NNS	False
DDI-MedLine.d197.s3	should	126	131	O	should	uld	ould	MD	False
DDI-MedLine.d197.s3	pay	133	135	O	pay	pay	pay	NN	False
DDI-MedLine.d197.s3	more	137	140	O	more	ore	more	RBR	False
DDI-MedLine.d197.s3	attention	142	150	O	attention	ion	tion	NN	False
DDI-MedLine.d197.s3	to	152	153	O	to	to	to	TO	False
DDI-MedLine.d197.s3	such	155	158	O	such	uch	such	JJ	False
DDI-MedLine.d197.s3	interactions	160	171	O	interactions	ons	ions	NNS	False
DDI-MedLine.d197.s3	in	173	174	O	in	in	in	IN	False
DDI-MedLine.d197.s3	the	176	178	O	the	the	the	DT	False
DDI-MedLine.d197.s3	future	180	185	O	future	ure	ture	NN	False
DDI-MedLine.d197.s3	.	186	186	O	.	.	.	.	False

DDI-MedLine.d197.s4	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d197.s4	number	2	7	O	number	ber	mber	NN	False
DDI-MedLine.d197.s4	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d197.s4	drugs	12	16	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s4	can	18	20	O	can	can	can	MD	False
DDI-MedLine.d197.s4	interfere	22	30	O	interfere	ere	fere	RB	False
DDI-MedLine.d197.s4	with	32	35	O	with	ith	with	IN	False
DDI-MedLine.d197.s4	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d197.s4	vitamin	41	47	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d197.s4	D	49	49	I-group	D	D	D	NN	brand
DDI-MedLine.d197.s4	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d197.s4	bone	55	58	O	bone	one	bone	NN	False
DDI-MedLine.d197.s4	metabolism	60	69	O	metabolism	ism	lism	NN	False
DDI-MedLine.d197.s4	.	70	70	O	.	.	.	.	False

DDI-MedLine.d197.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d197.s5	drug-induced	4	15	O	drug-induced	ced	uced	JJ	False
DDI-MedLine.d197.s5	activation	17	26	O	activation	ion	tion	NN	False
DDI-MedLine.d197.s5	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d197.s5	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d197.s5	pregnane	35	42	O	pregnane	ane	nane	NN	False
DDI-MedLine.d197.s5	X	44	44	O	X	X	X	NN	brand
DDI-MedLine.d197.s5	receptor	46	53	O	receptor	tor	ptor	NN	False
DDI-MedLine.d197.s5	(	55	55	O	(	(	(	(	False
DDI-MedLine.d197.s5	PXR	56	58	O	PXR	PXR	PXR	NN	brand
DDI-MedLine.d197.s5	)	59	59	O	)	)	)	)	False
DDI-MedLine.d197.s5	is	61	62	O	is	is	is	VBZ	False
DDI-MedLine.d197.s5	likely	64	69	O	likely	ely	kely	JJ	False
DDI-MedLine.d197.s5	to	71	72	O	to	to	to	TO	False
DDI-MedLine.d197.s5	enhance	74	80	O	enhance	nce	ance	NN	False
DDI-MedLine.d197.s5	CYP24	82	86	O	CYP24	P24	YP24	NN	brand
DDI-MedLine.d197.s5	expression	88	97	O	expression	ion	sion	NN	False
DDI-MedLine.d197.s5	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d197.s5	the	103	105	O	the	the	the	DT	False
DDI-MedLine.d197.s5	catabolism	107	116	O	catabolism	ism	lism	NN	False
DDI-MedLine.d197.s5	of	118	119	O	of	of	of	IN	False
DDI-MedLine.d197.s5	25	121	122	O	25	25	25	CD	False
DDI-MedLine.d197.s5	(	123	123	O	(	(	(	(	False
DDI-MedLine.d197.s5	OH	124	125	O	OH	OH	OH	UH	brand
DDI-MedLine.d197.s5	)	126	126	O	)	)	)	)	False
DDI-MedLine.d197.s5	D	127	127	O	D	D	D	NN	brand
DDI-MedLine.d197.s5	,	128	128	O	,	,	,	,	False
DDI-MedLine.d197.s5	leading	130	136	O	leading	ing	ding	VBG	False
DDI-MedLine.d197.s5	to	138	139	O	to	to	to	TO	False
DDI-MedLine.d197.s5	vitamin	141	147	O	vitamin	min	amin	NN	False
DDI-MedLine.d197.s5	D	149	149	O	D	D	D	NN	brand
DDI-MedLine.d197.s5	deficiency	151	160	O	deficiency	ncy	ency	NN	False
DDI-MedLine.d197.s5	.	161	161	O	.	.	.	.	False

DDI-MedLine.d197.s6	PXR-ligands	0	10	O	PXR-ligands	nds	ands	NNS	False
DDI-MedLine.d197.s6	include	12	18	O	include	ude	lude	NN	False
DDI-MedLine.d197.s6	a	20	20	O	a	a	a	DT	False
DDI-MedLine.d197.s6	wide	22	25	O	wide	ide	wide	JJ	False
DDI-MedLine.d197.s6	variety	27	33	O	variety	ety	iety	NN	False
DDI-MedLine.d197.s6	of	35	36	O	of	of	of	IN	False
DDI-MedLine.d197.s6	pharmaceutical	38	51	O	pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d197.s6	agents	53	58	O	agents	nts	ents	NNS	False
DDI-MedLine.d197.s6	,	59	59	O	,	,	,	,	False
DDI-MedLine.d197.s6	such	61	64	O	such	uch	such	JJ	False
DDI-MedLine.d197.s6	as	66	67	O	as	as	as	IN	False
DDI-MedLine.d197.s6	antiepileptic	69	81	B-group	antiepileptic	tic	ptic	JJ	False
DDI-MedLine.d197.s6	drugs	83	87	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s6	,	88	88	O	,	,	,	,	False
DDI-MedLine.d197.s6	taxol	90	94	B-brand	taxol	xol	axol	NN	False
DDI-MedLine.d197.s6	,	95	95	O	,	,	,	,	False
DDI-MedLine.d197.s6	rifampicin	97	106	B-drug	rifampicin	cin	icin	NN	drug
DDI-MedLine.d197.s6	,	107	107	O	,	,	,	,	False
DDI-MedLine.d197.s6	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d197.s6	human	113	117	B-group	human	man	uman	NN	False
DDI-MedLine.d197.s6	immunodeficiency	119	134	I-group	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d197.s6	virus	136	140	I-group	virus	rus	irus	NN	False
DDI-MedLine.d197.s6	protease	142	149	I-group	protease	ase	ease	NN	False
DDI-MedLine.d197.s6	inhibitors	151	160	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d197.s6	such	162	165	O	such	uch	such	JJ	False
DDI-MedLine.d197.s6	as	167	168	O	as	as	as	IN	False
DDI-MedLine.d197.s6	ritonavir	170	178	B-drug	ritonavir	vir	avir	NN	False
DDI-MedLine.d197.s6	and	180	182	O	and	and	and	CC	False
DDI-MedLine.d197.s6	saquinavir	184	193	B-drug	saquinavir	vir	avir	NN	False
DDI-MedLine.d197.s6	.	194	194	O	.	.	.	.	False

DDI-MedLine.d197.s7	Beside	0	5	O	Beside	ide	side	IN	False
DDI-MedLine.d197.s7	this	7	10	O	this	his	this	DT	False
DDI-MedLine.d197.s7	,	11	11	O	,	,	,	,	False
DDI-MedLine.d197.s7	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d197.s7	medication	17	26	O	medication	ion	tion	NN	False
DDI-MedLine.d197.s7	oriented	28	35	O	oriented	ted	nted	VBN	False
DDI-MedLine.d197.s7	supplementation	37	51	O	supplementation	ion	tion	NN	False
DDI-MedLine.d197.s7	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d197.s7	vitamin	56	62	B-group	vitamin	min	amin	NN	False
DDI-MedLine.d197.s7	D	64	64	I-group	D	D	D	NN	brand
DDI-MedLine.d197.s7	can	66	68	O	can	can	can	MD	False
DDI-MedLine.d197.s7	also	70	73	O	also	lso	also	RB	False
DDI-MedLine.d197.s7	ameliorate	75	84	O	ameliorate	ate	rate	NN	False
DDI-MedLine.d197.s7	the	86	88	O	the	the	the	DT	False
DDI-MedLine.d197.s7	pharmacologic	90	102	O	pharmacologic	gic	ogic	NN	False
DDI-MedLine.d197.s7	action	104	109	O	action	ion	tion	NN	False
DDI-MedLine.d197.s7	of	111	112	O	of	of	of	IN	False
DDI-MedLine.d197.s7	many	114	117	O	many	any	many	JJ	False
DDI-MedLine.d197.s7	drugs	119	123	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s7	,	124	124	O	,	,	,	,	False
DDI-MedLine.d197.s7	such	126	129	O	such	uch	such	JJ	False
DDI-MedLine.d197.s7	as	131	132	O	as	as	as	IN	False
DDI-MedLine.d197.s7	bisphosphonates	134	148	B-group	bisphosphonates	tes	ates	NNS	False
DDI-MedLine.d197.s7	,	149	149	O	,	,	,	,	False
DDI-MedLine.d197.s7	statins	151	157	B-group	statins	ins	tins	NNS	False
DDI-MedLine.d197.s7	and	159	161	O	and	and	and	CC	False
DDI-MedLine.d197.s7	cytostatic	163	172	B-group	cytostatic	tic	atic	JJ	False
DDI-MedLine.d197.s7	drugs	174	178	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d197.s7	.	179	179	O	.	.	.	.	False

DDI-MedLine.d151.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d151.s0	Seniors	1	7	O	Seniors	ors	iors	NNS	False
DDI-MedLine.d151.s0	and	9	11	O	and	and	and	CC	False
DDI-MedLine.d151.s0	cardiovascular	13	26	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d151.s0	medications	28	38	O	medications	ons	ions	NNS	False
DDI-MedLine.d151.s0	]	39	39	O	]	]	]	NN	False
DDI-MedLine.d151.s0	.	40	40	O	.	.	.	.	False

DDI-MedLine.d151.s1	Authors	0	6	O	Authors	ors	hors	NNS	False
DDI-MedLine.d151.s1	analyze	8	14	O	analyze	yze	lyze	NN	False
DDI-MedLine.d151.s1	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d151.s1	situation	20	28	O	situation	ion	tion	NN	False
DDI-MedLine.d151.s1	in	30	31	O	in	in	in	IN	False
DDI-MedLine.d151.s1	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d151.s1	therapy	37	43	O	therapy	apy	rapy	NN	False
DDI-MedLine.d151.s1	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d151.s1	cardiovascular	48	61	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d151.s1	diseases	63	70	O	diseases	ses	ases	NNS	False
DDI-MedLine.d151.s1	--	71	72	O	--	--	--	:	False
DDI-MedLine.d151.s1	unsatisfactory	73	86	O	unsatisfactory	ory	tory	NN	False
DDI-MedLine.d151.s1	situation	88	96	O	situation	ion	tion	NN	False
DDI-MedLine.d151.s1	especially	98	107	O	especially	lly	ally	RB	False
DDI-MedLine.d151.s1	from	109	112	O	from	rom	from	IN	False
DDI-MedLine.d151.s1	the	114	116	O	the	the	the	DT	False
DDI-MedLine.d151.s1	dyslipidaemia	118	130	O	dyslipidaemia	mia	emia	NN	False
DDI-MedLine.d151.s1	point	132	136	O	point	int	oint	NN	False
DDI-MedLine.d151.s1	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d151.s1	view	141	144	O	view	iew	view	NN	False
DDI-MedLine.d151.s1	.	145	145	O	.	.	.	.	False

DDI-MedLine.d151.s2	Different	0	8	O	Different	ent	rent	NN	False
DDI-MedLine.d151.s2	groups	10	15	O	groups	ups	oups	NNS	False
DDI-MedLine.d151.s2	of	17	18	O	of	of	of	IN	False
DDI-MedLine.d151.s2	medications	20	30	O	medications	ons	ions	NNS	False
DDI-MedLine.d151.s2	are	32	34	O	are	are	are	VBP	False
DDI-MedLine.d151.s2	discussed	36	44	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d151.s2	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d151.s2	their	50	54	O	their	eir	heir	PRP$	False
DDI-MedLine.d151.s2	risks	56	60	O	risks	sks	isks	NNS	False
DDI-MedLine.d151.s2	for	62	64	O	for	for	for	IN	False
DDI-MedLine.d151.s2	elderly	66	72	O	elderly	rly	erly	RB	False
DDI-MedLine.d151.s2	patients	74	81	O	patients	nts	ents	NNS	False
DDI-MedLine.d151.s2	.	82	82	O	.	.	.	.	False

DDI-MedLine.d151.s3	Angiotensin	0	10	B-group	Angiotensin	sin	nsin	NN	False
DDI-MedLine.d151.s3	converting	12	21	I-group	converting	ing	ting	VBG	False
DDI-MedLine.d151.s3	enzyme	23	28	I-group	enzyme	yme	zyme	NN	False
DDI-MedLine.d151.s3	blockers	30	37	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d151.s3	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d151.s3	their	43	47	O	their	eir	heir	PRP$	False
DDI-MedLine.d151.s3	influence	49	57	O	influence	nce	ence	NN	False
DDI-MedLine.d151.s3	on	59	60	O	on	on	on	IN	False
DDI-MedLine.d151.s3	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d151.s3	endothelial	66	76	O	endothelial	ial	lial	JJ	False
DDI-MedLine.d151.s3	dysfunction	78	88	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d151.s3	,	89	89	O	,	,	,	,	False
DDI-MedLine.d151.s3	but	91	93	O	but	but	but	CC	False
DDI-MedLine.d151.s3	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d151.s3	risk	99	102	O	risk	isk	risk	NN	False
DDI-MedLine.d151.s3	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d151.s3	hyperpotassemia	107	121	O	hyperpotassemia	mia	emia	NN	False
DDI-MedLine.d151.s3	are	123	125	O	are	are	are	VBP	False
DDI-MedLine.d151.s3	showed	127	132	O	showed	wed	owed	VBD	False
DDI-MedLine.d151.s3	.	133	133	O	.	.	.	.	False

DDI-MedLine.d151.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d151.s4	risk	4	7	O	risk	isk	risk	NN	False
DDI-MedLine.d151.s4	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d151.s4	gastrointestinal	12	27	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d151.s4	bleeding	29	36	O	bleeding	ing	ding	NN	False
DDI-MedLine.d151.s4	during	38	43	O	during	ing	ring	IN	False
DDI-MedLine.d151.s4	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d151.s4	treatment	49	57	O	treatment	ent	ment	NN	False
DDI-MedLine.d151.s4	with	59	62	O	with	ith	with	IN	False
DDI-MedLine.d151.s4	antiagregants	64	76	B-group	antiagregants	nts	ants	NNS	False
DDI-MedLine.d151.s4	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d151.s4	anticoagulants	82	95	B-group	anticoagulants	nts	ants	NNS	False
DDI-MedLine.d151.s4	,	96	96	O	,	,	,	,	False
DDI-MedLine.d151.s4	the	98	100	O	the	the	the	DT	False
DDI-MedLine.d151.s4	risk	102	105	O	risk	isk	risk	NN	False
DDI-MedLine.d151.s4	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d151.s4	bradycardia	110	120	O	bradycardia	dia	rdia	NN	False
DDI-MedLine.d151.s4	in	122	123	O	in	in	in	IN	False
DDI-MedLine.d151.s4	beta-blockade	125	137	O	beta-blockade	ade	kade	NN	False
DDI-MedLine.d151.s4	,	138	138	O	,	,	,	,	False
DDI-MedLine.d151.s4	possible	140	147	O	possible	ble	ible	JJ	False
DDI-MedLine.d151.s4	interactions	149	160	O	interactions	ons	ions	NNS	False
DDI-MedLine.d151.s4	with	162	165	O	with	ith	with	IN	False
DDI-MedLine.d151.s4	other	167	171	O	other	her	ther	JJ	False
DDI-MedLine.d151.s4	medications	173	183	O	medications	ons	ions	NNS	False
DDI-MedLine.d151.s4	lowering	185	192	O	lowering	ing	ring	VBG	False
DDI-MedLine.d151.s4	the	194	196	O	the	the	the	DT	False
DDI-MedLine.d151.s4	heart	198	202	O	heart	art	eart	NN	False
DDI-MedLine.d151.s4	rate	204	207	O	rate	ate	rate	NN	False
DDI-MedLine.d151.s4	are	209	211	O	are	are	are	VBP	False
DDI-MedLine.d151.s4	discussed	213	221	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d151.s4	.	222	222	O	.	.	.	.	False

DDI-MedLine.d151.s5	Attention	0	8	O	Attention	ion	tion	NN	False
DDI-MedLine.d151.s5	is	10	11	O	is	is	is	VBZ	False
DDI-MedLine.d151.s5	paid	13	16	O	paid	aid	paid	NN	False
DDI-MedLine.d151.s5	to	18	19	O	to	to	to	TO	False
DDI-MedLine.d151.s5	calcium	21	27	B-group	calcium	ium	cium	NN	drug
DDI-MedLine.d151.s5	channel	29	35	I-group	channel	nel	nnel	NNS	False
DDI-MedLine.d151.s5	blockers	37	44	I-group	blockers	ers	kers	NNS	False
DDI-MedLine.d151.s5	,	45	45	O	,	,	,	,	False
DDI-MedLine.d151.s5	diuretics	47	55	B-group	diuretics	ics	tics	NNS	False
DDI-MedLine.d151.s5	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d151.s5	digoxin	61	67	B-drug	digoxin	xin	oxin	NN	False
DDI-MedLine.d151.s5	.	68	68	O	.	.	.	.	False

DDI-MedLine.d151.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d151.s6	table	4	8	O	table	ble	able	NN	False
DDI-MedLine.d151.s6	containing	10	19	O	containing	ing	ning	VBG	False
DDI-MedLine.d151.s6	possible	21	28	O	possible	ble	ible	JJ	False
DDI-MedLine.d151.s6	clinical	30	37	O	clinical	cal	ical	JJ	False
DDI-MedLine.d151.s6	symptoms	39	46	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d151.s6	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d151.s6	unwanted	51	58	O	unwanted	ted	nted	JJ	False
DDI-MedLine.d151.s6	side	60	63	O	side	ide	side	NN	False
DDI-MedLine.d151.s6	effect	65	70	O	effect	ect	fect	NN	False
DDI-MedLine.d151.s6	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d151.s6	most	75	78	O	most	ost	most	JJS	False
DDI-MedLine.d151.s6	frequently	80	89	O	frequently	tly	ntly	RB	False
DDI-MedLine.d151.s6	used	91	94	O	used	sed	used	VBN	False
DDI-MedLine.d151.s6	cardiovascular	96	109	O	cardiovascular	lar	ular	NN	False
DDI-MedLine.d151.s6	medications	111	121	O	medications	ons	ions	NNS	False
DDI-MedLine.d151.s6	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d151.s6	elderly	126	132	O	elderly	rly	erly	RB	False
DDI-MedLine.d151.s6	is	134	135	O	is	is	is	VBZ	False
DDI-MedLine.d151.s6	added	137	141	O	added	ded	dded	VBD	False
DDI-MedLine.d151.s6	as	143	144	O	as	as	as	IN	False
DDI-MedLine.d151.s6	the	146	148	O	the	the	the	DT	False
DDI-MedLine.d151.s6	conclusion	150	159	O	conclusion	ion	sion	NN	False
DDI-MedLine.d151.s6	of	161	162	O	of	of	of	IN	False
DDI-MedLine.d151.s6	the	164	166	O	the	the	the	DT	False
DDI-MedLine.d151.s6	article	168	174	O	article	cle	icle	NN	False
DDI-MedLine.d151.s6	.	175	175	O	.	.	.	.	False

DDI-MedLine.d142.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d142.s0	Effects	1	7	O	Effects	cts	ects	NNS	False
DDI-MedLine.d142.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d142.s0	glycyrrhiza	12	22	B-drug_n	glycyrrhiza	iza	hiza	NN	False
DDI-MedLine.d142.s0	extract	24	30	I-drug_n	extract	act	ract	NN	False
DDI-MedLine.d142.s0	on	32	33	O	on	on	on	IN	False
DDI-MedLine.d142.s0	pharmacokinetics	35	50	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d142.s0	property	52	59	O	property	rty	erty	NN	False
DDI-MedLine.d142.s0	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d142.s0	daphnetin	64	72	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s0	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d142.s0	rats	77	80	O	rats	ats	rats	NNS	False
DDI-MedLine.d142.s0	]	81	81	O	]	]	]	NN	False
DDI-MedLine.d142.s0	.	82	82	O	.	.	.	.	False

DDI-MedLine.d142.s1	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d142.s1	research	3	10	O	research	rch	arch	NN	False
DDI-MedLine.d142.s1	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d142.s1	influence	16	24	O	influence	nce	ence	NN	False
DDI-MedLine.d142.s1	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d142.s1	glycyrrhiza	29	39	B-drug_n	glycyrrhiza	iza	hiza	NN	False
DDI-MedLine.d142.s1	extract	41	47	I-drug_n	extract	act	ract	NN	False
DDI-MedLine.d142.s1	on	49	50	O	on	on	on	IN	False
DDI-MedLine.d142.s1	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d142.s1	pharmacokinetics	56	71	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d142.s1	characteristic	73	86	O	characteristic	tic	stic	JJ	False
DDI-MedLine.d142.s1	parameters	88	97	O	parameters	ers	ters	NNS	False
DDI-MedLine.d142.s1	of	99	100	O	of	of	of	IN	False
DDI-MedLine.d142.s1	daphnetin	102	110	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s1	,	111	111	O	,	,	,	,	False
DDI-MedLine.d142.s1	which	113	117	O	which	ich	hich	WDT	False
DDI-MedLine.d142.s1	was	119	121	O	was	was	was	VBD	False
DDI-MedLine.d142.s1	aimed	123	127	O	aimed	med	imed	VBN	False
DDI-MedLine.d142.s1	to	129	130	O	to	to	to	TO	False
DDI-MedLine.d142.s1	explore	132	138	O	explore	ore	lore	NN	False
DDI-MedLine.d142.s1	the	140	142	O	the	the	the	DT	False
DDI-MedLine.d142.s1	rationality	144	154	O	rationality	ity	lity	NN	False
DDI-MedLine.d142.s1	of	156	157	O	of	of	of	IN	False
DDI-MedLine.d142.s1	concert	159	165	O	concert	ert	cert	NN	False
DDI-MedLine.d142.s1	application	167	177	O	application	ion	tion	NN	False
DDI-MedLine.d142.s1	of	179	180	O	of	of	of	IN	False
DDI-MedLine.d142.s1	drugs	182	186	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d142.s1	.	187	187	O	.	.	.	.	False

DDI-MedLine.d142.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d142.s2	rats	4	7	O	rats	ats	rats	NNS	False
DDI-MedLine.d142.s2	received	9	16	O	received	ved	ived	VBN	False
DDI-MedLine.d142.s2	intragastric	18	29	O	intragastric	ric	tric	NN	False
DDI-MedLine.d142.s2	administration	31	44	O	administration	ion	tion	NN	False
DDI-MedLine.d142.s2	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d142.s2	daphnetin	49	57	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s2	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d142.s2	glycyrrhiza	63	73	B-drug_n	glycyrrhiza	iza	hiza	NN	False
DDI-MedLine.d142.s2	extract	75	81	I-drug_n	extract	act	ract	NN	False
DDI-MedLine.d142.s2	containing	83	92	O	containing	ing	ning	VBG	False
DDI-MedLine.d142.s2	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d142.s2	same	98	101	O	same	ame	same	JJ	False
DDI-MedLine.d142.s2	daphnetin	103	111	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s2	respectively	113	124	O	respectively	ely	vely	RB	False
DDI-MedLine.d142.s2	.	125	125	O	.	.	.	.	False

DDI-MedLine.d142.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d142.s3	blood	4	8	O	blood	ood	lood	NN	False
DDI-MedLine.d142.s3	concentration	10	22	O	concentration	ion	tion	NN	False
DDI-MedLine.d142.s3	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d142.s3	daphnetin	27	35	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s3	was	37	39	O	was	was	was	VBD	False
DDI-MedLine.d142.s3	assayed	41	47	O	assayed	yed	ayed	NNS	False
DDI-MedLine.d142.s3	by	49	50	O	by	by	by	IN	False
DDI-MedLine.d142.s3	LC-MS	52	56	O	LC-MS	-MS	C-MS	JJ	brand
DDI-MedLine.d142.s3	.	57	57	O	.	.	.	.	False

DDI-MedLine.d142.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d142.s4	data	4	7	O	data	ata	data	NNS	False
DDI-MedLine.d142.s4	was	9	11	O	was	was	was	VBD	False
DDI-MedLine.d142.s4	processed	13	21	O	processed	sed	ssed	VBN	False
DDI-MedLine.d142.s4	by	23	24	O	by	by	by	IN	False
DDI-MedLine.d142.s4	program	26	32	O	program	ram	gram	NN	False
DDI-MedLine.d142.s4	DAS2.1.1	34	41	O	DAS2.1.1	1.1	.1.1	NN	brand
DDI-MedLine.d142.s4	.	42	42	O	.	.	.	.	False

DDI-MedLine.d142.s5	Glycyrrhiza	0	10	O	Glycyrrhiza	iza	hiza	NN	False
DDI-MedLine.d142.s5	extract	12	18	O	extract	act	ract	NN	False
DDI-MedLine.d142.s5	can	20	22	O	can	can	can	MD	False
DDI-MedLine.d142.s5	reduce	24	29	O	reduce	uce	duce	VB	False
DDI-MedLine.d142.s5	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d142.s5	t	35	35	O	t	t	t	NN	False
DDI-MedLine.d142.s5	(	36	36	O	(	(	(	(	False
DDI-MedLine.d142.s5	1/2	37	39	O	1/2	1/2	1/2	CD	False
DDI-MedLine.d142.s5	)	40	40	O	)	)	)	)	False
DDI-MedLine.d142.s5	,	41	41	O	,	,	,	,	False
DDI-MedLine.d142.s5	tmax	43	46	O	tmax	max	tmax	NN	False
DDI-MedLine.d142.s5	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d142.s5	Ke	52	53	O	Ke	Ke	Ke	NNP	False
DDI-MedLine.d142.s5	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d142.s5	daphnetin	58	66	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s5	,	67	67	O	,	,	,	,	False
DDI-MedLine.d142.s5	while	69	73	O	while	ile	hile	IN	False
DDI-MedLine.d142.s5	increased	75	83	O	increased	sed	ased	VBN	False
DDI-MedLine.d142.s5	the	85	87	O	the	the	the	DT	False
DDI-MedLine.d142.s5	Ka	89	90	O	Ka	Ka	Ka	NNP	False
DDI-MedLine.d142.s5	and	92	94	O	and	and	and	CC	False
DDI-MedLine.d142.s5	AUC	96	98	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d142.s5	(	99	99	O	(	(	(	(	False
DDI-MedLine.d142.s5	0-infinity	100	109	O	0-infinity	ity	nity	NN	False
DDI-MedLine.d142.s5	)	110	110	O	)	)	)	)	False
DDI-MedLine.d142.s5	.	111	111	O	.	.	.	.	False

DDI-MedLine.d142.s6	Glycyrrhiza	0	10	O	Glycyrrhiza	iza	hiza	NN	False
DDI-MedLine.d142.s6	extract	12	18	O	extract	act	ract	NN	False
DDI-MedLine.d142.s6	promoted	20	27	O	promoted	ted	oted	VBN	False
DDI-MedLine.d142.s6	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d142.s6	oral	33	36	O	oral	ral	oral	JJ	False
DDI-MedLine.d142.s6	absorption	38	47	O	absorption	ion	tion	NN	False
DDI-MedLine.d142.s6	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d142.s6	daphnetin	52	60	B-drug_n	daphnetin	tin	etin	NN	False
DDI-MedLine.d142.s6	,	61	61	O	,	,	,	,	False
DDI-MedLine.d142.s6	slowed	63	68	O	slowed	wed	owed	VBD	False
DDI-MedLine.d142.s6	down	70	73	O	down	own	down	RB	False
DDI-MedLine.d142.s6	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d142.s6	elimination	79	89	O	elimination	ion	tion	NN	False
DDI-MedLine.d142.s6	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d142.s6	increased	95	103	O	increased	sed	ased	VBN	False
DDI-MedLine.d142.s6	the	105	107	O	the	the	the	DT	False
DDI-MedLine.d142.s6	biological	109	118	O	biological	cal	ical	JJ	False
DDI-MedLine.d142.s6	availability	120	131	O	availability	ity	lity	NN	False
DDI-MedLine.d142.s6	.	132	132	O	.	.	.	.	False

DDI-MedLine.d144.s0	Older	0	4	O	Older	der	lder	JJR	False
DDI-MedLine.d144.s0	adults	6	11	O	adults	lts	ults	NNS	False
DDI-MedLine.d144.s0	with	13	16	O	with	ith	with	IN	False
DDI-MedLine.d144.s0	multi-morbidity	18	32	O	multi-morbidity	ity	dity	NN	False
DDI-MedLine.d144.s0	:	33	33	O	:	:	:	:	False
DDI-MedLine.d144.s0	medication	35	44	O	medication	ion	tion	NN	False
DDI-MedLine.d144.s0	management	46	55	O	management	ent	ment	NN	False
DDI-MedLine.d144.s0	processes	57	65	O	processes	ses	sses	NNS	False
DDI-MedLine.d144.s0	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d144.s0	design	71	76	O	design	ign	sign	NN	False
DDI-MedLine.d144.s0	implications	78	89	O	implications	ons	ions	NNS	False
DDI-MedLine.d144.s0	for	91	93	O	for	for	for	IN	False
DDI-MedLine.d144.s0	personal	95	102	O	personal	nal	onal	JJ	False
DDI-MedLine.d144.s0	health	104	109	O	health	lth	alth	NN	False
DDI-MedLine.d144.s0	applications	111	122	O	applications	ons	ions	NNS	False
DDI-MedLine.d144.s0	.	123	123	O	.	.	.	.	False

DDI-MedLine.d144.s1	Older	0	4	O	Older	der	lder	JJR	False
DDI-MedLine.d144.s1	adults	6	11	O	adults	lts	ults	NNS	False
DDI-MedLine.d144.s1	often	13	17	O	often	ten	ften	RB	False
DDI-MedLine.d144.s1	have	19	22	O	have	ave	have	VB	False
DDI-MedLine.d144.s1	multiple	24	31	O	multiple	ple	iple	NN	False
DDI-MedLine.d144.s1	chronic	33	39	O	chronic	nic	onic	NN	False
DDI-MedLine.d144.s1	problems	41	48	O	problems	ems	lems	NNS	False
DDI-MedLine.d144.s1	requiring	50	58	O	requiring	ing	ring	VBG	False
DDI-MedLine.d144.s1	them	60	63	O	them	hem	them	PRP	False
DDI-MedLine.d144.s1	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d144.s1	manage	68	73	O	manage	age	nage	NN	False
DDI-MedLine.d144.s1	complex	75	81	O	complex	lex	plex	JJ	False
DDI-MedLine.d144.s1	medication	83	92	O	medication	ion	tion	NN	False
DDI-MedLine.d144.s1	regimens	94	101	O	regimens	ens	mens	NNS	False
DDI-MedLine.d144.s1	overseen	103	110	O	overseen	een	seen	NN	False
DDI-MedLine.d144.s1	by	112	113	O	by	by	by	IN	False
DDI-MedLine.d144.s1	various	115	121	O	various	ous	ious	JJ	False
DDI-MedLine.d144.s1	clinicians	123	132	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d144.s1	.	133	133	O	.	.	.	.	False

DDI-MedLine.d144.s2	Personal	0	7	O	Personal	nal	onal	JJ	False
DDI-MedLine.d144.s2	health	9	14	O	health	lth	alth	NN	False
DDI-MedLine.d144.s2	applications	16	27	O	applications	ons	ions	NNS	False
DDI-MedLine.d144.s2	(	29	29	O	(	(	(	(	False
DDI-MedLine.d144.s2	PHAs	30	33	O	PHAs	HAs	PHAs	NN	False
DDI-MedLine.d144.s2	)	34	34	O	)	)	)	)	False
DDI-MedLine.d144.s2	show	36	39	O	show	how	show	NN	False
DDI-MedLine.d144.s2	promise	41	47	O	promise	ise	mise	NN	False
DDI-MedLine.d144.s2	assisting	49	57	O	assisting	ing	ting	VBG	False
DDI-MedLine.d144.s2	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d144.s2	medication	62	71	O	medication	ion	tion	NN	False
DDI-MedLine.d144.s2	self-management	73	87	O	self-management	ent	ment	NN	False
DDI-MedLine.d144.s2	,	88	88	O	,	,	,	,	False
DDI-MedLine.d144.s2	but	90	92	O	but	but	but	CC	False
DDI-MedLine.d144.s2	adoption	94	101	O	adoption	ion	tion	NN	False
DDI-MedLine.d144.s2	of	103	104	O	of	of	of	IN	False
DDI-MedLine.d144.s2	new	106	108	O	new	new	new	JJ	False
DDI-MedLine.d144.s2	computer	110	117	O	computer	ter	uter	NN	False
DDI-MedLine.d144.s2	technologies	119	130	O	technologies	ies	gies	NNS	False
DDI-MedLine.d144.s2	by	132	133	O	by	by	by	IN	False
DDI-MedLine.d144.s2	this	135	138	O	this	his	this	DT	False
DDI-MedLine.d144.s2	population	140	149	O	population	ion	tion	NN	False
DDI-MedLine.d144.s2	is	151	152	O	is	is	is	VBZ	False
DDI-MedLine.d144.s2	challenging	154	164	O	challenging	ing	ging	VBG	False
DDI-MedLine.d144.s2	.	165	165	O	.	.	.	.	False

DDI-MedLine.d144.s3	Optimizing	0	9	O	Optimizing	ing	zing	VBG	False
DDI-MedLine.d144.s3	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d144.s3	utility	15	21	O	utility	ity	lity	NN	False
DDI-MedLine.d144.s3	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d144.s3	PHAs	26	29	O	PHAs	HAs	PHAs	NN	False
DDI-MedLine.d144.s3	requires	31	38	O	requires	res	ires	VBZ	False
DDI-MedLine.d144.s3	a	40	40	O	a	a	a	DT	False
DDI-MedLine.d144.s3	thorough	42	49	O	thorough	ugh	ough	NN	False
DDI-MedLine.d144.s3	understanding	51	63	O	understanding	ing	ding	VBG	False
DDI-MedLine.d144.s3	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d144.s3	older	68	72	O	older	der	lder	JJR	False
DDI-MedLine.d144.s3	adults	74	79	O	adults	lts	ults	NNS	False
DDI-MedLine.d144.s3	'	80	80	O	'	'	'	''	False
DDI-MedLine.d144.s3	needs	82	86	O	needs	eds	eeds	NNS	False
DDI-MedLine.d144.s3	,	87	87	O	,	,	,	,	False
DDI-MedLine.d144.s3	preferences	89	99	O	preferences	ces	nces	NNS	False
DDI-MedLine.d144.s3	,	100	100	O	,	,	,	,	False
DDI-MedLine.d144.s3	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d144.s3	practices	106	114	O	practices	ces	ices	NNS	False
DDI-MedLine.d144.s3	.	115	115	O	.	.	.	.	False

DDI-MedLine.d228.s0	Pulmonary	0	8	O	Pulmonary	ary	nary	JJ	False
DDI-MedLine.d228.s0	tuberculosis	10	21	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d228.s0	:	22	22	O	:	:	:	:	False
DDI-MedLine.d228.s0	clinical	24	31	O	clinical	cal	ical	JJ	False
DDI-MedLine.d228.s0	features	33	40	O	features	res	ures	NNS	False
DDI-MedLine.d228.s0	and	42	44	O	and	and	and	CC	False
DDI-MedLine.d228.s0	patient	46	52	O	patient	ent	ient	NN	False
DDI-MedLine.d228.s0	management	54	63	O	management	ent	ment	NN	False
DDI-MedLine.d228.s0	.	64	64	O	.	.	.	.	False

DDI-MedLine.d228.s1	Pulmonary	0	8	O	Pulmonary	ary	nary	JJ	False
DDI-MedLine.d228.s1	tuberculosis	10	21	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d228.s1	(	23	23	O	(	(	(	(	False
DDI-MedLine.d228.s1	TB	24	25	O	TB	TB	TB	NN	brand
DDI-MedLine.d228.s1	)	26	26	O	)	)	)	)	False
DDI-MedLine.d228.s1	is	28	29	O	is	is	is	VBZ	False
DDI-MedLine.d228.s1	a	31	31	O	a	a	a	DT	False
DDI-MedLine.d228.s1	common	33	38	O	common	mon	mmon	JJ	False
DDI-MedLine.d228.s1	infectious	40	49	O	infectious	ous	ious	JJ	False
DDI-MedLine.d228.s1	disease	51	57	O	disease	ase	ease	NN	False
DDI-MedLine.d228.s1	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d228.s1	a	63	63	O	a	a	a	DT	False
DDI-MedLine.d228.s1	major	65	69	O	major	jor	ajor	JJ	False
DDI-MedLine.d228.s1	cause	71	75	O	cause	use	ause	NN	False
DDI-MedLine.d228.s1	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d228.s1	illness	80	86	O	illness	ess	ness	NN	False
DDI-MedLine.d228.s1	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d228.s1	death	92	96	O	death	ath	eath	NN	False
DDI-MedLine.d228.s1	throughout	98	107	O	throughout	out	hout	IN	False
DDI-MedLine.d228.s1	the	109	111	O	the	the	the	DT	False
DDI-MedLine.d228.s1	world	113	117	O	world	rld	orld	NN	False
DDI-MedLine.d228.s1	,	118	118	O	,	,	,	,	False
DDI-MedLine.d228.s1	particularly	120	131	O	particularly	rly	arly	RB	False
DDI-MedLine.d228.s1	in	133	134	O	in	in	in	IN	False
DDI-MedLine.d228.s1	developing	136	145	O	developing	ing	ping	VBG	False
DDI-MedLine.d228.s1	countries	147	155	O	countries	ies	ries	NNS	False
DDI-MedLine.d228.s1	.	156	156	O	.	.	.	.	False

DDI-MedLine.d228.s2	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d228.s2	article	5	11	O	article	cle	icle	NN	False
DDI-MedLine.d228.s2	explores	13	20	O	explores	res	ores	NNS	False
DDI-MedLine.d228.s2	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d228.s2	difference	26	35	O	difference	nce	ence	NN	False
DDI-MedLine.d228.s2	between	37	43	O	between	een	ween	IN	False
DDI-MedLine.d228.s2	latent	45	50	O	latent	ent	tent	NN	False
DDI-MedLine.d228.s2	TB	52	53	O	TB	TB	TB	NN	brand
DDI-MedLine.d228.s2	infection	55	63	O	infection	ion	tion	NN	False
DDI-MedLine.d228.s2	and	65	67	O	and	and	and	CC	False
DDI-MedLine.d228.s2	active	69	74	O	active	ive	tive	JJ	False
DDI-MedLine.d228.s2	TB	76	77	O	TB	TB	TB	NN	brand
DDI-MedLine.d228.s2	disease	79	85	O	disease	ase	ease	NN	False
DDI-MedLine.d228.s2	,	86	86	O	,	,	,	,	False
DDI-MedLine.d228.s2	and	88	90	O	and	and	and	CC	False
DDI-MedLine.d228.s2	discusses	92	100	O	discusses	ses	sses	NNS	False
DDI-MedLine.d228.s2	the	102	104	O	the	the	the	DT	False
DDI-MedLine.d228.s2	pharmacological	106	120	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d228.s2	management	122	131	O	management	ent	ment	NN	False
DDI-MedLine.d228.s2	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d228.s2	TB	136	137	O	TB	TB	TB	NN	brand
DDI-MedLine.d228.s2	and	139	141	O	and	and	and	CC	False
DDI-MedLine.d228.s2	issues	143	148	O	issues	ues	sues	NNS	False
DDI-MedLine.d228.s2	around	150	155	O	around	und	ound	IN	False
DDI-MedLine.d228.s2	adherence	157	165	O	adherence	nce	ence	NN	False
DDI-MedLine.d228.s2	to	167	168	O	to	to	to	TO	False
DDI-MedLine.d228.s2	medication	170	179	O	medication	ion	tion	NN	False
DDI-MedLine.d228.s2	.	180	180	O	.	.	.	.	False

DDI-MedLine.d228.s3	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d228.s3	TB	9	10	O	TB	TB	TB	NN	brand
DDI-MedLine.d228.s3	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d228.s3	usually	15	21	O	usually	lly	ally	RB	False
DDI-MedLine.d228.s3	managed	23	29	O	managed	ged	aged	VBN	False
DDI-MedLine.d228.s3	by	31	32	O	by	by	by	IN	False
DDI-MedLine.d228.s3	specialist	34	43	O	specialist	ist	list	NN	False
DDI-MedLine.d228.s3	teams	45	49	O	teams	ams	eams	NNS	False
DDI-MedLine.d228.s3	it	51	52	O	it	it	it	PRP	False
DDI-MedLine.d228.s3	is	54	55	O	is	is	is	VBZ	False
DDI-MedLine.d228.s3	essential	57	65	O	essential	ial	tial	JJ	False
DDI-MedLine.d228.s3	that	67	70	O	that	hat	that	IN	False
DDI-MedLine.d228.s3	all	72	74	O	all	all	all	DT	False
DDI-MedLine.d228.s3	practitioners	76	88	O	practitioners	ers	ners	NNS	False
DDI-MedLine.d228.s3	have	90	93	O	have	ave	have	VB	False
DDI-MedLine.d228.s3	an	95	96	O	an	an	an	DT	False
DDI-MedLine.d228.s3	understanding	98	110	O	understanding	ing	ding	VBG	False
DDI-MedLine.d228.s3	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d228.s3	the	115	117	O	the	the	the	DT	False
DDI-MedLine.d228.s3	signs	119	123	O	signs	gns	igns	NNS	False
DDI-MedLine.d228.s3	and	125	127	O	and	and	and	CC	False
DDI-MedLine.d228.s3	symptoms	129	136	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d228.s3	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d228.s3	the	141	143	O	the	the	the	DT	False
DDI-MedLine.d228.s3	disease	145	151	O	disease	ase	ease	NN	False
DDI-MedLine.d228.s3	to	153	154	O	to	to	to	TO	False
DDI-MedLine.d228.s3	ensure	156	161	O	ensure	ure	sure	VB	False
DDI-MedLine.d228.s3	early	163	167	O	early	rly	arly	RB	False
DDI-MedLine.d228.s3	referral	169	176	O	referral	ral	rral	JJ	False
DDI-MedLine.d228.s3	and	178	180	O	and	and	and	CC	False
DDI-MedLine.d228.s3	accurate	182	189	O	accurate	ate	rate	NN	False
DDI-MedLine.d228.s3	diagnosis	191	199	O	diagnosis	sis	osis	NN	False
DDI-MedLine.d228.s3	.	200	200	O	.	.	.	.	False

DDI-MedLine.d196.s0	Single-dose	0	10	O	Single-dose	ose	dose	JJ	False
DDI-MedLine.d196.s0	bioequivalence	12	25	O	bioequivalence	nce	ence	NN	False
DDI-MedLine.d196.s0	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d196.s0	105-mg	30	35	O	105-mg	-mg	5-mg	JJ	False
DDI-MedLine.d196.s0	fenofibric	37	46	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s0	acid	48	51	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s0	tablets	53	59	O	tablets	ets	lets	NNS	False
DDI-MedLine.d196.s0	versus	61	66	O	versus	sus	rsus	NN	False
DDI-MedLine.d196.s0	145-mg	68	73	O	145-mg	-mg	5-mg	JJ	False
DDI-MedLine.d196.s0	fenofibrate	75	85	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s0	tablets	87	93	O	tablets	ets	lets	NNS	False
DDI-MedLine.d196.s0	under	95	99	O	under	der	nder	IN	False
DDI-MedLine.d196.s0	fasting	101	107	O	fasting	ing	ting	VBG	False
DDI-MedLine.d196.s0	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d196.s0	fed	113	115	O	fed	fed	fed	NN	False
DDI-MedLine.d196.s0	conditions	117	126	O	conditions	ons	ions	NNS	False
DDI-MedLine.d196.s0	:	127	127	O	:	:	:	:	False
DDI-MedLine.d196.s0	a	129	129	O	a	a	a	DT	False
DDI-MedLine.d196.s0	report	131	136	O	report	ort	port	NN	False
DDI-MedLine.d196.s0	of	138	139	O	of	of	of	IN	False
DDI-MedLine.d196.s0	two	141	143	O	two	two	two	CD	False
DDI-MedLine.d196.s0	phase	145	149	O	phase	ase	hase	NN	False
DDI-MedLine.d196.s0	I	151	151	O	I	I	I	PRP	brand
DDI-MedLine.d196.s0	,	152	152	O	,	,	,	,	False
DDI-MedLine.d196.s0	open-label	154	163	O	open-label	bel	abel	NN	False
DDI-MedLine.d196.s0	,	164	164	O	,	,	,	,	False
DDI-MedLine.d196.s0	single-dose	166	176	O	single-dose	ose	dose	JJ	False
DDI-MedLine.d196.s0	,	177	177	O	,	,	,	,	False
DDI-MedLine.d196.s0	randomized	179	188	O	randomized	zed	ized	VBN	False
DDI-MedLine.d196.s0	,	189	189	O	,	,	,	,	False
DDI-MedLine.d196.s0	crossover	191	199	O	crossover	ver	over	NN	False
DDI-MedLine.d196.s0	clinical	201	208	O	clinical	cal	ical	JJ	False
DDI-MedLine.d196.s0	trials	210	215	O	trials	als	ials	NNS	False
DDI-MedLine.d196.s0	.	216	216	O	.	.	.	.	False

DDI-MedLine.d196.s1	Fenofibrate	0	10	B-drug	Fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s1	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d196.s1	used	15	18	O	used	sed	used	VBN	False
DDI-MedLine.d196.s1	to	20	21	O	to	to	to	TO	False
DDI-MedLine.d196.s1	treat	23	27	O	treat	eat	reat	NN	False
DDI-MedLine.d196.s1	primary	29	35	O	primary	ary	mary	NN	False
DDI-MedLine.d196.s1	hypercholesterolemia	37	56	O	hypercholesterolemia	mia	emia	NN	False
DDI-MedLine.d196.s1	,	57	57	O	,	,	,	,	False
DDI-MedLine.d196.s1	mixed	59	63	O	mixed	xed	ixed	JJ	False
DDI-MedLine.d196.s1	lipidemia	65	73	O	lipidemia	mia	emia	NN	False
DDI-MedLine.d196.s1	,	74	74	O	,	,	,	,	False
DDI-MedLine.d196.s1	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d196.s1	hypertriglyceridemia	80	99	O	hypertriglyceridemia	mia	emia	NN	False
DDI-MedLine.d196.s1	in	101	102	O	in	in	in	IN	False
DDI-MedLine.d196.s1	adults	104	109	O	adults	lts	ults	NNS	False
DDI-MedLine.d196.s1	who	111	113	O	who	who	who	WP	False
DDI-MedLine.d196.s1	do	115	116	O	do	do	do	VB	False
DDI-MedLine.d196.s1	not	118	120	O	not	not	not	RB	False
DDI-MedLine.d196.s1	respond	122	128	O	respond	ond	pond	NN	False
DDI-MedLine.d196.s1	to	130	131	O	to	to	to	TO	False
DDI-MedLine.d196.s1	nonpharmacologic	133	148	O	nonpharmacologic	gic	ogic	NN	False
DDI-MedLine.d196.s1	measures	150	157	O	measures	res	ures	NNS	False
DDI-MedLine.d196.s1	.	158	158	O	.	.	.	.	False

DDI-MedLine.d196.s2	Fenofibrate	0	10	B-drug	Fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s2	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d196.s2	a	15	15	O	a	a	a	DT	False
DDI-MedLine.d196.s2	prodrug	17	23	O	prodrug	rug	drug	NN	False
DDI-MedLine.d196.s2	that	25	28	O	that	hat	that	IN	False
DDI-MedLine.d196.s2	is	30	31	O	is	is	is	VBZ	False
DDI-MedLine.d196.s2	rapidly	33	39	O	rapidly	dly	idly	RB	False
DDI-MedLine.d196.s2	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d196.s2	completely	45	54	O	completely	ely	tely	RB	False
DDI-MedLine.d196.s2	hydrolyzed	56	65	O	hydrolyzed	zed	yzed	VBN	False
DDI-MedLine.d196.s2	to	67	68	O	to	to	to	TO	False
DDI-MedLine.d196.s2	fenofibric	70	79	B-drug_n	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s2	acid	81	84	I-drug_n	acid	cid	acid	NN	False
DDI-MedLine.d196.s2	,	85	85	O	,	,	,	,	False
DDI-MedLine.d196.s2	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d196.s2	active	91	96	O	active	ive	tive	JJ	False
DDI-MedLine.d196.s2	moiety	98	103	O	moiety	ety	iety	NN	False
DDI-MedLine.d196.s2	.	104	104	O	.	.	.	.	False

DDI-MedLine.d196.s3	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d196.s3	new	2	4	O	new	new	new	JJ	False
DDI-MedLine.d196.s3	orally	6	11	O	orally	lly	ally	RB	False
DDI-MedLine.d196.s3	administered	13	24	O	administered	red	ered	VBN	False
DDI-MedLine.d196.s3	agent	26	30	O	agent	ent	gent	NN	False
DDI-MedLine.d196.s3	,	31	31	O	,	,	,	,	False
DDI-MedLine.d196.s3	fenofibric	33	42	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s3	acid	44	47	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s3	,	48	48	O	,	,	,	,	False
DDI-MedLine.d196.s3	was	50	52	O	was	was	was	VBD	False
DDI-MedLine.d196.s3	developed	54	62	O	developed	ped	oped	NN	False
DDI-MedLine.d196.s3	as	64	65	O	as	as	as	IN	False
DDI-MedLine.d196.s3	an	67	68	O	an	an	an	DT	False
DDI-MedLine.d196.s3	alternative	70	80	O	alternative	ive	tive	NN	False
DDI-MedLine.d196.s3	to	82	83	O	to	to	to	TO	False
DDI-MedLine.d196.s3	fenofibrate	85	95	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s3	.	96	96	O	.	.	.	.	False

DDI-MedLine.d196.s4	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d196.s4	separate	4	11	O	separate	ate	rate	JJ	False
DDI-MedLine.d196.s4	studies	13	19	O	studies	ies	dies	NNS	False
DDI-MedLine.d196.s4	were	21	24	O	were	ere	were	VBD	False
DDI-MedLine.d196.s4	conducted	26	34	O	conducted	ted	cted	VBN	False
DDI-MedLine.d196.s4	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d196.s4	evaluate	39	46	O	evaluate	ate	uate	NN	False
DDI-MedLine.d196.s4	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d196.s4	bioequivalence	52	65	O	bioequivalence	nce	ence	NN	False
DDI-MedLine.d196.s4	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d196.s4	fenofibric	70	79	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s4	acid	81	84	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s4	relative	86	93	O	relative	ive	tive	NN	False
DDI-MedLine.d196.s4	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d196.s4	fenofibrate	98	108	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s4	under	110	114	O	under	der	nder	IN	False
DDI-MedLine.d196.s4	fasted	116	121	O	fasted	ted	sted	VBN	False
DDI-MedLine.d196.s4	and	123	125	O	and	and	and	CC	False
DDI-MedLine.d196.s4	fed	127	129	O	fed	fed	fed	NN	False
DDI-MedLine.d196.s4	(	131	131	O	(	(	(	(	False
DDI-MedLine.d196.s4	standard	132	139	O	standard	ard	dard	NN	False
DDI-MedLine.d196.s4	breakfast	141	149	O	breakfast	ast	fast	NN	False
DDI-MedLine.d196.s4	)	150	150	O	)	)	)	)	False
DDI-MedLine.d196.s4	conditions	152	161	O	conditions	ons	ions	NNS	False
DDI-MedLine.d196.s4	,	162	162	O	,	,	,	,	False
DDI-MedLine.d196.s4	characterize	164	175	O	characterize	ize	rize	NN	False
DDI-MedLine.d196.s4	the	177	179	O	the	the	the	DT	False
DDI-MedLine.d196.s4	pharmacokinetic	181	195	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d196.s4	profile	197	203	O	profile	ile	file	NN	False
DDI-MedLine.d196.s4	,	204	204	O	,	,	,	,	False
DDI-MedLine.d196.s4	and	206	208	O	and	and	and	CC	False
DDI-MedLine.d196.s4	assess	210	215	O	assess	ess	sess	NN	False
DDI-MedLine.d196.s4	the	217	219	O	the	the	the	DT	False
DDI-MedLine.d196.s4	safety	221	226	O	safety	ety	fety	NN	False
DDI-MedLine.d196.s4	and	228	230	O	and	and	and	CC	False
DDI-MedLine.d196.s4	tolerability	232	243	O	tolerability	ity	lity	NN	False
DDI-MedLine.d196.s4	of	245	246	O	of	of	of	IN	False
DDI-MedLine.d196.s4	fenofibric	248	257	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s4	acid	259	262	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s4	.	263	263	O	.	.	.	.	False

DDI-MedLine.d196.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d196.s5	study	3	7	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s5	1	9	9	O	1	1	1	CD	False
DDI-MedLine.d196.s5	(	11	11	O	(	(	(	(	False
DDI-MedLine.d196.s5	fasted	12	17	O	fasted	ted	sted	VBN	False
DDI-MedLine.d196.s5	)	18	18	O	)	)	)	)	False
DDI-MedLine.d196.s5	,	19	19	O	,	,	,	,	False
DDI-MedLine.d196.s5	during	21	26	O	during	ing	ring	IN	False
DDI-MedLine.d196.s5	each	28	31	O	each	ach	each	DT	False
DDI-MedLine.d196.s5	study	33	37	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s5	period	39	44	O	period	iod	riod	NN	False
DDI-MedLine.d196.s5	,	45	45	O	,	,	,	,	False
DDI-MedLine.d196.s5	volunteers	47	56	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s5	received	58	65	O	received	ved	ived	VBN	False
DDI-MedLine.d196.s5	a	67	67	O	a	a	a	DT	False
DDI-MedLine.d196.s5	single	69	74	O	single	gle	ngle	JJ	False
DDI-MedLine.d196.s5	105-mg	76	81	O	105-mg	-mg	5-mg	JJ	False
DDI-MedLine.d196.s5	dose	83	86	O	dose	ose	dose	NN	False
DDI-MedLine.d196.s5	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d196.s5	fenofibric	91	100	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s5	acid	102	105	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s5	or	107	108	O	or	or	or	CC	False
DDI-MedLine.d196.s5	single	110	115	O	single	gle	ngle	JJ	False
DDI-MedLine.d196.s5	145-mg	117	122	O	145-mg	-mg	5-mg	JJ	False
DDI-MedLine.d196.s5	dose	124	127	O	dose	ose	dose	NN	False
DDI-MedLine.d196.s5	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d196.s5	fenofibrate	132	142	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s5	(	144	144	O	(	(	(	(	False
DDI-MedLine.d196.s5	depending	145	153	O	depending	ing	ding	VBG	False
DDI-MedLine.d196.s5	on	155	156	O	on	on	on	IN	False
DDI-MedLine.d196.s5	their	158	162	O	their	eir	heir	PRP$	False
DDI-MedLine.d196.s5	randomization	164	176	O	randomization	ion	tion	NN	False
DDI-MedLine.d196.s5	scheme	178	183	O	scheme	eme	heme	NN	False
DDI-MedLine.d196.s5	)	184	184	O	)	)	)	)	False
DDI-MedLine.d196.s5	after	186	190	O	after	ter	fter	IN	False
DDI-MedLine.d196.s5	an	192	193	O	an	an	an	DT	False
DDI-MedLine.d196.s5	overnight	195	203	O	overnight	ght	ight	NN	False
DDI-MedLine.d196.s5	fast	205	208	O	fast	ast	fast	NN	False
DDI-MedLine.d196.s5	(	210	210	O	(	(	(	(	False
DDI-MedLine.d196.s5	a	211	211	O	a	a	a	DT	False
DDI-MedLine.d196.s5	minimum	213	219	O	minimum	mum	imum	NN	False
DDI-MedLine.d196.s5	fast	221	224	O	fast	ast	fast	NN	False
DDI-MedLine.d196.s5	of	226	227	O	of	of	of	IN	False
DDI-MedLine.d196.s5	10	229	230	O	10	10	10	CD	False
DDI-MedLine.d196.s5	hours	232	236	O	hours	urs	ours	NNS	False
DDI-MedLine.d196.s5	)	237	237	O	)	)	)	)	False
DDI-MedLine.d196.s5	.	238	238	O	.	.	.	.	False

DDI-MedLine.d196.s6	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d196.s6	7-day	2	6	O	7-day	day	-day	JJ	False
DDI-MedLine.d196.s6	washout	8	14	O	washout	out	hout	NN	False
DDI-MedLine.d196.s6	period	16	21	O	period	iod	riod	NN	False
DDI-MedLine.d196.s6	followed	23	30	O	followed	wed	owed	VBD	False
DDI-MedLine.d196.s6	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d196.s6	first	36	40	O	first	rst	irst	RB	False
DDI-MedLine.d196.s6	treatment	42	50	O	treatment	ent	ment	NN	False
DDI-MedLine.d196.s6	period	52	57	O	period	iod	riod	NN	False
DDI-MedLine.d196.s6	,	58	58	O	,	,	,	,	False
DDI-MedLine.d196.s6	after	60	64	O	after	ter	fter	IN	False
DDI-MedLine.d196.s6	which	66	70	O	which	ich	hich	WDT	False
DDI-MedLine.d196.s6	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d196.s6	volunteers	76	85	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s6	received	87	94	O	received	ved	ived	VBN	False
DDI-MedLine.d196.s6	the	96	98	O	the	the	the	DT	False
DDI-MedLine.d196.s6	alternate	100	108	O	alternate	ate	nate	NN	False
DDI-MedLine.d196.s6	treatment	110	118	O	treatment	ent	ment	NN	False
DDI-MedLine.d196.s6	.	119	119	O	.	.	.	.	False

DDI-MedLine.d196.s7	Study	0	4	O	Study	udy	tudy	NN	False
DDI-MedLine.d196.s7	2	6	6	O	2	2	2	CD	False
DDI-MedLine.d196.s7	followed	8	15	O	followed	wed	owed	VBD	False
DDI-MedLine.d196.s7	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d196.s7	similar	19	25	O	similar	lar	ilar	JJ	False
DDI-MedLine.d196.s7	dosing	27	32	O	dosing	ing	sing	VBG	False
DDI-MedLine.d196.s7	scheme	34	39	O	scheme	eme	heme	NN	False
DDI-MedLine.d196.s7	and	41	43	O	and	and	and	CC	False
DDI-MedLine.d196.s7	differed	45	52	O	differed	red	ered	VBN	False
DDI-MedLine.d196.s7	only	54	57	O	only	nly	only	RB	False
DDI-MedLine.d196.s7	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d196.s7	that	62	65	O	that	hat	that	IN	False
DDI-MedLine.d196.s7	volunteers	67	76	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s7	received	78	85	O	received	ved	ived	VBN	False
DDI-MedLine.d196.s7	their	87	91	O	their	eir	heir	PRP$	False
DDI-MedLine.d196.s7	single	93	98	O	single	gle	ngle	JJ	False
DDI-MedLine.d196.s7	dose	100	103	O	dose	ose	dose	NN	False
DDI-MedLine.d196.s7	after	105	109	O	after	ter	fter	IN	False
DDI-MedLine.d196.s7	being	111	115	O	being	ing	eing	VBG	False
DDI-MedLine.d196.s7	fed	117	119	O	fed	fed	fed	NN	False
DDI-MedLine.d196.s7	a	121	121	O	a	a	a	DT	False
DDI-MedLine.d196.s7	standard	123	130	O	standard	ard	dard	NN	False
DDI-MedLine.d196.s7	meal	132	135	O	meal	eal	meal	NN	False
DDI-MedLine.d196.s7	(	137	137	O	(	(	(	(	False
DDI-MedLine.d196.s7	575	138	140	O	575	575	575	CD	False
DDI-MedLine.d196.s7	calories	142	149	O	calories	ies	ries	NNS	False
DDI-MedLine.d196.s7	,	150	150	O	,	,	,	,	False
DDI-MedLine.d196.s7	of	152	153	O	of	of	of	IN	False
DDI-MedLine.d196.s7	which	155	159	O	which	ich	hich	WDT	False
DDI-MedLine.d196.s7	36	161	162	O	36	36	36	CD	False
DDI-MedLine.d196.s7	%	163	163	O	%	%	%	NN	False
DDI-MedLine.d196.s7	were	165	168	O	were	ere	were	VBD	False
DDI-MedLine.d196.s7	contributed	170	180	O	contributed	ted	uted	VBD	False
DDI-MedLine.d196.s7	by	182	183	O	by	by	by	IN	False
DDI-MedLine.d196.s7	fat	185	187	O	fat	fat	fat	NN	False
DDI-MedLine.d196.s7	)	188	188	O	)	)	)	)	False
DDI-MedLine.d196.s7	.	189	189	O	.	.	.	.	False

DDI-MedLine.d196.s8	Serial	0	5	O	Serial	ial	rial	JJ	False
DDI-MedLine.d196.s8	blood	7	11	O	blood	ood	lood	NN	False
DDI-MedLine.d196.s8	samples	13	19	O	samples	les	ples	NNS	False
DDI-MedLine.d196.s8	in	21	22	O	in	in	in	IN	False
DDI-MedLine.d196.s8	both	24	27	O	both	oth	both	DT	False
DDI-MedLine.d196.s8	studies	29	35	O	studies	ies	dies	NNS	False
DDI-MedLine.d196.s8	were	37	40	O	were	ere	were	VBD	False
DDI-MedLine.d196.s8	collected	42	50	O	collected	ted	cted	VBN	False
DDI-MedLine.d196.s8	up	52	53	O	up	up	up	RB	False
DDI-MedLine.d196.s8	to	55	56	O	to	to	to	TO	False
DDI-MedLine.d196.s8	72	58	59	O	72	72	72	CD	False
DDI-MedLine.d196.s8	hours	61	65	O	hours	urs	ours	NNS	False
DDI-MedLine.d196.s8	after	67	71	O	after	ter	fter	IN	False
DDI-MedLine.d196.s8	drug	73	76	O	drug	rug	drug	NN	False
DDI-MedLine.d196.s8	administration	78	91	O	administration	ion	tion	NN	False
DDI-MedLine.d196.s8	.	92	92	O	.	.	.	.	False

DDI-MedLine.d196.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d196.s9	pharmacokinetic	4	18	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d196.s9	parameters	20	29	O	parameters	ers	ters	NNS	False
DDI-MedLine.d196.s9	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d196.s9	interest	34	41	O	interest	est	rest	NN	False
DDI-MedLine.d196.s9	for	43	45	O	for	for	for	IN	False
DDI-MedLine.d196.s9	assessing	47	55	O	assessing	ing	sing	VBG	False
DDI-MedLine.d196.s9	bioequivalence	57	70	O	bioequivalence	nce	ence	NN	False
DDI-MedLine.d196.s9	were	72	75	O	were	ere	were	VBD	False
DDI-MedLine.d196.s9	AUC	77	79	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d196.s9	(	80	80	O	(	(	(	(	False
DDI-MedLine.d196.s9	0-t	81	83	O	0-t	0-t	0-t	NN	False
DDI-MedLine.d196.s9	)	84	84	O	)	)	)	)	False
DDI-MedLine.d196.s9	,	85	85	O	,	,	,	,	False
DDI-MedLine.d196.s9	AUC	87	89	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d196.s9	(	90	90	O	(	(	(	(	False
DDI-MedLine.d196.s9	0-	91	92	O	0-	0-	0-	NN	False
DDI-MedLine.d196.s9	)	96	96	O	)	)	)	)	False
DDI-MedLine.d196.s9	,	97	97	O	,	,	,	,	False
DDI-MedLine.d196.s9	C	99	99	O	C	C	C	SYM	brand
DDI-MedLine.d196.s9	(	100	100	O	(	(	(	(	False
DDI-MedLine.d196.s9	max	101	103	O	max	max	max	NN	False
DDI-MedLine.d196.s9	)	104	104	O	)	)	)	)	False
DDI-MedLine.d196.s9	,	105	105	O	,	,	,	,	False
DDI-MedLine.d196.s9	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d196.s9	T	111	111	O	T	T	T	NN	brand
DDI-MedLine.d196.s9	(	112	112	O	(	(	(	(	False
DDI-MedLine.d196.s9	max	113	115	O	max	max	max	NN	False
DDI-MedLine.d196.s9	)	116	116	O	)	)	)	)	False
DDI-MedLine.d196.s9	.	117	117	O	.	.	.	.	False

DDI-MedLine.d196.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d196.s10	criterion	4	12	O	criterion	ion	rion	NN	False
DDI-MedLine.d196.s10	for	14	16	O	for	for	for	IN	False
DDI-MedLine.d196.s10	a	18	18	O	a	a	a	DT	False
DDI-MedLine.d196.s10	lack	20	23	O	lack	ack	lack	NN	False
DDI-MedLine.d196.s10	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d196.s10	difference	28	37	O	difference	nce	ence	NN	False
DDI-MedLine.d196.s10	between	39	45	O	between	een	ween	IN	False
DDI-MedLine.d196.s10	products	47	54	O	products	cts	ucts	NNS	False
DDI-MedLine.d196.s10	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d196.s10	a	60	60	O	a	a	a	DT	False
DDI-MedLine.d196.s10	90	62	63	O	90	90	90	CD	False
DDI-MedLine.d196.s10	%	64	64	O	%	%	%	NN	False
DDI-MedLine.d196.s10	CI	66	67	O	CI	CI	CI	NN	brand
DDI-MedLine.d196.s10	between	69	75	O	between	een	ween	IN	False
DDI-MedLine.d196.s10	0.80	77	80	O	0.80	.80	0.80	CD	False
DDI-MedLine.d196.s10	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d196.s10	1.25	86	89	O	1.25	.25	1.25	CD	False
DDI-MedLine.d196.s10	for	91	93	O	for	for	for	IN	False
DDI-MedLine.d196.s10	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d196.s10	fenofibric	99	108	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s10	acid	110	113	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s10	:	114	114	O	:	:	:	:	False
DDI-MedLine.d196.s10	fenofibrate	115	125	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s10	ratios	127	132	O	ratios	ios	tios	NNS	False
DDI-MedLine.d196.s10	for	134	136	O	for	for	for	IN	False
DDI-MedLine.d196.s10	AUC	138	140	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d196.s10	(	141	141	O	(	(	(	(	False
DDI-MedLine.d196.s10	0-t	142	144	O	0-t	0-t	0-t	NN	False
DDI-MedLine.d196.s10	)	145	145	O	)	)	)	)	False
DDI-MedLine.d196.s10	,	146	146	O	,	,	,	,	False
DDI-MedLine.d196.s10	AUC	148	150	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d196.s10	(	151	151	O	(	(	(	(	False
DDI-MedLine.d196.s10	0-	152	153	O	0-	0-	0-	NN	False
DDI-MedLine.d196.s10	)	157	157	O	)	)	)	)	False
DDI-MedLine.d196.s10	,	158	158	O	,	,	,	,	False
DDI-MedLine.d196.s10	and	160	162	O	and	and	and	CC	False
DDI-MedLine.d196.s10	C	164	164	O	C	C	C	SYM	brand
DDI-MedLine.d196.s10	(	165	165	O	(	(	(	(	False
DDI-MedLine.d196.s10	max	166	168	O	max	max	max	NN	False
DDI-MedLine.d196.s10	.	169	169	O	.	.	.	.	False
DDI-MedLine.d196.s10	)	170	170	O	)	)	)	)	False

DDI-MedLine.d196.s11	Tolerability	0	11	O	Tolerability	ity	lity	NN	False
DDI-MedLine.d196.s11	was	13	15	O	was	was	was	VBD	False
DDI-MedLine.d196.s11	assessed	17	24	O	assessed	sed	ssed	VBN	False
DDI-MedLine.d196.s11	by	26	27	O	by	by	by	IN	False
DDI-MedLine.d196.s11	adverse	29	35	O	adverse	rse	erse	NN	False
DDI-MedLine.d196.s11	events	37	42	O	events	nts	ents	NNS	False
DDI-MedLine.d196.s11	(	44	44	O	(	(	(	(	False
DDI-MedLine.d196.s11	AEs	45	47	O	AEs	AEs	AEs	NN	False
DDI-MedLine.d196.s11	)	48	48	O	)	)	)	)	False
DDI-MedLine.d196.s11	,	49	49	O	,	,	,	,	False
DDI-MedLine.d196.s11	laboratory	51	60	O	laboratory	ory	tory	NN	False
DDI-MedLine.d196.s11	parameters	62	71	O	parameters	ers	ters	NNS	False
DDI-MedLine.d196.s11	,	72	72	O	,	,	,	,	False
DDI-MedLine.d196.s11	vital	74	78	O	vital	tal	ital	NN	False
DDI-MedLine.d196.s11	signs	80	84	O	signs	gns	igns	NNS	False
DDI-MedLine.d196.s11	,	85	85	O	,	,	,	,	False
DDI-MedLine.d196.s11	and	87	89	O	and	and	and	CC	False
DDI-MedLine.d196.s11	physical	91	98	O	physical	cal	ical	JJ	False
DDI-MedLine.d196.s11	examinations	100	111	O	examinations	ons	ions	NNS	False
DDI-MedLine.d196.s11	.	112	112	O	.	.	.	.	False

DDI-MedLine.d196.s12	Volunteers	0	9	O	Volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s12	in	11	12	O	in	in	in	IN	False
DDI-MedLine.d196.s12	study	14	18	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s12	1	20	20	O	1	1	1	CD	False
DDI-MedLine.d196.s12	(	22	22	O	(	(	(	(	False
DDI-MedLine.d196.s12	fasted	23	28	O	fasted	ted	sted	VBN	False
DDI-MedLine.d196.s12	;	29	29	O	;	;	;	:	False
DDI-MedLine.d196.s12	n	31	31	O	n	n	n	NN	False
DDI-MedLine.d196.s12	=	33	33	O	=	=	=	NN	False
DDI-MedLine.d196.s12	54	35	36	O	54	54	54	CD	False
DDI-MedLine.d196.s12	)	37	37	O	)	)	)	)	False
DDI-MedLine.d196.s12	were	39	42	O	were	ere	were	VBD	False
DDI-MedLine.d196.s12	aged	44	47	O	aged	ged	aged	VBN	False
DDI-MedLine.d196.s12	18	49	50	O	18	18	18	CD	False
DDI-MedLine.d196.s12	to	52	53	O	to	to	to	TO	False
DDI-MedLine.d196.s12	43	55	56	O	43	43	43	CD	False
DDI-MedLine.d196.s12	years	58	62	O	years	ars	ears	NNS	False
DDI-MedLine.d196.s12	;	63	63	O	;	;	;	:	False

DDI-MedLine.d196.s13	19	0	1	O	19	19	19	CD	False
DDI-MedLine.d196.s13	(	3	3	O	(	(	(	(	False
DDI-MedLine.d196.s13	35	4	5	O	35	35	35	CD	False
DDI-MedLine.d196.s13	%	6	6	O	%	%	%	NN	False
DDI-MedLine.d196.s13	)	7	7	O	)	)	)	)	False
DDI-MedLine.d196.s13	were	9	12	O	were	ere	were	VBD	False
DDI-MedLine.d196.s13	men	14	16	O	men	men	men	NNS	False
DDI-MedLine.d196.s13	and	18	20	O	and	and	and	CC	False
DDI-MedLine.d196.s13	35	22	23	O	35	35	35	CD	False
DDI-MedLine.d196.s13	(	25	25	O	(	(	(	(	False
DDI-MedLine.d196.s13	65	26	27	O	65	65	65	CD	False
DDI-MedLine.d196.s13	%	28	28	O	%	%	%	NN	False
DDI-MedLine.d196.s13	)	29	29	O	)	)	)	)	False
DDI-MedLine.d196.s13	were	31	34	O	were	ere	were	VBD	False
DDI-MedLine.d196.s13	women	36	40	O	women	men	omen	NNS	False
DDI-MedLine.d196.s13	;	41	41	O	;	;	;	:	False

DDI-MedLine.d196.s14	mean	0	3	O	mean	ean	mean	NN	False
DDI-MedLine.d196.s14	weight	5	10	O	weight	ght	ight	NN	False
DDI-MedLine.d196.s14	was	12	14	O	was	was	was	VBD	False
DDI-MedLine.d196.s14	155.2	16	20	O	155.2	5.2	55.2	CD	False
DDI-MedLine.d196.s14	pounds	22	27	O	pounds	nds	unds	NNS	False
DDI-MedLine.d196.s14	(	29	29	O	(	(	(	(	False
DDI-MedLine.d196.s14	range	30	34	O	range	nge	ange	NN	False
DDI-MedLine.d196.s14	,	35	35	O	,	,	,	,	False
DDI-MedLine.d196.s14	103.0-267.0	37	47	O	103.0-267.0	7.0	67.0	JJ	False
DDI-MedLine.d196.s14	pounds	49	54	O	pounds	nds	unds	NNS	False
DDI-MedLine.d196.s14	)	55	55	O	)	)	)	)	False
DDI-MedLine.d196.s14	;	56	56	O	;	;	;	:	False

DDI-MedLine.d196.s15	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d196.s15	48	4	5	O	48	48	48	CD	False
DDI-MedLine.d196.s15	(	7	7	O	(	(	(	(	False
DDI-MedLine.d196.s15	89	8	9	O	89	89	89	CD	False
DDI-MedLine.d196.s15	%	10	10	O	%	%	%	NN	False
DDI-MedLine.d196.s15	)	11	11	O	)	)	)	)	False
DDI-MedLine.d196.s15	were	13	16	O	were	ere	were	VBD	False
DDI-MedLine.d196.s15	white	18	22	O	white	ite	hite	JJ	False
DDI-MedLine.d196.s15	,	23	23	O	,	,	,	,	False
DDI-MedLine.d196.s15	1	25	25	O	1	1	1	CD	False
DDI-MedLine.d196.s15	(	27	27	O	(	(	(	(	False
DDI-MedLine.d196.s15	2	28	28	O	2	2	2	CD	False
DDI-MedLine.d196.s15	%	29	29	O	%	%	%	NN	False
DDI-MedLine.d196.s15	)	30	30	O	)	)	)	)	False
DDI-MedLine.d196.s15	was	32	34	O	was	was	was	VBD	False
DDI-MedLine.d196.s15	black	36	40	O	black	ack	lack	JJ	False
DDI-MedLine.d196.s15	,	41	41	O	,	,	,	,	False
DDI-MedLine.d196.s15	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d196.s15	5	47	47	O	5	5	5	CD	False
DDI-MedLine.d196.s15	(	49	49	O	(	(	(	(	False
DDI-MedLine.d196.s15	9	50	50	O	9	9	9	CD	False
DDI-MedLine.d196.s15	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d196.s15	)	52	52	O	)	)	)	)	False
DDI-MedLine.d196.s15	were	54	57	O	were	ere	were	VBD	False
DDI-MedLine.d196.s15	white/American	59	72	O	white/American	can	ican	JJ	False
DDI-MedLine.d196.s15	Indian/Alaskan	74	87	O	Indian/Alaskan	kan	skan	NN	False
DDI-MedLine.d196.s15	native/Asian	89	100	O	native/Asian	ian	sian	JJ	False
DDI-MedLine.d196.s15	.	101	101	O	.	.	.	.	False

DDI-MedLine.d196.s16	Volunteers	0	9	O	Volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s16	in	11	12	O	in	in	in	IN	False
DDI-MedLine.d196.s16	study	14	18	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s16	2	20	20	O	2	2	2	CD	False
DDI-MedLine.d196.s16	(	22	22	O	(	(	(	(	False
DDI-MedLine.d196.s16	fed	23	25	O	fed	fed	fed	NN	False
DDI-MedLine.d196.s16	;	26	26	O	;	;	;	:	False
DDI-MedLine.d196.s16	n	28	28	O	n	n	n	NN	False
DDI-MedLine.d196.s16	=	30	30	O	=	=	=	NN	False
DDI-MedLine.d196.s16	54	32	33	O	54	54	54	CD	False
DDI-MedLine.d196.s16	)	34	34	O	)	)	)	)	False
DDI-MedLine.d196.s16	were	36	39	O	were	ere	were	VBD	False
DDI-MedLine.d196.s16	aged	41	44	O	aged	ged	aged	VBN	False
DDI-MedLine.d196.s16	18	46	47	O	18	18	18	CD	False
DDI-MedLine.d196.s16	to	49	50	O	to	to	to	TO	False
DDI-MedLine.d196.s16	43	52	53	O	43	43	43	CD	False
DDI-MedLine.d196.s16	years	55	59	O	years	ars	ears	NNS	False
DDI-MedLine.d196.s16	;	60	60	O	;	;	;	:	False

DDI-MedLine.d196.s17	27	0	1	O	27	27	27	CD	False
DDI-MedLine.d196.s17	(	3	3	O	(	(	(	(	False
DDI-MedLine.d196.s17	50	4	5	O	50	50	50	CD	False
DDI-MedLine.d196.s17	%	6	6	O	%	%	%	NN	False
DDI-MedLine.d196.s17	)	7	7	O	)	)	)	)	False
DDI-MedLine.d196.s17	were	9	12	O	were	ere	were	VBD	False
DDI-MedLine.d196.s17	men	14	16	O	men	men	men	NNS	False
DDI-MedLine.d196.s17	and	18	20	O	and	and	and	CC	False
DDI-MedLine.d196.s17	27	22	23	O	27	27	27	CD	False
DDI-MedLine.d196.s17	(	25	25	O	(	(	(	(	False
DDI-MedLine.d196.s17	50	26	27	O	50	50	50	CD	False
DDI-MedLine.d196.s17	%	28	28	O	%	%	%	NN	False
DDI-MedLine.d196.s17	)	29	29	O	)	)	)	)	False
DDI-MedLine.d196.s17	were	31	34	O	were	ere	were	VBD	False
DDI-MedLine.d196.s17	women	36	40	O	women	men	omen	NNS	False
DDI-MedLine.d196.s17	;	41	41	O	;	;	;	:	False

DDI-MedLine.d196.s18	mean	0	3	O	mean	ean	mean	NN	False
DDI-MedLine.d196.s18	weight	5	10	O	weight	ght	ight	NN	False
DDI-MedLine.d196.s18	was	12	14	O	was	was	was	VBD	False
DDI-MedLine.d196.s18	161.9	16	20	O	161.9	1.9	61.9	CD	False
DDI-MedLine.d196.s18	pounds	22	27	O	pounds	nds	unds	NNS	False
DDI-MedLine.d196.s18	(	29	29	O	(	(	(	(	False
DDI-MedLine.d196.s18	range	30	34	O	range	nge	ange	NN	False
DDI-MedLine.d196.s18	,	35	35	O	,	,	,	,	False
DDI-MedLine.d196.s18	112.0-225.0	37	47	O	112.0-225.0	5.0	25.0	JJ	False
DDI-MedLine.d196.s18	pounds	49	54	O	pounds	nds	unds	NNS	False
DDI-MedLine.d196.s18	)	55	55	O	)	)	)	)	False
DDI-MedLine.d196.s18	;	56	56	O	;	;	;	:	False

DDI-MedLine.d196.s19	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d196.s19	51	4	5	O	51	51	51	CD	False
DDI-MedLine.d196.s19	(	7	7	O	(	(	(	(	False
DDI-MedLine.d196.s19	94	8	9	O	94	94	94	CD	False
DDI-MedLine.d196.s19	%	10	10	O	%	%	%	NN	False
DDI-MedLine.d196.s19	)	11	11	O	)	)	)	)	False
DDI-MedLine.d196.s19	were	13	16	O	were	ere	were	VBD	False
DDI-MedLine.d196.s19	white	18	22	O	white	ite	hite	JJ	False
DDI-MedLine.d196.s19	(	24	24	O	(	(	(	(	False
DDI-MedLine.d196.s19	including	25	33	O	including	ing	ding	VBG	False
DDI-MedLine.d196.s19	2	35	35	O	2	2	2	CD	False
DDI-MedLine.d196.s19	Hispanic	37	44	O	Hispanic	nic	anic	JJ	False
DDI-MedLine.d196.s19	)	45	45	O	)	)	)	)	False
DDI-MedLine.d196.s19	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d196.s19	3	51	51	O	3	3	3	CD	False
DDI-MedLine.d196.s19	(	53	53	O	(	(	(	(	False
DDI-MedLine.d196.s19	6	54	54	O	6	6	6	CD	False
DDI-MedLine.d196.s19	%	55	55	O	%	%	%	NN	False
DDI-MedLine.d196.s19	)	56	56	O	)	)	)	)	False
DDI-MedLine.d196.s19	were	58	61	O	were	ere	were	VBD	False
DDI-MedLine.d196.s19	black	63	67	O	black	ack	lack	JJ	False
DDI-MedLine.d196.s19	.	68	68	O	.	.	.	.	False

DDI-MedLine.d196.s20	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d196.s20	90	4	5	O	90	90	90	CD	False
DDI-MedLine.d196.s20	%	6	6	O	%	%	%	NN	False
DDI-MedLine.d196.s20	CIs	8	10	O	CIs	CIs	CIs	NN	False
DDI-MedLine.d196.s20	about	12	16	O	about	out	bout	IN	False
DDI-MedLine.d196.s20	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d196.s20	ratio	22	26	O	ratio	tio	atio	NN	False
DDI-MedLine.d196.s20	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d196.s20	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d196.s20	fenofibric	35	44	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s20	acid	46	49	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s20	geometric	51	59	O	geometric	ric	tric	NN	False
DDI-MedLine.d196.s20	mean	61	64	O	mean	ean	mean	NN	False
DDI-MedLine.d196.s20	to	66	67	O	to	to	to	TO	False
DDI-MedLine.d196.s20	the	69	71	O	the	the	the	DT	False
DDI-MedLine.d196.s20	fenofibrate	73	83	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s20	geometric	85	93	O	geometric	ric	tric	NN	False
DDI-MedLine.d196.s20	mean	95	98	O	mean	ean	mean	NN	False
DDI-MedLine.d196.s20	were	100	103	O	were	ere	were	VBD	False
DDI-MedLine.d196.s20	within	105	110	O	within	hin	thin	IN	False
DDI-MedLine.d196.s20	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d196.s20	80	116	117	O	80	80	80	CD	False
DDI-MedLine.d196.s20	%	118	118	O	%	%	%	NN	False
DDI-MedLine.d196.s20	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d196.s20	125	124	126	O	125	125	125	CD	False
DDI-MedLine.d196.s20	%	127	127	O	%	%	%	NN	False
DDI-MedLine.d196.s20	limits	129	134	O	limits	its	mits	NNS	False
DDI-MedLine.d196.s20	for	136	138	O	for	for	for	IN	False
DDI-MedLine.d196.s20	the	140	142	O	the	the	the	DT	False
DDI-MedLine.d196.s20	pharmacokinetic	144	158	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d196.s20	parameters	160	169	O	parameters	ers	ters	NNS	False
DDI-MedLine.d196.s20	C	171	171	O	C	C	C	SYM	brand
DDI-MedLine.d196.s20	(	172	172	O	(	(	(	(	False
DDI-MedLine.d196.s20	max	173	175	O	max	max	max	NN	False
DDI-MedLine.d196.s20	)	176	176	O	)	)	)	)	False
DDI-MedLine.d196.s20	,	177	177	O	,	,	,	,	False
DDI-MedLine.d196.s20	AUC	179	181	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d196.s20	(	182	182	O	(	(	(	(	False
DDI-MedLine.d196.s20	0-t	183	185	O	0-t	0-t	0-t	NN	False
DDI-MedLine.d196.s20	)	186	186	O	)	)	)	)	False
DDI-MedLine.d196.s20	,	187	187	O	,	,	,	,	False
DDI-MedLine.d196.s20	and	189	191	O	and	and	and	CC	False
DDI-MedLine.d196.s20	AUC	193	195	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d196.s20	(	196	196	O	(	(	(	(	False
DDI-MedLine.d196.s20	0-	197	198	O	0-	0-	0-	NN	False
DDI-MedLine.d196.s20	)	202	202	O	)	)	)	)	False
DDI-MedLine.d196.s20	of	204	205	O	of	of	of	IN	False
DDI-MedLine.d196.s20	the	207	209	O	the	the	the	DT	False
DDI-MedLine.d196.s20	ln-transformed	211	224	O	ln-transformed	med	rmed	JJ	False
DDI-MedLine.d196.s20	data	226	229	O	data	ata	data	NNS	False
DDI-MedLine.d196.s20	in	231	232	O	in	in	in	IN	False
DDI-MedLine.d196.s20	both	234	237	O	both	oth	both	DT	False
DDI-MedLine.d196.s20	study	239	243	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s20	1	245	245	O	1	1	1	CD	False
DDI-MedLine.d196.s20	(	247	247	O	(	(	(	(	False
DDI-MedLine.d196.s20	fasted	248	253	O	fasted	ted	sted	VBN	False
DDI-MedLine.d196.s20	)	254	254	O	)	)	)	)	False
DDI-MedLine.d196.s20	and	256	258	O	and	and	and	CC	False
DDI-MedLine.d196.s20	study	260	264	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s20	2	266	266	O	2	2	2	CD	False
DDI-MedLine.d196.s20	.	267	267	O	.	.	.	.	False

DDI-MedLine.d196.s21	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d196.s21	study	3	7	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s21	1	9	9	O	1	1	1	CD	False
DDI-MedLine.d196.s21	(	11	11	O	(	(	(	(	False
DDI-MedLine.d196.s21	fasted	12	17	O	fasted	ted	sted	VBN	False
DDI-MedLine.d196.s21	)	18	18	O	)	)	)	)	False
DDI-MedLine.d196.s21	,	19	19	O	,	,	,	,	False
DDI-MedLine.d196.s21	14	21	22	O	14	14	14	CD	False
DDI-MedLine.d196.s21	volunteers	24	33	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s21	(	35	35	O	(	(	(	(	False
DDI-MedLine.d196.s21	26	36	37	O	26	26	26	CD	False
DDI-MedLine.d196.s21	%	38	38	O	%	%	%	NN	False
DDI-MedLine.d196.s21	)	39	39	O	)	)	)	)	False
DDI-MedLine.d196.s21	experienced	41	51	O	experienced	ced	nced	JJ	False
DDI-MedLine.d196.s21	a	53	53	O	a	a	a	DT	False
DDI-MedLine.d196.s21	total	55	59	O	total	tal	otal	JJ	False
DDI-MedLine.d196.s21	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d196.s21	29	64	65	O	29	29	29	CD	False
DDI-MedLine.d196.s21	AEs	67	69	O	AEs	AEs	AEs	NN	False
DDI-MedLine.d196.s21	;	70	70	O	;	;	;	:	False

DDI-MedLine.d196.s22	the	0	2	O	the	the	the	DT	False
DDI-MedLine.d196.s22	most	4	7	O	most	ost	most	JJS	False
DDI-MedLine.d196.s22	common	9	14	O	common	mon	mmon	JJ	False
DDI-MedLine.d196.s22	nonlaboratory	16	28	O	nonlaboratory	ory	tory	NN	False
DDI-MedLine.d196.s22	AEs	30	32	O	AEs	AEs	AEs	NN	False
DDI-MedLine.d196.s22	were	34	37	O	were	ere	were	VBD	False
DDI-MedLine.d196.s22	dizziness	39	47	O	dizziness	ess	ness	NN	False
DDI-MedLine.d196.s22	(	49	49	O	(	(	(	(	False
DDI-MedLine.d196.s22	6	50	50	O	6	6	6	CD	False
DDI-MedLine.d196.s22	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d196.s22	)	52	52	O	)	)	)	)	False
DDI-MedLine.d196.s22	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d196.s22	headache	58	65	O	headache	che	ache	NN	False
DDI-MedLine.d196.s22	(	67	67	O	(	(	(	(	False
DDI-MedLine.d196.s22	4	68	68	O	4	4	4	CD	False
DDI-MedLine.d196.s22	%	69	69	O	%	%	%	NN	False
DDI-MedLine.d196.s22	)	70	70	O	)	)	)	)	False
DDI-MedLine.d196.s22	.	71	71	O	.	.	.	.	False

DDI-MedLine.d196.s23	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d196.s23	study	3	7	O	study	udy	tudy	NN	False
DDI-MedLine.d196.s23	2	9	9	O	2	2	2	CD	False
DDI-MedLine.d196.s23	,	10	10	O	,	,	,	,	False
DDI-MedLine.d196.s23	12	12	13	O	12	12	12	CD	False
DDI-MedLine.d196.s23	volunteers	15	24	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s23	(	26	26	O	(	(	(	(	False
DDI-MedLine.d196.s23	22	27	28	O	22	22	22	CD	False
DDI-MedLine.d196.s23	%	29	29	O	%	%	%	NN	False
DDI-MedLine.d196.s23	)	30	30	O	)	)	)	)	False
DDI-MedLine.d196.s23	experienced	32	42	O	experienced	ced	nced	JJ	False
DDI-MedLine.d196.s23	a	44	44	O	a	a	a	DT	False
DDI-MedLine.d196.s23	total	46	50	O	total	tal	otal	JJ	False
DDI-MedLine.d196.s23	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d196.s23	19	55	56	O	19	19	19	CD	False
DDI-MedLine.d196.s23	AEs	58	60	O	AEs	AEs	AEs	NN	False
DDI-MedLine.d196.s23	;	61	61	O	;	;	;	:	False

DDI-MedLine.d196.s24	the	0	2	O	the	the	the	DT	False
DDI-MedLine.d196.s24	most	4	7	O	most	ost	most	JJS	False
DDI-MedLine.d196.s24	common	9	14	O	common	mon	mmon	JJ	False
DDI-MedLine.d196.s24	nonlaboratory	16	28	O	nonlaboratory	ory	tory	NN	False
DDI-MedLine.d196.s24	AEs	30	32	O	AEs	AEs	AEs	NN	False
DDI-MedLine.d196.s24	were	34	37	O	were	ere	were	VBD	False
DDI-MedLine.d196.s24	headache	39	46	O	headache	che	ache	NN	False
DDI-MedLine.d196.s24	(	48	48	O	(	(	(	(	False
DDI-MedLine.d196.s24	17	49	50	O	17	17	17	CD	False
DDI-MedLine.d196.s24	%	51	51	O	%	%	%	NN	False
DDI-MedLine.d196.s24	)	52	52	O	)	)	)	)	False
DDI-MedLine.d196.s24	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d196.s24	dry	58	60	O	dry	dry	dry	NN	False
DDI-MedLine.d196.s24	throat	62	67	O	throat	oat	roat	NN	False
DDI-MedLine.d196.s24	(	69	69	O	(	(	(	(	False
DDI-MedLine.d196.s24	4	70	70	O	4	4	4	CD	False
DDI-MedLine.d196.s24	%	71	71	O	%	%	%	NN	False
DDI-MedLine.d196.s24	)	72	72	O	)	)	)	)	False
DDI-MedLine.d196.s24	.	73	73	O	.	.	.	.	False

DDI-MedLine.d196.s25	AEs	0	2	O	AEs	AEs	AEs	NN	False
DDI-MedLine.d196.s25	were	4	7	O	were	ere	were	VBD	False
DDI-MedLine.d196.s25	generally	9	17	O	generally	lly	ally	RB	False
DDI-MedLine.d196.s25	mild	19	22	O	mild	ild	mild	NN	False
DDI-MedLine.d196.s25	or	24	25	O	or	or	or	CC	False
DDI-MedLine.d196.s25	moderate	27	34	O	moderate	ate	rate	NN	False
DDI-MedLine.d196.s25	in	36	37	O	in	in	in	IN	False
DDI-MedLine.d196.s25	intensity	39	47	O	intensity	ity	sity	NN	False
DDI-MedLine.d196.s25	.	48	48	O	.	.	.	.	False

DDI-MedLine.d196.s26	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d196.s26	these	3	7	O	these	ese	hese	DT	False
DDI-MedLine.d196.s26	2	9	9	O	2	2	2	CD	False
DDI-MedLine.d196.s26	single-dose	11	21	O	single-dose	ose	dose	JJ	False
DDI-MedLine.d196.s26	studies	23	29	O	studies	ies	dies	NNS	False
DDI-MedLine.d196.s26	,	30	30	O	,	,	,	,	False
DDI-MedLine.d196.s26	these	32	36	O	these	ese	hese	DT	False
DDI-MedLine.d196.s26	healthy	38	44	O	healthy	thy	lthy	JJ	False
DDI-MedLine.d196.s26	volunteers	46	55	O	volunteers	ers	eers	NNS	False
DDI-MedLine.d196.s26	administered	57	68	O	administered	red	ered	VBN	False
DDI-MedLine.d196.s26	a	70	70	O	a	a	a	DT	False
DDI-MedLine.d196.s26	single	72	77	O	single	gle	ngle	JJ	False
DDI-MedLine.d196.s26	oral	79	82	O	oral	ral	oral	JJ	False
DDI-MedLine.d196.s26	dose	84	87	O	dose	ose	dose	NN	False
DDI-MedLine.d196.s26	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d196.s26	105-mg	92	97	O	105-mg	-mg	5-mg	JJ	False
DDI-MedLine.d196.s26	fenofibric	99	108	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s26	acid	110	113	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s26	met	115	117	O	met	met	met	NN	False
DDI-MedLine.d196.s26	the	119	121	O	the	the	the	DT	False
DDI-MedLine.d196.s26	US	123	124	O	US	US	US	NN	brand
DDI-MedLine.d196.s26	Food	126	129	O	Food	ood	Food	NN	False
DDI-MedLine.d196.s26	and	131	133	O	and	and	and	CC	False
DDI-MedLine.d196.s26	Drug	135	138	O	Drug	rug	Drug	NN	False
DDI-MedLine.d196.s26	Administration	140	153	O	Administration	ion	tion	NN	False
DDI-MedLine.d196.s26	regulatory	155	164	O	regulatory	ory	tory	JJ	False
DDI-MedLine.d196.s26	criteria	166	173	O	criteria	ria	eria	NNS	False
DDI-MedLine.d196.s26	for	175	177	O	for	for	for	IN	False
DDI-MedLine.d196.s26	assuming	179	186	O	assuming	ing	ming	VBG	False
DDI-MedLine.d196.s26	bioequivalence	188	201	O	bioequivalence	nce	ence	NN	False
DDI-MedLine.d196.s26	to	203	204	O	to	to	to	TO	False
DDI-MedLine.d196.s26	a	206	206	O	a	a	a	DT	False
DDI-MedLine.d196.s26	single	208	213	O	single	gle	ngle	JJ	False
DDI-MedLine.d196.s26	oral	215	218	O	oral	ral	oral	JJ	False
DDI-MedLine.d196.s26	dose	220	223	O	dose	ose	dose	NN	False
DDI-MedLine.d196.s26	of	225	226	O	of	of	of	IN	False
DDI-MedLine.d196.s26	145-mg	228	233	O	145-mg	-mg	5-mg	JJ	False
DDI-MedLine.d196.s26	fenofibrate	235	245	B-drug	fenofibrate	ate	rate	NN	False
DDI-MedLine.d196.s26	tablets	247	253	O	tablets	ets	lets	NNS	False
DDI-MedLine.d196.s26	with	255	258	O	with	ith	with	IN	False
DDI-MedLine.d196.s26	respect	260	266	O	respect	ect	pect	NN	False
DDI-MedLine.d196.s26	to	268	269	O	to	to	to	TO	False
DDI-MedLine.d196.s26	the	271	273	O	the	the	the	DT	False
DDI-MedLine.d196.s26	rate	275	278	O	rate	ate	rate	NN	False
DDI-MedLine.d196.s26	and	280	282	O	and	and	and	CC	False
DDI-MedLine.d196.s26	extent	284	289	O	extent	ent	tent	NN	False
DDI-MedLine.d196.s26	of	291	292	O	of	of	of	IN	False
DDI-MedLine.d196.s26	fenofibric	294	303	B-drug	fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s26	acid	305	308	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s26	absorption	310	319	O	absorption	ion	tion	NN	False
DDI-MedLine.d196.s26	in	321	322	O	in	in	in	IN	False
DDI-MedLine.d196.s26	both	324	327	O	both	oth	both	DT	False
DDI-MedLine.d196.s26	fed	329	331	O	fed	fed	fed	NN	False
DDI-MedLine.d196.s26	and	333	335	O	and	and	and	CC	False
DDI-MedLine.d196.s26	fasted	337	342	O	fasted	ted	sted	VBN	False
DDI-MedLine.d196.s26	states	344	349	O	states	tes	ates	NNS	False
DDI-MedLine.d196.s26	.	350	350	O	.	.	.	.	False

DDI-MedLine.d196.s27	Fenofibric	0	9	B-drug	Fenofibric	ric	bric	NN	False
DDI-MedLine.d196.s27	acid	11	14	I-drug	acid	cid	acid	NN	False
DDI-MedLine.d196.s27	at	16	17	O	at	at	at	IN	False
DDI-MedLine.d196.s27	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d196.s27	dose	23	26	O	dose	ose	dose	NN	False
DDI-MedLine.d196.s27	studied	28	34	O	studied	ied	died	VBN	False
DDI-MedLine.d196.s27	was	36	38	O	was	was	was	VBD	False
DDI-MedLine.d196.s27	well	40	43	O	well	ell	well	RB	False
DDI-MedLine.d196.s27	tolerated	45	53	O	tolerated	ted	ated	VBN	False
DDI-MedLine.d196.s27	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d196.s27	this	58	61	O	this	his	this	DT	False
DDI-MedLine.d196.s27	population	63	72	O	population	ion	tion	NN	False
DDI-MedLine.d196.s27	.	73	73	O	.	.	.	.	False

DDI-MedLine.d203.s0	Potential	0	8	O	Potential	ial	tial	JJ	False
DDI-MedLine.d203.s0	underuse	10	17	O	underuse	use	ruse	NN	False
DDI-MedLine.d203.s0	,	18	18	O	,	,	,	,	False
DDI-MedLine.d203.s0	overuse	20	26	O	overuse	use	ruse	NN	False
DDI-MedLine.d203.s0	,	27	27	O	,	,	,	,	False
DDI-MedLine.d203.s0	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d203.s0	inappropriate	33	45	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d203.s0	use	47	49	O	use	use	use	NN	False
DDI-MedLine.d203.s0	of	51	52	O	of	of	of	IN	False
DDI-MedLine.d203.s0	antidepressants	54	68	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d203.s0	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d203.s0	older	73	77	O	older	der	lder	JJR	False
DDI-MedLine.d203.s0	veteran	79	85	O	veteran	ran	eran	NN	False
DDI-MedLine.d203.s0	nursing	87	93	O	nursing	ing	sing	NN	False
DDI-MedLine.d203.s0	home	95	98	O	home	ome	home	NN	False
DDI-MedLine.d203.s0	residents	100	108	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s0	.	109	109	O	.	.	.	.	False

DDI-MedLine.d203.s1	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d203.s1	examine	3	9	O	examine	ine	mine	NN	drug
DDI-MedLine.d203.s1	prevalence	11	20	O	prevalence	nce	ence	NN	False
DDI-MedLine.d203.s1	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d203.s1	resident-	26	34	O	resident-	nt-	ent-	NN	False
DDI-MedLine.d203.s1	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d203.s1	site-level	40	49	O	site-level	vel	evel	NN	False
DDI-MedLine.d203.s1	factors	51	57	O	factors	ors	tors	NNS	False
DDI-MedLine.d203.s1	associated	59	68	O	associated	ted	ated	VBN	False
DDI-MedLine.d203.s1	with	70	73	O	with	ith	with	IN	False
DDI-MedLine.d203.s1	potential	75	83	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s1	underuse	85	92	O	underuse	use	ruse	NN	False
DDI-MedLine.d203.s1	,	93	93	O	,	,	,	,	False
DDI-MedLine.d203.s1	overuse	95	101	O	overuse	use	ruse	NN	False
DDI-MedLine.d203.s1	,	102	102	O	,	,	,	,	False
DDI-MedLine.d203.s1	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d203.s1	inappropriate	108	120	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d203.s1	use	122	124	O	use	use	use	NN	False
DDI-MedLine.d203.s1	of	126	127	O	of	of	of	IN	False
DDI-MedLine.d203.s1	antidepressants	129	143	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d203.s1	in	145	146	O	in	in	in	IN	False
DDI-MedLine.d203.s1	older	148	152	O	older	der	lder	JJR	False
DDI-MedLine.d203.s1	Veterans	154	161	O	Veterans	ans	rans	NNS	False
DDI-MedLine.d203.s1	Affairs	163	169	O	Affairs	irs	airs	NNS	False
DDI-MedLine.d203.s1	(	171	171	O	(	(	(	(	False
DDI-MedLine.d203.s1	VA	172	173	O	VA	VA	VA	NN	brand
DDI-MedLine.d203.s1	)	174	174	O	)	)	)	)	False
DDI-MedLine.d203.s1	Community	176	184	O	Community	ity	nity	NNP	False
DDI-MedLine.d203.s1	Living	186	191	O	Living	ing	ving	VBG	False
DDI-MedLine.d203.s1	Center	193	198	O	Center	ter	nter	NNP	False
DDI-MedLine.d203.s1	(	200	200	O	(	(	(	(	False
DDI-MedLine.d203.s1	CLC	201	203	O	CLC	CLC	CLC	NN	brand
DDI-MedLine.d203.s1	)	204	204	O	)	)	)	)	False
DDI-MedLine.d203.s1	residents	206	214	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s1	.	215	215	O	.	.	.	.	False

DDI-MedLine.d203.s2	Longitudinal	0	11	O	Longitudinal	nal	inal	JJ	False
DDI-MedLine.d203.s2	study	13	17	O	study	udy	tudy	NN	False
DDI-MedLine.d203.s2	.	18	18	O	.	.	.	.	False

DDI-MedLine.d203.s3	One	0	2	O	One	One	One	CD	False
DDI-MedLine.d203.s3	hundred	4	10	O	hundred	red	dred	VBN	False
DDI-MedLine.d203.s3	thirty-three	12	23	O	thirty-three	ree	hree	JJ	False
DDI-MedLine.d203.s3	VA	25	26	O	VA	VA	VA	NN	brand
DDI-MedLine.d203.s3	CLCs	28	31	O	CLCs	LCs	CLCs	NN	False
DDI-MedLine.d203.s3	.	32	32	O	.	.	.	.	False

DDI-MedLine.d203.s4	Three	0	4	O	Three	ree	hree	CD	False
DDI-MedLine.d203.s4	thousand	6	13	O	thousand	and	sand	NN	False
DDI-MedLine.d203.s4	six	15	17	O	six	six	six	CD	False
DDI-MedLine.d203.s4	hundred	19	25	O	hundred	red	dred	VBN	False
DDI-MedLine.d203.s4	ninety-two	27	36	O	ninety-two	two	-two	JJ	False
DDI-MedLine.d203.s4	veterans	38	45	O	veterans	ans	rans	NNS	False
DDI-MedLine.d203.s4	aged	47	50	O	aged	ged	aged	VBN	False
DDI-MedLine.d203.s4	65	52	53	O	65	65	65	CD	False
DDI-MedLine.d203.s4	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d203.s4	older	59	63	O	older	der	lder	JJR	False
DDI-MedLine.d203.s4	admitted	65	72	O	admitted	ted	tted	VBN	False
DDI-MedLine.d203.s4	between	74	80	O	between	een	ween	IN	False
DDI-MedLine.d203.s4	January	82	88	O	January	ary	uary	NNP	False
DDI-MedLine.d203.s4	1	90	90	O	1	1	1	CD	False
DDI-MedLine.d203.s4	,	91	91	O	,	,	,	,	False
DDI-MedLine.d203.s4	2004	93	96	O	2004	004	2004	CD	False
DDI-MedLine.d203.s4	,	97	97	O	,	,	,	,	False
DDI-MedLine.d203.s4	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d203.s4	June	103	106	O	June	une	June	NNP	False
DDI-MedLine.d203.s4	3	108	108	O	3	3	3	CD	False
DDI-MedLine.d203.s4	,	109	109	O	,	,	,	,	False
DDI-MedLine.d203.s4	2005	111	114	O	2005	005	2005	CD	False
DDI-MedLine.d203.s4	,	115	115	O	,	,	,	,	False
DDI-MedLine.d203.s4	with	117	120	O	with	ith	with	IN	False
DDI-MedLine.d203.s4	long	122	125	O	long	ong	long	RB	False
DDI-MedLine.d203.s4	stays	127	131	O	stays	ays	tays	NNS	False
DDI-MedLine.d203.s4	(	133	133	O	(	(	(	(	False
DDI-MedLine.d203.s4	90	138	139	O	90	90	90	CD	False
DDI-MedLine.d203.s4	days	141	144	O	days	ays	days	NNS	False
DDI-MedLine.d203.s4	)	145	145	O	)	)	)	)	False
DDI-MedLine.d203.s4	.	146	146	O	.	.	.	.	False

DDI-MedLine.d203.s5	Prevalence	0	9	O	Prevalence	nce	ence	NN	False
DDI-MedLine.d203.s5	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d203.s5	potential	14	22	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s5	underuse	24	31	O	underuse	use	ruse	NN	False
DDI-MedLine.d203.s5	,	32	32	O	,	,	,	,	False
DDI-MedLine.d203.s5	inappropriate	34	46	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d203.s5	use	48	50	O	use	use	use	NN	False
DDI-MedLine.d203.s5	,	51	51	O	,	,	,	,	False
DDI-MedLine.d203.s5	and	53	55	O	and	and	and	CC	False
DDI-MedLine.d203.s5	overuse	57	63	O	overuse	use	ruse	NN	False
DDI-MedLine.d203.s5	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d203.s5	antidepressants	68	82	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d203.s5	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d203.s5	residents	87	95	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s5	with	97	100	O	with	ith	with	IN	False
DDI-MedLine.d203.s5	and	102	104	O	and	and	and	CC	False
DDI-MedLine.d203.s5	without	106	112	O	without	out	hout	IN	False
DDI-MedLine.d203.s5	depression	114	123	O	depression	ion	sion	NN	False
DDI-MedLine.d203.s5	(	125	125	O	(	(	(	(	False
DDI-MedLine.d203.s5	as	126	127	O	as	as	as	IN	False
DDI-MedLine.d203.s5	documented	129	138	O	documented	ted	nted	VBN	False
DDI-MedLine.d203.s5	according	140	148	O	according	ing	ding	VBG	False
DDI-MedLine.d203.s5	to	150	151	O	to	to	to	TO	False
DDI-MedLine.d203.s5	International	153	165	O	International	nal	onal	NNP	False
DDI-MedLine.d203.s5	Classification	167	180	O	Classification	ion	tion	NN	False
DDI-MedLine.d203.s5	of	182	183	O	of	of	of	IN	False
DDI-MedLine.d203.s5	Diseases	185	192	O	Diseases	ses	ases	NNS	False
DDI-MedLine.d203.s5	,	193	193	O	,	,	,	,	False
DDI-MedLine.d203.s5	Ninth	195	199	O	Ninth	nth	inth	JJ	False
DDI-MedLine.d203.s5	Revision	201	208	O	Revision	ion	sion	NN	False
DDI-MedLine.d203.s5	,	209	209	O	,	,	,	,	False
DDI-MedLine.d203.s5	Clinical	211	218	O	Clinical	cal	ical	JJ	False
DDI-MedLine.d203.s5	Modification	220	231	O	Modification	ion	tion	NN	False
DDI-MedLine.d203.s5	,	232	232	O	,	,	,	,	False
DDI-MedLine.d203.s5	codes	234	238	O	codes	des	odes	NNS	False
DDI-MedLine.d203.s5	or	240	241	O	or	or	or	CC	False
DDI-MedLine.d203.s5	Depression	243	252	O	Depression	ion	sion	NN	False
DDI-MedLine.d203.s5	Rating	254	259	O	Rating	ing	ting	VBG	False
DDI-MedLine.d203.s5	Scale	261	265	O	Scale	ale	cale	NN	False
DDI-MedLine.d203.s5	)	266	266	O	)	)	)	)	False
DDI-MedLine.d203.s5	.	267	267	O	.	.	.	.	False

DDI-MedLine.d203.s6	Selective	0	8	B-group	Selective	ive	tive	JJ	False
DDI-MedLine.d203.s6	serotonin	10	18	I-group	serotonin	nin	onin	NN	False
DDI-MedLine.d203.s6	reuptake	20	27	I-group	reuptake	ake	take	NN	False
DDI-MedLine.d203.s6	inhibitors	29	38	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d203.s6	were	40	43	O	were	ere	were	VBD	False
DDI-MedLine.d203.s6	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d203.s6	most	49	52	O	most	ost	most	JJS	False
DDI-MedLine.d203.s6	commonly	54	61	O	commonly	nly	only	RB	False
DDI-MedLine.d203.s6	prescribed	63	72	O	prescribed	bed	ibed	NNS	False
DDI-MedLine.d203.s6	antidepressant	74	87	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d203.s6	.	88	88	O	.	.	.	.	False

DDI-MedLine.d203.s7	Of	0	1	O	Of	Of	Of	IN	False
DDI-MedLine.d203.s7	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d203.s7	877	7	9	O	877	877	877	CD	False
DDI-MedLine.d203.s7	residents	11	19	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s7	with	21	24	O	with	ith	with	IN	False
DDI-MedLine.d203.s7	depression	26	35	O	depression	ion	sion	NN	False
DDI-MedLine.d203.s7	,	36	36	O	,	,	,	,	False
DDI-MedLine.d203.s7	25.4	38	41	O	25.4	5.4	25.4	CD	False
DDI-MedLine.d203.s7	%	42	42	O	%	%	%	NN	False
DDI-MedLine.d203.s7	did	44	46	O	did	did	did	VBD	False
DDI-MedLine.d203.s7	not	48	50	O	not	not	not	RB	False
DDI-MedLine.d203.s7	receive	52	58	O	receive	ive	eive	NN	False
DDI-MedLine.d203.s7	an	60	61	O	an	an	an	DT	False
DDI-MedLine.d203.s7	antidepressant	63	76	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d203.s7	,	77	77	O	,	,	,	,	False
DDI-MedLine.d203.s7	suggesting	79	88	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d203.s7	potential	90	98	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s7	underuse	100	107	O	underuse	use	ruse	NN	False
DDI-MedLine.d203.s7	.	108	108	O	.	.	.	.	False

DDI-MedLine.d203.s8	Of	0	1	O	Of	Of	Of	IN	False
DDI-MedLine.d203.s8	residents	3	11	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s8	with	13	16	O	with	ith	with	IN	False
DDI-MedLine.d203.s8	depression	18	27	O	depression	ion	sion	NN	False
DDI-MedLine.d203.s8	who	29	31	O	who	who	who	WP	False
DDI-MedLine.d203.s8	received	33	40	O	received	ved	ived	VBN	False
DDI-MedLine.d203.s8	antidepressants	42	56	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d203.s8	,	57	57	O	,	,	,	,	False
DDI-MedLine.d203.s8	57.5	59	62	O	57.5	7.5	57.5	CD	False
DDI-MedLine.d203.s8	%	63	63	O	%	%	%	NN	False
DDI-MedLine.d203.s8	had	65	67	O	had	had	had	VBD	False
DDI-MedLine.d203.s8	potential	69	77	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s8	inappropriate	79	91	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d203.s8	use	93	95	O	use	use	use	NN	False
DDI-MedLine.d203.s8	due	97	99	O	due	due	due	JJ	False
DDI-MedLine.d203.s8	primarily	101	109	O	primarily	ily	rily	RB	False
DDI-MedLine.d203.s8	to	111	112	O	to	to	to	TO	False
DDI-MedLine.d203.s8	problems	114	121	O	problems	ems	lems	NNS	False
DDI-MedLine.d203.s8	seen	123	126	O	seen	een	seen	VBN	False
DDI-MedLine.d203.s8	with	128	131	O	with	ith	with	IN	False
DDI-MedLine.d203.s8	drug-drug	133	141	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d203.s8	and	143	145	O	and	and	and	CC	False
DDI-MedLine.d203.s8	drug-disease	147	158	O	drug-disease	ase	ease	NN	False
DDI-MedLine.d203.s8	interactions	160	171	O	interactions	ons	ions	NNS	False
DDI-MedLine.d203.s8	.	172	172	O	.	.	.	.	False

DDI-MedLine.d203.s9	Of	0	1	O	Of	Of	Of	IN	False
DDI-MedLine.d203.s9	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d203.s9	2,815	7	11	O	2,815	815	,815	CD	False
DDI-MedLine.d203.s9	residents	13	21	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s9	who	23	25	O	who	who	who	WP	False
DDI-MedLine.d203.s9	did	27	29	O	did	did	did	VBD	False
DDI-MedLine.d203.s9	not	31	33	O	not	not	not	RB	False
DDI-MedLine.d203.s9	have	35	38	O	have	ave	have	VB	False
DDI-MedLine.d203.s9	depression	40	49	O	depression	ion	sion	NN	False
DDI-MedLine.d203.s9	,	50	50	O	,	,	,	,	False
DDI-MedLine.d203.s9	1,190	52	56	O	1,190	190	,190	CD	False
DDI-MedLine.d203.s9	(	58	58	O	(	(	(	(	False
DDI-MedLine.d203.s9	42.3	59	62	O	42.3	2.3	42.3	CD	False
DDI-MedLine.d203.s9	%	63	63	O	%	%	%	NN	False
DDI-MedLine.d203.s9	)	64	64	O	)	)	)	)	False
DDI-MedLine.d203.s9	were	66	69	O	were	ere	were	VBD	False
DDI-MedLine.d203.s9	prescribed	71	80	O	prescribed	bed	ibed	NNS	False
DDI-MedLine.d203.s9	one	82	84	O	one	one	one	CD	False
DDI-MedLine.d203.s9	or	86	87	O	or	or	or	CC	False
DDI-MedLine.d203.s9	more	89	92	O	more	ore	more	RBR	False
DDI-MedLine.d203.s9	antidepressants	94	108	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d203.s9	;	109	109	O	;	;	;	:	False

DDI-MedLine.d203.s10	only	0	3	O	only	nly	only	RB	False
DDI-MedLine.d203.s10	48	5	6	O	48	48	48	CD	False
DDI-MedLine.d203.s10	(	8	8	O	(	(	(	(	False
DDI-MedLine.d203.s10	4.0	9	11	O	4.0	4.0	4.0	CD	False
DDI-MedLine.d203.s10	%	12	12	O	%	%	%	NN	False
DDI-MedLine.d203.s10	)	13	13	O	)	)	)	)	False
DDI-MedLine.d203.s10	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d203.s10	these	18	22	O	these	ese	hese	DT	False
DDI-MedLine.d203.s10	had	24	26	O	had	had	had	VBD	False
DDI-MedLine.d203.s10	a	28	28	O	a	a	a	DT	False
DDI-MedLine.d203.s10	Food	30	33	O	Food	ood	Food	NN	False
DDI-MedLine.d203.s10	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d203.s10	Drug	39	42	O	Drug	rug	Drug	NN	False
DDI-MedLine.d203.s10	Administration-approved	44	66	O	Administration-approved	ved	oved	JJ	False
DDI-MedLine.d203.s10	labeled	68	74	O	labeled	led	eled	VBN	False
DDI-MedLine.d203.s10	indication	76	85	O	indication	ion	tion	NN	False
DDI-MedLine.d203.s10	,	86	86	O	,	,	,	,	False
DDI-MedLine.d203.s10	suggesting	88	97	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d203.s10	potential	99	107	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s10	overuse	109	115	O	overuse	use	ruse	NN	False
DDI-MedLine.d203.s10	.	116	116	O	.	.	.	.	False

DDI-MedLine.d203.s11	Overall	0	6	O	Overall	all	rall	JJ	False
DDI-MedLine.d203.s11	,	7	7	O	,	,	,	,	False
DDI-MedLine.d203.s11	only	9	12	O	only	nly	only	RB	False
DDI-MedLine.d203.s11	17.6	14	17	O	17.6	7.6	17.6	CD	False
DDI-MedLine.d203.s11	%	18	18	O	%	%	%	NN	False
DDI-MedLine.d203.s11	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d203.s11	antidepressant	23	36	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d203.s11	use	38	40	O	use	use	use	NN	False
DDI-MedLine.d203.s11	was	42	44	O	was	was	was	VBD	False
DDI-MedLine.d203.s11	appropriate	46	56	O	appropriate	ate	iate	NN	False
DDI-MedLine.d203.s11	(	58	58	O	(	(	(	(	False
DDI-MedLine.d203.s11	324/1,844	59	67	O	324/1,844	844	,844	CD	False
DDI-MedLine.d203.s11	)	68	68	O	)	)	)	)	False
DDI-MedLine.d203.s11	.	69	69	O	.	.	.	.	False

DDI-MedLine.d203.s12	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d203.s12	only	4	7	O	only	nly	only	RB	False
DDI-MedLine.d203.s12	consistent	9	18	O	consistent	ent	tent	NN	False
DDI-MedLine.d203.s12	resident	20	27	O	resident	ent	dent	NN	False
DDI-MedLine.d203.s12	factor	29	34	O	factor	tor	ctor	NN	False
DDI-MedLine.d203.s12	associated	36	45	O	associated	ted	ated	VBN	False
DDI-MedLine.d203.s12	with	47	50	O	with	ith	with	IN	False
DDI-MedLine.d203.s12	potential	52	60	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s12	underuse	62	69	O	underuse	use	ruse	NN	False
DDI-MedLine.d203.s12	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d203.s12	overuse	75	81	O	overuse	use	ruse	NN	False
DDI-MedLine.d203.s12	use	83	85	O	use	use	use	NN	False
DDI-MedLine.d203.s12	was	87	89	O	was	was	was	VBD	False
DDI-MedLine.d203.s12	taking	91	96	O	taking	ing	king	VBG	False
DDI-MedLine.d203.s12	an	98	99	O	an	an	an	DT	False
DDI-MedLine.d203.s12	antipsychotic	101	113	B-group	antipsychotic	tic	otic	JJ	False
DDI-MedLine.d203.s12	without	115	121	O	without	out	hout	IN	False
DDI-MedLine.d203.s12	evidence	123	130	O	evidence	nce	ence	NN	False
DDI-MedLine.d203.s12	of	132	133	O	of	of	of	IN	False
DDI-MedLine.d203.s12	schizophrenia	135	147	O	schizophrenia	nia	enia	NN	False
DDI-MedLine.d203.s12	(	149	149	O	(	(	(	(	False
DDI-MedLine.d203.s12	underuse	150	157	O	underuse	use	ruse	NN	False
DDI-MedLine.d203.s12	:	158	158	O	:	:	:	:	False
DDI-MedLine.d203.s12	adjusted	160	167	O	adjusted	ted	sted	VBN	False
DDI-MedLine.d203.s12	relative	169	176	O	relative	ive	tive	NN	False
DDI-MedLine.d203.s12	risk	178	181	O	risk	isk	risk	NN	False
DDI-MedLine.d203.s12	ratio	183	187	O	ratio	tio	atio	NN	False
DDI-MedLine.d203.s12	(	189	189	O	(	(	(	(	False
DDI-MedLine.d203.s12	ARRR	190	193	O	ARRR	RRR	ARRR	NN	brand
DDI-MedLine.d203.s12	)	194	194	O	)	)	)	)	False
DDI-MedLine.d203.s12	=0.56	195	199	O	=0.56	.56	0.56	NN	False
DDI-MedLine.d203.s12	,	200	200	O	,	,	,	,	False
DDI-MedLine.d203.s12	95	202	203	O	95	95	95	CD	False
DDI-MedLine.d203.s12	%	204	204	O	%	%	%	NN	False
DDI-MedLine.d203.s12	confidence	206	215	O	confidence	nce	ence	NN	False
DDI-MedLine.d203.s12	interval	217	224	O	interval	val	rval	NN	False
DDI-MedLine.d203.s12	(	226	226	O	(	(	(	(	False
DDI-MedLine.d203.s12	CI	227	228	O	CI	CI	CI	NN	brand
DDI-MedLine.d203.s12	)	229	229	O	)	)	)	)	False
DDI-MedLine.d203.s12	=0.33-0.94	230	239	O	=0.33-0.94	.94	0.94	NN	False
DDI-MedLine.d203.s12	;	240	240	O	;	;	;	:	False
DDI-MedLine.d203.s12	overuse	242	248	O	overuse	use	ruse	NN	False
DDI-MedLine.d203.s12	:	249	249	O	:	:	:	:	False
DDI-MedLine.d203.s12	adjusted	251	258	O	adjusted	ted	sted	VBN	False
DDI-MedLine.d203.s12	odds	260	263	O	odds	dds	odds	NNS	False
DDI-MedLine.d203.s12	ratio=1.52	265	274	O	ratio=1.52	.52	1.52	NN	False
DDI-MedLine.d203.s12	,	275	275	O	,	,	,	,	False
DDI-MedLine.d203.s12	95	277	278	O	95	95	95	CD	False
DDI-MedLine.d203.s12	%	279	279	O	%	%	%	NN	False
DDI-MedLine.d203.s12	CI=1.21-1.91	281	292	O	CI=1.21-1.91	.91	1.91	NN	brand
DDI-MedLine.d203.s12	)	293	293	O	)	)	)	)	False
DDI-MedLine.d203.s12	.	294	294	O	.	.	.	.	False

DDI-MedLine.d203.s13	Having	0	5	O	Having	ing	ving	VBG	False
DDI-MedLine.d203.s13	moderate	7	14	O	moderate	ate	rate	NN	False
DDI-MedLine.d203.s13	to	16	17	O	to	to	to	TO	False
DDI-MedLine.d203.s13	severe	19	24	O	severe	ere	vere	JJ	False
DDI-MedLine.d203.s13	pain	26	29	O	pain	ain	pain	NN	False
DDI-MedLine.d203.s13	(	31	31	O	(	(	(	(	False
DDI-MedLine.d203.s13	ARRR=1.54	32	40	O	ARRR=1.54	.54	1.54	NN	brand
DDI-MedLine.d203.s13	,	41	41	O	,	,	,	,	False
DDI-MedLine.d203.s13	95	43	44	O	95	95	95	CD	False
DDI-MedLine.d203.s13	%	45	45	O	%	%	%	NN	False
DDI-MedLine.d203.s13	CI=1.08-2.20	47	58	O	CI=1.08-2.20	.20	2.20	NN	brand
DDI-MedLine.d203.s13	)	59	59	O	)	)	)	)	False
DDI-MedLine.d203.s13	and	61	63	O	and	and	and	CC	False
DDI-MedLine.d203.s13	the	65	67	O	the	the	the	DT	False
DDI-MedLine.d203.s13	prescribing	69	79	O	prescribing	ing	bing	VBG	False
DDI-MedLine.d203.s13	of	81	82	O	of	of	of	IN	False
DDI-MedLine.d203.s13	an	84	85	O	an	an	an	DT	False
DDI-MedLine.d203.s13	anxiolytic	87	96	B-group	anxiolytic	tic	ytic	JJ	False
DDI-MedLine.d203.s13	or	98	99	O	or	or	or	CC	False
DDI-MedLine.d203.s13	hypnotic	101	108	B-group	hypnotic	tic	otic	JJ	False
DDI-MedLine.d203.s13	(	110	110	O	(	(	(	(	False
DDI-MedLine.d203.s13	ARRR=1.33	111	119	O	ARRR=1.33	.33	1.33	NN	brand
DDI-MedLine.d203.s13	,	120	120	O	,	,	,	,	False
DDI-MedLine.d203.s13	95	122	123	O	95	95	95	CD	False
DDI-MedLine.d203.s13	%	124	124	O	%	%	%	NN	False
DDI-MedLine.d203.s13	CI=1.02-1.74	126	137	O	CI=1.02-1.74	.74	1.74	NN	brand
DDI-MedLine.d203.s13	)	138	138	O	)	)	)	)	False
DDI-MedLine.d203.s13	increased	140	148	O	increased	sed	ased	VBN	False
DDI-MedLine.d203.s13	the	150	152	O	the	the	the	DT	False
DDI-MedLine.d203.s13	risk	154	157	O	risk	isk	risk	NN	False
DDI-MedLine.d203.s13	of	159	160	O	of	of	of	IN	False
DDI-MedLine.d203.s13	potential	162	170	O	potential	ial	tial	JJ	False
DDI-MedLine.d203.s13	inappropriate	172	184	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d203.s13	antidepressant	186	199	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d203.s13	use	201	203	O	use	use	use	NN	False
DDI-MedLine.d203.s13	.	204	204	O	.	.	.	.	False

DDI-MedLine.d203.s14	Potential	0	8	O	Potential	ial	tial	JJ	False
DDI-MedLine.d203.s14	problems	10	17	O	problems	ems	lems	NNS	False
DDI-MedLine.d203.s14	with	19	22	O	with	ith	with	IN	False
DDI-MedLine.d203.s14	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d203.s14	use	28	30	O	use	use	use	NN	False
DDI-MedLine.d203.s14	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d203.s14	antidepressants	35	49	B-group	antidepressants	nts	ants	NNS	False
DDI-MedLine.d203.s14	were	51	54	O	were	ere	were	VBD	False
DDI-MedLine.d203.s14	frequently	56	65	O	frequently	tly	ntly	RB	False
DDI-MedLine.d203.s14	observed	67	74	O	observed	ved	rved	VBN	False
DDI-MedLine.d203.s14	in	76	77	O	in	in	in	IN	False
DDI-MedLine.d203.s14	older	79	83	O	older	der	lder	JJR	False
DDI-MedLine.d203.s14	U.S	85	87	O	U.S	U.S	U.S	NN	brand
DDI-MedLine.d203.s14	.	88	88	O	.	.	.	.	False

DDI-MedLine.d203.s15	veteran	0	6	O	veteran	ran	eran	NN	False
DDI-MedLine.d203.s15	CLC	8	10	O	CLC	CLC	CLC	NN	brand
DDI-MedLine.d203.s15	residents	12	20	O	residents	nts	ents	NNS	False
DDI-MedLine.d203.s15	.	21	21	O	.	.	.	.	False

DDI-MedLine.d203.s16	Future	0	5	O	Future	ure	ture	NN	False
DDI-MedLine.d203.s16	studies	7	13	O	studies	ies	dies	NNS	False
DDI-MedLine.d203.s16	are	15	17	O	are	are	are	VBP	False
DDI-MedLine.d203.s16	needed	19	24	O	needed	ded	eded	VBN	False
DDI-MedLine.d203.s16	to	26	27	O	to	to	to	TO	False
DDI-MedLine.d203.s16	examine	29	35	O	examine	ine	mine	NN	drug
DDI-MedLine.d203.s16	the	37	39	O	the	the	the	DT	False
DDI-MedLine.d203.s16	true	41	44	O	true	rue	true	JJ	False
DDI-MedLine.d203.s16	risks	46	50	O	risks	sks	isks	NNS	False
DDI-MedLine.d203.s16	and	52	54	O	and	and	and	CC	False
DDI-MedLine.d203.s16	benefits	56	63	O	benefits	its	fits	NNS	False
DDI-MedLine.d203.s16	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d203.s16	antidepressant	68	81	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d203.s16	use	83	85	O	use	use	use	NN	False
DDI-MedLine.d203.s16	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d203.s16	CLC	90	92	O	CLC	CLC	CLC	NN	brand
DDI-MedLine.d203.s16	and	94	96	O	and	and	and	CC	False
DDI-MedLine.d203.s16	non-VA	98	103	O	non-VA	-VA	n-VA	JJ	False
DDI-MedLine.d203.s16	nursing	105	111	O	nursing	ing	sing	NN	False
DDI-MedLine.d203.s16	homes	113	117	O	homes	mes	omes	NNS	False
DDI-MedLine.d203.s16	.	118	118	O	.	.	.	.	False

DDI-MedLine.d188.s0	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d188.s0	makes	3	7	O	makes	kes	akes	VBZ	False
DDI-MedLine.d188.s0	scents	9	14	O	scents	nts	ents	NNS	False
DDI-MedLine.d188.s0	.	15	15	O	.	.	.	.	False

DDI-MedLine.d188.s1	Aromatherapy	0	11	O	Aromatherapy	apy	rapy	NN	False
DDI-MedLine.d188.s1	,	12	12	O	,	,	,	,	False
DDI-MedLine.d188.s1	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d188.s1	the	18	20	O	the	the	the	DT	False
DDI-MedLine.d188.s1	claims	22	27	O	claims	ims	aims	NNS	False
DDI-MedLine.d188.s1	made	29	32	O	made	ade	made	VBN	False
DDI-MedLine.d188.s1	for	34	36	O	for	for	for	IN	False
DDI-MedLine.d188.s1	it	38	39	O	it	it	it	PRP	False
DDI-MedLine.d188.s1	,	40	40	O	,	,	,	,	False
DDI-MedLine.d188.s1	is	42	43	O	is	is	is	VBZ	False
DDI-MedLine.d188.s1	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d188.s1	subject	49	55	O	subject	ect	ject	NN	False
DDI-MedLine.d188.s1	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d188.s1	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d188.s1	second	64	69	O	second	ond	cond	JJ	False
DDI-MedLine.d188.s1	article	71	77	O	article	cle	icle	NN	False
DDI-MedLine.d188.s1	in	79	80	O	in	in	in	IN	False
DDI-MedLine.d188.s1	our	82	84	O	our	our	our	PRP$	False
DDI-MedLine.d188.s1	six-part	86	93	O	six-part	art	part	NN	False
DDI-MedLine.d188.s1	series	95	100	O	series	ies	ries	NN	False
DDI-MedLine.d188.s1	on	102	103	O	on	on	on	IN	False
DDI-MedLine.d188.s1	alternative	105	115	O	alternative	ive	tive	NN	False
DDI-MedLine.d188.s1	and	117	119	O	and	and	and	CC	False
DDI-MedLine.d188.s1	complementary	121	133	O	complementary	ary	tary	NN	False
DDI-MedLine.d188.s1	therapies	135	143	O	therapies	ies	pies	NNS	False
DDI-MedLine.d188.s1	.	144	144	O	.	.	.	.	False

DDI-MedLine.d152.s0	Mechanisms	0	9	O	Mechanisms	sms	isms	NNS	False
DDI-MedLine.d152.s0	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d152.s0	drug	14	17	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s0	toxicity	19	26	O	toxicity	ity	city	NN	False
DDI-MedLine.d152.s0	or	28	29	O	or	or	or	CC	False
DDI-MedLine.d152.s0	intolerance	31	41	O	intolerance	nce	ance	NN	False
DDI-MedLine.d152.s0	.	42	42	O	.	.	.	.	False

DDI-MedLine.d152.s1	Classically	0	10	O	Classically	lly	ally	RB	False
DDI-MedLine.d152.s1	,	11	11	O	,	,	,	,	False
DDI-MedLine.d152.s1	adverse	13	19	O	adverse	rse	erse	NN	False
DDI-MedLine.d152.s1	drug	21	24	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s1	reactions	26	34	O	reactions	ons	ions	NNS	False
DDI-MedLine.d152.s1	had	36	38	O	had	had	had	VBD	False
DDI-MedLine.d152.s1	been	40	43	O	been	een	been	VBN	False
DDI-MedLine.d152.s1	considered	45	54	O	considered	red	ered	VBN	False
DDI-MedLine.d152.s1	as	56	57	O	as	as	as	IN	False
DDI-MedLine.d152.s1	type	59	62	O	type	ype	type	NN	False
DDI-MedLine.d152.s1	A	64	64	O	A	A	A	DT	brand
DDI-MedLine.d152.s1	reactions	66	74	O	reactions	ons	ions	NNS	False
DDI-MedLine.d152.s1	which	76	80	O	which	ich	hich	WDT	False
DDI-MedLine.d152.s1	are	82	84	O	are	are	are	VBP	False
DDI-MedLine.d152.s1	related	86	92	O	related	ted	ated	JJ	False
DDI-MedLine.d152.s1	to	94	95	O	to	to	to	TO	False
DDI-MedLine.d152.s1	the	97	99	O	the	the	the	DT	False
DDI-MedLine.d152.s1	main	101	104	O	main	ain	main	JJ	False
DDI-MedLine.d152.s1	pharmacological	106	120	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d152.s1	action	122	127	O	action	ion	tion	NN	False
DDI-MedLine.d152.s1	of	129	130	O	of	of	of	IN	False
DDI-MedLine.d152.s1	the	132	134	O	the	the	the	DT	False
DDI-MedLine.d152.s1	drug	136	139	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s1	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d152.s1	therefore	145	153	O	therefore	ore	fore	RB	False
DDI-MedLine.d152.s1	are	155	157	O	are	are	are	VBP	False
DDI-MedLine.d152.s1	predictable	159	169	O	predictable	ble	able	JJ	False
DDI-MedLine.d152.s1	.	170	170	O	.	.	.	.	False

DDI-MedLine.d152.s2	Such	0	3	O	Such	uch	Such	JJ	False
DDI-MedLine.d152.s2	reactions	5	13	O	reactions	ons	ions	NNS	False
DDI-MedLine.d152.s2	are	15	17	O	are	are	are	VBP	False
DDI-MedLine.d152.s2	predictable	19	29	O	predictable	ble	able	JJ	False
DDI-MedLine.d152.s2	,	30	30	O	,	,	,	,	False
DDI-MedLine.d152.s2	reversible	32	41	O	reversible	ble	ible	JJ	False
DDI-MedLine.d152.s2	,	42	42	O	,	,	,	,	False
DDI-MedLine.d152.s2	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d152.s2	usually	48	54	O	usually	lly	ally	RB	False
DDI-MedLine.d152.s2	can	56	58	O	can	can	can	MD	False
DDI-MedLine.d152.s2	be	60	61	O	be	be	be	VB	False
DDI-MedLine.d152.s2	managed	63	69	O	managed	ged	aged	VBN	False
DDI-MedLine.d152.s2	by	71	72	O	by	by	by	IN	False
DDI-MedLine.d152.s2	lowering	74	81	O	lowering	ing	ring	VBG	False
DDI-MedLine.d152.s2	the	83	85	O	the	the	the	DT	False
DDI-MedLine.d152.s2	dose	87	90	O	dose	ose	dose	NN	False
DDI-MedLine.d152.s2	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d152.s2	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d152.s2	offending	99	107	O	offending	ing	ding	VBG	False
DDI-MedLine.d152.s2	drug	109	112	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s2	.	113	113	O	.	.	.	.	False

DDI-MedLine.d152.s3	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d152.s3	,	7	7	O	,	,	,	,	False
DDI-MedLine.d152.s3	other	9	13	O	other	her	ther	JJ	False
DDI-MedLine.d152.s3	adverse	15	21	O	adverse	rse	erse	NN	False
DDI-MedLine.d152.s3	effects	23	29	O	effects	cts	ects	NNS	False
DDI-MedLine.d152.s3	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d152.s3	drugs	34	38	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d152.s3	can	40	42	O	can	can	can	MD	False
DDI-MedLine.d152.s3	occur	44	48	O	occur	cur	ccur	NN	False
DDI-MedLine.d152.s3	which	50	54	O	which	ich	hich	WDT	False
DDI-MedLine.d152.s3	are	56	58	O	are	are	are	VBP	False
DDI-MedLine.d152.s3	unrelated	60	68	O	unrelated	ted	ated	JJ	False
DDI-MedLine.d152.s3	to	70	71	O	to	to	to	TO	False
DDI-MedLine.d152.s3	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d152.s3	main	77	80	O	main	ain	main	JJ	False
DDI-MedLine.d152.s3	pharmacological	82	96	O	pharmacological	cal	ical	JJ	False
DDI-MedLine.d152.s3	action	98	103	O	action	ion	tion	NN	False
DDI-MedLine.d152.s3	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d152.s3	the	108	110	O	the	the	the	DT	False
DDI-MedLine.d152.s3	drug	112	115	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s3	-	117	117	O	-	-	-	:	False
DDI-MedLine.d152.s3	type	119	122	O	type	ype	type	NN	False
DDI-MedLine.d152.s3	B	124	124	O	B	B	B	NN	brand
DDI-MedLine.d152.s3	reactions	126	134	O	reactions	ons	ions	NNS	False
DDI-MedLine.d152.s3	.	135	135	O	.	.	.	.	False

DDI-MedLine.d152.s4	Such	0	3	O	Such	uch	Such	JJ	False
DDI-MedLine.d152.s4	adverse	5	11	O	adverse	rse	erse	NN	False
DDI-MedLine.d152.s4	effects	13	19	O	effects	cts	ects	NNS	False
DDI-MedLine.d152.s4	are	21	23	O	are	are	are	VBP	False
DDI-MedLine.d152.s4	termed	25	30	O	termed	med	rmed	VBN	False
DDI-MedLine.d152.s4	idiosyncratic	32	44	O	idiosyncratic	tic	atic	JJ	False
DDI-MedLine.d152.s4	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d152.s4	are	50	52	O	are	are	are	VBP	False
DDI-MedLine.d152.s4	often	54	58	O	often	ten	ften	RB	False
DDI-MedLine.d152.s4	initiated	60	68	O	initiated	ted	ated	VBN	False
DDI-MedLine.d152.s4	by	70	71	O	by	by	by	IN	False
DDI-MedLine.d152.s4	metabolites	73	83	O	metabolites	tes	ites	NNS	False
DDI-MedLine.d152.s4	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d152.s4	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d152.s4	parent	92	97	O	parent	ent	rent	NN	False
DDI-MedLine.d152.s4	drug	99	102	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s4	or	104	105	O	or	or	or	CC	False
DDI-MedLine.d152.s4	by	107	108	O	by	by	by	IN	False
DDI-MedLine.d152.s4	other	110	114	O	other	her	ther	JJ	False
DDI-MedLine.d152.s4	indirect	116	123	O	indirect	ect	rect	NN	False
DDI-MedLine.d152.s4	mechanisms	125	134	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d152.s4	.	135	135	O	.	.	.	.	False

DDI-MedLine.d152.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d152.s5	detailed	4	11	O	detailed	led	iled	JJ	False
DDI-MedLine.d152.s5	understanding	13	25	O	understanding	ing	ding	VBG	False
DDI-MedLine.d152.s5	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d152.s5	adverse	30	36	O	adverse	rse	erse	NN	False
DDI-MedLine.d152.s5	drug	38	41	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s5	events	43	48	O	events	nts	ents	NNS	False
DDI-MedLine.d152.s5	has	50	52	O	has	has	has	VBZ	False
DDI-MedLine.d152.s5	become	54	59	O	become	ome	come	NN	False
DDI-MedLine.d152.s5	a	61	61	O	a	a	a	DT	False
DDI-MedLine.d152.s5	major	63	67	O	major	jor	ajor	JJ	False
DDI-MedLine.d152.s5	focus	69	73	O	focus	cus	ocus	NN	False
DDI-MedLine.d152.s5	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d152.s5	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d152.s5	regulatory	82	91	O	regulatory	ory	tory	JJ	False
DDI-MedLine.d152.s5	agencies	93	100	O	agencies	ies	cies	NNS	False
DDI-MedLine.d152.s5	throughout	102	111	O	throughout	out	hout	IN	False
DDI-MedLine.d152.s5	the	113	115	O	the	the	the	DT	False
DDI-MedLine.d152.s5	world	117	121	O	world	rld	orld	NN	False
DDI-MedLine.d152.s5	.	122	122	O	.	.	.	.	False

DDI-MedLine.d152.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d152.s6	pharmacotherapy	4	18	O	pharmacotherapy	apy	rapy	NN	False
DDI-MedLine.d152.s6	of	20	21	O	of	of	of	IN	False
DDI-MedLine.d152.s6	gastrointestinal	23	38	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d152.s6	and	40	42	O	and	and	and	CC	False
DDI-MedLine.d152.s6	liver	44	48	O	liver	ver	iver	NN	False
DDI-MedLine.d152.s6	disorders	50	58	O	disorders	ers	ders	NNS	False
DDI-MedLine.d152.s6	is	60	61	O	is	is	is	VBZ	False
DDI-MedLine.d152.s6	becoming	63	70	O	becoming	ing	ming	VBG	False
DDI-MedLine.d152.s6	increasingly	72	83	O	increasingly	gly	ngly	RB	False
DDI-MedLine.d152.s6	complex	85	91	O	complex	lex	plex	JJ	False
DDI-MedLine.d152.s6	.	92	92	O	.	.	.	.	False

DDI-MedLine.d152.s7	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d152.s7	recent	3	8	O	recent	ent	cent	JJ	False
DDI-MedLine.d152.s7	years	10	14	O	years	ars	ears	NNS	False
DDI-MedLine.d152.s7	,	15	15	O	,	,	,	,	False
DDI-MedLine.d152.s7	with	17	20	O	with	ith	with	IN	False
DDI-MedLine.d152.s7	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d152.s7	advent	26	31	O	advent	ent	vent	NN	False
DDI-MedLine.d152.s7	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d152.s7	novel	36	40	O	novel	vel	ovel	NN	False
DDI-MedLine.d152.s7	therapeutic	42	52	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d152.s7	agents	54	59	O	agents	nts	ents	NNS	False
DDI-MedLine.d152.s7	to	61	62	O	to	to	to	TO	False
DDI-MedLine.d152.s7	treat	64	68	O	treat	eat	reat	NN	False
DDI-MedLine.d152.s7	a	70	70	O	a	a	a	DT	False
DDI-MedLine.d152.s7	host	72	75	O	host	ost	host	NN	False
DDI-MedLine.d152.s7	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d152.s7	disorders	80	88	O	disorders	ers	ders	NNS	False
DDI-MedLine.d152.s7	,	89	89	O	,	,	,	,	False
DDI-MedLine.d152.s7	including	91	99	O	including	ing	ding	VBG	False
DDI-MedLine.d152.s7	viral	101	105	O	viral	ral	iral	JJ	False
DDI-MedLine.d152.s7	hepatitis	107	115	O	hepatitis	tis	itis	NN	False
DDI-MedLine.d152.s7	,	116	116	O	,	,	,	,	False
DDI-MedLine.d152.s7	gastrointestinal	118	133	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d152.s7	motility	135	142	O	motility	ity	lity	NN	False
DDI-MedLine.d152.s7	disorders	144	152	O	disorders	ers	ders	NNS	False
DDI-MedLine.d152.s7	,	153	153	O	,	,	,	,	False
DDI-MedLine.d152.s7	inflammatory	155	166	O	inflammatory	ory	tory	NN	False
DDI-MedLine.d152.s7	bowel	168	172	O	bowel	wel	owel	NN	False
DDI-MedLine.d152.s7	disease	174	180	O	disease	ase	ease	NN	False
DDI-MedLine.d152.s7	and	182	184	O	and	and	and	CC	False
DDI-MedLine.d152.s7	others	186	191	O	others	ers	hers	NNS	False
DDI-MedLine.d152.s7	,	192	192	O	,	,	,	,	False
DDI-MedLine.d152.s7	the	194	196	O	the	the	the	DT	False
DDI-MedLine.d152.s7	potential	198	206	O	potential	ial	tial	JJ	False
DDI-MedLine.d152.s7	for	208	210	O	for	for	for	IN	False
DDI-MedLine.d152.s7	serious	212	218	O	serious	ous	ious	JJ	False
DDI-MedLine.d152.s7	clinically	220	229	O	clinically	lly	ally	RB	False
DDI-MedLine.d152.s7	relevant	231	238	O	relevant	ant	vant	NN	False
DDI-MedLine.d152.s7	drug	240	243	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s7	reactions	245	253	O	reactions	ons	ions	NNS	False
DDI-MedLine.d152.s7	has	255	257	O	has	has	has	VBZ	False
DDI-MedLine.d152.s7	increased	259	267	O	increased	sed	ased	VBN	False
DDI-MedLine.d152.s7	.	268	268	O	.	.	.	.	False

DDI-MedLine.d152.s8	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d152.s8	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d152.s8	pharmacotherapy	7	21	O	pharmacotherapy	apy	rapy	NN	False
DDI-MedLine.d152.s8	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d152.s8	gastrointestinal	26	41	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d152.s8	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d152.s8	liver	47	51	O	liver	ver	iver	NN	False
DDI-MedLine.d152.s8	diseases	53	60	O	diseases	ses	ases	NNS	False
DDI-MedLine.d152.s8	,	61	61	O	,	,	,	,	False
DDI-MedLine.d152.s8	a	63	63	O	a	a	a	DT	False
DDI-MedLine.d152.s8	significant	65	75	O	significant	ant	cant	JJ	False
DDI-MedLine.d152.s8	number	77	82	O	number	ber	mber	NN	False
DDI-MedLine.d152.s8	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d152.s8	adverse	87	93	O	adverse	rse	erse	NN	False
DDI-MedLine.d152.s8	events	95	100	O	events	nts	ents	NNS	False
DDI-MedLine.d152.s8	that	102	105	O	that	hat	that	IN	False
DDI-MedLine.d152.s8	occur	107	111	O	occur	cur	ccur	NN	False
DDI-MedLine.d152.s8	can	113	115	O	can	can	can	MD	False
DDI-MedLine.d152.s8	be	117	118	O	be	be	be	VB	False
DDI-MedLine.d152.s8	explained	120	128	O	explained	ned	ined	VBD	False
DDI-MedLine.d152.s8	by	130	131	O	by	by	by	IN	False
DDI-MedLine.d152.s8	drug	133	136	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s8	interactions	138	149	O	interactions	ons	ions	NNS	False
DDI-MedLine.d152.s8	.	150	150	O	.	.	.	.	False

DDI-MedLine.d152.s9	Some	0	3	O	Some	ome	Some	DT	False
DDI-MedLine.d152.s9	pharmacokinetic	5	19	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d152.s9	drug	21	24	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s9	interactions	26	37	O	interactions	ons	ions	NNS	False
DDI-MedLine.d152.s9	are	39	41	O	are	are	are	VBP	False
DDI-MedLine.d152.s9	based	43	47	O	based	sed	ased	VBN	False
DDI-MedLine.d152.s9	on	49	50	O	on	on	on	IN	False
DDI-MedLine.d152.s9	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d152.s9	competitive	56	66	O	competitive	ive	tive	JJ	False
DDI-MedLine.d152.s9	inhibition	68	77	O	inhibition	ion	tion	NN	False
DDI-MedLine.d152.s9	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d152.s9	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d152.s9	rate	86	89	O	rate	ate	rate	NN	False
DDI-MedLine.d152.s9	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d152.s9	drug	94	97	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s9	metabolism	99	108	O	metabolism	ism	lism	NN	False
DDI-MedLine.d152.s9	of	110	111	O	of	of	of	IN	False
DDI-MedLine.d152.s9	one	113	115	O	one	one	one	CD	False
DDI-MedLine.d152.s9	of	117	118	O	of	of	of	IN	False
DDI-MedLine.d152.s9	the	120	122	O	the	the	the	DT	False
DDI-MedLine.d152.s9	drugs	124	128	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d152.s9	,	129	129	O	,	,	,	,	False
DDI-MedLine.d152.s9	leading	131	137	O	leading	ing	ding	VBG	False
DDI-MedLine.d152.s9	to	139	140	O	to	to	to	TO	False
DDI-MedLine.d152.s9	an	142	143	O	an	an	an	DT	False
DDI-MedLine.d152.s9	increased	145	153	O	increased	sed	ased	VBN	False
DDI-MedLine.d152.s9	concentration	155	167	O	concentration	ion	tion	NN	False
DDI-MedLine.d152.s9	of	169	170	O	of	of	of	IN	False
DDI-MedLine.d152.s9	the	172	174	O	the	the	the	DT	False
DDI-MedLine.d152.s9	drug	176	179	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s9	which	181	185	O	which	ich	hich	WDT	False
DDI-MedLine.d152.s9	was	187	189	O	was	was	was	VBD	False
DDI-MedLine.d152.s9	not	191	193	O	not	not	not	RB	False
DDI-MedLine.d152.s9	intended	195	202	O	intended	ded	nded	VBN	False
DDI-MedLine.d152.s9	.	203	203	O	.	.	.	.	False

DDI-MedLine.d152.s10	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d152.s10	other	3	7	O	other	her	ther	JJ	False
DDI-MedLine.d152.s10	examples	9	16	O	examples	les	ples	NNS	False
DDI-MedLine.d152.s10	,	17	17	O	,	,	,	,	False
DDI-MedLine.d152.s10	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d152.s10	interaction	23	33	O	interaction	ion	tion	NN	False
DDI-MedLine.d152.s10	can	35	37	O	can	can	can	MD	False
DDI-MedLine.d152.s10	be	39	40	O	be	be	be	VB	False
DDI-MedLine.d152.s10	mechanistic	42	52	O	mechanistic	tic	stic	JJ	False
DDI-MedLine.d152.s10	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d152.s10	which	57	61	O	which	ich	hich	WDT	False
DDI-MedLine.d152.s10	one	63	65	O	one	one	one	CD	False
DDI-MedLine.d152.s10	or	67	68	O	or	or	or	CC	False
DDI-MedLine.d152.s10	more	70	73	O	more	ore	more	RBR	False
DDI-MedLine.d152.s10	drugs	75	79	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d152.s10	when	81	84	O	when	hen	when	WRB	False
DDI-MedLine.d152.s10	co-administered	86	100	O	co-administered	red	ered	JJ	False
DDI-MedLine.d152.s10	potentiate	102	111	O	potentiate	ate	iate	NN	False
DDI-MedLine.d152.s10	each	113	116	O	each	ach	each	DT	False
DDI-MedLine.d152.s10	other	118	122	O	other	her	ther	JJ	False
DDI-MedLine.d152.s10	's	123	124	O	's	's	's	POS	False
DDI-MedLine.d152.s10	actions	126	132	O	actions	ons	ions	NNS	False
DDI-MedLine.d152.s10	without	134	140	O	without	out	hout	IN	False
DDI-MedLine.d152.s10	any	142	144	O	any	any	any	DT	False
DDI-MedLine.d152.s10	change	146	151	O	change	nge	ange	NN	False
DDI-MedLine.d152.s10	in	153	154	O	in	in	in	IN	False
DDI-MedLine.d152.s10	drug	156	159	O	drug	rug	drug	NN	False
DDI-MedLine.d152.s10	levels	161	166	O	levels	els	vels	NNS	False
DDI-MedLine.d152.s10	,	167	167	O	,	,	,	,	False
DDI-MedLine.d152.s10	termed	169	174	O	termed	med	rmed	VBN	False
DDI-MedLine.d152.s10	pharmacodynamic	176	190	O	pharmacodynamic	mic	amic	NN	False
DDI-MedLine.d152.s10	interactions	192	203	O	interactions	ons	ions	NNS	False
DDI-MedLine.d152.s10	.	204	204	O	.	.	.	.	False

DDI-MedLine.d172.s0	Clarity	0	6	O	Clarity	ity	rity	NN	False
DDI-MedLine.d172.s0	and	8	10	O	and	and	and	CC	False
DDI-MedLine.d172.s0	applicability	12	24	O	applicability	ity	lity	NN	False
DDI-MedLine.d172.s0	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d172.s0	drug-drug	29	37	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d172.s0	interaction	39	49	O	interaction	ion	tion	NN	False
DDI-MedLine.d172.s0	management	51	60	O	management	ent	ment	NN	False
DDI-MedLine.d172.s0	guidelines	62	71	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s0	:	72	72	O	:	:	:	:	False
DDI-MedLine.d172.s0	a	74	74	O	a	a	a	DT	False
DDI-MedLine.d172.s0	systematic	76	85	O	systematic	tic	atic	JJ	False
DDI-MedLine.d172.s0	appraisal	87	95	O	appraisal	sal	isal	NN	False
DDI-MedLine.d172.s0	by	97	98	O	by	by	by	IN	False
DDI-MedLine.d172.s0	general	100	106	O	general	ral	eral	JJ	False
DDI-MedLine.d172.s0	practitioners	108	120	O	practitioners	ers	ners	NNS	False
DDI-MedLine.d172.s0	and	122	124	O	and	and	and	CC	False
DDI-MedLine.d172.s0	community	126	134	O	community	ity	nity	NN	False
DDI-MedLine.d172.s0	pharmacists	136	146	O	pharmacists	sts	ists	NNS	False
DDI-MedLine.d172.s0	in	148	149	O	in	in	in	IN	False
DDI-MedLine.d172.s0	the	151	153	O	the	the	the	DT	False
DDI-MedLine.d172.s0	Netherlands	155	165	O	Netherlands	nds	ands	NNS	False
DDI-MedLine.d172.s0	.	166	166	O	.	.	.	.	False

DDI-MedLine.d172.s1	Despite	0	6	O	Despite	ite	pite	IN	False
DDI-MedLine.d172.s1	the	8	10	O	the	the	the	DT	False
DDI-MedLine.d172.s1	availability	12	23	O	availability	ity	lity	NN	False
DDI-MedLine.d172.s1	and	25	27	O	and	and	and	CC	False
DDI-MedLine.d172.s1	daily	29	33	O	daily	ily	aily	JJ	False
DDI-MedLine.d172.s1	use	35	37	O	use	use	use	NN	False
DDI-MedLine.d172.s1	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d172.s1	computerized	42	53	O	computerized	zed	ized	VBN	False
DDI-MedLine.d172.s1	drug-drug	55	63	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d172.s1	interaction	65	75	O	interaction	ion	tion	NN	False
DDI-MedLine.d172.s1	surveillance	77	88	O	surveillance	nce	ance	NN	False
DDI-MedLine.d172.s1	systems	90	96	O	systems	ems	tems	NNS	False
DDI-MedLine.d172.s1	,	97	97	O	,	,	,	,	False
DDI-MedLine.d172.s1	exposure	99	106	O	exposure	ure	sure	NN	False
DDI-MedLine.d172.s1	to	108	109	O	to	to	to	TO	False
DDI-MedLine.d172.s1	potentially	111	121	O	potentially	lly	ally	RB	False
DDI-MedLine.d172.s1	relevant	123	130	O	relevant	ant	vant	NN	False
DDI-MedLine.d172.s1	drug-drug	132	140	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d172.s1	interactions	142	153	O	interactions	ons	ions	NNS	False
DDI-MedLine.d172.s1	(	155	155	O	(	(	(	(	False
DDI-MedLine.d172.s1	DDIs	156	159	O	DDIs	DIs	DDIs	NN	False
DDI-MedLine.d172.s1	)	160	160	O	)	)	)	)	False
DDI-MedLine.d172.s1	continues	162	170	O	continues	ues	nues	VBZ	False
DDI-MedLine.d172.s1	.	171	171	O	.	.	.	.	False

DDI-MedLine.d172.s2	DDI	0	2	O	DDI	DDI	DDI	NN	brand
DDI-MedLine.d172.s2	management	4	13	O	management	ent	ment	NN	False
DDI-MedLine.d172.s2	guidelines	15	24	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s2	are	26	28	O	are	are	are	VBP	False
DDI-MedLine.d172.s2	often	30	34	O	often	ten	ften	RB	False
DDI-MedLine.d172.s2	inadequate	36	45	O	inadequate	ate	uate	NN	False
DDI-MedLine.d172.s2	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d172.s2	clear	51	55	O	clear	ear	lear	JJ	False
DDI-MedLine.d172.s2	management	57	66	O	management	ent	ment	NN	False
DDI-MedLine.d172.s2	options	68	74	O	options	ons	ions	NNS	False
DDI-MedLine.d172.s2	are	76	78	O	are	are	are	VBP	False
DDI-MedLine.d172.s2	lacking	80	86	O	lacking	ing	king	VBG	False
DDI-MedLine.d172.s2	,	87	87	O	,	,	,	,	False
DDI-MedLine.d172.s2	which	89	93	O	which	ich	hich	WDT	False
DDI-MedLine.d172.s2	attributes	95	104	O	attributes	tes	utes	NNS	False
DDI-MedLine.d172.s2	to	106	107	O	to	to	to	TO	False
DDI-MedLine.d172.s2	overriding	109	118	O	overriding	ing	ding	VBG	False
DDI-MedLine.d172.s2	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d172.s2	DDI	123	125	O	DDI	DDI	DDI	NN	brand
DDI-MedLine.d172.s2	signals	127	133	O	signals	als	nals	NNS	False
DDI-MedLine.d172.s2	.	134	134	O	.	.	.	.	False

DDI-MedLine.d172.s3	Although	0	7	O	Although	ugh	ough	IN	False
DDI-MedLine.d172.s3	general	9	15	O	general	ral	eral	JJ	False
DDI-MedLine.d172.s3	criteria	17	24	O	criteria	ria	eria	NNS	False
DDI-MedLine.d172.s3	for	26	28	O	for	for	for	IN	False
DDI-MedLine.d172.s3	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d172.s3	development	34	44	O	development	ent	ment	NN	False
DDI-MedLine.d172.s3	and	46	48	O	and	and	and	CC	False
DDI-MedLine.d172.s3	reporting	50	58	O	reporting	ing	ting	NN	False
DDI-MedLine.d172.s3	of	60	61	O	of	of	of	IN	False
DDI-MedLine.d172.s3	high-quality	63	74	O	high-quality	ity	lity	NN	False
DDI-MedLine.d172.s3	clinical	76	83	O	clinical	cal	ical	JJ	False
DDI-MedLine.d172.s3	practice	85	92	O	practice	ice	tice	NN	False
DDI-MedLine.d172.s3	guidelines	94	103	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s3	have	105	108	O	have	ave	have	VB	False
DDI-MedLine.d172.s3	been	110	113	O	been	een	been	VBN	False
DDI-MedLine.d172.s3	identified	115	124	O	identified	ied	fied	VBN	False
DDI-MedLine.d172.s3	,	125	125	O	,	,	,	,	False
DDI-MedLine.d172.s3	it	127	128	O	it	it	it	PRP	False
DDI-MedLine.d172.s3	appears	130	136	O	appears	ars	ears	VBZ	False
DDI-MedLine.d172.s3	these	138	142	O	these	ese	hese	DT	False
DDI-MedLine.d172.s3	have	144	147	O	have	ave	have	VB	False
DDI-MedLine.d172.s3	not	149	151	O	not	not	not	RB	False
DDI-MedLine.d172.s3	yet	153	155	O	yet	yet	yet	RB	False
DDI-MedLine.d172.s3	been	157	160	O	been	een	been	VBN	False
DDI-MedLine.d172.s3	applied	162	168	O	applied	ied	lied	VBN	False
DDI-MedLine.d172.s3	to	170	171	O	to	to	to	TO	False
DDI-MedLine.d172.s3	DDI	173	175	O	DDI	DDI	DDI	NN	brand
DDI-MedLine.d172.s3	management	177	186	O	management	ent	ment	NN	False
DDI-MedLine.d172.s3	guidelines	188	197	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s3	.	198	198	O	.	.	.	.	False

DDI-MedLine.d172.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d172.s4	aim	4	6	O	aim	aim	aim	NN	False
DDI-MedLine.d172.s4	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d172.s4	the	11	13	O	the	the	the	DT	False
DDI-MedLine.d172.s4	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d172.s4	was	21	23	O	was	was	was	VBD	False
DDI-MedLine.d172.s4	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d172.s4	assess	28	33	O	assess	ess	sess	NN	False
DDI-MedLine.d172.s4	the	35	37	O	the	the	the	DT	False
DDI-MedLine.d172.s4	clarity	39	45	O	clarity	ity	rity	NN	False
DDI-MedLine.d172.s4	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d172.s4	applicability	51	63	O	applicability	ity	lity	NN	False
DDI-MedLine.d172.s4	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d172.s4	guidelines	68	77	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s4	for	79	81	O	for	for	for	IN	False
DDI-MedLine.d172.s4	the	83	85	O	the	the	the	DT	False
DDI-MedLine.d172.s4	management	87	96	O	management	ent	ment	NN	False
DDI-MedLine.d172.s4	of	98	99	O	of	of	of	IN	False
DDI-MedLine.d172.s4	potentially	101	111	O	potentially	lly	ally	RB	False
DDI-MedLine.d172.s4	harmful	113	119	O	harmful	ful	mful	NN	False
DDI-MedLine.d172.s4	DDIs	121	124	O	DDIs	DIs	DDIs	NN	False
DDI-MedLine.d172.s4	.	125	125	O	.	.	.	.	False

DDI-MedLine.d172.s5	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d172.s5	selected	3	10	O	selected	ted	cted	VBN	False
DDI-MedLine.d172.s5	13	12	13	O	13	13	13	CD	False
DDI-MedLine.d172.s5	DDIs	15	18	O	DDIs	DIs	DDIs	NN	False
DDI-MedLine.d172.s5	that	20	23	O	that	hat	that	IN	False
DDI-MedLine.d172.s5	are	25	27	O	are	are	are	VBP	False
DDI-MedLine.d172.s5	potentially	29	39	O	potentially	lly	ally	RB	False
DDI-MedLine.d172.s5	harmful	41	47	O	harmful	ful	mful	NN	False
DDI-MedLine.d172.s5	for	49	51	O	for	for	for	IN	False
DDI-MedLine.d172.s5	patients	53	60	O	patients	nts	ents	NNS	False
DDI-MedLine.d172.s5	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d172.s5	frequently	66	75	O	frequently	tly	ntly	RB	False
DDI-MedLine.d172.s5	occur	77	81	O	occur	cur	ccur	NN	False
DDI-MedLine.d172.s5	in	83	84	O	in	in	in	IN	False
DDI-MedLine.d172.s5	community	86	94	O	community	ity	nity	NN	False
DDI-MedLine.d172.s5	pharmacy	96	103	O	pharmacy	acy	macy	NN	False
DDI-MedLine.d172.s5	practice	105	112	O	practice	ice	tice	NN	False
DDI-MedLine.d172.s5	in	114	115	O	in	in	in	IN	False
DDI-MedLine.d172.s5	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d172.s5	Netherlands	121	131	O	Netherlands	nds	ands	NNS	False
DDI-MedLine.d172.s5	.	132	132	O	.	.	.	.	False

DDI-MedLine.d172.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d172.s6	clarity	4	10	O	clarity	ity	rity	NN	False
DDI-MedLine.d172.s6	and	12	14	O	and	and	and	CC	False
DDI-MedLine.d172.s6	applicability	16	28	O	applicability	ity	lity	NN	False
DDI-MedLine.d172.s6	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d172.s6	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d172.s6	management	37	46	O	management	ent	ment	NN	False
DDI-MedLine.d172.s6	guidelines	48	57	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s6	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d172.s6	these	62	66	O	these	ese	hese	DT	False
DDI-MedLine.d172.s6	DDIs	68	71	O	DDIs	DIs	DDIs	NN	False
DDI-MedLine.d172.s6	were	73	76	O	were	ere	were	VBD	False
DDI-MedLine.d172.s6	appraised	78	86	O	appraised	sed	ised	VBN	False
DDI-MedLine.d172.s6	using	88	92	O	using	ing	sing	VBG	False
DDI-MedLine.d172.s6	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d172.s6	appropriate	98	108	O	appropriate	ate	iate	NN	False
DDI-MedLine.d172.s6	two	110	112	O	two	two	two	CD	False
DDI-MedLine.d172.s6	domains	114	120	O	domains	ins	ains	NNS	False
DDI-MedLine.d172.s6	-	122	122	O	-	-	-	:	False
DDI-MedLine.d172.s6	'Clarity	124	131	O	'Clarity	ity	rity	NN	False
DDI-MedLine.d172.s6	and	133	135	O	and	and	and	CC	False
DDI-MedLine.d172.s6	presentation	137	148	O	presentation	ion	tion	NN	False
DDI-MedLine.d172.s6	'	149	149	O	'	'	'	''	False
DDI-MedLine.d172.s6	and	151	153	O	and	and	and	CC	False
DDI-MedLine.d172.s6	'Applicability	155	168	O	'Applicability	ity	lity	NN	False
DDI-MedLine.d172.s6	'	169	169	O	'	'	'	''	False
DDI-MedLine.d172.s6	,	170	170	O	,	,	,	,	False
DDI-MedLine.d172.s6	of	172	173	O	of	of	of	IN	False
DDI-MedLine.d172.s6	the	175	177	O	the	the	the	DT	False
DDI-MedLine.d172.s6	validated	179	187	O	validated	ted	ated	VBN	False
DDI-MedLine.d172.s6	Appraisal	189	197	O	Appraisal	sal	isal	NN	False
DDI-MedLine.d172.s6	of	199	200	O	of	of	of	IN	False
DDI-MedLine.d172.s6	Guidelines	202	211	O	Guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s6	for	213	215	O	for	for	for	IN	False
DDI-MedLine.d172.s6	Research	217	224	O	Research	rch	arch	NN	False
DDI-MedLine.d172.s6	and	226	228	O	and	and	and	CC	False
DDI-MedLine.d172.s6	Evaluation	230	239	O	Evaluation	ion	tion	NN	False
DDI-MedLine.d172.s6	(	241	241	O	(	(	(	(	False
DDI-MedLine.d172.s6	AGREE	242	246	O	AGREE	REE	GREE	NN	brand
DDI-MedLine.d172.s6	)	247	247	O	)	)	)	)	False
DDI-MedLine.d172.s6	Instrument	249	258	O	Instrument	ent	ment	NN	False
DDI-MedLine.d172.s6	.	259	259	O	.	.	.	.	False

DDI-MedLine.d172.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d172.s7	appraisal	4	12	O	appraisal	sal	isal	NN	False
DDI-MedLine.d172.s7	was	14	16	O	was	was	was	VBD	False
DDI-MedLine.d172.s7	performed	18	26	O	performed	med	rmed	VBN	False
DDI-MedLine.d172.s7	by	28	29	O	by	by	by	IN	False
DDI-MedLine.d172.s7	12	31	32	O	12	12	12	CD	False
DDI-MedLine.d172.s7	community	34	42	O	community	ity	nity	NN	False
DDI-MedLine.d172.s7	pharmacists	44	54	O	pharmacists	sts	ists	NNS	False
DDI-MedLine.d172.s7	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d172.s7	12	60	61	O	12	12	12	CD	False
DDI-MedLine.d172.s7	general	63	69	O	general	ral	eral	JJ	False
DDI-MedLine.d172.s7	practitioners	71	83	O	practitioners	ers	ners	NNS	False
DDI-MedLine.d172.s7	.	84	84	O	.	.	.	.	False

DDI-MedLine.d172.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d172.s8	standardized	4	15	O	standardized	zed	ized	VBN	False
DDI-MedLine.d172.s8	domain	17	22	O	domain	ain	main	NN	False
DDI-MedLine.d172.s8	scores	24	29	O	scores	res	ores	NNS	False
DDI-MedLine.d172.s8	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d172.s8	mean	35	38	O	mean	ean	mean	NN	False
DDI-MedLine.d172.s8	item	40	43	O	item	tem	item	NN	False
DDI-MedLine.d172.s8	scores	45	50	O	scores	res	ores	NNS	False
DDI-MedLine.d172.s8	for	52	54	O	for	for	for	IN	False
DDI-MedLine.d172.s8	'Clarity	56	63	O	'Clarity	ity	rity	NN	False
DDI-MedLine.d172.s8	and	65	67	O	and	and	and	CC	False
DDI-MedLine.d172.s8	presentation	69	80	O	presentation	ion	tion	NN	False
DDI-MedLine.d172.s8	'	81	81	O	'	'	'	''	False
DDI-MedLine.d172.s8	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d172.s8	'Applicability	87	100	O	'Applicability	ity	lity	NN	False
DDI-MedLine.d172.s8	'	101	101	O	'	'	'	''	False
DDI-MedLine.d172.s8	were	103	106	O	were	ere	were	VBD	False
DDI-MedLine.d172.s8	compared	108	115	O	compared	red	ared	VBN	False
DDI-MedLine.d172.s8	.	116	116	O	.	.	.	.	False

DDI-MedLine.d172.s9	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d172.s9	DDI	4	6	O	DDI	DDI	DDI	NN	brand
DDI-MedLine.d172.s9	management	8	17	O	management	ent	ment	NN	False
DDI-MedLine.d172.s9	guidelines	19	28	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s9	were	30	33	O	were	ere	were	VBD	False
DDI-MedLine.d172.s9	generally	35	43	O	generally	lly	ally	RB	False
DDI-MedLine.d172.s9	found	45	49	O	found	und	ound	NN	False
DDI-MedLine.d172.s9	to	51	52	O	to	to	to	TO	False
DDI-MedLine.d172.s9	score	54	58	O	score	ore	core	NN	False
DDI-MedLine.d172.s9	well	60	63	O	well	ell	well	RB	False
DDI-MedLine.d172.s9	on	65	66	O	on	on	on	IN	False
DDI-MedLine.d172.s9	'Clarity	68	75	O	'Clarity	ity	rity	NN	False
DDI-MedLine.d172.s9	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d172.s9	presentation	81	92	O	presentation	ion	tion	NN	False
DDI-MedLine.d172.s9	'	93	93	O	'	'	'	''	False
DDI-MedLine.d172.s9	,	94	94	O	,	,	,	,	False
DDI-MedLine.d172.s9	but	96	98	O	but	but	but	CC	False
DDI-MedLine.d172.s9	poorly	100	105	O	poorly	rly	orly	RB	False
DDI-MedLine.d172.s9	with	107	110	O	with	ith	with	IN	False
DDI-MedLine.d172.s9	respect	112	118	O	respect	ect	pect	NN	False
DDI-MedLine.d172.s9	to	120	121	O	to	to	to	TO	False
DDI-MedLine.d172.s9	'Applicability	123	136	O	'Applicability	ity	lity	NN	False
DDI-MedLine.d172.s9	'	137	137	O	'	'	'	''	False
DDI-MedLine.d172.s9	(	139	139	O	(	(	(	(	False
DDI-MedLine.d172.s9	standardized	140	151	O	standardized	zed	ized	VBN	False
DDI-MedLine.d172.s9	domain	153	158	O	domain	ain	main	NN	False
DDI-MedLine.d172.s9	scores	160	165	O	scores	res	ores	NNS	False
DDI-MedLine.d172.s9	68.0	167	170	O	68.0	8.0	68.0	CD	False
DDI-MedLine.d172.s9	vs	172	173	O	vs	vs	vs	NN	False
DDI-MedLine.d172.s9	26.1	175	178	O	26.1	6.1	26.1	CD	False
DDI-MedLine.d172.s9	%	179	179	O	%	%	%	NN	False
DDI-MedLine.d172.s9	)	180	180	O	)	)	)	)	False
DDI-MedLine.d172.s9	.	181	181	O	.	.	.	.	False

DDI-MedLine.d172.s10	Within	0	5	O	Within	hin	thin	IN	False
DDI-MedLine.d172.s10	the	7	9	O	the	the	the	DT	False
DDI-MedLine.d172.s10	domain	11	16	O	domain	ain	main	NN	False
DDI-MedLine.d172.s10	'Clarity	18	25	O	'Clarity	ity	rity	NN	False
DDI-MedLine.d172.s10	and	27	29	O	and	and	and	CC	False
DDI-MedLine.d172.s10	presentation	31	42	O	presentation	ion	tion	NN	False
DDI-MedLine.d172.s10	'	43	43	O	'	'	'	''	False
DDI-MedLine.d172.s10	,	44	44	O	,	,	,	,	False
DDI-MedLine.d172.s10	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d172.s10	item	50	53	O	item	tem	item	NN	False
DDI-MedLine.d172.s10	'tools	55	60	O	'tools	ols	ools	NNS	False
DDI-MedLine.d172.s10	for	62	64	O	for	for	for	IN	False
DDI-MedLine.d172.s10	application	66	76	O	application	ion	tion	NN	False
DDI-MedLine.d172.s10	'	77	77	O	'	'	'	''	False
DDI-MedLine.d172.s10	received	79	86	O	received	ved	ived	VBN	False
DDI-MedLine.d172.s10	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d172.s10	lowest	92	97	O	lowest	est	west	JJS	False
DDI-MedLine.d172.s10	scores	99	104	O	scores	res	ores	NNS	False
DDI-MedLine.d172.s10	.	105	105	O	.	.	.	.	False

DDI-MedLine.d172.s11	Within	0	5	O	Within	hin	thin	IN	False
DDI-MedLine.d172.s11	the	7	9	O	the	the	the	DT	False
DDI-MedLine.d172.s11	domain	11	16	O	domain	ain	main	NN	False
DDI-MedLine.d172.s11	'Applicability	18	31	O	'Applicability	ity	lity	NN	False
DDI-MedLine.d172.s11	'	32	32	O	'	'	'	''	False
DDI-MedLine.d172.s11	,	33	33	O	,	,	,	,	False
DDI-MedLine.d172.s11	cost	35	38	O	cost	ost	cost	NN	False
DDI-MedLine.d172.s11	implications	40	51	O	implications	ons	ions	NNS	False
DDI-MedLine.d172.s11	,	52	52	O	,	,	,	,	False
DDI-MedLine.d172.s11	organizational	54	67	O	organizational	nal	onal	JJ	False
DDI-MedLine.d172.s11	barriers	69	76	O	barriers	ers	iers	NNS	False
DDI-MedLine.d172.s11	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d172.s11	key	82	84	O	key	key	key	NN	False
DDI-MedLine.d172.s11	review	86	91	O	review	iew	view	NN	False
DDI-MedLine.d172.s11	criteria	93	100	O	criteria	ria	eria	NNS	False
DDI-MedLine.d172.s11	were	102	105	O	were	ere	were	VBD	False
DDI-MedLine.d172.s11	all	107	109	O	all	all	all	DT	False
DDI-MedLine.d172.s11	poorly	111	116	O	poorly	rly	orly	RB	False
DDI-MedLine.d172.s11	documented	118	127	O	documented	ted	nted	VBN	False
DDI-MedLine.d172.s11	.	128	128	O	.	.	.	.	False

DDI-MedLine.d172.s12	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d172.s12	guidelines	4	13	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s12	presented	15	23	O	presented	ted	nted	VBN	False
DDI-MedLine.d172.s12	non-directive	25	37	O	non-directive	ive	tive	JJ	False
DDI-MedLine.d172.s12	advice	39	44	O	advice	ice	vice	NN	False
DDI-MedLine.d172.s12	using	46	50	O	using	ing	sing	VBG	False
DDI-MedLine.d172.s12	words	52	56	O	words	rds	ords	NNS	False
DDI-MedLine.d172.s12	such	58	61	O	such	uch	such	JJ	False
DDI-MedLine.d172.s12	as	63	64	O	as	as	as	IN	False
DDI-MedLine.d172.s12	'consider	66	74	O	'consider	der	ider	NN	False
DDI-MedLine.d172.s12	'	75	75	O	'	'	'	''	False
DDI-MedLine.d172.s12	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d172.s12	'regularly	81	90	O	'regularly	rly	arly	RB	False
DDI-MedLine.d172.s12	'	91	91	O	'	'	'	''	False
DDI-MedLine.d172.s12	.	92	92	O	.	.	.	.	False

DDI-MedLine.d172.s13	Developers	0	9	O	Developers	ers	pers	NNS	False
DDI-MedLine.d172.s13	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d172.s13	DDI	14	16	O	DDI	DDI	DDI	NN	brand
DDI-MedLine.d172.s13	management	18	27	O	management	ent	ment	NN	False
DDI-MedLine.d172.s13	guidelines	29	38	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s13	should	40	45	O	should	uld	ould	MD	False
DDI-MedLine.d172.s13	take	47	50	O	take	ake	take	VB	False
DDI-MedLine.d172.s13	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d172.s13	appropriate	56	66	O	appropriate	ate	iate	NN	False
DDI-MedLine.d172.s13	domains	68	74	O	domains	ins	ains	NNS	False
DDI-MedLine.d172.s13	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d172.s13	the	79	81	O	the	the	the	DT	False
DDI-MedLine.d172.s13	AGREE	83	87	O	AGREE	REE	GREE	NN	brand
DDI-MedLine.d172.s13	Instrument	89	98	O	Instrument	ent	ment	NN	False
DDI-MedLine.d172.s13	into	100	103	O	into	nto	into	IN	False
DDI-MedLine.d172.s13	consideration	105	117	O	consideration	ion	tion	NN	False
DDI-MedLine.d172.s13	in	119	120	O	in	in	in	IN	False
DDI-MedLine.d172.s13	their	122	126	O	their	eir	heir	PRP$	False
DDI-MedLine.d172.s13	development	128	138	O	development	ent	ment	NN	False
DDI-MedLine.d172.s13	processes	140	148	O	processes	ses	sses	NNS	False
DDI-MedLine.d172.s13	.	149	149	O	.	.	.	.	False

DDI-MedLine.d172.s14	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d172.s14	applicability	4	16	O	applicability	ity	lity	NN	False
DDI-MedLine.d172.s14	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d172.s14	DDI	21	23	O	DDI	DDI	DDI	NN	brand
DDI-MedLine.d172.s14	management	25	34	O	management	ent	ment	NN	False
DDI-MedLine.d172.s14	guidelines	36	45	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d172.s14	should	47	52	O	should	uld	ould	MD	False
DDI-MedLine.d172.s14	be	54	55	O	be	be	be	VB	False
DDI-MedLine.d172.s14	pretested	57	65	O	pretested	ted	sted	VBN	False
DDI-MedLine.d172.s14	before	67	72	O	before	ore	fore	IN	False
DDI-MedLine.d172.s14	publishing	74	83	O	publishing	ing	hing	NN	False
DDI-MedLine.d172.s14	.	84	84	O	.	.	.	.	False

DDI-MedLine.d172.s15	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d172.s15	improve	3	9	O	improve	ove	rove	VB	False
DDI-MedLine.d172.s15	guideline	11	19	O	guideline	ine	line	NN	drug
DDI-MedLine.d172.s15	quality	21	27	O	quality	ity	lity	NN	False
DDI-MedLine.d172.s15	,	28	28	O	,	,	,	,	False
DDI-MedLine.d172.s15	more	30	33	O	more	ore	more	RBR	False
DDI-MedLine.d172.s15	attention	35	43	O	attention	ion	tion	NN	False
DDI-MedLine.d172.s15	should	45	50	O	should	uld	ould	MD	False
DDI-MedLine.d172.s15	particularly	52	63	O	particularly	rly	arly	RB	False
DDI-MedLine.d172.s15	be	65	66	O	be	be	be	VB	False
DDI-MedLine.d172.s15	paid	68	71	O	paid	aid	paid	NN	False
DDI-MedLine.d172.s15	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d172.s15	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d172.s15	available	80	88	O	available	ble	able	JJ	False
DDI-MedLine.d172.s15	tools	90	94	O	tools	ols	ools	NNS	False
DDI-MedLine.d172.s15	for	96	98	O	for	for	for	IN	False
DDI-MedLine.d172.s15	applications	100	111	O	applications	ons	ions	NNS	False
DDI-MedLine.d172.s15	and	113	115	O	and	and	and	CC	False
DDI-MedLine.d172.s15	cost	117	120	O	cost	ost	cost	NN	False
DDI-MedLine.d172.s15	implications	122	133	O	implications	ons	ions	NNS	False
DDI-MedLine.d172.s15	.	134	134	O	.	.	.	.	False

DDI-MedLine.d156.s0	ABC	0	2	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s0	transporters	4	15	O	transporters	ers	ters	NNS	False
DDI-MedLine.d156.s0	influence	17	25	O	influence	nce	ence	NN	False
DDI-MedLine.d156.s0	sensitivity	27	37	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d156.s0	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d156.s0	Brugia	42	47	O	Brugia	gia	ugia	NN	False
DDI-MedLine.d156.s0	malayi	49	54	O	malayi	ayi	layi	NN	False
DDI-MedLine.d156.s0	to	56	57	O	to	to	to	TO	False
DDI-MedLine.d156.s0	moxidectin	59	68	B-drug_n	moxidectin	tin	ctin	NN	False
DDI-MedLine.d156.s0	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d156.s0	have	74	77	O	have	ave	have	VB	False
DDI-MedLine.d156.s0	potential	79	87	O	potential	ial	tial	JJ	False
DDI-MedLine.d156.s0	roles	89	93	O	roles	les	oles	NNS	group
DDI-MedLine.d156.s0	in	95	96	O	in	in	in	IN	False
DDI-MedLine.d156.s0	drug	98	101	O	drug	rug	drug	NN	False
DDI-MedLine.d156.s0	resistance	103	112	O	resistance	nce	ance	NN	False
DDI-MedLine.d156.s0	.	113	113	O	.	.	.	.	False

DDI-MedLine.d156.s1	Some	0	3	O	Some	ome	Some	DT	False
DDI-MedLine.d156.s1	ABC	5	7	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s1	transporters	9	20	O	transporters	ers	ters	NNS	False
DDI-MedLine.d156.s1	play	22	25	O	play	lay	play	NN	False
DDI-MedLine.d156.s1	a	27	27	O	a	a	a	DT	False
DDI-MedLine.d156.s1	significant	29	39	O	significant	ant	cant	JJ	False
DDI-MedLine.d156.s1	role	41	44	O	role	ole	role	NN	False
DDI-MedLine.d156.s1	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d156.s1	human	49	53	O	human	man	uman	NN	False
DDI-MedLine.d156.s1	health	55	60	O	health	lth	alth	NN	False
DDI-MedLine.d156.s1	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d156.s1	illness	66	72	O	illness	ess	ness	NN	False
DDI-MedLine.d156.s1	because	74	80	O	because	use	ause	IN	False
DDI-MedLine.d156.s1	they	82	85	O	they	hey	they	PRP	False
DDI-MedLine.d156.s1	confer	87	92	O	confer	fer	nfer	NN	False
DDI-MedLine.d156.s1	multidrug	94	102	O	multidrug	rug	drug	NN	False
DDI-MedLine.d156.s1	resistance	104	113	O	resistance	nce	ance	NN	False
DDI-MedLine.d156.s1	(	115	115	O	(	(	(	(	False
DDI-MedLine.d156.s1	MDR	116	118	O	MDR	MDR	MDR	NN	brand
DDI-MedLine.d156.s1	)	119	119	O	)	)	)	)	False
DDI-MedLine.d156.s1	through	121	127	O	through	ugh	ough	IN	False
DDI-MedLine.d156.s1	their	129	133	O	their	eir	heir	PRP$	False
DDI-MedLine.d156.s1	overexpression	135	148	O	overexpression	ion	sion	NN	False
DDI-MedLine.d156.s1	.	149	149	O	.	.	.	.	False

DDI-MedLine.d156.s2	Compounds	0	8	O	Compounds	nds	unds	NNS	False
DDI-MedLine.d156.s2	that	10	13	O	that	hat	that	IN	False
DDI-MedLine.d156.s2	inhibit	15	21	O	inhibit	bit	ibit	NN	False
DDI-MedLine.d156.s2	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d156.s2	drug	27	30	O	drug	rug	drug	NN	False
DDI-MedLine.d156.s2	efflux	32	37	O	efflux	lux	flux	NN	False
DDI-MedLine.d156.s2	mechanism	39	47	O	mechanism	ism	nism	NN	False
DDI-MedLine.d156.s2	can	49	51	O	can	can	can	MD	False
DDI-MedLine.d156.s2	improve	53	59	O	improve	ove	rove	VB	False
DDI-MedLine.d156.s2	efficacy	61	68	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d156.s2	or	70	71	O	or	or	or	CC	False
DDI-MedLine.d156.s2	reverse	73	79	O	reverse	rse	erse	NN	False
DDI-MedLine.d156.s2	resistance	81	90	O	resistance	nce	ance	NN	False
DDI-MedLine.d156.s2	.	91	91	O	.	.	.	.	False

DDI-MedLine.d156.s3	Of	0	1	O	Of	Of	Of	IN	False
DDI-MedLine.d156.s3	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d156.s3	eight	7	11	O	eight	ght	ight	CD	False
DDI-MedLine.d156.s3	described	13	21	O	described	bed	ibed	NN	False
DDI-MedLine.d156.s3	ABC	23	25	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s3	transporter	27	37	O	transporter	ter	rter	NN	False
DDI-MedLine.d156.s3	subfamilies	39	49	O	subfamilies	ies	lies	NNS	False
DDI-MedLine.d156.s3	,	50	50	O	,	,	,	,	False
DDI-MedLine.d156.s3	those	52	56	O	those	ose	hose	DT	False
DDI-MedLine.d156.s3	proteins	58	65	O	proteins	ins	eins	NNS	False
DDI-MedLine.d156.s3	conferring	67	76	O	conferring	ing	ring	VBG	False
DDI-MedLine.d156.s3	MDR	78	80	O	MDR	MDR	MDR	NN	brand
DDI-MedLine.d156.s3	in	82	83	O	in	in	in	IN	False
DDI-MedLine.d156.s3	humans	85	90	O	humans	ans	mans	NNS	False
DDI-MedLine.d156.s3	are	92	94	O	are	are	are	VBP	False
DDI-MedLine.d156.s3	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d156.s3	subfamilies	99	109	O	subfamilies	ies	lies	NNS	False
DDI-MedLine.d156.s3	A	111	111	O	A	A	A	DT	brand
DDI-MedLine.d156.s3	,	112	112	O	,	,	,	,	False
DDI-MedLine.d156.s3	B	114	114	O	B	B	B	NN	brand
DDI-MedLine.d156.s3	,	115	115	O	,	,	,	,	False
DDI-MedLine.d156.s3	C	117	117	O	C	C	C	SYM	brand
DDI-MedLine.d156.s3	,	118	118	O	,	,	,	,	False
DDI-MedLine.d156.s3	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d156.s3	G	124	124	O	G	G	G	NN	brand
DDI-MedLine.d156.s3	.	125	125	O	.	.	.	.	False

DDI-MedLine.d156.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d156.s4	nematodes	3	11	O	nematodes	des	odes	NNS	False
DDI-MedLine.d156.s4	,	12	12	O	,	,	,	,	False
DDI-MedLine.d156.s4	transporters	14	25	O	transporters	ers	ters	NNS	False
DDI-MedLine.d156.s4	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d156.s4	subfamilies	30	40	O	subfamilies	ies	lies	NNS	False
DDI-MedLine.d156.s4	B	42	42	O	B	B	B	NN	brand
DDI-MedLine.d156.s4	and	44	46	O	and	and	and	CC	False
DDI-MedLine.d156.s4	C	48	48	O	C	C	C	SYM	brand
DDI-MedLine.d156.s4	are	50	52	O	are	are	are	VBP	False
DDI-MedLine.d156.s4	suggested	54	62	O	suggested	ted	sted	VBN	False
DDI-MedLine.d156.s4	to	64	65	O	to	to	to	TO	False
DDI-MedLine.d156.s4	confer	67	72	O	confer	fer	nfer	NN	False
DDI-MedLine.d156.s4	resistance	74	83	O	resistance	nce	ance	NN	False
DDI-MedLine.d156.s4	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d156.s4	ivermectin	88	97	B-drug	ivermectin	tin	ctin	NN	False
DDI-MedLine.d156.s4	.	98	98	O	.	.	.	.	False

DDI-MedLine.d156.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d156.s5	Brugia	4	9	O	Brugia	gia	ugia	NN	False
DDI-MedLine.d156.s5	malayi	11	16	O	malayi	ayi	layi	NN	False
DDI-MedLine.d156.s5	ABC	18	20	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s5	transporter	22	32	O	transporter	ter	rter	NN	False
DDI-MedLine.d156.s5	superfamily	34	44	O	superfamily	ily	mily	RB	False
DDI-MedLine.d156.s5	was	46	48	O	was	was	was	VBD	False
DDI-MedLine.d156.s5	examined	50	57	O	examined	ned	ined	VBN	False
DDI-MedLine.d156.s5	to	59	60	O	to	to	to	TO	False
DDI-MedLine.d156.s5	assess	62	67	O	assess	ess	sess	NN	False
DDI-MedLine.d156.s5	their	69	73	O	their	eir	heir	PRP$	False
DDI-MedLine.d156.s5	potential	75	83	O	potential	ial	tial	JJ	False
DDI-MedLine.d156.s5	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d156.s5	influence	88	96	O	influence	nce	ence	NN	False
DDI-MedLine.d156.s5	sensitivity	98	108	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d156.s5	to	110	111	O	to	to	to	TO	False
DDI-MedLine.d156.s5	moxidectin	113	122	B-drug_n	moxidectin	tin	ctin	NN	False
DDI-MedLine.d156.s5	.	123	123	O	.	.	.	.	False

DDI-MedLine.d156.s6	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d156.s6	was	6	8	O	was	was	was	VBD	False
DDI-MedLine.d156.s6	an	10	11	O	an	an	an	DT	False
DDI-MedLine.d156.s6	increase	13	20	O	increase	ase	ease	NN	False
DDI-MedLine.d156.s6	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d156.s6	expression	25	34	O	expression	ion	sion	NN	False
DDI-MedLine.d156.s6	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d156.s6	ABC	39	41	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s6	transporters	43	54	O	transporters	ers	ters	NNS	False
DDI-MedLine.d156.s6	in	56	57	O	in	in	in	IN	False
DDI-MedLine.d156.s6	subfamilies	59	69	O	subfamilies	ies	lies	NNS	False
DDI-MedLine.d156.s6	A	71	71	O	A	A	A	DT	brand
DDI-MedLine.d156.s6	,	72	72	O	,	,	,	,	False
DDI-MedLine.d156.s6	B	74	74	O	B	B	B	NN	brand
DDI-MedLine.d156.s6	,	75	75	O	,	,	,	,	False
DDI-MedLine.d156.s6	C	77	77	O	C	C	C	SYM	brand
DDI-MedLine.d156.s6	,	78	78	O	,	,	,	,	False
DDI-MedLine.d156.s6	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d156.s6	G	84	84	O	G	G	G	NN	brand
DDI-MedLine.d156.s6	following	86	94	O	following	ing	wing	VBG	False
DDI-MedLine.d156.s6	treatment	96	104	O	treatment	ent	ment	NN	False
DDI-MedLine.d156.s6	.	105	105	O	.	.	.	.	False

DDI-MedLine.d156.s7	Co-administration	0	16	O	Co-administration	ion	tion	NN	False
DDI-MedLine.d156.s7	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d156.s7	moxidectin	21	30	B-drug_n	moxidectin	tin	ctin	NN	False
DDI-MedLine.d156.s7	with	32	35	O	with	ith	with	IN	False
DDI-MedLine.d156.s7	inhibitors	37	46	O	inhibitors	ors	tors	NNS	False
DDI-MedLine.d156.s7	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d156.s7	ABC	51	53	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s7	transporter	55	65	O	transporter	ter	rter	NN	False
DDI-MedLine.d156.s7	function	67	74	O	function	ion	tion	NN	False
DDI-MedLine.d156.s7	did	76	78	O	did	did	did	VBD	False
DDI-MedLine.d156.s7	not	80	82	O	not	not	not	RB	False
DDI-MedLine.d156.s7	enhance	84	90	O	enhance	nce	ance	NN	False
DDI-MedLine.d156.s7	sensitivity	92	102	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d156.s7	to	104	105	O	to	to	to	TO	False
DDI-MedLine.d156.s7	moxidectin	107	116	B-drug_n	moxidectin	tin	ctin	NN	False
DDI-MedLine.d156.s7	in	118	119	O	in	in	in	IN	False
DDI-MedLine.d156.s7	males	121	125	O	males	les	ales	NNS	False
DDI-MedLine.d156.s7	;	126	126	O	;	;	;	:	False

DDI-MedLine.d156.s8	however	0	6	O	however	ver	ever	RB	False
DDI-MedLine.d156.s8	,	7	7	O	,	,	,	,	False
DDI-MedLine.d156.s8	sensitivity	9	19	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d156.s8	was	21	23	O	was	was	was	VBD	False
DDI-MedLine.d156.s8	significantly	25	37	O	significantly	tly	ntly	RB	False
DDI-MedLine.d156.s8	enhanced	39	46	O	enhanced	ced	nced	VBN	False
DDI-MedLine.d156.s8	in	48	49	O	in	in	in	IN	False
DDI-MedLine.d156.s8	females	51	57	O	females	les	ales	NNS	False
DDI-MedLine.d156.s8	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d156.s8	microfilariae	63	75	O	microfilariae	iae	riae	NN	False
DDI-MedLine.d156.s8	.	76	76	O	.	.	.	.	False

DDI-MedLine.d156.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d156.s9	work	4	7	O	work	ork	work	NN	False
DDI-MedLine.d156.s9	suggests	9	16	O	suggests	sts	ests	NNS	False
DDI-MedLine.d156.s9	that	18	21	O	that	hat	that	IN	False
DDI-MedLine.d156.s9	ABC	23	25	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d156.s9	transporters	27	38	O	transporters	ers	ters	NNS	False
DDI-MedLine.d156.s9	influence	40	48	O	influence	nce	ence	NN	False
DDI-MedLine.d156.s9	sensitivity	50	60	O	sensitivity	ity	vity	NN	False
DDI-MedLine.d156.s9	to	62	63	O	to	to	to	TO	False
DDI-MedLine.d156.s9	moxidectin	65	74	B-drug_n	moxidectin	tin	ctin	NN	False
DDI-MedLine.d156.s9	and	76	78	O	and	and	and	CC	False
DDI-MedLine.d156.s9	have	80	83	O	have	ave	have	VB	False
DDI-MedLine.d156.s9	a	85	85	O	a	a	a	DT	False
DDI-MedLine.d156.s9	potential	87	95	O	potential	ial	tial	JJ	False
DDI-MedLine.d156.s9	role	97	100	O	role	ole	role	NN	False
DDI-MedLine.d156.s9	in	102	103	O	in	in	in	IN	False
DDI-MedLine.d156.s9	drug	105	108	O	drug	rug	drug	NN	False
DDI-MedLine.d156.s9	resistance	110	119	O	resistance	nce	ance	NN	False
DDI-MedLine.d156.s9	.	120	120	O	.	.	.	.	False

DDI-MedLine.d150.s0	Network	0	6	O	Network	ork	work	NN	False
DDI-MedLine.d150.s0	neighbors	8	16	O	neighbors	ors	bors	NNS	False
DDI-MedLine.d150.s0	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d150.s0	drug	21	24	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s0	targets	26	32	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s0	contribute	34	43	O	contribute	ute	bute	NN	False
DDI-MedLine.d150.s0	to	45	46	O	to	to	to	TO	False
DDI-MedLine.d150.s0	drug	48	51	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s0	side-effect	53	63	O	side-effect	ect	fect	JJ	False
DDI-MedLine.d150.s0	similarity	65	74	O	similarity	ity	rity	NN	False
DDI-MedLine.d150.s0	.	75	75	O	.	.	.	.	False

DDI-MedLine.d150.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d150.s1	pharmacology	3	14	O	pharmacology	ogy	logy	NN	False
DDI-MedLine.d150.s1	,	15	15	O	,	,	,	,	False
DDI-MedLine.d150.s1	it	17	18	O	it	it	it	PRP	False
DDI-MedLine.d150.s1	is	20	21	O	is	is	is	VBZ	False
DDI-MedLine.d150.s1	essential	23	31	O	essential	ial	tial	JJ	False
DDI-MedLine.d150.s1	to	33	34	O	to	to	to	TO	False
DDI-MedLine.d150.s1	identify	36	43	O	identify	ify	tify	VB	False
DDI-MedLine.d150.s1	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d150.s1	molecular	49	57	O	molecular	lar	ular	NN	False
DDI-MedLine.d150.s1	mechanisms	59	68	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d150.s1	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d150.s1	drug	73	76	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s1	action	78	83	O	action	ion	tion	NN	False
DDI-MedLine.d150.s1	in	85	86	O	in	in	in	IN	False
DDI-MedLine.d150.s1	order	88	92	O	order	der	rder	NN	False
DDI-MedLine.d150.s1	to	94	95	O	to	to	to	TO	False
DDI-MedLine.d150.s1	understand	97	106	O	understand	and	tand	NN	False
DDI-MedLine.d150.s1	adverse	108	114	O	adverse	rse	erse	NN	False
DDI-MedLine.d150.s1	side	116	119	O	side	ide	side	NN	False
DDI-MedLine.d150.s1	effects	121	127	O	effects	cts	ects	NNS	False
DDI-MedLine.d150.s1	.	128	128	O	.	.	.	.	False

DDI-MedLine.d150.s2	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d150.s2	adverse	6	12	O	adverse	rse	erse	NN	False
DDI-MedLine.d150.s2	side	14	17	O	side	ide	side	NN	False
DDI-MedLine.d150.s2	effects	19	25	O	effects	cts	ects	NNS	False
DDI-MedLine.d150.s2	have	27	30	O	have	ave	have	VB	False
DDI-MedLine.d150.s2	been	32	35	O	been	een	been	VBN	False
DDI-MedLine.d150.s2	used	37	40	O	used	sed	used	VBN	False
DDI-MedLine.d150.s2	to	42	43	O	to	to	to	TO	False
DDI-MedLine.d150.s2	infer	45	49	O	infer	fer	nfer	NN	False
DDI-MedLine.d150.s2	whether	51	57	O	whether	her	ther	IN	False
DDI-MedLine.d150.s2	two	59	61	O	two	two	two	CD	False
DDI-MedLine.d150.s2	drugs	63	67	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d150.s2	share	69	73	O	share	are	hare	NN	False
DDI-MedLine.d150.s2	a	75	75	O	a	a	a	DT	False
DDI-MedLine.d150.s2	target	77	82	O	target	get	rget	NN	False
DDI-MedLine.d150.s2	protein	84	90	O	protein	ein	tein	NN	False
DDI-MedLine.d150.s2	.	91	91	O	.	.	.	.	False

DDI-MedLine.d150.s3	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d150.s3	,	7	7	O	,	,	,	,	False
DDI-MedLine.d150.s3	side-effect	9	19	O	side-effect	ect	fect	JJ	False
DDI-MedLine.d150.s3	similarity	21	30	O	similarity	ity	rity	NN	False
DDI-MedLine.d150.s3	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d150.s3	drugs	35	39	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d150.s3	could	41	45	O	could	uld	ould	MD	False
DDI-MedLine.d150.s3	also	47	50	O	also	lso	also	RB	False
DDI-MedLine.d150.s3	be	52	53	O	be	be	be	VB	False
DDI-MedLine.d150.s3	caused	55	60	O	caused	sed	used	VBN	False
DDI-MedLine.d150.s3	by	62	63	O	by	by	by	IN	False
DDI-MedLine.d150.s3	their	65	69	O	their	eir	heir	PRP$	False
DDI-MedLine.d150.s3	target	71	76	O	target	get	rget	NN	False
DDI-MedLine.d150.s3	proteins	78	85	O	proteins	ins	eins	NNS	False
DDI-MedLine.d150.s3	being	87	91	O	being	ing	eing	VBG	False
DDI-MedLine.d150.s3	close	93	97	O	close	ose	lose	RB	False
DDI-MedLine.d150.s3	in	99	100	O	in	in	in	IN	False
DDI-MedLine.d150.s3	a	102	102	O	a	a	a	DT	False
DDI-MedLine.d150.s3	molecular	104	112	O	molecular	lar	ular	NN	False
DDI-MedLine.d150.s3	network	114	120	O	network	ork	work	NN	False
DDI-MedLine.d150.s3	,	121	121	O	,	,	,	,	False
DDI-MedLine.d150.s3	which	123	127	O	which	ich	hich	WDT	False
DDI-MedLine.d150.s3	as	129	130	O	as	as	as	IN	False
DDI-MedLine.d150.s3	such	132	135	O	such	uch	such	JJ	False
DDI-MedLine.d150.s3	could	137	141	O	could	uld	ould	MD	False
DDI-MedLine.d150.s3	cause	143	147	O	cause	use	ause	NN	False
DDI-MedLine.d150.s3	similar	149	155	O	similar	lar	ilar	JJ	False
DDI-MedLine.d150.s3	downstream	157	166	O	downstream	eam	ream	NN	False
DDI-MedLine.d150.s3	effects	168	174	O	effects	cts	ects	NNS	False
DDI-MedLine.d150.s3	.	175	175	O	.	.	.	.	False

DDI-MedLine.d150.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d150.s4	this	3	6	O	this	his	this	DT	False
DDI-MedLine.d150.s4	study	8	12	O	study	udy	tudy	NN	False
DDI-MedLine.d150.s4	,	13	13	O	,	,	,	,	False
DDI-MedLine.d150.s4	we	15	16	O	we	we	we	PRP	False
DDI-MedLine.d150.s4	investigated	18	29	O	investigated	ted	ated	VBN	False
DDI-MedLine.d150.s4	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d150.s4	proportion	35	44	O	proportion	ion	tion	NN	False
DDI-MedLine.d150.s4	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d150.s4	side-effect	49	59	O	side-effect	ect	fect	JJ	False
DDI-MedLine.d150.s4	similarities	61	72	O	similarities	ies	ties	NNS	False
DDI-MedLine.d150.s4	that	74	77	O	that	hat	that	IN	False
DDI-MedLine.d150.s4	is	79	80	O	is	is	is	VBZ	False
DDI-MedLine.d150.s4	due	82	84	O	due	due	due	JJ	False
DDI-MedLine.d150.s4	to	86	87	O	to	to	to	TO	False
DDI-MedLine.d150.s4	targets	89	95	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s4	that	97	100	O	that	hat	that	IN	False
DDI-MedLine.d150.s4	are	102	104	O	are	are	are	VBP	False
DDI-MedLine.d150.s4	close	106	110	O	close	ose	lose	RB	False
DDI-MedLine.d150.s4	in	112	113	O	in	in	in	IN	False
DDI-MedLine.d150.s4	the	115	117	O	the	the	the	DT	False
DDI-MedLine.d150.s4	network	119	125	O	network	ork	work	NN	False
DDI-MedLine.d150.s4	compared	127	134	O	compared	red	ared	VBN	False
DDI-MedLine.d150.s4	to	136	137	O	to	to	to	TO	False
DDI-MedLine.d150.s4	shared	139	144	O	shared	red	ared	VBN	False
DDI-MedLine.d150.s4	drug	146	149	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s4	targets	151	157	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s4	.	158	158	O	.	.	.	.	False

DDI-MedLine.d150.s5	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d150.s5	found	3	7	O	found	und	ound	NN	False
DDI-MedLine.d150.s5	that	9	12	O	that	hat	that	IN	False
DDI-MedLine.d150.s5	only	14	17	O	only	nly	only	RB	False
DDI-MedLine.d150.s5	a	19	19	O	a	a	a	DT	False
DDI-MedLine.d150.s5	minor	21	25	O	minor	nor	inor	NN	False
DDI-MedLine.d150.s5	fraction	27	34	O	fraction	ion	tion	NN	False
DDI-MedLine.d150.s5	of	36	37	O	of	of	of	IN	False
DDI-MedLine.d150.s5	side-effect	39	49	O	side-effect	ect	fect	JJ	False
DDI-MedLine.d150.s5	similarities	51	62	O	similarities	ies	ties	NNS	False
DDI-MedLine.d150.s5	(	64	64	O	(	(	(	(	False
DDI-MedLine.d150.s5	5.8	65	67	O	5.8	5.8	5.8	CD	False
DDI-MedLine.d150.s5	%	69	69	O	%	%	%	NN	False
DDI-MedLine.d150.s5	)	70	70	O	)	)	)	)	False
DDI-MedLine.d150.s5	are	72	74	O	are	are	are	VBP	False
DDI-MedLine.d150.s5	caused	76	81	O	caused	sed	used	VBN	False
DDI-MedLine.d150.s5	by	83	84	O	by	by	by	IN	False
DDI-MedLine.d150.s5	drugs	86	90	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d150.s5	targeting	92	100	O	targeting	ing	ting	VBG	False
DDI-MedLine.d150.s5	proteins	102	109	O	proteins	ins	eins	NNS	False
DDI-MedLine.d150.s5	close	111	115	O	close	ose	lose	RB	False
DDI-MedLine.d150.s5	in	117	118	O	in	in	in	IN	False
DDI-MedLine.d150.s5	the	120	122	O	the	the	the	DT	False
DDI-MedLine.d150.s5	network	124	130	O	network	ork	work	NN	False
DDI-MedLine.d150.s5	,	131	131	O	,	,	,	,	False
DDI-MedLine.d150.s5	compared	133	140	O	compared	red	ared	VBN	False
DDI-MedLine.d150.s5	to	142	143	O	to	to	to	TO	False
DDI-MedLine.d150.s5	side-effect	145	155	O	side-effect	ect	fect	JJ	False
DDI-MedLine.d150.s5	similarities	157	168	O	similarities	ies	ties	NNS	False
DDI-MedLine.d150.s5	caused	170	175	O	caused	sed	used	VBN	False
DDI-MedLine.d150.s5	by	177	178	O	by	by	by	IN	False
DDI-MedLine.d150.s5	overlapping	180	190	O	overlapping	ing	ping	VBG	False
DDI-MedLine.d150.s5	drug	192	195	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s5	targets	197	203	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s5	(	205	205	O	(	(	(	(	False
DDI-MedLine.d150.s5	64	206	207	O	64	64	64	CD	False
DDI-MedLine.d150.s5	%	208	208	O	%	%	%	NN	False
DDI-MedLine.d150.s5	)	209	209	O	)	)	)	)	False
DDI-MedLine.d150.s5	.	210	210	O	.	.	.	.	False

DDI-MedLine.d150.s6	Moreover	0	7	O	Moreover	ver	over	RB	False
DDI-MedLine.d150.s6	,	8	8	O	,	,	,	,	False
DDI-MedLine.d150.s6	these	10	14	O	these	ese	hese	DT	False
DDI-MedLine.d150.s6	targets	16	22	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s6	that	24	27	O	that	hat	that	IN	False
DDI-MedLine.d150.s6	cause	29	33	O	cause	use	ause	NN	False
DDI-MedLine.d150.s6	similar	35	41	O	similar	lar	ilar	JJ	False
DDI-MedLine.d150.s6	side	43	46	O	side	ide	side	NN	False
DDI-MedLine.d150.s6	effects	48	54	O	effects	cts	ects	NNS	False
DDI-MedLine.d150.s6	are	56	58	O	are	are	are	VBP	False
DDI-MedLine.d150.s6	more	60	63	O	more	ore	more	RBR	False
DDI-MedLine.d150.s6	often	65	69	O	often	ten	ften	RB	False
DDI-MedLine.d150.s6	in	71	72	O	in	in	in	IN	False
DDI-MedLine.d150.s6	a	74	74	O	a	a	a	DT	False
DDI-MedLine.d150.s6	linear	76	81	O	linear	ear	near	NN	False
DDI-MedLine.d150.s6	part	83	86	O	part	art	part	NN	False
DDI-MedLine.d150.s6	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d150.s6	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d150.s6	network	95	101	O	network	ork	work	NN	False
DDI-MedLine.d150.s6	,	102	102	O	,	,	,	,	False
DDI-MedLine.d150.s6	having	104	109	O	having	ing	ving	VBG	False
DDI-MedLine.d150.s6	two	111	113	O	two	two	two	CD	False
DDI-MedLine.d150.s6	or	115	116	O	or	or	or	CC	False
DDI-MedLine.d150.s6	less	118	121	O	less	ess	less	RBR	False
DDI-MedLine.d150.s6	interactions	123	134	O	interactions	ons	ions	NNS	False
DDI-MedLine.d150.s6	,	135	135	O	,	,	,	,	False
DDI-MedLine.d150.s6	than	137	140	O	than	han	than	IN	False
DDI-MedLine.d150.s6	drug	142	145	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s6	targets	147	153	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s6	in	155	156	O	in	in	in	IN	False
DDI-MedLine.d150.s6	general	158	164	O	general	ral	eral	JJ	False
DDI-MedLine.d150.s6	.	165	165	O	.	.	.	.	False

DDI-MedLine.d150.s7	Based	0	4	O	Based	sed	ased	VBN	False
DDI-MedLine.d150.s7	on	6	7	O	on	on	on	IN	False
DDI-MedLine.d150.s7	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d150.s7	examples	13	20	O	examples	les	ples	NNS	False
DDI-MedLine.d150.s7	,	21	21	O	,	,	,	,	False
DDI-MedLine.d150.s7	we	23	24	O	we	we	we	PRP	False
DDI-MedLine.d150.s7	gained	26	31	O	gained	ned	ined	VBN	False
DDI-MedLine.d150.s7	novel	33	37	O	novel	vel	ovel	NN	False
DDI-MedLine.d150.s7	insight	39	45	O	insight	ght	ight	NN	False
DDI-MedLine.d150.s7	into	47	50	O	into	nto	into	IN	False
DDI-MedLine.d150.s7	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d150.s7	molecular	56	64	O	molecular	lar	ular	NN	False
DDI-MedLine.d150.s7	mechanisms	66	75	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d150.s7	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d150.s7	side	80	83	O	side	ide	side	NN	False
DDI-MedLine.d150.s7	effects	85	91	O	effects	cts	ects	NNS	False
DDI-MedLine.d150.s7	associated	93	102	O	associated	ted	ated	VBN	False
DDI-MedLine.d150.s7	with	104	107	O	with	ith	with	IN	False
DDI-MedLine.d150.s7	several	109	115	O	several	ral	eral	JJ	False
DDI-MedLine.d150.s7	drug	117	120	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s7	targets	122	128	O	targets	ets	gets	NNS	False
DDI-MedLine.d150.s7	.	129	129	O	.	.	.	.	False

DDI-MedLine.d150.s8	Looking	0	6	O	Looking	ing	king	VBG	False
DDI-MedLine.d150.s8	forward	8	14	O	forward	ard	ward	RB	False
DDI-MedLine.d150.s8	,	15	15	O	,	,	,	,	False
DDI-MedLine.d150.s8	such	17	20	O	such	uch	such	JJ	False
DDI-MedLine.d150.s8	analyses	22	29	O	analyses	ses	yses	NNS	False
DDI-MedLine.d150.s8	will	31	34	O	will	ill	will	MD	False
DDI-MedLine.d150.s8	be	36	37	O	be	be	be	VB	False
DDI-MedLine.d150.s8	extremely	39	47	O	extremely	ely	mely	RB	False
DDI-MedLine.d150.s8	useful	49	54	O	useful	ful	eful	JJ	False
DDI-MedLine.d150.s8	in	56	57	O	in	in	in	IN	False
DDI-MedLine.d150.s8	the	59	61	O	the	the	the	DT	False
DDI-MedLine.d150.s8	process	63	69	O	process	ess	cess	NN	False
DDI-MedLine.d150.s8	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d150.s8	drug	74	77	O	drug	rug	drug	NN	False
DDI-MedLine.d150.s8	development	79	89	O	development	ent	ment	NN	False
DDI-MedLine.d150.s8	to	91	92	O	to	to	to	TO	False
DDI-MedLine.d150.s8	better	94	99	O	better	ter	tter	RBR	False
DDI-MedLine.d150.s8	understand	101	110	O	understand	and	tand	NN	False
DDI-MedLine.d150.s8	adverse	112	118	O	adverse	rse	erse	NN	False
DDI-MedLine.d150.s8	side	120	123	O	side	ide	side	NN	False
DDI-MedLine.d150.s8	effects	125	131	O	effects	cts	ects	NNS	False
DDI-MedLine.d150.s8	.	132	132	O	.	.	.	.	False

DDI-MedLine.d191.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d191.s0	Study	1	5	O	Study	udy	tudy	NN	False
DDI-MedLine.d191.s0	on	7	8	O	on	on	on	IN	False
DDI-MedLine.d191.s0	synergic	10	17	O	synergic	gic	rgic	NN	False
DDI-MedLine.d191.s0	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d191.s0	decreasing	23	32	O	decreasing	ing	sing	VBG	False
DDI-MedLine.d191.s0	toxic	34	38	O	toxic	xic	oxic	NN	False
DDI-MedLine.d191.s0	effects	40	46	O	effects	cts	ects	NNS	False
DDI-MedLine.d191.s0	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d191.s0	mineral	51	57	O	mineral	ral	eral	NN	False
DDI-MedLine.d191.s0	water	59	63	O	water	ter	ater	NN	False
DDI-MedLine.d191.s0	and	65	67	O	and	and	and	CC	False
DDI-MedLine.d191.s0	Chinese	69	75	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d191.s0	herbal	77	82	O	herbal	bal	rbal	NN	False
DDI-MedLine.d191.s0	compound	84	91	O	compound	und	ound	NN	False
DDI-MedLine.d191.s0	preparation	93	103	O	preparation	ion	tion	NN	False
DDI-MedLine.d191.s0	on	105	106	O	on	on	on	IN	False
DDI-MedLine.d191.s0	cisplatin	108	116	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d191.s0	]	117	117	O	]	]	]	NN	False
DDI-MedLine.d191.s0	.	118	118	O	.	.	.	.	False

DDI-MedLine.d191.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d191.s1	synergic	4	11	O	synergic	gic	rgic	NN	False
DDI-MedLine.d191.s1	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d191.s1	decreasing	17	26	O	decreasing	ing	sing	VBG	False
DDI-MedLine.d191.s1	toxic	28	32	O	toxic	xic	oxic	NN	False
DDI-MedLine.d191.s1	effects	34	40	O	effects	cts	ects	NNS	False
DDI-MedLine.d191.s1	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d191.s1	mineral	45	51	O	mineral	ral	eral	NN	False
DDI-MedLine.d191.s1	water	53	57	O	water	ter	ater	NN	False
DDI-MedLine.d191.s1	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d191.s1	Chinese	63	69	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d191.s1	herbal	71	76	O	herbal	bal	rbal	NN	False
DDI-MedLine.d191.s1	compound	78	85	O	compound	und	ound	NN	False
DDI-MedLine.d191.s1	preparation	87	97	O	preparation	ion	tion	NN	False
DDI-MedLine.d191.s1	(	99	99	O	(	(	(	(	False
DDI-MedLine.d191.s1	MWCHCP	100	105	O	MWCHCP	HCP	CHCP	NN	brand
DDI-MedLine.d191.s1	)	106	106	O	)	)	)	)	False
DDI-MedLine.d191.s1	on	108	109	O	on	on	on	IN	False
DDI-MedLine.d191.s1	cisplatin	111	119	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d191.s1	were	121	124	O	were	ere	were	VBD	False
DDI-MedLine.d191.s1	investigated	126	137	O	investigated	ted	ated	VBN	False
DDI-MedLine.d191.s1	in	139	140	O	in	in	in	IN	False
DDI-MedLine.d191.s1	sarcoma	142	148	O	sarcoma	oma	coma	NN	False
DDI-MedLine.d191.s1	180	150	152	O	180	180	180	CD	False
DDI-MedLine.d191.s1	(	154	154	O	(	(	(	(	False
DDI-MedLine.d191.s1	S180	155	158	O	S180	180	S180	NN	brand
DDI-MedLine.d191.s1	)	159	159	O	)	)	)	)	False
DDI-MedLine.d191.s1	mice	161	164	O	mice	ice	mice	NN	False
DDI-MedLine.d191.s1	.	165	165	O	.	.	.	.	False

DDI-MedLine.d191.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d191.s2	S180	4	7	O	S180	180	S180	NN	brand
DDI-MedLine.d191.s2	mice	9	12	O	mice	ice	mice	NN	False
DDI-MedLine.d191.s2	were	14	17	O	were	ere	were	VBD	False
DDI-MedLine.d191.s2	treated	19	25	O	treated	ted	ated	VBN	False
DDI-MedLine.d191.s2	for	27	29	O	for	for	for	IN	False
DDI-MedLine.d191.s2	5	31	31	O	5	5	5	CD	False
DDI-MedLine.d191.s2	days	33	36	O	days	ays	days	NNS	False
DDI-MedLine.d191.s2	with	38	41	O	with	ith	with	IN	False
DDI-MedLine.d191.s2	intraperitoneal	43	57	O	intraperitoneal	eal	neal	NN	False
DDI-MedLine.d191.s2	injection	59	67	O	injection	ion	tion	NN	False
DDI-MedLine.d191.s2	of	69	70	O	of	of	of	IN	False
DDI-MedLine.d191.s2	cisplatin	72	80	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d191.s2	(	81	81	O	(	(	(	(	False
DDI-MedLine.d191.s2	7.33	82	85	O	7.33	.33	7.33	CD	False
DDI-MedLine.d191.s2	mg	87	88	O	mg	mg	mg	NN	False
DDI-MedLine.d191.s2	x	90	90	O	x	x	x	NN	False
DDI-MedLine.d191.s2	kg	92	93	O	kg	kg	kg	NN	False
DDI-MedLine.d191.s2	(	94	94	O	(	(	(	(	False
DDI-MedLine.d191.s2	-1	95	96	O	-1	-1	-1	NN	False
DDI-MedLine.d191.s2	)	97	97	O	)	)	)	)	False
DDI-MedLine.d191.s2	)	98	98	O	)	)	)	)	False
DDI-MedLine.d191.s2	and	100	102	O	and	and	and	CC	False
DDI-MedLine.d191.s2	oral	104	107	O	oral	ral	oral	JJ	False
DDI-MedLine.d191.s2	administration	109	122	O	administration	ion	tion	NN	False
DDI-MedLine.d191.s2	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d191.s2	MWCHCP	127	132	O	MWCHCP	HCP	CHCP	NN	brand
DDI-MedLine.d191.s2	(	133	133	O	(	(	(	(	False
DDI-MedLine.d191.s2	1	134	134	O	1	1	1	CD	False
DDI-MedLine.d191.s2	925	136	138	O	925	925	925	CD	False
DDI-MedLine.d191.s2	,	139	139	O	,	,	,	,	False
DDI-MedLine.d191.s2	3	141	141	O	3	3	3	CD	False
DDI-MedLine.d191.s2	850	143	145	O	850	850	850	CD	False
DDI-MedLine.d191.s2	,	146	146	O	,	,	,	,	False
DDI-MedLine.d191.s2	7	148	148	O	7	7	7	CD	False
DDI-MedLine.d191.s2	700	150	152	O	700	700	700	CD	False
DDI-MedLine.d191.s2	mg	154	155	O	mg	mg	mg	NN	False
DDI-MedLine.d191.s2	x	157	157	O	x	x	x	NN	False
DDI-MedLine.d191.s2	kg	159	160	O	kg	kg	kg	NN	False
DDI-MedLine.d191.s2	(	161	161	O	(	(	(	(	False
DDI-MedLine.d191.s2	-1	162	163	O	-1	-1	-1	NN	False
DDI-MedLine.d191.s2	)	164	164	O	)	)	)	)	False
DDI-MedLine.d191.s2	)	165	165	O	)	)	)	)	False
DDI-MedLine.d191.s2	.	166	166	O	.	.	.	.	False

DDI-MedLine.d191.s3	Then	0	3	O	Then	hen	Then	RB	False
DDI-MedLine.d191.s3	the	5	7	O	the	the	the	DT	False
DDI-MedLine.d191.s3	mice	9	12	O	mice	ice	mice	NN	False
DDI-MedLine.d191.s3	were	14	17	O	were	ere	were	VBD	False
DDI-MedLine.d191.s3	killed	19	24	O	killed	led	lled	VBN	False
DDI-MedLine.d191.s3	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d191.s3	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d191.s3	tumor	34	38	O	tumor	mor	umor	NN	False
DDI-MedLine.d191.s3	growth	40	45	O	growth	wth	owth	NN	False
DDI-MedLine.d191.s3	inhibition	47	56	O	inhibition	ion	tion	NN	False
DDI-MedLine.d191.s3	rate	58	61	O	rate	ate	rate	NN	False
DDI-MedLine.d191.s3	,	62	62	O	,	,	,	,	False
DDI-MedLine.d191.s3	organ	64	68	O	organ	gan	rgan	NN	False
DDI-MedLine.d191.s3	index	70	74	O	index	dex	ndex	NN	False
DDI-MedLine.d191.s3	,	75	75	O	,	,	,	,	False
DDI-MedLine.d191.s3	diarrhea	77	84	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d191.s3	index	86	90	O	index	dex	ndex	NN	False
DDI-MedLine.d191.s3	were	92	95	O	were	ere	were	VBD	False
DDI-MedLine.d191.s3	determined	97	106	O	determined	ned	ined	VBN	False
DDI-MedLine.d191.s3	.	107	107	O	.	.	.	.	False

DDI-MedLine.d191.s4	Observe	0	6	O	Observe	rve	erve	NN	False
DDI-MedLine.d191.s4	pathological	8	19	O	pathological	cal	ical	JJ	False
DDI-MedLine.d191.s4	sections	21	28	O	sections	ons	ions	NNS	False
DDI-MedLine.d191.s4	of	30	31	O	of	of	of	IN	False
DDI-MedLine.d191.s4	stomach	33	39	O	stomach	ach	mach	NN	False
DDI-MedLine.d191.s4	to	41	42	O	to	to	to	TO	False
DDI-MedLine.d191.s4	study	44	48	O	study	udy	tudy	NN	False
DDI-MedLine.d191.s4	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d191.s4	protective	54	63	O	protective	ive	tive	NN	False
DDI-MedLine.d191.s4	effect	65	70	O	effect	ect	fect	NN	False
DDI-MedLine.d191.s4	of	72	73	O	of	of	of	IN	False
DDI-MedLine.d191.s4	MWCHCP	75	80	O	MWCHCP	HCP	CHCP	NN	brand
DDI-MedLine.d191.s4	.	81	81	O	.	.	.	.	False

DDI-MedLine.d191.s5	Reverse	0	6	O	Reverse	rse	erse	NN	False
DDI-MedLine.d191.s5	transcription-polymerase	8	31	O	transcription-polymerase	ase	rase	NN	False
DDI-MedLine.d191.s5	chain	33	37	O	chain	ain	hain	NN	False
DDI-MedLine.d191.s5	reaction	39	46	O	reaction	ion	tion	NN	False
DDI-MedLine.d191.s5	(	48	48	O	(	(	(	(	False
DDI-MedLine.d191.s5	RT-PCR	49	54	O	RT-PCR	PCR	-PCR	JJ	brand
DDI-MedLine.d191.s5	)	55	55	O	)	)	)	)	False
DDI-MedLine.d191.s5	was	57	59	O	was	was	was	VBD	False
DDI-MedLine.d191.s5	applied	61	67	O	applied	ied	lied	VBN	False
DDI-MedLine.d191.s5	to	69	70	O	to	to	to	TO	False
DDI-MedLine.d191.s5	investigate	72	82	O	investigate	ate	gate	NN	False
DDI-MedLine.d191.s5	the	84	86	O	the	the	the	DT	False
DDI-MedLine.d191.s5	tumour	88	93	O	tumour	our	mour	NN	False
DDI-MedLine.d191.s5	necrosis	95	102	O	necrosis	sis	osis	NN	False
DDI-MedLine.d191.s5	factor-alpha	104	115	O	factor-alpha	pha	lpha	NN	False
DDI-MedLine.d191.s5	(	117	117	O	(	(	(	(	False
DDI-MedLine.d191.s5	TNF-alpha	118	126	O	TNF-alpha	pha	lpha	NN	False
DDI-MedLine.d191.s5	)	127	127	O	)	)	)	)	False
DDI-MedLine.d191.s5	expression	129	138	O	expression	ion	sion	NN	False
DDI-MedLine.d191.s5	level	140	144	O	level	vel	evel	NN	False
DDI-MedLine.d191.s5	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d191.s5	the	149	151	O	the	the	the	DT	False
DDI-MedLine.d191.s5	intestine	153	161	O	intestine	ine	tine	NN	drug
DDI-MedLine.d191.s5	.	162	162	O	.	.	.	.	False

DDI-MedLine.d191.s6	Combining	0	8	O	Combining	ing	ning	VBG	False
DDI-MedLine.d191.s6	with	10	13	O	with	ith	with	IN	False
DDI-MedLine.d191.s6	cisplatin	15	23	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d191.s6	and	25	27	O	and	and	and	CC	False
DDI-MedLine.d191.s6	MWCHCP	29	34	O	MWCHCP	HCP	CHCP	NN	brand
DDI-MedLine.d191.s6	caused	36	41	O	caused	sed	used	VBN	False
DDI-MedLine.d191.s6	a	43	43	O	a	a	a	DT	False
DDI-MedLine.d191.s6	tendency	45	52	O	tendency	ncy	ency	NN	False
DDI-MedLine.d191.s6	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d191.s6	increasing	57	66	O	increasing	ing	sing	VBG	False
DDI-MedLine.d191.s6	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d191.s6	tumor	72	76	O	tumor	mor	umor	NN	False
DDI-MedLine.d191.s6	growth	78	83	O	growth	wth	owth	NN	False
DDI-MedLine.d191.s6	inhibition	85	94	O	inhibition	ion	tion	NN	False
DDI-MedLine.d191.s6	rate	96	99	O	rate	ate	rate	NN	False
DDI-MedLine.d191.s6	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d191.s6	significant	105	115	O	significant	ant	cant	JJ	False
DDI-MedLine.d191.s6	attenution	117	126	O	attenution	ion	tion	NN	False
DDI-MedLine.d191.s6	of	128	129	O	of	of	of	IN	False
DDI-MedLine.d191.s6	cisplatin-induced	131	147	O	cisplatin-induced	ced	uced	JJ	False
DDI-MedLine.d191.s6	diarrhea	149	156	O	diarrhea	hea	rhea	NN	False
DDI-MedLine.d191.s6	,	157	157	O	,	,	,	,	False
DDI-MedLine.d191.s6	visceral	159	166	O	visceral	ral	eral	JJ	False
DDI-MedLine.d191.s6	organ	168	172	O	organ	gan	rgan	NN	False
DDI-MedLine.d191.s6	injury	174	179	O	injury	ury	jury	NN	False
DDI-MedLine.d191.s6	,	180	180	O	,	,	,	,	False
DDI-MedLine.d191.s6	gastric	182	188	O	gastric	ric	tric	NN	False
DDI-MedLine.d191.s6	mucosal	190	196	O	mucosal	sal	osal	NN	False
DDI-MedLine.d191.s6	injury	198	203	O	injury	ury	jury	NN	False
DDI-MedLine.d191.s6	and	205	207	O	and	and	and	CC	False
DDI-MedLine.d191.s6	decreased	209	217	O	decreased	sed	ased	VBN	False
DDI-MedLine.d191.s6	TNF-alpha	219	227	O	TNF-alpha	pha	lpha	NN	False
DDI-MedLine.d191.s6	mRNA	229	232	O	mRNA	RNA	mRNA	NN	False
DDI-MedLine.d191.s6	level	234	238	O	level	vel	evel	NN	False
DDI-MedLine.d191.s6	of	240	241	O	of	of	of	IN	False
DDI-MedLine.d191.s6	intestine	243	251	O	intestine	ine	tine	NN	drug
DDI-MedLine.d191.s6	.	252	252	O	.	.	.	.	False

DDI-MedLine.d191.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d191.s7	present	4	10	O	present	ent	sent	NN	False
DDI-MedLine.d191.s7	findings	12	19	O	findings	ngs	ings	NNS	False
DDI-MedLine.d191.s7	suggest	21	27	O	suggest	est	gest	NN	False
DDI-MedLine.d191.s7	that	29	32	O	that	hat	that	IN	False
DDI-MedLine.d191.s7	MWCHCP	34	39	O	MWCHCP	HCP	CHCP	NN	brand
DDI-MedLine.d191.s7	increases	41	49	O	increases	ses	ases	NNS	False
DDI-MedLine.d191.s7	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d191.s7	inhibition	55	64	O	inhibition	ion	tion	NN	False
DDI-MedLine.d191.s7	rate	66	69	O	rate	ate	rate	NN	False
DDI-MedLine.d191.s7	of	71	72	O	of	of	of	IN	False
DDI-MedLine.d191.s7	tumor	74	78	O	tumor	mor	umor	NN	False
DDI-MedLine.d191.s7	growth	80	85	O	growth	wth	owth	NN	False
DDI-MedLine.d191.s7	of	87	88	O	of	of	of	IN	False
DDI-MedLine.d191.s7	cisplatin	90	98	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d191.s7	and	100	102	O	and	and	and	CC	False
DDI-MedLine.d191.s7	has	104	106	O	has	has	has	VBZ	False
DDI-MedLine.d191.s7	a	108	108	O	a	a	a	DT	False
DDI-MedLine.d191.s7	beneficial	110	119	O	beneficial	ial	cial	JJ	False
DDI-MedLine.d191.s7	influence	121	129	O	influence	nce	ence	NN	False
DDI-MedLine.d191.s7	on	131	132	O	on	on	on	IN	False
DDI-MedLine.d191.s7	gastrointestinal	134	149	O	gastrointestinal	nal	inal	NN	False
DDI-MedLine.d191.s7	lesion	151	156	O	lesion	ion	sion	NN	False
DDI-MedLine.d191.s7	induced	158	164	O	induced	ced	uced	JJ	False
DDI-MedLine.d191.s7	by	166	167	O	by	by	by	IN	False
DDI-MedLine.d191.s7	cisplatin	169	177	B-drug	cisplatin	tin	atin	NN	False
DDI-MedLine.d191.s7	.	178	178	O	.	.	.	.	False

DDI-MedLine.d230.s0	Effects	0	6	O	Effects	cts	ects	NNS	False
DDI-MedLine.d230.s0	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d230.s0	neferine	11	18	B-drug_n	neferine	ine	rine	NN	drug
DDI-MedLine.d230.s0	on	20	21	O	on	on	on	IN	False
DDI-MedLine.d230.s0	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d230.s0	pharmacokinetics	27	42	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d230.s0	of	44	45	O	of	of	of	IN	False
DDI-MedLine.d230.s0	amiodarone	47	56	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s0	in	58	59	O	in	in	in	IN	False
DDI-MedLine.d230.s0	rats	61	64	O	rats	ats	rats	NNS	False
DDI-MedLine.d230.s0	.	65	65	O	.	.	.	.	False

DDI-MedLine.d230.s1	Amiodarone	0	9	B-drug	Amiodarone	one	rone	NN	False
DDI-MedLine.d230.s1	,	10	10	O	,	,	,	,	False
DDI-MedLine.d230.s1	an	12	13	O	an	an	an	DT	False
DDI-MedLine.d230.s1	iodinated	15	23	O	iodinated	ted	ated	VBN	False
DDI-MedLine.d230.s1	benzofuran	25	34	O	benzofuran	ran	uran	NN	False
DDI-MedLine.d230.s1	derivative	36	45	O	derivative	ive	tive	JJ	False
DDI-MedLine.d230.s1	with	47	50	O	with	ith	with	IN	False
DDI-MedLine.d230.s1	predominantly	52	64	O	predominantly	tly	ntly	RB	False
DDI-MedLine.d230.s1	class	66	70	O	class	ass	lass	NN	False
DDI-MedLine.d230.s1	III	72	74	O	III	III	III	NN	brand
DDI-MedLine.d230.s1	anti-arrhythmic	76	90	O	anti-arrhythmic	mic	hmic	JJ	False
DDI-MedLine.d230.s1	effects	92	98	O	effects	cts	ects	NNS	False
DDI-MedLine.d230.s1	,	99	99	O	,	,	,	,	False
DDI-MedLine.d230.s1	is	101	102	O	is	is	is	VBZ	False
DDI-MedLine.d230.s1	used	104	107	O	used	sed	used	VBN	False
DDI-MedLine.d230.s1	to	109	110	O	to	to	to	TO	False
DDI-MedLine.d230.s1	treat	112	116	O	treat	eat	reat	NN	False
DDI-MedLine.d230.s1	supraventricular	118	133	O	supraventricular	lar	ular	NN	False
DDI-MedLine.d230.s1	and	135	137	O	and	and	and	CC	False
DDI-MedLine.d230.s1	ventricular	139	149	O	ventricular	lar	ular	NN	False
DDI-MedLine.d230.s1	arrhythmias	151	161	O	arrhythmias	ias	mias	NNS	False
DDI-MedLine.d230.s1	.	162	162	O	.	.	.	.	False

DDI-MedLine.d230.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d230.s2	purpose	4	10	O	purpose	ose	pose	NN	False
DDI-MedLine.d230.s2	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d230.s2	this	15	18	O	this	his	this	DT	False
DDI-MedLine.d230.s2	study	20	24	O	study	udy	tudy	NN	False
DDI-MedLine.d230.s2	was	26	28	O	was	was	was	VBD	False
DDI-MedLine.d230.s2	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d230.s2	assess	33	38	O	assess	ess	sess	NN	False
DDI-MedLine.d230.s2	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d230.s2	potential	44	52	O	potential	ial	tial	JJ	False
DDI-MedLine.d230.s2	of	54	55	O	of	of	of	IN	False
DDI-MedLine.d230.s2	neferine	57	64	B-drug_n	neferine	ine	rine	NN	drug
DDI-MedLine.d230.s2	,	65	65	O	,	,	,	,	False
DDI-MedLine.d230.s2	an	67	68	O	an	an	an	DT	False
DDI-MedLine.d230.s2	effective	70	78	O	effective	ive	tive	JJ	False
DDI-MedLine.d230.s2	anti-pulmonary	80	93	O	anti-pulmonary	ary	nary	JJ	False
DDI-MedLine.d230.s2	fibrosis	95	102	O	fibrosis	sis	osis	NN	False
DDI-MedLine.d230.s2	drug	104	107	O	drug	rug	drug	NN	False
DDI-MedLine.d230.s2	isolated	109	116	O	isolated	ted	ated	JJ	False
DDI-MedLine.d230.s2	from	118	121	O	from	rom	from	IN	False
DDI-MedLine.d230.s2	the	123	125	O	the	the	the	DT	False
DDI-MedLine.d230.s2	embryo	127	132	O	embryo	ryo	bryo	NN	False
DDI-MedLine.d230.s2	of	134	135	O	of	of	of	IN	False
DDI-MedLine.d230.s2	Nelumbo	137	143	O	Nelumbo	mbo	umbo	NN	False
DDI-MedLine.d230.s2	nucifera	145	152	O	nucifera	era	fera	NN	False
DDI-MedLine.d230.s2	Gaertner	154	161	O	Gaertner	ner	tner	NN	False
DDI-MedLine.d230.s2	's	162	163	O	's	's	's	POS	False
DDI-MedLine.d230.s2	seeds	165	169	O	seeds	eds	eeds	NNS	False
DDI-MedLine.d230.s2	,	170	170	O	,	,	,	,	False
DDI-MedLine.d230.s2	to	172	173	O	to	to	to	TO	False
DDI-MedLine.d230.s2	alter	175	179	O	alter	ter	lter	NN	False
DDI-MedLine.d230.s2	the	181	183	O	the	the	the	DT	False
DDI-MedLine.d230.s2	pharmacokinetic	185	199	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d230.s2	profile	201	207	O	profile	ile	file	NN	False
DDI-MedLine.d230.s2	of	209	210	O	of	of	of	IN	False
DDI-MedLine.d230.s2	amiodarone	212	221	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s2	.	222	222	O	.	.	.	.	False

DDI-MedLine.d230.s3	Experimental	0	11	O	Experimental	tal	ntal	JJ	False
DDI-MedLine.d230.s3	Sprague-Dawley	13	26	O	Sprague-Dawley	ley	wley	NN	False
DDI-MedLine.d230.s3	rats	28	31	O	rats	ats	rats	NNS	False
DDI-MedLine.d230.s3	were	33	36	O	were	ere	were	VBD	False
DDI-MedLine.d230.s3	randomly	38	45	O	randomly	mly	omly	RB	False
DDI-MedLine.d230.s3	divided	47	53	O	divided	ded	ided	VBN	False
DDI-MedLine.d230.s3	into	55	58	O	into	nto	into	IN	False
DDI-MedLine.d230.s3	two	60	62	O	two	two	two	CD	False
DDI-MedLine.d230.s3	groups	64	69	O	groups	ups	oups	NNS	False
DDI-MedLine.d230.s3	.	70	70	O	.	.	.	.	False

DDI-MedLine.d230.s4	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d230.s4	groups	3	8	O	groups	ups	oups	NNS	False
DDI-MedLine.d230.s4	1	10	10	O	1	1	1	CD	False
DDI-MedLine.d230.s4	and	12	14	O	and	and	and	CC	False
DDI-MedLine.d230.s4	2	16	16	O	2	2	2	CD	False
DDI-MedLine.d230.s4	,	17	17	O	,	,	,	,	False
DDI-MedLine.d230.s4	amiodarone	19	28	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s4	was	30	32	O	was	was	was	VBD	False
DDI-MedLine.d230.s4	given	34	38	O	given	ven	iven	VBN	False
DDI-MedLine.d230.s4	to	40	41	O	to	to	to	TO	False
DDI-MedLine.d230.s4	rats	43	46	O	rats	ats	rats	NNS	False
DDI-MedLine.d230.s4	by	48	49	O	by	by	by	IN	False
DDI-MedLine.d230.s4	intragastric	51	62	O	intragastric	ric	tric	NN	False
DDI-MedLine.d230.s4	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d230.s4	intravenous	68	78	O	intravenous	ous	nous	JJ	False
DDI-MedLine.d230.s4	administration	80	93	O	administration	ion	tion	NN	False
DDI-MedLine.d230.s4	,	94	94	O	,	,	,	,	False
DDI-MedLine.d230.s4	respectively	96	107	O	respectively	ely	vely	RB	False
DDI-MedLine.d230.s4	,	108	108	O	,	,	,	,	False
DDI-MedLine.d230.s4	while	110	114	O	while	ile	hile	IN	False
DDI-MedLine.d230.s4	neferine	116	123	B-drug_n	neferine	ine	rine	NN	drug
DDI-MedLine.d230.s4	was	125	127	O	was	was	was	VBD	False
DDI-MedLine.d230.s4	co-administratered	129	146	O	co-administratered	red	ered	JJ	False
DDI-MedLine.d230.s4	by	148	149	O	by	by	by	IN	False
DDI-MedLine.d230.s4	intragastric	151	162	O	intragastric	ric	tric	NN	False
DDI-MedLine.d230.s4	administration	164	177	O	administration	ion	tion	NN	False
DDI-MedLine.d230.s4	.	178	178	O	.	.	.	.	False

DDI-MedLine.d230.s5	Blood	0	4	O	Blood	ood	lood	NN	False
DDI-MedLine.d230.s5	samples	6	12	O	samples	les	ples	NNS	False
DDI-MedLine.d230.s5	were	14	17	O	were	ere	were	VBD	False
DDI-MedLine.d230.s5	collected	19	27	O	collected	ted	cted	VBN	False
DDI-MedLine.d230.s5	from	29	32	O	from	rom	from	IN	False
DDI-MedLine.d230.s5	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d230.s5	orbital	38	44	O	orbital	tal	ital	NN	False
DDI-MedLine.d230.s5	venous	46	51	O	venous	ous	nous	JJ	False
DDI-MedLine.d230.s5	plexus	53	58	O	plexus	xus	exus	NN	False
DDI-MedLine.d230.s5	at	60	61	O	at	at	at	IN	False
DDI-MedLine.d230.s5	indicated	63	71	O	indicated	ted	ated	VBN	False
DDI-MedLine.d230.s5	time	73	76	O	time	ime	time	NN	False
DDI-MedLine.d230.s5	points	78	83	O	points	nts	ints	NNS	False
DDI-MedLine.d230.s5	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d230.s5	were	89	92	O	were	ere	were	VBD	False
DDI-MedLine.d230.s5	analyzed	94	101	O	analyzed	zed	yzed	VBN	False
DDI-MedLine.d230.s5	for	103	105	O	for	for	for	IN	False
DDI-MedLine.d230.s5	amiodarone	107	116	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s5	concentration	118	130	O	concentration	ion	tion	NN	False
DDI-MedLine.d230.s5	using	132	136	O	using	ing	sing	VBG	False
DDI-MedLine.d230.s5	RP-HPLC	138	144	O	RP-HPLC	PLC	HPLC	JJ	brand
DDI-MedLine.d230.s5	.	145	145	O	.	.	.	.	False

DDI-MedLine.d230.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d230.s6	geometric	4	12	O	geometric	ric	tric	NN	False
DDI-MedLine.d230.s6	mean	14	17	O	mean	ean	mean	NN	False
DDI-MedLine.d230.s6	ratio	19	23	O	ratio	tio	atio	NN	False
DDI-MedLine.d230.s6	for	25	27	O	for	for	for	IN	False
DDI-MedLine.d230.s6	C	29	29	O	C	C	C	SYM	brand
DDI-MedLine.d230.s6	(	30	30	O	(	(	(	(	False
DDI-MedLine.d230.s6	max	31	33	O	max	max	max	NN	False
DDI-MedLine.d230.s6	)	34	34	O	)	)	)	)	False
DDI-MedLine.d230.s6	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d230.s6	AUC	40	42	O	AUC	AUC	AUC	NN	brand
DDI-MedLine.d230.s6	(	43	43	O	(	(	(	(	False
DDI-MedLine.d230.s6	0-96	44	47	O	0-96	-96	0-96	NN	False
DDI-MedLine.d230.s6	)	48	48	O	)	)	)	)	False
DDI-MedLine.d230.s6	was	50	52	O	was	was	was	VBD	False
DDI-MedLine.d230.s6	calculated	54	63	O	calculated	ted	ated	VBN	False
DDI-MedLine.d230.s6	.	64	64	O	.	.	.	.	False

DDI-MedLine.d230.s7	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d230.s7	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d230.s7	no	11	12	O	no	no	no	DT	False
DDI-MedLine.d230.s7	significant	14	24	O	significant	ant	cant	JJ	False
DDI-MedLine.d230.s7	differences	26	36	O	differences	ces	nces	NNS	False
DDI-MedLine.d230.s7	between	38	44	O	between	een	ween	IN	False
DDI-MedLine.d230.s7	the	46	48	O	the	the	the	DT	False
DDI-MedLine.d230.s7	pharmacokinetics	50	65	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d230.s7	parameters	67	76	O	parameters	ers	ters	NNS	False
DDI-MedLine.d230.s7	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d230.s7	amiodarone	81	90	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s7	administered	92	103	O	administered	red	ered	VBN	False
DDI-MedLine.d230.s7	intravenously	105	117	O	intravenously	sly	usly	RB	False
DDI-MedLine.d230.s7	or	119	120	O	or	or	or	CC	False
DDI-MedLine.d230.s7	intragastrically	122	137	O	intragastrically	lly	ally	RB	False
DDI-MedLine.d230.s7	and	139	141	O	and	and	and	CC	False
DDI-MedLine.d230.s7	the	143	145	O	the	the	the	DT	False
DDI-MedLine.d230.s7	control	147	153	O	control	rol	trol	NN	False
DDI-MedLine.d230.s7	(	155	155	O	(	(	(	(	False
DDI-MedLine.d230.s7	without	156	162	O	without	out	hout	IN	False
DDI-MedLine.d230.s7	neferine	164	171	B-drug_n	neferine	ine	rine	NN	drug
DDI-MedLine.d230.s7	)	172	172	O	)	)	)	)	False
DDI-MedLine.d230.s7	group	174	178	O	group	oup	roup	NN	False
DDI-MedLine.d230.s7	(	180	180	O	(	(	(	(	False
DDI-MedLine.d230.s7	with	181	184	O	with	ith	with	IN	False
DDI-MedLine.d230.s7	ratios	186	191	O	ratios	ios	tios	NNS	False
DDI-MedLine.d230.s7	of	193	194	O	of	of	of	IN	False
DDI-MedLine.d230.s7	0.7-1.4	196	202	O	0.7-1.4	1.4	-1.4	NN	False
DDI-MedLine.d230.s7	in	204	205	O	in	in	in	IN	False
DDI-MedLine.d230.s7	all	207	209	O	all	all	all	DT	False
DDI-MedLine.d230.s7	experimental	211	222	O	experimental	tal	ntal	NN	False
DDI-MedLine.d230.s7	groups	224	229	O	groups	ups	oups	NNS	False
DDI-MedLine.d230.s7	)	230	230	O	)	)	)	)	False
DDI-MedLine.d230.s7	,	231	231	O	,	,	,	,	False
DDI-MedLine.d230.s7	suggesting	233	242	O	suggesting	ing	ting	VBG	False
DDI-MedLine.d230.s7	that	244	247	O	that	hat	that	IN	False
DDI-MedLine.d230.s7	neferine	249	256	B-drug_n	neferine	ine	rine	NN	drug
DDI-MedLine.d230.s7	had	258	260	O	had	had	had	VBD	False
DDI-MedLine.d230.s7	no	262	263	O	no	no	no	DT	False
DDI-MedLine.d230.s7	effect	265	270	O	effect	ect	fect	NN	False
DDI-MedLine.d230.s7	on	272	273	O	on	on	on	IN	False
DDI-MedLine.d230.s7	amiodarone	275	284	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s7	plasma	286	291	O	plasma	sma	asma	NN	False
DDI-MedLine.d230.s7	pharmacokinetics	293	308	O	pharmacokinetics	ics	tics	NNS	False
DDI-MedLine.d230.s7	.	309	309	O	.	.	.	.	False

DDI-MedLine.d230.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d230.s8	dosage	4	9	O	dosage	age	sage	NN	False
DDI-MedLine.d230.s8	regimen	11	17	O	regimen	men	imen	NNS	False
DDI-MedLine.d230.s8	of	19	20	O	of	of	of	IN	False
DDI-MedLine.d230.s8	amiodarone	22	31	B-drug	amiodarone	one	rone	NN	False
DDI-MedLine.d230.s8	does	33	36	O	does	oes	does	VBZ	False
DDI-MedLine.d230.s8	not	38	40	O	not	not	not	RB	False
DDI-MedLine.d230.s8	need	42	45	O	need	eed	need	NN	False
DDI-MedLine.d230.s8	to	47	48	O	to	to	to	TO	False
DDI-MedLine.d230.s8	be	50	51	O	be	be	be	VB	False
DDI-MedLine.d230.s8	taken	53	57	O	taken	ken	aken	VBN	False
DDI-MedLine.d230.s8	into	59	62	O	into	nto	into	IN	False
DDI-MedLine.d230.s8	consideration	64	76	O	consideration	ion	tion	NN	False
DDI-MedLine.d230.s8	when	78	81	O	when	hen	when	WRB	False
DDI-MedLine.d230.s8	combined	83	90	O	combined	ned	ined	VBN	False
DDI-MedLine.d230.s8	with	92	95	O	with	ith	with	IN	False
DDI-MedLine.d230.s8	neferine	97	104	B-drug_n	neferine	ine	rine	NN	drug
DDI-MedLine.d230.s8	.	105	105	O	.	.	.	.	False

DDI-MedLine.d146.s0	Post-exposure	0	12	O	Post-exposure	ure	sure	NN	False
DDI-MedLine.d146.s0	prophylaxis	14	24	O	prophylaxis	xis	axis	NN	False
DDI-MedLine.d146.s0	for	26	28	O	for	for	for	IN	False
DDI-MedLine.d146.s0	H1N1	30	33	O	H1N1	1N1	H1N1	NN	brand
DDI-MedLine.d146.s0	with	35	38	O	with	ith	with	IN	False
DDI-MedLine.d146.s0	oseltamivir	40	50	B-drug	oseltamivir	vir	ivir	NN	False
DDI-MedLine.d146.s0	in	52	53	O	in	in	in	IN	False
DDI-MedLine.d146.s0	renal	55	59	O	renal	nal	enal	NN	False
DDI-MedLine.d146.s0	allograft	61	69	O	allograft	aft	raft	NN	False
DDI-MedLine.d146.s0	recipient	71	79	O	recipient	ent	ient	NN	False
DDI-MedLine.d146.s0	--	80	81	O	--	--	--	:	False
DDI-MedLine.d146.s0	safe	82	85	O	safe	afe	safe	JJ	False
DDI-MedLine.d146.s0	and	87	89	O	and	and	and	CC	False
DDI-MedLine.d146.s0	effective	91	99	O	effective	ive	tive	JJ	False
DDI-MedLine.d146.s0	without	101	107	O	without	out	hout	IN	False
DDI-MedLine.d146.s0	any	109	111	O	any	any	any	DT	False
DDI-MedLine.d146.s0	immunosuppresive	113	128	B-group	immunosuppresive	ive	sive	JJ	False
DDI-MedLine.d146.s0	drug	130	133	I-group	drug	rug	drug	NN	False
DDI-MedLine.d146.s0	interaction	135	145	O	interaction	ion	tion	NN	False
DDI-MedLine.d146.s0	.	146	146	O	.	.	.	.	False

DDI-MedLine.d146.s1	Kidney	0	5	O	Kidney	ney	dney	NN	False
DDI-MedLine.d146.s1	transplant	7	16	O	transplant	ant	lant	NN	False
DDI-MedLine.d146.s1	recipients	18	27	O	recipients	nts	ents	NNS	False
DDI-MedLine.d146.s1	are	29	31	O	are	are	are	VBP	False
DDI-MedLine.d146.s1	at	33	34	O	at	at	at	IN	False
DDI-MedLine.d146.s1	a	36	36	O	a	a	a	DT	False
DDI-MedLine.d146.s1	high	38	41	O	high	igh	high	JJ	False
DDI-MedLine.d146.s1	risk	43	46	O	risk	isk	risk	NN	False
DDI-MedLine.d146.s1	for	48	50	O	for	for	for	IN	False
DDI-MedLine.d146.s1	H1N1	52	55	O	H1N1	1N1	H1N1	NN	brand
DDI-MedLine.d146.s1	infection	57	65	O	infection	ion	tion	NN	False
DDI-MedLine.d146.s1	associated	67	76	O	associated	ted	ated	VBN	False
DDI-MedLine.d146.s1	complications	78	90	O	complications	ons	ions	NNS	False
DDI-MedLine.d146.s1	during	92	97	O	during	ing	ring	IN	False
DDI-MedLine.d146.s1	the	99	101	O	the	the	the	DT	False
DDI-MedLine.d146.s1	current	103	109	O	current	ent	rent	JJ	False
DDI-MedLine.d146.s1	pandemic	111	118	O	pandemic	mic	emic	NN	False
DDI-MedLine.d146.s1	.	119	119	O	.	.	.	.	False

DDI-MedLine.d146.s2	Prevention	0	9	O	Prevention	ion	tion	NN	False
DDI-MedLine.d146.s2	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d146.s2	infection	14	22	O	infection	ion	tion	NN	False
DDI-MedLine.d146.s2	by	24	25	O	by	by	by	IN	False
DDI-MedLine.d146.s2	immunization	27	38	O	immunization	ion	tion	NN	False
DDI-MedLine.d146.s2	,	39	39	O	,	,	,	,	False
DDI-MedLine.d146.s2	together	41	48	O	together	her	ther	RB	False
DDI-MedLine.d146.s2	with	50	53	O	with	ith	with	IN	False
DDI-MedLine.d146.s2	early	55	59	O	early	rly	arly	RB	False
DDI-MedLine.d146.s2	recognition	61	71	O	recognition	ion	tion	NN	False
DDI-MedLine.d146.s2	and	73	75	O	and	and	and	CC	False
DDI-MedLine.d146.s2	prompt	77	82	O	prompt	mpt	ompt	NN	False
DDI-MedLine.d146.s2	antiviral	84	92	O	antiviral	ral	iral	JJ	False
DDI-MedLine.d146.s2	treatment	94	102	O	treatment	ent	ment	NN	False
DDI-MedLine.d146.s2	are	104	106	O	are	are	are	VBP	False
DDI-MedLine.d146.s2	critical	108	115	O	critical	cal	ical	JJ	False
DDI-MedLine.d146.s2	.	116	116	O	.	.	.	.	False

DDI-MedLine.d146.s3	Post-exposure	0	12	O	Post-exposure	ure	sure	NN	False
DDI-MedLine.d146.s3	prophylaxis	14	24	O	prophylaxis	xis	axis	NN	False
DDI-MedLine.d146.s3	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d146.s3	H1N1	29	32	O	H1N1	1N1	H1N1	NN	brand
DDI-MedLine.d146.s3	with	34	37	O	with	ith	with	IN	False
DDI-MedLine.d146.s3	oseltamivir	39	49	B-drug	oseltamivir	vir	ivir	NN	False
DDI-MedLine.d146.s3	was	51	53	O	was	was	was	VBD	False
DDI-MedLine.d146.s3	safe	55	58	O	safe	afe	safe	JJ	False
DDI-MedLine.d146.s3	,	59	59	O	,	,	,	,	False
DDI-MedLine.d146.s3	effective	61	69	O	effective	ive	tive	JJ	False
DDI-MedLine.d146.s3	and	71	73	O	and	and	and	CC	False
DDI-MedLine.d146.s3	well	75	78	O	well	ell	well	RB	False
DDI-MedLine.d146.s3	tolerated	80	88	O	tolerated	ted	ated	VBN	False
DDI-MedLine.d146.s3	to	90	91	O	to	to	to	TO	False
DDI-MedLine.d146.s3	prevent	93	99	O	prevent	ent	vent	NN	False
DDI-MedLine.d146.s3	H1N1	101	104	O	H1N1	1N1	H1N1	NN	brand
DDI-MedLine.d146.s3	influenza	106	114	O	influenza	nza	enza	NN	False
DDI-MedLine.d146.s3	A	116	116	O	A	A	A	DT	brand
DDI-MedLine.d146.s3	virus	118	122	O	virus	rus	irus	NN	False
DDI-MedLine.d146.s3	infection	124	132	O	infection	ion	tion	NN	False
DDI-MedLine.d146.s3	in	134	135	O	in	in	in	IN	False
DDI-MedLine.d146.s3	newly	137	141	O	newly	wly	ewly	RB	False
DDI-MedLine.d146.s3	transplanted	143	154	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d146.s3	renal	156	160	O	renal	nal	enal	NN	False
DDI-MedLine.d146.s3	allograft	162	170	O	allograft	aft	raft	NN	False
DDI-MedLine.d146.s3	recipient	172	180	O	recipient	ent	ient	NN	False
DDI-MedLine.d146.s3	receiving	182	190	O	receiving	ing	ving	VBG	False
DDI-MedLine.d146.s3	triple	192	197	O	triple	ple	iple	NN	False
DDI-MedLine.d146.s3	immunosuppression	199	215	O	immunosuppression	ion	sion	NN	False
DDI-MedLine.d146.s3	without	217	223	O	without	out	hout	IN	False
DDI-MedLine.d146.s3	any	225	227	O	any	any	any	DT	False
DDI-MedLine.d146.s3	interaction	229	239	O	interaction	ion	tion	NN	False
DDI-MedLine.d146.s3	with	241	244	O	with	ith	with	IN	False
DDI-MedLine.d146.s3	tacrolimus	246	255	B-drug	tacrolimus	mus	imus	NN	False
DDI-MedLine.d146.s3	level	257	261	O	level	vel	evel	NN	False
DDI-MedLine.d146.s3	.	262	262	O	.	.	.	.	False

DDI-MedLine.d146.s4	Oseltamivir	0	10	B-drug	Oseltamivir	vir	ivir	NN	False
DDI-MedLine.d146.s4	was	12	14	O	was	was	was	VBD	False
DDI-MedLine.d146.s4	effective	16	24	O	effective	ive	tive	JJ	False
DDI-MedLine.d146.s4	for	26	28	O	for	for	for	IN	False
DDI-MedLine.d146.s4	post-exposure	30	42	O	post-exposure	ure	sure	NN	False
DDI-MedLine.d146.s4	prophylaxis	44	54	O	prophylaxis	xis	axis	NN	False
DDI-MedLine.d146.s4	of	56	57	O	of	of	of	IN	False
DDI-MedLine.d146.s4	H1N1	59	62	O	H1N1	1N1	H1N1	NN	brand
DDI-MedLine.d146.s4	in	64	65	O	in	in	in	IN	False
DDI-MedLine.d146.s4	close	67	71	O	close	ose	lose	RB	False
DDI-MedLine.d146.s4	contact	73	79	O	contact	act	tact	NN	False
DDI-MedLine.d146.s4	.	80	80	O	.	.	.	.	False

DDI-MedLine.d177.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d177.s0	Polypharmacy	1	12	O	Polypharmacy	acy	macy	NN	False
DDI-MedLine.d177.s0	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d177.s0	drug	18	21	O	drug	rug	drug	NN	False
DDI-MedLine.d177.s0	interactions	23	34	O	interactions	ons	ions	NNS	False
DDI-MedLine.d177.s0	]	35	35	O	]	]	]	NN	False
DDI-MedLine.d177.s0	.	36	36	O	.	.	.	.	False

DDI-MedLine.d177.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d177.s1	growing	4	10	O	growing	ing	wing	VBG	False
DDI-MedLine.d177.s1	consumption	12	22	O	consumption	ion	tion	NN	False
DDI-MedLine.d177.s1	of	24	25	O	of	of	of	IN	False
DDI-MedLine.d177.s1	drugs	27	31	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d177.s1	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d177.s1	other	37	41	O	other	her	ther	JJ	False
DDI-MedLine.d177.s1	numerous	43	50	O	numerous	ous	rous	JJ	False
DDI-MedLine.d177.s1	factors	52	58	O	factors	ors	tors	NNS	False
DDI-MedLine.d177.s1	relates	60	66	O	relates	tes	ates	NNS	False
DDI-MedLine.d177.s1	to	68	69	O	to	to	to	TO	False
DDI-MedLine.d177.s1	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d177.s1	increasing	75	84	O	increasing	ing	sing	VBG	False
DDI-MedLine.d177.s1	incidence	86	94	O	incidence	nce	ence	NN	False
DDI-MedLine.d177.s1	of	96	97	O	of	of	of	IN	False
DDI-MedLine.d177.s1	polypharmacy	99	110	O	polypharmacy	acy	macy	NN	False
DDI-MedLine.d177.s1	.	111	111	O	.	.	.	.	False

DDI-MedLine.d177.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d177.s2	proportion	4	13	O	proportion	ion	tion	NN	False
DDI-MedLine.d177.s2	of	15	16	O	of	of	of	IN	False
DDI-MedLine.d177.s2	patients	18	25	O	patients	nts	ents	NNS	False
DDI-MedLine.d177.s2	currently	27	35	O	currently	tly	ntly	RB	False
DDI-MedLine.d177.s2	treated	37	43	O	treated	ted	ated	VBN	False
DDI-MedLine.d177.s2	with	45	48	O	with	ith	with	IN	False
DDI-MedLine.d177.s2	5	50	50	O	5	5	5	CD	False
DDI-MedLine.d177.s2	or	52	53	O	or	or	or	CC	False
DDI-MedLine.d177.s2	more	55	58	O	more	ore	more	RBR	False
DDI-MedLine.d177.s2	medicines	60	68	O	medicines	nes	ines	NNS	group
DDI-MedLine.d177.s2	at	70	71	O	at	at	at	IN	False
DDI-MedLine.d177.s2	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d177.s2	elderly	77	83	O	elderly	rly	erly	RB	False
DDI-MedLine.d177.s2	population	85	94	O	population	ion	tion	NN	False
DDI-MedLine.d177.s2	in	96	97	O	in	in	in	IN	False
DDI-MedLine.d177.s2	particular	99	108	O	particular	lar	ular	JJ	False
DDI-MedLine.d177.s2	is	110	111	O	is	is	is	VBZ	False
DDI-MedLine.d177.s2	30-60	113	117	O	30-60	-60	0-60	JJ	False
DDI-MedLine.d177.s2	%	118	118	O	%	%	%	NN	False
DDI-MedLine.d177.s2	of	120	121	O	of	of	of	IN	False
DDI-MedLine.d177.s2	patients	123	130	O	patients	nts	ents	NNS	False
DDI-MedLine.d177.s2	.	131	131	O	.	.	.	.	False

DDI-MedLine.d177.s3	Repeatedly	0	9	O	Repeatedly	dly	edly	RB	False
DDI-MedLine.d177.s3	has	11	13	O	has	has	has	VBZ	False
DDI-MedLine.d177.s3	been	15	18	O	been	een	been	VBN	False
DDI-MedLine.d177.s3	proven	20	25	O	proven	ven	oven	NN	False
DDI-MedLine.d177.s3	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d177.s3	dependence	31	40	O	dependence	nce	ence	NN	False
DDI-MedLine.d177.s3	between	42	48	O	between	een	ween	IN	False
DDI-MedLine.d177.s3	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d177.s3	number	54	59	O	number	ber	mber	NN	False
DDI-MedLine.d177.s3	of	61	62	O	of	of	of	IN	False
DDI-MedLine.d177.s3	concomitant	64	74	O	concomitant	ant	tant	NN	False
DDI-MedLine.d177.s3	drugs	76	80	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d177.s3	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d177.s3	occurrence	86	95	O	occurrence	nce	ence	NN	False
DDI-MedLine.d177.s3	of	97	98	O	of	of	of	IN	False
DDI-MedLine.d177.s3	adverse	100	106	O	adverse	rse	erse	NN	False
DDI-MedLine.d177.s3	effects	108	114	O	effects	cts	ects	NNS	False
DDI-MedLine.d177.s3	,	115	115	O	,	,	,	,	False
DDI-MedLine.d177.s3	patients	117	124	O	patients	nts	ents	NNS	False
DDI-MedLine.d177.s3	requiring	126	134	O	requiring	ing	ring	VBG	False
DDI-MedLine.d177.s3	hospitalization	136	150	O	hospitalization	ion	tion	NN	False
DDI-MedLine.d177.s3	,	151	151	O	,	,	,	,	False
DDI-MedLine.d177.s3	or	153	154	O	or	or	or	CC	False
DDI-MedLine.d177.s3	incidence	156	164	O	incidence	nce	ence	NN	False
DDI-MedLine.d177.s3	of	166	167	O	of	of	of	IN	False
DDI-MedLine.d177.s3	moderate	169	176	O	moderate	ate	rate	NN	False
DDI-MedLine.d177.s3	and	178	180	O	and	and	and	CC	False
DDI-MedLine.d177.s3	serious	182	188	O	serious	ous	ious	JJ	False
DDI-MedLine.d177.s3	drug	190	193	O	drug	rug	drug	NN	False
DDI-MedLine.d177.s3	interactions	195	206	O	interactions	ons	ions	NNS	False
DDI-MedLine.d177.s3	.	207	207	O	.	.	.	.	False

DDI-MedLine.d177.s4	Some	0	3	O	Some	ome	Some	DT	False
DDI-MedLine.d177.s4	works	5	9	O	works	rks	orks	NNS	False
DDI-MedLine.d177.s4	show	11	14	O	show	how	show	NN	False
DDI-MedLine.d177.s4	that	16	19	O	that	hat	that	IN	False
DDI-MedLine.d177.s4	it	21	22	O	it	it	it	PRP	False
DDI-MedLine.d177.s4	is	24	25	O	is	is	is	VBZ	False
DDI-MedLine.d177.s4	possible	27	34	O	possible	ble	ible	JJ	False
DDI-MedLine.d177.s4	to	36	37	O	to	to	to	TO	False
DDI-MedLine.d177.s4	satisfactorily	39	52	O	satisfactorily	ily	rily	RB	False
DDI-MedLine.d177.s4	address	54	60	O	address	ess	ress	NN	False
DDI-MedLine.d177.s4	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d177.s4	issues	66	71	O	issues	ues	sues	NNS	False
DDI-MedLine.d177.s4	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d177.s4	polypharmacy	76	87	O	polypharmacy	acy	macy	NN	False
DDI-MedLine.d177.s4	,	88	88	O	,	,	,	,	False
DDI-MedLine.d177.s4	but	90	92	O	but	but	but	CC	False
DDI-MedLine.d177.s4	it	94	95	O	it	it	it	PRP	False
DDI-MedLine.d177.s4	requires	97	104	O	requires	res	ires	VBZ	False
DDI-MedLine.d177.s4	great	106	110	O	great	eat	reat	JJ	False
DDI-MedLine.d177.s4	courage	112	118	O	courage	age	rage	NN	False
DDI-MedLine.d177.s4	and	120	122	O	and	and	and	CC	False
DDI-MedLine.d177.s4	an	124	125	O	an	an	an	DT	False
DDI-MedLine.d177.s4	interdisciplinary	127	143	O	interdisciplinary	ary	nary	JJ	False
DDI-MedLine.d177.s4	approach	145	152	O	approach	ach	oach	NN	False
DDI-MedLine.d177.s4	involving	154	162	O	involving	ing	ving	VBG	False
DDI-MedLine.d177.s4	modern	164	169	O	modern	ern	dern	JJ	False
DDI-MedLine.d177.s4	information	171	181	O	information	ion	tion	NN	False
DDI-MedLine.d177.s4	technology	183	192	O	technology	ogy	logy	NN	False
DDI-MedLine.d177.s4	.	193	193	O	.	.	.	.	False

DDI-MedLine.d205.s0	Tuberculosis	0	11	O	Tuberculosis	sis	osis	NN	False
DDI-MedLine.d205.s0	and	13	15	O	and	and	and	CC	False
DDI-MedLine.d205.s0	HIV	17	19	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d205.s0	co-infection	21	32	O	co-infection	ion	tion	NN	False
DDI-MedLine.d205.s0	:	33	33	O	:	:	:	:	False
DDI-MedLine.d205.s0	screening	35	43	O	screening	ing	ning	VBG	False
DDI-MedLine.d205.s0	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d205.s0	treatment	49	57	O	treatment	ent	ment	NN	False
DDI-MedLine.d205.s0	strategies	59	68	O	strategies	ies	gies	NNS	False
DDI-MedLine.d205.s0	.	69	69	O	.	.	.	.	False

DDI-MedLine.d205.s1	Globally	0	7	O	Globally	lly	ally	RB	False
DDI-MedLine.d205.s1	,	8	8	O	,	,	,	,	False
DDI-MedLine.d205.s1	tuberculosis	10	21	O	tuberculosis	sis	osis	NN	False
DDI-MedLine.d205.s1	(	23	23	O	(	(	(	(	False
DDI-MedLine.d205.s1	TB	24	25	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s1	)	26	26	O	)	)	)	)	False
DDI-MedLine.d205.s1	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d205.s1	HIV	32	34	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d205.s1	interact	36	43	O	interact	act	ract	NN	False
DDI-MedLine.d205.s1	in	45	46	O	in	in	in	IN	False
DDI-MedLine.d205.s1	deadly	48	53	O	deadly	dly	adly	RB	False
DDI-MedLine.d205.s1	synergy	55	61	O	synergy	rgy	ergy	NN	False
DDI-MedLine.d205.s1	.	62	62	O	.	.	.	.	False

DDI-MedLine.d205.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d205.s2	high	4	7	O	high	igh	high	JJ	False
DDI-MedLine.d205.s2	burden	9	14	O	burden	den	rden	NN	False
DDI-MedLine.d205.s2	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d205.s2	TB	19	20	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s2	among	22	26	O	among	ong	mong	IN	False
DDI-MedLine.d205.s2	HIV-infected	28	39	O	HIV-infected	ted	cted	JJ	False
DDI-MedLine.d205.s2	individuals	41	51	O	individuals	als	uals	NNS	False
DDI-MedLine.d205.s2	underlies	53	61	O	underlies	ies	lies	NNS	False
DDI-MedLine.d205.s2	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d205.s2	importance	67	76	O	importance	nce	ance	NN	False
DDI-MedLine.d205.s2	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d205.s2	TB	81	82	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s2	diagnosis	84	92	O	diagnosis	sis	osis	NN	False
DDI-MedLine.d205.s2	,	93	93	O	,	,	,	,	False
DDI-MedLine.d205.s2	treatment	95	103	O	treatment	ent	ment	NN	False
DDI-MedLine.d205.s2	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d205.s2	prevention	109	118	O	prevention	ion	tion	NN	False
DDI-MedLine.d205.s2	for	120	122	O	for	for	for	IN	False
DDI-MedLine.d205.s2	clinicians	124	133	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d205.s2	involved	135	142	O	involved	ved	lved	VBN	False
DDI-MedLine.d205.s2	in	144	145	O	in	in	in	IN	False
DDI-MedLine.d205.s2	HIV	147	149	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d205.s2	care	151	154	O	care	are	care	NN	False
DDI-MedLine.d205.s2	.	155	155	O	.	.	.	.	False

DDI-MedLine.d205.s3	Despite	0	6	O	Despite	ite	pite	IN	False
DDI-MedLine.d205.s3	expanding	8	16	O	expanding	ing	ding	VBG	False
DDI-MedLine.d205.s3	access	18	23	O	access	ess	cess	NN	False
DDI-MedLine.d205.s3	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d205.s3	antiretroviral	28	41	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d205.s3	therapy	43	49	O	therapy	apy	rapy	NN	False
DDI-MedLine.d205.s3	(	51	51	O	(	(	(	(	False
DDI-MedLine.d205.s3	ART	52	54	O	ART	ART	ART	NN	brand
DDI-MedLine.d205.s3	)	55	55	O	)	)	)	)	False
DDI-MedLine.d205.s3	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d205.s3	treat	60	64	O	treat	eat	reat	NN	False
DDI-MedLine.d205.s3	HIV	66	68	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d205.s3	infection	70	78	O	infection	ion	tion	NN	False
DDI-MedLine.d205.s3	in	80	81	O	in	in	in	IN	False
DDI-MedLine.d205.s3	resource-limited	83	98	O	resource-limited	ted	ited	JJ	False
DDI-MedLine.d205.s3	settings	100	107	O	settings	ngs	ings	NNS	False
DDI-MedLine.d205.s3	,	108	108	O	,	,	,	,	False
DDI-MedLine.d205.s3	many	110	113	O	many	any	many	JJ	False
DDI-MedLine.d205.s3	individuals	115	125	O	individuals	als	uals	NNS	False
DDI-MedLine.d205.s3	in	127	128	O	in	in	in	IN	False
DDI-MedLine.d205.s3	need	130	133	O	need	eed	need	NN	False
DDI-MedLine.d205.s3	of	135	136	O	of	of	of	IN	False
DDI-MedLine.d205.s3	therapy	138	144	O	therapy	apy	rapy	NN	False
DDI-MedLine.d205.s3	initiate	146	153	O	initiate	ate	iate	NN	False
DDI-MedLine.d205.s3	ART	155	157	O	ART	ART	ART	NN	brand
DDI-MedLine.d205.s3	too	159	161	O	too	too	too	RB	False
DDI-MedLine.d205.s3	late	163	166	O	late	ate	late	RB	False
DDI-MedLine.d205.s3	and	168	170	O	and	and	and	CC	False
DDI-MedLine.d205.s3	have	172	175	O	have	ave	have	VB	False
DDI-MedLine.d205.s3	already	177	183	O	already	ady	eady	RB	False
DDI-MedLine.d205.s3	developed	185	193	O	developed	ped	oped	NN	False
DDI-MedLine.d205.s3	clinically	195	204	O	clinically	lly	ally	RB	False
DDI-MedLine.d205.s3	significant	206	216	O	significant	ant	cant	JJ	False
DDI-MedLine.d205.s3	TB	218	219	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s3	by	221	222	O	by	by	by	IN	False
DDI-MedLine.d205.s3	the	224	226	O	the	the	the	DT	False
DDI-MedLine.d205.s3	time	228	231	O	time	ime	time	NN	False
DDI-MedLine.d205.s3	they	233	236	O	they	hey	they	PRP	False
DDI-MedLine.d205.s3	present	238	244	O	present	ent	sent	NN	False
DDI-MedLine.d205.s3	for	246	248	O	for	for	for	IN	False
DDI-MedLine.d205.s3	care	250	253	O	care	are	care	NN	False
DDI-MedLine.d205.s3	.	254	254	O	.	.	.	.	False

DDI-MedLine.d205.s4	Many	0	3	O	Many	any	Many	JJ	False
DDI-MedLine.d205.s4	co-infected	5	15	O	co-infected	ted	cted	JJ	False
DDI-MedLine.d205.s4	individuals	17	27	O	individuals	als	uals	NNS	False
DDI-MedLine.d205.s4	are	29	31	O	are	are	are	VBP	False
DDI-MedLine.d205.s4	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d205.s4	need	36	39	O	need	eed	need	NN	False
DDI-MedLine.d205.s4	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d205.s4	concurrent	44	53	O	concurrent	ent	rent	NN	False
DDI-MedLine.d205.s4	ART	55	57	O	ART	ART	ART	NN	brand
DDI-MedLine.d205.s4	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d205.s4	anti-TB	63	69	O	anti-TB	-TB	i-TB	NN	False
DDI-MedLine.d205.s4	therapy	71	77	O	therapy	apy	rapy	NN	False
DDI-MedLine.d205.s4	,	78	78	O	,	,	,	,	False
DDI-MedLine.d205.s4	which	80	84	O	which	ich	hich	WDT	False
DDI-MedLine.d205.s4	dramatically	86	97	O	dramatically	lly	ally	RB	False
DDI-MedLine.d205.s4	improves	99	106	O	improves	ves	oves	NNS	False
DDI-MedLine.d205.s4	survival	108	115	O	survival	val	ival	NN	False
DDI-MedLine.d205.s4	,	116	116	O	,	,	,	,	False
DDI-MedLine.d205.s4	but	118	120	O	but	but	but	CC	False
DDI-MedLine.d205.s4	also	122	125	O	also	lso	also	RB	False
DDI-MedLine.d205.s4	raises	127	132	O	raises	ses	ises	NNS	False
DDI-MedLine.d205.s4	several	134	140	O	several	ral	eral	JJ	False
DDI-MedLine.d205.s4	management	142	151	O	management	ent	ment	NN	False
DDI-MedLine.d205.s4	challenges	153	162	O	challenges	ges	nges	NNS	False
DDI-MedLine.d205.s4	,	163	163	O	,	,	,	,	False
DDI-MedLine.d205.s4	including	165	173	O	including	ing	ding	VBG	False
DDI-MedLine.d205.s4	drug	175	178	O	drug	rug	drug	NN	False
DDI-MedLine.d205.s4	interactions	180	191	O	interactions	ons	ions	NNS	False
DDI-MedLine.d205.s4	,	192	192	O	,	,	,	,	False
DDI-MedLine.d205.s4	shared	194	199	O	shared	red	ared	VBN	False
DDI-MedLine.d205.s4	drug	201	204	O	drug	rug	drug	NN	False
DDI-MedLine.d205.s4	toxicities	206	215	O	toxicities	ies	ties	NNS	False
DDI-MedLine.d205.s4	and	217	219	O	and	and	and	CC	False
DDI-MedLine.d205.s4	TB	221	222	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s4	immune	224	229	O	immune	une	mune	NN	False
DDI-MedLine.d205.s4	reconstitution	231	244	O	reconstitution	ion	tion	NN	False
DDI-MedLine.d205.s4	inflammatory	246	257	O	inflammatory	ory	tory	NN	False
DDI-MedLine.d205.s4	syndrome	259	266	O	syndrome	ome	rome	NN	False
DDI-MedLine.d205.s4	(	268	268	O	(	(	(	(	False
DDI-MedLine.d205.s4	IRIS	269	272	O	IRIS	RIS	IRIS	NN	brand
DDI-MedLine.d205.s4	)	273	273	O	)	)	)	)	False
DDI-MedLine.d205.s4	.	274	274	O	.	.	.	.	False

DDI-MedLine.d205.s5	Due	0	2	O	Due	Due	Due	JJ	False
DDI-MedLine.d205.s5	to	4	5	O	to	to	to	TO	False
DDI-MedLine.d205.s5	the	7	9	O	the	the	the	DT	False
DDI-MedLine.d205.s5	survival	11	18	O	survival	val	ival	NN	False
DDI-MedLine.d205.s5	benefits	20	27	O	benefits	its	fits	NNS	False
DDI-MedLine.d205.s5	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d205.s5	promptly	32	39	O	promptly	tly	ptly	RB	False
DDI-MedLine.d205.s5	initiating	41	50	O	initiating	ing	ting	VBG	False
DDI-MedLine.d205.s5	ART	52	54	O	ART	ART	ART	NN	brand
DDI-MedLine.d205.s5	among	56	60	O	among	ong	mong	IN	False
DDI-MedLine.d205.s5	all	62	64	O	all	all	all	DT	False
DDI-MedLine.d205.s5	HIV-infected	66	77	O	HIV-infected	ted	cted	JJ	False
DDI-MedLine.d205.s5	individuals	79	89	O	individuals	als	uals	NNS	False
DDI-MedLine.d205.s5	,	90	90	O	,	,	,	,	False
DDI-MedLine.d205.s5	including	92	100	O	including	ing	ding	VBG	False
DDI-MedLine.d205.s5	those	102	106	O	those	ose	hose	DT	False
DDI-MedLine.d205.s5	with	108	111	O	with	ith	with	IN	False
DDI-MedLine.d205.s5	TB	113	114	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s5	,	115	115	O	,	,	,	,	False
DDI-MedLine.d205.s5	it	117	118	O	it	it	it	PRP	False
DDI-MedLine.d205.s5	is	120	121	O	is	is	is	VBZ	False
DDI-MedLine.d205.s5	recommended	123	133	O	recommended	ded	nded	VBN	False
DDI-MedLine.d205.s5	that	135	138	O	that	hat	that	IN	False
DDI-MedLine.d205.s5	co-infected	140	150	O	co-infected	ted	cted	JJ	False
DDI-MedLine.d205.s5	individuals	152	162	O	individuals	als	uals	NNS	False
DDI-MedLine.d205.s5	receive	164	170	O	receive	ive	eive	NN	False
DDI-MedLine.d205.s5	treatment	172	180	O	treatment	ent	ment	NN	False
DDI-MedLine.d205.s5	for	182	184	O	for	for	for	IN	False
DDI-MedLine.d205.s5	both	186	189	O	both	oth	both	DT	False
DDI-MedLine.d205.s5	diseases	191	198	O	diseases	ses	ases	NNS	False
DDI-MedLine.d205.s5	,	199	199	O	,	,	,	,	False
DDI-MedLine.d205.s5	regardless	201	210	O	regardless	ess	less	RB	False
DDI-MedLine.d205.s5	of	212	213	O	of	of	of	IN	False
DDI-MedLine.d205.s5	CD4+	215	218	O	CD4+	D4+	CD4+	NN	brand
DDI-MedLine.d205.s5	cell	220	223	O	cell	ell	cell	NN	False
DDI-MedLine.d205.s5	count	225	229	O	count	unt	ount	NN	False
DDI-MedLine.d205.s5	.	230	230	O	.	.	.	.	False

DDI-MedLine.d205.s6	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d205.s6	review	3	8	O	review	iew	view	NN	False
DDI-MedLine.d205.s6	current	10	16	O	current	ent	rent	JJ	False
DDI-MedLine.d205.s6	screening	18	26	O	screening	ing	ning	VBG	False
DDI-MedLine.d205.s6	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d205.s6	treatment	32	40	O	treatment	ent	ment	NN	False
DDI-MedLine.d205.s6	strategies	42	51	O	strategies	ies	gies	NNS	False
DDI-MedLine.d205.s6	for	53	55	O	for	for	for	IN	False
DDI-MedLine.d205.s6	TB	57	58	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s6	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d205.s6	HIV	64	66	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d205.s6	co-infection	68	79	O	co-infection	ion	tion	NN	False
DDI-MedLine.d205.s6	.	80	80	O	.	.	.	.	False

DDI-MedLine.d205.s7	Recent	0	5	O	Recent	ent	cent	NN	False
DDI-MedLine.d205.s7	findings	7	14	O	findings	ngs	ings	NNS	False
DDI-MedLine.d205.s7	and	16	18	O	and	and	and	CC	False
DDI-MedLine.d205.s7	ongoing	20	26	O	ongoing	ing	oing	VBG	False
DDI-MedLine.d205.s7	studies	28	34	O	studies	ies	dies	NNS	False
DDI-MedLine.d205.s7	will	36	39	O	will	ill	will	MD	False
DDI-MedLine.d205.s7	assist	41	46	O	assist	ist	sist	NN	False
DDI-MedLine.d205.s7	clinicians	48	57	O	clinicians	ans	ians	NNS	False
DDI-MedLine.d205.s7	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d205.s7	managing	62	69	O	managing	ing	ging	VBG	False
DDI-MedLine.d205.s7	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d205.s7	prevention	75	84	O	prevention	ion	tion	NN	False
DDI-MedLine.d205.s7	and	86	88	O	and	and	and	CC	False
DDI-MedLine.d205.s7	treatment	90	98	O	treatment	ent	ment	NN	False
DDI-MedLine.d205.s7	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d205.s7	TB	103	104	O	TB	TB	TB	NN	brand
DDI-MedLine.d205.s7	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d205.s7	HIV	110	112	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d205.s7	co-infection	114	125	O	co-infection	ion	tion	NN	False
DDI-MedLine.d205.s7	,	126	126	O	,	,	,	,	False
DDI-MedLine.d205.s7	which	128	132	O	which	ich	hich	WDT	False
DDI-MedLine.d205.s7	remains	134	140	O	remains	ins	ains	NNS	False
DDI-MedLine.d205.s7	a	142	142	O	a	a	a	DT	False
DDI-MedLine.d205.s7	major	144	148	O	major	jor	ajor	JJ	False
DDI-MedLine.d205.s7	global	150	155	O	global	bal	obal	JJ	False
DDI-MedLine.d205.s7	health	157	162	O	health	lth	alth	NN	False
DDI-MedLine.d205.s7	challenge	164	172	O	challenge	nge	enge	NN	False
DDI-MedLine.d205.s7	.	173	173	O	.	.	.	.	False

DDI-MedLine.d178.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d178.s0	Ticagrelor	1	10	B-drug	Ticagrelor	lor	elor	NN	False
DDI-MedLine.d178.s0	:	11	11	O	:	:	:	:	False
DDI-MedLine.d178.s0	a	13	13	O	a	a	a	DT	False
DDI-MedLine.d178.s0	novel	15	19	O	novel	vel	ovel	NN	False
DDI-MedLine.d178.s0	antiplatelet	21	32	B-group	antiplatelet	let	elet	NN	False
DDI-MedLine.d178.s0	agent	34	38	I-group	agent	ent	gent	NN	False
DDI-MedLine.d178.s0	for	40	42	O	for	for	for	IN	False
DDI-MedLine.d178.s0	patients	44	51	O	patients	nts	ents	NNS	False
DDI-MedLine.d178.s0	with	53	56	O	with	ith	with	IN	False
DDI-MedLine.d178.s0	acute	58	62	O	acute	ute	cute	NN	False
DDI-MedLine.d178.s0	coronary	64	71	O	coronary	ary	nary	NN	False
DDI-MedLine.d178.s0	syndrome	73	80	O	syndrome	ome	rome	NN	False
DDI-MedLine.d178.s0	]	81	81	O	]	]	]	NN	False
DDI-MedLine.d178.s0	.	82	82	O	.	.	.	.	False

DDI-MedLine.d178.s1	Ticagrelor	0	9	B-drug	Ticagrelor	lor	elor	NN	False
DDI-MedLine.d178.s1	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d178.s1	an	14	15	O	an	an	an	DT	False
DDI-MedLine.d178.s1	oral	17	20	O	oral	ral	oral	JJ	False
DDI-MedLine.d178.s1	,	21	21	O	,	,	,	,	False
DDI-MedLine.d178.s1	reversible	23	32	O	reversible	ble	ible	JJ	False
DDI-MedLine.d178.s1	blocker	34	40	O	blocker	ker	cker	NN	False
DDI-MedLine.d178.s1	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d178.s1	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d178.s1	P2Y12	49	53	O	P2Y12	Y12	2Y12	NN	brand
DDI-MedLine.d178.s1	adenosine	55	63	O	adenosine	ine	sine	NN	drug
DDI-MedLine.d178.s1	receptor	65	72	O	receptor	tor	ptor	NN	False
DDI-MedLine.d178.s1	.	73	73	O	.	.	.	.	False

DDI-MedLine.d178.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d178.s2	clinical	3	10	O	clinical	cal	ical	JJ	False
DDI-MedLine.d178.s2	trials	12	17	O	trials	als	ials	NNS	False
DDI-MedLine.d178.s2	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d178.s2	antiplatelet	23	34	B-group	antiplatelet	let	elet	NN	False
DDI-MedLine.d178.s2	agent	36	40	I-group	agent	ent	gent	NN	False
DDI-MedLine.d178.s2	reduced	42	48	O	reduced	ced	uced	VBN	False
DDI-MedLine.d178.s2	significantly	50	62	O	significantly	tly	ntly	RB	False
DDI-MedLine.d178.s2	vascular	64	71	O	vascular	lar	ular	NN	False
DDI-MedLine.d178.s2	mortality	73	81	O	mortality	ity	lity	NN	False
DDI-MedLine.d178.s2	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d178.s2	death	87	91	O	death	ath	eath	NN	False
DDI-MedLine.d178.s2	from	93	96	O	from	rom	from	IN	False
DDI-MedLine.d178.s2	any	98	100	O	any	any	any	DT	False
DDI-MedLine.d178.s2	cause	102	106	O	cause	use	ause	NN	False
DDI-MedLine.d178.s2	when	108	111	O	when	hen	when	WRB	False
DDI-MedLine.d178.s2	compared	113	120	O	compared	red	ared	VBN	False
DDI-MedLine.d178.s2	to	122	123	O	to	to	to	TO	False
DDI-MedLine.d178.s2	clopidogrel	125	135	B-drug	clopidogrel	rel	grel	NN	False
DDI-MedLine.d178.s2	in	137	138	O	in	in	in	IN	False
DDI-MedLine.d178.s2	patients	140	147	O	patients	nts	ents	NNS	False
DDI-MedLine.d178.s2	with	149	152	O	with	ith	with	IN	False
DDI-MedLine.d178.s2	acute	154	158	O	acute	ute	cute	NN	False
DDI-MedLine.d178.s2	coronary	160	167	O	coronary	ary	nary	NN	False
DDI-MedLine.d178.s2	syndrome	169	176	O	syndrome	ome	rome	NN	False
DDI-MedLine.d178.s2	.	177	177	O	.	.	.	.	False

DDI-MedLine.d198.s0	Structural	0	9	O	Structural	ral	ural	JJ	False
DDI-MedLine.d198.s0	basis	11	15	O	basis	sis	asis	NN	False
DDI-MedLine.d198.s0	for	17	19	O	for	for	for	IN	False
DDI-MedLine.d198.s0	alcohol	21	27	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s0	modulation	29	38	O	modulation	ion	tion	NN	False
DDI-MedLine.d198.s0	of	40	41	O	of	of	of	IN	False
DDI-MedLine.d198.s0	a	43	43	O	a	a	a	DT	False
DDI-MedLine.d198.s0	pentameric	45	54	O	pentameric	ric	eric	NN	False
DDI-MedLine.d198.s0	ligand-gated	56	67	O	ligand-gated	ted	ated	JJ	False
DDI-MedLine.d198.s0	ion	69	71	O	ion	ion	ion	NN	False
DDI-MedLine.d198.s0	channel	73	79	O	channel	nel	nnel	NNS	False
DDI-MedLine.d198.s0	.	80	80	O	.	.	.	.	False

DDI-MedLine.d198.s1	Despite	0	6	O	Despite	ite	pite	IN	False
DDI-MedLine.d198.s1	its	8	10	O	its	its	its	PRP$	False
DDI-MedLine.d198.s1	long	12	15	O	long	ong	long	RB	False
DDI-MedLine.d198.s1	history	17	23	O	history	ory	tory	NN	False
DDI-MedLine.d198.s1	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d198.s1	use	28	30	O	use	use	use	NN	False
DDI-MedLine.d198.s1	and	32	34	O	and	and	and	CC	False
DDI-MedLine.d198.s1	abuse	36	40	O	abuse	use	buse	NN	False
DDI-MedLine.d198.s1	in	42	43	O	in	in	in	IN	False
DDI-MedLine.d198.s1	human	45	49	O	human	man	uman	NN	False
DDI-MedLine.d198.s1	culture	51	57	O	culture	ure	ture	NN	False
DDI-MedLine.d198.s1	,	58	58	O	,	,	,	,	False
DDI-MedLine.d198.s1	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d198.s1	molecular	64	72	O	molecular	lar	ular	NN	False
DDI-MedLine.d198.s1	basis	74	78	O	basis	sis	asis	NN	False
DDI-MedLine.d198.s1	for	80	82	O	for	for	for	IN	False
DDI-MedLine.d198.s1	alcohol	84	90	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s1	action	92	97	O	action	ion	tion	NN	False
DDI-MedLine.d198.s1	in	99	100	O	in	in	in	IN	False
DDI-MedLine.d198.s1	the	102	104	O	the	the	the	DT	False
DDI-MedLine.d198.s1	brain	106	110	O	brain	ain	rain	NN	False
DDI-MedLine.d198.s1	is	112	113	O	is	is	is	VBZ	False
DDI-MedLine.d198.s1	poorly	115	120	O	poorly	rly	orly	RB	False
DDI-MedLine.d198.s1	understood	122	131	O	understood	ood	tood	NN	False
DDI-MedLine.d198.s1	.	132	132	O	.	.	.	.	False

DDI-MedLine.d198.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d198.s2	recent	4	9	O	recent	ent	cent	JJ	False
DDI-MedLine.d198.s2	determination	11	23	O	determination	ion	tion	NN	False
DDI-MedLine.d198.s2	of	25	26	O	of	of	of	IN	False
DDI-MedLine.d198.s2	the	28	30	O	the	the	the	DT	False
DDI-MedLine.d198.s2	atomic-scale	32	43	O	atomic-scale	ale	cale	JJ	False
DDI-MedLine.d198.s2	structure	45	53	O	structure	ure	ture	NN	False
DDI-MedLine.d198.s2	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d198.s2	GLIC	58	61	O	GLIC	LIC	GLIC	NN	brand
DDI-MedLine.d198.s2	,	62	62	O	,	,	,	,	False
DDI-MedLine.d198.s2	a	64	64	O	a	a	a	DT	False
DDI-MedLine.d198.s2	prokaryotic	66	76	O	prokaryotic	tic	otic	JJ	False
DDI-MedLine.d198.s2	member	78	83	O	member	ber	mber	NN	False
DDI-MedLine.d198.s2	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d198.s2	the	88	90	O	the	the	the	DT	False
DDI-MedLine.d198.s2	pentameric	92	101	O	pentameric	ric	eric	NN	False
DDI-MedLine.d198.s2	ligand-gated	103	114	O	ligand-gated	ted	ated	JJ	False
DDI-MedLine.d198.s2	ion	116	118	O	ion	ion	ion	NN	False
DDI-MedLine.d198.s2	channel	120	126	O	channel	nel	nnel	NNS	False
DDI-MedLine.d198.s2	(	128	128	O	(	(	(	(	False
DDI-MedLine.d198.s2	pLGIC	129	133	O	pLGIC	GIC	LGIC	NN	False
DDI-MedLine.d198.s2	)	134	134	O	)	)	)	)	False
DDI-MedLine.d198.s2	family	136	141	O	family	ily	mily	NN	False
DDI-MedLine.d198.s2	,	142	142	O	,	,	,	,	False
DDI-MedLine.d198.s2	provides	144	151	O	provides	des	ides	VBZ	group
DDI-MedLine.d198.s2	a	153	153	O	a	a	a	DT	False
DDI-MedLine.d198.s2	unique	155	160	O	unique	que	ique	NN	False
DDI-MedLine.d198.s2	opportunity	162	172	O	opportunity	ity	nity	NN	False
DDI-MedLine.d198.s2	to	174	175	O	to	to	to	TO	False
DDI-MedLine.d198.s2	characterize	177	188	O	characterize	ize	rize	NN	False
DDI-MedLine.d198.s2	the	190	192	O	the	the	the	DT	False
DDI-MedLine.d198.s2	structural	194	203	O	structural	ral	ural	JJ	False
DDI-MedLine.d198.s2	basis	205	209	O	basis	sis	asis	NN	False
DDI-MedLine.d198.s2	for	211	213	O	for	for	for	IN	False
DDI-MedLine.d198.s2	modulation	215	224	O	modulation	ion	tion	NN	False
DDI-MedLine.d198.s2	of	226	227	O	of	of	of	IN	False
DDI-MedLine.d198.s2	these	229	233	O	these	ese	hese	DT	False
DDI-MedLine.d198.s2	channels	235	242	O	channels	els	nels	NNS	False
DDI-MedLine.d198.s2	,	243	243	O	,	,	,	,	False
DDI-MedLine.d198.s2	many	245	248	O	many	any	many	JJ	False
DDI-MedLine.d198.s2	of	250	251	O	of	of	of	IN	False
DDI-MedLine.d198.s2	which	253	257	O	which	ich	hich	WDT	False
DDI-MedLine.d198.s2	are	259	261	O	are	are	are	VBP	False
DDI-MedLine.d198.s2	alcohol	263	269	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s2	targets	271	277	O	targets	ets	gets	NNS	False
DDI-MedLine.d198.s2	in	279	280	O	in	in	in	IN	False
DDI-MedLine.d198.s2	brain	282	286	O	brain	ain	rain	NN	False
DDI-MedLine.d198.s2	.	287	287	O	.	.	.	.	False

DDI-MedLine.d198.s3	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d198.s3	observed	3	10	O	observed	ved	rved	VBN	False
DDI-MedLine.d198.s3	that	12	15	O	that	hat	that	IN	False
DDI-MedLine.d198.s3	GLIC	17	20	O	GLIC	LIC	GLIC	NN	brand
DDI-MedLine.d198.s3	recapitulates	22	34	O	recapitulates	tes	ates	NNS	False
DDI-MedLine.d198.s3	bimodal	36	42	O	bimodal	dal	odal	NN	False
DDI-MedLine.d198.s3	modulation	44	53	O	modulation	ion	tion	NN	False
DDI-MedLine.d198.s3	by	55	56	O	by	by	by	IN	False
DDI-MedLine.d198.s3	n-alcohols	58	67	O	n-alcohols	ols	hols	NNS	False
DDI-MedLine.d198.s3	,	68	68	O	,	,	,	,	False
DDI-MedLine.d198.s3	similar	70	76	O	similar	lar	ilar	JJ	False
DDI-MedLine.d198.s3	to	78	79	O	to	to	to	TO	False
DDI-MedLine.d198.s3	some	81	84	O	some	ome	some	DT	False
DDI-MedLine.d198.s3	eukaryotic	86	95	O	eukaryotic	tic	otic	JJ	False
DDI-MedLine.d198.s3	pLGICs	97	102	O	pLGICs	ICs	GICs	NN	False
DDI-MedLine.d198.s3	:	103	103	O	:	:	:	:	False
DDI-MedLine.d198.s3	methanol	105	112	B-drug_n	methanol	nol	anol	NN	False
DDI-MedLine.d198.s3	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d198.s3	ethanol	118	124	B-drug	ethanol	nol	anol	NN	False
DDI-MedLine.d198.s3	weakly	126	131	O	weakly	kly	akly	NN	False
DDI-MedLine.d198.s3	potentiated	133	143	O	potentiated	ted	ated	VBN	False
DDI-MedLine.d198.s3	proton-activated	145	160	O	proton-activated	ted	ated	JJ	False
DDI-MedLine.d198.s3	currents	162	169	O	currents	nts	ents	NNS	False
DDI-MedLine.d198.s3	in	171	172	O	in	in	in	IN	False
DDI-MedLine.d198.s3	GLIC	174	177	O	GLIC	LIC	GLIC	NN	brand
DDI-MedLine.d198.s3	,	178	178	O	,	,	,	,	False
DDI-MedLine.d198.s3	whereas	180	186	O	whereas	eas	reas	NNS	False
DDI-MedLine.d198.s3	n-alcohols	188	197	O	n-alcohols	ols	hols	NNS	False
DDI-MedLine.d198.s3	larger	199	204	O	larger	ger	rger	JJR	False
DDI-MedLine.d198.s3	than	206	209	O	than	han	than	IN	False
DDI-MedLine.d198.s3	ethanol	211	217	O	ethanol	nol	anol	NN	False
DDI-MedLine.d198.s3	inhibited	219	227	O	inhibited	ted	ited	VBN	False
DDI-MedLine.d198.s3	them	229	232	O	them	hem	them	PRP	False
DDI-MedLine.d198.s3	.	233	233	O	.	.	.	.	False

DDI-MedLine.d198.s4	Mapping	0	6	O	Mapping	ing	ping	VBG	False
DDI-MedLine.d198.s4	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d198.s4	residues	11	18	O	residues	ues	dues	NNS	False
DDI-MedLine.d198.s4	important	20	28	O	important	ant	tant	JJ	False
DDI-MedLine.d198.s4	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d198.s4	alcohol	33	39	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s4	modulation	41	50	O	modulation	ion	tion	NN	False
DDI-MedLine.d198.s4	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d198.s4	ionotropic	55	64	O	ionotropic	pic	opic	NN	False
DDI-MedLine.d198.s4	receptors	66	74	O	receptors	ors	tors	NNS	False
DDI-MedLine.d198.s4	for	76	78	O	for	for	for	IN	False
DDI-MedLine.d198.s4	glycine	80	86	O	glycine	ine	cine	NN	drug
DDI-MedLine.d198.s4	,	87	87	O	,	,	,	,	False
DDI-MedLine.d198.s4	-aminobutyric	91	103	O	-aminobutyric	ric	yric	NN	False
DDI-MedLine.d198.s4	acid	105	108	O	acid	cid	acid	NN	False
DDI-MedLine.d198.s4	,	109	109	O	,	,	,	,	False
DDI-MedLine.d198.s4	and	111	113	O	and	and	and	CC	False
DDI-MedLine.d198.s4	acetylcholine	115	127	O	acetylcholine	ine	line	NN	drug
DDI-MedLine.d198.s4	onto	129	132	O	onto	nto	onto	IN	False
DDI-MedLine.d198.s4	GLIC	134	137	O	GLIC	LIC	GLIC	NN	brand
DDI-MedLine.d198.s4	revealed	139	146	O	revealed	led	aled	VBD	False
DDI-MedLine.d198.s4	their	148	152	O	their	eir	heir	PRP$	False
DDI-MedLine.d198.s4	proximity	154	162	O	proximity	ity	mity	NN	False
DDI-MedLine.d198.s4	to	164	165	O	to	to	to	TO	False
DDI-MedLine.d198.s4	transmembrane	167	179	O	transmembrane	ane	rane	NN	False
DDI-MedLine.d198.s4	cavities	181	188	O	cavities	ies	ties	NNS	False
DDI-MedLine.d198.s4	that	190	193	O	that	hat	that	IN	False
DDI-MedLine.d198.s4	may	195	197	O	may	may	may	MD	False
DDI-MedLine.d198.s4	accommodate	199	209	O	accommodate	ate	date	NN	False
DDI-MedLine.d198.s4	one	211	213	O	one	one	one	CD	False
DDI-MedLine.d198.s4	or	215	216	O	or	or	or	CC	False
DDI-MedLine.d198.s4	more	218	221	O	more	ore	more	RBR	False
DDI-MedLine.d198.s4	alcohol	223	229	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s4	molecules	231	239	O	molecules	les	ules	NNS	False
DDI-MedLine.d198.s4	.	240	240	O	.	.	.	.	False

DDI-MedLine.d198.s5	Site-directed	0	12	O	Site-directed	ted	cted	JJ	False
DDI-MedLine.d198.s5	mutations	14	22	O	mutations	ons	ions	NNS	False
DDI-MedLine.d198.s5	in	24	25	O	in	in	in	IN	False
DDI-MedLine.d198.s5	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d198.s5	pore-lining	31	41	O	pore-lining	ing	ning	NN	False
DDI-MedLine.d198.s5	M2	43	44	O	M2	M2	M2	NN	brand
DDI-MedLine.d198.s5	helix	46	50	O	helix	lix	elix	NN	False
DDI-MedLine.d198.s5	allowed	52	58	O	allowed	wed	owed	VBN	False
DDI-MedLine.d198.s5	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d198.s5	identification	64	77	O	identification	ion	tion	NN	False
DDI-MedLine.d198.s5	of	79	80	O	of	of	of	IN	False
DDI-MedLine.d198.s5	four	82	85	O	four	our	four	CD	False
DDI-MedLine.d198.s5	residues	87	94	O	residues	ues	dues	NNS	False
DDI-MedLine.d198.s5	that	96	99	O	that	hat	that	IN	False
DDI-MedLine.d198.s5	influence	101	109	O	influence	nce	ence	NN	False
DDI-MedLine.d198.s5	alcohol	111	117	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s5	potentiation	119	130	O	potentiation	ion	tion	NN	False
DDI-MedLine.d198.s5	,	131	131	O	,	,	,	,	False
DDI-MedLine.d198.s5	with	133	136	O	with	ith	with	IN	False
DDI-MedLine.d198.s5	the	138	140	O	the	the	the	DT	False
DDI-MedLine.d198.s5	direction	142	150	O	direction	ion	tion	NN	False
DDI-MedLine.d198.s5	of	152	153	O	of	of	of	IN	False
DDI-MedLine.d198.s5	their	155	159	O	their	eir	heir	PRP$	False
DDI-MedLine.d198.s5	effects	161	167	O	effects	cts	ects	NNS	False
DDI-MedLine.d198.s5	reflecting	169	178	O	reflecting	ing	ting	VBG	False
DDI-MedLine.d198.s5	-helical	182	189	O	-helical	cal	ical	JJ	False
DDI-MedLine.d198.s5	structure	191	199	O	structure	ure	ture	NN	False
DDI-MedLine.d198.s5	.	200	200	O	.	.	.	.	False

DDI-MedLine.d198.s6	At	0	1	O	At	At	At	IN	False
DDI-MedLine.d198.s6	one	3	5	O	one	one	one	CD	False
DDI-MedLine.d198.s6	of	7	8	O	of	of	of	IN	False
DDI-MedLine.d198.s6	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d198.s6	potentiation-enhancing	14	35	O	potentiation-enhancing	ing	cing	NN	False
DDI-MedLine.d198.s6	residues	37	44	O	residues	ues	dues	NNS	False
DDI-MedLine.d198.s6	,	45	45	O	,	,	,	,	False
DDI-MedLine.d198.s6	decreased	47	55	O	decreased	sed	ased	VBN	False
DDI-MedLine.d198.s6	side	57	60	O	side	ide	side	NN	False
DDI-MedLine.d198.s6	chain	62	66	O	chain	ain	hain	NN	False
DDI-MedLine.d198.s6	volume	68	73	O	volume	ume	lume	NN	False
DDI-MedLine.d198.s6	converted	75	83	O	converted	ted	rted	VBN	False
DDI-MedLine.d198.s6	GLIC	85	88	O	GLIC	LIC	GLIC	NN	brand
DDI-MedLine.d198.s6	into	90	93	O	into	nto	into	IN	False
DDI-MedLine.d198.s6	a	95	95	O	a	a	a	DT	False
DDI-MedLine.d198.s6	highly	97	102	O	highly	hly	ghly	RB	False
DDI-MedLine.d198.s6	ethanol-sensitive	104	120	O	ethanol-sensitive	ive	tive	JJ	False
DDI-MedLine.d198.s6	channel	122	128	O	channel	nel	nnel	NNS	False
DDI-MedLine.d198.s6	,	129	129	O	,	,	,	,	False
DDI-MedLine.d198.s6	comparable	131	140	O	comparable	ble	able	JJ	False
DDI-MedLine.d198.s6	to	142	143	O	to	to	to	TO	False
DDI-MedLine.d198.s6	its	145	147	O	its	its	its	PRP$	False
DDI-MedLine.d198.s6	eukaryotic	149	158	O	eukaryotic	tic	otic	JJ	False
DDI-MedLine.d198.s6	relatives	160	168	O	relatives	ves	ives	NNS	False
DDI-MedLine.d198.s6	.	169	169	O	.	.	.	.	False

DDI-MedLine.d198.s7	Covalent	0	7	O	Covalent	ent	lent	NN	False
DDI-MedLine.d198.s7	labeling	9	16	O	labeling	ing	ling	VBG	False
DDI-MedLine.d198.s7	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d198.s7	M2	21	22	O	M2	M2	M2	NN	brand
DDI-MedLine.d198.s7	positions	24	32	O	positions	ons	ions	NNS	False
DDI-MedLine.d198.s7	with	34	37	O	with	ith	with	IN	False
DDI-MedLine.d198.s7	an	39	40	O	an	an	an	DT	False
DDI-MedLine.d198.s7	alcohol	42	48	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s7	analog	50	55	O	analog	log	alog	NN	False
DDI-MedLine.d198.s7	,	56	56	O	,	,	,	,	False
DDI-MedLine.d198.s7	a	58	58	O	a	a	a	DT	False
DDI-MedLine.d198.s7	methanethiosulfonate	60	79	O	methanethiosulfonate	ate	nate	NN	False
DDI-MedLine.d198.s7	reagent	81	87	O	reagent	ent	gent	NN	False
DDI-MedLine.d198.s7	,	88	88	O	,	,	,	,	False
DDI-MedLine.d198.s7	further	90	96	O	further	her	ther	RB	False
DDI-MedLine.d198.s7	implicated	98	107	O	implicated	ted	ated	VBN	False
DDI-MedLine.d198.s7	residues	109	116	O	residues	ues	dues	NNS	False
DDI-MedLine.d198.s7	at	118	119	O	at	at	at	IN	False
DDI-MedLine.d198.s7	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d198.s7	extracellular	125	137	O	extracellular	lar	ular	NN	False
DDI-MedLine.d198.s7	end	139	141	O	end	end	end	NN	False
DDI-MedLine.d198.s7	of	143	144	O	of	of	of	IN	False
DDI-MedLine.d198.s7	the	146	148	O	the	the	the	DT	False
DDI-MedLine.d198.s7	helix	150	154	O	helix	lix	elix	NN	False
DDI-MedLine.d198.s7	in	156	157	O	in	in	in	IN	False
DDI-MedLine.d198.s7	alcohol	159	165	O	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s7	binding	167	173	O	binding	ing	ding	NN	False
DDI-MedLine.d198.s7	.	174	174	O	.	.	.	.	False

DDI-MedLine.d198.s8	Molecular	0	8	O	Molecular	lar	ular	JJ	False
DDI-MedLine.d198.s8	dynamics	10	17	O	dynamics	ics	mics	NNS	False
DDI-MedLine.d198.s8	simulations	19	29	O	simulations	ons	ions	NNS	False
DDI-MedLine.d198.s8	elucidated	31	40	O	elucidated	ted	ated	VBN	False
DDI-MedLine.d198.s8	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d198.s8	structural	46	55	O	structural	ral	ural	JJ	False
DDI-MedLine.d198.s8	consequences	57	68	O	consequences	ces	nces	NNS	False
DDI-MedLine.d198.s8	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d198.s8	a	73	73	O	a	a	a	DT	False
DDI-MedLine.d198.s8	potentiation-enhancing	75	96	O	potentiation-enhancing	ing	cing	NN	False
DDI-MedLine.d198.s8	mutation	98	105	O	mutation	ion	tion	NN	False
DDI-MedLine.d198.s8	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d198.s8	suggested	111	119	O	suggested	ted	sted	VBN	False
DDI-MedLine.d198.s8	a	121	121	O	a	a	a	DT	False
DDI-MedLine.d198.s8	structural	123	132	O	structural	ral	ural	JJ	False
DDI-MedLine.d198.s8	mechanism	134	142	O	mechanism	ism	nism	NN	False
DDI-MedLine.d198.s8	for	144	146	O	for	for	for	IN	False
DDI-MedLine.d198.s8	alcohol	148	154	B-drug	alcohol	hol	ohol	NN	False
DDI-MedLine.d198.s8	potentiation	156	167	O	potentiation	ion	tion	NN	False
DDI-MedLine.d198.s8	via	169	171	O	via	via	via	IN	False
DDI-MedLine.d198.s8	interaction	173	183	O	interaction	ion	tion	NN	False
DDI-MedLine.d198.s8	with	185	188	O	with	ith	with	IN	False
DDI-MedLine.d198.s8	a	190	190	O	a	a	a	DT	False
DDI-MedLine.d198.s8	transmembrane	192	204	O	transmembrane	ane	rane	NN	False
DDI-MedLine.d198.s8	cavity	206	211	O	cavity	ity	vity	NN	False
DDI-MedLine.d198.s8	previously	213	222	O	previously	sly	usly	RB	False
DDI-MedLine.d198.s8	termed	224	229	O	termed	med	rmed	VBN	False
DDI-MedLine.d198.s8	the	231	233	O	the	the	the	DT	False
DDI-MedLine.d198.s8	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d198.s8	linking	236	242	O	linking	ing	king	VBG	False
DDI-MedLine.d198.s8	tunnel	244	249	O	tunnel	nel	nnel	NN	False
DDI-MedLine.d198.s8	.	250	250	O	.	.	.	.	False
DDI-MedLine.d198.s8	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d198.s9	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d198.s9	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d198.s9	provide	14	20	O	provide	ide	vide	NN	False
DDI-MedLine.d198.s9	a	22	22	O	a	a	a	DT	False
DDI-MedLine.d198.s9	unique	24	29	O	unique	que	ique	NN	False
DDI-MedLine.d198.s9	structural	31	40	O	structural	ral	ural	JJ	False
DDI-MedLine.d198.s9	model	42	46	O	model	del	odel	NN	False
DDI-MedLine.d198.s9	for	48	50	O	for	for	for	IN	False
DDI-MedLine.d198.s9	independent	52	62	O	independent	ent	dent	JJ	False
DDI-MedLine.d198.s9	potentiating	64	75	O	potentiating	ing	ting	VBG	False
DDI-MedLine.d198.s9	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d198.s9	inhibitory	81	90	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d198.s9	interactions	92	103	O	interactions	ons	ions	NNS	False
DDI-MedLine.d198.s9	of	105	106	O	of	of	of	IN	False
DDI-MedLine.d198.s9	n-alcohols	108	117	O	n-alcohols	ols	hols	NNS	False
DDI-MedLine.d198.s9	with	119	122	O	with	ith	with	IN	False
DDI-MedLine.d198.s9	a	124	124	O	a	a	a	DT	False
DDI-MedLine.d198.s9	pLGIC	126	130	O	pLGIC	GIC	LGIC	NN	False
DDI-MedLine.d198.s9	family	132	137	O	family	ily	mily	NN	False
DDI-MedLine.d198.s9	member	139	144	O	member	ber	mber	NN	False
DDI-MedLine.d198.s9	.	145	145	O	.	.	.	.	False

DDI-MedLine.d186.s0	Motor	0	4	O	Motor	tor	otor	NNP	False
DDI-MedLine.d186.s0	deficits	6	13	O	deficits	its	cits	NNS	False
DDI-MedLine.d186.s0	and	15	17	O	and	and	and	CC	False
DDI-MedLine.d186.s0	recovery	19	26	O	recovery	ery	very	NN	False
DDI-MedLine.d186.s0	in	28	29	O	in	in	in	IN	False
DDI-MedLine.d186.s0	rats	31	34	O	rats	ats	rats	NNS	False
DDI-MedLine.d186.s0	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d186.s0	unilateral	41	50	O	unilateral	ral	eral	JJ	False
DDI-MedLine.d186.s0	spinal	52	57	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s0	cord	59	62	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s0	hemisection	64	74	O	hemisection	ion	tion	NN	False
DDI-MedLine.d186.s0	mimic	76	80	O	mimic	mic	imic	NN	False
DDI-MedLine.d186.s0	the	82	84	O	the	the	the	DT	False
DDI-MedLine.d186.s0	Brown-Sequard	86	98	O	Brown-Sequard	ard	uard	NN	False
DDI-MedLine.d186.s0	syndrome	100	107	O	syndrome	ome	rome	NN	False
DDI-MedLine.d186.s0	.	108	108	O	.	.	.	.	False

DDI-MedLine.d186.s1	Cervical	0	7	O	Cervical	cal	ical	JJ	False
DDI-MedLine.d186.s1	incomplete	9	18	O	incomplete	ete	lete	NN	False
DDI-MedLine.d186.s1	spinal	20	25	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s1	cord	27	30	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s1	injuries	32	39	O	injuries	ies	ries	NNS	False
DDI-MedLine.d186.s1	often	41	45	O	often	ten	ften	RB	False
DDI-MedLine.d186.s1	lead	47	50	O	lead	ead	lead	NN	False
DDI-MedLine.d186.s1	to	52	53	O	to	to	to	TO	False
DDI-MedLine.d186.s1	severe	55	60	O	severe	ere	vere	JJ	False
DDI-MedLine.d186.s1	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d186.s1	persistent	66	75	O	persistent	ent	tent	NN	False
DDI-MedLine.d186.s1	impairments	77	87	O	impairments	nts	ents	NNS	False
DDI-MedLine.d186.s1	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d186.s1	sensorimotor	92	103	O	sensorimotor	tor	otor	NN	False
DDI-MedLine.d186.s1	functions	105	113	O	functions	ons	ions	NNS	False
DDI-MedLine.d186.s1	and	115	117	O	and	and	and	CC	False
DDI-MedLine.d186.s1	are	119	121	O	are	are	are	VBP	False
DDI-MedLine.d186.s1	clinically	123	132	O	clinically	lly	ally	RB	False
DDI-MedLine.d186.s1	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d186.s1	most	138	141	O	most	ost	most	JJS	False
DDI-MedLine.d186.s1	frequent	143	150	O	frequent	ent	uent	NN	False
DDI-MedLine.d186.s1	type	152	155	O	type	ype	type	NN	False
DDI-MedLine.d186.s1	of	157	158	O	of	of	of	IN	False
DDI-MedLine.d186.s1	spinal	160	165	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s1	cord	167	170	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s1	injury	172	177	O	injury	ury	jury	NN	False
DDI-MedLine.d186.s1	.	178	178	O	.	.	.	.	False

DDI-MedLine.d186.s2	Understanding	0	12	O	Understanding	ing	ding	VBG	False
DDI-MedLine.d186.s2	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d186.s2	motor	18	22	O	motor	tor	otor	NN	False
DDI-MedLine.d186.s2	impairments	24	34	O	impairments	nts	ents	NNS	False
DDI-MedLine.d186.s2	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d186.s2	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d186.s2	possible	44	51	O	possible	ble	ible	JJ	False
DDI-MedLine.d186.s2	functional	53	62	O	functional	nal	onal	JJ	False
DDI-MedLine.d186.s2	recovery	64	71	O	recovery	ery	very	NN	False
DDI-MedLine.d186.s2	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d186.s2	upper	76	80	O	upper	per	pper	JJ	False
DDI-MedLine.d186.s2	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d186.s2	lower	86	90	O	lower	wer	ower	JJR	False
DDI-MedLine.d186.s2	extremities	92	102	O	extremities	ies	ties	NNS	False
DDI-MedLine.d186.s2	is	104	105	O	is	is	is	VBZ	False
DDI-MedLine.d186.s2	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d186.s2	great	110	114	O	great	eat	reat	JJ	False
DDI-MedLine.d186.s2	importance	116	125	O	importance	nce	ance	NN	False
DDI-MedLine.d186.s2	.	126	126	O	.	.	.	.	False

DDI-MedLine.d186.s3	Animal	0	5	O	Animal	mal	imal	NN	False
DDI-MedLine.d186.s3	models	7	12	O	models	els	dels	NNS	False
DDI-MedLine.d186.s3	investigating	14	26	O	investigating	ing	ting	VBG	False
DDI-MedLine.d186.s3	motor	28	32	O	motor	tor	otor	NN	False
DDI-MedLine.d186.s3	dysfunction	34	44	O	dysfunction	ion	tion	NN	False
DDI-MedLine.d186.s3	following	46	54	O	following	ing	wing	VBG	False
DDI-MedLine.d186.s3	cervical	56	63	O	cervical	cal	ical	JJ	False
DDI-MedLine.d186.s3	spinal	65	70	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s3	cord	72	75	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s3	injury	77	82	O	injury	ury	jury	NN	False
DDI-MedLine.d186.s3	are	84	86	O	are	are	are	VBP	False
DDI-MedLine.d186.s3	rare	88	91	O	rare	are	rare	NN	False
DDI-MedLine.d186.s3	.	92	92	O	.	.	.	.	False

DDI-MedLine.d186.s4	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d186.s4	analysed	3	10	O	analysed	sed	ysed	VBN	False
DDI-MedLine.d186.s4	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d186.s4	differential	16	27	O	differential	ial	tial	NN	False
DDI-MedLine.d186.s4	spontaneous	29	39	O	spontaneous	ous	eous	JJ	False
DDI-MedLine.d186.s4	recovery	41	48	O	recovery	ery	very	NN	False
DDI-MedLine.d186.s4	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d186.s4	fore-	53	57	O	fore-	re-	ore-	NN	False
DDI-MedLine.d186.s4	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d186.s4	hindlimb	63	70	O	hindlimb	imb	limb	NN	False
DDI-MedLine.d186.s4	locomotion	72	81	O	locomotion	ion	tion	NN	False
DDI-MedLine.d186.s4	by	83	84	O	by	by	by	IN	False
DDI-MedLine.d186.s4	detailed	86	93	O	detailed	led	iled	JJ	False
DDI-MedLine.d186.s4	kinematic	95	103	O	kinematic	tic	atic	JJ	False
DDI-MedLine.d186.s4	analysis	105	112	O	analysis	sis	ysis	NN	False
DDI-MedLine.d186.s4	in	114	115	O	in	in	in	IN	False
DDI-MedLine.d186.s4	adult	117	121	O	adult	ult	dult	NN	False
DDI-MedLine.d186.s4	rats	123	126	O	rats	ats	rats	NNS	False
DDI-MedLine.d186.s4	with	128	131	O	with	ith	with	IN	False
DDI-MedLine.d186.s4	unilateral	133	142	O	unilateral	ral	eral	JJ	False
DDI-MedLine.d186.s4	C4/C5	144	148	O	C4/C5	/C5	4/C5	NN	brand
DDI-MedLine.d186.s4	hemisection	150	160	O	hemisection	ion	tion	NN	False
DDI-MedLine.d186.s4	,	161	161	O	,	,	,	,	False
DDI-MedLine.d186.s4	a	163	163	O	a	a	a	DT	False
DDI-MedLine.d186.s4	lesion	165	170	O	lesion	ion	sion	NN	False
DDI-MedLine.d186.s4	that	172	175	O	that	hat	that	IN	False
DDI-MedLine.d186.s4	leads	177	181	O	leads	ads	eads	NNS	False
DDI-MedLine.d186.s4	to	183	184	O	to	to	to	TO	False
DDI-MedLine.d186.s4	the	186	188	O	the	the	the	DT	False
DDI-MedLine.d186.s4	Brown-S	190	196	O	Brown-S	n-S	wn-S	NN	False
DDI-MedLine.d186.s4	quard	199	203	O	quard	ard	uard	NN	False
DDI-MedLine.d186.s4	syndrome	205	212	O	syndrome	ome	rome	NN	False
DDI-MedLine.d186.s4	in	214	215	O	in	in	in	IN	False
DDI-MedLine.d186.s4	humans	217	222	O	humans	ans	mans	NNS	False
DDI-MedLine.d186.s4	.	223	223	O	.	.	.	.	False

DDI-MedLine.d186.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d186.s5	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d186.s5	showed	12	17	O	showed	wed	owed	VBD	False
DDI-MedLine.d186.s5	disproportionately	19	36	O	disproportionately	ely	tely	RB	False
DDI-MedLine.d186.s5	better	38	43	O	better	ter	tter	RBR	False
DDI-MedLine.d186.s5	performance	45	55	O	performance	nce	ance	NN	False
DDI-MedLine.d186.s5	of	57	58	O	of	of	of	IN	False
DDI-MedLine.d186.s5	hindlimb	60	67	O	hindlimb	imb	limb	NN	False
DDI-MedLine.d186.s5	compared	69	76	O	compared	red	ared	VBN	False
DDI-MedLine.d186.s5	with	78	81	O	with	ith	with	IN	False
DDI-MedLine.d186.s5	forelimb	83	90	O	forelimb	imb	limb	NN	False
DDI-MedLine.d186.s5	locomotion	92	101	O	locomotion	ion	tion	NN	False
DDI-MedLine.d186.s5	;	102	102	O	;	;	;	:	False

DDI-MedLine.d186.s6	hindlimb	0	7	O	hindlimb	imb	limb	NN	False
DDI-MedLine.d186.s6	locomotion	9	18	O	locomotion	ion	tion	NN	False
DDI-MedLine.d186.s6	showed	20	25	O	showed	wed	owed	VBD	False
DDI-MedLine.d186.s6	substantial	27	37	O	substantial	ial	tial	JJ	False
DDI-MedLine.d186.s6	recovery	39	46	O	recovery	ery	very	NN	False
DDI-MedLine.d186.s6	,	47	47	O	,	,	,	,	False
DDI-MedLine.d186.s6	whereas	49	55	O	whereas	eas	reas	NNS	False
DDI-MedLine.d186.s6	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d186.s6	ipsilesional	61	72	O	ipsilesional	nal	onal	JJ	False
DDI-MedLine.d186.s6	forelimb	74	81	O	forelimb	imb	limb	NN	False
DDI-MedLine.d186.s6	remained	83	90	O	remained	ned	ined	VBD	False
DDI-MedLine.d186.s6	in	92	93	O	in	in	in	IN	False
DDI-MedLine.d186.s6	a	95	95	O	a	a	a	DT	False
DDI-MedLine.d186.s6	very	97	100	O	very	ery	very	RB	False
DDI-MedLine.d186.s6	poor	102	105	O	poor	oor	poor	JJ	False
DDI-MedLine.d186.s6	functional	107	116	O	functional	nal	onal	JJ	False
DDI-MedLine.d186.s6	state	118	122	O	state	ate	tate	NN	False
DDI-MedLine.d186.s6	.	123	123	O	.	.	.	.	False

DDI-MedLine.d186.s7	Such	0	3	O	Such	uch	Such	JJ	False
DDI-MedLine.d186.s7	a	5	5	O	a	a	a	DT	False
DDI-MedLine.d186.s7	differential	7	18	O	differential	ial	tial	NN	False
DDI-MedLine.d186.s7	motor	20	24	O	motor	tor	otor	NN	False
DDI-MedLine.d186.s7	recovery	26	33	O	recovery	ery	very	NN	False
DDI-MedLine.d186.s7	pattern	35	41	O	pattern	ern	tern	NN	False
DDI-MedLine.d186.s7	is	43	44	O	is	is	is	VBZ	False
DDI-MedLine.d186.s7	also	46	49	O	also	lso	also	RB	False
DDI-MedLine.d186.s7	known	51	55	O	known	own	nown	VBN	False
DDI-MedLine.d186.s7	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d186.s7	occur	60	64	O	occur	cur	ccur	NN	False
DDI-MedLine.d186.s7	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d186.s7	monkeys	69	75	O	monkeys	eys	keys	NNS	False
DDI-MedLine.d186.s7	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d186.s7	in	81	82	O	in	in	in	IN	False
DDI-MedLine.d186.s7	humans	84	89	O	humans	ans	mans	NNS	False
DDI-MedLine.d186.s7	after	91	95	O	after	ter	fter	IN	False
DDI-MedLine.d186.s7	similar	97	103	O	similar	lar	ilar	JJ	False
DDI-MedLine.d186.s7	spinal	105	110	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s7	cord	112	115	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s7	lesions	117	123	O	lesions	ons	ions	NNS	False
DDI-MedLine.d186.s7	.	124	124	O	.	.	.	.	False

DDI-MedLine.d186.s8	On	0	1	O	On	On	On	IN	False
DDI-MedLine.d186.s8	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d186.s8	lesioned	7	14	O	lesioned	ned	oned	VBN	False
DDI-MedLine.d186.s8	side	16	19	O	side	ide	side	NN	False
DDI-MedLine.d186.s8	,	20	20	O	,	,	,	,	False
DDI-MedLine.d186.s8	cortico-	22	29	O	cortico-	co-	ico-	NN	False
DDI-MedLine.d186.s8	,	30	30	O	,	,	,	,	False
DDI-MedLine.d186.s8	rubro-	32	37	O	rubro-	ro-	bro-	NN	False
DDI-MedLine.d186.s8	,	38	38	O	,	,	,	,	False
DDI-MedLine.d186.s8	vestibulo-	40	49	O	vestibulo-	lo-	ulo-	NN	False
DDI-MedLine.d186.s8	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d186.s8	reticulospinal	55	68	O	reticulospinal	nal	inal	NN	False
DDI-MedLine.d186.s8	tracts	70	75	O	tracts	cts	acts	NNS	False
DDI-MedLine.d186.s8	and	77	79	O	and	and	and	CC	False
DDI-MedLine.d186.s8	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d186.s8	important	85	93	O	important	ant	tant	JJ	False
DDI-MedLine.d186.s8	modulatory	95	104	O	modulatory	ory	tory	NN	False
DDI-MedLine.d186.s8	serotonergic	106	117	O	serotonergic	gic	rgic	NN	False
DDI-MedLine.d186.s8	,	118	118	O	,	,	,	,	False
DDI-MedLine.d186.s8	dopaminergic	120	131	O	dopaminergic	gic	rgic	NN	False
DDI-MedLine.d186.s8	and	133	135	O	and	and	and	CC	False
DDI-MedLine.d186.s8	noradrenergic	137	149	O	noradrenergic	gic	rgic	NN	False
DDI-MedLine.d186.s8	fibre	151	155	O	fibre	bre	ibre	NN	False
DDI-MedLine.d186.s8	systems	157	163	O	systems	ems	tems	NNS	False
DDI-MedLine.d186.s8	were	165	168	O	were	ere	were	VBD	False
DDI-MedLine.d186.s8	interrupted	170	180	O	interrupted	ted	pted	VBN	False
DDI-MedLine.d186.s8	by	182	183	O	by	by	by	IN	False
DDI-MedLine.d186.s8	the	185	187	O	the	the	the	DT	False
DDI-MedLine.d186.s8	lesion	189	194	O	lesion	ion	sion	NN	False
DDI-MedLine.d186.s8	.	195	195	O	.	.	.	.	False

DDI-MedLine.d186.s9	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d186.s9	an	3	4	O	an	an	an	DT	False
DDI-MedLine.d186.s9	attempt	6	12	O	attempt	mpt	empt	NN	False
DDI-MedLine.d186.s9	to	14	15	O	to	to	to	TO	False
DDI-MedLine.d186.s9	facilitate	17	26	O	facilitate	ate	tate	NN	False
DDI-MedLine.d186.s9	locomotion	28	37	O	locomotion	ion	tion	NN	False
DDI-MedLine.d186.s9	,	38	38	O	,	,	,	,	False
DDI-MedLine.d186.s9	different	40	48	O	different	ent	rent	JJ	False
DDI-MedLine.d186.s9	monoaminergic	50	62	O	monoaminergic	gic	rgic	NN	False
DDI-MedLine.d186.s9	agonists	64	71	O	agonists	sts	ists	NNS	False
DDI-MedLine.d186.s9	were	73	76	O	were	ere	were	VBD	False
DDI-MedLine.d186.s9	injected	78	85	O	injected	ted	cted	VBN	False
DDI-MedLine.d186.s9	intrathecally	87	99	O	intrathecally	lly	ally	RB	False
DDI-MedLine.d186.s9	.	100	100	O	.	.	.	.	False

DDI-MedLine.d186.s10	Injections	0	9	O	Injections	ons	ions	NNS	False
DDI-MedLine.d186.s10	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d186.s10	specific	14	21	O	specific	fic	ific	JJ	False
DDI-MedLine.d186.s10	serotonergic	23	34	O	serotonergic	gic	rgic	NN	False
DDI-MedLine.d186.s10	and	36	38	O	and	and	and	CC	False
DDI-MedLine.d186.s10	noradrenergic	40	52	O	noradrenergic	gic	rgic	NN	False
DDI-MedLine.d186.s10	agonists	54	61	O	agonists	sts	ists	NNS	False
DDI-MedLine.d186.s10	in	63	64	O	in	in	in	IN	False
DDI-MedLine.d186.s10	the	66	68	O	the	the	the	DT	False
DDI-MedLine.d186.s10	chronic	70	76	O	chronic	nic	onic	NN	False
DDI-MedLine.d186.s10	phase	78	82	O	phase	ase	hase	NN	False
DDI-MedLine.d186.s10	after	84	88	O	after	ter	fter	IN	False
DDI-MedLine.d186.s10	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d186.s10	spinal	94	99	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s10	cord	101	104	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s10	lesion	106	111	O	lesion	ion	sion	NN	False
DDI-MedLine.d186.s10	revealed	113	120	O	revealed	led	aled	VBD	False
DDI-MedLine.d186.s10	remarkable	122	131	O	remarkable	ble	able	JJ	False
DDI-MedLine.d186.s10	,	132	132	O	,	,	,	,	False
DDI-MedLine.d186.s10	although	134	141	O	although	ugh	ough	IN	False
DDI-MedLine.d186.s10	mostly	143	148	O	mostly	tly	stly	RB	False
DDI-MedLine.d186.s10	functionally	150	161	O	functionally	lly	ally	RB	False
DDI-MedLine.d186.s10	negative	163	170	O	negative	ive	tive	JJ	False
DDI-MedLine.d186.s10	,	171	171	O	,	,	,	,	False
DDI-MedLine.d186.s10	modulations	173	183	O	modulations	ons	ions	NNS	False
DDI-MedLine.d186.s10	of	185	186	O	of	of	of	IN	False
DDI-MedLine.d186.s10	particular	188	197	O	particular	lar	ular	JJ	False
DDI-MedLine.d186.s10	parameters	199	208	O	parameters	ers	ters	NNS	False
DDI-MedLine.d186.s10	of	210	211	O	of	of	of	IN	False
DDI-MedLine.d186.s10	hindlimb	213	220	O	hindlimb	imb	limb	NN	False
DDI-MedLine.d186.s10	locomotion	222	231	O	locomotion	ion	tion	NN	False
DDI-MedLine.d186.s10	.	232	232	O	.	.	.	.	False

DDI-MedLine.d186.s11	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d186.s11	contrast	3	10	O	contrast	ast	rast	NN	False
DDI-MedLine.d186.s11	,	11	11	O	,	,	,	,	False
DDI-MedLine.d186.s11	forelimb	13	20	O	forelimb	imb	limb	NN	False
DDI-MedLine.d186.s11	locomotion	22	31	O	locomotion	ion	tion	NN	False
DDI-MedLine.d186.s11	was	33	35	O	was	was	was	VBD	False
DDI-MedLine.d186.s11	mostly	37	42	O	mostly	tly	stly	RB	False
DDI-MedLine.d186.s11	unresponsive	44	55	O	unresponsive	ive	sive	JJ	False
DDI-MedLine.d186.s11	to	57	58	O	to	to	to	TO	False
DDI-MedLine.d186.s11	these	60	64	O	these	ese	hese	DT	False
DDI-MedLine.d186.s11	agonists	66	73	O	agonists	sts	ists	NNS	False
DDI-MedLine.d186.s11	.	74	74	O	.	.	.	.	False

DDI-MedLine.d186.s12	These	0	4	O	These	ese	hese	DT	False
DDI-MedLine.d186.s12	results	6	12	O	results	lts	ults	NNS	False
DDI-MedLine.d186.s12	,	13	13	O	,	,	,	,	False
DDI-MedLine.d186.s12	therefore	15	23	O	therefore	ore	fore	RB	False
DDI-MedLine.d186.s12	,	24	24	O	,	,	,	,	False
DDI-MedLine.d186.s12	show	26	29	O	show	how	show	NN	False
DDI-MedLine.d186.s12	fundamental	31	41	O	fundamental	tal	ntal	JJ	False
DDI-MedLine.d186.s12	differences	43	53	O	differences	ces	nces	NNS	False
DDI-MedLine.d186.s12	between	55	61	O	between	een	ween	IN	False
DDI-MedLine.d186.s12	fore-	63	67	O	fore-	re-	ore-	NN	False
DDI-MedLine.d186.s12	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d186.s12	hindlimb	73	80	O	hindlimb	imb	limb	NN	False
DDI-MedLine.d186.s12	spinal	82	87	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s12	motor	89	93	O	motor	tor	otor	NN	False
DDI-MedLine.d186.s12	circuitries	95	105	O	circuitries	ies	ries	NNS	False
DDI-MedLine.d186.s12	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d186.s12	their	111	115	O	their	eir	heir	PRP$	False
DDI-MedLine.d186.s12	functional	117	126	O	functional	nal	onal	JJ	False
DDI-MedLine.d186.s12	dependence	128	137	O	dependence	nce	ence	NN	False
DDI-MedLine.d186.s12	on	139	140	O	on	on	on	IN	False
DDI-MedLine.d186.s12	remaining	142	150	O	remaining	ing	ning	VBG	False
DDI-MedLine.d186.s12	descending	152	161	O	descending	ing	ding	VBG	False
DDI-MedLine.d186.s12	inputs	163	168	O	inputs	uts	puts	NNS	False
DDI-MedLine.d186.s12	and	170	172	O	and	and	and	CC	False
DDI-MedLine.d186.s12	exogenous	174	182	O	exogenous	ous	nous	JJ	False
DDI-MedLine.d186.s12	spinal	184	189	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s12	excitation	191	200	O	excitation	ion	tion	NN	False
DDI-MedLine.d186.s12	.	201	201	O	.	.	.	.	False

DDI-MedLine.d186.s13	Understanding	0	12	O	Understanding	ing	ding	VBG	False
DDI-MedLine.d186.s13	these	14	18	O	these	ese	hese	DT	False
DDI-MedLine.d186.s13	differences	20	30	O	differences	ces	nces	NNS	False
DDI-MedLine.d186.s13	may	32	34	O	may	may	may	MD	False
DDI-MedLine.d186.s13	help	36	39	O	help	elp	help	NN	False
DDI-MedLine.d186.s13	to	41	42	O	to	to	to	TO	False
DDI-MedLine.d186.s13	develop	44	50	O	develop	lop	elop	VB	False
DDI-MedLine.d186.s13	future	52	57	O	future	ure	ture	NN	False
DDI-MedLine.d186.s13	therapeutic	59	69	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d186.s13	strategies	71	80	O	strategies	ies	gies	NNS	False
DDI-MedLine.d186.s13	to	82	83	O	to	to	to	TO	False
DDI-MedLine.d186.s13	improve	85	91	O	improve	ove	rove	VB	False
DDI-MedLine.d186.s13	upper	93	97	O	upper	per	pper	JJ	False
DDI-MedLine.d186.s13	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d186.s13	lower	103	107	O	lower	wer	ower	JJR	False
DDI-MedLine.d186.s13	limb	109	112	O	limb	imb	limb	NN	False
DDI-MedLine.d186.s13	function	114	121	O	function	ion	tion	NN	False
DDI-MedLine.d186.s13	in	123	124	O	in	in	in	IN	False
DDI-MedLine.d186.s13	patients	126	133	O	patients	nts	ents	NNS	False
DDI-MedLine.d186.s13	with	135	138	O	with	ith	with	IN	False
DDI-MedLine.d186.s13	incomplete	140	149	O	incomplete	ete	lete	NN	False
DDI-MedLine.d186.s13	cervical	151	158	O	cervical	cal	ical	JJ	False
DDI-MedLine.d186.s13	spinal	160	165	O	spinal	nal	inal	NN	False
DDI-MedLine.d186.s13	cord	167	170	O	cord	ord	cord	NN	False
DDI-MedLine.d186.s13	injuries	172	179	O	injuries	ies	ries	NNS	False
DDI-MedLine.d186.s13	.	180	180	O	.	.	.	.	False

DDI-MedLine.d222.s0	Treatment	0	8	O	Treatment	ent	ment	NN	False
DDI-MedLine.d222.s0	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d222.s0	nicotine	13	20	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d222.s0	dependence	22	31	O	dependence	nce	ence	NN	False
DDI-MedLine.d222.s0	with	33	36	O	with	ith	with	IN	False
DDI-MedLine.d222.s0	Chantix	38	44	B-brand	Chantix	tix	ntix	NN	False
DDI-MedLine.d222.s0	(	46	46	O	(	(	(	(	False
DDI-MedLine.d222.s0	varenicline	47	57	B-drug	varenicline	ine	line	NN	drug
DDI-MedLine.d222.s0	)	58	58	O	)	)	)	)	False
DDI-MedLine.d222.s0	.	59	59	O	.	.	.	.	False

DDI-MedLine.d222.s1	Varenicline	0	10	B-drug	Varenicline	ine	line	NN	drug
DDI-MedLine.d222.s1	is	12	13	O	is	is	is	VBZ	False
DDI-MedLine.d222.s1	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d222.s1	generic	19	25	O	generic	ric	eric	NN	False
DDI-MedLine.d222.s1	name	27	30	O	name	ame	name	NN	False
DDI-MedLine.d222.s1	for	32	34	O	for	for	for	IN	False
DDI-MedLine.d222.s1	Chantix	36	42	B-brand	Chantix	tix	ntix	NN	False
DDI-MedLine.d222.s1	,	43	43	O	,	,	,	,	False
DDI-MedLine.d222.s1	the	45	47	O	the	the	the	DT	False
DDI-MedLine.d222.s1	newest	49	54	O	newest	est	west	JJS	False
DDI-MedLine.d222.s1	drug	56	59	O	drug	rug	drug	NN	False
DDI-MedLine.d222.s1	available	61	69	O	available	ble	able	JJ	False
DDI-MedLine.d222.s1	for	71	73	O	for	for	for	IN	False
DDI-MedLine.d222.s1	the	75	77	O	the	the	the	DT	False
DDI-MedLine.d222.s1	treatment	79	87	O	treatment	ent	ment	NN	False
DDI-MedLine.d222.s1	of	89	90	O	of	of	of	IN	False
DDI-MedLine.d222.s1	tobacco	92	98	O	tobacco	cco	acco	NN	False
DDI-MedLine.d222.s1	dependence	100	109	O	dependence	nce	ence	NN	False
DDI-MedLine.d222.s1	.	110	110	O	.	.	.	.	False

DDI-MedLine.d222.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d222.s2	a	3	3	O	a	a	a	DT	False
DDI-MedLine.d222.s2	randomized	5	14	O	randomized	zed	ized	VBN	False
DDI-MedLine.d222.s2	controlled	16	25	O	controlled	led	lled	VBN	False
DDI-MedLine.d222.s2	clinical	27	34	O	clinical	cal	ical	JJ	False
DDI-MedLine.d222.s2	trial	36	40	O	trial	ial	rial	NN	False
DDI-MedLine.d222.s2	,	41	41	O	,	,	,	,	False
DDI-MedLine.d222.s2	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d222.s2	abstinence	47	56	O	abstinence	nce	ence	NN	False
DDI-MedLine.d222.s2	rate	58	61	O	rate	ate	rate	NN	False
DDI-MedLine.d222.s2	at	63	64	O	at	at	at	IN	False
DDI-MedLine.d222.s2	1	66	66	O	1	1	1	CD	False
DDI-MedLine.d222.s2	year	68	71	O	year	ear	year	NN	False
DDI-MedLine.d222.s2	for	73	75	O	for	for	for	IN	False
DDI-MedLine.d222.s2	patients	77	84	O	patients	nts	ents	NNS	False
DDI-MedLine.d222.s2	using	86	90	O	using	ing	sing	VBG	False
DDI-MedLine.d222.s2	varencline	92	101	B-drug	varencline	ine	line	NN	drug
DDI-MedLine.d222.s2	was	103	105	O	was	was	was	VBD	False
DDI-MedLine.d222.s2	superior	107	114	O	superior	ior	rior	JJ	False
DDI-MedLine.d222.s2	to	116	117	O	to	to	to	TO	False
DDI-MedLine.d222.s2	that	119	122	O	that	hat	that	IN	False
DDI-MedLine.d222.s2	of	124	125	O	of	of	of	IN	False
DDI-MedLine.d222.s2	patients	127	134	O	patients	nts	ents	NNS	False
DDI-MedLine.d222.s2	in	136	137	O	in	in	in	IN	False
DDI-MedLine.d222.s2	the	139	141	O	the	the	the	DT	False
DDI-MedLine.d222.s2	group	143	147	O	group	oup	roup	NN	False
DDI-MedLine.d222.s2	using	149	153	O	using	ing	sing	VBG	False
DDI-MedLine.d222.s2	bupropion	155	163	B-drug	bupropion	ion	pion	NN	False
DDI-MedLine.d222.s2	SR	165	166	I-drug	SR	SR	SR	NN	brand
DDI-MedLine.d222.s2	(	168	168	O	(	(	(	(	False
DDI-MedLine.d222.s2	Zyban	169	173	B-brand	Zyban	ban	yban	NN	False
DDI-MedLine.d222.s2	)	174	174	O	)	)	)	)	False
DDI-MedLine.d222.s2	and	176	178	O	and	and	and	CC	False
DDI-MedLine.d222.s2	in	180	181	O	in	in	in	IN	False
DDI-MedLine.d222.s2	the	183	185	O	the	the	the	DT	False
DDI-MedLine.d222.s2	placebo	187	193	O	placebo	ebo	cebo	NN	False
DDI-MedLine.d222.s2	group	195	199	O	group	oup	roup	NN	False
DDI-MedLine.d222.s2	(	201	201	O	(	(	(	(	False
DDI-MedLine.d222.s2	11	202	203	O	11	11	11	CD	False
DDI-MedLine.d222.s2	)	204	204	O	)	)	)	)	False
DDI-MedLine.d222.s2	.	205	205	O	.	.	.	.	False

DDI-MedLine.d222.s3	Varenicline	0	10	B-drug	Varenicline	ine	line	NN	drug
DDI-MedLine.d222.s3	reduces	12	18	O	reduces	ces	uces	NNS	False
DDI-MedLine.d222.s3	nicotine	20	27	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d222.s3	withdrawal	29	38	O	withdrawal	wal	awal	NN	False
DDI-MedLine.d222.s3	symptoms	40	47	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d222.s3	,	48	48	O	,	,	,	,	False
DDI-MedLine.d222.s3	cigarette	50	58	O	cigarette	tte	ette	NN	False
DDI-MedLine.d222.s3	craving	60	66	O	craving	ing	ving	VBG	False
DDI-MedLine.d222.s3	and	68	70	O	and	and	and	CC	False
DDI-MedLine.d222.s3	nicotine	72	79	B-drug	nicotine	ine	tine	NN	drug
DDI-MedLine.d222.s3	satisfaction	81	92	O	satisfaction	ion	tion	NN	False
DDI-MedLine.d222.s3	.	93	93	O	.	.	.	.	False

DDI-MedLine.d222.s4	Post-market	0	10	O	Post-market	ket	rket	NN	False
DDI-MedLine.d222.s4	reports	12	18	O	reports	rts	orts	NNS	False
DDI-MedLine.d222.s4	prompted	20	27	O	prompted	ted	pted	VBN	False
DDI-MedLine.d222.s4	a	29	29	O	a	a	a	DT	False
DDI-MedLine.d222.s4	warning	31	37	O	warning	ing	ning	VBG	False
DDI-MedLine.d222.s4	of	39	40	O	of	of	of	IN	False
DDI-MedLine.d222.s4	serious	42	48	O	serious	ous	ious	JJ	False
DDI-MedLine.d222.s4	adverse	50	56	O	adverse	rse	erse	NN	False
DDI-MedLine.d222.s4	neuropsychiatric	58	73	O	neuropsychiatric	ric	tric	JJ	False
DDI-MedLine.d222.s4	events	75	80	O	events	nts	ents	NNS	False
DDI-MedLine.d222.s4	in	82	83	O	in	in	in	IN	False
DDI-MedLine.d222.s4	patients	85	92	O	patients	nts	ents	NNS	False
DDI-MedLine.d222.s4	taking	94	99	O	taking	ing	king	VBG	False
DDI-MedLine.d222.s4	varenicline	101	111	B-drug	varenicline	ine	line	NN	drug
DDI-MedLine.d222.s4	.	112	112	O	.	.	.	.	False

DDI-MedLine.d222.s5	As	0	1	O	As	As	As	IN	False
DDI-MedLine.d222.s5	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d222.s5	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d222.s5	case	10	13	O	case	ase	case	NN	False
DDI-MedLine.d222.s5	with	15	18	O	with	ith	with	IN	False
DDI-MedLine.d222.s5	any	20	22	O	any	any	any	DT	False
DDI-MedLine.d222.s5	surgical	24	31	O	surgical	cal	ical	JJ	False
DDI-MedLine.d222.s5	procedure	33	41	O	procedure	ure	dure	NN	False
DDI-MedLine.d222.s5	and/or	43	48	O	and/or	/or	d/or	NN	False
DDI-MedLine.d222.s5	prescription	50	61	O	prescription	ion	tion	NN	False
DDI-MedLine.d222.s5	medication	63	72	O	medication	ion	tion	NN	False
DDI-MedLine.d222.s5	,	73	73	O	,	,	,	,	False
DDI-MedLine.d222.s5	full	75	78	O	full	ull	full	JJ	False
DDI-MedLine.d222.s5	disclosure	80	89	O	disclosure	ure	sure	NN	False
DDI-MedLine.d222.s5	of	91	92	O	of	of	of	IN	False
DDI-MedLine.d222.s5	the	94	96	O	the	the	the	DT	False
DDI-MedLine.d222.s5	risks	98	102	O	risks	sks	isks	NNS	False
DDI-MedLine.d222.s5	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d222.s5	benefits	108	115	O	benefits	its	fits	NNS	False
DDI-MedLine.d222.s5	should	117	122	O	should	uld	ould	MD	False
DDI-MedLine.d222.s5	be	124	125	O	be	be	be	VB	False
DDI-MedLine.d222.s5	discussed	127	135	O	discussed	sed	ssed	VBN	False
DDI-MedLine.d222.s5	with	137	140	O	with	ith	with	IN	False
DDI-MedLine.d222.s5	the	142	144	O	the	the	the	DT	False
DDI-MedLine.d222.s5	patient	146	152	O	patient	ent	ient	NN	False
DDI-MedLine.d222.s5	.	153	153	O	.	.	.	.	False

DDI-MedLine.d222.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d222.s6	significant	4	14	O	significant	ant	cant	JJ	False
DDI-MedLine.d222.s6	health	16	21	O	health	lth	alth	NN	False
DDI-MedLine.d222.s6	benefits	23	30	O	benefits	its	fits	NNS	False
DDI-MedLine.d222.s6	of	32	33	O	of	of	of	IN	False
DDI-MedLine.d222.s6	quitting	35	42	O	quitting	ing	ting	VBG	False
DDI-MedLine.d222.s6	smoking	44	50	O	smoking	ing	king	NN	False
DDI-MedLine.d222.s6	should	52	57	O	should	uld	ould	MD	False
DDI-MedLine.d222.s6	be	59	60	O	be	be	be	VB	False
DDI-MedLine.d222.s6	weighed	62	68	O	weighed	hed	ghed	VBN	False
DDI-MedLine.d222.s6	against	70	76	O	against	nst	inst	IN	False
DDI-MedLine.d222.s6	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d222.s6	individual	82	91	O	individual	ual	dual	JJ	False
DDI-MedLine.d222.s6	's	92	93	O	's	's	's	POS	False
DDI-MedLine.d222.s6	risk	95	98	O	risk	isk	risk	NN	False
DDI-MedLine.d222.s6	of	100	101	O	of	of	of	IN	False
DDI-MedLine.d222.s6	adverse	103	109	O	adverse	rse	erse	NN	False
DDI-MedLine.d222.s6	events	111	116	O	events	nts	ents	NNS	False
DDI-MedLine.d222.s6	associated	118	127	O	associated	ted	ated	VBN	False
DDI-MedLine.d222.s6	with	129	132	O	with	ith	with	IN	False
DDI-MedLine.d222.s6	the	134	136	O	the	the	the	DT	False
DDI-MedLine.d222.s6	use	138	140	O	use	use	use	NN	False
DDI-MedLine.d222.s6	of	142	143	O	of	of	of	IN	False
DDI-MedLine.d222.s6	varenicline	145	155	B-drug	varenicline	ine	line	NN	drug
DDI-MedLine.d222.s6	for	157	159	O	for	for	for	IN	False
DDI-MedLine.d222.s6	smoking	161	167	O	smoking	ing	king	NN	False
DDI-MedLine.d222.s6	cessation	169	177	O	cessation	ion	tion	NN	False
DDI-MedLine.d222.s6	.	178	178	O	.	.	.	.	False

DDI-MedLine.d170.s0	Positive	0	7	O	Positive	ive	tive	JJ	False
DDI-MedLine.d170.s0	shifts	9	14	O	shifts	fts	ifts	NNS	False
DDI-MedLine.d170.s0	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d170.s0	the	19	21	O	the	the	the	DT	False
DDI-MedLine.d170.s0	GABAA	23	27	O	GABAA	BAA	ABAA	NN	brand
DDI-MedLine.d170.s0	receptor	29	36	O	receptor	tor	ptor	NN	False
DDI-MedLine.d170.s0	reversal	38	45	O	reversal	sal	rsal	NN	False
DDI-MedLine.d170.s0	potential	47	55	O	potential	ial	tial	JJ	False
DDI-MedLine.d170.s0	due	57	59	O	due	due	due	JJ	False
DDI-MedLine.d170.s0	to	61	62	O	to	to	to	TO	False
DDI-MedLine.d170.s0	altered	64	70	O	altered	red	ered	VBN	False
DDI-MedLine.d170.s0	chloride	72	79	O	chloride	ide	ride	NN	False
DDI-MedLine.d170.s0	homeostasis	81	91	O	homeostasis	sis	asis	NN	False
DDI-MedLine.d170.s0	is	93	94	O	is	is	is	VBZ	False
DDI-MedLine.d170.s0	widespread	96	105	O	widespread	ead	read	JJ	False
DDI-MedLine.d170.s0	after	107	111	O	after	ter	fter	IN	False
DDI-MedLine.d170.s0	status	113	118	O	status	tus	atus	NN	False
DDI-MedLine.d170.s0	epilepticus	120	130	O	epilepticus	cus	icus	NN	False
DDI-MedLine.d170.s0	.	131	131	O	.	.	.	.	False

DDI-MedLine.d170.s1	-Aminobutyric	0	12	O	-Aminobutyric	ric	yric	NN	False
DDI-MedLine.d170.s1	acid	14	17	O	acid	cid	acid	NN	False
DDI-MedLine.d170.s1	(	19	19	O	(	(	(	(	False
DDI-MedLine.d170.s1	GABA	20	23	O	GABA	ABA	GABA	NN	brand
DDI-MedLine.d170.s1	)	24	24	O	)	)	)	)	False
DDI-MedLine.d170.s1	ergic	25	29	O	ergic	gic	rgic	NN	False
DDI-MedLine.d170.s1	transmission	31	42	O	transmission	ion	sion	NN	False
DDI-MedLine.d170.s1	plays	44	48	O	plays	ays	lays	NNS	False
DDI-MedLine.d170.s1	an	50	51	O	an	an	an	DT	False
DDI-MedLine.d170.s1	important	53	61	O	important	ant	tant	JJ	False
DDI-MedLine.d170.s1	role	63	66	O	role	ole	role	NN	False
DDI-MedLine.d170.s1	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d170.s1	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d170.s1	initiation	75	84	O	initiation	ion	tion	NN	False
DDI-MedLine.d170.s1	of	86	87	O	of	of	of	IN	False
DDI-MedLine.d170.s1	epileptic	89	97	O	epileptic	tic	ptic	JJ	False
DDI-MedLine.d170.s1	activity	99	106	O	activity	ity	vity	NN	False
DDI-MedLine.d170.s1	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d170.s1	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d170.s1	generation	116	125	O	generation	ion	tion	NN	False
DDI-MedLine.d170.s1	of	127	128	O	of	of	of	IN	False
DDI-MedLine.d170.s1	ictal	130	134	O	ictal	tal	ctal	NN	False
DDI-MedLine.d170.s1	discharges	136	145	O	discharges	ges	rges	NNS	False
DDI-MedLine.d170.s1	.	146	146	O	.	.	.	.	False

DDI-MedLine.d170.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d170.s2	functional	4	13	O	functional	nal	onal	JJ	False
DDI-MedLine.d170.s2	alterations	15	25	O	alterations	ons	ions	NNS	False
DDI-MedLine.d170.s2	in	27	28	O	in	in	in	IN	False
DDI-MedLine.d170.s2	the	30	32	O	the	the	the	DT	False
DDI-MedLine.d170.s2	epileptiform	34	45	O	epileptiform	orm	form	NN	False
DDI-MedLine.d170.s2	hippocampus	47	57	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d170.s2	critically	59	68	O	critically	lly	ally	RB	False
DDI-MedLine.d170.s2	depend	70	75	O	depend	end	pend	NN	False
DDI-MedLine.d170.s2	on	77	78	O	on	on	on	IN	False
DDI-MedLine.d170.s2	GABAergic	80	88	O	GABAergic	gic	rgic	NNP	False
DDI-MedLine.d170.s2	mechanisms	90	99	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d170.s2	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d170.s2	cation-chloride	105	119	O	cation-chloride	ide	ride	NN	False
DDI-MedLine.d170.s2	cotransporters	121	134	O	cotransporters	ers	ters	NNS	False
DDI-MedLine.d170.s2	.	135	135	O	.	.	.	.	False

DDI-MedLine.d170.s3	To	0	1	O	To	To	To	TO	False
DDI-MedLine.d170.s3	understand	3	12	O	understand	and	tand	NN	False
DDI-MedLine.d170.s3	the	14	16	O	the	the	the	DT	False
DDI-MedLine.d170.s3	cellular	18	25	O	cellular	lar	ular	JJ	False
DDI-MedLine.d170.s3	basis	27	31	O	basis	sis	asis	NN	False
DDI-MedLine.d170.s3	of	33	34	O	of	of	of	IN	False
DDI-MedLine.d170.s3	specific	36	43	O	specific	fic	ific	JJ	False
DDI-MedLine.d170.s3	functional	45	54	O	functional	nal	onal	JJ	False
DDI-MedLine.d170.s3	alterations	56	66	O	alterations	ons	ions	NNS	False
DDI-MedLine.d170.s3	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d170.s3	the	71	73	O	the	the	the	DT	False
DDI-MedLine.d170.s3	epileptic	75	83	O	epileptic	tic	ptic	JJ	False
DDI-MedLine.d170.s3	hippocampus	85	95	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d170.s3	,	96	96	O	,	,	,	,	False
DDI-MedLine.d170.s3	we	98	99	O	we	we	we	PRP	False
DDI-MedLine.d170.s3	studied	101	107	O	studied	ied	died	VBN	False
DDI-MedLine.d170.s3	physiologic	109	119	O	physiologic	gic	ogic	NN	False
DDI-MedLine.d170.s3	characteristics	121	135	O	characteristics	ics	tics	NNS	False
DDI-MedLine.d170.s3	and	137	139	O	and	and	and	CC	False
DDI-MedLine.d170.s3	pharmacologically	141	157	O	pharmacologically	lly	ally	RB	False
DDI-MedLine.d170.s3	isolated	159	166	O	isolated	ted	ated	JJ	False
DDI-MedLine.d170.s3	evoked	168	173	O	evoked	ked	oked	VBN	False
DDI-MedLine.d170.s3	GABA	175	178	O	GABA	ABA	GABA	NN	brand
DDI-MedLine.d170.s3	(	179	179	O	(	(	(	(	False
DDI-MedLine.d170.s3	A	180	180	O	A	A	A	DT	brand
DDI-MedLine.d170.s3	)	181	181	O	)	)	)	)	False
DDI-MedLine.d170.s3	receptor-mediated	183	199	O	receptor-mediated	ted	ated	JJ	False
DDI-MedLine.d170.s3	inhibitory	201	210	O	inhibitory	ory	tory	NN	False
DDI-MedLine.d170.s3	postsynaptic	212	223	O	postsynaptic	tic	ptic	JJ	False
DDI-MedLine.d170.s3	currents	225	232	O	currents	nts	ents	NNS	False
DDI-MedLine.d170.s3	(	234	234	O	(	(	(	(	False
DDI-MedLine.d170.s3	IPSCs	235	239	O	IPSCs	SCs	PSCs	NN	False
DDI-MedLine.d170.s3	)	240	240	O	)	)	)	)	False
DDI-MedLine.d170.s3	recorded	242	249	O	recorded	ded	rded	VBN	False
DDI-MedLine.d170.s3	from	251	254	O	from	rom	from	IN	False
DDI-MedLine.d170.s3	principal	256	264	O	principal	pal	ipal	NN	False
DDI-MedLine.d170.s3	neurons	266	272	O	neurons	ons	rons	NNS	False
DDI-MedLine.d170.s3	in	274	275	O	in	in	in	IN	False
DDI-MedLine.d170.s3	hippocampal	277	287	O	hippocampal	pal	mpal	NN	False
DDI-MedLine.d170.s3	slices	289	294	O	slices	ces	ices	NNS	False
DDI-MedLine.d170.s3	from	296	299	O	from	rom	from	IN	False
DDI-MedLine.d170.s3	status	301	306	O	status	tus	atus	NN	False
DDI-MedLine.d170.s3	epilepticus	308	318	O	epilepticus	cus	icus	NN	False
DDI-MedLine.d170.s3	(	320	320	O	(	(	(	(	False
DDI-MedLine.d170.s3	SE	321	322	O	SE	SE	SE	NN	brand
DDI-MedLine.d170.s3	)	323	323	O	)	)	)	)	False
DDI-MedLine.d170.s3	and	325	327	O	and	and	and	CC	False
DDI-MedLine.d170.s3	control	329	335	O	control	rol	trol	NN	False
DDI-MedLine.d170.s3	rats	337	340	O	rats	ats	rats	NNS	False
DDI-MedLine.d170.s3	using	342	346	O	using	ing	sing	VBG	False
DDI-MedLine.d170.s3	whole-cell	348	357	O	whole-cell	ell	cell	NN	False
DDI-MedLine.d170.s3	and	359	361	O	and	and	and	CC	False
DDI-MedLine.d170.s3	gramicidin	363	372	O	gramicidin	din	idin	NN	False
DDI-MedLine.d170.s3	perforated	374	383	O	perforated	ted	ated	VBN	False
DDI-MedLine.d170.s3	patch-clamp	385	395	O	patch-clamp	amp	lamp	NN	False
DDI-MedLine.d170.s3	recordings	397	406	O	recordings	ngs	ings	NNS	False
DDI-MedLine.d170.s3	.	407	407	O	.	.	.	.	False

DDI-MedLine.d170.s4	Whereas	0	6	O	Whereas	eas	reas	NNS	False
DDI-MedLine.d170.s4	the	8	10	O	the	the	the	DT	False
DDI-MedLine.d170.s4	resting	12	18	O	resting	ing	ting	VBG	False
DDI-MedLine.d170.s4	membrane	20	27	O	membrane	ane	rane	NN	False
DDI-MedLine.d170.s4	potential	29	37	O	potential	ial	tial	JJ	False
DDI-MedLine.d170.s4	and	39	41	O	and	and	and	CC	False
DDI-MedLine.d170.s4	input	43	47	O	input	put	nput	NN	False
DDI-MedLine.d170.s4	resistance	49	58	O	resistance	nce	ance	NN	False
DDI-MedLine.d170.s4	were	60	63	O	were	ere	were	VBD	False
DDI-MedLine.d170.s4	not	65	67	O	not	not	not	RB	False
DDI-MedLine.d170.s4	significantly	69	81	O	significantly	tly	ntly	RB	False
DDI-MedLine.d170.s4	different	83	91	O	different	ent	rent	JJ	False
DDI-MedLine.d170.s4	between	93	99	O	between	een	ween	IN	False
DDI-MedLine.d170.s4	control	101	107	O	control	rol	trol	NN	False
DDI-MedLine.d170.s4	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d170.s4	epileptic	113	121	O	epileptic	tic	ptic	JJ	False
DDI-MedLine.d170.s4	tissue	123	128	O	tissue	sue	ssue	NN	False
DDI-MedLine.d170.s4	,	129	129	O	,	,	,	,	False
DDI-MedLine.d170.s4	the	131	133	O	the	the	the	DT	False
DDI-MedLine.d170.s4	reversal	135	142	O	reversal	sal	rsal	NN	False
DDI-MedLine.d170.s4	potential	144	152	O	potential	ial	tial	JJ	False
DDI-MedLine.d170.s4	(	154	154	O	(	(	(	(	False
DDI-MedLine.d170.s4	E	155	155	O	E	E	E	NN	brand
DDI-MedLine.d170.s4	(	156	156	O	(	(	(	(	False
DDI-MedLine.d170.s4	GABA	157	160	O	GABA	ABA	GABA	NN	brand
DDI-MedLine.d170.s4	)	161	161	O	)	)	)	)	False
DDI-MedLine.d170.s4	)	163	163	O	)	)	)	)	False
DDI-MedLine.d170.s4	of	165	166	O	of	of	of	IN	False
DDI-MedLine.d170.s4	IPSCs	168	172	O	IPSCs	SCs	PSCs	NN	False
DDI-MedLine.d170.s4	was	174	176	O	was	was	was	VBD	False
DDI-MedLine.d170.s4	significantly	178	190	O	significantly	tly	ntly	RB	False
DDI-MedLine.d170.s4	shifted	192	198	O	shifted	ted	fted	VBN	False
DDI-MedLine.d170.s4	to	200	201	O	to	to	to	TO	False
DDI-MedLine.d170.s4	more	203	206	O	more	ore	more	RBR	False
DDI-MedLine.d170.s4	positive	208	215	O	positive	ive	tive	JJ	False
DDI-MedLine.d170.s4	values	217	222	O	values	ues	lues	NNS	False
DDI-MedLine.d170.s4	in	224	225	O	in	in	in	IN	False
DDI-MedLine.d170.s4	SE	227	228	O	SE	SE	SE	NN	brand
DDI-MedLine.d170.s4	rats	230	233	O	rats	ats	rats	NNS	False
DDI-MedLine.d170.s4	with	235	238	O	with	ith	with	IN	False
DDI-MedLine.d170.s4	regard	240	245	O	regard	ard	gard	NN	False
DDI-MedLine.d170.s4	to	247	248	O	to	to	to	TO	False
DDI-MedLine.d170.s4	the	250	252	O	the	the	the	DT	False
DDI-MedLine.d170.s4	resting	254	260	O	resting	ing	ting	VBG	False
DDI-MedLine.d170.s4	membrane	262	269	O	membrane	ane	rane	NN	False
DDI-MedLine.d170.s4	potential	271	279	O	potential	ial	tial	JJ	False
DDI-MedLine.d170.s4	.	280	280	O	.	.	.	.	False

DDI-MedLine.d170.s5	Pharmacologic	0	12	O	Pharmacologic	gic	ogic	NN	False
DDI-MedLine.d170.s5	experiments	14	24	O	experiments	nts	ents	NNS	False
DDI-MedLine.d170.s5	and	26	28	O	and	and	and	CC	False
DDI-MedLine.d170.s5	quantitative	30	41	O	quantitative	ive	tive	NN	False
DDI-MedLine.d170.s5	reverse	43	49	O	reverse	rse	erse	NN	False
DDI-MedLine.d170.s5	transcriptase	51	63	O	transcriptase	ase	tase	NN	False
DDI-MedLine.d170.s5	polymerase	65	74	O	polymerase	ase	rase	NN	False
DDI-MedLine.d170.s5	chain	76	80	O	chain	ain	hain	NN	False
DDI-MedLine.d170.s5	reaction	82	89	O	reaction	ion	tion	NN	False
DDI-MedLine.d170.s5	(	91	91	O	(	(	(	(	False
DDI-MedLine.d170.s5	RT-PCR	92	97	O	RT-PCR	PCR	-PCR	JJ	brand
DDI-MedLine.d170.s5	)	98	98	O	)	)	)	)	False
DDI-MedLine.d170.s5	showed	100	105	O	showed	wed	owed	VBD	False
DDI-MedLine.d170.s5	that	107	110	O	that	hat	that	IN	False
DDI-MedLine.d170.s5	the	112	114	O	the	the	the	DT	False
DDI-MedLine.d170.s5	observed	116	123	O	observed	ved	rved	VBN	False
DDI-MedLine.d170.s5	changes	125	131	O	changes	ges	nges	NNS	False
DDI-MedLine.d170.s5	in	133	134	O	in	in	in	IN	False
DDI-MedLine.d170.s5	the	136	138	O	the	the	the	DT	False
DDI-MedLine.d170.s5	epileptic	140	148	O	epileptic	tic	ptic	JJ	False
DDI-MedLine.d170.s5	tissue	150	155	O	tissue	sue	ssue	NN	False
DDI-MedLine.d170.s5	were	157	160	O	were	ere	were	VBD	False
DDI-MedLine.d170.s5	due	162	164	O	due	due	due	JJ	False
DDI-MedLine.d170.s5	to	166	167	O	to	to	to	TO	False
DDI-MedLine.d170.s5	a	169	169	O	a	a	a	DT	False
DDI-MedLine.d170.s5	decreased	171	179	O	decreased	sed	ased	VBN	False
DDI-MedLine.d170.s5	ratio	181	185	O	ratio	tio	atio	NN	False
DDI-MedLine.d170.s5	of	187	188	O	of	of	of	IN	False
DDI-MedLine.d170.s5	the	190	192	O	the	the	the	DT	False
DDI-MedLine.d170.s5	main	194	197	O	main	ain	main	JJ	False
DDI-MedLine.d170.s5	Cl	199	200	O	Cl	Cl	Cl	NN	False
DDI-MedLine.d170.s5	(	201	201	O	(	(	(	(	False
DDI-MedLine.d170.s5	-	202	202	O	-	-	-	:	False
DDI-MedLine.d170.s5	)	203	203	O	)	)	)	)	False
DDI-MedLine.d170.s5	extrusion	205	213	O	extrusion	ion	sion	NN	False
DDI-MedLine.d170.s5	transporter	215	225	O	transporter	ter	rter	NN	False
DDI-MedLine.d170.s5	(	227	227	O	(	(	(	(	False
DDI-MedLine.d170.s5	K	228	228	O	K	K	K	NNP	brand
DDI-MedLine.d170.s5	(	229	229	O	(	(	(	(	False
DDI-MedLine.d170.s5	+	230	230	O	+	+	+	NN	False
DDI-MedLine.d170.s5	)	231	231	O	)	)	)	)	False
DDI-MedLine.d170.s5	-Cl	233	235	O	-Cl	-Cl	-Cl	NN	False
DDI-MedLine.d170.s5	(	236	236	O	(	(	(	(	False
DDI-MedLine.d170.s5	-	237	237	O	-	-	-	:	False
DDI-MedLine.d170.s5	)	238	238	O	)	)	)	)	False
DDI-MedLine.d170.s5	cotransporter	240	252	O	cotransporter	ter	rter	NN	False
DDI-MedLine.d170.s5	,	253	253	O	,	,	,	,	False
DDI-MedLine.d170.s5	KCC2	255	258	O	KCC2	CC2	KCC2	NNP	brand
DDI-MedLine.d170.s5	)	259	259	O	)	)	)	)	False
DDI-MedLine.d170.s5	to	261	262	O	to	to	to	TO	False
DDI-MedLine.d170.s5	the	264	266	O	the	the	the	DT	False
DDI-MedLine.d170.s5	main	268	271	O	main	ain	main	JJ	False
DDI-MedLine.d170.s5	Cl	273	274	O	Cl	Cl	Cl	NN	False
DDI-MedLine.d170.s5	(	275	275	O	(	(	(	(	False
DDI-MedLine.d170.s5	-	276	276	O	-	-	-	:	False
DDI-MedLine.d170.s5	)	277	277	O	)	)	)	)	False
DDI-MedLine.d170.s5	uptake	279	284	O	uptake	ake	take	NN	False
DDI-MedLine.d170.s5	transporter	286	296	O	transporter	ter	rter	NN	False
DDI-MedLine.d170.s5	(	298	298	O	(	(	(	(	False
DDI-MedLine.d170.s5	Na	299	300	O	Na	Na	Na	NN	False
DDI-MedLine.d170.s5	(	301	301	O	(	(	(	(	False
DDI-MedLine.d170.s5	+	302	302	O	+	+	+	NN	False
DDI-MedLine.d170.s5	)	303	303	O	)	)	)	)	False
DDI-MedLine.d170.s5	-K	305	306	O	-K	-K	-K	NN	brand
DDI-MedLine.d170.s5	(	307	307	O	(	(	(	(	False
DDI-MedLine.d170.s5	+	308	308	O	+	+	+	NN	False
DDI-MedLine.d170.s5	)	309	309	O	)	)	)	)	False
DDI-MedLine.d170.s5	-2Cl	311	314	O	-2Cl	2Cl	-2Cl	NN	False
DDI-MedLine.d170.s5	(	315	315	O	(	(	(	(	False
DDI-MedLine.d170.s5	-	316	316	O	-	-	-	:	False
DDI-MedLine.d170.s5	)	317	317	O	)	)	)	)	False
DDI-MedLine.d170.s5	cotransporter	319	331	O	cotransporter	ter	rter	NN	False
DDI-MedLine.d170.s5	,	332	332	O	,	,	,	,	False
DDI-MedLine.d170.s5	NKCC1	334	338	O	NKCC1	CC1	KCC1	NN	brand
DDI-MedLine.d170.s5	)	339	339	O	)	)	)	)	False
DDI-MedLine.d170.s5	.	340	340	O	.	.	.	.	False

DDI-MedLine.d170.s6	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d170.s6	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d170.s6	suggest	12	18	O	suggest	est	gest	NN	False
DDI-MedLine.d170.s6	that	20	23	O	that	hat	that	IN	False
DDI-MedLine.d170.s6	alterations	25	35	O	alterations	ons	ions	NNS	False
DDI-MedLine.d170.s6	of	37	38	O	of	of	of	IN	False
DDI-MedLine.d170.s6	cation-chloride	40	54	O	cation-chloride	ide	ride	NN	False
DDI-MedLine.d170.s6	cotransporter	56	68	O	cotransporter	ter	rter	NN	False
DDI-MedLine.d170.s6	functions	70	78	O	functions	ons	ions	NNS	False
DDI-MedLine.d170.s6	,	79	79	O	,	,	,	,	False
DDI-MedLine.d170.s6	comprising	81	90	O	comprising	ing	sing	VBG	False
DDI-MedLine.d170.s6	a	92	92	O	a	a	a	DT	False
DDI-MedLine.d170.s6	higher	94	99	O	higher	her	gher	JJR	False
DDI-MedLine.d170.s6	NKCC1	101	105	O	NKCC1	CC1	KCC1	NN	brand
DDI-MedLine.d170.s6	action	107	112	O	action	ion	tion	NN	False
DDI-MedLine.d170.s6	,	113	113	O	,	,	,	,	False
DDI-MedLine.d170.s6	contribute	115	124	O	contribute	ute	bute	NN	False
DDI-MedLine.d170.s6	to	126	127	O	to	to	to	TO	False
DDI-MedLine.d170.s6	hyperexcitability	129	145	O	hyperexcitability	ity	lity	NN	False
DDI-MedLine.d170.s6	within	147	152	O	within	hin	thin	IN	False
DDI-MedLine.d170.s6	the	154	156	O	the	the	the	DT	False
DDI-MedLine.d170.s6	hippocampus	158	168	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d170.s6	following	170	178	O	following	ing	wing	VBG	False
DDI-MedLine.d170.s6	SE	180	181	O	SE	SE	SE	NN	brand
DDI-MedLine.d170.s6	.	182	182	O	.	.	.	.	False

DDI-MedLine.d206.s0	Evaluation	0	9	O	Evaluation	ion	tion	NN	False
DDI-MedLine.d206.s0	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d206.s0	antidepressant	14	27	O	antidepressant	ant	sant	NN	False
DDI-MedLine.d206.s0	like	29	32	O	like	ike	like	IN	False
DDI-MedLine.d206.s0	activity	34	41	O	activity	ity	vity	NN	False
DDI-MedLine.d206.s0	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d206.s0	curcumin	46	53	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s0	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d206.s0	its	59	61	O	its	its	its	PRP$	False
DDI-MedLine.d206.s0	combination	63	73	O	combination	ion	tion	NN	False
DDI-MedLine.d206.s0	with	75	78	O	with	ith	with	IN	False
DDI-MedLine.d206.s0	fluoxetine	80	89	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d206.s0	and	91	93	O	and	and	and	CC	False
DDI-MedLine.d206.s0	imipramine	95	104	B-drug	imipramine	ine	mine	NN	drug
DDI-MedLine.d206.s0	:	105	105	O	:	:	:	:	False
DDI-MedLine.d206.s0	an	107	108	O	an	an	an	DT	False
DDI-MedLine.d206.s0	acute	110	114	O	acute	ute	cute	NN	False
DDI-MedLine.d206.s0	and	116	118	O	and	and	and	CC	False
DDI-MedLine.d206.s0	chronic	120	126	O	chronic	nic	onic	NN	False
DDI-MedLine.d206.s0	study	128	132	O	study	udy	tudy	NN	False
DDI-MedLine.d206.s0	.	133	133	O	.	.	.	.	False

DDI-MedLine.d206.s1	Curcumin	0	7	B-drug_n	Curcumin	min	umin	NN	False
DDI-MedLine.d206.s1	is	9	10	O	is	is	is	VBZ	False
DDI-MedLine.d206.s1	the	12	14	O	the	the	the	DT	False
DDI-MedLine.d206.s1	active	16	21	O	active	ive	tive	JJ	False
DDI-MedLine.d206.s1	ingredient	23	32	O	ingredient	ent	ient	NN	False
DDI-MedLine.d206.s1	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d206.s1	commonly	37	44	O	commonly	nly	only	RB	False
DDI-MedLine.d206.s1	used	46	49	O	used	sed	used	VBN	False
DDI-MedLine.d206.s1	spice	51	55	O	spice	ice	pice	NN	False
DDI-MedLine.d206.s1	Curuma	57	62	O	Curuma	uma	ruma	NN	False
DDI-MedLine.d206.s1	longa	64	68	O	longa	nga	onga	NN	False
DDI-MedLine.d206.s1	Linn	70	73	O	Linn	inn	Linn	NN	False
DDI-MedLine.d206.s1	.	74	74	O	.	.	.	.	False

DDI-MedLine.d206.s2	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d206.s2	the	3	5	O	the	the	the	DT	False
DDI-MedLine.d206.s2	present	7	13	O	present	ent	sent	NN	False
DDI-MedLine.d206.s2	study	15	19	O	study	udy	tudy	NN	False
DDI-MedLine.d206.s2	,	20	20	O	,	,	,	,	False
DDI-MedLine.d206.s2	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d206.s2	antidepressant	26	39	O	antidepressant	ant	sant	NN	False
DDI-MedLine.d206.s2	like	41	44	O	like	ike	like	IN	False
DDI-MedLine.d206.s2	activity	46	53	O	activity	ity	vity	NN	False
DDI-MedLine.d206.s2	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d206.s2	curcumin	58	65	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s2	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d206.s2	its	71	73	O	its	its	its	PRP$	False
DDI-MedLine.d206.s2	combination	75	85	O	combination	ion	tion	NN	False
DDI-MedLine.d206.s2	with	87	90	O	with	ith	with	IN	False
DDI-MedLine.d206.s2	fluoxetine	92	101	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d206.s2	and	103	105	O	and	and	and	CC	False
DDI-MedLine.d206.s2	imipramine	107	116	B-drug	imipramine	ine	mine	NN	drug
DDI-MedLine.d206.s2	was	118	120	O	was	was	was	VBD	False
DDI-MedLine.d206.s2	studied	122	128	O	studied	ied	died	VBN	False
DDI-MedLine.d206.s2	in	130	131	O	in	in	in	IN	False
DDI-MedLine.d206.s2	acute	133	137	O	acute	ute	cute	NN	False
DDI-MedLine.d206.s2	model	139	143	O	model	del	odel	NN	False
DDI-MedLine.d206.s2	(	145	145	O	(	(	(	(	False
DDI-MedLine.d206.s2	three	146	150	O	three	ree	hree	CD	False
DDI-MedLine.d206.s2	doses	152	156	O	doses	ses	oses	NNS	False
DDI-MedLine.d206.s2	24	158	159	O	24	24	24	CD	False
DDI-MedLine.d206.s2	,	160	160	O	,	,	,	,	False
DDI-MedLine.d206.s2	5	162	162	O	5	5	5	CD	False
DDI-MedLine.d206.s2	and	164	166	O	and	and	and	CC	False
DDI-MedLine.d206.s2	1	168	168	O	1	1	1	CD	False
DDI-MedLine.d206.s2	h	170	170	O	h	h	h	NN	False
DDI-MedLine.d206.s2	before	172	177	O	before	ore	fore	IN	False
DDI-MedLine.d206.s2	test	179	182	O	test	est	test	NN	False
DDI-MedLine.d206.s2	)	183	183	O	)	)	)	)	False
DDI-MedLine.d206.s2	of	185	186	O	of	of	of	IN	False
DDI-MedLine.d206.s2	forced	188	193	O	forced	ced	rced	VBN	False
DDI-MedLine.d206.s2	swimming	195	202	O	swimming	ing	ming	VBG	False
DDI-MedLine.d206.s2	test	204	207	O	test	est	test	NN	False
DDI-MedLine.d206.s2	(	209	209	O	(	(	(	(	False
DDI-MedLine.d206.s2	FST	210	212	O	FST	FST	FST	NN	brand
DDI-MedLine.d206.s2	)	213	213	O	)	)	)	)	False
DDI-MedLine.d206.s2	in	215	216	O	in	in	in	IN	False
DDI-MedLine.d206.s2	glass	218	222	O	glass	ass	lass	NN	False
DDI-MedLine.d206.s2	jar	224	226	O	jar	jar	jar	NN	False
DDI-MedLine.d206.s2	and	228	230	O	and	and	and	CC	False
DDI-MedLine.d206.s2	tail	232	235	O	tail	ail	tail	NN	False
DDI-MedLine.d206.s2	suspension	237	246	O	suspension	ion	sion	NN	False
DDI-MedLine.d206.s2	test	248	251	O	test	est	test	NN	False
DDI-MedLine.d206.s2	(	253	253	O	(	(	(	(	False
DDI-MedLine.d206.s2	TST	254	256	O	TST	TST	TST	NN	brand
DDI-MedLine.d206.s2	)	257	257	O	)	)	)	)	False
DDI-MedLine.d206.s2	in	259	260	O	in	in	in	IN	False
DDI-MedLine.d206.s2	mice	262	265	O	mice	ice	mice	NN	False
DDI-MedLine.d206.s2	and	267	269	O	and	and	and	CC	False
DDI-MedLine.d206.s2	in	271	272	O	in	in	in	IN	False
DDI-MedLine.d206.s2	chronic	274	280	O	chronic	nic	onic	NN	False
DDI-MedLine.d206.s2	model	282	286	O	model	del	odel	NN	False
DDI-MedLine.d206.s2	(	288	288	O	(	(	(	(	False
DDI-MedLine.d206.s2	14	289	290	O	14	14	14	CD	False
DDI-MedLine.d206.s2	day	292	294	O	day	day	day	NN	False
DDI-MedLine.d206.s2	study	296	300	O	study	udy	tudy	NN	False
DDI-MedLine.d206.s2	)	301	301	O	)	)	)	)	False
DDI-MedLine.d206.s2	of	303	304	O	of	of	of	IN	False
DDI-MedLine.d206.s2	FST	306	308	O	FST	FST	FST	NN	brand
DDI-MedLine.d206.s2	with	310	313	O	with	ith	with	IN	False
DDI-MedLine.d206.s2	water	315	319	O	water	ter	ater	NN	False
DDI-MedLine.d206.s2	wheel	321	325	O	wheel	eel	heel	NN	False
DDI-MedLine.d206.s2	in	327	328	O	in	in	in	IN	False
DDI-MedLine.d206.s2	rats	330	333	O	rats	ats	rats	NNS	False
DDI-MedLine.d206.s2	.	334	334	O	.	.	.	.	False

DDI-MedLine.d206.s3	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d206.s3	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d206.s3	tests	8	12	O	tests	sts	ests	NNS	False
DDI-MedLine.d206.s3	were	14	17	O	were	ere	were	VBD	False
DDI-MedLine.d206.s3	carried	19	25	O	carried	ied	ried	VBN	False
DDI-MedLine.d206.s3	out	27	29	O	out	out	out	IN	False
DDI-MedLine.d206.s3	in	31	32	O	in	in	in	IN	False
DDI-MedLine.d206.s3	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d206.s3	following	38	46	O	following	ing	wing	VBG	False
DDI-MedLine.d206.s3	seven	48	52	O	seven	ven	even	CD	False
DDI-MedLine.d206.s3	groups	54	59	O	groups	ups	oups	NNS	False
DDI-MedLine.d206.s3	(	61	61	O	(	(	(	(	False
DDI-MedLine.d206.s3	n	62	62	O	n	n	n	NN	False
DDI-MedLine.d206.s3	=	64	64	O	=	=	=	NN	False
DDI-MedLine.d206.s3	6	66	66	O	6	6	6	CD	False
DDI-MedLine.d206.s3	in	68	69	O	in	in	in	IN	False
DDI-MedLine.d206.s3	each	71	74	O	each	ach	each	DT	False
DDI-MedLine.d206.s3	group	76	80	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	)	81	81	O	)	)	)	)	False
DDI-MedLine.d206.s3	,	82	82	O	,	,	,	,	False
DDI-MedLine.d206.s3	drugs	84	88	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d206.s3	being	90	94	O	being	ing	eing	VBG	False
DDI-MedLine.d206.s3	given	96	100	O	given	ven	iven	VBN	False
DDI-MedLine.d206.s3	orally	102	107	O	orally	lly	ally	RB	False
DDI-MedLine.d206.s3	(	109	109	O	(	(	(	(	False
DDI-MedLine.d206.s3	doses	110	114	O	doses	ses	oses	NNS	False
DDI-MedLine.d206.s3	for	116	118	O	for	for	for	IN	False
DDI-MedLine.d206.s3	mice	120	123	O	mice	ice	mice	NN	False
DDI-MedLine.d206.s3	)	124	124	O	)	)	)	)	False
DDI-MedLine.d206.s3	:	125	125	O	:	:	:	:	False
DDI-MedLine.d206.s3	Group	127	131	O	Group	oup	roup	NNP	False
DDI-MedLine.d206.s3	1	133	133	O	1	1	1	CD	False
DDI-MedLine.d206.s3	(	135	135	O	(	(	(	(	False
DDI-MedLine.d206.s3	vehicle	136	142	O	vehicle	cle	icle	NN	False
DDI-MedLine.d206.s3	)	143	143	O	)	)	)	)	False
DDI-MedLine.d206.s3	,	144	144	O	,	,	,	,	False
DDI-MedLine.d206.s3	group	146	150	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	2	152	152	O	2	2	2	CD	False
DDI-MedLine.d206.s3	(	154	154	O	(	(	(	(	False
DDI-MedLine.d206.s3	curcumin	155	162	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s3	50	164	165	O	50	50	50	CD	False
DDI-MedLine.d206.s3	mg/kg	167	171	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	)	172	172	O	)	)	)	)	False
DDI-MedLine.d206.s3	,	173	173	O	,	,	,	,	False
DDI-MedLine.d206.s3	group	175	179	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	3	181	181	O	3	3	3	CD	False
DDI-MedLine.d206.s3	(	183	183	O	(	(	(	(	False
DDI-MedLine.d206.s3	curcumin	184	191	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s3	100	193	195	O	100	100	100	CD	False
DDI-MedLine.d206.s3	mg/kg	197	201	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	)	202	202	O	)	)	)	)	False
DDI-MedLine.d206.s3	,	203	203	O	,	,	,	,	False
DDI-MedLine.d206.s3	group	205	209	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	4	211	211	O	4	4	4	CD	False
DDI-MedLine.d206.s3	(	213	213	O	(	(	(	(	False
DDI-MedLine.d206.s3	fluoxetine	214	223	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d206.s3	20	225	226	O	20	20	20	CD	False
DDI-MedLine.d206.s3	mg/kg	228	232	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	)	233	233	O	)	)	)	)	False
DDI-MedLine.d206.s3	,	234	234	O	,	,	,	,	False
DDI-MedLine.d206.s3	group	236	240	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	5	242	242	O	5	5	5	CD	False
DDI-MedLine.d206.s3	(	244	244	O	(	(	(	(	False
DDI-MedLine.d206.s3	imipramine	245	254	B-drug	imipramine	ine	mine	NN	drug
DDI-MedLine.d206.s3	15	256	257	O	15	15	15	CD	False
DDI-MedLine.d206.s3	mg/kg	259	263	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	)	264	264	O	)	)	)	)	False
DDI-MedLine.d206.s3	,	265	265	O	,	,	,	,	False
DDI-MedLine.d206.s3	group	267	271	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	6	273	273	O	6	6	6	CD	False
DDI-MedLine.d206.s3	(	275	275	O	(	(	(	(	False
DDI-MedLine.d206.s3	curcumin	276	283	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s3	100	285	287	O	100	100	100	CD	False
DDI-MedLine.d206.s3	mg/kg	289	293	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	plus	295	298	O	plus	lus	plus	CC	False
DDI-MedLine.d206.s3	fluoxetine	300	309	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d206.s3	20	311	312	O	20	20	20	CD	False
DDI-MedLine.d206.s3	mg/kg	314	318	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	)	319	319	O	)	)	)	)	False
DDI-MedLine.d206.s3	and	321	323	O	and	and	and	CC	False
DDI-MedLine.d206.s3	group	325	329	O	group	oup	roup	NN	False
DDI-MedLine.d206.s3	7	331	331	O	7	7	7	CD	False
DDI-MedLine.d206.s3	(	333	333	O	(	(	(	(	False
DDI-MedLine.d206.s3	curcumin	334	341	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s3	100	343	345	O	100	100	100	CD	False
DDI-MedLine.d206.s3	mg/kg	347	351	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	plus	353	356	O	plus	lus	plus	CC	False
DDI-MedLine.d206.s3	imipramine	358	367	B-drug	imipramine	ine	mine	NN	drug
DDI-MedLine.d206.s3	15	369	370	O	15	15	15	CD	False
DDI-MedLine.d206.s3	mg/kg	372	376	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s3	)	377	377	O	)	)	)	)	False
DDI-MedLine.d206.s3	.	378	378	O	.	.	.	.	False

DDI-MedLine.d206.s4	Equivalent	0	9	O	Equivalent	ent	lent	NN	False
DDI-MedLine.d206.s4	doses	11	15	O	doses	ses	oses	NNS	False
DDI-MedLine.d206.s4	for	17	19	O	for	for	for	IN	False
DDI-MedLine.d206.s4	rats	21	24	O	rats	ats	rats	NNS	False
DDI-MedLine.d206.s4	were	26	29	O	were	ere	were	VBD	False
DDI-MedLine.d206.s4	used	31	34	O	used	sed	used	VBN	False
DDI-MedLine.d206.s4	.	35	35	O	.	.	.	.	False

DDI-MedLine.d206.s5	Both	0	3	O	Both	oth	Both	DT	False
DDI-MedLine.d206.s5	the	5	7	O	the	the	the	DT	False
DDI-MedLine.d206.s5	acute	9	13	O	acute	ute	cute	NN	False
DDI-MedLine.d206.s5	model	15	19	O	model	del	odel	NN	False
DDI-MedLine.d206.s5	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d206.s5	FST	24	26	O	FST	FST	FST	NN	brand
DDI-MedLine.d206.s5	and	28	30	O	and	and	and	CC	False
DDI-MedLine.d206.s5	TST	32	34	O	TST	TST	TST	NN	brand
DDI-MedLine.d206.s5	,	35	35	O	,	,	,	,	False
DDI-MedLine.d206.s5	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d206.s5	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d206.s5	chronic	45	51	O	chronic	nic	onic	NN	False
DDI-MedLine.d206.s5	model	53	57	O	model	del	odel	NN	False
DDI-MedLine.d206.s5	of	59	60	O	of	of	of	IN	False
DDI-MedLine.d206.s5	FST	62	64	O	FST	FST	FST	NN	brand
DDI-MedLine.d206.s5	with	66	69	O	with	ith	with	IN	False
DDI-MedLine.d206.s5	water	71	75	O	water	ter	ater	NN	False
DDI-MedLine.d206.s5	wheel	77	81	O	wheel	eel	heel	NN	False
DDI-MedLine.d206.s5	showed	83	88	O	showed	wed	owed	VBD	False
DDI-MedLine.d206.s5	significant	90	100	O	significant	ant	cant	JJ	False
DDI-MedLine.d206.s5	antidepressant	102	115	O	antidepressant	ant	sant	NN	False
DDI-MedLine.d206.s5	like	117	120	O	like	ike	like	IN	False
DDI-MedLine.d206.s5	activity	122	129	O	activity	ity	vity	NN	False
DDI-MedLine.d206.s5	of	131	132	O	of	of	of	IN	False
DDI-MedLine.d206.s5	curcumin	134	141	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s5	in	143	144	O	in	in	in	IN	False
DDI-MedLine.d206.s5	100	146	148	O	100	100	100	CD	False
DDI-MedLine.d206.s5	mg/kg	150	154	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s5	dose	156	159	O	dose	ose	dose	NN	False
DDI-MedLine.d206.s5	as	161	162	O	as	as	as	IN	False
DDI-MedLine.d206.s5	compared	164	171	O	compared	red	ared	VBN	False
DDI-MedLine.d206.s5	to	173	174	O	to	to	to	TO	False
DDI-MedLine.d206.s5	vehicle	176	182	O	vehicle	cle	icle	NN	False
DDI-MedLine.d206.s5	control	184	190	O	control	rol	trol	NN	False
DDI-MedLine.d206.s5	(	192	192	O	(	(	(	(	False
DDI-MedLine.d206.s5	p	193	193	O	p	p	p	NN	False
DDI-MedLine.d206.s5	<	195	195	O	<	<	<	NN	False
DDI-MedLine.d206.s5	0.05	197	200	O	0.05	.05	0.05	CD	False
DDI-MedLine.d206.s5	)	201	201	O	)	)	)	)	False
DDI-MedLine.d206.s5	.	202	202	O	.	.	.	.	False

DDI-MedLine.d206.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d206.s6	effect	4	9	O	effect	ect	fect	NN	False
DDI-MedLine.d206.s6	of	11	12	O	of	of	of	IN	False
DDI-MedLine.d206.s6	curcumin	14	21	B-drug_n	curcumin	min	umin	NN	False
DDI-MedLine.d206.s6	(	23	23	O	(	(	(	(	False
DDI-MedLine.d206.s6	100	24	26	O	100	100	100	CD	False
DDI-MedLine.d206.s6	mg/kg	28	32	O	mg/kg	/kg	g/kg	NN	False
DDI-MedLine.d206.s6	)	33	33	O	)	)	)	)	False
DDI-MedLine.d206.s6	was	35	37	O	was	was	was	VBD	False
DDI-MedLine.d206.s6	similar	39	45	O	similar	lar	ilar	JJ	False
DDI-MedLine.d206.s6	to	47	48	O	to	to	to	TO	False
DDI-MedLine.d206.s6	that	50	53	O	that	hat	that	IN	False
DDI-MedLine.d206.s6	of	55	56	O	of	of	of	IN	False
DDI-MedLine.d206.s6	fluoxetine	58	67	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d206.s6	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d206.s6	imipramine	73	82	B-drug	imipramine	ine	mine	NN	drug
DDI-MedLine.d206.s6	(	84	84	O	(	(	(	(	False
DDI-MedLine.d206.s6	p	85	85	O	p	p	p	NN	False
DDI-MedLine.d206.s6	>	87	87	O	>	>	>	NN	False
DDI-MedLine.d206.s6	0.05	89	92	O	0.05	.05	0.05	CD	False
DDI-MedLine.d206.s6	)	93	93	O	)	)	)	)	False
DDI-MedLine.d206.s6	but	95	97	O	but	but	but	CC	False
DDI-MedLine.d206.s6	its	99	101	O	its	its	its	PRP$	False
DDI-MedLine.d206.s6	addition	103	110	O	addition	ion	tion	NN	False
DDI-MedLine.d206.s6	to	112	113	O	to	to	to	TO	False
DDI-MedLine.d206.s6	fluoxetine	115	124	B-drug	fluoxetine	ine	tine	NN	drug
DDI-MedLine.d206.s6	and	126	128	O	and	and	and	CC	False
DDI-MedLine.d206.s6	imipramine	130	139	B-drug	imipramine	ine	mine	NN	drug
DDI-MedLine.d206.s6	did	141	143	O	did	did	did	VBD	False
DDI-MedLine.d206.s6	not	145	147	O	not	not	not	RB	False
DDI-MedLine.d206.s6	improve	149	155	O	improve	ove	rove	VB	False
DDI-MedLine.d206.s6	their	157	161	O	their	eir	heir	PRP$	False
DDI-MedLine.d206.s6	antidepressant	163	176	O	antidepressant	ant	sant	NN	False
DDI-MedLine.d206.s6	activity	178	185	O	activity	ity	vity	NN	False
DDI-MedLine.d206.s6	(	187	187	O	(	(	(	(	False
DDI-MedLine.d206.s6	p	188	188	O	p	p	p	NN	False
DDI-MedLine.d206.s6	>	190	190	O	>	>	>	NN	False
DDI-MedLine.d206.s6	0.05	192	195	O	0.05	.05	0.05	CD	False
DDI-MedLine.d206.s6	)	196	196	O	)	)	)	)	False
DDI-MedLine.d206.s6	.	197	197	O	.	.	.	.	False

DDI-MedLine.d206.s7	Curcumin	0	7	B-drug_n	Curcumin	min	umin	NN	False
DDI-MedLine.d206.s7	increased	9	17	O	increased	sed	ased	VBN	False
DDI-MedLine.d206.s7	both	19	22	O	both	oth	both	DT	False
DDI-MedLine.d206.s7	the	24	26	O	the	the	the	DT	False
DDI-MedLine.d206.s7	swimming	28	35	O	swimming	ing	ming	VBG	False
DDI-MedLine.d206.s7	and	37	39	O	and	and	and	CC	False
DDI-MedLine.d206.s7	climbing	41	48	O	climbing	ing	bing	VBG	False
DDI-MedLine.d206.s7	behavior	50	57	O	behavior	ior	vior	NN	False
DDI-MedLine.d206.s7	in	59	60	O	in	in	in	IN	False
DDI-MedLine.d206.s7	FST	62	64	O	FST	FST	FST	NN	brand
DDI-MedLine.d206.s7	,	65	65	O	,	,	,	,	False
DDI-MedLine.d206.s7	thus	67	70	O	thus	hus	thus	RB	False
DDI-MedLine.d206.s7	its	72	74	O	its	its	its	PRP$	False
DDI-MedLine.d206.s7	antidepressant	76	89	O	antidepressant	ant	sant	NN	False
DDI-MedLine.d206.s7	like	91	94	O	like	ike	like	IN	False
DDI-MedLine.d206.s7	activity	96	103	O	activity	ity	vity	NN	False
DDI-MedLine.d206.s7	could	105	109	O	could	uld	ould	MD	False
DDI-MedLine.d206.s7	be	111	112	O	be	be	be	VB	False
DDI-MedLine.d206.s7	due	114	116	O	due	due	due	JJ	False
DDI-MedLine.d206.s7	to	118	119	O	to	to	to	TO	False
DDI-MedLine.d206.s7	an	121	122	O	an	an	an	DT	False
DDI-MedLine.d206.s7	increase	124	131	O	increase	ase	ease	NN	False
DDI-MedLine.d206.s7	in	133	134	O	in	in	in	IN	False
DDI-MedLine.d206.s7	serotonin	136	144	O	serotonin	nin	onin	NN	False
DDI-MedLine.d206.s7	,	145	145	O	,	,	,	,	False
DDI-MedLine.d206.s7	norepinephrine	147	160	O	norepinephrine	ine	rine	NN	drug
DDI-MedLine.d206.s7	and	162	164	O	and	and	and	CC	False
DDI-MedLine.d206.s7	dopamine	166	173	O	dopamine	ine	mine	NN	drug
DDI-MedLine.d206.s7	levels	175	180	O	levels	els	vels	NNS	False
DDI-MedLine.d206.s7	in	182	183	O	in	in	in	IN	False
DDI-MedLine.d206.s7	the	185	187	O	the	the	the	DT	False
DDI-MedLine.d206.s7	brain	189	193	O	brain	ain	rain	NN	False
DDI-MedLine.d206.s7	.	194	194	O	.	.	.	.	False

DDI-MedLine.d206.s8	Curcumin	0	7	B-drug_n	Curcumin	min	umin	NN	False
DDI-MedLine.d206.s8	can	9	11	O	can	can	can	MD	False
DDI-MedLine.d206.s8	be	13	14	O	be	be	be	VB	False
DDI-MedLine.d206.s8	a	16	16	O	a	a	a	DT	False
DDI-MedLine.d206.s8	useful	18	23	O	useful	ful	eful	JJ	False
DDI-MedLine.d206.s8	antidepressant	25	38	B-group	antidepressant	ant	sant	NN	False
DDI-MedLine.d206.s8	especially	40	49	O	especially	lly	ally	RB	False
DDI-MedLine.d206.s8	in	51	52	O	in	in	in	IN	False
DDI-MedLine.d206.s8	cases	54	58	O	cases	ses	ases	NNS	False
DDI-MedLine.d206.s8	which	60	64	O	which	ich	hich	WDT	False
DDI-MedLine.d206.s8	respond	66	72	O	respond	ond	pond	NN	False
DDI-MedLine.d206.s8	to	74	75	O	to	to	to	TO	False
DDI-MedLine.d206.s8	drugs	77	81	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d206.s8	having	83	88	O	having	ing	ving	VBG	False
DDI-MedLine.d206.s8	mixed	90	94	O	mixed	xed	ixed	JJ	False
DDI-MedLine.d206.s8	effects	96	102	O	effects	cts	ects	NNS	False
DDI-MedLine.d206.s8	on	104	105	O	on	on	on	IN	False
DDI-MedLine.d206.s8	serotonin	107	115	O	serotonin	nin	onin	NN	False
DDI-MedLine.d206.s8	and	117	119	O	and	and	and	CC	False
DDI-MedLine.d206.s8	catecholamines	121	134	O	catecholamines	nes	ines	NNS	group
DDI-MedLine.d206.s8	levels	136	141	O	levels	els	vels	NNS	False
DDI-MedLine.d206.s8	in	143	144	O	in	in	in	IN	False
DDI-MedLine.d206.s8	the	146	148	O	the	the	the	DT	False
DDI-MedLine.d206.s8	brain	150	154	O	brain	ain	rain	NN	False
DDI-MedLine.d206.s8	.	155	155	O	.	.	.	.	False

DDI-MedLine.d153.s0	Determination	0	12	O	Determination	ion	tion	NN	False
DDI-MedLine.d153.s0	of	14	15	O	of	of	of	IN	False
DDI-MedLine.d153.s0	propiverine	17	27	B-drug	propiverine	ine	rine	NN	drug
DDI-MedLine.d153.s0	hydrochloride	29	41	I-drug	hydrochloride	ide	ride	NN	False
DDI-MedLine.d153.s0	in	43	44	O	in	in	in	IN	False
DDI-MedLine.d153.s0	human	46	50	O	human	man	uman	NN	False
DDI-MedLine.d153.s0	plasma	52	57	O	plasma	sma	asma	NN	False
DDI-MedLine.d153.s0	by	59	60	O	by	by	by	IN	False
DDI-MedLine.d153.s0	high	62	65	O	high	igh	high	JJ	False
DDI-MedLine.d153.s0	performance	67	77	O	performance	nce	ance	NN	False
DDI-MedLine.d153.s0	liquid	79	84	O	liquid	uid	quid	NN	False
DDI-MedLine.d153.s0	chromatography-tandem	86	106	O	chromatography-tandem	dem	ndem	NN	False
DDI-MedLine.d153.s0	mass	108	111	O	mass	ass	mass	NN	False
DDI-MedLine.d153.s0	spectrometry	113	124	O	spectrometry	try	etry	NN	False
DDI-MedLine.d153.s0	:	125	125	O	:	:	:	:	False
DDI-MedLine.d153.s0	application	127	137	O	application	ion	tion	NN	False
DDI-MedLine.d153.s0	to	139	140	O	to	to	to	TO	False
DDI-MedLine.d153.s0	the	142	144	O	the	the	the	DT	False
DDI-MedLine.d153.s0	pharmacokinetic	146	160	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d153.s0	study	162	166	O	study	udy	tudy	NN	False
DDI-MedLine.d153.s0	of	168	169	O	of	of	of	IN	False
DDI-MedLine.d153.s0	a	171	171	O	a	a	a	DT	False
DDI-MedLine.d153.s0	sustained	173	181	O	sustained	ned	ined	VBN	False
DDI-MedLine.d153.s0	release	183	189	O	release	ase	ease	NN	False
DDI-MedLine.d153.s0	formulation	191	201	O	formulation	ion	tion	NN	False
DDI-MedLine.d153.s0	.	202	202	O	.	.	.	.	False

DDI-MedLine.d153.s1	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d153.s1	rapid	2	6	O	rapid	pid	apid	JJ	False
DDI-MedLine.d153.s1	,	7	7	O	,	,	,	,	False
DDI-MedLine.d153.s1	sensitive	9	17	O	sensitive	ive	tive	JJ	False
DDI-MedLine.d153.s1	and	19	21	O	and	and	and	CC	False
DDI-MedLine.d153.s1	reliable	23	30	O	reliable	ble	able	JJ	False
DDI-MedLine.d153.s1	high	32	35	O	high	igh	high	JJ	False
DDI-MedLine.d153.s1	performance	37	47	O	performance	nce	ance	NN	False
DDI-MedLine.d153.s1	liquid	49	54	O	liquid	uid	quid	NN	False
DDI-MedLine.d153.s1	chromatography-tandem	56	76	O	chromatography-tandem	dem	ndem	NN	False
DDI-MedLine.d153.s1	mass	78	81	O	mass	ass	mass	NN	False
DDI-MedLine.d153.s1	spectrometry	83	94	O	spectrometry	try	etry	NN	False
DDI-MedLine.d153.s1	(	96	96	O	(	(	(	(	False
DDI-MedLine.d153.s1	HPLC-MS/MS	97	106	O	HPLC-MS/MS	/MS	S/MS	NN	brand
DDI-MedLine.d153.s1	)	107	107	O	)	)	)	)	False
DDI-MedLine.d153.s1	method	109	114	O	method	hod	thod	NN	False
DDI-MedLine.d153.s1	was	116	118	O	was	was	was	VBD	False
DDI-MedLine.d153.s1	developed	120	128	O	developed	ped	oped	NN	False
DDI-MedLine.d153.s1	and	130	132	O	and	and	and	CC	False
DDI-MedLine.d153.s1	validated	134	142	O	validated	ted	ated	VBN	False
DDI-MedLine.d153.s1	for	144	146	O	for	for	for	IN	False
DDI-MedLine.d153.s1	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d153.s1	determination	152	164	O	determination	ion	tion	NN	False
DDI-MedLine.d153.s1	of	166	167	O	of	of	of	IN	False
DDI-MedLine.d153.s1	propiverine	169	179	B-drug	propiverine	ine	rine	NN	drug
DDI-MedLine.d153.s1	hydrochloride	181	193	I-drug	hydrochloride	ide	ride	NN	False
DDI-MedLine.d153.s1	(	195	195	O	(	(	(	(	False
DDI-MedLine.d153.s1	CAS	196	198	O	CAS	CAS	CAS	NN	brand
DDI-MedLine.d153.s1	54556-98-8	200	209	O	54556-98-8	8-8	98-8	JJ	False
DDI-MedLine.d153.s1	)	210	210	O	)	)	)	)	False
DDI-MedLine.d153.s1	in	212	213	O	in	in	in	IN	False
DDI-MedLine.d153.s1	human	215	219	O	human	man	uman	NN	False
DDI-MedLine.d153.s1	plasma	221	226	O	plasma	sma	asma	NN	False
DDI-MedLine.d153.s1	using	228	232	O	using	ing	sing	VBG	False
DDI-MedLine.d153.s1	cetirizine	234	243	B-drug	cetirizine	ine	zine	NN	drug
DDI-MedLine.d153.s1	di-hydrochloride	245	260	I-drug	di-hydrochloride	ide	ride	NN	False
DDI-MedLine.d153.s1	as	262	263	O	as	as	as	IN	False
DDI-MedLine.d153.s1	internal	265	272	O	internal	nal	rnal	JJ	False
DDI-MedLine.d153.s1	standard	274	281	O	standard	ard	dard	NN	False
DDI-MedLine.d153.s1	(	283	283	O	(	(	(	(	False
DDI-MedLine.d153.s1	IS	284	285	O	IS	IS	IS	NN	brand
DDI-MedLine.d153.s1	,	286	286	O	,	,	,	,	False
DDI-MedLine.d153.s1	CAS	288	290	O	CAS	CAS	CAS	NN	brand
DDI-MedLine.d153.s1	8388-51-0	292	300	O	8388-51-0	1-0	51-0	JJ	False
DDI-MedLine.d153.s1	)	301	301	O	)	)	)	)	False
DDI-MedLine.d153.s1	.	302	302	O	.	.	.	.	False

DDI-MedLine.d153.s2	Following	0	8	O	Following	ing	wing	VBG	False
DDI-MedLine.d153.s2	liquid-liquid	10	22	O	liquid-liquid	uid	quid	NN	False
DDI-MedLine.d153.s2	extraction	24	33	O	extraction	ion	tion	NN	False
DDI-MedLine.d153.s2	with	35	38	O	with	ith	with	IN	False
DDI-MedLine.d153.s2	ethyl	40	44	B-drug_n	ethyl	hyl	thyl	NN	False
DDI-MedLine.d153.s2	acetate	46	52	I-drug_n	acetate	ate	tate	NN	False
DDI-MedLine.d153.s2	,	53	53	O	,	,	,	,	False
DDI-MedLine.d153.s2	the	55	57	O	the	the	the	DT	False
DDI-MedLine.d153.s2	separation	59	68	O	separation	ion	tion	NN	False
DDI-MedLine.d153.s2	was	70	72	O	was	was	was	VBD	False
DDI-MedLine.d153.s2	performed	74	82	O	performed	med	rmed	VBN	False
DDI-MedLine.d153.s2	on	84	85	O	on	on	on	IN	False
DDI-MedLine.d153.s2	a	87	87	O	a	a	a	DT	False
DDI-MedLine.d153.s2	reverse	89	95	O	reverse	rse	erse	NN	False
DDI-MedLine.d153.s2	phase	97	101	O	phase	ase	hase	NN	False
DDI-MedLine.d153.s2	C18	103	105	O	C18	C18	C18	NN	brand
DDI-MedLine.d153.s2	column	107	112	O	column	umn	lumn	NN	False
DDI-MedLine.d153.s2	with	114	117	O	with	ith	with	IN	False
DDI-MedLine.d153.s2	a	119	119	O	a	a	a	DT	False
DDI-MedLine.d153.s2	mobile	121	126	O	mobile	ile	bile	NN	False
DDI-MedLine.d153.s2	phase	128	132	O	phase	ase	hase	NN	False
DDI-MedLine.d153.s2	consisted	134	142	O	consisted	ted	sted	VBN	False
DDI-MedLine.d153.s2	of	144	145	O	of	of	of	IN	False
DDI-MedLine.d153.s2	methanol-ammonium	147	163	B-drug_n	methanol-ammonium	ium	nium	NN	drug
DDI-MedLine.d153.s2	acetate	165	171	I-drug_n	acetate	ate	tate	NN	False
DDI-MedLine.d153.s2	(	173	173	O	(	(	(	(	False
DDI-MedLine.d153.s2	pH	174	175	O	pH	pH	pH	NN	False
DDI-MedLine.d153.s2	4.0	177	179	O	4.0	4.0	4.0	CD	False
DDI-MedLine.d153.s2	;	180	180	O	;	;	;	:	False
DDI-MedLine.d153.s2	10	182	183	O	10	10	10	CD	False
DDI-MedLine.d153.s2	mM	185	186	O	mM	mM	mM	NN	False
DDI-MedLine.d153.s2	)	187	187	O	)	)	)	)	False
DDI-MedLine.d153.s2	(	189	189	O	(	(	(	(	False
DDI-MedLine.d153.s2	70:30	190	194	O	70:30	:30	0:30	CD	False
DDI-MedLine.d153.s2	,	195	195	O	,	,	,	,	False
DDI-MedLine.d153.s2	v/v	197	199	O	v/v	v/v	v/v	NN	False
DDI-MedLine.d153.s2	)	200	200	O	)	)	)	)	False
DDI-MedLine.d153.s2	.	201	201	O	.	.	.	.	False

DDI-MedLine.d153.s3	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d153.s3	detection	4	12	O	detection	ion	tion	NN	False
DDI-MedLine.d153.s3	was	14	16	O	was	was	was	VBD	False
DDI-MedLine.d153.s3	performed	18	26	O	performed	med	rmed	VBN	False
DDI-MedLine.d153.s3	by	28	29	O	by	by	by	IN	False
DDI-MedLine.d153.s3	a	31	31	O	a	a	a	DT	False
DDI-MedLine.d153.s3	triple-quadrupole	33	49	O	triple-quadrupole	ole	pole	JJ	False
DDI-MedLine.d153.s3	mass	51	54	O	mass	ass	mass	NN	False
DDI-MedLine.d153.s3	spectrometer	56	67	O	spectrometer	ter	eter	NN	False
DDI-MedLine.d153.s3	in	69	70	O	in	in	in	IN	False
DDI-MedLine.d153.s3	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d153.s3	positive	76	83	O	positive	ive	tive	JJ	False
DDI-MedLine.d153.s3	ion	85	87	O	ion	ion	ion	NN	False
DDI-MedLine.d153.s3	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d153.s3	multiple	93	100	O	multiple	ple	iple	NN	False
DDI-MedLine.d153.s3	reaction	102	109	O	reaction	ion	tion	NN	False
DDI-MedLine.d153.s3	monitoring	111	120	O	monitoring	ing	ring	NN	False
DDI-MedLine.d153.s3	(	122	122	O	(	(	(	(	False
DDI-MedLine.d153.s3	MRM	123	125	O	MRM	MRM	MRM	NN	brand
DDI-MedLine.d153.s3	)	126	126	O	)	)	)	)	False
DDI-MedLine.d153.s3	mode	128	131	O	mode	ode	mode	NN	False
DDI-MedLine.d153.s3	,	132	132	O	,	,	,	,	False
DDI-MedLine.d153.s3	m/z	134	136	O	m/z	m/z	m/z	NN	False
DDI-MedLine.d153.s3	368.3	138	142	O	368.3	8.3	68.3	CD	False
DDI-MedLine.d153.s3	--	144	145	O	--	--	--	:	False
DDI-MedLine.d153.s3	>	146	146	O	>	>	>	NN	False

DDI-MedLine.d153.s4	116.1	0	4	O	116.1	6.1	16.1	CD	False
DDI-MedLine.d153.s4	for	6	8	O	for	for	for	IN	False
DDI-MedLine.d153.s4	propiverine	10	20	B-drug	propiverine	ine	rine	NN	drug
DDI-MedLine.d153.s4	and	22	24	O	and	and	and	CC	False
DDI-MedLine.d153.s4	m/z	26	28	O	m/z	m/z	m/z	NN	False
DDI-MedLine.d153.s4	389.2	30	34	O	389.2	9.2	89.2	CD	False
DDI-MedLine.d153.s4	--	36	37	O	--	--	--	:	False
DDI-MedLine.d153.s4	>	38	38	O	>	>	>	NN	False

DDI-MedLine.d153.s5	201.0	0	4	O	201.0	1.0	01.0	CD	False
DDI-MedLine.d153.s5	for	6	8	O	for	for	for	IN	False
DDI-MedLine.d153.s5	the	10	12	O	the	the	the	DT	False
DDI-MedLine.d153.s5	IS	14	15	O	IS	IS	IS	NN	brand
DDI-MedLine.d153.s5	.	16	16	O	.	.	.	.	False

DDI-MedLine.d153.s6	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d153.s6	calibration	4	14	O	calibration	ion	tion	NN	False
DDI-MedLine.d153.s6	curve	16	20	O	curve	rve	urve	NN	False
DDI-MedLine.d153.s6	fitted	22	27	O	fitted	ted	tted	VBN	False
DDI-MedLine.d153.s6	well	29	32	O	well	ell	well	RB	False
DDI-MedLine.d153.s6	over	34	37	O	over	ver	over	IN	False
DDI-MedLine.d153.s6	the	39	41	O	the	the	the	DT	False
DDI-MedLine.d153.s6	concentration	43	55	O	concentration	ion	tion	NN	False
DDI-MedLine.d153.s6	range	57	61	O	range	nge	ange	NN	False
DDI-MedLine.d153.s6	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d153.s6	0.2-200	66	72	O	0.2-200	200	-200	NN	False
DDI-MedLine.d153.s6	ng/mL	74	78	O	ng/mL	/mL	g/mL	NN	False
DDI-MedLine.d153.s6	(	80	80	O	(	(	(	(	False
DDI-MedLine.d153.s6	all	81	83	O	all	all	all	DT	False
DDI-MedLine.d153.s6	the	85	87	O	the	the	the	DT	False
DDI-MedLine.d153.s6	concentration	89	101	O	concentration	ion	tion	NN	False
DDI-MedLine.d153.s6	data	103	106	O	data	ata	data	NNS	False
DDI-MedLine.d153.s6	in	108	109	O	in	in	in	IN	False
DDI-MedLine.d153.s6	this	111	114	O	this	his	this	DT	False
DDI-MedLine.d153.s6	study	116	120	O	study	udy	tudy	NN	False
DDI-MedLine.d153.s6	are	122	124	O	are	are	are	VBP	False
DDI-MedLine.d153.s6	related	126	132	O	related	ted	ated	JJ	False
DDI-MedLine.d153.s6	to	134	135	O	to	to	to	TO	False
DDI-MedLine.d153.s6	salt	137	140	O	salt	alt	salt	NN	False
DDI-MedLine.d153.s6	(	142	142	O	(	(	(	(	False
DDI-MedLine.d153.s6	propiverine	143	153	B-drug	propiverine	ine	rine	NN	drug
DDI-MedLine.d153.s6	hydrochloride	155	167	I-drug	hydrochloride	ide	ride	NN	False
DDI-MedLine.d153.s6	)	168	168	O	)	)	)	)	False
DDI-MedLine.d153.s6	)	169	169	O	)	)	)	)	False
DDI-MedLine.d153.s6	.	170	170	O	.	.	.	.	False

DDI-MedLine.d153.s7	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d153.s7	limit	4	8	O	limit	mit	imit	NN	False
DDI-MedLine.d153.s7	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d153.s7	detection	13	21	O	detection	ion	tion	NN	False
DDI-MedLine.d153.s7	(	23	23	O	(	(	(	(	False
DDI-MedLine.d153.s7	LOD	24	26	O	LOD	LOD	LOD	NN	brand
DDI-MedLine.d153.s7	)	27	27	O	)	)	)	)	False
DDI-MedLine.d153.s7	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d153.s7	lower	33	37	O	lower	wer	ower	JJR	False
DDI-MedLine.d153.s7	limit	39	43	O	limit	mit	imit	NN	False
DDI-MedLine.d153.s7	of	45	46	O	of	of	of	IN	False
DDI-MedLine.d153.s7	quantification	48	61	O	quantification	ion	tion	NN	False
DDI-MedLine.d153.s7	(	63	63	O	(	(	(	(	False
DDI-MedLine.d153.s7	LLOQ	64	67	O	LLOQ	LOQ	LLOQ	NN	brand
DDI-MedLine.d153.s7	)	68	68	O	)	)	)	)	False
DDI-MedLine.d153.s7	in	70	71	O	in	in	in	IN	False
DDI-MedLine.d153.s7	human	73	77	O	human	man	uman	NN	False
DDI-MedLine.d153.s7	plasma	79	84	O	plasma	sma	asma	NN	False
DDI-MedLine.d153.s7	were	86	89	O	were	ere	were	VBD	False
DDI-MedLine.d153.s7	0.05	91	94	O	0.05	.05	0.05	CD	False
DDI-MedLine.d153.s7	and	96	98	O	and	and	and	CC	False
DDI-MedLine.d153.s7	0.2	100	102	O	0.2	0.2	0.2	CD	False
DDI-MedLine.d153.s7	ng/mL	104	108	O	ng/mL	/mL	g/mL	NN	False
DDI-MedLine.d153.s7	,	109	109	O	,	,	,	,	False
DDI-MedLine.d153.s7	respectively	111	122	O	respectively	ely	vely	RB	False
DDI-MedLine.d153.s7	.	123	123	O	.	.	.	.	False

DDI-MedLine.d153.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d153.s8	method	4	9	O	method	hod	thod	NN	False
DDI-MedLine.d153.s8	was	11	13	O	was	was	was	VBD	False
DDI-MedLine.d153.s8	proved	15	20	O	proved	ved	oved	VBN	False
DDI-MedLine.d153.s8	to	22	23	O	to	to	to	TO	False
DDI-MedLine.d153.s8	be	25	26	O	be	be	be	VB	False
DDI-MedLine.d153.s8	rapid	28	32	O	rapid	pid	apid	JJ	False
DDI-MedLine.d153.s8	,	33	33	O	,	,	,	,	False
DDI-MedLine.d153.s8	sensitive	35	43	O	sensitive	ive	tive	JJ	False
DDI-MedLine.d153.s8	,	44	44	O	,	,	,	,	False
DDI-MedLine.d153.s8	specific	46	53	O	specific	fic	ific	JJ	False
DDI-MedLine.d153.s8	,	54	54	O	,	,	,	,	False
DDI-MedLine.d153.s8	accurate	56	63	O	accurate	ate	rate	NN	False
DDI-MedLine.d153.s8	and	65	67	O	and	and	and	CC	False
DDI-MedLine.d153.s8	reproducible	69	80	O	reproducible	ble	ible	JJ	False
DDI-MedLine.d153.s8	and	82	84	O	and	and	and	CC	False
DDI-MedLine.d153.s8	has	86	88	O	has	has	has	VBZ	False
DDI-MedLine.d153.s8	been	90	93	O	been	een	been	VBN	False
DDI-MedLine.d153.s8	successfully	95	106	O	successfully	lly	ully	RB	False
DDI-MedLine.d153.s8	applied	108	114	O	applied	ied	lied	VBN	False
DDI-MedLine.d153.s8	to	116	117	O	to	to	to	TO	False
DDI-MedLine.d153.s8	a	119	119	O	a	a	a	DT	False
DDI-MedLine.d153.s8	pharmacokinetic	121	135	O	pharmacokinetic	tic	etic	JJ	False
DDI-MedLine.d153.s8	study	137	141	O	study	udy	tudy	NN	False
DDI-MedLine.d153.s8	of	143	144	O	of	of	of	IN	False
DDI-MedLine.d153.s8	propiverine	146	156	B-drug	propiverine	ine	rine	NN	drug
DDI-MedLine.d153.s8	hydrochloride	158	170	I-drug	hydrochloride	ide	ride	NN	False
DDI-MedLine.d153.s8	sustained	172	180	O	sustained	ned	ined	VBN	False
DDI-MedLine.d153.s8	release	182	188	O	release	ase	ease	NN	False
DDI-MedLine.d153.s8	capsules	190	197	O	capsules	les	ules	NNS	False
DDI-MedLine.d153.s8	(	199	199	O	(	(	(	(	False
DDI-MedLine.d153.s8	the	200	202	O	the	the	the	DT	False
DDI-MedLine.d153.s8	30	204	205	O	30	30	30	CD	False
DDI-MedLine.d153.s8	mg	207	208	O	mg	mg	mg	NN	False
DDI-MedLine.d153.s8	dose	210	213	O	dose	ose	dose	NN	False
DDI-MedLine.d153.s8	in	215	216	O	in	in	in	IN	False
DDI-MedLine.d153.s8	this	218	221	O	this	his	this	DT	False

DDI-MedLine.d148.s0	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d148.s0	circadian	2	10	O	circadian	ian	dian	NN	False
DDI-MedLine.d148.s0	clock	12	16	O	clock	ock	lock	NN	False
DDI-MedLine.d148.s0	in	18	19	O	in	in	in	IN	False
DDI-MedLine.d148.s0	hippocampus	21	31	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d148.s0	is	33	34	O	is	is	is	VBZ	False
DDI-MedLine.d148.s0	regulated	36	44	O	regulated	ted	ated	VBN	False
DDI-MedLine.d148.s0	by	46	47	O	by	by	by	IN	False
DDI-MedLine.d148.s0	interaction	49	59	O	interaction	ion	tion	NN	False
DDI-MedLine.d148.s0	between	61	67	O	between	een	ween	IN	False
DDI-MedLine.d148.s0	oligophrenin-1	69	82	O	oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s0	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d148.s0	Rev-erb	88	94	O	Rev-erb	erb	-erb	NN	False
DDI-MedLine.d148.s0	.	97	97	O	.	.	.	.	False
DDI-MedLine.d148.s0	Oligophrenin-1	100	113	O	Oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s0	regulates	115	123	O	regulates	tes	ates	NNS	False
DDI-MedLine.d148.s0	dendritic	125	133	O	dendritic	tic	itic	JJ	False
DDI-MedLine.d148.s0	spine	135	139	O	spine	ine	pine	NN	drug
DDI-MedLine.d148.s0	morphology	141	150	O	morphology	ogy	logy	NN	False
DDI-MedLine.d148.s0	in	152	153	O	in	in	in	IN	False
DDI-MedLine.d148.s0	the	155	157	O	the	the	the	DT	False
DDI-MedLine.d148.s0	brain	159	163	O	brain	ain	rain	NN	False
DDI-MedLine.d148.s0	.	164	164	O	.	.	.	.	False

DDI-MedLine.d148.s1	Mutations	0	8	O	Mutations	ons	ions	NNS	False
DDI-MedLine.d148.s1	in	10	11	O	in	in	in	IN	False
DDI-MedLine.d148.s1	the	13	15	O	the	the	the	DT	False
DDI-MedLine.d148.s1	oligophrenin-1	17	30	O	oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s1	gene	32	35	O	gene	ene	gene	NN	False
DDI-MedLine.d148.s1	(	37	37	O	(	(	(	(	False
DDI-MedLine.d148.s1	OPHN1	38	42	O	OPHN1	HN1	PHN1	NN	brand
DDI-MedLine.d148.s1	)	43	43	O	)	)	)	)	False
DDI-MedLine.d148.s1	cause	45	49	O	cause	use	ause	NN	False
DDI-MedLine.d148.s1	intellectual	51	62	O	intellectual	ual	tual	JJ	False
DDI-MedLine.d148.s1	disability	64	73	O	disability	ity	lity	NN	False
DDI-MedLine.d148.s1	.	74	74	O	.	.	.	.	False

DDI-MedLine.d148.s2	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d148.s2	discovered	3	12	O	discovered	red	ered	VBN	False
DDI-MedLine.d148.s2	a	14	14	O	a	a	a	DT	False
DDI-MedLine.d148.s2	previously	16	25	O	previously	sly	usly	RB	False
DDI-MedLine.d148.s2	unknown	27	33	O	unknown	own	nown	JJ	False
DDI-MedLine.d148.s2	partner	35	41	O	partner	ner	tner	NN	False
DDI-MedLine.d148.s2	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d148.s2	oligophrenin-1	46	59	O	oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s2	,	60	60	O	,	,	,	,	False
DDI-MedLine.d148.s2	Rev-erb	62	68	O	Rev-erb	erb	-erb	NN	False
DDI-MedLine.d148.s2	,	71	71	O	,	,	,	,	False
DDI-MedLine.d148.s2	a	73	73	O	a	a	a	DT	False
DDI-MedLine.d148.s2	nuclear	75	81	O	nuclear	ear	lear	JJ	False
DDI-MedLine.d148.s2	receptor	83	90	O	receptor	tor	ptor	NN	False
DDI-MedLine.d148.s2	that	92	95	O	that	hat	that	IN	False
DDI-MedLine.d148.s2	represses	97	105	O	represses	ses	sses	NNS	False
DDI-MedLine.d148.s2	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d148.s2	transcription	111	123	O	transcription	ion	tion	NN	False
DDI-MedLine.d148.s2	of	125	126	O	of	of	of	IN	False
DDI-MedLine.d148.s2	circadian	128	136	O	circadian	ian	dian	NN	False
DDI-MedLine.d148.s2	oscillators	138	148	O	oscillators	ors	tors	NNS	False
DDI-MedLine.d148.s2	.	149	149	O	.	.	.	.	False

DDI-MedLine.d148.s3	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d148.s3	found	3	7	O	found	und	ound	NN	False
DDI-MedLine.d148.s3	that	9	12	O	that	hat	that	IN	False
DDI-MedLine.d148.s3	oligophrenin-1	14	27	O	oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s3	interacts	29	37	O	interacts	cts	acts	NNS	False
DDI-MedLine.d148.s3	with	39	42	O	with	ith	with	IN	False
DDI-MedLine.d148.s3	Rev-erb	44	50	O	Rev-erb	erb	-erb	NN	False
DDI-MedLine.d148.s3	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d148.s3	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d148.s3	mouse	61	65	O	mouse	use	ouse	NN	False
DDI-MedLine.d148.s3	brain	67	71	O	brain	ain	rain	NN	False
DDI-MedLine.d148.s3	,	72	72	O	,	,	,	,	False
DDI-MedLine.d148.s3	causing	74	80	O	causing	ing	sing	VBG	False
DDI-MedLine.d148.s3	it	82	83	O	it	it	it	PRP	False
DDI-MedLine.d148.s3	to	85	86	O	to	to	to	TO	False
DDI-MedLine.d148.s3	locate	88	93	O	locate	ate	cate	NN	False
DDI-MedLine.d148.s3	to	95	96	O	to	to	to	TO	False
DDI-MedLine.d148.s3	dendrites	98	106	O	dendrites	tes	ites	NNS	False
DDI-MedLine.d148.s3	,	107	107	O	,	,	,	,	False
DDI-MedLine.d148.s3	reducing	109	116	O	reducing	ing	cing	VBG	False
DDI-MedLine.d148.s3	its	118	120	O	its	its	its	PRP$	False
DDI-MedLine.d148.s3	repressor	122	130	O	repressor	sor	ssor	NN	False
DDI-MedLine.d148.s3	activity	132	139	O	activity	ity	vity	NN	False
DDI-MedLine.d148.s3	and	141	143	O	and	and	and	CC	False
DDI-MedLine.d148.s3	protecting	145	154	O	protecting	ing	ting	VBG	False
DDI-MedLine.d148.s3	it	156	157	O	it	it	it	PRP	False
DDI-MedLine.d148.s3	from	159	162	O	from	rom	from	IN	False
DDI-MedLine.d148.s3	degradation	164	174	O	degradation	ion	tion	NN	False
DDI-MedLine.d148.s3	.	175	175	O	.	.	.	.	False

DDI-MedLine.d148.s4	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d148.s4	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d148.s4	indicate	12	19	O	indicate	ate	cate	NN	False
DDI-MedLine.d148.s4	the	21	23	O	the	the	the	DT	False
DDI-MedLine.d148.s4	presence	25	32	O	presence	nce	ence	NN	False
DDI-MedLine.d148.s4	of	34	35	O	of	of	of	IN	False
DDI-MedLine.d148.s4	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d148.s4	circadian	39	47	O	circadian	ian	dian	NN	False
DDI-MedLine.d148.s4	oscillator	49	58	O	oscillator	tor	ator	NN	False
DDI-MedLine.d148.s4	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d148.s4	the	63	65	O	the	the	the	DT	False
DDI-MedLine.d148.s4	hippocampus	67	77	O	hippocampus	pus	mpus	NN	False
DDI-MedLine.d148.s4	,	78	78	O	,	,	,	,	False
DDI-MedLine.d148.s4	involving	80	88	O	involving	ing	ving	VBG	False
DDI-MedLine.d148.s4	the	90	92	O	the	the	the	DT	False
DDI-MedLine.d148.s4	clock	94	98	O	clock	ock	lock	NN	False
DDI-MedLine.d148.s4	gene	100	103	O	gene	ene	gene	NN	False
DDI-MedLine.d148.s4	Bmal1	105	109	O	Bmal1	al1	mal1	NN	False
DDI-MedLine.d148.s4	(	111	111	O	(	(	(	(	False
DDI-MedLine.d148.s4	also	112	115	O	also	lso	also	RB	False
DDI-MedLine.d148.s4	known	117	121	O	known	own	nown	VBN	False
DDI-MedLine.d148.s4	as	123	124	O	as	as	as	IN	False
DDI-MedLine.d148.s4	Arntl	126	130	O	Arntl	ntl	rntl	NN	False
DDI-MedLine.d148.s4	)	131	131	O	)	)	)	)	False
DDI-MedLine.d148.s4	,	132	132	O	,	,	,	,	False
DDI-MedLine.d148.s4	that	134	137	O	that	hat	that	IN	False
DDI-MedLine.d148.s4	is	139	140	O	is	is	is	VBZ	False
DDI-MedLine.d148.s4	modulated	142	150	O	modulated	ted	ated	VBN	False
DDI-MedLine.d148.s4	by	152	153	O	by	by	by	IN	False
DDI-MedLine.d148.s4	Rev-erb	155	161	O	Rev-erb	erb	-erb	NN	False
DDI-MedLine.d148.s4	and	165	167	O	and	and	and	CC	False
DDI-MedLine.d148.s4	requires	169	176	O	requires	res	ires	VBZ	False
DDI-MedLine.d148.s4	oligophrenin-1	178	191	O	oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s4	for	193	195	O	for	for	for	IN	False
DDI-MedLine.d148.s4	normal	197	202	O	normal	mal	rmal	JJ	False
DDI-MedLine.d148.s4	oscillation	204	214	O	oscillation	ion	tion	NN	False
DDI-MedLine.d148.s4	.	215	215	O	.	.	.	.	False

DDI-MedLine.d148.s5	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d148.s5	also	3	6	O	also	lso	also	RB	False
DDI-MedLine.d148.s5	found	8	12	O	found	und	ound	NN	False
DDI-MedLine.d148.s5	that	14	17	O	that	hat	that	IN	False
DDI-MedLine.d148.s5	synaptic	19	26	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d148.s5	activity	28	35	O	activity	ity	vity	NN	False
DDI-MedLine.d148.s5	induced	37	43	O	induced	ced	uced	JJ	False
DDI-MedLine.d148.s5	Rev-erb	45	51	O	Rev-erb	erb	-erb	NN	False
DDI-MedLine.d148.s5	localization	55	66	O	localization	ion	tion	NN	False
DDI-MedLine.d148.s5	to	68	69	O	to	to	to	TO	False
DDI-MedLine.d148.s5	dendrites	71	79	O	dendrites	tes	ites	NNS	False
DDI-MedLine.d148.s5	and	81	83	O	and	and	and	CC	False
DDI-MedLine.d148.s5	spines	85	90	O	spines	nes	ines	NNS	group
DDI-MedLine.d148.s5	,	91	91	O	,	,	,	,	False
DDI-MedLine.d148.s5	a	93	93	O	a	a	a	DT	False
DDI-MedLine.d148.s5	process	95	101	O	process	ess	cess	NN	False
DDI-MedLine.d148.s5	that	103	106	O	that	hat	that	IN	False
DDI-MedLine.d148.s5	is	108	109	O	is	is	is	VBZ	False
DDI-MedLine.d148.s5	mediated	111	118	O	mediated	ted	ated	VBN	False
DDI-MedLine.d148.s5	by	120	121	O	by	by	by	IN	False
DDI-MedLine.d148.s5	AMPA	123	126	O	AMPA	MPA	AMPA	NN	brand
DDI-MedLine.d148.s5	receptor	128	135	O	receptor	tor	ptor	NN	False
DDI-MedLine.d148.s5	activation	137	146	O	activation	ion	tion	NN	False
DDI-MedLine.d148.s5	and	148	150	O	and	and	and	CC	False
DDI-MedLine.d148.s5	requires	152	159	O	requires	res	ires	VBZ	False
DDI-MedLine.d148.s5	oligophrenin-1	161	174	O	oligophrenin-1	n-1	in-1	NN	False
DDI-MedLine.d148.s5	.	175	175	O	.	.	.	.	False

DDI-MedLine.d148.s6	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d148.s6	data	4	7	O	data	ata	data	NNS	False
DDI-MedLine.d148.s6	reveal	9	14	O	reveal	eal	veal	NN	False
DDI-MedLine.d148.s6	new	16	18	O	new	new	new	JJ	False
DDI-MedLine.d148.s6	interactions	20	31	O	interactions	ons	ions	NNS	False
DDI-MedLine.d148.s6	between	33	39	O	between	een	ween	IN	False
DDI-MedLine.d148.s6	synaptic	41	48	O	synaptic	tic	ptic	JJ	False
DDI-MedLine.d148.s6	activity	50	57	O	activity	ity	vity	NN	False
DDI-MedLine.d148.s6	and	59	61	O	and	and	and	CC	False
DDI-MedLine.d148.s6	circadian	63	71	O	circadian	ian	dian	NN	False
DDI-MedLine.d148.s6	oscillators	73	83	O	oscillators	ors	tors	NNS	False
DDI-MedLine.d148.s6	,	84	84	O	,	,	,	,	False
DDI-MedLine.d148.s6	and	86	88	O	and	and	and	CC	False
DDI-MedLine.d148.s6	delineate	90	98	O	delineate	ate	eate	NN	False
DDI-MedLine.d148.s6	a	100	100	O	a	a	a	DT	False
DDI-MedLine.d148.s6	new	102	104	O	new	new	new	JJ	False
DDI-MedLine.d148.s6	means	106	110	O	means	ans	eans	NNS	False
DDI-MedLine.d148.s6	of	112	113	O	of	of	of	IN	False
DDI-MedLine.d148.s6	communication	115	127	O	communication	ion	tion	NN	False
DDI-MedLine.d148.s6	between	129	135	O	between	een	ween	IN	False
DDI-MedLine.d148.s6	nucleus	137	143	O	nucleus	eus	leus	NN	False
DDI-MedLine.d148.s6	and	145	147	O	and	and	and	CC	False
DDI-MedLine.d148.s6	synapse	149	155	O	synapse	pse	apse	NN	False
DDI-MedLine.d148.s6	that	157	160	O	that	hat	that	IN	False
DDI-MedLine.d148.s6	may	162	164	O	may	may	may	MD	False
DDI-MedLine.d148.s6	provide	166	172	O	provide	ide	vide	NN	False
DDI-MedLine.d148.s6	insight	174	180	O	insight	ght	ight	NN	False
DDI-MedLine.d148.s6	into	182	185	O	into	nto	into	IN	False
DDI-MedLine.d148.s6	normal	187	192	O	normal	mal	rmal	JJ	False
DDI-MedLine.d148.s6	plasticity	194	203	O	plasticity	ity	city	NN	False
DDI-MedLine.d148.s6	and	205	207	O	and	and	and	CC	False
DDI-MedLine.d148.s6	the	209	211	O	the	the	the	DT	False
DDI-MedLine.d148.s6	etiology	213	220	O	etiology	ogy	logy	NN	False
DDI-MedLine.d148.s6	of	222	223	O	of	of	of	IN	False
DDI-MedLine.d148.s6	intellectual	225	236	O	intellectual	ual	tual	JJ	False
DDI-MedLine.d148.s6	disability	238	247	O	disability	ity	lity	NN	False
DDI-MedLine.d148.s6	.	248	248	O	.	.	.	.	False

DDI-MedLine.d167.s0	Opportunities	0	12	O	Opportunities	ies	ties	NNS	False
DDI-MedLine.d167.s0	and	14	16	O	and	and	and	CC	False
DDI-MedLine.d167.s0	challenges	18	27	O	challenges	ges	nges	NNS	False
DDI-MedLine.d167.s0	in	29	30	O	in	in	in	IN	False
DDI-MedLine.d167.s0	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d167.s0	development	36	46	O	development	ent	ment	NN	False
DDI-MedLine.d167.s0	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d167.s0	experimental	51	62	O	experimental	tal	ntal	NN	False
DDI-MedLine.d167.s0	drug	64	67	O	drug	rug	drug	NN	False
DDI-MedLine.d167.s0	combinations	69	80	O	combinations	ons	ions	NNS	False
DDI-MedLine.d167.s0	for	82	84	O	for	for	for	IN	False
DDI-MedLine.d167.s0	cancer	86	91	O	cancer	cer	ncer	NN	False
DDI-MedLine.d167.s0	.	92	92	O	.	.	.	.	False

DDI-MedLine.d167.s1	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d167.s1	is	3	4	O	is	is	is	VBZ	False
DDI-MedLine.d167.s1	becoming	6	13	O	becoming	ing	ming	VBG	False
DDI-MedLine.d167.s1	increasingly	15	26	O	increasingly	gly	ngly	RB	False
DDI-MedLine.d167.s1	evident	28	34	O	evident	ent	dent	NN	False
DDI-MedLine.d167.s1	that	36	39	O	that	hat	that	IN	False
DDI-MedLine.d167.s1	cancers	41	47	O	cancers	ers	cers	NNS	False
DDI-MedLine.d167.s1	are	49	51	O	are	are	are	VBP	False
DDI-MedLine.d167.s1	dependent	53	61	O	dependent	ent	dent	NN	False
DDI-MedLine.d167.s1	on	63	64	O	on	on	on	IN	False
DDI-MedLine.d167.s1	a	66	66	O	a	a	a	DT	False
DDI-MedLine.d167.s1	number	68	73	O	number	ber	mber	NN	False
DDI-MedLine.d167.s1	of	75	76	O	of	of	of	IN	False
DDI-MedLine.d167.s1	altered	78	84	O	altered	red	ered	VBN	False
DDI-MedLine.d167.s1	molecular	86	94	O	molecular	lar	ular	NN	False
DDI-MedLine.d167.s1	pathways	96	103	O	pathways	ays	ways	NNS	False
DDI-MedLine.d167.s1	and	105	107	O	and	and	and	CC	False
DDI-MedLine.d167.s1	can	109	111	O	can	can	can	MD	False
DDI-MedLine.d167.s1	develop	113	119	O	develop	lop	elop	VB	False
DDI-MedLine.d167.s1	diverse	121	127	O	diverse	rse	erse	NN	False
DDI-MedLine.d167.s1	mechanisms	129	138	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d167.s1	of	140	141	O	of	of	of	IN	False
DDI-MedLine.d167.s1	resistance	143	152	O	resistance	nce	ance	NN	False
DDI-MedLine.d167.s1	to	154	155	O	to	to	to	TO	False
DDI-MedLine.d167.s1	therapy	157	163	O	therapy	apy	rapy	NN	False
DDI-MedLine.d167.s1	with	165	168	O	with	ith	with	IN	False
DDI-MedLine.d167.s1	single	170	175	O	single	gle	ngle	JJ	False
DDI-MedLine.d167.s1	agents	177	182	O	agents	nts	ents	NNS	False
DDI-MedLine.d167.s1	.	183	183	O	.	.	.	.	False

DDI-MedLine.d167.s2	Therefore	0	8	O	Therefore	ore	fore	RB	False
DDI-MedLine.d167.s2	,	9	9	O	,	,	,	,	False
DDI-MedLine.d167.s2	combination	11	21	O	combination	ion	tion	NN	False
DDI-MedLine.d167.s2	regimens	23	30	O	regimens	ens	mens	NNS	False
DDI-MedLine.d167.s2	may	32	34	O	may	may	may	MD	False
DDI-MedLine.d167.s2	provide	36	42	O	provide	ide	vide	NN	False
DDI-MedLine.d167.s2	the	44	46	O	the	the	the	DT	False
DDI-MedLine.d167.s2	best	48	51	O	best	est	best	JJS	False
DDI-MedLine.d167.s2	hope	53	56	O	hope	ope	hope	NN	False
DDI-MedLine.d167.s2	for	58	60	O	for	for	for	IN	False
DDI-MedLine.d167.s2	effective	62	70	O	effective	ive	tive	JJ	False
DDI-MedLine.d167.s2	therapies	72	80	O	therapies	ies	pies	NNS	False
DDI-MedLine.d167.s2	with	82	85	O	with	ith	with	IN	False
DDI-MedLine.d167.s2	durable	87	93	O	durable	ble	able	JJ	False
DDI-MedLine.d167.s2	effects	95	101	O	effects	cts	ects	NNS	False
DDI-MedLine.d167.s2	.	102	102	O	.	.	.	.	False

DDI-MedLine.d167.s3	Despite	0	6	O	Despite	ite	pite	IN	False
DDI-MedLine.d167.s3	preclinical	8	18	O	preclinical	cal	ical	JJ	False
DDI-MedLine.d167.s3	data	20	23	O	data	ata	data	NNS	False
DDI-MedLine.d167.s3	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d167.s3	support	28	34	O	support	ort	port	NN	False
DDI-MedLine.d167.s3	this	36	39	O	this	his	this	DT	False
DDI-MedLine.d167.s3	notion	41	46	O	notion	ion	tion	NN	False
DDI-MedLine.d167.s3	,	47	47	O	,	,	,	,	False
DDI-MedLine.d167.s3	there	49	53	O	there	ere	here	RB	False
DDI-MedLine.d167.s3	are	55	57	O	are	are	are	VBP	False
DDI-MedLine.d167.s3	many	59	62	O	many	any	many	JJ	False
DDI-MedLine.d167.s3	challenges	64	73	O	challenges	ges	nges	NNS	False
DDI-MedLine.d167.s3	to	75	76	O	to	to	to	TO	False
DDI-MedLine.d167.s3	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d167.s3	development	82	92	O	development	ent	ment	NN	False
DDI-MedLine.d167.s3	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d167.s3	targeted	97	104	O	targeted	ted	eted	VBN	False
DDI-MedLine.d167.s3	combinations	106	117	O	combinations	ons	ions	NNS	False
DDI-MedLine.d167.s3	including	119	127	O	including	ing	ding	VBG	False
DDI-MedLine.d167.s3	scientific	129	138	O	scientific	fic	ific	JJ	False
DDI-MedLine.d167.s3	,	139	139	O	,	,	,	,	False
DDI-MedLine.d167.s3	economic	141	148	O	economic	mic	omic	JJ	False
DDI-MedLine.d167.s3	,	149	149	O	,	,	,	,	False
DDI-MedLine.d167.s3	legal	151	155	O	legal	gal	egal	JJ	False
DDI-MedLine.d167.s3	,	156	156	O	,	,	,	,	False
DDI-MedLine.d167.s3	and	158	160	O	and	and	and	CC	False
DDI-MedLine.d167.s3	regulatory	162	171	O	regulatory	ory	tory	JJ	False
DDI-MedLine.d167.s3	barriers	173	180	O	barriers	ers	iers	NNS	False
DDI-MedLine.d167.s3	.	181	181	O	.	.	.	.	False

DDI-MedLine.d167.s4	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d167.s4	discussion	2	11	O	discussion	ion	sion	NN	False
DDI-MedLine.d167.s4	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d167.s4	these	16	20	O	these	ese	hese	DT	False
DDI-MedLine.d167.s4	challenges	22	31	O	challenges	ges	nges	NNS	False
DDI-MedLine.d167.s4	and	33	35	O	and	and	and	CC	False
DDI-MedLine.d167.s4	identification	37	50	O	identification	ion	tion	NN	False
DDI-MedLine.d167.s4	of	52	53	O	of	of	of	IN	False
DDI-MedLine.d167.s4	models	55	60	O	models	els	dels	NNS	False
DDI-MedLine.d167.s4	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d167.s4	best	66	69	O	best	est	best	JJS	False
DDI-MedLine.d167.s4	practices	71	79	O	practices	ces	ices	NNS	False
DDI-MedLine.d167.s4	are	81	83	O	are	are	are	VBP	False
DDI-MedLine.d167.s4	presented	85	93	O	presented	ted	nted	VBN	False
DDI-MedLine.d167.s4	with	95	98	O	with	ith	with	IN	False
DDI-MedLine.d167.s4	intent	100	105	O	intent	ent	tent	NN	False
DDI-MedLine.d167.s4	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d167.s4	aiding	110	115	O	aiding	ing	ding	VBG	False
DDI-MedLine.d167.s4	the	117	119	O	the	the	the	DT	False
DDI-MedLine.d167.s4	research	121	128	O	research	rch	arch	NN	False
DDI-MedLine.d167.s4	community	130	138	O	community	ity	nity	NN	False
DDI-MedLine.d167.s4	in	140	141	O	in	in	in	IN	False
DDI-MedLine.d167.s4	addressing	143	152	O	addressing	ing	sing	VBG	False
DDI-MedLine.d167.s4	real	154	157	O	real	eal	real	JJ	False
DDI-MedLine.d167.s4	and	159	161	O	and	and	and	CC	False
DDI-MedLine.d167.s4	perceived	163	171	O	perceived	ved	ived	VBN	False
DDI-MedLine.d167.s4	barriers	173	180	O	barriers	ers	iers	NNS	False
DDI-MedLine.d167.s4	to	182	183	O	to	to	to	TO	False
DDI-MedLine.d167.s4	the	185	187	O	the	the	the	DT	False
DDI-MedLine.d167.s4	development	189	199	O	development	ent	ment	NN	False
DDI-MedLine.d167.s4	of	201	202	O	of	of	of	IN	False
DDI-MedLine.d167.s4	combination	204	214	O	combination	ion	tion	NN	False
DDI-MedLine.d167.s4	therapies	216	224	O	therapies	ies	pies	NNS	False
DDI-MedLine.d167.s4	for	226	228	O	for	for	for	IN	False
DDI-MedLine.d167.s4	cancer	230	235	O	cancer	cer	ncer	NN	False
DDI-MedLine.d167.s4	.	236	236	O	.	.	.	.	False

DDI-MedLine.d165.s0	CPP-ACP	0	6	B-drug_n	CPP-ACP	ACP	-ACP	NN	brand
DDI-MedLine.d165.s0	complex	8	14	I-drug_n	complex	lex	plex	JJ	False
DDI-MedLine.d165.s0	as	16	17	O	as	as	as	IN	False
DDI-MedLine.d165.s0	a	19	19	O	a	a	a	DT	False
DDI-MedLine.d165.s0	new	21	23	O	new	new	new	JJ	False
DDI-MedLine.d165.s0	adjunctive	25	34	O	adjunctive	ive	tive	JJ	False
DDI-MedLine.d165.s0	agent	36	40	O	agent	ent	gent	NN	False
DDI-MedLine.d165.s0	for	42	44	O	for	for	for	IN	False
DDI-MedLine.d165.s0	remineralisation	46	61	O	remineralisation	ion	tion	NN	False
DDI-MedLine.d165.s0	:	62	62	O	:	:	:	:	False
DDI-MedLine.d165.s0	a	64	64	O	a	a	a	DT	False
DDI-MedLine.d165.s0	review	66	71	O	review	iew	view	NN	False
DDI-MedLine.d165.s0	.	72	72	O	.	.	.	.	False

DDI-MedLine.d165.s1	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d165.s1	addition	3	10	O	addition	ion	tion	NN	False
DDI-MedLine.d165.s1	to	12	13	O	to	to	to	TO	False
DDI-MedLine.d165.s1	regular	15	21	O	regular	lar	ular	JJ	False
DDI-MedLine.d165.s1	professional	23	34	O	professional	nal	onal	JJ	False
DDI-MedLine.d165.s1	oral	36	39	O	oral	ral	oral	JJ	False
DDI-MedLine.d165.s1	hygiene	41	47	O	hygiene	ene	iene	NN	False
DDI-MedLine.d165.s1	visits	49	54	O	visits	its	sits	NNS	False
DDI-MedLine.d165.s1	and	56	58	O	and	and	and	CC	False
DDI-MedLine.d165.s1	the	60	62	O	the	the	the	DT	False
DDI-MedLine.d165.s1	application	64	74	O	application	ion	tion	NN	False
DDI-MedLine.d165.s1	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d165.s1	appropriate	79	89	O	appropriate	ate	iate	NN	False
DDI-MedLine.d165.s1	preventive	91	100	O	preventive	ive	tive	NN	False
DDI-MedLine.d165.s1	medications	102	112	O	medications	ons	ions	NNS	False
DDI-MedLine.d165.s1	,	113	113	O	,	,	,	,	False
DDI-MedLine.d165.s1	successful	115	124	O	successful	ful	sful	JJ	False
DDI-MedLine.d165.s1	preventive	126	135	O	preventive	ive	tive	NN	False
DDI-MedLine.d165.s1	strategies	137	146	O	strategies	ies	gies	NNS	False
DDI-MedLine.d165.s1	involve	148	154	O	involve	lve	olve	NN	False
DDI-MedLine.d165.s1	oral	156	159	O	oral	ral	oral	JJ	False
DDI-MedLine.d165.s1	health	161	166	O	health	lth	alth	NN	False
DDI-MedLine.d165.s1	promotion	168	176	O	promotion	ion	tion	NN	False
DDI-MedLine.d165.s1	,	177	177	O	,	,	,	,	False
DDI-MedLine.d165.s1	patient	179	185	O	patient	ent	ient	NN	False
DDI-MedLine.d165.s1	education	187	195	O	education	ion	tion	NN	False
DDI-MedLine.d165.s1	and	197	199	O	and	and	and	CC	False
DDI-MedLine.d165.s1	patient	201	207	O	patient	ent	ient	NN	False
DDI-MedLine.d165.s1	compliance	209	218	O	compliance	nce	ance	NN	False
DDI-MedLine.d165.s1	.	219	219	O	.	.	.	.	False

DDI-MedLine.d165.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d165.s2	Casein	4	9	B-drug_n	Casein	ein	sein	NN	False
DDI-MedLine.d165.s2	phosphopeptide-amorphous	11	34	I-drug_n	phosphopeptide-amorphous	ous	hous	JJ	False
DDI-MedLine.d165.s2	calcium	36	42	I-drug_n	calcium	ium	cium	NN	drug
DDI-MedLine.d165.s2	phosphate	44	52	I-drug_n	phosphate	ate	hate	NN	False
DDI-MedLine.d165.s2	(	54	54	I-drug_n	(	(	(	(	False
DDI-MedLine.d165.s2	CPP-ACP	55	61	I-drug_n	CPP-ACP	ACP	-ACP	NN	brand
DDI-MedLine.d165.s2	)	62	62	I-drug_n	)	)	)	)	False
DDI-MedLine.d165.s2	complex	64	70	I-drug_n	complex	lex	plex	JJ	False
DDI-MedLine.d165.s2	has	72	74	O	has	has	has	VBZ	False
DDI-MedLine.d165.s2	been	76	79	O	been	een	been	VBN	False
DDI-MedLine.d165.s2	shown	81	85	O	shown	own	hown	VBN	False
DDI-MedLine.d165.s2	to	87	88	O	to	to	to	TO	False
DDI-MedLine.d165.s2	remineralise	90	101	O	remineralise	ise	lise	NN	False
DDI-MedLine.d165.s2	tooth	103	107	O	tooth	oth	ooth	NN	False
DDI-MedLine.d165.s2	surfaces	109	116	O	surfaces	ces	aces	NNS	False
DDI-MedLine.d165.s2	in	118	119	O	in	in	in	IN	False
DDI-MedLine.d165.s2	situ	121	124	O	situ	itu	situ	NN	False
DDI-MedLine.d165.s2	when	126	129	O	when	hen	when	WRB	False
DDI-MedLine.d165.s2	delivered	131	139	O	delivered	red	ered	VBN	False
DDI-MedLine.d165.s2	in	141	142	O	in	in	in	IN	False
DDI-MedLine.d165.s2	oral	144	147	O	oral	ral	oral	JJ	False
DDI-MedLine.d165.s2	care	149	152	O	care	are	care	NN	False
DDI-MedLine.d165.s2	products	154	161	O	products	cts	ucts	NNS	False
DDI-MedLine.d165.s2	.	162	162	O	.	.	.	.	False

DDI-MedLine.d165.s3	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d165.s3	complex	5	11	O	complex	lex	plex	JJ	False
DDI-MedLine.d165.s3	has	13	15	O	has	has	has	VBZ	False
DDI-MedLine.d165.s3	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d165.s3	unique	19	24	O	unique	que	ique	NN	False
DDI-MedLine.d165.s3	ability	26	32	O	ability	ity	lity	NN	False
DDI-MedLine.d165.s3	to	34	35	O	to	to	to	TO	False
DDI-MedLine.d165.s3	deliver	37	43	O	deliver	ver	iver	NN	False
DDI-MedLine.d165.s3	bio-available	45	57	O	bio-available	ble	able	JJ	False
DDI-MedLine.d165.s3	calcium	59	65	B-drug	calcium	ium	cium	NN	drug
DDI-MedLine.d165.s3	and	67	69	O	and	and	and	CC	False
DDI-MedLine.d165.s3	phosphate	71	79	B-drug	phosphate	ate	hate	NN	False
DDI-MedLine.d165.s3	when	81	84	O	when	hen	when	WRB	False
DDI-MedLine.d165.s3	they	86	89	O	they	hey	they	PRP	False
DDI-MedLine.d165.s3	are	91	93	O	are	are	are	VBP	False
DDI-MedLine.d165.s3	needed	95	100	O	needed	ded	eded	VBN	False
DDI-MedLine.d165.s3	most	102	105	O	most	ost	most	JJS	False
DDI-MedLine.d165.s3	.	106	106	O	.	.	.	.	False

DDI-MedLine.d165.s4	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d165.s4	effectiveness	4	16	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d165.s4	of	18	19	O	of	of	of	IN	False
DDI-MedLine.d165.s4	casein	21	26	O	casein	ein	sein	NN	False
DDI-MedLine.d165.s4	derivatives	28	38	O	derivatives	ves	ives	NNS	False
DDI-MedLine.d165.s4	,	39	39	O	,	,	,	,	False
DDI-MedLine.d165.s4	specifically	41	52	O	specifically	lly	ally	RB	False
DDI-MedLine.d165.s4	CCP-ACP	54	60	B-drug_n	CCP-ACP	ACP	-ACP	NN	brand
DDI-MedLine.d165.s4	,	61	61	O	,	,	,	,	False
DDI-MedLine.d165.s4	in	63	64	O	in	in	in	IN	False
DDI-MedLine.d165.s4	caries	66	71	O	caries	ies	ries	NNS	False
DDI-MedLine.d165.s4	prevention	73	82	O	prevention	ion	tion	NN	False
DDI-MedLine.d165.s4	and	84	86	O	and	and	and	CC	False
DDI-MedLine.d165.s4	lesion	88	93	O	lesion	ion	sion	NN	False
DDI-MedLine.d165.s4	reversal	95	102	O	reversal	sal	rsal	NN	False
DDI-MedLine.d165.s4	has	104	106	O	has	has	has	VBZ	False
DDI-MedLine.d165.s4	been	108	111	O	been	een	been	VBN	False
DDI-MedLine.d165.s4	supported	113	121	O	supported	ted	rted	VBN	False
DDI-MedLine.d165.s4	by	123	124	O	by	by	by	IN	False
DDI-MedLine.d165.s4	many	126	129	O	many	any	many	JJ	False
DDI-MedLine.d165.s4	controlled	131	140	O	controlled	led	lled	VBN	False
DDI-MedLine.d165.s4	clinical	142	149	O	clinical	cal	ical	JJ	False
DDI-MedLine.d165.s4	studies	151	157	O	studies	ies	dies	NNS	False
DDI-MedLine.d165.s4	.	158	158	O	.	.	.	.	False

DDI-MedLine.d165.s5	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d165.s5	review	5	10	O	review	iew	view	NN	False
DDI-MedLine.d165.s5	summarises	12	21	O	summarises	ses	ises	NNS	False
DDI-MedLine.d165.s5	the	23	25	O	the	the	the	DT	False
DDI-MedLine.d165.s5	research	27	34	O	research	rch	arch	NN	False
DDI-MedLine.d165.s5	on	36	37	O	on	on	on	IN	False
DDI-MedLine.d165.s5	Casein	39	44	B-drug_n	Casein	ein	sein	NN	False
DDI-MedLine.d165.s5	phosphopeptide-amorphous	46	69	I-drug_n	phosphopeptide-amorphous	ous	hous	JJ	False
DDI-MedLine.d165.s5	calcium	71	77	I-drug_n	calcium	ium	cium	NN	drug
DDI-MedLine.d165.s5	phosphate	79	87	I-drug_n	phosphate	ate	hate	NN	False
DDI-MedLine.d165.s5	complex	89	95	I-drug_n	complex	lex	plex	JJ	False
DDI-MedLine.d165.s5	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d165.s5	provides	101	108	O	provides	des	ides	VBZ	group
DDI-MedLine.d165.s5	information	110	120	O	information	ion	tion	NN	False
DDI-MedLine.d165.s5	related	122	128	O	related	ted	ated	JJ	False
DDI-MedLine.d165.s5	to	130	131	O	to	to	to	TO	False
DDI-MedLine.d165.s5	its	133	135	O	its	its	its	PRP$	False
DDI-MedLine.d165.s5	benefit	137	143	O	benefit	fit	efit	NN	False
DDI-MedLine.d165.s5	in	145	146	O	in	in	in	IN	False
DDI-MedLine.d165.s5	dentistry	148	156	O	dentistry	try	stry	NN	False
DDI-MedLine.d165.s5	.	157	157	O	.	.	.	.	False

DDI-MedLine.d165.s6	Further	0	6	O	Further	her	ther	RB	False
DDI-MedLine.d165.s6	research	8	15	O	research	rch	arch	NN	False
DDI-MedLine.d165.s6	is	17	18	O	is	is	is	VBZ	False
DDI-MedLine.d165.s6	required	20	27	O	required	red	ired	VBN	False
DDI-MedLine.d165.s6	to	29	30	O	to	to	to	TO	False
DDI-MedLine.d165.s6	provide	32	38	O	provide	ide	vide	NN	False
DDI-MedLine.d165.s6	a	40	40	O	a	a	a	DT	False
DDI-MedLine.d165.s6	scientifically	42	55	O	scientifically	lly	ally	RB	False
DDI-MedLine.d165.s6	supported	57	65	O	supported	ted	rted	VBN	False
DDI-MedLine.d165.s6	recommendation	67	80	O	recommendation	ion	tion	NN	False
DDI-MedLine.d165.s6	for	82	84	O	for	for	for	IN	False
DDI-MedLine.d165.s6	other	86	90	O	other	her	ther	JJ	False
DDI-MedLine.d165.s6	clinical	92	99	O	clinical	cal	ical	JJ	False
DDI-MedLine.d165.s6	applications	101	112	O	applications	ons	ions	NNS	False
DDI-MedLine.d165.s6	.	113	113	O	.	.	.	.	False

DDI-MedLine.d171.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d171.s0	Infections	1	10	O	Infections	ons	ions	NNS	False
DDI-MedLine.d171.s0	with	12	15	O	with	ith	with	IN	False
DDI-MedLine.d171.s0	human	17	21	O	human	man	uman	NN	False
DDI-MedLine.d171.s0	immunodeficiency	23	38	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d171.s0	viruses	40	46	O	viruses	ses	uses	NNS	False
DDI-MedLine.d171.s0	.	47	47	O	.	.	.	.	False
DDI-MedLine.d171.s0	Part	49	52	O	Part	art	Part	NN	False
DDI-MedLine.d171.s0	II	54	55	O	II	II	II	NN	brand
DDI-MedLine.d171.s0	:	56	56	O	:	:	:	:	False
DDI-MedLine.d171.s0	Antiretroviral	58	71	B-group	Antiretroviral	ral	iral	JJ	False
DDI-MedLine.d171.s0	drugs	73	77	I-group	drugs	ugs	rugs	NNS	False
DDI-MedLine.d171.s0	,	78	78	O	,	,	,	,	False
DDI-MedLine.d171.s0	therapeutic	80	90	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d171.s0	options	92	98	O	options	ons	ions	NNS	False
DDI-MedLine.d171.s0	,	99	99	O	,	,	,	,	False
DDI-MedLine.d171.s0	and	101	103	O	and	and	and	CC	False
DDI-MedLine.d171.s0	diagnostics	105	115	O	diagnostics	ics	tics	NNS	False
DDI-MedLine.d171.s0	]	116	116	O	]	]	]	NN	False
DDI-MedLine.d171.s0	.	117	117	O	.	.	.	.	False

DDI-MedLine.d171.s1	Infections	0	9	O	Infections	ons	ions	NNS	False
DDI-MedLine.d171.s1	with	11	14	O	with	ith	with	IN	False
DDI-MedLine.d171.s1	the	16	18	O	the	the	the	DT	False
DDI-MedLine.d171.s1	human	20	24	O	human	man	uman	NN	False
DDI-MedLine.d171.s1	immunodeficiency	26	41	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d171.s1	virus	43	47	O	virus	rus	irus	NN	False
DDI-MedLine.d171.s1	1	49	49	O	1	1	1	CD	False
DDI-MedLine.d171.s1	(	51	51	O	(	(	(	(	False
DDI-MedLine.d171.s1	HIV-	52	55	O	HIV-	IV-	HIV-	NN	brand
DDI-MedLine.d171.s1	1	57	57	O	1	1	1	CD	False
DDI-MedLine.d171.s1	)	58	58	O	)	)	)	)	False
DDI-MedLine.d171.s1	lead	60	63	O	lead	ead	lead	NN	False
DDI-MedLine.d171.s1	to	65	66	O	to	to	to	TO	False
DDI-MedLine.d171.s1	the	68	70	O	the	the	the	DT	False
DDI-MedLine.d171.s1	acquired	72	79	O	acquired	red	ired	VBN	False
DDI-MedLine.d171.s1	immunodeficiency	81	96	O	immunodeficiency	ncy	ency	NN	False
DDI-MedLine.d171.s1	syndrome	98	105	O	syndrome	ome	rome	NN	False
DDI-MedLine.d171.s1	(	107	107	O	(	(	(	(	False
DDI-MedLine.d171.s1	AIDS	108	111	O	AIDS	IDS	AIDS	NN	brand
DDI-MedLine.d171.s1	)	112	112	O	)	)	)	)	False
DDI-MedLine.d171.s1	,	113	113	O	,	,	,	,	False
DDI-MedLine.d171.s1	resulting	115	123	O	resulting	ing	ting	VBG	False
DDI-MedLine.d171.s1	in	125	126	O	in	in	in	IN	False
DDI-MedLine.d171.s1	the	128	130	O	the	the	the	DT	False
DDI-MedLine.d171.s1	establishment	132	144	O	establishment	ent	ment	NN	False
DDI-MedLine.d171.s1	of	146	147	O	of	of	of	IN	False
DDI-MedLine.d171.s1	a	149	149	O	a	a	a	DT	False
DDI-MedLine.d171.s1	wide	151	154	O	wide	ide	wide	JJ	False
DDI-MedLine.d171.s1	range	156	160	O	range	nge	ange	NN	False
DDI-MedLine.d171.s1	of	162	163	O	of	of	of	IN	False
DDI-MedLine.d171.s1	severe	165	170	O	severe	ere	vere	JJ	False
DDI-MedLine.d171.s1	opportunistic	172	184	O	opportunistic	tic	stic	JJ	False
DDI-MedLine.d171.s1	infections	186	195	O	infections	ons	ions	NNS	False
DDI-MedLine.d171.s1	.	196	196	O	.	.	.	.	False

DDI-MedLine.d171.s2	Since	0	4	O	Since	nce	ince	IN	False
DDI-MedLine.d171.s2	the	6	8	O	the	the	the	DT	False
DDI-MedLine.d171.s2	introduction	10	21	O	introduction	ion	tion	NN	False
DDI-MedLine.d171.s2	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d171.s2	the	26	28	O	the	the	the	DT	False
DDI-MedLine.d171.s2	highly	30	35	B-group	highly	hly	ghly	RB	False
DDI-MedLine.d171.s2	active	37	42	I-group	active	ive	tive	JJ	False
DDI-MedLine.d171.s2	antiretroviral	44	57	I-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d171.s2	therapy	59	65	O	therapy	apy	rapy	NN	False
DDI-MedLine.d171.s2	(	67	67	O	(	(	(	(	False
DDI-MedLine.d171.s2	HAART	68	72	O	HAART	ART	AART	NN	brand
DDI-MedLine.d171.s2	)	73	73	O	)	)	)	)	False
DDI-MedLine.d171.s2	into	75	78	O	into	nto	into	IN	False
DDI-MedLine.d171.s2	the	80	82	O	the	the	the	DT	False
DDI-MedLine.d171.s2	treatment	84	92	O	treatment	ent	ment	NN	False
DDI-MedLine.d171.s2	of	94	95	O	of	of	of	IN	False
DDI-MedLine.d171.s2	HIV	97	99	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d171.s2	infections	101	110	O	infections	ons	ions	NNS	False
DDI-MedLine.d171.s2	,	111	111	O	,	,	,	,	False
DDI-MedLine.d171.s2	in	113	114	O	in	in	in	IN	False
DDI-MedLine.d171.s2	many	116	119	O	many	any	many	JJ	False
DDI-MedLine.d171.s2	cases	121	125	O	cases	ses	ases	NNS	False
DDI-MedLine.d171.s2	a	127	127	O	a	a	a	DT	False
DDI-MedLine.d171.s2	delayed	129	135	O	delayed	yed	ayed	NNS	False
DDI-MedLine.d171.s2	appearance	137	146	O	appearance	nce	ance	NN	False
DDI-MedLine.d171.s2	of	148	149	O	of	of	of	IN	False
DDI-MedLine.d171.s2	AIDS-defining	151	163	O	AIDS-defining	ing	ning	NN	False
DDI-MedLine.d171.s2	diseases	165	172	O	diseases	ses	ases	NNS	False
DDI-MedLine.d171.s2	is	174	175	O	is	is	is	VBZ	False
DDI-MedLine.d171.s2	achievable	177	186	O	achievable	ble	able	JJ	False
DDI-MedLine.d171.s2	.	187	187	O	.	.	.	.	False

DDI-MedLine.d171.s3	Life	0	3	O	Life	ife	Life	NN	False
DDI-MedLine.d171.s3	expectancy	5	14	O	expectancy	ncy	ancy	NN	False
DDI-MedLine.d171.s3	of	16	17	O	of	of	of	IN	False
DDI-MedLine.d171.s3	antiretrovirally	19	34	O	antiretrovirally	lly	ally	RB	False
DDI-MedLine.d171.s3	treated	36	42	O	treated	ted	ated	VBN	False
DDI-MedLine.d171.s3	HIV-infected	44	55	O	HIV-infected	ted	cted	JJ	False
DDI-MedLine.d171.s3	people	57	62	O	people	ple	ople	NNS	False
DDI-MedLine.d171.s3	applying	64	71	O	applying	ing	ying	VBG	False
DDI-MedLine.d171.s3	HAART	73	77	O	HAART	ART	AART	NN	brand
DDI-MedLine.d171.s3	could	79	83	O	could	uld	ould	MD	False
DDI-MedLine.d171.s3	be	85	86	O	be	be	be	VB	False
DDI-MedLine.d171.s3	considerably	88	99	O	considerably	bly	ably	RB	False
DDI-MedLine.d171.s3	extended	101	108	O	extended	ded	nded	VBN	False
DDI-MedLine.d171.s3	and	110	112	O	and	and	and	CC	False
DDI-MedLine.d171.s3	now	114	116	O	now	now	now	RB	False
DDI-MedLine.d171.s3	resembles	118	126	O	resembles	les	bles	NNS	False
DDI-MedLine.d171.s3	that	128	131	O	that	hat	that	IN	False
DDI-MedLine.d171.s3	of	133	134	O	of	of	of	IN	False
DDI-MedLine.d171.s3	several	136	142	O	several	ral	eral	JJ	False
DDI-MedLine.d171.s3	other	144	148	O	other	her	ther	JJ	False
DDI-MedLine.d171.s3	chronic	150	156	O	chronic	nic	onic	NN	False
DDI-MedLine.d171.s3	diseases	158	165	O	diseases	ses	ases	NNS	False
DDI-MedLine.d171.s3	.	166	166	O	.	.	.	.	False

DDI-MedLine.d171.s4	For	0	2	O	For	For	For	IN	False
DDI-MedLine.d171.s4	the	4	6	O	the	the	the	DT	False
DDI-MedLine.d171.s4	initial	8	14	O	initial	ial	tial	JJ	False
DDI-MedLine.d171.s4	treatment	16	24	O	treatment	ent	ment	NN	False
DDI-MedLine.d171.s4	of	26	27	O	of	of	of	IN	False
DDI-MedLine.d171.s4	HIV-1	29	33	O	HIV-1	V-1	IV-1	NN	brand
DDI-MedLine.d171.s4	infection	35	43	O	infection	ion	tion	NN	False
DDI-MedLine.d171.s4	,	44	44	O	,	,	,	,	False
DDI-MedLine.d171.s4	an	46	47	O	an	an	an	DT	False
DDI-MedLine.d171.s4	adjunction	49	58	O	adjunction	ion	tion	NN	False
DDI-MedLine.d171.s4	with	60	63	O	with	ith	with	IN	False
DDI-MedLine.d171.s4	three	65	69	O	three	ree	hree	CD	False
DDI-MedLine.d171.s4	antiretroviral	71	84	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d171.s4	agents	86	91	I-group	agents	nts	ents	NNS	False
DDI-MedLine.d171.s4	is	93	94	O	is	is	is	VBZ	False
DDI-MedLine.d171.s4	generally	96	104	O	generally	lly	ally	RB	False
DDI-MedLine.d171.s4	used	106	109	O	used	sed	used	VBN	False
DDI-MedLine.d171.s4	.	110	110	O	.	.	.	.	False

DDI-MedLine.d171.s5	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d171.s5	most	3	6	O	most	ost	most	JJS	False
DDI-MedLine.d171.s5	cases	8	12	O	cases	ses	ases	NNS	False
DDI-MedLine.d171.s5	,	13	13	O	,	,	,	,	False
DDI-MedLine.d171.s5	the	15	17	O	the	the	the	DT	False
DDI-MedLine.d171.s5	application	19	29	O	application	ion	tion	NN	False
DDI-MedLine.d171.s5	of	31	32	O	of	of	of	IN	False
DDI-MedLine.d171.s5	two	34	36	O	two	two	two	CD	False
DDI-MedLine.d171.s5	nucleoside	38	47	B-group	nucleoside	ide	side	RB	False
DDI-MedLine.d171.s5	or	49	50	I-group	or	or	or	CC	False
DDI-MedLine.d171.s5	nucleotide	52	61	I-group	nucleotide	ide	tide	RB	False
DDI-MedLine.d171.s5	reverse	63	69	I-group	reverse	rse	erse	NN	False
DDI-MedLine.d171.s5	transcriptase	71	83	I-group	transcriptase	ase	tase	NN	False
DDI-MedLine.d171.s5	inhibitors	85	94	I-group	inhibitors	ors	tors	NNS	False
DDI-MedLine.d171.s5	(	96	96	O	(	(	(	(	False
DDI-MedLine.d171.s5	NRTI	97	100	B-group	NRTI	RTI	NRTI	NN	brand
DDI-MedLine.d171.s5	)	101	101	O	)	)	)	)	False
DDI-MedLine.d171.s5	together	103	110	O	together	her	ther	RB	False
DDI-MedLine.d171.s5	with	112	115	O	with	ith	with	IN	False
DDI-MedLine.d171.s5	a	117	117	O	a	a	a	DT	False
DDI-MedLine.d171.s5	non-nucleoside	119	132	B-group	non-nucleoside	ide	side	JJ	False
DDI-MedLine.d171.s5	reverse	134	140	I-group	reverse	rse	erse	NN	False
DDI-MedLine.d171.s5	transcriptase	142	154	I-group	transcriptase	ase	tase	NN	False
DDI-MedLine.d171.s5	inhibitor	156	164	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d171.s5	(	166	166	O	(	(	(	(	False
DDI-MedLine.d171.s5	NNRTI	167	171	B-group	NNRTI	RTI	NRTI	NN	brand
DDI-MedLine.d171.s5	)	172	172	O	)	)	)	)	False
DDI-MedLine.d171.s5	,	173	173	O	,	,	,	,	False
DDI-MedLine.d171.s5	a	175	175	O	a	a	a	DT	False
DDI-MedLine.d171.s5	protease	177	184	B-group	protease	ase	ease	NN	False
DDI-MedLine.d171.s5	inhibitor	186	194	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d171.s5	(	196	196	O	(	(	(	(	False
DDI-MedLine.d171.s5	PI	197	198	B-group	PI	PI	PI	NN	brand
DDI-MedLine.d171.s5	)	199	199	O	)	)	)	)	False
DDI-MedLine.d171.s5	or	201	202	O	or	or	or	CC	False
DDI-MedLine.d171.s5	an	204	205	O	an	an	an	DT	False
DDI-MedLine.d171.s5	integrase	207	215	B-group	integrase	ase	rase	NN	False
DDI-MedLine.d171.s5	inhibitor	217	225	I-group	inhibitor	tor	itor	NN	False
DDI-MedLine.d171.s5	(	227	227	O	(	(	(	(	False
DDI-MedLine.d171.s5	II	228	229	B-group	II	II	II	NN	brand
DDI-MedLine.d171.s5	)	230	230	O	)	)	)	)	False
DDI-MedLine.d171.s5	is	232	233	O	is	is	is	VBZ	False
DDI-MedLine.d171.s5	recommended	235	245	O	recommended	ded	nded	VBN	False
DDI-MedLine.d171.s5	.	246	246	O	.	.	.	.	False

DDI-MedLine.d171.s6	Before	0	5	O	Before	ore	fore	IN	False
DDI-MedLine.d171.s6	and	7	9	O	and	and	and	CC	False
DDI-MedLine.d171.s6	during	11	16	O	during	ing	ring	IN	False
DDI-MedLine.d171.s6	antiretroviral	18	31	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d171.s6	treatment	33	41	O	treatment	ent	ment	NN	False
DDI-MedLine.d171.s6	,	42	42	O	,	,	,	,	False
DDI-MedLine.d171.s6	antiretroviral	44	57	B-group	antiretroviral	ral	iral	JJ	False
DDI-MedLine.d171.s6	drug	59	62	O	drug	rug	drug	NN	False
DDI-MedLine.d171.s6	resistances	64	74	O	resistances	ces	nces	NNS	False
DDI-MedLine.d171.s6	,	75	75	O	,	,	,	,	False
DDI-MedLine.d171.s6	individual	77	86	O	individual	ual	dual	JJ	False
DDI-MedLine.d171.s6	tolerance	88	96	O	tolerance	nce	ance	NN	False
DDI-MedLine.d171.s6	profiles	98	105	O	profiles	les	iles	NNS	False
DDI-MedLine.d171.s6	and	107	109	O	and	and	and	CC	False
DDI-MedLine.d171.s6	the	111	113	O	the	the	the	DT	False
DDI-MedLine.d171.s6	needs	115	119	O	needs	eds	eeds	NNS	False
DDI-MedLine.d171.s6	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d171.s6	the	124	126	O	the	the	the	DT	False
DDI-MedLine.d171.s6	individual	128	137	O	individual	ual	dual	JJ	False
DDI-MedLine.d171.s6	patient	139	145	O	patient	ent	ient	NN	False
DDI-MedLine.d171.s6	,	146	146	O	,	,	,	,	False
DDI-MedLine.d171.s6	as	148	149	O	as	as	as	IN	False
DDI-MedLine.d171.s6	well	151	154	O	well	ell	well	RB	False
DDI-MedLine.d171.s6	as	156	157	O	as	as	as	IN	False
DDI-MedLine.d171.s6	several	159	165	O	several	ral	eral	JJ	False
DDI-MedLine.d171.s6	interactions	167	178	O	interactions	ons	ions	NNS	False
DDI-MedLine.d171.s6	with	180	183	O	with	ith	with	IN	False
DDI-MedLine.d171.s6	other	185	189	O	other	her	ther	JJ	False
DDI-MedLine.d171.s6	drugs	191	195	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d171.s6	have	197	200	O	have	ave	have	VB	False
DDI-MedLine.d171.s6	to	202	203	O	to	to	to	TO	False
DDI-MedLine.d171.s6	be	205	206	O	be	be	be	VB	False
DDI-MedLine.d171.s6	considered	208	217	O	considered	red	ered	VBN	False
DDI-MedLine.d171.s6	.	218	218	O	.	.	.	.	False

DDI-MedLine.d171.s7	Diagnostics	0	10	O	Diagnostics	ics	tics	NNS	False
DDI-MedLine.d171.s7	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d171.s7	HIV	15	17	O	HIV	HIV	HIV	NN	brand
DDI-MedLine.d171.s7	infection	19	27	O	infection	ion	tion	NN	False
DDI-MedLine.d171.s7	is	29	30	O	is	is	is	VBZ	False
DDI-MedLine.d171.s7	based	32	36	O	based	sed	ased	VBN	False
DDI-MedLine.d171.s7	upon	38	41	O	upon	pon	upon	IN	False
DDI-MedLine.d171.s7	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d171.s7	proof	47	51	O	proof	oof	roof	NN	False
DDI-MedLine.d171.s7	of	53	54	O	of	of	of	IN	False
DDI-MedLine.d171.s7	specific	56	63	O	specific	fic	ific	JJ	False
DDI-MedLine.d171.s7	antibodies	65	74	O	antibodies	ies	dies	NNS	False
DDI-MedLine.d171.s7	.	75	75	O	.	.	.	.	False

DDI-MedLine.d160.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d160.s0	Summary	1	7	O	Summary	ary	mary	JJ	False
DDI-MedLine.d160.s0	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d160.s0	revised	12	18	O	revised	sed	ised	VBN	False
DDI-MedLine.d160.s0	contents	20	27	O	contents	nts	ents	NNS	False
DDI-MedLine.d160.s0	of	29	30	O	of	of	of	IN	False
DDI-MedLine.d160.s0	medical	32	38	O	medical	cal	ical	JJ	False
DDI-MedLine.d160.s0	standards	40	48	O	standards	rds	ards	NNS	False
DDI-MedLine.d160.s0	of	50	51	O	of	of	of	IN	False
DDI-MedLine.d160.s0	preparation	53	63	O	preparation	ion	tion	NN	False
DDI-MedLine.d160.s0	recorded	65	72	O	recorded	ded	rded	VBN	False
DDI-MedLine.d160.s0	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d160.s0	Chinese	77	83	O	Chinese	ese	nese	JJ	False
DDI-MedLine.d160.s0	Pharmacopeia	85	96	O	Pharmacopeia	eia	peia	NN	False
DDI-MedLine.d160.s0	(	98	98	O	(	(	(	(	False
DDI-MedLine.d160.s0	I	99	99	O	I	I	I	PRP	brand
DDI-MedLine.d160.s0	division	101	108	O	division	ion	sion	NN	False
DDI-MedLine.d160.s0	,	109	109	O	,	,	,	,	False
DDI-MedLine.d160.s0	2010	111	114	O	2010	010	2010	CD	False
DDI-MedLine.d160.s0	edition	116	122	O	edition	ion	tion	NN	False
DDI-MedLine.d160.s0	)	123	123	O	)	)	)	)	False
DDI-MedLine.d160.s0	]	124	124	O	]	]	]	NN	False
DDI-MedLine.d160.s0	.	125	125	O	.	.	.	.	False

DDI-MedLine.d160.s1	China	0	4	O	China	ina	hina	NNP	False
DDI-MedLine.d160.s1	pharmacopoeia	6	18	O	pharmacopoeia	eia	oeia	NN	False
DDI-MedLine.d160.s1	is	20	21	O	is	is	is	VBZ	False
DDI-MedLine.d160.s1	a	23	23	O	a	a	a	DT	False
DDI-MedLine.d160.s1	civil	25	29	O	civil	vil	ivil	JJ	False
DDI-MedLine.d160.s1	code	31	34	O	code	ode	code	NN	False
DDI-MedLine.d160.s1	which	36	40	O	which	ich	hich	WDT	False
DDI-MedLine.d160.s1	is	42	43	O	is	is	is	VBZ	False
DDI-MedLine.d160.s1	to	45	46	O	to	to	to	TO	False
DDI-MedLine.d160.s1	ensure	48	53	O	ensure	ure	sure	VB	False
DDI-MedLine.d160.s1	pharmaceutical	55	68	O	pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d160.s1	quality	70	76	O	quality	ity	lity	NN	False
DDI-MedLine.d160.s1	and	78	80	O	and	and	and	CC	False
DDI-MedLine.d160.s1	protect	82	88	O	protect	ect	tect	NN	False
DDI-MedLine.d160.s1	people	90	95	O	people	ple	ople	NNS	False
DDI-MedLine.d160.s1	's	96	97	O	's	's	's	POS	False
DDI-MedLine.d160.s1	drug	99	102	O	drug	rug	drug	NN	False
DDI-MedLine.d160.s1	safety	104	109	O	safety	ety	fety	NN	False
DDI-MedLine.d160.s1	and	111	113	O	and	and	and	CC	False
DDI-MedLine.d160.s1	effectiveness	115	127	O	effectiveness	ess	ness	NN	False
DDI-MedLine.d160.s1	.	128	128	O	.	.	.	.	False

DDI-MedLine.d160.s2	Drug	0	3	O	Drug	rug	Drug	NN	False
DDI-MedLine.d160.s2	standards	5	13	O	standards	rds	ards	NNS	False
DDI-MedLine.d160.s2	are	15	17	O	are	are	are	VBP	False
DDI-MedLine.d160.s2	consist	19	25	O	consist	ist	sist	NN	False
DDI-MedLine.d160.s2	of	27	28	O	of	of	of	IN	False
DDI-MedLine.d160.s2	two	30	32	O	two	two	two	CD	False
DDI-MedLine.d160.s2	parts	34	38	O	parts	rts	arts	NNS	False
DDI-MedLine.d160.s2	,	39	39	O	,	,	,	,	False
DDI-MedLine.d160.s2	the	41	43	O	the	the	the	DT	False
DDI-MedLine.d160.s2	pharmaceutical	45	58	O	pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d160.s2	standards	60	68	O	standards	rds	ards	NNS	False
DDI-MedLine.d160.s2	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d160.s2	medical	74	80	O	medical	cal	ical	JJ	False
DDI-MedLine.d160.s2	standards	82	90	O	standards	rds	ards	NNS	False
DDI-MedLine.d160.s2	.	91	91	O	.	.	.	.	False

DDI-MedLine.d160.s3	Medical	0	6	O	Medical	cal	ical	JJ	False
DDI-MedLine.d160.s3	standards	8	16	O	standards	rds	ards	NNS	False
DDI-MedLine.d160.s3	include	18	24	O	include	ude	lude	NN	False
DDI-MedLine.d160.s3	four	26	29	O	four	our	four	CD	False
DDI-MedLine.d160.s3	contents	31	38	O	contents	nts	ents	NNS	False
DDI-MedLine.d160.s3	,	39	39	O	,	,	,	,	False
DDI-MedLine.d160.s3	such	41	44	O	such	uch	such	JJ	False
DDI-MedLine.d160.s3	as	46	47	O	as	as	as	IN	False
DDI-MedLine.d160.s3	prescription	49	60	O	prescription	ion	tion	NN	False
DDI-MedLine.d160.s3	,	61	61	O	,	,	,	,	False
DDI-MedLine.d160.s3	function	63	70	O	function	ion	tion	NN	False
DDI-MedLine.d160.s3	and	72	74	O	and	and	and	CC	False
DDI-MedLine.d160.s3	indications	76	86	O	indications	ons	ions	NNS	False
DDI-MedLine.d160.s3	,	87	87	O	,	,	,	,	False
DDI-MedLine.d160.s3	usage	89	93	O	usage	age	sage	NN	False
DDI-MedLine.d160.s3	and	95	97	O	and	and	and	CC	False
DDI-MedLine.d160.s3	dosage	99	104	O	dosage	age	sage	NN	False
DDI-MedLine.d160.s3	and	106	108	O	and	and	and	CC	False
DDI-MedLine.d160.s3	attentions	110	119	O	attentions	ons	ions	NNS	False
DDI-MedLine.d160.s3	.	120	120	O	.	.	.	.	False

DDI-MedLine.d160.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d160.s4	paper	5	9	O	paper	per	aper	NN	False
DDI-MedLine.d160.s4	summarized	11	20	O	summarized	zed	ized	VBN	False
DDI-MedLine.d160.s4	the	22	24	O	the	the	the	DT	False
DDI-MedLine.d160.s4	revised	26	32	O	revised	sed	ised	VBN	False
DDI-MedLine.d160.s4	contents	34	41	O	contents	nts	ents	NNS	False
DDI-MedLine.d160.s4	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d160.s4	medical	46	52	O	medical	cal	ical	JJ	False
DDI-MedLine.d160.s4	standards	54	62	O	standards	rds	ards	NNS	False
DDI-MedLine.d160.s4	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d160.s4	suggested	68	76	O	suggested	ted	sted	VBN	False
DDI-MedLine.d160.s4	some	78	81	O	some	ome	some	DT	False
DDI-MedLine.d160.s4	propositions	83	94	O	propositions	ons	ions	NNS	False
DDI-MedLine.d160.s4	.	95	95	O	.	.	.	.	False

DDI-MedLine.d175.s0	Unrecognized	0	11	O	Unrecognized	zed	ized	VBN	False
DDI-MedLine.d175.s0	fatalities	13	22	O	fatalities	ies	ties	NNS	False
DDI-MedLine.d175.s0	related	24	30	O	related	ted	ated	JJ	False
DDI-MedLine.d175.s0	to	32	33	O	to	to	to	TO	False
DDI-MedLine.d175.s0	colchicine	35	44	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s0	in	46	47	O	in	in	in	IN	False
DDI-MedLine.d175.s0	hospitalized	49	60	O	hospitalized	zed	ized	VBN	False
DDI-MedLine.d175.s0	patients	62	69	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s0	.	70	70	O	.	.	.	.	False

DDI-MedLine.d175.s1	Colchicine	0	9	B-drug	Colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s1	is	11	12	O	is	is	is	VBZ	False
DDI-MedLine.d175.s1	commonly	14	21	O	commonly	nly	only	RB	False
DDI-MedLine.d175.s1	used	23	26	O	used	sed	used	VBN	False
DDI-MedLine.d175.s1	for	28	30	O	for	for	for	IN	False
DDI-MedLine.d175.s1	the	32	34	O	the	the	the	DT	False
DDI-MedLine.d175.s1	treatment	36	44	O	treatment	ent	ment	NN	False
DDI-MedLine.d175.s1	of	46	47	O	of	of	of	IN	False
DDI-MedLine.d175.s1	gout	49	52	O	gout	out	gout	NN	False
DDI-MedLine.d175.s1	and	54	56	O	and	and	and	CC	False
DDI-MedLine.d175.s1	occasionally	58	69	O	occasionally	lly	ally	RB	False
DDI-MedLine.d175.s1	for	71	73	O	for	for	for	IN	False
DDI-MedLine.d175.s1	other	75	79	O	other	her	ther	JJ	False
DDI-MedLine.d175.s1	inflammatory	81	92	O	inflammatory	ory	tory	NN	False
DDI-MedLine.d175.s1	diseases	94	101	O	diseases	ses	ases	NNS	False
DDI-MedLine.d175.s1	.	102	102	O	.	.	.	.	False

DDI-MedLine.d175.s2	It	0	1	O	It	It	It	PRP	False
DDI-MedLine.d175.s2	has	3	5	O	has	has	has	VBZ	False
DDI-MedLine.d175.s2	a	7	7	O	a	a	a	DT	False
DDI-MedLine.d175.s2	narrow	9	14	O	narrow	row	rrow	NN	False
DDI-MedLine.d175.s2	therapeutic	16	26	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d175.s2	index	28	32	O	index	dex	ndex	NN	False
DDI-MedLine.d175.s2	and	34	36	O	and	and	and	CC	False
DDI-MedLine.d175.s2	the	38	40	O	the	the	the	DT	False
DDI-MedLine.d175.s2	potential	42	50	O	potential	ial	tial	JJ	False
DDI-MedLine.d175.s2	for	52	54	O	for	for	for	IN	False
DDI-MedLine.d175.s2	severe	56	61	O	severe	ere	vere	JJ	False
DDI-MedLine.d175.s2	or	63	64	O	or	or	or	CC	False
DDI-MedLine.d175.s2	fatal	66	70	O	fatal	tal	atal	NN	False
DDI-MedLine.d175.s2	toxicity	72	79	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s2	.	80	80	O	.	.	.	.	False

DDI-MedLine.d175.s3	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d175.s3	sought	3	8	O	sought	ght	ught	NN	False
DDI-MedLine.d175.s3	to	10	11	O	to	to	to	TO	False
DDI-MedLine.d175.s3	determine	13	21	O	determine	ine	mine	NN	drug
DDI-MedLine.d175.s3	(	23	23	O	(	(	(	(	False
DDI-MedLine.d175.s3	1	24	24	O	1	1	1	CD	False
DDI-MedLine.d175.s3	)	25	25	O	)	)	)	)	False
DDI-MedLine.d175.s3	the	27	29	O	the	the	the	DT	False
DDI-MedLine.d175.s3	frequency	31	39	O	frequency	ncy	ency	NN	False
DDI-MedLine.d175.s3	of	41	42	O	of	of	of	IN	False
DDI-MedLine.d175.s3	colchicine	44	53	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s3	toxicity	55	62	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s3	among	64	68	O	among	ong	mong	IN	False
DDI-MedLine.d175.s3	hospitalized	70	81	O	hospitalized	zed	ized	VBN	False
DDI-MedLine.d175.s3	patients	83	90	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s3	taking	92	97	O	taking	ing	king	VBG	False
DDI-MedLine.d175.s3	colchicine	99	108	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s3	who	110	112	O	who	who	who	WP	False
DDI-MedLine.d175.s3	died	114	117	O	died	ied	died	VBD	False
DDI-MedLine.d175.s3	during	119	124	O	during	ing	ring	IN	False
DDI-MedLine.d175.s3	an	126	127	O	an	an	an	DT	False
DDI-MedLine.d175.s3	admission	129	137	O	admission	ion	sion	NN	False
DDI-MedLine.d175.s3	,	138	138	O	,	,	,	,	False
DDI-MedLine.d175.s3	(	140	140	O	(	(	(	(	False
DDI-MedLine.d175.s3	2	141	141	O	2	2	2	CD	False
DDI-MedLine.d175.s3	)	142	142	O	)	)	)	)	False
DDI-MedLine.d175.s3	the	144	146	O	the	the	the	DT	False
DDI-MedLine.d175.s3	likelihood	148	157	O	likelihood	ood	hood	NN	False
DDI-MedLine.d175.s3	that	159	162	O	that	hat	that	IN	False
DDI-MedLine.d175.s3	colchicine	164	173	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s3	contributed	175	185	O	contributed	ted	uted	VBD	False
DDI-MedLine.d175.s3	to	187	188	O	to	to	to	TO	False
DDI-MedLine.d175.s3	death	190	194	O	death	ath	eath	NN	False
DDI-MedLine.d175.s3	,	195	195	O	,	,	,	,	False
DDI-MedLine.d175.s3	(	197	197	O	(	(	(	(	False
DDI-MedLine.d175.s3	3	198	198	O	3	3	3	CD	False
DDI-MedLine.d175.s3	)	199	199	O	)	)	)	)	False
DDI-MedLine.d175.s3	whether	201	207	O	whether	her	ther	IN	False
DDI-MedLine.d175.s3	patients	209	216	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s3	were	218	221	O	were	ere	were	VBD	False
DDI-MedLine.d175.s3	taking	223	228	O	taking	ing	king	VBG	False
DDI-MedLine.d175.s3	interacting	230	240	O	interacting	ing	ting	VBG	False
DDI-MedLine.d175.s3	medications	242	252	O	medications	ons	ions	NNS	False
DDI-MedLine.d175.s3	that	254	257	O	that	hat	that	IN	False
DDI-MedLine.d175.s3	could	259	263	O	could	uld	ould	MD	False
DDI-MedLine.d175.s3	have	265	268	O	have	ave	have	VB	False
DDI-MedLine.d175.s3	contributed	270	280	O	contributed	ted	uted	VBD	False
DDI-MedLine.d175.s3	to	282	283	O	to	to	to	TO	False
DDI-MedLine.d175.s3	toxicity	285	292	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s3	,	293	293	O	,	,	,	,	False
DDI-MedLine.d175.s3	and	295	297	O	and	and	and	CC	False
DDI-MedLine.d175.s3	(	299	299	O	(	(	(	(	False
DDI-MedLine.d175.s3	4	300	300	O	4	4	4	CD	False
DDI-MedLine.d175.s3	)	301	301	O	)	)	)	)	False
DDI-MedLine.d175.s3	whether	303	309	O	whether	her	ther	IN	False
DDI-MedLine.d175.s3	colchicine	311	320	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s3	dosing	322	327	O	dosing	ing	sing	VBG	False
DDI-MedLine.d175.s3	among	329	333	O	among	ong	mong	IN	False
DDI-MedLine.d175.s3	these	335	339	O	these	ese	hese	DT	False
DDI-MedLine.d175.s3	patients	341	348	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s3	adhered	350	356	O	adhered	red	ered	VBN	False
DDI-MedLine.d175.s3	to	358	359	O	to	to	to	TO	False
DDI-MedLine.d175.s3	established	361	371	O	established	hed	shed	VBN	False
DDI-MedLine.d175.s3	guidelines	373	382	O	guidelines	nes	ines	NNS	group
DDI-MedLine.d175.s3	.	383	383	O	.	.	.	.	False

DDI-MedLine.d175.s4	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d175.s4	conducted	3	11	O	conducted	ted	cted	VBN	False
DDI-MedLine.d175.s4	an	13	14	O	an	an	an	DT	False
DDI-MedLine.d175.s4	IRB-approved	16	27	O	IRB-approved	ved	oved	JJ	False
DDI-MedLine.d175.s4	,	28	28	O	,	,	,	,	False
DDI-MedLine.d175.s4	retrospective	30	42	O	retrospective	ive	tive	NN	False
DDI-MedLine.d175.s4	chart	44	48	O	chart	art	hart	NN	False
DDI-MedLine.d175.s4	review	50	55	O	review	iew	view	NN	False
DDI-MedLine.d175.s4	at	57	58	O	at	at	at	IN	False
DDI-MedLine.d175.s4	an	60	61	O	an	an	an	DT	False
DDI-MedLine.d175.s4	urban	63	67	O	urban	ban	rban	JJ	False
DDI-MedLine.d175.s4	,	68	68	O	,	,	,	,	False
DDI-MedLine.d175.s4	tertiary	70	77	O	tertiary	ary	iary	JJ	False
DDI-MedLine.d175.s4	care	79	82	O	care	are	care	NN	False
DDI-MedLine.d175.s4	,	83	83	O	,	,	,	,	False
DDI-MedLine.d175.s4	1228-bed	85	92	O	1228-bed	bed	-bed	JJ	False
DDI-MedLine.d175.s4	,	93	93	O	,	,	,	,	False
DDI-MedLine.d175.s4	university	95	104	O	university	ity	sity	NN	False
DDI-MedLine.d175.s4	hospital	106	113	O	hospital	tal	ital	NN	False
DDI-MedLine.d175.s4	.	114	114	O	.	.	.	.	False

DDI-MedLine.d175.s5	Subjects	0	7	O	Subjects	cts	ects	NNS	False
DDI-MedLine.d175.s5	included	9	16	O	included	ded	uded	VBD	False
DDI-MedLine.d175.s5	hospitalized	18	29	O	hospitalized	zed	ized	VBN	False
DDI-MedLine.d175.s5	patients	31	38	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s5	who	40	42	O	who	who	who	WP	False
DDI-MedLine.d175.s5	received	44	51	O	received	ved	ived	VBN	False
DDI-MedLine.d175.s5	colchicine	53	62	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s5	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d175.s5	died	68	71	O	died	ied	died	VBD	False
DDI-MedLine.d175.s5	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d175.s5	hospital	76	83	O	hospital	tal	ital	NN	False
DDI-MedLine.d175.s5	between	85	91	O	between	een	ween	IN	False
DDI-MedLine.d175.s5	1	93	93	O	1	1	1	CD	False
DDI-MedLine.d175.s5	January	95	101	O	January	ary	uary	NNP	False
DDI-MedLine.d175.s5	2000	103	106	O	2000	000	2000	CD	False
DDI-MedLine.d175.s5	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d175.s5	28	112	113	O	28	28	28	CD	False
DDI-MedLine.d175.s5	February	115	122	O	February	ary	uary	NNP	False
DDI-MedLine.d175.s5	2007	124	127	O	2007	007	2007	CD	False
DDI-MedLine.d175.s5	.	128	128	O	.	.	.	.	False

DDI-MedLine.d175.s6	We	0	1	O	We	We	We	PRP	False
DDI-MedLine.d175.s6	reviewed	3	10	O	reviewed	wed	ewed	VBN	False
DDI-MedLine.d175.s6	charts	12	17	O	charts	rts	arts	NNS	False
DDI-MedLine.d175.s6	for	19	21	O	for	for	for	IN	False
DDI-MedLine.d175.s6	signs	23	27	O	signs	gns	igns	NNS	False
DDI-MedLine.d175.s6	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d175.s6	symptoms	33	40	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d175.s6	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d175.s6	colchicine	45	54	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s6	toxicity	56	63	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s6	.	64	64	O	.	.	.	.	False

DDI-MedLine.d175.s7	An	0	1	O	An	An	An	DT	False
DDI-MedLine.d175.s7	expert	3	8	O	expert	ert	pert	NN	False
DDI-MedLine.d175.s7	panel	10	14	O	panel	nel	anel	NN	False
DDI-MedLine.d175.s7	reviewed	16	23	O	reviewed	wed	ewed	VBN	False
DDI-MedLine.d175.s7	each	25	28	O	each	ach	each	DT	False
DDI-MedLine.d175.s7	case	30	33	O	case	ase	case	NN	False
DDI-MedLine.d175.s7	and	35	37	O	and	and	and	CC	False
DDI-MedLine.d175.s7	classified	39	48	O	classified	ied	fied	VBN	False
DDI-MedLine.d175.s7	the	50	52	O	the	the	the	DT	False
DDI-MedLine.d175.s7	likelihood	54	63	O	likelihood	ood	hood	NN	False
DDI-MedLine.d175.s7	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d175.s7	colchicine	68	77	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s7	toxicity	79	86	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s7	,	87	87	O	,	,	,	,	False
DDI-MedLine.d175.s7	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d175.s7	likelihood	93	102	O	likelihood	ood	hood	NN	False
DDI-MedLine.d175.s7	of	104	105	O	of	of	of	IN	False
DDI-MedLine.d175.s7	a	107	107	O	a	a	a	DT	False
DDI-MedLine.d175.s7	causal	109	114	O	causal	sal	usal	NN	False
DDI-MedLine.d175.s7	role	116	119	O	role	ole	role	NN	False
DDI-MedLine.d175.s7	of	121	122	O	of	of	of	IN	False
DDI-MedLine.d175.s7	colchicine	124	133	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s7	in	135	136	O	in	in	in	IN	False
DDI-MedLine.d175.s7	the	138	140	O	the	the	the	DT	False
DDI-MedLine.d175.s7	death	142	146	O	death	ath	eath	NN	False
DDI-MedLine.d175.s7	using	148	152	O	using	ing	sing	VBG	False
DDI-MedLine.d175.s7	the	154	156	O	the	the	the	DT	False
DDI-MedLine.d175.s7	WHO	158	160	O	WHO	WHO	WHO	WP	brand
DDI-MedLine.d175.s7	classification	162	175	O	classification	ion	tion	NN	False
DDI-MedLine.d175.s7	system	177	182	O	system	tem	stem	NN	False
DDI-MedLine.d175.s7	,	183	183	O	,	,	,	,	False
DDI-MedLine.d175.s7	and	185	187	O	and	and	and	CC	False
DDI-MedLine.d175.s7	the	189	191	O	the	the	the	DT	False
DDI-MedLine.d175.s7	appropriateness	193	207	O	appropriateness	ess	ness	NN	False
DDI-MedLine.d175.s7	of	209	210	O	of	of	of	IN	False
DDI-MedLine.d175.s7	colchicine	212	221	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s7	dosing	223	228	O	dosing	ing	sing	VBG	False
DDI-MedLine.d175.s7	.	229	229	O	.	.	.	.	False

DDI-MedLine.d175.s8	Thirty-seven	0	11	O	Thirty-seven	ven	even	JJ	False
DDI-MedLine.d175.s8	hospitalized	13	24	O	hospitalized	zed	ized	VBN	False
DDI-MedLine.d175.s8	patients	26	33	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s8	who	35	37	O	who	who	who	WP	False
DDI-MedLine.d175.s8	died	39	42	O	died	ied	died	VBD	False
DDI-MedLine.d175.s8	during	44	49	O	during	ing	ring	IN	False
DDI-MedLine.d175.s8	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d175.s8	86-month	55	62	O	86-month	nth	onth	JJ	False
DDI-MedLine.d175.s8	study	64	68	O	study	udy	tudy	NN	False
DDI-MedLine.d175.s8	period	70	75	O	period	iod	riod	NN	False
DDI-MedLine.d175.s8	received	77	84	O	received	ved	ived	VBN	False
DDI-MedLine.d175.s8	colchicine	86	95	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s8	.	96	96	O	.	.	.	.	False

DDI-MedLine.d175.s9	Toxicity	0	7	O	Toxicity	ity	city	NN	False
DDI-MedLine.d175.s9	was	9	11	O	was	was	was	VBD	False
DDI-MedLine.d175.s9	unlikely	13	20	O	unlikely	ely	kely	JJ	False
DDI-MedLine.d175.s9	in	22	23	O	in	in	in	IN	False
DDI-MedLine.d175.s9	20/37	25	29	O	20/37	/37	0/37	CD	False
DDI-MedLine.d175.s9	,	30	30	O	,	,	,	,	False
DDI-MedLine.d175.s9	possible	32	39	O	possible	ble	ible	JJ	False
DDI-MedLine.d175.s9	in	41	42	O	in	in	in	IN	False
DDI-MedLine.d175.s9	8/37	44	47	O	8/37	/37	8/37	CD	False
DDI-MedLine.d175.s9	,	48	48	O	,	,	,	,	False
DDI-MedLine.d175.s9	likely	50	55	O	likely	ely	kely	JJ	False
DDI-MedLine.d175.s9	in	57	58	O	in	in	in	IN	False
DDI-MedLine.d175.s9	5/37	60	63	O	5/37	/37	5/37	CD	False
DDI-MedLine.d175.s9	,	64	64	O	,	,	,	,	False
DDI-MedLine.d175.s9	and	66	68	O	and	and	and	CC	False
DDI-MedLine.d175.s9	certain	70	76	O	certain	ain	tain	JJ	False
DDI-MedLine.d175.s9	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d175.s9	4/37	81	84	O	4/37	/37	4/37	CD	False
DDI-MedLine.d175.s9	.	85	85	O	.	.	.	.	False

DDI-MedLine.d175.s10	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d175.s10	contributing	2	13	O	contributing	ing	ting	VBG	False
DDI-MedLine.d175.s10	role	15	18	O	role	ole	role	NN	False
DDI-MedLine.d175.s10	for	20	22	O	for	for	for	IN	False
DDI-MedLine.d175.s10	colchicine	24	33	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s10	in	35	36	O	in	in	in	IN	False
DDI-MedLine.d175.s10	causing	38	44	O	causing	ing	sing	VBG	False
DDI-MedLine.d175.s10	death	46	50	O	death	ath	eath	NN	False
DDI-MedLine.d175.s10	was	52	54	O	was	was	was	VBD	False
DDI-MedLine.d175.s10	unlikely	56	63	O	unlikely	ely	kely	JJ	False
DDI-MedLine.d175.s10	in	65	66	O	in	in	in	IN	False
DDI-MedLine.d175.s10	24/37	68	72	O	24/37	/37	4/37	CD	False
DDI-MedLine.d175.s10	,	73	73	O	,	,	,	,	False
DDI-MedLine.d175.s10	possible	75	82	O	possible	ble	ible	JJ	False
DDI-MedLine.d175.s10	in	84	85	O	in	in	in	IN	False
DDI-MedLine.d175.s10	7/37	87	90	O	7/37	/37	7/37	CD	False
DDI-MedLine.d175.s10	,	91	91	O	,	,	,	,	False
DDI-MedLine.d175.s10	likely	93	98	O	likely	ely	kely	JJ	False
DDI-MedLine.d175.s10	in	100	101	O	in	in	in	IN	False
DDI-MedLine.d175.s10	3/37	103	106	O	3/37	/37	3/37	CD	False
DDI-MedLine.d175.s10	,	107	107	O	,	,	,	,	False
DDI-MedLine.d175.s10	and	109	111	O	and	and	and	CC	False
DDI-MedLine.d175.s10	certain	113	119	O	certain	ain	tain	JJ	False
DDI-MedLine.d175.s10	in	121	122	O	in	in	in	IN	False
DDI-MedLine.d175.s10	3/37	124	127	O	3/37	/37	3/37	CD	False
DDI-MedLine.d175.s10	.	128	128	O	.	.	.	.	False

DDI-MedLine.d175.s11	Colchicine	0	9	B-drug	Colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s11	doses	11	15	O	doses	ses	oses	NNS	False
DDI-MedLine.d175.s11	(	17	17	O	(	(	(	(	False
DDI-MedLine.d175.s11	based	18	22	O	based	sed	ased	VBN	False
DDI-MedLine.d175.s11	on	24	25	O	on	on	on	IN	False
DDI-MedLine.d175.s11	creatinine	27	36	O	creatinine	ine	nine	NN	drug
DDI-MedLine.d175.s11	clearance	38	46	O	clearance	nce	ance	NN	False
DDI-MedLine.d175.s11	)	47	47	O	)	)	)	)	False
DDI-MedLine.d175.s11	exceeded	49	56	O	exceeded	ded	eded	VBD	False
DDI-MedLine.d175.s11	the	58	60	O	the	the	the	DT	False
DDI-MedLine.d175.s11	accepted	62	69	O	accepted	ted	pted	JJ	False
DDI-MedLine.d175.s11	range	71	75	O	range	nge	ange	NN	False
DDI-MedLine.d175.s11	for	77	79	O	for	for	for	IN	False
DDI-MedLine.d175.s11	12	81	82	O	12	12	12	CD	False
DDI-MedLine.d175.s11	patients	84	91	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s11	,	92	92	O	,	,	,	,	False
DDI-MedLine.d175.s11	including	94	102	O	including	ing	ding	VBG	False
DDI-MedLine.d175.s11	10	104	105	O	10	10	10	CD	False
DDI-MedLine.d175.s11	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d175.s11	17	110	111	O	17	17	17	CD	False
DDI-MedLine.d175.s11	cases	113	117	O	cases	ses	ases	NNS	False
DDI-MedLine.d175.s11	of	119	120	O	of	of	of	IN	False
DDI-MedLine.d175.s11	toxicity	122	129	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s11	and	131	133	O	and	and	and	CC	False
DDI-MedLine.d175.s11	8	135	135	O	8	8	8	CD	False
DDI-MedLine.d175.s11	of	137	138	O	of	of	of	IN	False
DDI-MedLine.d175.s11	13	140	141	O	13	13	13	CD	False
DDI-MedLine.d175.s11	cases	143	147	O	cases	ses	ases	NNS	False
DDI-MedLine.d175.s11	of	149	150	O	of	of	of	IN	False
DDI-MedLine.d175.s11	death	152	156	O	death	ath	eath	NN	False
DDI-MedLine.d175.s11	classified	158	167	O	classified	ied	fied	VBN	False
DDI-MedLine.d175.s11	as	169	170	O	as	as	as	IN	False
DDI-MedLine.d175.s11	possible	172	179	O	possible	ble	ible	JJ	False
DDI-MedLine.d175.s11	or	181	182	O	or	or	or	CC	False
DDI-MedLine.d175.s11	higher	184	189	O	higher	her	gher	JJR	False
DDI-MedLine.d175.s11	.	190	190	O	.	.	.	.	False

DDI-MedLine.d175.s12	Seventeen	0	8	O	Seventeen	een	teen	NN	False
DDI-MedLine.d175.s12	patients	10	17	O	patients	nts	ents	NNS	False
DDI-MedLine.d175.s12	received	19	26	O	received	ved	ived	VBN	False
DDI-MedLine.d175.s12	interacting	28	38	O	interacting	ing	ting	VBG	False
DDI-MedLine.d175.s12	medications	40	50	O	medications	ons	ions	NNS	False
DDI-MedLine.d175.s12	,	51	51	O	,	,	,	,	False
DDI-MedLine.d175.s12	including	53	61	O	including	ing	ding	VBG	False
DDI-MedLine.d175.s12	8	63	63	O	8	8	8	CD	False
DDI-MedLine.d175.s12	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d175.s12	17	68	69	O	17	17	17	CD	False
DDI-MedLine.d175.s12	cases	71	75	O	cases	ses	ases	NNS	False
DDI-MedLine.d175.s12	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d175.s12	toxicity	80	87	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s12	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d175.s12	8	93	93	O	8	8	8	CD	False
DDI-MedLine.d175.s12	of	95	96	O	of	of	of	IN	False
DDI-MedLine.d175.s12	13	98	99	O	13	13	13	CD	False
DDI-MedLine.d175.s12	cases	101	105	O	cases	ses	ases	NNS	False
DDI-MedLine.d175.s12	of	107	108	O	of	of	of	IN	False
DDI-MedLine.d175.s12	death	110	114	O	death	ath	eath	NN	False
DDI-MedLine.d175.s12	classified	116	125	O	classified	ied	fied	VBN	False
DDI-MedLine.d175.s12	as	127	128	O	as	as	as	IN	False
DDI-MedLine.d175.s12	possible	130	137	O	possible	ble	ible	JJ	False
DDI-MedLine.d175.s12	or	139	140	O	or	or	or	CC	False
DDI-MedLine.d175.s12	higher	142	147	O	higher	her	gher	JJR	False
DDI-MedLine.d175.s12	.	148	148	O	.	.	.	.	False

DDI-MedLine.d175.s13	Colchicine	0	9	B-drug	Colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s13	toxicity	11	18	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s13	was	20	22	O	was	was	was	VBD	False
DDI-MedLine.d175.s13	frequent	24	31	O	frequent	ent	uent	NN	False
DDI-MedLine.d175.s13	in	33	34	O	in	in	in	IN	False
DDI-MedLine.d175.s13	this	36	39	O	this	his	this	DT	False
DDI-MedLine.d175.s13	cohort	41	46	O	cohort	ort	hort	NN	False
DDI-MedLine.d175.s13	and	48	50	O	and	and	and	CC	False
DDI-MedLine.d175.s13	may	52	54	O	may	may	may	MD	False
DDI-MedLine.d175.s13	have	56	59	O	have	ave	have	VB	False
DDI-MedLine.d175.s13	contributed	61	71	O	contributed	ted	uted	VBD	False
DDI-MedLine.d175.s13	to	73	74	O	to	to	to	TO	False
DDI-MedLine.d175.s13	about	76	80	O	about	out	bout	IN	False
DDI-MedLine.d175.s13	one-third	82	90	O	one-third	ird	hird	NN	False
DDI-MedLine.d175.s13	of	92	93	O	of	of	of	IN	False
DDI-MedLine.d175.s13	the	95	97	O	the	the	the	DT	False
DDI-MedLine.d175.s13	deaths	99	104	O	deaths	ths	aths	NNS	False
DDI-MedLine.d175.s13	.	105	105	O	.	.	.	.	False

DDI-MedLine.d175.s14	Inappropriate	0	12	O	Inappropriate	ate	iate	NN	False
DDI-MedLine.d175.s14	dosing	14	19	O	dosing	ing	sing	VBG	False
DDI-MedLine.d175.s14	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d175.s14	colchicine	24	33	B-drug	colchicine	ine	cine	NN	drug
DDI-MedLine.d175.s14	occurred	35	42	O	occurred	red	rred	VBD	False
DDI-MedLine.d175.s14	frequently	44	53	O	frequently	tly	ntly	RB	False
DDI-MedLine.d175.s14	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d175.s14	was	59	61	O	was	was	was	VBD	False
DDI-MedLine.d175.s14	related	63	69	O	related	ted	ated	JJ	False
DDI-MedLine.d175.s14	to	71	72	O	to	to	to	TO	False
DDI-MedLine.d175.s14	toxicity	74	81	O	toxicity	ity	city	NN	False
DDI-MedLine.d175.s14	and	83	85	O	and	and	and	CC	False
DDI-MedLine.d175.s14	death	87	91	O	death	ath	eath	NN	False
DDI-MedLine.d175.s14	.	92	92	O	.	.	.	.	False

DDI-MedLine.d229.s0	Novel	0	4	O	Novel	vel	ovel	NN	False
DDI-MedLine.d229.s0	insights	6	13	O	insights	hts	ghts	NNS	False
DDI-MedLine.d229.s0	into	15	18	O	into	nto	into	IN	False
DDI-MedLine.d229.s0	the	20	22	O	the	the	the	DT	False
DDI-MedLine.d229.s0	synergistic	24	34	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d229.s0	interaction	36	46	O	interaction	ion	tion	NN	False
DDI-MedLine.d229.s0	of	48	49	O	of	of	of	IN	False
DDI-MedLine.d229.s0	Bortezomib	51	60	B-drug	Bortezomib	mib	omib	NN	False
DDI-MedLine.d229.s0	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d229.s0	TRAIL	66	70	O	TRAIL	AIL	RAIL	NN	brand
DDI-MedLine.d229.s0	:	71	71	O	:	:	:	:	False
DDI-MedLine.d229.s0	tBid	73	76	O	tBid	Bid	tBid	NN	False
DDI-MedLine.d229.s0	provides	78	85	O	provides	des	ides	VBZ	group
DDI-MedLine.d229.s0	the	87	89	O	the	the	the	DT	False
DDI-MedLine.d229.s0	link	91	94	O	link	ink	link	NN	False
DDI-MedLine.d229.s0	.	95	95	O	.	.	.	.	False

DDI-MedLine.d229.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d229.s1	proteasome	4	13	O	proteasome	ome	some	NN	False
DDI-MedLine.d229.s1	inhibitor	15	23	O	inhibitor	tor	itor	NN	False
DDI-MedLine.d229.s1	Bortezomib	25	34	B-drug	Bortezomib	mib	omib	NN	False
DDI-MedLine.d229.s1	has	36	38	O	has	has	has	VBZ	False
DDI-MedLine.d229.s1	been	40	43	O	been	een	been	VBN	False
DDI-MedLine.d229.s1	identified	45	54	O	identified	ied	fied	VBN	False
DDI-MedLine.d229.s1	as	56	57	O	as	as	as	IN	False
DDI-MedLine.d229.s1	a	59	59	O	a	a	a	DT	False
DDI-MedLine.d229.s1	potent	61	66	O	potent	ent	tent	NN	False
DDI-MedLine.d229.s1	enhancer	68	75	O	enhancer	cer	ncer	NN	False
DDI-MedLine.d229.s1	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d229.s1	TRAIL-induced	80	92	O	TRAIL-induced	ced	uced	JJ	False
DDI-MedLine.d229.s1	apoptosis	94	102	O	apoptosis	sis	osis	NN	False
DDI-MedLine.d229.s1	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d229.s1	several	107	113	O	several	ral	eral	JJ	False
DDI-MedLine.d229.s1	human	115	119	O	human	man	uman	NN	False
DDI-MedLine.d229.s1	cancers	121	127	O	cancers	ers	cers	NNS	False
DDI-MedLine.d229.s1	.	128	128	O	.	.	.	.	False

DDI-MedLine.d229.s2	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d229.s2	,	7	7	O	,	,	,	,	False
DDI-MedLine.d229.s2	the	9	11	O	the	the	the	DT	False
DDI-MedLine.d229.s2	identification	13	26	O	identification	ion	tion	NN	False
DDI-MedLine.d229.s2	of	28	29	O	of	of	of	IN	False
DDI-MedLine.d229.s2	the	31	33	O	the	the	the	DT	False
DDI-MedLine.d229.s2	underlying	35	44	O	underlying	ing	ying	VBG	False
DDI-MedLine.d229.s2	molecular	46	54	O	molecular	lar	ular	NN	False
DDI-MedLine.d229.s2	mechanisms	56	65	O	mechanisms	sms	isms	NNS	False
DDI-MedLine.d229.s2	of	67	68	O	of	of	of	IN	False
DDI-MedLine.d229.s2	this	70	73	O	this	his	this	DT	False
DDI-MedLine.d229.s2	synergistic	75	85	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d229.s2	cell	87	90	O	cell	ell	cell	NN	False
DDI-MedLine.d229.s2	death	92	96	O	death	ath	eath	NN	False
DDI-MedLine.d229.s2	induction	98	106	O	induction	ion	tion	NN	False
DDI-MedLine.d229.s2	has	108	110	O	has	has	has	VBZ	False
DDI-MedLine.d229.s2	been	112	115	O	been	een	been	VBN	False
DDI-MedLine.d229.s2	ongoing	117	123	O	ongoing	ing	oing	VBG	False
DDI-MedLine.d229.s2	over	125	128	O	over	ver	over	IN	False
DDI-MedLine.d229.s2	the	130	132	O	the	the	the	DT	False
DDI-MedLine.d229.s2	last	134	137	O	last	ast	last	JJ	False
DDI-MedLine.d229.s2	years	139	143	O	years	ars	ears	NNS	False
DDI-MedLine.d229.s2	.	144	144	O	.	.	.	.	False

DDI-MedLine.d229.s3	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d229.s3	recent	2	7	O	recent	ent	cent	JJ	False
DDI-MedLine.d229.s3	study	9	13	O	study	udy	tudy	NN	False
DDI-MedLine.d229.s3	identifies	15	24	O	identifies	ies	fies	NNS	False
DDI-MedLine.d229.s3	a	26	26	O	a	a	a	DT	False
DDI-MedLine.d229.s3	new	28	30	O	new	new	new	JJ	False
DDI-MedLine.d229.s3	mechanism	32	40	O	mechanism	ism	nism	NN	False
DDI-MedLine.d229.s3	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d229.s3	action	45	50	O	action	ion	tion	NN	False
DDI-MedLine.d229.s3	for	52	54	O	for	for	for	IN	False
DDI-MedLine.d229.s3	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d229.s3	synergism	60	68	O	synergism	ism	gism	NN	False
DDI-MedLine.d229.s3	of	70	71	O	of	of	of	IN	False
DDI-MedLine.d229.s3	TRAIL	73	77	O	TRAIL	AIL	RAIL	NN	brand
DDI-MedLine.d229.s3	and	79	81	O	and	and	and	CC	False
DDI-MedLine.d229.s3	Bortezomib	83	92	B-drug	Bortezomib	mib	omib	NN	False
DDI-MedLine.d229.s3	.	93	93	O	.	.	.	.	False

DDI-MedLine.d226.s0	[	0	0	O	[	[	[	NN	False
DDI-MedLine.d226.s0	Does	1	4	O	Does	oes	Does	NNS	False
DDI-MedLine.d226.s0	implementation	6	19	O	implementation	ion	tion	NN	False
DDI-MedLine.d226.s0	of	21	22	O	of	of	of	IN	False
DDI-MedLine.d226.s0	benchmarking	24	35	O	benchmarking	ing	king	NN	False
DDI-MedLine.d226.s0	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d226.s0	quality	40	46	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s0	circles	48	54	O	circles	les	cles	NNS	False
DDI-MedLine.d226.s0	improve	56	62	O	improve	ove	rove	VB	False
DDI-MedLine.d226.s0	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d226.s0	quality	68	74	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s0	of	76	77	O	of	of	of	IN	False
DDI-MedLine.d226.s0	care	79	82	O	care	are	care	NN	False
DDI-MedLine.d226.s0	of	84	85	O	of	of	of	IN	False
DDI-MedLine.d226.s0	patients	87	94	O	patients	nts	ents	NNS	False
DDI-MedLine.d226.s0	with	96	99	O	with	ith	with	IN	False
DDI-MedLine.d226.s0	asthma	101	106	O	asthma	hma	thma	NN	False
DDI-MedLine.d226.s0	and	108	110	O	and	and	and	CC	False
DDI-MedLine.d226.s0	reduce	112	117	O	reduce	uce	duce	VB	False
DDI-MedLine.d226.s0	drug	119	122	O	drug	rug	drug	NN	False
DDI-MedLine.d226.s0	interaction	124	134	O	interaction	ion	tion	NN	False
DDI-MedLine.d226.s0	]	136	136	O	]	]	]	NN	False
DDI-MedLine.d226.s0	.	137	137	O	.	.	.	.	False

DDI-MedLine.d226.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d226.s1	purpose	4	10	O	purpose	ose	pose	NN	False
DDI-MedLine.d226.s1	of	12	13	O	of	of	of	IN	False
DDI-MedLine.d226.s1	this	15	18	O	this	his	this	DT	False
DDI-MedLine.d226.s1	cluster-randomised	20	37	O	cluster-randomised	sed	ised	JJ	False
DDI-MedLine.d226.s1	controlled	39	48	O	controlled	led	lled	VBN	False
DDI-MedLine.d226.s1	trial	50	54	O	trial	ial	rial	NN	False
DDI-MedLine.d226.s1	was	56	58	O	was	was	was	VBD	False
DDI-MedLine.d226.s1	to	60	61	O	to	to	to	TO	False
DDI-MedLine.d226.s1	evaluate	63	70	O	evaluate	ate	uate	NN	False
DDI-MedLine.d226.s1	the	72	74	O	the	the	the	DT	False
DDI-MedLine.d226.s1	efficacy	76	83	O	efficacy	acy	cacy	NN	False
DDI-MedLine.d226.s1	of	85	86	O	of	of	of	IN	False
DDI-MedLine.d226.s1	quality	88	94	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s1	circles	96	102	O	circles	les	cles	NNS	False
DDI-MedLine.d226.s1	(	104	104	O	(	(	(	(	False
DDI-MedLine.d226.s1	QCs	105	107	O	QCs	QCs	QCs	NN	False
DDI-MedLine.d226.s1	)	108	108	O	)	)	)	)	False
DDI-MedLine.d226.s1	working	110	116	O	working	ing	king	VBG	False
DDI-MedLine.d226.s1	either	118	123	O	either	her	ther	DT	False
DDI-MedLine.d226.s1	with	125	128	O	with	ith	with	IN	False
DDI-MedLine.d226.s1	general	130	136	O	general	ral	eral	JJ	False
DDI-MedLine.d226.s1	data-based	138	147	O	data-based	sed	ased	JJ	False
DDI-MedLine.d226.s1	feedback	149	156	O	feedback	ack	back	NN	False
DDI-MedLine.d226.s1	or	158	159	O	or	or	or	CC	False
DDI-MedLine.d226.s1	with	161	164	O	with	ith	with	IN	False
DDI-MedLine.d226.s1	an	166	167	O	an	an	an	DT	False
DDI-MedLine.d226.s1	open	169	172	O	open	pen	open	JJ	False
DDI-MedLine.d226.s1	benchmark	174	182	O	benchmark	ark	mark	NN	False
DDI-MedLine.d226.s1	within	184	189	O	within	hin	thin	IN	False
DDI-MedLine.d226.s1	the	191	193	O	the	the	the	DT	False
DDI-MedLine.d226.s1	field	195	199	O	field	eld	ield	NN	False
DDI-MedLine.d226.s1	of	201	202	O	of	of	of	IN	False
DDI-MedLine.d226.s1	asthma	204	209	O	asthma	hma	thma	NN	False
DDI-MedLine.d226.s1	care	211	214	O	care	are	care	NN	False
DDI-MedLine.d226.s1	and	216	218	O	and	and	and	CC	False
DDI-MedLine.d226.s1	drug-drug	220	228	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d226.s1	interactions	230	241	O	interactions	ons	ions	NNS	False
DDI-MedLine.d226.s1	.	242	242	O	.	.	.	.	False

DDI-MedLine.d226.s2	Twelve	0	5	O	Twelve	lve	elve	NN	False
DDI-MedLine.d226.s2	QCs	7	9	O	QCs	QCs	QCs	NN	False
DDI-MedLine.d226.s2	,	10	10	O	,	,	,	,	False
DDI-MedLine.d226.s2	involving	12	20	O	involving	ing	ving	VBG	False
DDI-MedLine.d226.s2	96	22	23	O	96	96	96	CD	False
DDI-MedLine.d226.s2	general	25	31	O	general	ral	eral	JJ	False
DDI-MedLine.d226.s2	practitioners	33	45	O	practitioners	ers	ners	NNS	False
DDI-MedLine.d226.s2	from	47	50	O	from	rom	from	IN	False
DDI-MedLine.d226.s2	85	52	53	O	85	85	85	CD	False
DDI-MedLine.d226.s2	practices	55	63	O	practices	ces	ices	NNS	False
DDI-MedLine.d226.s2	,	64	64	O	,	,	,	,	False
DDI-MedLine.d226.s2	were	66	69	O	were	ere	were	VBD	False
DDI-MedLine.d226.s2	randomised	71	80	O	randomised	sed	ised	VBN	False
DDI-MedLine.d226.s2	.	81	81	O	.	.	.	.	False

DDI-MedLine.d226.s3	Six	0	2	O	Six	Six	Six	NN	False
DDI-MedLine.d226.s3	QCs	4	6	O	QCs	QCs	QCs	NN	False
DDI-MedLine.d226.s3	worked	8	13	O	worked	ked	rked	VBN	False
DDI-MedLine.d226.s3	with	15	18	O	with	ith	with	IN	False
DDI-MedLine.d226.s3	traditional	20	30	O	traditional	nal	onal	JJ	False
DDI-MedLine.d226.s3	anonymous	32	40	O	anonymous	ous	mous	JJ	False
DDI-MedLine.d226.s3	feedback	42	49	O	feedback	ack	back	NN	False
DDI-MedLine.d226.s3	and	51	53	O	and	and	and	CC	False
DDI-MedLine.d226.s3	six	55	57	O	six	six	six	CD	False
DDI-MedLine.d226.s3	with	59	62	O	with	ith	with	IN	False
DDI-MedLine.d226.s3	an	64	65	O	an	an	an	DT	False
DDI-MedLine.d226.s3	open	67	70	O	open	pen	open	JJ	False
DDI-MedLine.d226.s3	benchmark	72	80	O	benchmark	ark	mark	NN	False
DDI-MedLine.d226.s3	.	81	81	O	.	.	.	.	False

DDI-MedLine.d226.s4	Two	0	2	O	Two	Two	Two	CD	False
DDI-MedLine.d226.s4	QC	4	5	O	QC	QC	QC	NN	brand
DDI-MedLine.d226.s4	meetings	7	14	O	meetings	ngs	ings	NNS	False
DDI-MedLine.d226.s4	supported	16	24	O	supported	ted	rted	VBN	False
DDI-MedLine.d226.s4	with	26	29	O	with	ith	with	IN	False
DDI-MedLine.d226.s4	feedback	31	38	O	feedback	ack	back	NN	False
DDI-MedLine.d226.s4	reports	40	46	O	reports	rts	orts	NNS	False
DDI-MedLine.d226.s4	were	48	51	O	were	ere	were	VBD	False
DDI-MedLine.d226.s4	held	53	56	O	held	eld	held	NN	False
DDI-MedLine.d226.s4	covering	58	65	O	covering	ing	ring	VBG	False
DDI-MedLine.d226.s4	the	67	69	O	the	the	the	DT	False
DDI-MedLine.d226.s4	topics	71	76	O	topics	ics	pics	NNS	False
DDI-MedLine.d226.s4	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d226.s4	drug-drug	79	87	O	drug-drug	rug	drug	NN	False
DDI-MedLine.d226.s4	interactions	89	100	O	interactions	ons	ions	NNS	False
DDI-MedLine.d226.s4	''	-1	0	O	''	''	''	''	False

DDI-MedLine.d226.s5	and	0	2	O	and	and	and	CC	False
DDI-MedLine.d226.s5	``	-1	0	O	``	``	``	``	False
DDI-MedLine.d226.s5	asthma	5	10	O	asthma	hma	thma	NN	False
DDI-MedLine.d226.s5	''	-1	0	O	''	''	''	''	False
DDI-MedLine.d226.s5	;	12	12	O	;	;	;	:	False

DDI-MedLine.d226.s6	in	0	1	O	in	in	in	IN	False
DDI-MedLine.d226.s6	both	3	6	O	both	oth	both	DT	False
DDI-MedLine.d226.s6	cases	8	12	O	cases	ses	ases	NNS	False
DDI-MedLine.d226.s6	discussions	14	24	O	discussions	ons	ions	NNS	False
DDI-MedLine.d226.s6	were	26	29	O	were	ere	were	VBD	False
DDI-MedLine.d226.s6	guided	31	36	O	guided	ded	ided	VBN	False
DDI-MedLine.d226.s6	by	38	39	O	by	by	by	IN	False
DDI-MedLine.d226.s6	a	41	41	O	a	a	a	DT	False
DDI-MedLine.d226.s6	trained	43	49	O	trained	ned	ined	VBN	False
DDI-MedLine.d226.s6	moderator	51	59	O	moderator	tor	ator	NN	False
DDI-MedLine.d226.s6	.	60	60	O	.	.	.	.	False

DDI-MedLine.d226.s7	Outcome	0	6	O	Outcome	ome	come	NN	False
DDI-MedLine.d226.s7	measures	8	15	O	measures	res	ures	NNS	False
DDI-MedLine.d226.s7	included	17	24	O	included	ded	uded	VBD	False
DDI-MedLine.d226.s7	health-related	26	39	O	health-related	ted	ated	JJ	False
DDI-MedLine.d226.s7	quality	41	47	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s7	of	49	50	O	of	of	of	IN	False
DDI-MedLine.d226.s7	life	52	55	O	life	ife	life	NN	False
DDI-MedLine.d226.s7	and	57	59	O	and	and	and	CC	False
DDI-MedLine.d226.s7	patient	61	67	O	patient	ent	ient	NN	False
DDI-MedLine.d226.s7	satisfaction	69	80	O	satisfaction	ion	tion	NN	False
DDI-MedLine.d226.s7	with	82	85	O	with	ith	with	IN	False
DDI-MedLine.d226.s7	treatment	87	95	O	treatment	ent	ment	NN	False
DDI-MedLine.d226.s7	,	96	96	O	,	,	,	,	False
DDI-MedLine.d226.s7	asthma	98	103	O	asthma	hma	thma	NN	False
DDI-MedLine.d226.s7	severity	105	112	O	severity	ity	rity	NN	False
DDI-MedLine.d226.s7	and	114	116	O	and	and	and	CC	False
DDI-MedLine.d226.s7	number	118	123	O	number	ber	mber	NN	False
DDI-MedLine.d226.s7	of	125	126	O	of	of	of	IN	False
DDI-MedLine.d226.s7	potentially	128	138	O	potentially	lly	ally	RB	False
DDI-MedLine.d226.s7	inappropriate	140	152	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d226.s7	drug	154	157	O	drug	rug	drug	NN	False
DDI-MedLine.d226.s7	combinations	159	170	O	combinations	ons	ions	NNS	False
DDI-MedLine.d226.s7	as	172	173	O	as	as	as	IN	False
DDI-MedLine.d226.s7	well	175	178	O	well	ell	well	RB	False
DDI-MedLine.d226.s7	as	180	181	O	as	as	as	IN	False
DDI-MedLine.d226.s7	the	183	185	O	the	the	the	DT	False
DDI-MedLine.d226.s7	general	187	193	O	general	ral	eral	JJ	False
DDI-MedLine.d226.s7	practitioners	195	207	O	practitioners	ers	ners	NNS	False
DDI-MedLine.d226.s7	'	208	208	O	'	'	'	''	False
DDI-MedLine.d226.s7	satisfaction	210	221	O	satisfaction	ion	tion	NN	False
DDI-MedLine.d226.s7	in	223	224	O	in	in	in	IN	False
DDI-MedLine.d226.s7	relation	226	233	O	relation	ion	tion	NN	False
DDI-MedLine.d226.s7	to	235	236	O	to	to	to	TO	False
DDI-MedLine.d226.s7	the	238	240	O	the	the	the	DT	False
DDI-MedLine.d226.s7	performance	242	252	O	performance	nce	ance	NN	False
DDI-MedLine.d226.s7	of	254	255	O	of	of	of	IN	False
DDI-MedLine.d226.s7	the	257	259	O	the	the	the	DT	False
DDI-MedLine.d226.s7	QC	261	262	O	QC	QC	QC	NN	brand
DDI-MedLine.d226.s7	.	263	263	O	.	.	.	.	False

DDI-MedLine.d226.s8	A	0	0	O	A	A	A	DT	brand
DDI-MedLine.d226.s8	significant	2	12	O	significant	ant	cant	JJ	False
DDI-MedLine.d226.s8	improvement	14	24	O	improvement	ent	ment	NN	False
DDI-MedLine.d226.s8	in	26	27	O	in	in	in	IN	False
DDI-MedLine.d226.s8	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d226.s8	treatment	33	41	O	treatment	ent	ment	NN	False
DDI-MedLine.d226.s8	of	43	44	O	of	of	of	IN	False
DDI-MedLine.d226.s8	asthma	46	51	O	asthma	hma	thma	NN	False
DDI-MedLine.d226.s8	was	53	55	O	was	was	was	VBD	False
DDI-MedLine.d226.s8	observed	57	64	O	observed	ved	rved	VBN	False
DDI-MedLine.d226.s8	in	66	67	O	in	in	in	IN	False
DDI-MedLine.d226.s8	both	69	72	O	both	oth	both	DT	False
DDI-MedLine.d226.s8	trial	74	78	O	trial	ial	rial	NN	False
DDI-MedLine.d226.s8	arms	80	83	O	arms	rms	arms	NNS	False
DDI-MedLine.d226.s8	.	84	84	O	.	.	.	.	False

DDI-MedLine.d226.s9	However	0	6	O	However	ver	ever	RB	False
DDI-MedLine.d226.s9	,	7	7	O	,	,	,	,	False
DDI-MedLine.d226.s9	there	9	13	O	there	ere	here	RB	False
DDI-MedLine.d226.s9	was	15	17	O	was	was	was	VBD	False
DDI-MedLine.d226.s9	only	19	22	O	only	nly	only	RB	False
DDI-MedLine.d226.s9	a	24	24	O	a	a	a	DT	False
DDI-MedLine.d226.s9	slight	26	31	O	slight	ght	ight	NN	False
DDI-MedLine.d226.s9	improvement	33	43	O	improvement	ent	ment	NN	False
DDI-MedLine.d226.s9	regarding	45	53	O	regarding	ing	ding	VBG	False
DDI-MedLine.d226.s9	inappropriate	55	67	O	inappropriate	ate	iate	NN	False
DDI-MedLine.d226.s9	drug	69	72	O	drug	rug	drug	NN	False
DDI-MedLine.d226.s9	combinations	74	85	O	combinations	ons	ions	NNS	False
DDI-MedLine.d226.s9	.	86	86	O	.	.	.	.	False

DDI-MedLine.d226.s10	There	0	4	O	There	ere	here	EX	False
DDI-MedLine.d226.s10	were	6	9	O	were	ere	were	VBD	False
DDI-MedLine.d226.s10	no	11	12	O	no	no	no	DT	False
DDI-MedLine.d226.s10	relevant	14	21	O	relevant	ant	vant	NN	False
DDI-MedLine.d226.s10	differences	23	33	O	differences	ces	nces	NNS	False
DDI-MedLine.d226.s10	between	35	41	O	between	een	ween	IN	False
DDI-MedLine.d226.s10	the	43	45	O	the	the	the	DT	False
DDI-MedLine.d226.s10	group	47	51	O	group	oup	roup	NN	False
DDI-MedLine.d226.s10	with	53	56	O	with	ith	with	IN	False
DDI-MedLine.d226.s10	open	58	61	O	open	pen	open	JJ	False
DDI-MedLine.d226.s10	benchmark	63	71	O	benchmark	ark	mark	NN	False
DDI-MedLine.d226.s10	(	73	73	O	(	(	(	(	False
DDI-MedLine.d226.s10	B-QC	74	77	O	B-QC	-QC	B-QC	NN	brand
DDI-MedLine.d226.s10	)	78	78	O	)	)	)	)	False
DDI-MedLine.d226.s10	and	80	82	O	and	and	and	CC	False
DDI-MedLine.d226.s10	traditional	84	94	O	traditional	nal	onal	JJ	False
DDI-MedLine.d226.s10	quality	96	102	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s10	circles	104	110	O	circles	les	cles	NNS	False
DDI-MedLine.d226.s10	(	112	112	O	(	(	(	(	False
DDI-MedLine.d226.s10	T-QC	113	116	O	T-QC	-QC	T-QC	NN	brand
DDI-MedLine.d226.s10	)	117	117	O	)	)	)	)	False
DDI-MedLine.d226.s10	.	118	118	O	.	.	.	.	False

DDI-MedLine.d226.s11	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d226.s11	physicians	4	13	O	physicians	ans	ians	NNS	False
DDI-MedLine.d226.s11	'	14	14	O	'	'	'	''	False
DDI-MedLine.d226.s11	satisfaction	16	27	O	satisfaction	ion	tion	NN	False
DDI-MedLine.d226.s11	with	29	32	O	with	ith	with	IN	False
DDI-MedLine.d226.s11	the	34	36	O	the	the	the	DT	False
DDI-MedLine.d226.s11	QC	38	39	O	QC	QC	QC	NN	brand
DDI-MedLine.d226.s11	performance	41	51	O	performance	nce	ance	NN	False
DDI-MedLine.d226.s11	was	53	55	O	was	was	was	VBD	False
DDI-MedLine.d226.s11	significantly	57	69	O	significantly	tly	ntly	RB	False
DDI-MedLine.d226.s11	higher	71	76	O	higher	her	gher	JJR	False
DDI-MedLine.d226.s11	in	78	79	O	in	in	in	IN	False
DDI-MedLine.d226.s11	the	81	83	O	the	the	the	DT	False
DDI-MedLine.d226.s11	T-QCs	85	89	O	T-QCs	QCs	-QCs	NN	False
DDI-MedLine.d226.s11	.	90	90	O	.	.	.	.	False

DDI-MedLine.d226.s12	General	0	6	O	General	ral	eral	NNP	False
DDI-MedLine.d226.s12	practitioners	8	20	O	practitioners	ers	ners	NNS	False
DDI-MedLine.d226.s12	seem	22	25	O	seem	eem	seem	NN	False
DDI-MedLine.d226.s12	to	27	28	O	to	to	to	TO	False
DDI-MedLine.d226.s12	take	30	33	O	take	ake	take	VB	False
DDI-MedLine.d226.s12	a	35	35	O	a	a	a	DT	False
DDI-MedLine.d226.s12	critical	37	44	O	critical	cal	ical	JJ	False
DDI-MedLine.d226.s12	perspective	46	56	O	perspective	ive	tive	NN	False
DDI-MedLine.d226.s12	about	58	62	O	about	out	bout	IN	False
DDI-MedLine.d226.s12	open	64	67	O	open	pen	open	JJ	False
DDI-MedLine.d226.s12	benchmarking	69	80	O	benchmarking	ing	king	NN	False
DDI-MedLine.d226.s12	in	82	83	O	in	in	in	IN	False
DDI-MedLine.d226.s12	quality	85	91	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s12	circles	93	99	O	circles	les	cles	NNS	False
DDI-MedLine.d226.s12	.	100	100	O	.	.	.	.	False

DDI-MedLine.d226.s13	Caution	0	6	O	Caution	ion	tion	NN	False
DDI-MedLine.d226.s13	should	8	13	O	should	uld	ould	MD	False
DDI-MedLine.d226.s13	be	15	16	O	be	be	be	VB	False
DDI-MedLine.d226.s13	used	18	21	O	used	sed	used	VBN	False
DDI-MedLine.d226.s13	when	23	26	O	when	hen	when	WRB	False
DDI-MedLine.d226.s13	implementing	28	39	O	implementing	ing	ting	VBG	False
DDI-MedLine.d226.s13	benchmarking	41	52	O	benchmarking	ing	king	NN	False
DDI-MedLine.d226.s13	in	54	55	O	in	in	in	IN	False
DDI-MedLine.d226.s13	a	57	57	O	a	a	a	DT	False
DDI-MedLine.d226.s13	quality	59	65	O	quality	ity	lity	NN	False
DDI-MedLine.d226.s13	circle	67	72	O	circle	cle	rcle	NN	False
DDI-MedLine.d226.s13	as	74	75	O	as	as	as	IN	False
DDI-MedLine.d226.s13	it	77	78	O	it	it	it	PRP	False
DDI-MedLine.d226.s13	did	80	82	O	did	did	did	VBD	False
DDI-MedLine.d226.s13	not	84	86	O	not	not	not	RB	False
DDI-MedLine.d226.s13	improve	88	94	O	improve	ove	rove	VB	False
DDI-MedLine.d226.s13	healthcare	96	105	O	healthcare	are	care	NN	False
DDI-MedLine.d226.s13	when	107	110	O	when	hen	when	WRB	False
DDI-MedLine.d226.s13	compared	112	119	O	compared	red	ared	VBN	False
DDI-MedLine.d226.s13	to	121	122	O	to	to	to	TO	False
DDI-MedLine.d226.s13	the	124	126	O	the	the	the	DT	False
DDI-MedLine.d226.s13	traditional	128	138	O	traditional	nal	onal	JJ	False
DDI-MedLine.d226.s13	procedure	140	148	O	procedure	ure	dure	NN	False
DDI-MedLine.d226.s13	with	150	153	O	with	ith	with	IN	False
DDI-MedLine.d226.s13	anonymised	155	164	O	anonymised	sed	ised	VBN	False
DDI-MedLine.d226.s13	comparisons	166	176	O	comparisons	ons	sons	NNS	False
DDI-MedLine.d226.s13	.	177	177	O	.	.	.	.	False

DDI-MedLine.d225.s0	Pharmacological	0	14	O	Pharmacological	cal	ical	JJ	False
DDI-MedLine.d225.s0	drugs	16	20	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d225.s0	inducing	22	29	O	inducing	ing	cing	VBG	False
DDI-MedLine.d225.s0	ototoxicity	31	41	O	ototoxicity	ity	city	NN	False
DDI-MedLine.d225.s0	,	42	42	O	,	,	,	,	False
DDI-MedLine.d225.s0	vestibular	44	53	O	vestibular	lar	ular	NN	False
DDI-MedLine.d225.s0	symptoms	55	62	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d225.s0	and	64	66	O	and	and	and	CC	False
DDI-MedLine.d225.s0	tinnitus	68	75	O	tinnitus	tus	itus	NN	False
DDI-MedLine.d225.s0	:	76	76	O	:	:	:	:	False
DDI-MedLine.d225.s0	a	78	78	O	a	a	a	DT	False
DDI-MedLine.d225.s0	reasoned	80	87	O	reasoned	ned	oned	VBN	False
DDI-MedLine.d225.s0	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d225.s0	updated	93	99	O	updated	ted	ated	VBN	False
DDI-MedLine.d225.s0	guide	101	105	O	guide	ide	uide	NN	False
DDI-MedLine.d225.s0	.	106	106	O	.	.	.	.	False

DDI-MedLine.d225.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d225.s1	present	4	10	O	present	ent	sent	NN	False
DDI-MedLine.d225.s1	work	12	15	O	work	ork	work	NN	False
DDI-MedLine.d225.s1	on	17	18	O	on	on	on	IN	False
DDI-MedLine.d225.s1	drug-induced	20	31	O	drug-induced	ced	uced	JJ	False
DDI-MedLine.d225.s1	ototoxicity	33	43	O	ototoxicity	ity	city	NN	False
DDI-MedLine.d225.s1	,	44	44	O	,	,	,	,	False
DDI-MedLine.d225.s1	tinnitus	46	53	O	tinnitus	tus	itus	NN	False
DDI-MedLine.d225.s1	and	55	57	O	and	and	and	CC	False
DDI-MedLine.d225.s1	vertigo	59	65	O	vertigo	igo	tigo	NN	False
DDI-MedLine.d225.s1	represents	67	76	O	represents	nts	ents	VBZ	False
DDI-MedLine.d225.s1	the	78	80	O	the	the	the	DT	False
DDI-MedLine.d225.s1	update	82	87	O	update	ate	date	NN	False
DDI-MedLine.d225.s1	and	89	91	O	and	and	and	CC	False
DDI-MedLine.d225.s1	revision	93	100	O	revision	ion	sion	NN	False
DDI-MedLine.d225.s1	of	102	103	O	of	of	of	IN	False
DDI-MedLine.d225.s1	a	105	105	O	a	a	a	DT	False
DDI-MedLine.d225.s1	previous	107	114	O	previous	ous	ious	JJ	False
DDI-MedLine.d225.s1	guide	116	120	O	guide	ide	uide	NN	False
DDI-MedLine.d225.s1	to	122	123	O	to	to	to	TO	False
DDI-MedLine.d225.s1	adverse	125	131	O	adverse	rse	erse	NN	False
DDI-MedLine.d225.s1	drug	133	136	O	drug	rug	drug	NN	False
DDI-MedLine.d225.s1	reactions	138	146	O	reactions	ons	ions	NNS	False
DDI-MedLine.d225.s1	for	148	150	O	for	for	for	IN	False
DDI-MedLine.d225.s1	italian	152	158	O	italian	ian	lian	JJ	False
DDI-MedLine.d225.s1	physicians	160	169	O	physicians	ans	ians	NNS	False
DDI-MedLine.d225.s1	(	171	171	O	(	(	(	(	False
DDI-MedLine.d225.s1	2005	172	175	O	2005	005	2005	CD	False
DDI-MedLine.d225.s1	)	176	176	O	)	)	)	)	False
DDI-MedLine.d225.s1	.	177	177	O	.	.	.	.	False

DDI-MedLine.d225.s2	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d225.s2	panorama	4	11	O	panorama	ama	rama	NN	False
DDI-MedLine.d225.s2	of	13	14	O	of	of	of	IN	False
DDI-MedLine.d225.s2	drug-induced	16	27	O	drug-induced	ced	uced	JJ	False
DDI-MedLine.d225.s2	side	29	32	O	side	ide	side	NN	False
DDI-MedLine.d225.s2	effects	34	40	O	effects	cts	ects	NNS	False
DDI-MedLine.d225.s2	causing	42	48	O	causing	ing	sing	VBG	False
DDI-MedLine.d225.s2	ototoxicity	50	60	O	ototoxicity	ity	city	NN	False
DDI-MedLine.d225.s2	or	62	63	O	or	or	or	CC	False
DDI-MedLine.d225.s2	symptoms	65	72	O	symptoms	oms	toms	NNS	False
DDI-MedLine.d225.s2	such	74	77	O	such	uch	such	JJ	False
DDI-MedLine.d225.s2	as	79	80	O	as	as	as	IN	False
DDI-MedLine.d225.s2	tinnitus	82	89	O	tinnitus	tus	itus	NN	False
DDI-MedLine.d225.s2	or	91	92	O	or	or	or	CC	False
DDI-MedLine.d225.s2	dizziness	94	102	O	dizziness	ess	ness	NN	False
DDI-MedLine.d225.s2	and	104	106	O	and	and	and	CC	False
DDI-MedLine.d225.s2	vertigo	108	114	O	vertigo	igo	tigo	NN	False
DDI-MedLine.d225.s2	has	116	118	O	has	has	has	VBZ	False
DDI-MedLine.d225.s2	enlarged	120	127	O	enlarged	ged	rged	VBN	False
DDI-MedLine.d225.s2	in	129	130	O	in	in	in	IN	False
DDI-MedLine.d225.s2	recent	132	137	O	recent	ent	cent	JJ	False
DDI-MedLine.d225.s2	years	139	143	O	years	ars	ears	NNS	False
DDI-MedLine.d225.s2	,	144	144	O	,	,	,	,	False
DDI-MedLine.d225.s2	thanks	146	151	O	thanks	nks	anks	NNS	False
DDI-MedLine.d225.s2	to	153	154	O	to	to	to	TO	False
DDI-MedLine.d225.s2	a	156	156	O	a	a	a	DT	False
DDI-MedLine.d225.s2	better	158	163	O	better	ter	tter	RBR	False
DDI-MedLine.d225.s2	knowledge	165	173	O	knowledge	dge	edge	NN	False
DDI-MedLine.d225.s2	and	175	177	O	and	and	and	CC	False
DDI-MedLine.d225.s2	a	179	179	O	a	a	a	DT	False
DDI-MedLine.d225.s2	more	181	184	O	more	ore	more	RBR	False
DDI-MedLine.d225.s2	specific	186	193	O	specific	fic	ific	JJ	False
DDI-MedLine.d225.s2	attention	195	203	O	attention	ion	tion	NN	False
DDI-MedLine.d225.s2	of	205	206	O	of	of	of	IN	False
DDI-MedLine.d225.s2	pharmaceutical	208	221	O	pharmaceutical	cal	ical	JJ	False
DDI-MedLine.d225.s2	firms	223	227	O	firms	rms	irms	NNS	False
DDI-MedLine.d225.s2	and	229	231	O	and	and	and	CC	False
DDI-MedLine.d225.s2	drug-control	233	244	O	drug-control	rol	trol	NN	False
DDI-MedLine.d225.s2	institutions	246	257	O	institutions	ons	ions	NNS	False
DDI-MedLine.d225.s2	.	258	258	O	.	.	.	.	False

DDI-MedLine.d225.s3	In	0	1	O	In	In	In	IN	False
DDI-MedLine.d225.s3	daily	3	7	O	daily	ily	aily	JJ	False
DDI-MedLine.d225.s3	clinical	9	16	O	clinical	cal	ical	JJ	False
DDI-MedLine.d225.s3	practice	18	25	O	practice	ice	tice	NN	False
DDI-MedLine.d225.s3	,	26	26	O	,	,	,	,	False
DDI-MedLine.d225.s3	there	28	32	O	there	ere	here	RB	False
DDI-MedLine.d225.s3	is	34	35	O	is	is	is	VBZ	False
DDI-MedLine.d225.s3	a	37	37	O	a	a	a	DT	False
DDI-MedLine.d225.s3	need	39	42	O	need	eed	need	NN	False
DDI-MedLine.d225.s3	for	44	46	O	for	for	for	IN	False
DDI-MedLine.d225.s3	the	48	50	O	the	the	the	DT	False
DDI-MedLine.d225.s3	family	52	57	O	family	ily	mily	NN	False
DDI-MedLine.d225.s3	physician	59	67	O	physician	ian	cian	NN	False
DDI-MedLine.d225.s3	and	69	71	O	and	and	and	CC	False
DDI-MedLine.d225.s3	the	73	75	O	the	the	the	DT	False
DDI-MedLine.d225.s3	ENT	77	79	O	ENT	ENT	ENT	NN	brand
DDI-MedLine.d225.s3	specialist	81	90	O	specialist	ist	list	NN	False
DDI-MedLine.d225.s3	or	92	93	O	or	or	or	CC	False
DDI-MedLine.d225.s3	audiologist	95	105	O	audiologist	ist	gist	NN	False
DDI-MedLine.d225.s3	(	107	107	O	(	(	(	(	False
DDI-MedLine.d225.s3	also	108	111	O	also	lso	also	RB	False
DDI-MedLine.d225.s3	in	113	114	O	in	in	in	IN	False
DDI-MedLine.d225.s3	consideration	116	128	O	consideration	ion	tion	NN	False
DDI-MedLine.d225.s3	of	130	131	O	of	of	of	IN	False
DDI-MedLine.d225.s3	the	133	135	O	the	the	the	DT	False
DDI-MedLine.d225.s3	possible	137	144	O	possible	ble	ible	JJ	False
DDI-MedLine.d225.s3	medico-legal	146	157	O	medico-legal	gal	egal	JJ	False
DDI-MedLine.d225.s3	implications	159	170	O	implications	ons	ions	NNS	False
DDI-MedLine.d225.s3	)	171	171	O	)	)	)	)	False
DDI-MedLine.d225.s3	to	173	174	O	to	to	to	TO	False
DDI-MedLine.d225.s3	focus	176	180	O	focus	cus	ocus	NN	False
DDI-MedLine.d225.s3	the	182	184	O	the	the	the	DT	False
DDI-MedLine.d225.s3	attention	186	194	O	attention	ion	tion	NN	False
DDI-MedLine.d225.s3	on	196	197	O	on	on	on	IN	False
DDI-MedLine.d225.s3	the	199	201	O	the	the	the	DT	False
DDI-MedLine.d225.s3	possible	203	210	O	possible	ble	ible	JJ	False
DDI-MedLine.d225.s3	risk	212	215	O	risk	isk	risk	NN	False
DDI-MedLine.d225.s3	of	217	218	O	of	of	of	IN	False
DDI-MedLine.d225.s3	otological	220	229	O	otological	cal	ical	JJ	False
DDI-MedLine.d225.s3	side	231	234	O	side	ide	side	NN	False
DDI-MedLine.d225.s3	effects	236	242	O	effects	cts	ects	NNS	False
DDI-MedLine.d225.s3	.	243	243	O	.	.	.	.	False

DDI-MedLine.d225.s4	This	0	3	O	This	his	This	DT	False
DDI-MedLine.d225.s4	would	5	9	O	would	uld	ould	MD	False
DDI-MedLine.d225.s4	allow	11	15	O	allow	low	llow	VB	False
DDI-MedLine.d225.s4	a	17	17	O	a	a	a	DT	False
DDI-MedLine.d225.s4	clinical	19	26	O	clinical	cal	ical	JJ	False
DDI-MedLine.d225.s4	risk-benefit	28	39	O	risk-benefit	fit	efit	NN	False
DDI-MedLine.d225.s4	evaluation	41	50	O	evaluation	ion	tion	NN	False
DDI-MedLine.d225.s4	,	51	51	O	,	,	,	,	False
DDI-MedLine.d225.s4	weighing	53	60	O	weighing	ing	hing	VBG	False
DDI-MedLine.d225.s4	the	62	64	O	the	the	the	DT	False
DDI-MedLine.d225.s4	possible	66	73	O	possible	ble	ible	JJ	False
DDI-MedLine.d225.s4	clinical	75	82	O	clinical	cal	ical	JJ	False
DDI-MedLine.d225.s4	advantage	84	92	O	advantage	age	tage	NN	False
DDI-MedLine.d225.s4	in	94	95	O	in	in	in	IN	False
DDI-MedLine.d225.s4	their	97	101	O	their	eir	heir	PRP$	False
DDI-MedLine.d225.s4	field	103	107	O	field	eld	ield	NN	False
DDI-MedLine.d225.s4	of	109	110	O	of	of	of	IN	False
DDI-MedLine.d225.s4	competence	112	121	O	competence	nce	ence	NN	False
DDI-MedLine.d225.s4	against	123	129	O	against	nst	inst	IN	False
DDI-MedLine.d225.s4	possible	131	138	O	possible	ble	ible	JJ	False
DDI-MedLine.d225.s4	otological	140	149	O	otological	cal	ical	JJ	False
DDI-MedLine.d225.s4	side-effects	151	162	O	side-effects	cts	ects	NNS	False
DDI-MedLine.d225.s4	.	163	163	O	.	.	.	.	False

DDI-MedLine.d225.s5	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d225.s5	list	4	7	O	list	ist	list	NN	False
DDI-MedLine.d225.s5	of	9	10	O	of	of	of	IN	False
DDI-MedLine.d225.s5	active	12	17	O	active	ive	tive	JJ	False
DDI-MedLine.d225.s5	ingredients	19	29	O	ingredients	nts	ents	NNS	False
DDI-MedLine.d225.s5	and	31	33	O	and	and	and	CC	False
DDI-MedLine.d225.s5	drugs	35	39	O	drugs	ugs	rugs	NNS	False
DDI-MedLine.d225.s5	is	41	42	O	is	is	is	VBZ	False
DDI-MedLine.d225.s5	subdivided	44	53	O	subdivided	ded	ided	VBD	False
DDI-MedLine.d225.s5	in	55	56	O	in	in	in	IN	False
DDI-MedLine.d225.s5	categories	58	67	O	categories	ies	ries	NNS	False
DDI-MedLine.d225.s5	based	69	73	O	based	sed	ased	VBN	False
DDI-MedLine.d225.s5	on	75	76	O	on	on	on	IN	False
DDI-MedLine.d225.s5	their	78	82	O	their	eir	heir	PRP$	False
DDI-MedLine.d225.s5	audiological	84	95	O	audiological	cal	ical	JJ	False
DDI-MedLine.d225.s5	and	97	99	O	and	and	and	CC	False
DDI-MedLine.d225.s5	otoneurological	101	115	O	otoneurological	cal	ical	JJ	False
DDI-MedLine.d225.s5	side-effects	117	128	O	side-effects	cts	ects	NNS	False
DDI-MedLine.d225.s5	,	129	129	O	,	,	,	,	False
DDI-MedLine.d225.s5	that	131	134	O	that	hat	that	IN	False
DDI-MedLine.d225.s5	have	136	139	O	have	ave	have	VB	False
DDI-MedLine.d225.s5	been	141	144	O	been	een	been	VBN	False
DDI-MedLine.d225.s5	signaled	146	153	O	signaled	led	aled	VBN	False
DDI-MedLine.d225.s5	by	155	156	O	by	by	by	IN	False
DDI-MedLine.d225.s5	the	158	160	O	the	the	the	DT	False
DDI-MedLine.d225.s5	drug	162	165	O	drug	rug	drug	NN	False
DDI-MedLine.d225.s5	companies	167	175	O	companies	ies	nies	NNS	False
DDI-MedLine.d225.s5	and/or	177	182	O	and/or	/or	d/or	NN	False
DDI-MedLine.d225.s5	ministerial	184	194	O	ministerial	ial	rial	NN	False
DDI-MedLine.d225.s5	notes	196	200	O	notes	tes	otes	NNS	False
DDI-MedLine.d225.s5	.	201	201	O	.	.	.	.	False

DDI-MedLine.d225.s6	Drugs	0	4	O	Drugs	ugs	rugs	NNS	False
DDI-MedLine.d225.s6	have	6	9	O	have	ave	have	VB	False
DDI-MedLine.d225.s6	also	11	14	O	also	lso	also	RB	False
DDI-MedLine.d225.s6	been	16	19	O	been	een	been	VBN	False
DDI-MedLine.d225.s6	subcategorized	21	34	O	subcategorized	zed	ized	VBN	False
DDI-MedLine.d225.s6	with	36	39	O	with	ith	with	IN	False
DDI-MedLine.d225.s6	regards	41	47	O	regards	rds	ards	NNS	False
DDI-MedLine.d225.s6	to	49	50	O	to	to	to	TO	False
DDI-MedLine.d225.s6	the	52	54	O	the	the	the	DT	False
DDI-MedLine.d225.s6	field	56	60	O	field	eld	ield	NN	False
DDI-MedLine.d225.s6	in	62	63	O	in	in	in	IN	False
DDI-MedLine.d225.s6	which	65	69	O	which	ich	hich	WDT	False
DDI-MedLine.d225.s6	they	71	74	O	they	hey	they	PRP	False
DDI-MedLine.d225.s6	are	76	78	O	are	are	are	VBP	False
DDI-MedLine.d225.s6	applied	80	86	O	applied	ied	lied	VBN	False
DDI-MedLine.d225.s6	,	87	87	O	,	,	,	,	False
DDI-MedLine.d225.s6	the	89	91	O	the	the	the	DT	False
DDI-MedLine.d225.s6	therapeutic	93	103	O	therapeutic	tic	utic	JJ	False
DDI-MedLine.d225.s6	indications	105	115	O	indications	ons	ions	NNS	False
DDI-MedLine.d225.s6	and	117	119	O	and	and	and	CC	False
DDI-MedLine.d225.s6	the	121	123	O	the	the	the	DT	False
DDI-MedLine.d225.s6	clinical	125	132	O	clinical	cal	ical	JJ	False
DDI-MedLine.d225.s6	behaviour	134	142	O	behaviour	our	iour	NN	False
DDI-MedLine.d225.s6	.	143	143	O	.	.	.	.	False

DDI-MedLine.d225.s7	They	0	3	O	They	hey	They	PRP	False
DDI-MedLine.d225.s7	have	5	8	O	have	ave	have	VB	False
DDI-MedLine.d225.s7	also	10	13	O	also	lso	also	RB	False
DDI-MedLine.d225.s7	been	15	18	O	been	een	been	VBN	False
DDI-MedLine.d225.s7	organized	20	28	O	organized	zed	ized	VBN	False
DDI-MedLine.d225.s7	in	30	31	O	in	in	in	IN	False
DDI-MedLine.d225.s7	alphabetical	33	44	O	alphabetical	cal	ical	JJ	False
DDI-MedLine.d225.s7	order	46	50	O	order	der	rder	NN	False
DDI-MedLine.d225.s7	,	51	51	O	,	,	,	,	False
DDI-MedLine.d225.s7	for	53	55	O	for	for	for	IN	False
DDI-MedLine.d225.s7	an	57	58	O	an	an	an	DT	False
DDI-MedLine.d225.s7	easier	60	65	O	easier	ier	sier	JJR	False
DDI-MedLine.d225.s7	consultation	67	78	O	consultation	ion	tion	NN	False
DDI-MedLine.d225.s7	.	79	79	O	.	.	.	.	False

DDI-MedLine.d225.s8	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d225.s8	guide	4	8	O	guide	ide	uide	NN	False
DDI-MedLine.d225.s8	above	10	14	O	above	ove	bove	IN	False
DDI-MedLine.d225.s8	,	15	15	O	,	,	,	,	False
DDI-MedLine.d225.s8	even	17	20	O	even	ven	even	RB	False
DDI-MedLine.d225.s8	if	22	23	O	if	if	if	IN	False
DDI-MedLine.d225.s8	initially	25	33	O	initially	lly	ally	RB	False
DDI-MedLine.d225.s8	conceived	35	43	O	conceived	ved	ived	VBN	False
DDI-MedLine.d225.s8	for	45	47	O	for	for	for	IN	False
DDI-MedLine.d225.s8	being	49	53	O	being	ing	eing	VBG	False
DDI-MedLine.d225.s8	used	55	58	O	used	sed	used	VBN	False
DDI-MedLine.d225.s8	in	60	61	O	in	in	in	IN	False
DDI-MedLine.d225.s8	Italy	63	67	O	Italy	aly	taly	NNP	False
DDI-MedLine.d225.s8	,	68	68	O	,	,	,	,	False
DDI-MedLine.d225.s8	also	70	73	O	also	lso	also	RB	False
DDI-MedLine.d225.s8	presents	75	82	O	presents	nts	ents	NNS	False
DDI-MedLine.d225.s8	a	84	84	O	a	a	a	DT	False
DDI-MedLine.d225.s8	more	86	89	O	more	ore	more	RBR	False
DDI-MedLine.d225.s8	general	91	97	O	general	ral	eral	JJ	False
DDI-MedLine.d225.s8	and	99	101	O	and	and	and	CC	False
DDI-MedLine.d225.s8	international	103	115	O	international	nal	onal	JJ	False
DDI-MedLine.d225.s8	interest	117	124	O	interest	est	rest	NN	False
DDI-MedLine.d225.s8	,	125	125	O	,	,	,	,	False
DDI-MedLine.d225.s8	expecially	127	136	O	expecially	lly	ally	RB	False
DDI-MedLine.d225.s8	as	138	139	O	as	as	as	IN	False
DDI-MedLine.d225.s8	for	141	143	O	for	for	for	IN	False
DDI-MedLine.d225.s8	as	145	146	O	as	as	as	IN	False
DDI-MedLine.d225.s8	the	148	150	O	the	the	the	DT	False
DDI-MedLine.d225.s8	concepts	152	159	O	concepts	pts	epts	NNS	False
DDI-MedLine.d225.s8	of	161	162	O	of	of	of	IN	False
DDI-MedLine.d225.s8	pharmacology	164	175	O	pharmacology	ogy	logy	NN	False
DDI-MedLine.d225.s8	and	177	179	O	and	and	and	CC	False
DDI-MedLine.d225.s8	the	181	183	O	the	the	the	DT	False
DDI-MedLine.d225.s8	features	185	192	O	features	res	ures	NNS	False
DDI-MedLine.d225.s8	of	194	195	O	of	of	of	IN	False
DDI-MedLine.d225.s8	the	197	199	O	the	the	the	DT	False
DDI-MedLine.d225.s8	active	201	206	O	active	ive	tive	JJ	False
DDI-MedLine.d225.s8	ingredients	208	218	O	ingredients	nts	ents	NNS	False
DDI-MedLine.d225.s8	are	220	222	O	are	are	are	VBP	False
DDI-MedLine.d225.s8	concerned	224	232	O	concerned	ned	rned	JJ	False
DDI-MedLine.d225.s8	.	233	233	O	.	.	.	.	False

DDI-MedLine.d225.s9	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d225.s9	guide	4	8	O	guide	ide	uide	NN	False
DDI-MedLine.d225.s9	is	10	11	O	is	is	is	VBZ	False
DDI-MedLine.d225.s9	,	12	12	O	,	,	,	,	False
DDI-MedLine.d225.s9	therefore	14	22	O	therefore	ore	fore	RB	False
DDI-MedLine.d225.s9	,	23	23	O	,	,	,	,	False
DDI-MedLine.d225.s9	useful	25	30	O	useful	ful	eful	JJ	False
DDI-MedLine.d225.s9	as	32	33	O	as	as	as	IN	False
DDI-MedLine.d225.s9	for	35	37	O	for	for	for	IN	False
DDI-MedLine.d225.s9	as	39	40	O	as	as	as	IN	False
DDI-MedLine.d225.s9	we	42	43	O	we	we	we	PRP	False
DDI-MedLine.d225.s9	are	45	47	O	are	are	are	VBP	False
DDI-MedLine.d225.s9	concerned	49	57	O	concerned	ned	rned	JJ	False
DDI-MedLine.d225.s9	to	59	60	O	to	to	to	TO	False
DDI-MedLine.d225.s9	any	62	64	O	any	any	any	DT	False
DDI-MedLine.d225.s9	physician	66	74	O	physician	ian	cian	NN	False
DDI-MedLine.d225.s9	,	75	75	O	,	,	,	,	False
DDI-MedLine.d225.s9	regardless	77	86	O	regardless	ess	less	RB	False
DDI-MedLine.d225.s9	of	88	89	O	of	of	of	IN	False
DDI-MedLine.d225.s9	the	91	93	O	the	the	the	DT	False
DDI-MedLine.d225.s9	country	95	101	O	country	try	ntry	NN	False
DDI-MedLine.d225.s9	he/she	103	108	O	he/she	she	/she	NN	False
DDI-MedLine.d225.s9	operates	110	117	O	operates	tes	ates	NNS	False
DDI-MedLine.d225.s9	in	119	120	O	in	in	in	IN	False
DDI-MedLine.d225.s9	.	121	121	O	.	.	.	.	False

DDI-MedLine.d158.s0	Combining	0	8	O	Combining	ing	ning	VBG	False
DDI-MedLine.d158.s0	chondroitinase	10	23	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s0	ABC	25	27	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s0	and	29	31	O	and	and	and	CC	False
DDI-MedLine.d158.s0	growth	33	38	O	growth	wth	owth	NN	False
DDI-MedLine.d158.s0	factors	40	46	O	factors	ors	tors	NNS	False
DDI-MedLine.d158.s0	promotes	48	55	O	promotes	tes	otes	NNS	False
DDI-MedLine.d158.s0	the	57	59	O	the	the	the	DT	False
DDI-MedLine.d158.s0	integration	61	71	O	integration	ion	tion	NN	False
DDI-MedLine.d158.s0	of	73	74	O	of	of	of	IN	False
DDI-MedLine.d158.s0	murine	76	81	O	murine	ine	rine	NN	drug
DDI-MedLine.d158.s0	retinal	83	89	O	retinal	nal	inal	JJ	False
DDI-MedLine.d158.s0	progenitor	91	100	O	progenitor	tor	itor	NN	False
DDI-MedLine.d158.s0	cells	102	106	O	cells	lls	ells	NNS	False
DDI-MedLine.d158.s0	transplanted	108	119	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d158.s0	into	121	124	O	into	nto	into	IN	False
DDI-MedLine.d158.s0	Rho	126	128	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s0	(	129	129	O	(	(	(	(	False
DDI-MedLine.d158.s0	-/-	130	132	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s0	)	133	133	O	)	)	)	)	False
DDI-MedLine.d158.s0	mice	135	138	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s0	.	139	139	O	.	.	.	.	False

DDI-MedLine.d158.s1	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d158.s1	aim	4	6	O	aim	aim	aim	NN	False
DDI-MedLine.d158.s1	of	8	9	O	of	of	of	IN	False
DDI-MedLine.d158.s1	this	11	14	O	this	his	this	DT	False
DDI-MedLine.d158.s1	study	16	20	O	study	udy	tudy	NN	False
DDI-MedLine.d158.s1	is	22	23	O	is	is	is	VBZ	False
DDI-MedLine.d158.s1	to	25	26	O	to	to	to	TO	False
DDI-MedLine.d158.s1	investigate	28	38	O	investigate	ate	gate	NN	False
DDI-MedLine.d158.s1	the	40	42	O	the	the	the	DT	False
DDI-MedLine.d158.s1	synergistic	44	54	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d158.s1	effect	56	61	O	effect	ect	fect	NN	False
DDI-MedLine.d158.s1	of	63	64	O	of	of	of	IN	False
DDI-MedLine.d158.s1	chondroitinase	66	79	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s1	ABC	81	83	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s1	and	85	87	O	and	and	and	CC	False
DDI-MedLine.d158.s1	growth	89	94	O	growth	wth	owth	NN	False
DDI-MedLine.d158.s1	factors	96	102	O	factors	ors	tors	NNS	False
DDI-MedLine.d158.s1	in	104	105	O	in	in	in	IN	False
DDI-MedLine.d158.s1	the	107	109	O	the	the	the	DT	False
DDI-MedLine.d158.s1	integration	111	121	O	integration	ion	tion	NN	False
DDI-MedLine.d158.s1	of	123	124	O	of	of	of	IN	False
DDI-MedLine.d158.s1	murine	126	131	O	murine	ine	rine	NN	drug
DDI-MedLine.d158.s1	retinal	133	139	O	retinal	nal	inal	JJ	False
DDI-MedLine.d158.s1	progenitor	141	150	O	progenitor	tor	itor	NN	False
DDI-MedLine.d158.s1	cells	152	156	O	cells	lls	ells	NNS	False
DDI-MedLine.d158.s1	(	158	158	O	(	(	(	(	False
DDI-MedLine.d158.s1	mRPCs	159	163	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s1	)	164	164	O	)	)	)	)	False
DDI-MedLine.d158.s1	transplanted	166	177	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d158.s1	into	179	182	O	into	nto	into	IN	False
DDI-MedLine.d158.s1	Rho	184	186	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s1	(	187	187	O	(	(	(	(	False
DDI-MedLine.d158.s1	-/-	188	190	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s1	)	191	191	O	)	)	)	)	False
DDI-MedLine.d158.s1	mice	193	196	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s1	.	197	197	O	.	.	.	.	False

DDI-MedLine.d158.s2	mRPCs	0	4	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s2	from	6	9	O	from	rom	from	IN	False
DDI-MedLine.d158.s2	P1	11	12	O	P1	P1	P1	NN	brand
DDI-MedLine.d158.s2	green	14	18	O	green	een	reen	JJ	False
DDI-MedLine.d158.s2	fluorescent	20	30	O	fluorescent	ent	cent	NN	False
DDI-MedLine.d158.s2	protein-transgenic	32	49	O	protein-transgenic	nic	enic	JJ	False
DDI-MedLine.d158.s2	mice	51	54	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s2	were	56	59	O	were	ere	were	VBD	False
DDI-MedLine.d158.s2	isolated	61	68	O	isolated	ted	ated	JJ	False
DDI-MedLine.d158.s2	and	70	72	O	and	and	and	CC	False
DDI-MedLine.d158.s2	expanded	74	81	O	expanded	ded	nded	VBN	False
DDI-MedLine.d158.s2	for	83	85	O	for	for	for	IN	False
DDI-MedLine.d158.s2	transplantation	87	101	O	transplantation	ion	tion	NN	False
DDI-MedLine.d158.s2	.	102	102	O	.	.	.	.	False

DDI-MedLine.d158.s3	All	0	2	O	All	All	All	DT	False
DDI-MedLine.d158.s3	mRPCs	4	8	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s3	of	10	11	O	of	of	of	IN	False
DDI-MedLine.d158.s3	20	13	14	O	20	20	20	CD	False
DDI-MedLine.d158.s3	passages	16	23	O	passages	ges	ages	NNS	False
DDI-MedLine.d158.s3	or	25	26	O	or	or	or	CC	False
DDI-MedLine.d158.s3	less	28	31	O	less	ess	less	RBR	False
DDI-MedLine.d158.s3	were	33	36	O	were	ere	were	VBD	False
DDI-MedLine.d158.s3	transplanted	38	49	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d158.s3	into	51	54	O	into	nto	into	IN	False
DDI-MedLine.d158.s3	the	56	58	O	the	the	the	DT	False
DDI-MedLine.d158.s3	subretinal	60	69	O	subretinal	nal	inal	JJ	False
DDI-MedLine.d158.s3	space	71	75	O	space	ace	pace	NN	False
DDI-MedLine.d158.s3	of	77	78	O	of	of	of	IN	False
DDI-MedLine.d158.s3	B6	80	81	O	B6	B6	B6	NN	brand
DDI-MedLine.d158.s3	mice	83	86	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s3	together	88	95	O	together	her	ther	RB	False
DDI-MedLine.d158.s3	with	97	100	O	with	ith	with	IN	False
DDI-MedLine.d158.s3	chondroitinase	102	115	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s3	ABC	117	119	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s3	,	120	120	O	,	,	,	,	False
DDI-MedLine.d158.s3	and	122	124	O	and	and	and	CC	False
DDI-MedLine.d158.s3	into	126	129	O	into	nto	into	IN	False
DDI-MedLine.d158.s3	Rho	131	133	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s3	(	134	134	O	(	(	(	(	False
DDI-MedLine.d158.s3	-/-	135	137	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s3	)	138	138	O	)	)	)	)	False
DDI-MedLine.d158.s3	mice	140	143	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s3	combined	145	152	O	combined	ned	ined	VBN	False
DDI-MedLine.d158.s3	with	154	157	O	with	ith	with	IN	False
DDI-MedLine.d158.s3	chondroitinase	159	172	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s3	ABC	174	176	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s3	,	177	177	O	,	,	,	,	False
DDI-MedLine.d158.s3	N-	179	180	B-drug_n	N-	N-	N-	NN	brand
DDI-MedLine.d158.s3	[	181	181	I-drug_n	[	[	[	NN	False
DDI-MedLine.d158.s3	N-	182	183	I-drug_n	N-	N-	N-	NN	brand
DDI-MedLine.d158.s3	(	184	184	I-drug_n	(	(	(	(	False
DDI-MedLine.d158.s3	3	185	185	I-drug_n	3	3	3	CD	False
DDI-MedLine.d158.s3	,	186	186	I-drug_n	,	,	,	,	False
DDI-MedLine.d158.s3	5-Difluorophenacetyl	188	207	I-drug_n	5-Difluorophenacetyl	tyl	etyl	JJ	False
DDI-MedLine.d158.s3	)	208	208	I-drug_n	)	)	)	)	False
DDI-MedLine.d158.s3	-L-alanyl	209	217	I-drug_n	-L-alanyl	nyl	anyl	NN	False
DDI-MedLine.d158.s3	]	218	218	I-drug_n	]	]	]	NN	False
DDI-MedLine.d158.s3	-S-phenylglycine	219	234	I-drug_n	-S-phenylglycine	ine	cine	NN	drug
DDI-MedLine.d158.s3	t-butyl	236	242	I-drug_n	t-butyl	tyl	utyl	NN	False
DDI-MedLine.d158.s3	ester	244	248	I-drug_n	ester	ter	ster	NN	False
DDI-MedLine.d158.s3	(	250	250	O	(	(	(	(	False
DDI-MedLine.d158.s3	DAPT	251	254	B-drug_n	DAPT	APT	DAPT	NN	brand
DDI-MedLine.d158.s3	)	255	255	O	)	)	)	)	False
DDI-MedLine.d158.s3	,	256	256	O	,	,	,	,	False
DDI-MedLine.d158.s3	and	258	260	O	and	and	and	CC	False
DDI-MedLine.d158.s3	insulin	262	268	B-drug_n	insulin	lin	ulin	NN	False
DDI-MedLine.d158.s3	growth	270	275	I-drug_n	growth	wth	owth	NN	False
DDI-MedLine.d158.s3	factor	277	282	I-drug_n	factor	tor	ctor	NN	False
DDI-MedLine.d158.s3	(	284	284	B-drug_n	(	(	(	(	False
DDI-MedLine.d158.s3	IGF	285	287	I-drug_n	IGF	IGF	IGF	NN	brand
DDI-MedLine.d158.s3	)	288	288	I-drug_n	)	)	)	)	False
DDI-MedLine.d158.s3	-1	289	290	I-drug_n	-1	-1	-1	NN	False
DDI-MedLine.d158.s3	.	291	291	O	.	.	.	.	False

DDI-MedLine.d158.s4	Cell	0	3	O	Cell	ell	Cell	NN	False
DDI-MedLine.d158.s4	counts	5	10	O	counts	nts	unts	NNS	False
DDI-MedLine.d158.s4	were	12	15	O	were	ere	were	VBD	False
DDI-MedLine.d158.s4	used	17	20	O	used	sed	used	VBN	False
DDI-MedLine.d158.s4	to	22	23	O	to	to	to	TO	False
DDI-MedLine.d158.s4	examine	25	31	O	examine	ine	mine	NN	drug
DDI-MedLine.d158.s4	the	33	35	O	the	the	the	DT	False
DDI-MedLine.d158.s4	migration	37	45	O	migration	ion	tion	NN	False
DDI-MedLine.d158.s4	and	47	49	O	and	and	and	CC	False
DDI-MedLine.d158.s4	survival	51	58	O	survival	val	ival	NN	False
DDI-MedLine.d158.s4	rate	60	63	O	rate	ate	rate	NN	False
DDI-MedLine.d158.s4	of	65	66	O	of	of	of	IN	False
DDI-MedLine.d158.s4	mRPCs	68	72	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s4	in	74	75	O	in	in	in	IN	False
DDI-MedLine.d158.s4	B6	77	78	O	B6	B6	B6	NN	brand
DDI-MedLine.d158.s4	mice	80	83	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s4	.	84	84	O	.	.	.	.	False

DDI-MedLine.d158.s5	Immunohistochemistry	0	19	O	Immunohistochemistry	try	stry	NN	False
DDI-MedLine.d158.s5	was	21	23	O	was	was	was	VBD	False
DDI-MedLine.d158.s5	used	25	28	O	used	sed	used	VBN	False
DDI-MedLine.d158.s5	to	30	31	O	to	to	to	TO	False
DDI-MedLine.d158.s5	evaluate	33	40	O	evaluate	ate	uate	NN	False
DDI-MedLine.d158.s5	the	42	44	O	the	the	the	DT	False
DDI-MedLine.d158.s5	differentiation	46	60	O	differentiation	ion	tion	NN	False
DDI-MedLine.d158.s5	and	62	64	O	and	and	and	CC	False
DDI-MedLine.d158.s5	integration	66	76	O	integration	ion	tion	NN	False
DDI-MedLine.d158.s5	of	78	79	O	of	of	of	IN	False
DDI-MedLine.d158.s5	mRPCs	81	85	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s5	in	87	88	O	in	in	in	IN	False
DDI-MedLine.d158.s5	B6	90	91	O	B6	B6	B6	NN	brand
DDI-MedLine.d158.s5	and	93	95	O	and	and	and	CC	False
DDI-MedLine.d158.s5	Rho	97	99	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s5	(	100	100	O	(	(	(	(	False
DDI-MedLine.d158.s5	-/-	101	103	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s5	)	104	104	O	)	)	)	)	False
DDI-MedLine.d158.s5	mice	106	109	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s5	.	110	110	O	.	.	.	.	False

DDI-MedLine.d158.s6	Our	0	2	O	Our	Our	Our	PRP$	False
DDI-MedLine.d158.s6	results	4	10	O	results	lts	ults	NNS	False
DDI-MedLine.d158.s6	show	12	15	O	show	how	show	NN	False
DDI-MedLine.d158.s6	that	17	20	O	that	hat	that	IN	False
DDI-MedLine.d158.s6	substantial	22	32	O	substantial	ial	tial	JJ	False
DDI-MedLine.d158.s6	numbers	34	40	O	numbers	ers	bers	NNS	False
DDI-MedLine.d158.s6	of	42	43	O	of	of	of	IN	False
DDI-MedLine.d158.s6	mRPCs	45	49	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s6	migrated	51	58	O	migrated	ted	ated	VBN	False
DDI-MedLine.d158.s6	and	60	62	O	and	and	and	CC	False
DDI-MedLine.d158.s6	survived	64	71	O	survived	ved	ived	VBN	False
DDI-MedLine.d158.s6	in	73	74	O	in	in	in	IN	False
DDI-MedLine.d158.s6	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d158.s6	retina	80	85	O	retina	ina	tina	NN	False
DDI-MedLine.d158.s6	when	87	90	O	when	hen	when	WRB	False
DDI-MedLine.d158.s6	transplanted	92	103	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d158.s6	with	105	108	O	with	ith	with	IN	False
DDI-MedLine.d158.s6	chondroitinase	110	123	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s6	ABC	125	127	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s6	into	129	132	O	into	nto	into	IN	False
DDI-MedLine.d158.s6	B6	134	135	O	B6	B6	B6	NN	brand
DDI-MedLine.d158.s6	and	137	139	O	and	and	and	CC	False
DDI-MedLine.d158.s6	Rho	141	143	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s6	(	144	144	O	(	(	(	(	False
DDI-MedLine.d158.s6	-/-	145	147	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s6	)	148	148	O	)	)	)	)	False
DDI-MedLine.d158.s6	mice	150	153	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s6	.	154	154	O	.	.	.	.	False

DDI-MedLine.d158.s7	Chondroitinase	0	13	O	Chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s7	ABC	15	17	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s7	disrupted	19	27	O	disrupted	ted	pted	VBN	False
DDI-MedLine.d158.s7	the	29	31	O	the	the	the	DT	False
DDI-MedLine.d158.s7	glial	33	37	O	glial	ial	lial	NN	False
DDI-MedLine.d158.s7	scar	39	42	O	scar	car	scar	NN	False
DDI-MedLine.d158.s7	around	44	49	O	around	und	ound	IN	False
DDI-MedLine.d158.s7	the	51	53	O	the	the	the	DT	False
DDI-MedLine.d158.s7	mRPCs	55	59	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s7	in	61	62	O	in	in	in	IN	False
DDI-MedLine.d158.s7	the	64	66	O	the	the	the	DT	False
DDI-MedLine.d158.s7	subretinal	68	77	O	subretinal	nal	inal	JJ	False
DDI-MedLine.d158.s7	space	79	83	O	space	ace	pace	NN	False
DDI-MedLine.d158.s7	.	84	84	O	.	.	.	.	False

DDI-MedLine.d158.s8	Only	0	3	O	Only	nly	Only	RB	False
DDI-MedLine.d158.s8	a	5	5	O	a	a	a	DT	False
DDI-MedLine.d158.s8	few	7	9	O	few	few	few	JJ	False
DDI-MedLine.d158.s8	mRPCs	11	15	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s8	expressed	17	25	O	expressed	sed	ssed	VBN	False
DDI-MedLine.d158.s8	recoverin	27	35	O	recoverin	rin	erin	NN	False
DDI-MedLine.d158.s8	in	37	38	O	in	in	in	IN	False
DDI-MedLine.d158.s8	B6	40	41	O	B6	B6	B6	NN	brand
DDI-MedLine.d158.s8	mice	43	46	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s8	.	47	47	O	.	.	.	.	False

DDI-MedLine.d158.s9	More	0	3	O	More	ore	More	RBR	False
DDI-MedLine.d158.s9	mRPCs	5	9	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s9	expressed	11	19	O	expressed	sed	ssed	VBN	False
DDI-MedLine.d158.s9	rhodopsin	21	29	O	rhodopsin	sin	psin	NN	False
DDI-MedLine.d158.s9	,	30	30	O	,	,	,	,	False
DDI-MedLine.d158.s9	recoverin	32	40	O	recoverin	rin	erin	NN	False
DDI-MedLine.d158.s9	,	41	41	O	,	,	,	,	False
DDI-MedLine.d158.s9	and	43	45	O	and	and	and	CC	False
DDI-MedLine.d158.s9	synaptophysin	47	59	O	synaptophysin	sin	ysin	NN	False
DDI-MedLine.d158.s9	after	61	65	O	after	ter	fter	IN	False
DDI-MedLine.d158.s9	transplantation	67	81	O	transplantation	ion	tion	NN	False
DDI-MedLine.d158.s9	into	83	86	O	into	nto	into	IN	False
DDI-MedLine.d158.s9	Rho	88	90	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s9	(	91	91	O	(	(	(	(	False
DDI-MedLine.d158.s9	-/-	92	94	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s9	)	95	95	O	)	)	)	)	False
DDI-MedLine.d158.s9	mice	97	100	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s9	when	102	105	O	when	hen	when	WRB	False
DDI-MedLine.d158.s9	combined	107	114	O	combined	ned	ined	VBN	False
DDI-MedLine.d158.s9	with	116	119	O	with	ith	with	IN	False
DDI-MedLine.d158.s9	chondroitinase	121	134	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s9	ABC	136	138	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s9	and	140	142	O	and	and	and	CC	False
DDI-MedLine.d158.s9	growth	144	149	O	growth	wth	owth	NN	False
DDI-MedLine.d158.s9	factors	151	157	O	factors	ors	tors	NNS	False
DDI-MedLine.d158.s9	.	158	158	O	.	.	.	.	False

DDI-MedLine.d158.s10	The	0	2	O	The	The	The	DT	False
DDI-MedLine.d158.s10	synergistic	4	14	O	synergistic	tic	stic	JJ	False
DDI-MedLine.d158.s10	effect	16	21	O	effect	ect	fect	NN	False
DDI-MedLine.d158.s10	of	23	24	O	of	of	of	IN	False
DDI-MedLine.d158.s10	chondroitinase	26	39	O	chondroitinase	ase	nase	NN	False
DDI-MedLine.d158.s10	ABC	41	43	O	ABC	ABC	ABC	NNP	brand
DDI-MedLine.d158.s10	and	45	47	O	and	and	and	CC	False
DDI-MedLine.d158.s10	growth	49	54	O	growth	wth	owth	NN	False
DDI-MedLine.d158.s10	factors	56	62	O	factors	ors	tors	NNS	False
DDI-MedLine.d158.s10	facilitates	64	74	O	facilitates	tes	ates	NNS	False
DDI-MedLine.d158.s10	the	76	78	O	the	the	the	DT	False
DDI-MedLine.d158.s10	anatomic	80	87	O	anatomic	mic	omic	JJ	False
DDI-MedLine.d158.s10	integration	89	99	O	integration	ion	tion	NN	False
DDI-MedLine.d158.s10	of	101	102	O	of	of	of	IN	False
DDI-MedLine.d158.s10	mRPCs	104	108	O	mRPCs	PCs	RPCs	NNS	False
DDI-MedLine.d158.s10	transplanted	110	121	O	transplanted	ted	nted	VBN	False
DDI-MedLine.d158.s10	into	123	126	O	into	nto	into	IN	False
DDI-MedLine.d158.s10	Rho	128	130	O	Rho	Rho	Rho	NN	False
DDI-MedLine.d158.s10	(	131	131	O	(	(	(	(	False
DDI-MedLine.d158.s10	-/-	132	134	O	-/-	-/-	-/-	NN	False
DDI-MedLine.d158.s10	)	135	135	O	)	)	)	)	False
DDI-MedLine.d158.s10	mice	137	140	O	mice	ice	mice	NN	False
DDI-MedLine.d158.s10	.	141	141	O	.	.	.	.	False

